FINAL PROGRAM

LOREM IPSUM DOLORLOREM IPSUM DOLOR

XXVI ISTH Congress and 63rd Annual SSC Meeting

1

FINAL PROGRAM


www.isth2017.org


XXVI ISTH Congress and 63rd Annual SSC Meeting XXVI ISTH Congress and 63rd Annual SSC Meeting

2 3

TABLE OF CONTENTS

Editor in Chief: Mary Cushman

July 2017

VOLUME 11 | NUMBER 7

Research and Practice in Thrombosis and Haemostasis (RPTH) is an exciting new open access journal from the International Society on Thrombosis and Haemostasis (ISTH) for innovative science and discourse among researchers, clinicians and patients in the global thrombosis and hematology community. In an ever-changing environment, RPTH offers an exciting medium for rigorous yet

rapid peer review and immediate dissemination of research.

The journal will publish basic, translational, clinical, population and implementation research in thrombosis, hemostasis, vascular disease and related areas with an aim to advance the treatment of patients.

Paper types covered by RPTH: original science, review articles on recent advances, debates, synthesis articles on research translation to practice and compelling case reports.

Join the Conversation!

A new open access journal from ISTH

Questions? Contact us at +1 919 929 3807

In this issue

Thrombotic complications

of myeloproliferative

neoplasms

New recombinant FVIIa:

pharmacokinetics and

efficacy

Crystal structure of an

ADAMTS13 mutant

Editor in Chief: Mary Cushman July 2017

VOLUME 11 | NUMBER 7

ISSN 2475-0379

www.rpth.isth.org

Editor in Chief: Mary Cushman Peer-Reviewed Open Access Journal Now Open for Submissions

Mary Cushman, M.D., M.Sc.Editor-in-Chief

Visit RPTH.ISTH.ORG to get started today!

@RPTHjournal

isth.org

The call for submissions to RPTH is now open. The ISTH is a global not-for-profit organization advancing the understanding, prevention, diagnosis and treatment of

thrombotic and bleeding disorders.

WIFI Username: ISTH2017 Password: sobibivv

Invitation and Welcome Messages 4–9ISTH 2017 Committees 10–13ISTH 2017 Abstract Reviewers 14–18ISTH Council 19ISTH SSC Committees 20ISTH Awards 23ISTH and ISTH 2017 Awards 24ISTH 2017 Awards 25–27About the ISTH 28–29

Program

Program Overview 32–34Program Day by Day 36–47

SSC and Educational Program 50–83 Special Sessions 86–87 Nurses Forum 90–96 Master Classes and Career Development Sessions 98–108

Scientific Program

Sunday, July 9, 2017 110Monday, July 10, 2017 112–146Tuesday, July 11, 2017 148–185Wednesday, July 12, 2017 187–213Thursday, July 13, 2017 215–228

Posters

Monday, July 10, 2017 230–311Tuesday, July 11, 2017 312–400Wednesday, July 12, 2017 401–482Publication Only 483–488

Congress Information

Venue and Contacts 492Venue Floor Plans 494–503ISTH 2017 Attendee Services and Innovations 504–507Congress Information 508–513ISTH 2017 Networking Events 515ISTH 2017 5K Charity Run/Walk 516Local Information 518Transportation in Berlin 519

Supported Symposia and Product Theater Overview and Listing

Exhibition and Congress Support 523Supported Symposiaand Product Theater Presentations 526–537

Exhibition and Exhibitors

Exhibition Floor Plan 540–543Exhibitior & Supporter List 544–549Company Profiles 550–579Corporate Meeting Suites 580–581Conflict of Interest Disclosure Information 582–583

Authors Index

Authors Index 586–604

Future ISTH Meetings and Congresses 605


4 5

WELCOME MESSAGEINVITATION AND WELCOME MESSAGE

Dear ISTH 2017 Congress participants,

We are pleased to welcome you to the XXVI International Society on Thrombosis and Haemostasis (ISTH) Congress and 63rd Annual Scientific and Standardization Committee (SSC) Meeting in Berlin, a city full of life with a distinctive culture and cosmopolitan blend of people and events.

Founded in the 13th century, Berlin has experienced an eventful history, with frequent and radical changes over the years that have continually transformed the city. Once divided by a wall for decades, Berlin is now seen as a global symbol for unity and a vibrant metropolis in the heart of Europe.

We are proud to host the congress for the first time in Berlin, Germany, after nearly 37 years follo-wing the inaugural ISTH congress, which was hosted in Montreux, Switzerland, in 1970. With the developments that have occurred in the field of thrombosis and hemostasis over the decades, this year’s congress motto truly hits the mark: “Transcending Scientific Boundaries.” Here at ISTH 2017, we are excited to welcome more than 8,000 scientists and clinicians from around the world focused in thrombosis and hemostasis who have the ambition and drive to push scientific boundaries in the field.

Saturday and the first half of Sunday are devoted to the 63rd Annual ISTH SSC Meeting. Work in progress, preliminary or final reports from the multitude of projects of the SSC, mixed with a wide variety of educational lectures focus on the critically important diagnostic and therapeutic standards, disease nomenclature, and classification that allow the field to work together toward real-time and patient-centric solutions.

The XXVI ISTH Congress kicks off with the opening ceremony on Sunday evening. We look forward to sharing a taste of history in medicine and science mixed with modern artists and music, which illustrates the river of knowledge. The opening ceremony will be followed by a networking reception in the exhibition halls.

The scientific part of the congress features 131 invited speakers, including eight plenary lectures by front-line scientists and 84 state-of-the-art lectures by leaders in their respective fields (accompa-nied by selected state-of-the-art papers in the Journal of Thrombosis and Haemostasis). The congress also offers 39 abstract symposia with an introductory review lecture, followed by oral presentations of top-scoring abstracts. A late-breaking session will be held on Tuesday highlighting important and timely results from clinical trials.

From Monday to Wednesday, poster sessions will be presented. For those who have reserved tickets, there are master classes covering 40 topics in the early mornings between Sunday to Wednesday, and career development sessions for small groups will be held from Monday to Wednesday at lunch time. Overall, more than 3,000 abstracts will be presented as oral or poster presentations.

During the lunch break, you have the opportunity to discuss poster presentations in the poster area and network with your colleagues followed by industry supported product theater presentations and supported symposia.

We are grateful to our industry partners for their generous support of the congress. We encourage you to visit the exhibition hall, attend product theater and supported symposia, learn about the latest diagnostic and therapeutic advances available to us and exchange ideas with representatives from the diagnostic and pharmaceutical industry.

On Wednesday evening, we invite you to attend the networking evening at the famous Tempodrom in downtown Berlin with live music and delicious catering by Sarah Wiener, a famous Austrian chef now living in Berlin. Make sure you purchase tickets to attend before it is sold out!

The congress closes on Thursday at noon with a session on the highlights of ISTH 2017, where you will hear a recap of selected, top-scoring presentations from both basic and clinical science.

Finally we are excited about the many new innovations that will be introduced at the congress. Be sure to download the ISTH 2017 mobile app and stay up to date and build your itinerary for the meeting.

We wish you an informative and memorable experience at ISTH 2017. We hope you will be inspired by the science, news, and innovation taking place at the congress, as well as by the culture of Berlin and its history.

Johannes Oldenburg, M.D. Ingrid Pabinger, M.D. Walter Ageno, M.D.ISTH XXVI Congress President ISTH Council Chair ISTH SSC Chair


6 7

WELCOME MESSAGEWELCOME MESSAGE

With this year's Congress, the title of which is "Transcending Scientific Boundaries," you are once again sending out an important signal with regard to global and cross-border advances in the pre-vention and treatment of thrombosis, blood coagulation disorders and related secondary diseases. Over 9,000 experts from 90 countries will be coming together at this event to report both on the latest scientific findings and their experience. They will be providing insights into the current state of research and identifying possibilities for further improving the life of patients the world over. Further-more, with your guidelines and the valuable recommendations on diagnosis and therapy that go with them, you are supporting family doctors and specialists in providing the best possible treatment for their patients.

I wish to express my sincere gratitude for your untiring efforts in the further development of the prevention, diagnosis and treatment of thrombosis and blood coagulation disorders, as well as the se-condary diseases that might accompany them. For this year's conference of the International Society of Thrombosis and Haemostasis, which is taking place in Germany for the first time this year, I wish you a successful outcome, with many new insights and an exciting exchange of know-how among the experts present.

Hermann GröheFederal Minister of HealthMember of the German Bundestag

Dear Participants of the ISTH 2017 Congress,

Welcome to Berlin!

I am delighted that you are holding this prestigious congress in Germany for the first time and have chosen Berlin as your venue. Experts from all over the world will gather here to explore the latest findings on endemic cardiovascular diseases.

As one of the world’s leading trade show and congress venues, Berlin offers ideal conditions for professional meetings. At the same time, as a modern health care capital with a long history, our city boasts an excellent scientific landscape. Along with Charité-Universitätsmedizin Berlin, Berlin’s flagship of modern medical research and practice, you will find a broad spectrum of public and pri-vate hospitals, excellent colleges and universities, and a host of renowned non-university research institutes doing cutting-edge research.

And so I would like to wish you all a productive and successful congress that is a source of useful insights and fresh professional inspiration. And, of course, I hope you will enjoy an unforgettable stay in Berlin – both at the conference sessions organized by your renowned medical society and on forays through our exciting city.

Michael MüllerGoverning Mayor of Berlin


8 9

WELCOME MESSAGE INVITATION AND WELCOME MESSAGE

TO STOP BLOOD CLOTS

& SAVE LIVESJOIN OUR

GLOBAL MOVEMENT

#WorldThrombosisDay #KnowThrombosis #KeepLifeFlowing

As a partner, supporter, community mobilizer. More than 800 groups already have. Will you?

JOIN USWORLDTHROMBOSISDAY.ORG

GLOBAL PARTNERS GLOBAL SUPPORTER

STAY CONNECTED

2017

ISTH Headquarters 610 Jones Ferry Road, Suite 205, Carrboro, NC 27510 USA Phone: +1 919 929-3807 www.isth.org

International Society on Thrombosis and Haemostasis, Inc. All rights reserved.

v

The mission of the Journal of Thrombosis and Haemostasis (JTH) is to advance science related to the important medical problems of thrombosis, bleeding disorders and vascular biology through the diffusion and exchange of information and ideas within the international research community. Editors invite both fundamental and clinical contributions.

An official journal of the

Benefits of publishing in JTH Speed: Submissions are quick and easy with our online system. Papers receive rapid peer review by JTH’s international editorial board and are published online within days of acceptance through Accepted Articles.

Impact: Your research will be read widely around the world, including exposure to the membership of the International Society on Thrombosis and Haemostasis. Our author tools provide you with extensive opportunities to drive your impact through social and online activity.

Reputation: For more than 13 years, JTH has provided a home for high quality research in the field of thrombosis and hemostasis. In conjunction with its prominent editors-in-chief, editorial board and associate editors, JTH has published some of the best authors in the field.

Submit online at jth.isth.org

Editors-in-Chief: Pieter Reitsma and Frits RosendaalImpact Factor: 5.565ISI Journal Citation Reports© Ranking: 2015: 6/63 (Peripheral Vascular Disease); 10/70 (Hematology)

17-2

84807


10 11

ISTH 2017 COMMITTEESISTH 2017 COMMITTEES

ISTH Organizing Committee

Local Organizing CommitteeJohannes Oldenburg, Germany Congress PresidentIngrid Pabinger, Austria Vice PresidentAnne Angelillo-Scherrer, Switzerland Scientific Program Co-ChairAndreas Greinacher, Germany Educational Program Chair/SSC LiaisonBettina Kemkes-Matthews, Germany GTH LiaisonChristoph Male, Austria Pediatric Topics LiaisonChristine Mannhalter, Austria Clinical Program ChairKlaus T. Preissner, Germany Basic Science Program ChairWolfram Ruf, Germany Scientific Program Coordinator/ Guest Editor: State-of-the-Art ReviewChristian Weber, Germany Scientific Program Co-Chair

Scientific Program Committee ChairsChristoph Binder, Austria Atherothrombosis and StrokeBerend Isermann, Germany Coagulant and Anticoagulant MechanismsBernd Engelmann, Germany Coagulation Signaling and ImmunityKarl Lackner, Germany Diagnostics and OMICsJohann Wojta, Austria Fibrinolysis and ProteolysisAndreas Tiede, Germany Hemorrhagic Disorders, HemophiliaStavros Konstantinides, Germany Management of ThromboembolismKatie Khair, United Kingdom Nurses and Allied HealthSabine Eichinger, Austria Pathogenesis of ThromboembolismChristoph Male, Austria PediatricsBernhard Nieswandt, Germany Platelets - BasicMeinrad Gawaz, Germany Platelets - ClinicalErhard Seifried, Germany Transfusion and BiotherapeuticsHellmut Augustin, Germany Vascular Biology and Angiogenesis

Scientific Program Committee

Atherothrombosis and StrokeChristoph Binder, Austria, ChairSteffen Massberg, Germany, Co-ChairSteen Dalby Kristensen, DenmarkLina Badimon, SpainIrene Lang, AustriaAndreas Zirlik, Germany

Coagulant and Anticoagulant MechanismsBerend Isermann, Germany, ChairThomas Renné, Germany, Co-ChairRodney Camire, United StatesBjörn Dahlbäck, SwedenChristophe Dubois, FranceTilman Hackeng, the NetherlandsPeter Lenting, France

Coagulation Signaling and ImmunityBernd Engelmann, Germany, ChairTriantafyllos Chavakis, Germany, Co-ChairTobias Fuchs, GermanyHeiko Herwald, SwedenCraig Morrell, United StatesHenri Versteeg, the NetherlandsHartmut Weiler, United States

Diagnostics and OMICsKarl Lackner, Germany, ChairPierre Morange, France, Co-ChairMihaela Delcea, GermanyJens Mueller, GermanyWillem Ouwehand, United KingdomMichael Spannagl, ItalyJohn Weisel, United States

Fibrinolysis and ProteolysisJohann Wojta, Austria, ChairFlorian Langer, Germany, Co-ChairThomas Bugge, United StatesPaul Declerck, BelgiumMarguerite Neerman Arbez, SwitzerlandMaria Stoppelli, ItalyAnnetta Undas, PolandJoost Meijers, the Netherlands

Hemorrhagic Disorders, HemophiliaAndreas Tiede, Germany, ChairReinhard Schneppenheim, Germany, Co-ChairDavid Lillicrap, CanadaChristoph Male, AustriaFlora Peyvandi, ItalyAlok Srivastava, ItalyJerzy Windyga, CanadaPeter Lenting, FranceDan Hart, United Kingdom

Management of ThromboembolismStavros Konstantinides, Germany, ChairJan Beyer-Westendorf, Germany, Co-ChairHarry Büller, the NetherlandsGuy Meyer, FranceUlrike Nowak-Göttl, GermanyMarc Righini, SwitzerlandSebastian Schellong, GermanyJeffrey Weitz, Canada

Pathogenesis of ThromboembolismSabine Eichinger, Austria, ChairBernd Pötzsch, Germany, Co-ChairCihan Ay, AustriaFrancesco Bernardi, ItalySaskia Middeldorp, the NetherlandsPieter Reitsma, the NetherlandsPer Morten Sandset, Norway

PediatricsChristoph Male, Austria, ChairManuela Albisetti, SwitzerlandBarbara Zieger, GermanyKarin Kurnik, GermanyUlrike Nowak-Göttl, Germany

Platelets – BasicBernhard Nieswandt, Germany, ChairBeate Kehrel, Germany, Co-ChairWolfgang Bergmeier, United StatesKen Clemetson, SwitzerlandChristian Gachet, FranceJohan Heemskerk, the NetherlandsSteve Watson, United Kingdom


12 13

ISTH 2017 COMMITTEESISTH 2017 COMMITTEES

Platelets – ClinicalMeinrad Gawaz, Germany, ChairJohanna Kremer Hovinga, Germany, Co-ChairTamam Bakchoul, GermanyCarlo Balduini, ItalyPierre Fontana, SwitzerlandPaul Knöbl, AustriaAlan Michelson, United States

Transfusion and BiotherapeuticsErhard Seifried, Germany, ChairPeter Horn, Germany, Co-ChairCedric Ghevaert, United KingdomBehrouz Mansouri Taleghani, GermanyPatrick Meybohm, GermanySimon Panzer, AustriaUlrich Sachs, Germany

Vascular Biology and AngiogenesisHellmut Augustin, Germany, ChairStefanie Dimmeler, Germany, Co-ChairChantal Boulanger, FranceJozef Dulak, PolandGou Young Koh, Republic of Korea

Nurses and Allied Health Maura Malone, United States, ChairBunis Packham, United Kingdom, Co-ChairRegina Butler, United StatesJennifer Maahs, United StatesJim Munn, United StatesFiona Newell, AustraliaAnne O’Sullivan, Ireland

International Advisory Board

Lorenzo Alberio, SwitzerlandCihan Ay, AustriaLina Badimon, SpainTamam Bakchoul, GermanyWolfgang Bergmeier, United StatesFrancesco Bernardi, ItalyChristoph Binder, AustriaVladimir Bogdanov, United StatesPaul Bray, United StatesBenjamin Brenner, IsraelThomas Bugge, United StatesHarry Büller, the NetherlandsRodney Camire, United StatesPeter Carmeliet, BelgiumMarco Cattaneo, ItalyTrian Chavakis, GermanyKen Clemetson, SwitzerlandBarry Coller, United StatesEd Conway, CanadaBjörn Dahlbäck, SwedenPhilippe de Moerloose, FrancePaul Declerck, BelgiumElisabetta Dejana, ItalyMihaela Delcea, GermanyCecile Denis, FranceFrançoise Dignat-George, FranceDonna DiMichele, United StatesJing-Fei Dong, United StatesChristoph Dubois, FranceCharles Esmon, United StatesAnna Falanga, ItalyJane Freedman, United StatesChristian Gachet, FranceDavid Gailani, United StatesIan Greer, United KingdomJohn Griffin, United StatesYves Gruel, FranceTilman Hackeng, the NetherlandsKatherine Hajjar, United StatesPaul Harrison, United KingdomJohan Heemskerk, the NetherlandsPhilip Hogg, AustraliaKurt Huber, AustriaShaun Jackson, Australia

Nigel Key, United StatesRobert, Klamroth, GermanyRalf Knöfler, GermanyWolfgang Korte, SwitzerlandJohanna Kremer Hovinga, SwitzerlandSriram Krishnaswamy, United StatesSteen Kristensen, DenmarkKarin Kurnik, GermanyBernhard Lämmle, SwitzerlandDavid Lane, United KingdomFlorian Langer, GermanyDan Lawrence, United StatesPeter Lenting, FranceMarcel Levi, the NetherlandsKlaus Ley, United StatesDavid Lillicrap, CanadaGregory Lip, United KingdomNigel Mackman, United StatesJonny Mahlangu, South AfricaMike Makris, United KingdomRobert Medcalf, AustraliaDiego Mezzano, ChileAlan Michelson, United StatesToshiyuki Miyata, JapanCraig Morrell, United StatesJames Morrissey, United StatesLaurent Mosnier, United StatesMichael Nagler, SwitzerlandAmit Nathwani, United KingdomMarguerite Neerman Arbez, SwitzerlandUlrike Nowak-Göttl, GermanyPaquita Nurden, FranceYukio Ozaki, JapanRafal Pawlinski, United StatesKarlheinz Peter, AustraliaFlora Peyvandi, ItalyEd Plow, United StatesMargaret Ragni, United StatesAnna Randi, United KingdomPieter Reitsma, the NetherlandsMarc Righini, SwitzerlandFrancesco Rodeghiero, ItalyMarc Rodger, CanadaFrits Rosendaal, the NetherlandsJ. Evan Sadler, United StatesPer Morten Sandset, Norway

Sam Schulman, CanadaJean-François Schved, FranceMichael Spannagl, GermanyMaria Stoppelli, ItalyHugo Ten Cate, the NetherlandsAnetta Undas, PolandTetsumei Urano, JapanMarijke van den Berg, the NetherlandsVictor van Hinsbergh, the NetherlandsKaren Vanhoorelbeke, BelgiumFreek Verheugt, the NetherlandsHenri Versteeg, the NetherlandsDenisa Wagner, United StatesChristopher Ward, AustraliaSteve Watson, United KingdomJeffrey Weitz, CanadaJerzy Windyga, PolandSidney Whiteheart, United StatesAlisa Wolberg, United StatesWalter Wuillemin, SwitzerlandBarbara Zieger, GermanyAndreas Zirlik, Germany


14 15

ISTH 2017 ABSTRACT REVIEWERSISTH 2017 ABSTRACT REVIEWERS

Walter Ageno, ItalyJosefin Ahnström, United KingdomLorenzo Alberio, SwitzerlandManuela Albisetti, SwitzerlandMarie-Christine Alessi, FranceRobert Andrews, AustraliaPantep Angchaisuksiri, ThailandAnne Angelillo-Scherrer, SwitzerlandDarko Antic, SerbiaGemma Arderiu, SpainRobert Ariens, United KingdomDonald Arnold, CanadaAlice Assinger, AustriaJan Astermark, SwedenHellmut Augustin, GermanyCihan Ay, AustriaLina Badimon, SpainJuan Jose Badimon, United StatesTamam Bakchoul, GermanyRoss Baker, AustraliaAlessandra Balduini, ItalyStefano Barco, GermanyAngelika Batorova, SlovakiaRupert Bauersachs, GermanyCecilia Becattini, ItalyMarkus Bender, GermanyFrauke Bergmann, GermanyWolfgang Bergmeier, United StatesFrancesco Bernardi, ItalyErik Berntorp, SwedenLaurent Bertoletti, FranceJan Beyer-Westendorf, GermanyChristoph Binder, AustriaTina Biss, United KingdomJan Blatny, Czech RepublicMarc Blondon, SwitzerlandMark Blostein, CanadaChristoph Bode, GermanyVladimir Bogdanov, United StatesEric Boilard, CanadaMariana Bonduel, ArgentinaMaria Borrell, SpainChantal Boulanger, FranceHenri Bounameaux, SwitzerlandVanessa Bouskill, CanadaLeonardo Brandao, Canada

Lawrence Brass, United StatesBenjamin Brenner, IsraelThomas Bugge, United StatesHarry Büller, the NetherlandsJames Bussel, United StatesRegina Butler, United StatesMarina Camera, ItalyScott Cameron, United StatesRodney Camire, United StatesSuzanne Cannegieter, the NetherlandsIlaria Canobbio, ItalyMadeline Cantini, United StatesManuel Carcao, CanadaMarc Carrier, CanadaGiancarlo Castaman, ItalyFrancis Castellino, United StatesElisabetta Castoldi, the NetherlandsMarco Cattaneo, ItalyElizabeth Chalmers, United KingdomAnthony Chan, CanadaMeera Chitlur, United StatesOlivier Christophe, FranceKenneth Clemetson, SwitzerlandAnder Cohen, United KingdomBarry Coller, United StatesPeter Collins, United KingdomMario Colucci, ItalyEd Conway, CanadaMichiel Coppens, the NetherlandsJavier Corral, SpainJudith Cosemans, the NetherlandsBenilde Cosmi, ItalyFrancis Couturaud, FranceJim Crawley, United KingdomJudit Cubedo, SpainMary Cushman, United StatesBjörn Dahlbäck, SwedenSteen Dalby Kristensen, DenmarkSven Danckwardt, GermanyArmando D'Angelo, ItalyPhilip de Groot, the NetherlandsBas de Laat, the NetherlandsMoniek de Maat, the NetherlandsSimon De Meyer, BelgiumPhilippe de Moerloose, SwitzerlandHans Deckmyn, Belgium

Paul Declerck, BelgiumRaimondo DeCristofaro, ItalyAhmet Muzaffer Demir, TurkeyCecile Denis, FranceFrancesco Dentali, ItalyKatrien Devreese, BelgiumScott Diamond, United StatesHans Christoph Diener, GermanyDonna DiMichele, United StatesMarcello DiNisio, ItalyReyhan Diz-Kücükkaya, TurkeyRoseline D'Oiron, FranceGerry Dolan, United KingdomJing-Fei Dong, United StatesJames Douketis, CanadaChistophe Dubois, FranceJozef Dulak, PolandSabine Eichinger, AustriaJeroen Eikenboom, the NetherlandsJonas Emsley, United KingdomBernd Engelmann, GermanyCarmen Escuriola, GermanyKoji Eto, JapanElena Faioni, ItalyAnna Falanga, ItalyAugusto Federici, ItalyKarin Fijnvandraat, the NetherlandsKathelijn Fischer, the NetherlandsRobert Flaumenhaft, United StatesIngrid Fleming, GermanyMatthew Flick, United StatesPierre Fontana, SwitzerlandAndrew L. Frelinger, United StatesTobias Fuchs, GermanyJanine Furmedge, AustraliaDavid Gailani, United StatesDavid Garcia, United StatesPablo Garcia de Frutos, SpainElizabeth Gardiner, AustraliaThomas Gary, AustriaMargarethe Geiger, AustriaHolger Gerhardt, GermanyGrigorios Gerotziafas, FranceCedric Ghevaert, United KingdomPaul Giangrande, United KingdomSam Goldhaber, United States

Jenny Goudemand, FranceSamantha Gouw, the NetherlandsAndreas Greinacher, GermanyPaolo Gresele, ItalyJohn Griffin, United StatesJean-Christophe Gris, FrancePeter Gross, CanadaErik Grove, DenmarkYves Gruel, FranceChris Guelcher, United StatesMayer Günter, GermanySylvia Haas, GermanyTilman Hackeng, the NetherlandsJohn-Bjarne Hansen, NorwayPaul Harrison, United KingdomCharles Hay, United KingdomBeatrice Hechler, FranceJohan W.M. Heemskerk, the NetherlandsHeiko Herwald, SwedenPhilip Hogg, AustraliaMike Holinstat, United StatesSusanne Holzhauer, GermanyPeter Horn, GermanyMarc Hoylaerts, BelgiumMenno Huisman, the NetherlandsJames Huntington, United KingdomAnne-Mette Hvas, DenmarkVera Ignjatovic, AustraliaBerend Isermann, GermanyShaun Jackson, AustraliaShannon Jackson, CanadaPaula James, CanadaMartine Jandrot-Perrus, FranceDavid Jiménez, SpainSusan Kahn, CanadaWalter Kahr, CanadaSandip Kanse, NorwayKaan Kavakli, TurkeyBeate Kehrel, GermanyBettina Kemkes-Matthes, GermanyGili Kenet, IsraelSteven K. Kerrigan, IrelandNigel Key, United StatesKate Khair, United KingdomBenjamin Kile, AustraliaPaul Kim, Canada


16 17

ISTH 2017 ABSTRACT REVIEWERSISTH 2017 ABSTRACT REVIEWERS

Robert Klamroth, GermanyFrederikus A. Klok, the NetherlandsCornelis (Kees) Kluft, the NetherlandsPaul Knöbl, AustriaRalf Knöfler, GermanyRory Koenen, GermanyChristoph Koenigs, GermanyGou Young Koh, Republic of KoreaOliver Königsbrügge, AustriaStavros Konstandinides, GermanyWolfgang Korte, SwitzerlandJohanna Kremer, SwitzerlandSririam Krishnaswamy, United StatesMarieke Kruip, the NetherlandsKarin Kurnik, GermanyKarl Lackner, GermanyBernhard Lämmle, GermanyDavid Lane, United KingdomFlorian Langer, GermanyMareike Lankeit, GermanyFrancois Lanza, FranceSanne Bøjet Larsen, DenmarkRiitta Lassila, FinlandMandy Lauw, the NetherlandsDan Lawrence, United StatesGrégoire le Gal, CanadaThomas Lecompte, SwitzerlandAgnes Lee, CanadaChristine Lee, United KingdomFrank Leebeek, the NetherlandsPeter Lenting, FranceCatherine Leon, FranceMarcel Levi, the NetherlandsRenhao Li, United StatesRi Liesner, United KingdomW.M. Lijfering, the NetherlandsRoger Lijnen, BelgiumDavid Lillicrap, CanadaEdelgard Lindhoff-Last, GermanyGregory Lip, United KingdomTon Lisman, the NetherlandsRustem Litvinov, United StatesRolf Ljung, SwedenColin Longstaff, United KingdomMarie Lordkipanidze, CanadaJennifer Maahs, United States

Coen Maas, the NetherlandsNigel Mackman, United StatesPatricia Maguire, IrelandJohnny Mahlangu, South AfricaMike Makris, United KingdomChristoph Male, AustriaMaura Malone, United StatesMaria Elisa Mancuso, ItalyPierre Mangin, FranceChristine Mannhalter, AustriaPier Mannuccio Mannucci, ItalyKarlyn Martin, United StatesIda Martinelli, ItalySteffen Massberg, GermanyPatti Massicotte, CanadaAlan Mast, United StatesManuel Mayr, United KingdomLucia Mazzolai, SwitzerlandOwen McCarty, United StatesSimon McRae, AustraliaRob Medcalf, AustraliaKarina Meijer, the NetherlandsJoost Meijers, the NetherlandsKelly Metcalf Pate, United StatesPatrick Meybohm, GermanyGuy Meyer, FranceDiego Mezzano, ChileAlan Michelson, United StatesSaskia Middeldorp, the NetherlandsLindsey Miles, United StatesLesley Mitchell, CanadaToshiyuki Miyata, JapanShigeki Miyata, JapanPaul Monagle, AustraliaPierre Morange, FranceCraig Morrell, United StatesJames Morrissey, United StatesJohn Morser, United StatesLaurent Mosnier, United StatesJens Mueller, GermanyGreta Mulders, the NetherlandsJim Munn, United StatesLaszlo Muszbek, HungaryNicola Mutch, United KingdomLinda Myrin-Westesson, SwedenMichael Nagler, Switzerland

Marguerite Neerman-Arbez, SwitzerlandClaude Negrier, FranceFiona Newall, AustraliaHeyu Ni, CanadaTim Nichols, United StatesGerry Nicolaes, the NetherlandsMarvin Nieman, United StatesBernhard Nieswandt, GermanyRienk Nieuwland, the NetherlandsUlrike Nowak-Göttl, GermanyPaquita Nurden, FranceJohannes Oldenburg, GermanyEl-Maarri Osman, LebanonYukio Ozaki, JapanMargareth Ozelo, BrazilIngrid Pabinger, AustriaBunis Packham, United KingdomTeresa Padro, SpainJohn Pasi, United KingdomCarlo Patrono, ItalyRafal Pawlinski, United StatesBernard Payrastre, FranceDirk Peetz, GermanyKarlheinz Peter, AustraliaFlora Peyvandi, ItalyHelen Philippou, United KingdomVictoria Ploplis, United StatesMichael Ploug, DenmarkEd Plow, United StatesAlastair Poole, United KingdomPaolo Prandoni, ItalyRoger Preston, IrelandKlaus T. Preissner, GermanyPatrick Provost, CanadaLeslie Raffini, United StatesMargeret Ragni, United StatesJacob Rand, United StatesGary Raskob, United StatesPieter Reitsma, the NetherlandsThomas Renné, GermanyJean-Luc Reny, SwitzerlandShoshana Revel-Vilk, IsraelAlireza Rezaie, United StatesMarc Righini, SwitzerlandDick Rijken, the NetherlandsHelia Robert-Ebadi, Switzerland

Bianca Rocca, ItalyFrancesco Rodeghiero, ItalyMarc Rodger, CanadaMatthew Rondina, United StatesFrits Rosendaal, the NetherlandsWolfram Ruf, GermanyUlrich Sachs, GermanyEvan Sadler, United StatesOlivier Sanchez, FrancePer Morten Sandset, NorwayKim Schafer, United StatesRichard Schäfer, GermanySebastian Schellong, GermanyPeter Schlenke, AustriaAlvin Schmaier, United StatesReinhard Schneppenheim, GermanySam Schulman, CanadaHarald Schulze, GermanyJean-François Schved, FranceErhard Seifried, GermanyJohn Semple, SwedenYotis Senis, United KingdomMelchior Seyfarth, GermanyDirk Sibbing, GermanyPaolo Simioni, ItalyMichael Spannagl, GermanySherry Spinelli, United StatesHenri Spronk, the NetherlandsAlessandro Squizzato, ItalyAlok Srivastava, IndiaEvi Stavrou, United StatesLucia Stefanini, ItalyRosen Steffen, SwedenScott Stevens, United StatesSophie Susen, FranceKatsue Suzuki-Inoue, JapanRoman Szabo, United StatesJason Taylor, United StatesArina ten Cate, the NetherlandsHugo Ten Cate, the NetherlandsAndreas Tiede, GermanyTorsten Tonn, GermanyAlberto Tosetto, ItalyPaula B. Tracy, United States Elena Tremoli, ItalySotirios Tsimikas, United States


18 19

ISTH COUNCILISTH 2017 ABSTRACT REVIEWERS

Edward (Ted) Tuddenham, United KingdomShirley Uitte de Willige, the NetherlandsAnetta Undas, PolandTetsumei Urano, JapanRolf Urbanus, the NetherlandsWilliam Vainchenker, FranceMarijke van den Berg, the NetherlandsNick Van Es, the NetherlandsChris van Geet, BelgiumVictor van Hinsbergh, the NetherlandsAstrid Van Hylckama Vlieg, the NetherlandsHeleen van Ommen, the NetherlandsKaren Vanhoorelbeke, BelgiumDavid Varon, IsraelPeter Verhamme, BelgiumHenri Versteeg, the NetherlandsGemma Vilahur, SpainDenis Vivien, FranceJan Voorberg, the NetherlandsDenisa Wagner, United StatesChristopher Ward, AustraliaTheodore Warkentin, CanadaSteve Watson, United KingdomChristian Weber, GermanyHartmut Weiler, United StatesJohn Weisel, United StatesJeffrey Weitz, CanadaJerzy Windyga, PolandJohann Wojta, AustriaAlisa Wolberg, United StatesWalter A. Wuillemin, SwitzerlandGuy Young, United StatesLaurent Yvan-Charvet, FranceRene Zahedi, GermanyBarbara Zieger, GermanyAndreas Zirlik, Germany

OfficersIngrid Pabinger, AustriaChairman (2016 – 2018)

Claire McLintock, New ZealandSecretary/Chairman-Elect (2016 – 2018)

Björn Dahlbäck, Sweden Treasurer (2015 – 2018)

Class of 2018Peter Lenting, FranceClaire McLintock, New ZealandJames Morrissey, United StatesIngrid Pabinger, AustriaJeffrey Weitz, Canada

Class of 2020Anna Falanga, Italy David Lillicrap, CanadaJosé López, United StatesSuely Rezende, BrazilSteve Watson, United Kingdom

Class of 2022Pantep Angchaisuksiri, ThailandMichael Makris, United KingdomFlora Peyvandi, ItalySam Schulman, CanadaAlisa Wolberg, United States

Ex-Officio Council MembersJ. Evan Sadler, United States Secretary General, ISTH

Johannes Oldenburg, Germany President, XXVI ISTH Congress Berlin, 2017

Sam Schulman, Canada Past President, XXV ISTH CongressToronto, 2015

Nigel Key, United States Immediate Past Chairman, ISTH Council

Pieter Reitsma, the NetherlandsEditor-in-Chief, Journal of Thrombosis and Haemostasis

Frits Rosendaal, the NetherlandsEditor-in-Chief, Journal of Thrombosis and Haemostasis

Walter Ageno, ItalyChairman, Scientific and Standardization Committee (SSC)


20 21

ISTH SSC COMMITTEES ISTH 2017 COMMITTEES

SSC Executive Committee 2016-2018Walter Ageno, Italy SSC ChairmanNicola Mutch, United Kingdom Secretary/Chairman-ElectSabine Eichinger, Austria Immediate Past SSC ChairmanDermot Cox, Ireland Ex-Officio: President, SSC 2018

Standing Committee Chairmen Anthony R. Hubbard, United Kingdom Coagulation StandardsPeter Lenting, France WHO-ISTH Standards Liaison Group

Subcommittee ChairmenJose A. Diaz, United States Animal, Cellular and Molecular Models of ThrombosisKeith B. Neeves, United States BiorheologyMark Crowther, Canada Control of AnticoagulationJecko Thachil, United Kingdom Disseminated Intravascular CoagulationGuy Young, United States Factor VIII, Factor IX and Rare Coagulation DisordersJoost Meijers, the Netherlands Factor XI and the Contact SystemVerena Schroeder, Switzerland Factor XIII and FibrinogenNicola Mutch, United Kingdom FibrinolysisWillem H. Ouwehand, United Kingdom Genomics in Thrombosis and HemostasisMarc Carrier, Canada Hemostasis and MalignancyBas de Laat, the Netherlands Lupus Anticoagulant/Antiphospholipid AntibodiesChristoph Male, Austria Pediatric and Neonatal Thrombosis and Hemostasis Charles Marc Samama, France Perioperative Thrombosis and HemostasisRichard A. Marlar, United States Plasma Coagulation InhibitorsDonald M. Arnold, Canada Platelet ImmunologyPaolo Gresele, Italy Platelet PhysiologyPaul A. Kyrle, Austria Predictive and Diagnostic Variables in Thrombotic DiseaseRienk Nieuwland, the Netherlands Vascular Biology Sandra Haberichter, United States Von Willebrand FactorRezan A. Abdul-Kadir, United Kingdom Women’s Health Issues in Thrombosis and Hemostasis

You are invited to attend the International Society on Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee (SSC) Annual Meeting. Held in Dublin, Ireland, from July 18–21, 2018, the ISTH SSC 2018 meeting is both engaging and informative. It is an excellent and affordable scientific event in the field of thrombosis and hemostasis that brings together the world’s leading experts.

ISTH SSC 2018

JOIN US IN 2018!

JULY 18-21

Join the Conversation!



22 23

ISTH AWARDS

Robert P. Grant Medal

The Robert P. Grant Medal is the highest award of the ISTH. It is presented during the bienni-al ISTH Congress in honor of research achie-vements, organizational activities, support of research activities, facilitation of institutional cooperation and communication, unusual tea-ching or educational initiatives and/or the de-velopment of concepts that result in a clearer understanding of research data.

This medal is named after Robert P. Grant, a renowned cardiologist who spent many years as a representative of the National Institutes of Health in Europe, traveling extensively and facilitating American-European collaboration in medical research and education.

The ISTH Grant Medal will be presented at the Opening Ceremony on Sunday, July 9.

Harold R. Roberts Medal

The ISTH Harold R. Roberts Award honors me-ritorious service to the Scientific and Standardi-zation Committee of the ISTH, beyond expecta-tions and over a significant period of time.

The Roberts Medal will be presented at the President’s Dinner on Monday, July 10.

Biennial Awards for Contributions to Hemostasis (BACH)

The ISTH’s Biennial Awards for Contributions to Hemostasis (BACH) are presented during the ISTH Congress to individuals who, in the opi-nion of their peers, have made significant con-tributions to research and education in blood coagulation.

The Investigator Recognition Awards recognize ISTH members whose accomplishments are in-ternationally regarded as exemplary models of excellence in research and mentoring excellence. The Distinguished Career Awards recognize ISTH members whose career contributions have significantly advanced the scientific communi-ty’s understanding of the diseases and disorders affecting hemostasis.

The ISTH BACH will be presented at the President’s Dinner on Monday, July 10.

The International Society on Thrombosis and Haemostasis (ISTH) invites you to join thousands of the world’s leading experts at the 27th ISTH Congress and 65th Annual Scientific and Standardization Committee (SSC) Meeting in Melbourne, Australia from July 6-10, 2019.

SAVETHE

DATE Join us in 2019!isth2019.org | #ISTH2019


24 25

ISTH 2017 AWARDSISTH AND ISTH 2017 AWARDS

2017 Recipients of the Biennial Awards for Contributions to Hemostasis (BACH)

Distinguished CareerPeter Carmeliet, BelgiumJames Huntington, United KingdomYasuo Ikeda, JapanBernhard Lämmle, GermanyPaula Tracy, United States

Investigator RecognitionRodney Camire, United StatesDouglas Cines, United StatesMark Crowther, CanadaCécile Denis, FranceMortimer Poncz, United States

ISTH 2017 Travel Awards

Travel Award recipients can go to the specific “Travel Award” desk in the Registration Area on the main entrance level of the CityCube Berlin to receive their grant. Grants can be collected between 08:00 on Saturday, July 8, through 12:00 on Tuesday, July 11. See page 513 for more information about travel grants.

Young Investigator Travel AwardsThe Young Investigator Travel Awards are pro-vided in the form of travel grants to medical trainees and young scientists (under 35 years of age as of July 7, 2017) who submitted highly rated abstracts.

Recipients of an ISTH 2017 Young Investigator Travel AwardSonia Aguila, IrelandMikel Allende, SwedenAna Belén Arroyo Rodríguez, SpainNathan Asquith, United KingdomFrancis Ayombil, United StatesElena Barbon, FranceSarah Beck, GermanyIsabelle Becker, GermanyRoelof Hendrik Bekendam, France

Cavan Bennett, United KingdomSeema Bhatlekar, United StatesInga Birkholz, GermanyIngrid Bistervels, the NetherlandsThomas Bonnard, AustraliaEmma Bouck, United StatesJoshua Brown, United StatesJames Robert Byrnes, United StatesThita Chiasakul, ThailandTheodora A.M. Claushuis, the NetherlandsSimon J. Cleary, United KingdomAdela Constantinescu-Bercu, United KingdomRoxane Darbousset, AustraliaKaren De Ceunynck, United StatesAnnika de Jong, the NetherlandsBelén de la Morena-Barrio, SpainMaría Eugenia de la Morena-Barrio, SpainCarsten Deppermann, CanadaDante Disharoon, United StatesIrving Donadon, ItalyCharlotte E.A. Dronkers, the NetherlandsTom Durrant, United KingdomÖzge Erdem, the NetherlandsCindy Espitia, SwitzerlandLine Holtet Evensen, NorwayMichaela Finsterbusch, AustraliaLaura Franco, ItalyRichard Y. Fu, United StatesLewis S. Gall, United KingdomMaxime Gauberti, FranceDorsaf Ghalloussi, United StatesSuvoshree Ghosh, GermanyCinzia Giaccherini, ItalyBenjamin Gillet, FranceKandace Gollomp, United StatesElla Grilz, AustriaSteven Grover, United StatesGiulia Gubbiotti, ItalyShuchi Gupta, GermanyAlexandre Guy, FranceKaitlin Hagan, United StatesLaura M. Haynes, United StatesLena Hell, AustriaJessica Heremans, BelgiumAnette Arbjerg Højen, DenmarkAnne Hollerbach, Germany

Johana Hrdinová, the NetherlandsJennifer Elizabeth Huffman, United StatesVaishali Inamdar, United StatesIsuru Induruwa, United KingdomIvan Ivanov, United StatesSjoert Bernardus Gerardus Jansen, the NetherlandsIan Johnston, United StatesLining Ju, AustraliaSergei Kalabushev, Russian FederationEllie Karampini, the NetherlandsSravya Kattula, United StatesCharlotte Kawecki, FranceOliver Königsbrügge, AustriaAnna Kopec, United StatesKim Jürgen Krott, GermanyJesse D. Lai, CanadaElodie Laridan, BelgiumChristine Lee, AustraliaRobert H Lee, United StatesMarcus Lehmann, United StatesGabriela Lesyk, CanadaLaurens Liesenborghs, BelgiumRandolph Lyde, United StatesSai Ma, ChinaKellie Machlus, United StatesAnnabel Maclachlan, United KingdomJayakumar Manoharan, GermanyMauritia C. Marijnen, the NetherlandsSara Martinez de Lizarrondo, FranceLisa-Marie Mauracher, AustriaHelen McPherson, United KingdomSimone Merlin, ItalyAlison Michels, CanadaAnnachiara Mitrugno, United StatesAmel Mohamadi, FranceBassem M. Mohammed, United StatesGael B. Morrow, United KingdomVincent Muczynski, FrancePatrick Münzer, GermanyMarion Mussbacher, AustriaMagdolna Nagy, the NetherlandsZoltan Nagy, United KingdomPrajeeda M. Nair, United StatesClément Naudin, SwedenManuel Navarro-Oviedo, SpainMiguel A.D. Neves, Canada

Giang N. Nguyen, United StatesGeorg Obermayer, AustriaCristina Olgasi, ItalyFergal O'Shaughnessy, IrelandOliver Pagel, GermanyVerónica Palma-Barqueros, SpainVishal Patel, CanadaAkruti Patel, United StatesMarie-Claude Pelland-Marcotte, CanadaSameera Peraramelli, United StatesVictoria Petermann, GermanyAnastasis Petri, United KingdomIvan Peyron, the NetherlandsSilvia Pignani, ItalyIrina Portier, BelgiumFlorian Posch, AustriaAnna D. Protopopova, United StatesMalgorzata Przeradzka, the NetherlandsCristina Puy, United StatesMichael Quach, United StatesOrla Rawley, CanadaJosé Miguel Rivera-Caravaca, SpainElien Roose, BelgiumManuel Salzmann, AustriaLuuk J.J. Scheres, the NetherlandsMaaike Schillemans, the NetherlandsMaria Isabel Schmidgen, GermanyDavid Emanuel Schmidt, the NetherlandsRogier Matijs Schoeman, United StatesMark Schreuder, the NetherlandsWaltraud Cornelia Schrottmaier, SwedenLisette M. Schütte, the NetherlandsFatemeh Shahneh, GermanyShana A. Shaya, CanadaSuzanne M. Silvis, the NetherlandsSatish Singh, United StatesHanne Skille, NorwayNicoletta Sorvillo, United StatesMarkus Spindler, GermanyBenedicte Stavik, NorwayRebecca Steubing, GermanyMichelle Storage, United StatesSaravanan Subramaniam, GermanyPierre Suchon, FranceRavi Talati, United StatesJulie L. Tarrant, Canada


26 27

ISTH 2017 AWARDSISTH 2017 AWARDS

Mara Toderici, SpainMary I. Underwood, United KingdomBetül Ünlü, the NetherlandsLiselotte M. van der Pol, the NetherlandsNick van Es, the NetherlandsThijs E. van Mens, the NetherlandsIris van Moort, the NetherlandsDaniel Verhoef, the NetherlandsTimo Vögtle, United KingdomJulia Volz, GermanyMinka J.A. Vries, the NetherlandsTony Walsh, United KingdomClaire S. Whyte, United KingdomChristopher Williams, United KingdomOrla Willis Fox, IrelandTine Leona Wyseure, United StatesAizhen Yang, ChinaJennifer Yeung, United StatesZe Zheng, United StatesArtem Zhmurov, Russian FederationMelanie Ziegler, Australia

Reach-the-World Travel Awards

The Reach-the-World Travel Awards are provi-ded in the form of travel grants to clinicians and scientists from Reach-the-World countries to enable participation from all areas of the world in the ISTH 2017 Congress.

Recipients of an ISTH 2017 Reach-the-World Travel AwardMagy Abdelwahab, EgyptMiguel Martin Abelleyro, ArgentinaAncy Abraham, IndiaShariq Ahmed, PakistanRomana Akbar, PakistanMoh'd Mohanad Ahmad Al-Dabet, GermanyJosé Antonio Alvarado Moreno, MexicoMiryam Paola Alvarez-Flores, BrazilYzabella Alves Campos Nogueira, BrazilNadia Arshad, NorwayOmolade Awodu, NigeriaAnna Balandina, Russian FederationErgul Berber, Turkey

Emilse Bermejo, ArgentinaAshish Bhalla, IndiaVolha D. Bichan, BelarusJelena Bodrozic, SerbiaMunira Borhany, PakistanChristina Castro Brommonschenkel, BrazilCarolina Cervio, ArgentinaChatree Chai-Adisaksopha, CanadaChia-Yau Chang, TaiwanXue Chen, ChinaKowit-Yu Chong, TaiwanHéléne Toinét Cronjé, South AfricaLan Dai, ChinaJing Dai, United StatesLina Paola D'Atri, ArgentinaZelda De Lange, South AfricaGabriela de Larrañaga, ArgentinaJean Gabriel de Souza, BrazilCélia Dos Santos, ArgentinaAnjalin Dsouza, IndiaBruno Kosa Lino Duarte, BrazilLuci Dusse, BrazilXuemei Fan, ChinaRoula Farah, LebanonBotheina Farweez, EgyptDaria Fedorova, Russian FederationRoberto J. Fonseca, BrazilMadankumar Ghatge, IndiaDaniel Gonçalves Chaves, BrazilYue Han, ChinaYating Hao, ChinaYang He, ChinaBidossessi Wilfried Hounkpe, BrazilKhon Huynh, VietnamAnastasia Ignatova, Russian FederationAsif Iqbal, BrazilShundong Ji, ChinaJaco Joubert, South AfricaSehar Khaliq, PakistanSumaira Khan, PakistanRuchika Kohli, United KingdomPatcharee Komvilaisak, ThailandOleksii Korzh, UkraineEkaterina Kropacheva, Russian FederationAna Clara Ladeira Cruz, BrazilSupakanya Lasom, Thailand

Huiyuan Li, ChinaYang Li, ChinaRuifang Li-Gao, the NetherlandsLin Lin, United StatesWenjie Liu, ChinaSusan Louw, South AfricaMingen Lyu, ChinaPankaj Malhotra, IndiaRam Lala Mallick, NepalRita Marchi, VenezuelaMarta Martinuzzo, ArgentinaSamuel S. Medina, BrazilHebe Agustina Mena, ArgentinaPredrag Miljic, SerbiaYanan Min, ChinaSilmara A.L. Montalvao, BrazilRobson Queiroz Monteiro, BrazilVania Maris Morelli, the NetherlandsJiny Nair, IndiaR. Natesirinilkul, ThailandDmitry Nechipurenko, Russian FederationBipin Nepal, NepalSergei Obydennyi, Russian FederationHelen Chioma Okoye, NigeriaDorathy Chioma Okpokam, NigeriaFernanda Orsi, BrazilJuvenal Paiva, ArgentinaMariana Sá Pereira, BrazilSilvia Perés, ArgentinaSithakom Phusanti, ThailandBunchoo Pongtanakul, ThailandAlessandra N.L. Prezotti, BrazilClaudia Pamela Radic, ArgentinaAnna Virgínia Calazans Romano, BrazilTheera Ruchutrakool, ThailandRoberta Casagrande Saez, BrazilAna Maria Salazar, VenezuelaRenu Saxena, IndiaMirta Schattner, ArgentinaTanusree Sengupta, IndiaAneeta Shahni, PakistanKhurrum Shahzad, PakistanAnkit Sharma, IndiaWenhong Shen, ChinaTaisiya Shepelyuk, Russian FederationPanlai Shi, China

Neeraj Sidharthan, IndiaSandra Martins Silva Soares, BrazilMichelle Sugimoto, BrazilAnastasia Sveshnikova, Russian FederationNing Tang, ChinaLakshmi Narasimha Rao Thota, IndiaHui-Ju Tsai, TaiwanIkramdin Ujjan, PakistanMaria Luiza Vilela Oliva, BrazilMaximiliano Jesus Villagra Iturre, ArgentinaNatalya Vorobyeva, Russian FederationBiljana Vučković, SerbiaYingchun Wang, United StatesJianbo Wu, ChinaXiaodong Xi, ChinaGabriela Goes Yamaguti-Hayakawa, BrazilJialu Yao, ChinaYuanjie Yu, the NetherlandsKiara Cristina Senger Zapponi, BrazilXian Zhang, ChinaDonglei Zhang, ChinaLitao Zhang, ChinaYIming Zhao, ChinaXiaojuan Zhao, United KingdomZeping Zhou, ChinaMingqing Zhu, China


28 29

ABOUT THE ISTHABOUT THE ISTH

The International Society on Thrombosis and Haemostasis (ISTH) is a global not-for-profit membership organization advancing the under-standing, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

The Society is dedicated to transformative scientific discoveries and clinical practices, the development of young professionals and the education of physicians, scientists and allied health professionals wherever they may live.

At the ISTH, we initiate and promote educati-on and outreach initiatives, research activities, scientific meetings, peer-reviewed publications, expert committees and the development of standards allowing a common language and approach to basic and clinical science all over the world.

Through its mission of building community and advancing knowledge, the Society also offers a complete portfolio of publications. They in-clude the new open-access journals: Journal of Thrombosis and Haemostasis (JTH) and Rese-arch and Practice in Thrombosis and Haemost-asis (RTH).

The Society also leads World Thrombosis Day on 13 October each year to focus attention on the often overlooked and misunderstood condition of thrombosis.

Today, the ISTH is the leading thrombosis-and hemostasis-related professional organization in the world with more than 4,500 members in 94 countries.

A highly-regarded Society poised on the leading edge of science, the ISTH offers a comprehen-sive membership that includes the following benefits:

ISTH membership benefits:

• Subscription and exclusive discounts on open access article submissions to the of-ficial ISTH publications: Journal of Throm-bosis and Haemostasis (JTH) and Research and Practice in Thrombosis and Haemost-asis (RTH)

• Priority registration and discounted fees for ISTH meetings and congresses

• Full access to the online ISTH Academy we-binars, webcasts and courses with Continu-ing Medical Education (CME) at academy.isth.org

• Access to ISTH member-only resources, in-cluding an increasing array of educational materials, communication and membership directory

• Eligibility to apply for travel grants, fellows-hips and awards

• Access to the ISTH Career Center and exclusive discounts to post job openings

• Opportunity to hold elected and/or appoin-ted offices, nominate and vote on Society matters

For more information or to join the ISTH, please contact:

ISTH Headquarters610 Jones Ferry Road, Suite 205Carrboro, NC 27510 USAT: +1 919-929-3807F: +1 919-929-3935E: [email protected]: www.isth.org

Join the conversation online!

Use #ISTH2017

www.facebook.com/internationalsocietythrom-bosisandhaemostasis

www.facebook.com/worldthrombosisday

www.twitter.com/isthwww.twitter.com/jthjournal www.twitter.com/rpthjournalwww.twitter.com/thrombosisday

www.youtube.com/user/ IntlSocThrombHemo

www.linkedin.com/company/2253026/ www.linkedin.com/groups/7025460

www.instagram.com/isthofficeteam/ www.instagram.com/worldthrombosisday/



30 31

NOTES

Program Overview




32 33

Saturday July 8, 2017

Registration 8:00–18:00

SSC & Education Program 1

9:00–13:15


14:00–18:15

Sunday July 9, 2017


Master Classes (ticket needed)

7:00–7:45

Nurses Sessions

8:00–17:30


8:00–12:15

World Thrombosis

Day Session

12:15–14:00

YIA/RtW Reception

12:15–13:00

Special Sessions

13:00–14:00

Supported Symposia 14:15–15:45


Opening Ceremony

18:15–19:15

Welcome Reception

in the Exhibition Halls19:15–20:45

Friday July 7, 2017


Monday July 10, 2017

Registration 6

:30

–19

:00


7:00–7:45

Nurses S

essions 8

:00

–17

:30

State of the Art 8:00–9:15

Oral Communications 9:30–10:45

Exhibition 1

0:3

0–1

7:0

0

Plenary Session 11:15–12:00

Lunch, Poster Session & Industry Exhibits

12:00–13:15

Product Theater

Presentations 12:15–13:00


Career Development

13:15–14:15

Abstract Symposia 14:45–16:15



Tuesday July 11, 2017

Registration 6

:30

–19

:00


7:00–7:45



Exhibition 1

0:3

0–1

7:0

0



12:00–13:15

Product Theater Presentations 12:15–13:00

Supported Symposia

13:15–14:30

Career Development 13:15–14:15




ISTH 2017 Charity Run & Walk

20:00–21:00

Victory Ceremony

Program Overview Program Overview




34 35

Wednesday, July 12, 2017

Registration 6

:30

–19

:00


7:00–7:45



Exhibition 1

0:3

0–1

7:0

0



12:00–13:15

Product Theater Presentations 12:15–13:00

Supported Symposia

13:15–14:30

Career Development 13:15–14:15



ISTH 2017 Congress

Networking Evening

18:30–23:30

Thursday, July 13, 2017

Registration 7

:30

–15

:00




Highlights of ISTH 12:30–13:30

Closing Remarks 13:30–13:45

Program Day by Day

Program Overview




36 37

A1 A2 A3 A5 A6 A7 A8

09:00

Predictive and Diagnostic Variables

in Thrombotic Disease

Lupus Anticoagulant/

Antiphospholipid Antibodies

Platelet Immunology

Women‘s Health Issues in Thrombosis and

Hemostasis

Vascular Biology

Factor VIII, IX and Rare Coagulation Disorders,

Part 1Fibrinolysis

09:00

09:30 09:30

10:00 10:00

10:30 10:30

11:00 Coffee Break Coffee Break 11:00

Predictive and Diagnostic Variables

in Thrombotic Disease

Lupus Anticoagulant/

Antiphospholipid Antibodies

Platelet Immunology

Women‘s Health Issues in Thrombosis and

Hemostasis

Vascular Biology


Part 1Fibrinolysis

11:30 11:30

12:00 12:00

12:30 12:30

13:00 13:00

Lunch Lunch13:30 13:30

14:00

Plasma Coagulation Inhibitors

Factor XIII and Fibrinogen

Von Willebrand

Factor

Pediatric and Neonatal Thrombosis

and HemostasisBiorheology Hemostasis

& Malignancy

Perioperative Thrombosis and

Hemostasis

14:00

14:30 14:30

15:00 15:00

15:30 15:30

16:00 Coffee Break Coffee Break 16:00

Plasma Coagulation Inhibitors

Factor XIII and Fibrinogen

Von Willebrand

Factor

Pediatric and Neonatal Thrombosis

and HemostasisBiorheology Hemostasis

& Malignancy

Perioperative Thrombosis and

Hemostasis

16:30 16:30

17:00 17:00

17:30 17:30

18:00 18:00

18:30 18:30

Saturday, July 8, 2017 Saturday, July 8, 2017




38 39

Hall B A1 A2 A3 A5 A6 A7 A8Exhibition Hall 2.2-4.5-6.2

M1 R2-R11 A4 M6 M8

07:00Master Classes(ticket needed)

07:00

07:30 07:30

08:00

Factor XI & the Contact

System

Genomics in Thrombosis and

Hemostasis

Platelet Physiology

Control of Anti-

coagulation

Disseminated Intravascular Coagulation


Part 2

Animal, Cellular and Molecular Models of

Thrombosis

08:00

08:30 08:30

09:00

Nurses Forum

: O

ptimal O

utcomes for P

atients and Families:

The Contribution of N

urses in 20

17

and Beyond

09:00

09:30 09:30

10:00 Break Break Break 10:00

Factor XI & the Contact

System

Genomics in Thrombosis and

Hemostasis

Platelet Physiology

Control of Anti-

coagulation

Disseminated Intravascular Coagulation


Part 2

Animal, Cellular and Molecular Models of

Thrombosis

10:30 10:30

11:00 11:00

11:30 11:30

12:00 12:00

Lunch Lunch Lunch

World Thrombosis

Day: Building Awareness

and Elevating Impact for the Global Burden of Thrombosis

YIA/RtW Reception12:30 12:30

13:00 Adopting New VTE and Cancer Guidelines: Is

Clinical Practice Improving?

Building Capacity Globally:

The Impact and Future of the IHTC and

Reach-the-World Programs

13:00

13:30 13:30

14:00 14:00

Supported Symposium

Supported Symposium

Supported Symposium

Supported Symposium

Supported Symposium

Supported Symposium

14:30 14:30

15:00 15:00

15:30 15:30

Coffee Break Coffee Break16:00 16:00

Supported Symposium

Supported Symposium

Supported Symposium

Supported Symposium

Supported Symposium

Supported Symposium

Supported Symposium

16:30 16:30

17:00 17:00

17:30 17:30

18:00 18:00

Opening Ceremony

18:30 18:30

19:00 19:00

Welcome Reception19:15 – 20:45

Sunday, July 9, 2017 Sunday, July 9, 2017




40 41

Hall B A1 A2 A3 A5 A6 A7 A8 New York London Berlin Budapest Helsinki 1 Helsinki 2 ParisExhibition Hall

2.2-4.2-6.2M1 R2-R11 R5-R8

07:00 Master Classes(ticket

needed)

07:00

07:30 07:30

08:00What

Happens After Acute VTE?

Regulation of Extra-cellular

Proteolysis

Leukocytes in Athero-sclerosis

Inflamma-tion and Barrier

Function

ISTH-WFH Joint

Session: Novel

Functions of VWF

Animal Models of Thrombo-sis and Hemost-

asis

Life and Death of Platelets

Nurses Forum

: Optim

al Outcom

es for Patients and Fam

ilies: The C

ontribution of Nurses in 2

01

7 and B

eyond

08:00

08:30 08:30

09:00 09:00

Break Break 09:30

Platelet Signaling

1

Cellu-lar and

Molecular Mecha-nisms of Fibrinoly-

sis

Animal Models in Throm-bosis

Platelets in

Develop-ment and

Malig-nancy

Mechanis-ms of (Pro)

Platelet Production

Protease-Activated Receptors

Rare Bleeding Disorders

VWF: Biosynthe-

sis and Me-chanisms of Action

Predictors of Throm-boembo-

lism

Pediatric Throm-bosis

ADAMTS 13 and

TTP Basic

Future Biothera-

peutics for Hemophi-lia A and B

09:30

10:00 10:00

10:30 10:30

Coffee Break in Exhibition Halls Coffee Break in Exhibition Halls11:00 11:00

Marion I. Barn-hart Memorial

Lecture: Platelet

Signaling

11:30 11:30

12:00

Lunch, Poster Session and Industry Exhibition in Exhibition Halls


Poster Session

12:00

Product Theater12:30 12:30

13:00 13:00

Supported Sym-

posium

Supported Sym-

posium

Supported Sym-

posium

Supported Sym-

posium

Supported Sym-

posium

Supported Sym-

posium

Supported Sym-

posium

Career Develop-

ment

13:30 13:30

14:00 14:00

14:30 Break Break 14:30

Clinical Research and Out-comes in Hemophi-

lia

Structural Biology in Coagula-

tion

Microbiota as an

Environ-mental Risk

Factor

Platelet Diagno-

stics

Autoim-mune

Throm-bocytope-

nia

Antiphos-pholipid

SyndromeFXIII

Platelet Receptor Signaling

Regulation of Vascular

Func-tion by

Noncoding RNAs

Bleeding Manage-

ment Under Oral Anticoagu-

lation

Risk Factors

for Carotid Atherosc-lerosis and

Stroke

Safety of Blood Compo-

nents and Blood

Transfu-sions

Rare Bleeding Disorders

15:00 15:00

15:30 15:30

16:00 16:00


Kenneth M. Brinkhous Memorial

Lecture: Hemo-philia Therapy - From Disease

to Cure

17:00 17:00


Gene Therapy for

Hemo-philia: Clinical

Anticoa-gulant

Regulators (Protein C, TFPI, AT)

Contact Pathway FVIII/IX

Platelets in Throm-

bosis

Platelet Life Span and Clea-

rance

Throm-bolysis in Disease

Immune Aspects

of Venous Throm-bosis

Cancer Associated Thrombo-sis: Risk

Prediction

VWF: Functional Implica-tions in

Health and Disease

Long-Term VTE Outco-mes and Compli-

cations of Treatment

Hemorr-hagic

Disorders: Pediatric Aspects

Hemophi-lia: Animal Models of Inhibitor

Formation

18:00 18:00

18:30 18:30

19:00 19:00

Monday, July 10, 2017 Monday, July 10, 2017




42 43

Hall B A1 A2 A3 A5 A6 A7 A8 New York London Berlin Budapest Helsinki 1 Helsinki 2 ParisExhibition Hall

2.2-4.2-6.2R2-R11 R5-R8

07:00 Master Classes (ticket

needed)

07:00

07:30 07:30

08:00

Novel Therapies for Hemo-

philia

Stem Cell

Enginee-ring

Novel Regulatory

Mecha-nisms of Coagula-

tion

Coagu-lation

Signaling

Current Pathophy-siological

Concepts of Thrombotic Microangio-

pathies

PlateletsIn

Develop-ment and Vascular Integrity

Venous Thromboem-bolism: Have

We Made Progress Sin-ce the Last Guidelines?

08:00

08:30 08:30

09:00 09:00

Break Break 09:30

Late Breaking

Animal Models in Hemost-

asis

Platelets and

Extracel-lular Com-pounds in Athero-

thrombosis

Coagula-tion and

Cancer

Platelet Function in Inflam-

mation

Platelet Signaling

2

VWF: Mecha-nisms of Clearance

Genetic Throm-

botic Risk Factors

Progress in Atrial

Fibrillation Manage-

ment

HITFuture The-rapies for

Hemophilia and VWD

Hemophilia: Clinical Science

New Approaches in Research and Diagno-

stics

Acquired Bleeding Disorders and DIC

09:30

10:00 10:00

10:30 10:30


Fritz Koller Plenary Lecture: Vascular

Diseases and Metabolism

11:30 11:30

12:00



PosterSession

12:00

Product Theater

12:30 12:30

13:00 13:00

Supported Sym-

posium

Supported Sym-

posium

Supported Sym-

posium

Supported Sym-

posium

Supported Sym-

posium

Supported Sym-

posium

Supported Sym-

posium

Career Develop-

ment

13:30 13:30

14:00 14:00

14:30 Break 14:30

VTE - Difficult

Decisions

TAFI and Other

Inhibitors of Fibri-nolysis

Coagulati-on System

and Athero-

thrombosis

Stem Cells,

Hetero-geneity,

Differenti-ation and Repro-

gramming

Extracellu-lar Nucleo-somes and

NETs in Throm-bosis

Platelets From

Bench to Clinic

Inherited Platelet

Disorders

Regulation of Coagu-

lation

Women‘s Issues in Venous Throm-

boembo-lism

Factor VIII Inhibitors in Conge-nital and Acquired Hemophi-

lia

Pediatric Thrombosis and Blee-

ding

Gene Editing and

Cellular Therapy

Micopar-ticles

15:00 15:00

15:30 15:30

16:00 16:00


Hanns Gotthard Lasch Plenary

Lecture: Management of

Thromboem-bolism

17:00 17:00


Extending Anticoa-gulation: Benefits Versus Risks

Intrinsic Coagu-lation

Pathway

Novel Pathways in Athero-sclerosis

Innate Immune

Cells

Coagu-lation

Proteins Beyond Hemost-

asis

Mega-karyopoie-

sis and Platelet

Biogenesis In Vivo

Platelet Antago-

nists

Cancer Associated

Throm-bosis

Factor VIIIa Mimetic Drugs:

Pharmacody-namics and Monitoring

Thrombo-philia

Thrombo-Embolic Di-sease - Risk Factors and Biomarkers

Manage-ment of Bleeding

and Trauma

Hemophilia: Basic

Science

18:00 18:00

18:30 18:30

19:00 19:00

Tuesday, July 11, 2017 Tuesday, July 11, 2017




44 45

Hall B A1 A2 A3 A5 A6 A7 A8 New York London Berlin Budapest Helsinki 1 Helsinki 2 Paris Exhibition Hall 2.2-4.2-6.2 R2-R11 R5-R8

07:00 Master Classes (ticket

needed)

07:00

07:30 07:30

08:00

Risk Factors of Venous

Thromboem-bolism

Neurobio-logy and Stroke

Factor XI and XII in Blood

Clotting and Beyond

Sepsis and Immunity

Platelets Beyond

Thrombosis

Metabolic Regulation and Vascu-lar Growth

Control

Hereditary Platelet

Disorders

08:00

08:30 08:30

09:00 09:00

Break Break09:30

Advances in Thrombo-

prophylaxis

Platelet Ac-tivation and Secretion

Structural Aspects of Fibrinogen and Fibrin

Regulation of Coagula-

tion

Sepsis and Hemostatic

Factors

Regula-tion and Function

of Platelet Integrins

Platelets in Infection

and Immu-nity

Translatio-nal Aspects in Inherited

Platelet Disorders

Predicting and Ma-

naging the Post-Throm-

botic Syndrome

Hemophi-lia: Risk of Inhibitor

Formation

Coagulati-on in Ext-racorporal Circulation

ADAMTS 13 and

TTP Clinical

Gene Therapy for

Hemo-philia:

Preclinical

09:30

10:00 10:00

10:30 10:30


Oscar D. Rat-noff Memorial

Lecture: Tissue Factor

Biology

11:30 11:30

12:00



Poster Session

12:00

Product Theater12:30 12:30

13:00 13:00

Supported Symposium

Supported Sym-

posium

Supported Sym-

posium

Supported Sym-

posium

Supported Sym-

posium

Career Develop-

ment

13:30 13:30

14:00 14:00


Clinical Ma-nagement

of Bleeding Disorders

New Aspects of Fibrinogen

Pathoge-nesis in

Thrombosis: Basic

Signaling Mechanis-ms in the

Vasculature

Ischemic Injury in

Heart and Brain

The Role of Platelets in Immuno-

competence

New Technology to Study Platelets

Coagula-tion and Immune

Responses

Manage-ment

Strategies in Acute VTE

VTE - Gaps of

EvidenceHIT

Women‘s Issues in Throm-

bosis and Hemost-

asis

miRNA as Diagnostic Biomarkers

15:00 15:00

15:30 15:30

16:00 16:00


Erwin Deutsch Plenary Lecture:

Transfusion Medicine and Cell Therapies

17:00 17:00

17:30 17:30

Wednesday, July 12, 2017 Wednesday, July 12, 2017




46 47

Hall B A1 A2 A3 A5 A6 A7 A8 New York London Berlin Budapest Helsinki 1

08:00

Megakary-poiesis

Epigenetic and Genetic Determinants of Hemostasis and Throm-

bosis

Nanotech-nology and Microflui-

dics in Diagnostic Approaches

Managing Thrombosis in Children

Inflamma-tion and Athero-

thrombosis

ISTH-EHA Joint Sessi-on: Cancer-Associated Thrombosis

Inhibitors in Hemophilia

08:00

08:30 08:30

09:00 09:00

Break Break09:30

Proficiency Testing and

Quality Control

Platelet Receptors

Vessel Wall and

Angiogenesis

Platelet Proteomics

and Genomics

Inherited Platelet

Disorders

Platelets and Inflammation

Regulation of Thrombosis and Beyond

Coagulation Factors and Inhibitors

Anticoagulation in the Real

World

DOACs and Beyond:

Translational Aspects

Future Gene and Cell Based Therapies for Hemophilia

Platelet Disorders, Acquired

09:30

10:00 10:00

10:30 10:30

Coffee Break Coffee Break11:00 11:00

Sol Sherry Memorial

Lecture: From Genomes to Stem Cells

11:30 11:30

12:00 12:00

12:30

Highlights of ISTH

12:30

13:00 13:00

13:30 13:30

14:00 14:00

Thursday, July 13, 2017 Thursday, July 13, 2017



48 49

NOTES

SSC and Educational Program

SSC PROGRAMSSC PROGRAM


50 51

Sat

urda

y

Saturday, July 8, 2017SSC Program

09:00 – 11:00 A1

SSC SessionPredictive and Diagnostic Variables in Thrombotic DiseaseChairman: Paul A. Kyrle, AustriaCo-Chairmen: Cecilia Becattini, Italy, Suzanne Cannegieter, the Netherlands, Geert-Jan Geersing, the Netherlands, John-Bjarne Hansen, Norway, Gregoire le Gal, France, Marc Righini, Switzerland 09:00 – 09:05 Welcome

Paul Kyrle, Austria

Diagnosis of VTEModerators: Gregoire le Gal, France, Marc Righini, Switzerland

09:05 – 09:15 Disease Prevalence Dependent Failure Rates

Frederikus Klok, the Netherlands 09:15 – 09:30 Adjudication of Death from PE

Philippe Girard, France

09:30 – 09:45 Common Data Elements ProjectGregoire le Gal, France

Ongoing Clinical StudiesModerators: Suzanne Cannegieter, the Netherlands, Geert-Jan Geersing, the Netherlands

09:45 – 09:55 VALID

Lisbeth Eischer, Austria 09:55 – 10:05 VISTA

Geert-Jan Geersing, the Netherlands 10:05 – 10:15 L-TRiP

Suzanne Cannegieter, the Netherlands 10:15 – 10:25 Apidulcis

Paolo Prandoni, ItalyGualtiero Palareti, Italy

10:25 – 10:35 HypercanMarina Marchetti, Italy

10:35 – 10:40 PecanGeert-Jan Geersing, the Netherlands

10:40 – 10:45 HOT-PEStavros Konstantinides, Germany

10:45 – 10:50 HOME-PEPierre-Marie Roy, France

10:50 – 10:55 THEIA

Frederikus Klok, the Netherlands 10:55 – 11:00 CLOT-3

Scott Stevens, United States

09:00 – 11:00 A2

SSC SessionLupus Anticoagulant/Antiphospholipid AntibodiesChairman: Bas de Laat, the NetherlandsCo-Chairmen: Maria Laura Bertolaccini, United Kingdom, Katrien Devreese, Belgium, Doruk Erkan, United States, Masahiro Ieko, Japan, Rolf T. Urbanus, the Netherlands, Denis G. Wahl, France

09:00 – 09:15 Update of the Multicenter Study on Solid Phase AssaysKatrien Devreese, Belgium

09:15 – 09:30 Cut-Off Values for Solid Phase Assays

Katrien Devreese, Belgium 09:30 – 09:40 Hydroxychloroquine for Secondary Prevention of Relapses in Primary

Antiphospholipid, SyndromeCristina Belizna, France

09:40 – 10:00 First Results out of the Multicenter Study on the Role of IgM in APS

Walid Chayoua, the Netherlands 10:00 – 10:10 New Subset for Antiphospholipid Antibodies for Diagnosis of Antiphospholipid

SyndromeKenji Oku, Japan

10:10 – 10:20 APTT Mixing Test for Diagnosis of the Lupus Anticoagulant

Osamu Kumano, Japan

10:20 – 10:35 Even More on the Great Mixing Test DebateGary Moore, United Kingdom

SS

C &

Edu

cati

onal

P

rogr

am



52 53

Sat

urda

y

10:35 – 10:55 Update on Treatment of APS Patients with DOACsVittorio Pengo, Italy

10:55 – 11:00 Trial on Rivaroxaban Versus Warfarin for Stroke Patients With

Antiphospholipid Syndrome, With or Without SLE (RISAPS)Hannah Cohen, United Kingdom

09:00 – 11:00 A3

SSC SessionPlatelet ImmunologyChairman: Donald Arnold, CanadaCo-Chairmen: Tamam Bakchoul, Germany, Brian Curtis, United States, Shigeki Miyata, Japan, Francois Mullier, Belgium, Rachel Petermann, France, Christopher M. Ward, Australia 09:00 – 09:20 Welcome and Introduction

Donald Arnold, Canada

Immune ThrombocytopeniaModerators: Shigeki Miyata, Japan, Francois Mullier, Belgium

09:20 – 09:40 Clinical and Laboratory Evaluation of Patients With Suspected ITP: IS TH-SSC Consensus on a Diagnostic AlgorithmDonald Arnold, Canada

09:40 – 10:00 Platelet Counting: Current Issues and Solutions

Francois Mullier, Belgium 10:00 – 10:20 Unconventional Destruction Pathways in ITP: Do We Need New Diagnostic Tools?

Tamam Bakchoul, Germany Neonatal Alloimmune Thrombocytopenia Moderators: Brian Curtis, United States, Rachel Petermann, France

10:20 – 10:40 Neonatal Alloimmune Thrombocytopenia in France and Switzerland:

Towards a Standardization of Our PracticeFrançoise Boehlen, SwitzerlandGérald Bertrand, France

10:40 – 11:00 Improving New and Old Testing Methods for Neonatal Alloimmune

Thrombocytopenia: Fetal Genotyping and Monoclonal Antibody-Immobilization of Platelet Antigen Testing with the apDia Kit.Rachel Petermann, France

09:00 – 11:00 A5

SSC SessionWomen's Health Issues in Thrombosis and HemostasisChairman: Rezan Kadir, United KingdomCo-Chairmen: Claudia Chi, Singapore, Hannah Cohen, United Kingdom, Ian A. Greer, United Kingdom, Susan Halimeh, Germany, Predrag Miljic, Serbia, Maha Othman, Canada Welcome and IntroductionModerator: Rezan Kadir, United Kingdom

09:00 – 09:05 Outline of the SSC and Overview of Activities

Rezan Kadir, United Kingdom 09:05 – 09:10 Report on the Women's Health Issues in Thrombosis and Hemostasis

Symposium 2017Benjamin Brenner, Israel

Subcommittee Session IModerators: Hannah Cohen, United Kingdom, Susan Halimeh, Germany

09:10 – 09:30 The Use of IVC Filter in Pregnancy

Maeve P. Crowley, Ireland 09:30 – 09:50 Thrombolysis (Systemic or Catheter Directed) in Pregnancy

James Douketis, Canada 09:50 – 10:10 Paroxysmal Nocturnal Hemoglobinuria (PNH) in Pregnancy

Morag Griffin, United Kingdom 10:10 – 10:30 Anti-Thrombin Deficiency in Pregnancy

Hannelore Rott, Germany 10:30 – 10:40 Ligneous Conjunctivitis in Women

Pratima Chowdary, United Kingdom 10:40 – 10:50 Pelvic Vein Thrombosis

Tejal Amin, United Kingdom 10:50 – 11:00 Risks of Thromboembolism Associated With Hormonal Contraceptives in

Japanese Women Compared to Western WomenTakao Kobayashi, Japan

SS

C &

Edu

cati

onal

P

rogr

am



54 55

Sat

urda

y

09:00 – 11:00 A6

SSC SessionVascular BiologyChairman: Rienk Nieuwland, the NetherlandsCo-Chairmen: Alexander Brill, United Kingdom, Chris Gardiner, United Kingdom, Emma C. Josefsson, Austrailia, Anna Randi, United Kingdom, Florence Sabatier, France, Pia Siljander, Finland

Extracellular VesiclesModerators: Chris Gardiner, United Kingdom, Pia Siljander, Finland

09:00 – 09:15 The Complex Relationship Between Low Density Lipoprotein and Extracellular

VesiclesPia Siljander, Finland

09:15 – 09:35 Measuring Extracellular Vesicle Concentrations: Standardize the Unknown

Edwin van der Pol, the Netherlands

09:35 – 09:45 New Strategies for Detection of Leucocyte-Derived Microvesicles by Fluo-Sensitive Flow CytometryRomaric Lacroix, France

09:45 – 10:00 Standardization of Vesicle Detection by Flow Cytometry

Rienk Nieuwland, the Netherlands Neutrophil Extracellular TrapsModerator: Alexander Brill, United Kingdom

10:00 – 10:20 Measuring NETsArturo Zychlinsky, Germany

10:20 – 10:40 Histone Citrullination as a Marker of NETosis in Mice

Kim Martinod, Belgium 10:40 – 11:00 A View on Challenges and Pitfalls When Studying Phagocyte Extracellular Traps

Maren von Köckritz-Blickwede, Germany

09:00 – 11:00 A7

SSC SessionFactor VIII, IX and Rare Coagulation Disorders, Part 1Chairman: Guy Young, United StatesCo-Chairmen: Manuel Carcao, Canada, Peter Collins, United Kingdom, Alfonso Iorio, Italy, Gili Kenet, Israel, Johnny Mahlangu, South Africa, Maria Elisa Mancuso, Italy

09:00 – 09:10 IntroductionGuy Young, United States

Achieving Higher Factor Levels: The "New" NormalModerators: Peter Collins, United Kingdom, Johnny Mahlangu, South Africa

09:10 – 09:40 FVIII: What Is an Achievable Trough With Current Products and at What Cost

Alfonso Iorio, Canada 09:40 – 10:10 FIX: What Is an Achievable Trough With Current Products and at What Cost

David Keeling, United Kingdom 10:10 – 10:50 Debate: Extended Half-Life Factor IX Versus Gene Therapy

Manuel Carcao, CanadaK. John Pasi, United Kingdom

10:50 – 11:00 Discussion

09:00 – 11:00 A8

SSC SessionFibrinolysisChairman: Nicola Mutch, United KingdomCo-Chairmen: Paul Kim, Canada, Krasimir Kolev, Hungary, Colin Longstaff, United Kingdom, Victoria Ploplis, United States, Guy Reed, United States, Tetsumei Urano, Japan

Standardization of Fibrinolytic Proteins 09:00 – 09:15 Standardization of D-dimer

Colin Longstaff, United Kingdom 09:15 – 09:30 Development of Shiny App Tools to Simplify and Standardize the Analysis of

Hemostasis Assay DataColin Longstaff, United Kingdom

SS

C &

Edu

cati

onal

P

rogr

am



56 57

Sat

urda

y

Defining Trauma Induced Coagulopathy (TIC) and Disseminated Intravascular Coagulation (DIC) 09:30 – 09:50 Coagulopathy of Traumatic Brain Injury: Pathophysiologic Origins Distinct From

Disseminated Intravascular CoagulationMark Walsh, United States

09:50 – 10:10 Viscoelastic Technology to Define TIC

Klaus Görlinger, Germany 10:10 – 10:30 Shock Induced Endotheliopathy (SHINE) and TIC

Pär Ingeman Johansson, Denmark 10:30 – 11:00 Activation of the Hemostasis System in Gram- and Gram+ Sepsis

Francis Castellino, United States

11:15 – 13:15 A1

SSC SessionPredictive and Diagnostic Variables in Thrombotic DiseaseChairman: Paul A. Kyrle, AustriaCo-Chairmen: Cecilia Becattini, Italy, Suzanne Cannegieter, the Netherlands, Geert-Jan Geersing, the Netherlands, John-Bjarne Hansen, Norway, Gregoire le Gal, France, Marc Righini, Switzerland

Education Session Moderators: John-Bjarne Hansen, Norway, Paul Kyrle, Austria

11:15 – 11:45 Big Data and IPD-Meta-Analysis: Novel Concepts for Future VTE Research

Geert-Jan Geersing, the Netherlands 11:45 – 12:15 Management of Pulmonary Embolism in Pregnancy

Cecilia Becattini, Italy Prediction of VTE Moderator: Cecilia Becattini Italy

12:15 – 12:35 D-Dimer Measured at Diagnosis of First Venous Thromboembolism and Future

Risk of Cancer and RecurrenceEsben Bjøri, Norway

12:35 – 12:55 Impact of Prothrombotic Genotypes on the Risk of Venous Thromboembolism

in CancerSigrid Braekkan, Norway

12:55 – 13:15 Discovery of Novel Biomarkers of Venous Thromboembolism by Plasma Proteomics

Jacob Odeberg, Sweden

11:15 – 13:15 A2

SSC SessionLupus Anticoagulant/Antiphospholipid AntibodiesChairman: Bas de Laat, the NetherlandsCo-Chairmen: Maria Laura Bertolaccini, United Kingdom, Katrien Devreese, Belgium, Doruk Erkan, United States, Masahiro Ieko, Japan, Rolf T. Urbanus, the Netherlands, Denis G. Wahl, France

Education Session 11:15 – 11:45 From Antibody-Antigen Structure to Diagnosis of APS Patients

Bas de Laat, the Netherlands

11:45 – 12:15 Clinical Challenges Facing an APS PatientDoruk Erkan, United States

12:15 – 12:30 Thrombin Generation and APS: Standardization of Assays

Romy Kremers, the Netherlands 12:30 – 12:45 Thrombin Generation Characteristics in APS According to Antiphospholipid

Antibody ProfileDenis Wahl, France

12:45 – 13:05 What Don't We Know About APS?

Philip de Groot, the Netherlands 13:05 – 13:15 APS-Mediated Complement Activation

Jacob Rand, United States

11:15 – 13:15 A3

SSC SessionPlatelet ImmunologyChairman: Donald Arnold, CanadaCo-Chairmen: Tamam Bakchoul, Germany, Brian Curtis, United States, Shigeki Miyata, Japan, Francois Mullier, Belgium, Rachel Petermann, France, Christopher M. Ward, Australia

Education Session 11:15 – 11:45 New Diagnostic Tools for Neonatal Alloimmune Thrombocytopenia

Ulrich J. Sachs, Germany 11:45 – 12:15 State of the Art Diagnostic Strategies for Heparin Induced Thrombocytopenia

Theodore Warkentin, Canada

SS

C &

Edu

cati

onal

P

rogr

am



58 59

Sat

urda

y

Heparin-Induced ThrombocytopeniaModerators: Tamam Bakchoul, Germany, Chris Ward, Australia

12:15 – 12:35 Nationwide Heparin-Induced Thrombocytopenia (HIT) Registry: Towards

Appropriate Diagnosis and Treatment of HIT in JapanShigeki Miyata, Japan

12:35 – 12:55 Cellular Response to PF4/Heparin Stimulation

Ischac Nazy, Canada

12:55 – 13:10 Multicenter Study to Validate Whole Blood Aggregometry for Testing of HIT Antibodies in Comparison to Washed Platelet Assays: Validation of Heparin-Induced Multi-Electrode Aggregometry Consensus ProtocolChris Ward, Australia

13:10 – 13:15 Closing Remarks


11:15 – 13:15 A5

SSC SessionWomen's Health Issues in Thrombosis and HemostasisChairman: Rezan Kadir, United KingdomCo-Chairmen: Claudia Chi, Singapore, Hannah Cohen, United Kingdom, Ian A. Greer, United Kingdom, Susan Halimeh, Germany, Predrag Miljic, Serbia, Maha Othman, Canada

Educational Session ModeratorsMaha Othman, United Kingdom, Ian Greer, United Kingdom

11:15 – 11:45 Harnessing the Power of Next Generation Sequencing for the Diagnosis of

Bleeding Disorders in WomenKeith Gomez, United Kingdom

11:45 – 12:15 DOACs and Women - Overview

Jan Beyer-Westendorf, Germany Subcommittee Session II - Registries and ProjectsModerators: Ida Martinelli, Italy, Predrag Miljic, Serbia

12:15 – 12:25 The Use of Thrombo-Elastography in Pregnancy: Registry

Maha Othman, Canada 12:25 – 12:35 PPH Core Outcome Set

Beverley Hunt, United Kingdom

12:35 – 12:45 PPH and Tranexamic Acid - WOMAN TrialBeverley Hunt, United Kingdom

12:45 – 12:55 Artemis – The YEARS Diagnostic Study in Pregnant Patients With Symptomatic PE

Menno Huisman, the Netherlands 12:55 – 13:05 On-Line International Survey on Management of Hormonal Contraceptive Use

After Diagnosis of an Acute VTEFrederikus Klok, the Netherlands

13:05 – 13:15 Assessment of the Thrombogenic Potential of Ovarian Stimulation / in Vitro

FertilizationAngela Pereira, United KingdomMaria Efthymiou, United Kingdom

11:15 – 13:15 A6

SSC SessionVascular BiologyChairman: Rienk Nieuwland, the NetherlandsCo-Chairmen: Alexander Brill, United Kingdom, Chris Gardiner, United Kingdom, Emma C. Josefsson, Australia, Anna Randi, United Kingdom, Florence Sabatier, France, Pia Siljander, Finland

Educational Session: AngiogenesisModerator: Rienk Nieuwland, the Netherlands

11:15 – 11:45 From Cells to Networks – Mechanisms in Vascular Patterning

Holger Gerhardt, Germany 11:45 – 12:15 Crosstalk Between the Hemostatic System and Angiogenesis

Anna Randi, United Kingdom

Round Table Discussion on Standardization of Measuring Endothelial Progenitor CellsModerator: Chris Gardiner, United Kingdom

12:15 – 12:45 Blood Outgrowth Endothelial Cells

Anna Randi, United KingdomFlorence Sabatier, FranceDavid Smadja, FranceJuan Melero-Martin, United StatesJeroen Eikenboom, the NetherlandsEster Weijers, the Netherlands

SS

C &

Edu

cati

onal

P

rogr

am



60 61

Sat

urda

y

12:45 – 13:15 Endothelial Progenitor CellsDavid Smadja, FranceFlorence Sabatier, FranceGian Paolo Fadini, Italy

11:15 – 13:15 A7

SSC SessionFactor VIII, IX and Rare Coagulation Disorders, Part 1Chairman: Guy Young, United StatesCo-Chairmen: Manuel Carcao, Canada, Peter Collins, United Kingdom, Alfonso Iorio, Italy, Gili Kenet, Israel, Johnny Mahlangu, South Africa, Maria Elisa Mancuso, Italy Education SessionModerator: Maria Elisa Mancuso, Italy

11:15 – 11:45 Gene Therapy: Recent Advances and Future Perspectives

Thierry VandenDriessche, Belgium 11:45 – 12:15 The Current and Future Treatment of Rare Bleeding Disorders

Flora Peyvandi, Italy

Rare Bleeding DisordersModerator: Manuel Carcao, Canada

12:15 – 12:35 Factor XI Update

Ophira Salomon, Israel 12:35 – 12:55 Congenital Fibrinogen Disorders: Update on Diagnosis and Management

Alessandro Cassini, Switzerland

Working Groups UpdateModerator: Guy Young, United States

12:55 – 13:00 Establishment of a Standard for FVIII Inhibitors

Koen Mertens, the Netherlands 13:00 – 13:05 Prophylaxis in Inhibitor Patients

Carmen Escuriola-Ettingshausen, Germany 13:05 – 13:10 Working Group on Pharmacokinetics and Population Pharmacokinetics

Alfonso Iorio, Canada 13:10 – 13:15 Post-Registration Surveillance for New Products


11:15 – 13:15 A8

SSC SessionFibrinolysisChairman: Nicola Mutch, United KingdomCo-Chairmen: Paul Kim, Canada, Krasimir Kolev, Hungary, Colin Longstaff, United Kingdom, Victoria Ploplis, United States, Guy Reed, United States, Tetsumei Urano, Japan

Educational Session: Clinical Manifestations of Trauma Induced Coagulopathy (TIC) andDisseminated Intravascular Coagulation (DIC)

11:15 – 11:45 TIC is Not DIC

Karim Brohi, United Kingdom 11:45 – 12:15 Disseminated Intravascular Coagulation in Trauma and Traumatic Shock

Satoshi Gando, Japan Fibrinolysis in Trauma Induced Coagulopathy

12:15 – 12:35 Fibrinolysis Shutdown in Trauma

Hunter Moore, United States 12:35 – 12:55 Anti-Fibrinolytics in Trauma: Unresolved Issues and Effects Nobody Talks About

Dominik Draxler, Australia 12:55 – 13:15 Tranexamic Acid Use in Europe and the United States: A Trauma Surgeons

ViewScott Thomas, United States

13:15 – 14:00 Lunch Break

14:00 – 16:00 A1

SSC SessionPlasma Coagulation InhibitorsChairman: Richard Marlar, United StatesCo-Chairmen: Herm Jan Brinkman, the Netherlands, Cecilia Guillermo, Uruguay, Ian Jennings, United Kingdom, Jun Teruya, United States, Hiroko Tsuda, Japan

Education SessionModerator: Richard Marlar, United States

14:00 – 14:30 Unique Non-Anticoagulant Functions of Protein C

Laurent Mosnier, United States

SS

C &

Edu

cati

onal

P

rogr

am



62 63

Sat

urda

y

14:30 – 15:00 TFPI: New Insights Into an Old InhibitorElisabetta Castoldi, the Netherlands

Working Session 1: Progress of Current Projects

15:00 – 15:15 Protein S Testing

Ian Jennings, United Kingdom 15:15 – 15:45 Racial Differences

Hiroko Tsuda, Japan 15:45 – 16:00 Discussion

14:00 – 16:00 A2

SSC SessionFactor XIII and FibrinogenChairman: Verena Schroeder, SwitzerlandCo-Chairmen: Zsuzsa Bagoly, Hungary, Matthew J. Flick, United States, Martin Guthold, United States, Helen Philippou, United Kingdom, Marlien Pieters, South Africa, Alisa Wolberg, United States

Education Session 14:00 – 14:30 Current View of Fibrin Structure and Clot Structure

Martin Guthold, United States 14:30 – 15:00 Fibrin Structure and Crosslinking in Disease

Alisa Wolberg, United States

Standardization TopicsModerators: Zsuzsa Bagoly, Hungary, Verena Schroeder, Switzerland

15:00 – 15:20 WHO 1st International Standard Factor XIII Plasma, (02/206): Collaborative

Study to Additionally Assign Value for Factor XIII B-Subunit (Both Total & Free)Sanj Raut, United Kingdom

15:20 – 15:40 Oligomeric State of Factor XIII Changes Upon Activation

Muriel Maurer, United States 15:40 – 16:00 A Follow-Up on the Question of Novel Guidelines for FXIII Deficiency

Verena Schroeder, Switzerland

14:00 – 16:00 A3

SSC SessionVon Willebrand FactorChairman: Sandra Haberichter, United SatesCo-Chairmen: Simon De Meyer, Belgium, Jorge Di Paoloa, United States, Veronica Flood, United States, Koichi Kokame, Japan, Frank W. Leebeek, the Netherlands, James O’Donnell, Ireland

Education Session: Advances in the Biology and Treatment of TTPModerators: Jorge Di Paola, United States, Sandra Haberichter, United States

14:00 – 14:30 ADAMTS13 Mediated Thrombolysis of T-PA-Resistant Occlusions in Ischemic

Stroke in MiceSimon De Meyer, Belgium

14:30 – 15:00 Advances in the Treatment of TTP

Marie Scully, United Kingdom ADAMTS13 and TTPModerators: Simon De Meyer, Belgium, Koichi Kokame, Japan

15:00 – 15:15 Immunoprofiling of ADAMTS13 Autoantibodies in TTP

Karen Vanhoorelbeke, Belgium 15:15 – 15:30 A Proposal of VWF Large Multimer Index for Standardization of the Quantitative

Description of VWF Multimers Among LaboratoriesHisanori Horiuchi, Japan

Comparison and Standardization of VWF-Platelet Binding AssaysModerators: Sandra Haberichter, United States, James O'Donnell, Ireland

15:30 – 15:45 VWF:GPIbM, VWF:Ab, and VWF:RCo in the Willebrand in the Netherlands

(WiN) CohortJohan Boender, the Netherlands

15:45 – 16:00 VWF:GPIbM, VWF:GPIbR, VWF:RCo in the Zimmerman Program

Sandra Haberichter, United States

SS

C &

Edu

cati

onal

P

rogr

am



64 65

Sat

urda

y

14:00 – 16:00 A5

SSC SessionPediatric and Neonatal Thrombosis and HemostasisChairman: Christoph Male, AustriaCo-Chairmen: Manuela Albisetti Pedroni, Switzerland, Anthony Chan, Canada, Fiona Newall, Australia, Sarah O'Brien, United States, Shoshana Revel-Vilk, Israel, Heleen Van Ommen, the Netherlands

Education Session 14:00 – 14:30 Post-Thrombotic Syndrome in Children

Maria Laura Avila, Canada 14:30 – 15:00 Therapeutic Options for Post-Thrombotic Syndrome

Oliver Schlager, Austria 15:00 – 15:20 Primary Prevention of CVC-Related VTE

Sarah O'Brien, United States 15:20 – 15:40 Diagnostic Imaging of VTE in Vascular Abnormalities

Leonardo Brandão, Canada 15:40 – 16:00 Results of the DIC Survey

Ziad Solh, Canada

14:00 – 16:00 A6

SSC SessionBiorheologyChairman: Keith Neeves, United StatesCo-Chairmen: Judith Cosemans, the Netherlands, Wilbur Lam, United States, Pierre Mangin, France, Warwick Nesbitt, Australia, Erik Westein, Australia

Education Session: The Biomechanics of Thrombus Formation 14:00 – 14:30 Fibrin Biomechanics

John Weisel, United States 14:30 – 15:00 Platelet Biomechanics

Wilbur Lam, United States

Novel Applications of Flow-Based DevicesModerator: Judith Cosemans, the Netherlands

15:00 – 15:25 Flow Chambers in Transfusion Medicine

Hendrik Feys, Belgium 15:25 – 15:50 Defining Coagulation Kinetics in a Flow Reactor

Laura Haynes, United States 15:50 – 16:00 Discussion

14:00 – 16:00 A7

SSC SessionHemostasis & MalignancyChairman: Marc Carrier, CanadaCo-Chairmen: Cihan Ay, Austria, Christophe Dubois, France, Nigel Mackman, United States, Guy Meyer, France, Simon Noble, United Kingdom, Casey O'Connell United States

Education Session 14:00 – 14:30 Intracranial Hemorrhage in Cancer Patients

Jeffrey Zwicker, United States 14:30 – 15:00 Mice Model of Thrombosis and Cancer

Christophe Dubois, France Updates on SSC Projects

15:00 – 15:20 New Guidance: Occult Cancer Detection in Patients With VTE

Aurélien Delluc, France 15:20 – 15:40 Developing a Tool to Assess QoL in Patients With CAT

Simon Noble, United Kingdom 15:40 – 16:00 Guidance: D-Dimer Use in Cancer Patients

Cihan Ay, Austria

SS

C &

Edu

cati

onal

P

rogr

am



66 67

Sat

urda

y

14:00 – 16:00 A8

SSC SessionPerioperative Thrombosis and HemostasisChairman: Charles Marc Samama, FranceCo-Chairmen: Pierre Albaladejo, France, James Douketis, Canada, Andreas Greinacher, Germany, Jerrold H. Levy, United States, Alex C. Spyropoulos, United States Education Session: The Global Problem of Perioperative Venous Thromboembolism Prevention, and How to Deliver Care

14:00 – 14:30 In-Patients

Beverley Hunt, United Kingdom 14:30 – 15:00 Day Surgery and Fast-Track Surgery Patients

Charles Marc Samama, France

Hemostasis and Thrombosis in the Perioperative Setting, Part 1Moderator: James Douketis, Canada

15:00 – 15:20 "Pharmacokinetic" Vs "Laboratory" Based Strategy on Management of OACs in

Elective ProceduresAlex Spyropoulos, United States

15:20 – 15:40 Bridging for VKA and DOACs: New Data

James Douketis, Canada 15:40 – 16:00 Use of Antidotes for Surgical Patients

Pierre Albaladejo, France

16:15 – 18:15 A1

SSC SessionPlasma Coagulation InhibitorsChairman: Richard Marlar, United StatesCo-Chairmen: Herm Jan Brinkman, the Netherlands, Cecilia Guillermo, Uruguay, Ian Jennings, United Kingdom, Jun Teruya, United States, Hiroko Tsuda, Japan Working Session 2: Manuscript Progress for Clinical Testing for AT, PC, PS and APC-R

16:15 – 16:25 Protein C

16:25 – 16:35 Protein SRichard Marlar, United States

16:35 – 16:45 Antithrombin Richard Marlar, United States

16:45 – 16:55 APC ResistanceGary Moore, United Kingdom

16:55 – 17:15 Discussion Working Session 3

17:15 – 17:35 Clinical Relevance of Other Potential Plasma Inhibitors

Jun Teruya, United States 17:35 – 17:50 PC & PS Def Type Distribution

Richard Marlar, United States 17:50 – 18:05 Conclusions

16:15 – 18:15 A2

SSC SessionFactor XIII and FibrinogenChairman: Verena Schroeder SwitzerlandCo-Chairmen: Zsuzsa Bagoly, Hungary, Matthew J. Flick, United States, Martin Guthold, United States, Helen Philippou, United Kingdom, Marlien Pieters, South Africa, Alisa Wolberg, United States

Scientific TopicsModerators: Verena Schroeder, Switzerland, Alisa Wolberg, United States

16:15 – 16:35 Novel Methodological Approach to the Detection and Characterization of Anti-

FXIII AntibodiesLászló Muszbek, Hungary

16:35 – 16:55 Effect of Factor XIII Levels and Polymorphisms on the Risk of Myocardial

Infarction in Young PatientsZsuzsanna Bereczky, Hungary Éva Katona, Hungary

16:55 – 17:15 Factor XIII Levels and Polymorphisms in Patients With Systemic Lupus

Erythematosus and Antiphospholipid SyndromeZsuzsa Bagoly, Hungary

17:15 – 17:35 Structure of Fibrin in Thrombi Extracted With Interventional Treatment of

Ischemic Coronary, Peripheral and Cerebral Artery DiseaseVeronika Farkas, Hungary

SS

C &

Edu

cati

onal

P

rogr

am



68 69

Sat

urda

y

17:35 – 17:55 Role of Fibrinogen and FXIII in Obesity and Metabolic InflammationMatthew Flick, United States

17:55 – 18:15 Congenital Fibrinogen Disorders: An Update

Marguerite Neerman-Arbez, Switzerland

16:15 – 18:15 A3

SSC SessionVon Willebrand FactorChairman: Sandra Haberichter, United StatesCo-Chairmen: Simon de Meyer, Belgium, Jorge Di Paoloa, United States, Veronica Flood, United States, Koichi Kokame, Japan, Frank W. Leebeek, the Netherlands, James O’Donnell, Ireland 16:15 – 16:25 Assignment of Standard for VWF:GPIbM and VWF:GPIbR

Anthony Hubbard, United Kingdom 16:25 – 16:35 Discussion Delineation Of "Low VWF" and Type 1 VWD – Results From Large Population StudiesModerators: Veronica Flood, United States, Frank Leebeek, the Netherlands

16:35 – 16:50 Results From the Canadian Study

Paula James, Canada 16:50 – 17:05 Results From the WiN study

Frank Leebeek, the Netherlands 17:05 – 17:20 Results From the Zimmerman Study

Pamela Christopherson, United States 17:20 – 17:35 Results From the Irish Study

Michelle Lavin, Ireland 17:35 – 17:45 Results From the EU Study

Augusto B. Federici, Italy 17:45 – 17:55 Results From the 3Winters-Ips Study

Augusto B. Federici, Italy 17:55 – 18:15 Discussion of Definitions and Guidelines

Veronica Flood, United States

16:15 – 18:15 A5

SSC SessionPediatric and Neonatal Thrombosis and HemostasisChairman: Christoph Male, AustriaCo-Chairmen: Manuela Albisetti Pedroni, Switzerland, Anthony Chan, Canada, Fiona Newall, Australia, Sarah O'Brien, United States, Shoshana Revel-Vilk, Israel, Heleen Van Ommen, the Netherlands

16:15 – 16:30 Position Paper: Catheter-Related Arterial ThrombosisManuela Albisetti, Switzerland

16:30 – 16:45 Position Paper: Pulmonary Embolism

Tina Biss, United Kingdom 16:45 – 17:00 Progress Report: Bleeding Disorder Clinic for Adolescent Females

Ayesha Zia, United States 17:00 – 17:15 Progress Report: Anticoagulation/Monitoring in Pediatric Extracorporeal

CirculationMeera Chitlur, United States

17:15 – 17:30 Proposal: International Collaborative Group on Pediatric VTE

Heleen Van Ommen, the Netherlands 17:30 – 17:45 Proposal: Management of TE Detected Incidentally

Anjali Sharathkumar, United States 17:45 – 18:00 Proposal: Definition, Promotion and Measurement of Adherence to Pediatric

Anticoagulant TherapiesFiona Newall, Australia

18:00 – 18:15 Proposal: Task Force for Pediatric Anticoagulant Development

Christoph Male, Austria

SS

C &

Edu

cati

onal

P

rogr

am



70 71

Sat

urda

y

16:15 – 18:15 A6

SSC SessionBiorheologyChairman: Keith Neeves, United StatesCo-Chairmen: Judith Cosemans, the Netherlands, Wilbur Lam, United States, Pierre Mangin, France, Warwick Nesbitt, Australia, Erik Westein, Australia

Building Endothelial Cell Function Into Flow ChambersModerator: Warwick Nesbitt, Australia

16:15 – 16:40 Endothelial Cell Culture in Microfluidic Systems

Wilbur Lam, United States 16:40 – 17:05 Thrombosis-On-A-Chip

Abhishek Jain, United States

New Mechanisms in Blood Flow-Dependent Platelet FunctionModerator: Pierre Mangin, France

17:05 – 17:30 Modeling in Flow the Role of GPVI in the Initiation of Thrombus Formation,

Growth, and LysisMartine Jandrot-Perrus, France

17:30 – 17:55 Selective Targeting of VWF in Shear Gradient Mediated Thrombus Formation

Erik Westein, Australia 17:55 – 18:15 Update on SSC Multicenter Study of Flow Chambers

Keith Neeves, United States

16:15 – 18:15 A7

SSC SessionHemostasis & MalignancyChairman: Marc Carrier, CanadaCo-Chairmen: Cihan Ay, Austria, Christophe Dubois, France, Nigel Mackman, United States, Guy Meyer, France, Simon Noble, United Kingdom, Casey O'Connell, United States

New Projects 16:15 – 16:35 Update of Guidance: New Insights on DOACs Use in CAT

Alok Khorana, United States

16:35 – 16:55 New Guidance: Anticoagulation for Atrial Fibrillation While Undergoing ChemotherapySimon Noble, United Kingdom

New Investigators Projects

16:55 – 17:15 IPDMA: Occult Cancer Detection in Patients With Unprovoked VTE

Nick van Es, the Netherlands 17:15 – 17:35 Pilot Trial: Management of Thrombocytopenia in CAT

Bethany Samuelson, United States 17:35 – 17:55 Cancer Detection in Patients With Von Willebrand Disease

Holleh Husseinzadeh, United States Updates of Ongoing Studies

17:55 – 18:00 Multinational Registry: Management of Antiplatelet and Anticoagulant Drugs

During ThrombocytopeniaAvi Leader, the Netherlands

18:00 – 18:10 External Validation of Thrombosis Lymphoma/ThroLy/Score

Darko Antic, Serbia 18:10 – 18:15 Updates of Ongoing CAT Studies

Marc Carrier, Canada

16:15 – 18:15 A8

SSC SessionPerioperative Thrombosis and HemostasisChairman: Charles Marc Samama, FranceCo-Chairmen: Pierre Albaladejo, France, James Douketis, Canada, Andreas Greinacher, Germany, Jerrold H. Levy, United States, Alex C. Spyropoulos, United States

Hemostasis and Thrombosis in the Perioperative Setting, Part 2Moderator: Charles Marc Samama, France

16:15 – 16:35 Platelet Transfusion in Patients With Acquired Platelet Defects

Andreas Greinacher, Germany 16:35 – 16:55 Use of Factor Concentrates for Managing Bleeding

Jerrold Levy, United States

SS

C &

Edu

cati

onal

P

rogr

am

SSC PROGRAM


73

Sun

day

SSC PROGRAM


72

16:55 – 17:15 Utility of TEG/ROTEM for Monitoring?Sophie Susen France

17:15 – 17:35 Ongoing Standardization Projects 17:35 – 17:55 Panel Discussion 17:55 – 18:15 Discussion With Experts

Sunday, July 9, 2017SSC Program

08:00 – 10:00 A1

SSC SessionFactor XI & the Contact SystemChairman: Joost C.M. Meijers, the NetherlandsCo-Chairmen: Edward Feener, United States, Heiko Herwald, Sweden, Coen Maas, the Netherlands, Owen J. McCarty, United States, Stephanie Smith, United States, Evi X. Stavrou, United States

08:00 – 08:05 OpeningJoost C.M. Meijers, the Netherlands

Polyphosphates and the Contact System

08:05 – 08:15 Structural Models of Contact System Activation and Ligand Binding

Jonas Emsley, United Kingdom 08:15 – 08:25 Comparing and Inhibiting the Procoagulant Activities of Nucleic Acids versus

PolyphosphateJames H. Morrissey, United States

08:25 – 08:35 Particles and Polymers

Coen Maas, the Netherlands 08:35 – 08:45 Targeting the Factor XII Activator Polyphosphate in Vivo

Thomas Renné, Sweden 08:45 – 09:15 Joint Discussion 09:15 – 09:30 The 1st International Standard for Blood Coagulation Factor XII, Plasma

Elaine Gray, United Kingdom 09:30 – 09:45 FXIa Contamination of IVIG

Mikhail Ovanesov, United States 09:45 – 10:00 Contact System in Diabetic Retinopathy

Edward Feener, United States

SS

C &

Edu

cati

onal

P

rogr

am



74 75

Sun

day

08:00 – 10:00 A2

SSC SessionGenomics in Thrombosis and HemostasisChairman: Willem H. Ouwehand, United KingdomCo-Chairmen: Daniel Bellissimo, United States, Paul F. Bray, United States, Kathleen Freson, Belgium, Anne Goodeve, United Kingdom, Michele P. Lambert, United States, Pieter Reitsma, the Netherlands

08:00 – 08:10 WelcomeWillem H. Ouwehand, United Kingdom

Updates on Diagnostic High Throughput Sequencing Tests

08:10 – 08:25 Molecular Diagnosis of Rare BPD Using NGS

Kate Downes, United Kingdom 08:25 – 08:40 Experiences from the ÖResund Region with Implementation of WES in Patients

with IBDEva Leinoe, Denmark

08:40 – 08:55 Tier-1 Genes: New Genes and Modes of Inheritance

Kathleen Freson, Belgium What Should I Tell My Patients?

08:55 – 09:10 From the Neonatal/Pediatric Perspective

Shoshana Revel-Vilk, Israel 09:10 – 09:25 Dealing with Variants of Uncertain Significance

Keith Gomez, United Kingdom Challenges of Interpretation (Part. I)

09:25 – 09:40 New Control Datasets and Updates to Variant Catalogs

Karyn Megy, United Kingdom 09:40 – 10:00 Challenges in Interpreting Genetic Data in Females At-Risk for Bleeding

DisordersJill Johnsen, United States

08:00 – 10:00 A3

SSC SessionPlatelet PhysiologyChairman: Paolo Gresele, ItalyCo-Chairmen: Hans Deckmyn, Belgium, Andrew L. Frelinger III, United States, Martine Jandrot-Perrus, France, Shinji Kunishima, Japan, Marie Lordkipanidzé, Canada, Jose Rivera, Spain

08:00 – 08:10 Overview of Platelet Physiology SSC and ProjectsPaolo Gresele, Italy

08:10 – 08:20 Evaluation of the ISTH Bleeding Assessment Tool (BAT) for the Assessment of

Inherited Platelet Disorders: Follow-Up DataPaolo Gresele, Italy

08:20 – 08:40 Measurement of Platelet Dimensions: Methods and Clinical Use: Guidance

from the SSC of the ISTHPatrizia Noris, Italy

08:40 – 08:50 Use of PRP in Regenerative Medicine: Where are we?

Jeremy Magalon, France 08:50 – 09:00 Use of Platelets in Regenerative Medicine: Guidance from the SSC of the ISTH

Paul Harrison, United Kingdom 09:00 – 09:20 Measurement of Platelet Secretion: Guidance from the SSC of the ISTH

Diego Mezzano, Chile 09:20 – 09:40 Diagnosis of Inherited Platelet Disorders on a Blood Smear: Survey and

WorkshopShinji Kunishima, Japan

09:40 – 10:00 Methods for the Conservation and Shipment of Platelets for Platelet Studies

Marie Lordkipanidzé, Canada

SS

C &

Edu

cati

onal

P

rogr

am



76 77

Sun

day

08:00 – 10:00 A5

SSC SessionControl of AnticoagulationChairman: Mark Crowther, CanadaCo-Chairmen: Chatree Chai-Adisaksopha, Canada, Benilde Cosmi, Italy, Adam Cuker, United States, Jonathan Douxfils, Belgium, Ismail Elalamy, France, Pieter W. Kamphuisen, the Netherlands

New and Ongoing projects 08:00 – 08:15 START SSC Event Registry: Overview

Walter Ageno, Italy 08:15 – 08:30 START Laboratory: DOAC Levels and Clinical Events?

Benilde Cosmi, Italy 08:30 – 08:45 Cerebral Vein Thrombosis Registry

Francesco Dentali, Italy 08:45 – 09:00 Classification of Major Bleeding

Karina Meijer, the Netherlands 09:00 – 09:15 Standard Method for Determination of the Plasma Prothrombin Time by Manual

Tilt Tube TechniqueAnton van den Besselaar, the Netherlands

09:15 – 09:30 Ad Hoc Working Party to Guide the Laboratory Measurements of the DOACs

Ismail Elalamy, France 09:30 – 09:45 Proposing for Establishment a WHO Reference Reagent for Human Factor Xa

Craig Thelwell, United Kingdom 09:45 – 10:00 Developing a Registry of the Outcomes of Stents in Patients with Venous

ThrombosisAndrea Cervi, Canada

08:00 – 10:00 A6

SSC SessionDisseminated Intravascular CoagulationChairman: Jecko Thachil, United KingdomCo-Chairmen: Marcello Di Nisio, Italy, Toshiaki Iba, Japan, Takashi Ito, Japan, Bernd Jilma, Austria, Alessandro Squizzato, Italy, Sacha Zeerleder, the Netherlands

08:00 – 08:20 Platelet-Neutrophil Interactions in SepsisDorith Claushuis, the Netherlands

08:20 – 08:40 Complement and Coagulation in Thromboinflammation

Bo Nilsson, Sweden 08:40 – 09:00 What’s New in Septic DIC?

Kazuma Yamakawa, Japan 09:00 – 09:20 What's New in Trauma-Related DIC?

Satoshi Gando, Japan 09:20 – 09:40 Challenges in the Critical Care Management of Sepsis

Ruth Kleinpell, United States 09:40 – 10:00 Global Sepsis Alliance

Marvin Zick, Germany

08:00 – 10:00 A7

SSC SessionFactor VIII, IX and Rare Coagulation Disorders, Part 2Chairman: Guy Young, United StatesCo-Chairmen: Manuel Carcao, Canada, Peter Collins, United Kingdom, Alfonso Iorio, Italy, Gili Kenet, Israel, Johnny Mahlangu, South Africa, Maria Elisa Mancuso, Italy Old and New Challenges in Immune Tolerance TherapyModerators: Peter Collins, United Kingdom, Guy Young, United States

08:00 – 08:20 Definitions of Tolerance—What Is/Should Be Different with EHL

Charles Hay, United Kingdom 08:20 – 08:40 When to Start and When to Stop and What Are the Relevant Outcomes

Rolf Ljung, Sweden

SS

C &

Edu

cati

onal

P

rogr

am



78 79

Sun

day

08:40 – 09:00 Debate on FVIII Products for ITI: Recombinant Versus Plasma-DerivedCarmen Escuriola-Ettingshausen, GermanyRi Liesner, United Kingdom

09:20 – 09:50 The Future of Inhibitor Eradication and Prevention in the Era of Non-Factor Products: A Theoretical Panel DiscussionShannon Meeks, United States Gili Kenet, Israel Maria Elisa Mancuso, Italy Julie Curtin, Australia

09:50 – 10:00 Discussion

08:00 – 10:00 A8

SSC SessionAnimal, Cellular and Molecular Models of ThrombosisChairman: Jose Diaz, United StatesCo-Chairmen: Brian Cooley, United States, Alexandra Kopic, Austria, Nobuo Nagai, Japan, Leslie Parise, United States, Denise E. Sabatino, United States AAA Pre-Clinical Models

08:00 – 08:30 AAA MODEL–Elastase Model

Sean English, United States 08:30 – 09:00 AAA Peri-Adventitial Model

John Curci, United States 09:00 – 09:30 AAA Angiotensin II Model

Alan Daugherty, United States 09:30 – 10:00 Cremaster Arteriole Laser-Injury Model of Thrombosis

Steve Grover, United States

10:15 – 12:15 A1

SSC SessionFactor XI & the Contact SystemChairman: Joost C.M. Meijers, the NetherlandsCo-Chairmen: Edward Feener, United States, Heiko Herwald, Sweden, Coen Maas, the Netherlands, Owen J. Mccarty, United States, Stephanie Smith, United States, Evi X. Stavrou, United States

Education Session 10:15 – 10:45 Vascular Biology of Factor XII and the Kallikrein/Kinin System

Alvin Schmaier, United States 10:45 – 11:15 Microfluidics and the Contact System

Scott Diamond, United States 11:15 – 11:30 Clinical Experience with Factor XI Inhibitors

Jeffrey I. Weitz, Canada 11:30 – 11:45 Bradykinin and Stroke

Sara Martinez de Lizarrondo, France 11:45 – 12:10 Nomenclature Proposal

Alvin Schmaier, United States

12:10 – 12:15 ClosureJoost C.M. Meijers, the Netherlands

10:15 – 12:15 A2

SSC SessionGenomics in Thrombosis and HemostasisChairman: Willem H. Ouwehand, United KingdomCo-Chairmen: Daniel Bellissimo, United States, Paul F. Bray, United States, Kathleen Freson, Belgium, Anne Goodeve, United Kingdom, Michele P. Lambert, United States, Pieter Reitsma, the Netherlands Education Session: Challenges of Interpretation (Part. II)

10:15 – 10:45 Global Collaborations on Variant Pathogenicity Assertions

through Expert Panels - ClinGen/ClinVarJonathan Berg, United States

10:45 – 11:15 Human Phenotype Ontology to Support Clinical Reporting

and Genomic DiagnosticsPeter Robinson, United States

11:15 – 11:30 Break

SS

C &

Edu

cati

onal

P

rogr

am



80 81

Sun

day

What’s new? 11:30 – 11:40 Assessing the Relevance of Non-Coding DNA Variants

Dominik Seelow, Germany 11:40 – 11:50 New Platelet Population Studies for Genomic Discovery

Andrew Johnson, United States 11:50 – 12:00 A Fast Association Test for Identifying Exonic and Non-Exonic

Pathogenic Variants Involved in Rare DiseasesErnest Turro, United Kingdom

12:00 – 12:15 Discussion/Closing the Session

Michelle Lambert, United States

10:15 – 12:15 A3

SSC SessionPlatelet PhysiologyChairman: Paolo Gresele, ItalyCo-Chairmen: Hans Deckmyn, Belgium, Andrew L. Frelinger III, United States, Martine Jandrot-Perrus, France, Shinji Kunishima, Japan, Marie Lordkipanidzé, Canada, Jose Rivera, Spain

Education Session 10:15 – 10:45 Cytoskeletal Dynamics in Megakaryocytes and Platelets

Markus Bender, Germany 10:45 – 11:15 The Granule Secretion Mechanisms and Actin Dynamics

Robert Flaumenhaft, United States 11:15 – 11:30 Abnormal αIIbβ3 and Cytoskeletal Perturbation Causing Platelet Dysfunction

Loredana Bury, Italy 11:30 – 11:45 How to Reach Consensus on Using the SSC LTA Guidelines:

the Netherlands ExperienceYvonne M.C. Henskens, the Netherlands

11:45 – 12:00 Standardization of Flow Cytometry for the Assessment of Platelets DisordersAndrew L. Frelinger III, United States José Rivera Pozo, Spain

12:00 – 12:15 Measurement of Soluble Markers of Platelet Activation: Methods and Use. A Project for Generation of GuidelinesHans Deckmyn, Belgium Martine Jandrot-Perrus, France

10:15 – 12:15 A5

SSC SessionControl of AnticoagulationChairman: Mark Crowther, CanadaCo-Chairmen: Chatree Chai-Adisaksopha, Canada, Benilde Cosmi, Italy, Adam Cuker, United States, Jonathan Douxfils, Belgium, Ismail Elalamy, France, Pieter W. Kamphuisen, the Netherlands

Education Session: The Role of Oral Vitamin K Antagonists in 2017 10:15 – 10:45 Current State of the Art with Oral VKA's:

Efficacy and Safety in Very Well Managed PatientsVittorio Pengo, Italy

10:45 – 11:15 Monitoring Oral VKA's – Should the Standard Prothrombin Time Be Replaced?Páll Torfi Önundarson, Iceland

Update in Control of Anticoagulation

11:15 – 11:35 Determination of DOAC Levels Using Various Coagulometers in Comparison

with LC-MS/MSJovan P. Antovic, Sweden

11:35 – 11:55 Point of Care vs Laboratory INR Determinations in Critically Ill Patients

Robin Zenlander, Sweden 11:55 – 12:15 Automated Thrombin Generation Assay in Bleeding Patients on Anticoagulant

Jonathan Douxfils, Belgium

SS

C &

Edu

cati

onal

P

rogr

am



82 83

Sun

day

10:15 – 12:15 A6

SSC SessionDisseminated Intravascular CoagulationChairman: Jecko Thachil, United KingdomCo-Chairmen: Marcello Di Nisio, Italy, Toshiaki Iba, Japan, Takashi Ito, Japan, Bernd Jilma, Austria, Alessandro Squizzato, Italy, Sacha Zeerleder, the Netherlands

Education Session 10:15 – 10:45 Histones and Neutrophil Extracellular Traps in Disseminated Intravascular Coagulation

Cheng-Hock Toh, United Kingdom 10:45 – 11:15 Perturbations in Hemostasis in Viral Hemorrhagic Fevers

Daniel Bausch, Switzerland 11:15 – 11:30 Acute DIC, Shock Liver, and Symmetrical Peripheral Gangrene: An Update

Theodore Warkentin, Canada 11:30 – 11:45 The Issues in DIC Diagnosis and Management

Alessandro Squizzato, Italy 11:45 – 12:00 International Survey on Pediatric DIC

Ziad Solh, Canada 12:00 – 12:15 Update on Obstetrical DIC

Offer Erez, Israel

10:15 – 12:15 A7

SSC SessionFactor VIII, IX and Rare Coagulation Disorders, Part 2Chairman: Guy Young, United StatesCo-Chairmen: Manuel Carcao, Canada, Peter Collins, United Kingdom, Alfonso Iorio, Italy, Gili Kenet, Israel, Johnny Mahlangu, South Africa, Maria Elisa Mancuso, Italy

Laboratory Assays UpdateModerators: Alfonso Iorio, Italy, Gili Kennet, Israel

10:15 – 10:30 Establishment of the 2nd International Standard for FIX (FIXa)

Elaine Gray, United Kingdom

10:30 – 10:45 U.S. National Inhibitor Surveillance Using a Central Laboratory: Testing Protocol and ResultsConnie Miller, United States

10:45 – 11:05 Measuring Extended Half-Life Factors in the LaboratoryGuy Young, United States

11:05 – 11:25 Implementing the Chromogenic Factor Assays in the Clinical Coagulation

LaboratorySteven Pipe, United States

11:25 – 11:45 Is All Thrombin Generation the Same?

Claude Negrier, France 11:45 – 12:05 Discussion 12:05 – 12:15 Closing

Guy Young, United States

10:15 – 12:15 A8

SSC SessionAnimal, Cellular and Molecular Models of ThrombosisChairman: Jose Diaz, United StatesCo-Chairmen: Brian Cooley, United States, Alexandra Kopic, Austria, Nobuo Nagai, Japan, Leslie Parise, United States, Denise E. Sabatino, United States Education Session: Pre-Clinical Models of VT

10:15 – 10:45 Murine IVC Thrombosis Model

Jose Diaz, United States 10:45 – 11:15 IVC Stenosis Model

Prakash Saha, United Kingdom 11:15 – 11:45 Directing Your Research: Unmet Needs from the Clinical Perspective

Fedor Lurie, United States 11:45 – 12:15 Benchside to Bedside to Community: The Role of Pre-Clinical Models

Alisa Wolberg, United States

Supported Symposia13:15 - 14:30 See page 526

SS

C &

Edu

cati

onal

P

rogr

am



85


84

NOTES

Special Sessions


86 87

SPECIAL SESSIONSSPECIAL SESSIONS

Sunday, July 9, 2017Special Sessions

12:00 – 13:00 M8

Special Session YIA/RtW Reception

12:15 – 14:00 M6

Special Session World Thrombosis Day: Building Awareness and Elevating Impact for the Global Burden of Thrombosis 12:15 – 12:25 Opening Remarks and Overview of World Thrombosis Day

Gary Raskob, United States 12:25 – 12:40 Presentation: The Global Burden of Thrombosis and the Case for a Systematic

Approach to VTE Risk Assessment in the Hospital SettingGary Raskob, United States

12:40 – 13:10 Partner Panel: Engagement, Awareness and Achieving Outcomes Around the

WorldModerator: Claire McLintock, New Zealand Lai Heng Lee, Singapore Alex Spyropoulos, United States Aurora de la Peña Díaz, Mexico Beverley Hunt, United Kingdom

13:10 – 13:30 Case Study: Governmental Partnership – The Centers for Disease Control and

Prevention (CDC) (USA) Initiative on Health-Care Associated VTECraig Hooper, United States

13:30 – 13:50 Private – Public Partnership: Corporate Engagement, Social Responsibility and

Partnership around World Thrombosis DayModerator: Jeffrey I. Weitz, Canada Paul Field, GermanyMark Gossett, United StatesCharlene Herndon, United States

13:50 – 14:00 Audience Q&A and World Thrombosis Day in 2017 and Beyond

Gary Raskob, United States

13:00 – 14:00 A4

Special SessionAdopting New VTE and Cancer Guidelines: Is Clinical Practice Improving?Chair: James Douketis, Canada 13:00 – 13:05 Introductory Remarks

James Douketis, Canada 13:05 – 13:25 VTE and Cancer – 2016 and Beyond

Dominique Farge-Bancel, France 13:25 – 13:40 Putting Guidelines Into Practice

Rupert Bauersachs, Germany 13:40 – 13:55 Looking to the Future

Panel Discussion 13:55 – 14:00 Concluding Remarks and Evaluation

James Douketis, Canada

13:00 – 14:00 M8

Special SessionBuilding Capacity Globally: The Impact and Future of the RtW and IHTC Programs

This session will focus on the ISTH Reach-the-World (RtW) programs, including fellowships and the new Regional Training Center (RTC) initiative, and the World Federation of Hemophilia (WFH) Inter-national Hemophilia Training Center (IHTC) fellowship program. Mentors from participating programs will share their experiences and provide guidance for those considering engaging with either the RtW or the IHTC programs. Future applicants will be able ask questions and connect with leaders from both programs.

Moderators: Dr. Miguel Escobar, United States, Prof. Flora Peyvandi, ItalyRtW Speakers: Dr. Suely Rezende, Brazil, Dr. Renu Saxena, IndiaIHTC Speakers: Dr. Magdy El Ekiaby, Egypt, Dr. Johnny Mahlangu, South Africa

Sun

day

Spe

cial

Ses

sion

s

SSC PROGRAM


89


88

NOTES

Nurses Forum

NURSES FORUMNURSES FORUM


90 91

Sun

day

Improving Patient Outcomes Through ResearchModerators: Bunis Packham, United Kingdom, Ann O’Sullivan, Ireland

11:00 – 11:35 NUR 03.1 Overview on Approach to Research

Fiona Newall, Australia

11:35 – 11:50 NUR 03.2 Nurse-Led Research: Cancer Associated Thrombosis

Karen French, United Kingdom 11:50 – 12:05 NUR 03.3 The Role of the Clinical Research Co-Ordinator in Clinical Trials

Margaret Nolan, Ireland 12:05 – 12:15 Panel Question and Answer 12:15 – 13:00 Lunch Break 13:00 – 13:15 NUR 03.4 Audit Service Evaluation

Bunis Packham, United Kingdom 13:15 – 13:30 NUR 03.5 Quality Improvement: An HTC Initiative

Regina Butler, United States 13:30 – 13:45 NUR 03.6 Improving Dental Care for Patients with Hemophilia in China

Kuixing Li, China 13:45 – 14:00 Panel Question and Answer 14:00 – 14:15 Break

Sunday, July 9, 2017Nurses Forum

08:55 – 17:15 M1

Nurses SessionNurses Forum: Optimal Outcomes for Patients and Families: The Contribution of Nurses in 2017 and Beyond Introduction: Optimal Outcomes for Patients and Families Moderator: Maura Malone, United States

08:55 – 09:10 NUR 01.1 Welcome and Introduction

Maura Malone, United States 09:10 – 09:25 NUR 01.2 Nursing Practice in Germany: Hemostasis

Manuela Siebert, Germany 09:25 – 09:40 NUR 01.3 Nursing Practice in Germany: Thrombosis

Karin Andritschke, Germany Improving Patient Outcomes through Transition of Care ProgramsModerators: Jennifer Maahs, United States, Brittany Savage, United States

09:40 – 10:00 NUR 02.1 Hemostasis Transition: Adolescent to Adulthood

Brittany Savage, United States 10:00 – 10:15 Break 10:15 – 10:25 NUR 02.2 Thrombosis Transition: Inpatient to Outpatient: A QI Project

Maura Malone, United States 10:25 – 10:35 NUR 02.3 Thrombosis Transition: Inpatient to Outpatient Infants and Children

Mary Lou MacDermott, United States 10:35 – 10:50 NUR 02.4 Hemostasis and Thrombosis Case Scenarios: The Legal Implications

James E. Munn, United States 10:50 – 11:00 Panel Question and Answer

Nur

ses

Foru

m



92 93

Mon

day

Monday, July 10, 2017Nurses Forum

08:00 – 17:30 M1

Nurses SessionNurses Forum: Optimal Outcomes for Patients and Families: The Contribution of Nurses in 2017 and Beyond Peer-Reviewed Abstracts From Nurses and Allied Health Professionals Moderators: Regina Butler, United States, Manuela Siebert, Germany

08:00 – 08:10 NUR 05.1 Delays in the Presentation of Chemotherapy Induced Venous

Thromboembolism: Scope of the Problem and Potential SolutionsS. Noble, N. Pease (United Kingdom)

08:10 – 08:20 NUR 05.2 Significant Reduction in Hospital Acquired Thrombosis: Impact of a National

Risk Assessment Target & Local Real-time ReportingH. Rowswell, T. Nokes (United Kingdom)

08:20 – 08:30 NUR 05.3 Impact of a Thrombosis Pharmacist in Optimizing Anticoagulation Management

in Paediatric PatientsE. Chung, C. Chan, M. Ho, J. Fung, L. Brandão, W. Seto (Canada)

08:30 – 08:40 NUR 05.4 St. Joseph's Healthcare Hamilton Perioperative Anticoagulation Clinic Quality

Improvement ProjectL. Sardo, J. Bayadinova (Canada)

08:40 – 08:50 NUR 05.5 National Quality Improvement for Transition from Pediatric to Adult Care:

Evaluation of a Pilot ProgramR. Malouin, F. Ann, L. Palmer, C. Thornburg, S. Dunn, L. Casto, J. Hill, B. Koval, D. Oldfield, V.L. Foster-Johnson (United States)

08:50 – 09:00 NUR 05.6 Nurse as Change Agent for Improved Nurse Safety and Patient Satisfaction

M. Blumenstein, C. Law, J. Whittle (United States) 09:00 – 09:15 Question and Answer 09:15 – 09:30 Break

Improving Patients‘ Outcomes Through Education of a Diverse PopulationModerators: Jim Munn, United States, Marilyn Blumenstein, United States

14:15 – 14:35 NUR 04.1 Approach of a Resourced Community to Nursing Education to Low Resource

Countries in AfricaAnne-Louise Cruickshank, South Africa

14:35 – 14:55 NUR 04.2 Development of Education in a Low Resource Environment: Both Teacher and

LearnerSulochana Badagabettu, India

14:55 – 15:10 NUR 04.3 Nursing Approach for Improving Outcomes in Religiously Diverse Communities:

AmishJennifer Maahs, United States

15:10 – 15:25 NUR 04.4 Nursing Approach for Improving Outcomes in Religiously Diverse Communities:

Muslim/JewishDalia Bashari, Israel

15:25 – 15:35 NUR 04.5 Knowledge and Awareness of Pharmacists about Venous Thromboembolism and

Anti Coagulation in PakistanS. Khan, S. Ahsan, A. Zehra, D.B. Moiz, S.S. Raza (Pakistan)

15:35 – 15:45 Panel Question and Answer 15:45 – 16:15 Coffee Break 16:15 – 17:15 Nurse Networking Reception N

urse

s Fo

rum



94 95

Mon

day

Peer-Reviewed Abstracts From Nurses and Allied Health Professionals Moderators: Jennifer Meldau, United States, Bunis Packham, United Kingdom

11:15 – 11:25 NUR 05.13 Implementation of the Nurse Practitioner Role in the Thrombosis Service at St.

Joseph's Healthcare, HamiltonL. Sardo, J. Bayadinova (Canada)

11:25 – 11:35 NUR 05.14 Nurse Practitioner-led Quality Improvement Project on Inferior Vena Cava Filter

Placement and Retrieval: A Patient Focused ApproachL. Sardo, J. Bayadinova, W. Lim (Canada)

11:35 – 11:45 NUR 05.16 Living with the Unpredictability of an Inhibitor as an Adolescent - Results of

the SO-HEROIC StudyK. Khair, L. Wollard, M. Holland (United Kingdom)

11:45 – 11:55 NUR 05.15 Providing Leadership in Thrombosis - A National Network for Nurses, Midwives

and AHPsE. Gee, L. Bonner, on behalf of the VTE National Nursing and Midwifery Network (United Kingdom)

11:55 – 12:00 Question and Answer 12:00 – 13:15 Lunch in Exhibition Halls Patient Reported Outcomes Moderators: Anne-Louise Cruickshank, South Africa, Ann O’Sullivan, Ireland

13:15 – 13:35 NUR 06.1 Doing My Treatment: Who Says I am Adherent?

Kate Khair, United Kingdom 13:35 – 13:55 NUR 06.2 Management of Health Anxiety in Thrombotic Patients: What Helps?

Patricia Byrne, Ireland 13:55 – 14:15 NUR 06.3 Anticoagulation Management Service: An NP Model

Jennifer Meldau, United States 14:15 – 14:30 Panel Question and Answer

14:30 – 14:45 Break in Exhibition Halls

Peer-Reviewed Abstracts From Nurses and Allied Health Professionals Moderators: Julia Hews- Girard, Canada, Jim Munn, United States

09:30 – 09:40 NUR 05.7 Lung Function, Functional Capacity and Heart Rate Recovery at Discharge in

Patients with Acute Pulmonary EmbolismJ.S. Danielsbacka, M. Fagevik Olsén, P.-O. Hansson, K. Mannerkorpi (Sweden)

09:40 – 09:50 NUR 05.8 Long-term Mental Well-being of Adolescents and Young Adults Diagnosed with

Venous Thromboembolism. A Multistage Mixed Methods StudyA.A. Højen, P.S. Dreyer, E.E. Sørensen, T.B. Larsen (Denmark)

09:50 – 10:00 NUR 05.9 Prevention of Hospital-acquired Venous Thromboembolism: The Project of

Effective Quality ImprovementG. Saharov, Y.N. Nadir, I. Tzoran, A. Jabareen, G. Heims, B. Brenner, Orit Gur (Israel)

10:00 – 10:10 NUR 05.10 A Unique National Plan for Prevention of Severe Familial Hemophilia

D. Bashari, V. Shemer, R. Dardik, B. Feldman, T. Brutman Barazani, D. Eli, G. Kenet (Israel)

10:10 – 10:20 NUR 05.11 Responding to Patient's Needs: Presenting a Framework of Support for

Psychological Distress Following VTER. Hunter, P. Bennett, S. Lewis, S. Noble (United Kingdom)

10:20 – 10:30 NUR 05.12 Effect of Comprehensive Hemophilia Education Programme (CHEP) for

Children and Youth on Knowledge and Quality of Life - A Pilot ProjectA. Dsouza, D. Nayak, A. Kurien (India)

10:30 – 10:45 Question and Answer 10:45 – 11:15 Coffee Break in Exhibition Halls

Nur

ses

Foru

m



97

NURSES FORUM


96

Master Classes and Career Development Sessions

These are ticketed events. Please be sure to arrive on-time as to not disrupt the session. If

you have not arrived to the session by 10 minutes after the start, your seat may be given

up to a participant on the waiting list.

Future Direction of Nursing Practice Moderator: Maura Malone, United States

14:45 – 15:00 NUR 07.1 Highlights: WFH, Net Hemophilia, Open Access Journal and GHNA Initiative

Kate Khair, United Kingdom 15:00 – 15:15 NUR 07.2 Identifying the Principles Guiding the Development and Delivery of Patient

Education in Thrombosis and Hemostasis Disorders: A Literature ReviewJ. Hews-Girard1, C. Guelcher2, J. Meldau2, E. McDonald1, F. Newell3 (1Canada, 2United States, 3Australia)

15:15 – 15:30 NUR 07.3 Preliminary ISTH Survey Results: Nurses Needs Assessment in Thrombosis and

HemostasisJames E. Munn, United States

15:30 – 16:45 Panel Question and Answer 16:45 – 17:00 Wrap-up

MASTER CLASSES


99

Sun

day

MASTER CLASSES


98

07:00 – 07:45 R9

Maintaining Vascular Flow: From Liquid to Solid to Liquid Again: The Dynamics of Clot Formation and LysisAlisa Wolberg, United States

07:00 – 07:45 R10 ITP: Clinical Aspects and Laboratory Testing


07:00 – 07:45 R11 Prophylaxis, Treatment (Including Use and Monitoring of Long-Acting

Formulations), and InhibitorsAlok Srivastava, India

Sunday, July 9, 2017Master Classes

07:00 – 07:45 R2 Coagulation and the Complement System

Edward M. Conway, Canada

07:00 – 07:45 R3 Personalized Treatment in Patients With VTE: Duration of Anticoagulation

Based on Prediction ModelsSabine Eichinger, Austria

07:00 – 07:45 R4

Perinterventional Management of Patients Receiving Antiplatelet TherapyAnne Godier, France

07:00 – 07:45 R5 Tests of Global Hemostasis: What Do They Mean and Why Would We Use

Them?Edelgard Lindhoff-Last, Germany

07:00 – 07:45 R6 Management Issues in Pediatric Thrombosis

Paul Monagle, Australia

07:00 – 07:45 R7 Laboratory Investigations for Suspected Bleeding Disorders

Reinhard Schneppenheim, Germany

07:00 – 07:45 R8 Bleeding Scores

Alberto Tosetto, Italy

Mas

ter

Cla

sses

& C

aree

r D

evel

opm

ent

Ses

sion

s

MASTER CLASSESMASTER CLASSES


100 101

Mon

day

07:00 – 07:45 R9 TTP Disease Models and Pathogenesis

Karen Vanhoorelbeke, Belgium

07:00 – 07:45 R10 Practical Issues of Antithrombotic Therapy: Bleeding and Reversal,

Perioperative Management and Drug InteractionsPeter Verhamme, Belgium

07:00 – 07:45 R11 Platelet Signaling

Wolfgang Bergmeier, United States

Monday, July 10, 2017Master Classes

07:00 – 07:45 R2 Methodology for Clinical Studies

Suzanne Cannegieter, the Netherlands

07:00 – 07:45 R3 Antiphospholipid Antibodies: Testing, Treatment, Prognosis

Mark Crowther, Canada

07:00 – 07:45 R4 Platelet Function Testing and Diagnosis of Platelet Function Disorders

Paolo Gresele, Italy

07:00 – 07:45 R5 VWD: Biology, Diagnosis, Therapy

David Lillicrap, Canada

07:00 – 07:45 R6 Platelet MicroRNAs: From Molecules to Patients

Manuel Mayr, United Kingdom

07:00 – 07:45 R7 Rare Bleeding Disorders


07:00 – 07:45 R8 Perioperative Anticoagulant Management

Charles Marc Samama, France

Mas

ter

Cla

sses

& C

aree

r D

evel

opm

ent

Ses

sion

s



102 103

Tues

day

07:00 – 07:45 R9 The Ups and Downs of Thrombin Generation

Armando Tripodi, Italy

07:00 – 07:45 R10 HIT: Delayed Onset, and Autoimmune HIT

Theodore Warkentin, Canada

07:00 – 07:45 R11 Glycans in Platelet Biology

Karin M. Hoffmeister, United States

Tuesday, July 11, 2017Master Classes

07:00 – 07:45 R2 Immune Mechanisms in Atherosclerosis

Christoph Binder, Austria

07:00 – 07:45 R3 Biophysics in Thrombosis and Hemostasis

Mihaela Delcea, Germany

07:00 – 07:45 R4 Platelets and Immunity

Meinhard Gawaz, Germany

07:00 – 07:45 R5 Coagulopathy in the Emergency Room

Wolfgang Korte, Switzerland

07:00 – 07:45 R6 Atrial Fibrillation: Anticoagulant Choice and Monitoring

Gregory Y.H. Lip, United Kingdom

07:00 – 07:45 R7 Targeting Platelet Receptors by Antibodies

Bernhard Nieswandt, Germany

07:00 – 07:45 R8 Polyphosphate

Thomas Renné, Sweden

Mas

ter

Cla

sses

& C

aree

r D

evel

opm

ent

Ses

sion

s



104 105

Wed

nesd

ay

07:00 – 07:45 R9 Platelet Disorders in Children and Newborns

Chris Van Geet, Belgium

07:00 – 07:45 R10 Laboratory Measurements and the Direct Oral Anticoagulants

Jeffrey I. Weitz, Canada

07:00 – 07:45 R11 Platelet Thrombus Formation

Lawrence Brass, United States

Wednesday, July 12, 2017Master Classes

07:00 – 07:45 R2 Treatment of Acute Deep Vein Thrombosis or Pulmonary Embolism

Harry Büller, the Netherlands

07:00 – 07:45 R3 Coagulation System: Mechanisms and Unanswered Questions

Björn Dahlbäck, Sweden

07:00 – 07:45 R4 Platelets and Coagulation

Johan W. M. Heemskerk, the Netherlands

07:00 – 07:45 R5 TTP Clinical

Johanna Kremer Hovinga, Switzerland

07:00 – 07:45 R6 Hormone Therapy, Pregnancy, and Thrombosis

Saskia Middeldorp, the Netherlands

07:00 – 07:45 R7 Genomics in Large Populations and Rare Inherited Bleeding and Platelet

Diseases: Are They Coming Together?Willem H. Ouwehand, United Kingdom

07:00 – 07:45 R8 Post-Thrombotic Syndrome

Arina ten Cate-Hoek, the Netherlands

Mas

ter

Cla

sses

& C

aree

r D

evel

opm

ent

Ses

sion

s


106 107

Tues

day

CAREER DEVELOPMENT SESSIONS

Tuesday, July 11, 2017Career Development Sessions

13:15 – 14:15 R5 How to Establish a Career in Thrombosis and Hemostasis in Reach-the-World

CountriesPantep Angchaisuksiri, Thailand

13:15 – 14:15 R6 Transitioning to Independence in a Research Career


13:15 – 14:15 R7 How to Set up Animal Studies

Bernhard Nieswandt, Germany

13:15 – 14:15 R8 How to Get Your Paper Published

Frits Rosendaal, the Netherlands


Monday, July 10, 2017Career Development Sessions

13:15 – 14:15 R5 Women at the Top: Building a Research Career as an Investigator

Karin M. Hoffmeister, United States

13:15 – 14:15 R6 How to Nurture a Mentor/Mentee Relationship

Ingrid Pabinger, Austria

13:15 – 14:15 R7 Tips for Preparing Successful Grant Applications

Wolfram Ruf, Germany

13:15 – 14:15 R8 Combining a Clinical and Research Career European View

Andreas Greinacher, Germany

Mas

ter

Cla

sses

& C

aree

r D

evel

opm

ent

Ses

sion

s

SSC PROGRAM


109


108

Scientific Program


Wednesday, July 12, 2017Career Development Sessions

13:15 – 14:15 R5 Combining a Clinical and Research Career: North American View

Mark Crowther, Canada

13:15 – 14:15 R6 ISTH Leadership: My Journey

Claire McLintock, New Zealand

13:15 – 14:15 R7 What Makes an Effective Journal Reviewer?

Klaus T. Preissner, Germany

13:15 – 14:15 R8 Keys to Convincing Scientific Presentations

Denisa Wagner, United States

SCIENTIFIC PROGRAM


111

Mon

day

SCIENTIFIC PROGRAM


110

Sunday, July 9, 2017Scientific Program

18:15 – 21:00 Hall B

Opening Ceremony

Scientific Program

Monday, July 10, 2017

Hall B and A rooms are in the CityCube.

Hall 7 rooms (city names) are in the Messe Berlin.

Legend

Plenary Sessions

State-of-the-Art Sessions

Oral Communication Sessions

Abstract Symposia Sessions

Supported Symposia

Product Theater Presentations

SCIENTIFIC PROGRAMSCIENTIFIC PROGRAM


112 113

Mon

day

Monday, July 10, 2017Scientific Program

State of the Art Symposia

08:00 – 09:15 Hall B

What Happens After Acute VTE?Chairs: Frederikus Klok, the Netherlands Heinrike Wilkens, Germany 08:00 – 08:25 SOA 01.1 Prediction of Recurrence

Sabine Eichinger, Austria 08:25 – 08:50 SOA 01.2 Prevention and Treatment of the Post-Thrombotic Syndrome

Arina ten Cate-Hoek, the Netherlands 08:50 – 09:15 SOA 01.3 Chronic Thromboembolic Pulmonary Hypertension

Irene Lang, Austria

08:00 – 09:15 A1

Regulation of Extracellular ProteolysisChairs: Johann Wojta, Austria Silvio Antoniak, United States 08:00 – 08:25 SOA 02.1 Novel Plasminogen Receptors in Cancer and Inflammation

Lindsey Miles, United States 08:25 – 08:50 SOA 02.2 Moonlighting Plasminogen Binding Proteins: Are Old Proteins Able to Learn

New Tricks?Malgorzata Wygrecka, Germany

08:50 – 09:15 SOA 02.3 PA System and Infection Diseases

Martina Sanderson-Smith, Australia

08:00 – 09:15 A3

Leukocytes in AtherosclerosisChairs: Andreas Zirlik, Germany Christian Weber, Germany

08:00 – 08:25 SOA 03.1 Vaccination Strategies in Atherosclerosis

Klaus Ley, United States 08:25 – 08:50 SOA 03.2 Macrophage Reprogramming in Atherosclerosis

Eicke Latz, Germany

08:50 – 09:15 SOA 03.3 Neutrophils in Atherosclerosis

Oliver Soehnlein, Germany

08:00 – 09:15 A5

Inflammation and Barrier FunctionChairs: Christoph Binder, Austria Silvia Fischer, Germany

08:00 – 08:25 SOA 04.1 Endothelial Cell Junctions in Inflammation

Beat Imhof, Switzerland 08:25 – 08:50 SOA 04.2 Novel Strategies for the Treatment of Sepsis and Blood-Barrier Dysfunction

Gou Young Koh, Republic of Korea

08:50 – 09:15 SOA 04.3 Dynamic Cellular Arrangement During Vascular Remodeling

Holger Gerhardt, Germany

08:00 – 09:15 A6

ISTH-WFH Joint Session: Novel Functions of VWFChairs: Johannes Oldenburg, Germany Alain Weill, France 08:00 – 08:25 SOA 05.1 VWF and Inflammation

Cecile Denis, France

Sta

te o

f th

e A

rt



114 115

Mon

day

08:25 – 08:50 SOA 05.2 VWF and Cerebral Malaria

James O'Donnell, Ireland 08:50 – 09:15 SOA 05.3 VWF in Tumor Thrombophilia and Metastasis

Stefan Schneider, Germany

08:00 – 09:15 A7

Animal Models of Thrombosis and HemostasisChairs: Christophe Dubois, France Jose Lopez, United States 08:00 – 08:25 SOA 06.1 Coagulation and Sickle Cell Disease

Rafal Pawlinski, United States 08:25 – 08:50 SOA 06.2 Hemostasis in Zebrafish

Pudur Jagadeeswaran, United States 08:50 – 09:15 SOA 06.3 Integrating the Platelet Signaling Network With the Hemostatic Response In Vivo

Lawrence Brass, United States

08:00 – 09:15 A8

Life and Death of PlateletsChairs: Oliver Borst, Germany Johan W. M. Heemskerk, the Netherlands 08:00 – 08:25 SOA 07.1 Regulation of Platelet Life and Death

Benjamin Kile, Australia 08:25 – 08:50 SOA 07.2 Procoagulant 'Zombie' Platelets

Johan W. M. Heemskerk, the Netherlands 08:50 – 09:15 SOA 07.3 Proinflammatory Function of Dying Platelets

Shaun Jackson, Australia

Oral Communications

09:30 – 10:45 Hall B

Platelet Signaling 1Chairs: Ingeborg Hers, United Kingdom Shaun Jackson, Australia 09:30 – 09:45 OC 06.1

Rap1A and Rap1B Functional Redundancy in Platelets and MegakaryocytesL. Stefanini (Italy)

09:45 – 10:00 OC 06.2

The Kinase-phosphatase Pair Csk-CD148 is a Critical Regulator of Platelet Reactivity to Vascular InjuryJ. Mori1, Z. Nagy1, R. Al Ghaithi1, S. Heising1, J.P. van Geffen2, M.J.E. Kuijpers2, J.W.M. Heemskerk2, P. Harrison1, A. Mazharian1, Y.A. Senis1 (1United Kingdom, 2the Netherlands)

10:00 – 10:15 OC 06.3

Major Role for Rac/Cdc42 in PI3Kβ-driven Platelet FunctionT. Durrant, T. Chessa, K. Anderson, L. Stephens, P. Hawkins, S. Moore, I. Hers (United Kingdom)

10:15 – 10:30 OC 06.4

CD40L Priming of Platelets and Activation of NF-κB are CD40-dependentK. Kojok, S. El-Akoum, M. Mohsen, W. Mourad, M. Yahye (Canada)

10:30 – 10:45 OC 06.5

Essential Role of GSK3α Phosphorylation in Restricting Platelet Activation and Thrombus FormationI. Hers, J.A. Wersall, E.O. Agbani, R.W. Hunter, A.W. Poole, S.F. Moore (United Kingdom)

09:30 – 10:45 A1

Cellular and Molecular Mechanisms of Fibrinolysis Chairs: Guy Reed, United States Roger Lijnen, Belgium

09:30 – 09:45 OC 01.1The Plasminogen Receptor Plg-RKT is Expressed on Platelets and Co-localises with Platelet-derived Plasminogen upon StimulationC.S. Whyte1, N.A. Booth1, M.M. Jalal1, R.J. Parmer2, L.A. Miles2, N.J. Mutch1 (1United Kingdom, 2United States)

Ora

ls



116 117

Mon

day

09:45 – 10:00 OC 01.2Dysregulation of Metabolic Homeostasis in Plasminogen ReceptorKT (Plg-RKT) Deficient MiceL. Miles, N. Baik, H. Bai, J. Wang, F. Samad, R. Parmer (United States)

10:00 – 10:15 OC 01.3

Neutrophil Extracellular Traps In Thrombi from Patients with Acute Ischemic StrokeE. Laridan, F. Denorme, L. Desender, O. François, T. Andersson, H. Deckmyn, K. Vanhoorelbeke, S.F. De Meyer (Belgium)

10:15 – 10:30 OC 01.4

A Hepatocyte Transcriptional Repressor DACH1 Exacerbates Defective Fibrinolysis in ObesityZ. Zheng, I. Tabas (United States)

10:30 – 10:45 OC 01.5Enhanced Fibrinolysis Using Magnetically Driven Functionalized MicrowheelsD. Disharoon, O. Tasci, K. Neeves, D. Marr, K. Rana (United States)

09:30 – 10:45 A3

Animal Models in Thrombosis Chairs: Nigel Mackman, United States Pudur Jagadeeswaran, United States

09:30 – 09:45 OC 02.1Maintaining Extraembryonic Expression Allows Generation of Adult Mice with Tissue Factor Pathway Inhibitor Gene DisruptionM. Storage, Q. Yang, M. Zhan, A. Mast, R. Sood (United States)

09:45 – 10:00 OC 02.2

Prostacyclin Prevents Deep Vein Thrombosis in COX-2 Knockout MiceP. Amadio, E. Tarantino, L. Sandrini, E. Tremoli, S.S. Barbieri (Italy)

10:00 – 10:15 OC 02.3

Deficiency of Platelet eNOS Produces a Pro-thrombotic PhenotypeS. Momi, G. Guglielmini, E. Falcinelli, P. Gresele (Italy)

10:15 – 10:30 OC 02.4

Amyloid Precursor Protein is a Regulator of Venous Thromboembolism in MiceI. Canobbio, S. Momi, C. Visconte, G.F. Guidetti, M. Zarà, J. Canino, E. Falcinelli, P. Gresele, M. Torti (Italy)

10:30 – 10:45 OC 02.5Absence of Platelet Thrombin Receptor Par4 Prevents Thrombotic and Stroke-like Phenotypes of Thrombomodulin Deficient miceM. Storage, Q. Yang, M. Zhan, R. Sood (United States)

09:30 – 10:45 A5

Platelets in Development and MalignancyChairs: Benjamin Kile, Australia Katsue Suzuki-Inoue, Japan 09:30 – 09:45 OC 03.1

Platelet Activation by CLEC-2-Podoplanin Interaction is Essential for Lung DevelopmentN. Tsukiji, O. Inoue, T. Shirai, S. Tamura, S. Otake, T. Sasaki, K. Satoh, Y. Ozaki, K. Suzuki-Inoue (Japan)

09:45 – 10:00 OC 03.2Platelet Microparticles Infiltrating Solid Tumors Transfer miRNAs and Modulate Tumor GrowthL. Goldfinger, J. Michael, J. Wurtzel, G.F. Mao, A.K. Rao, D. Tomar, M. Muniswamy, M. Nieman, J. Rowley, A. Weyrich (United States)

10:00 – 10:15 OC 03.3

Significance of Transforming Growth Factor-beta Signaling for Thrombofibrotic Remodeling in Murine Venous Thrombi and Human Chronic Thromboembolic Pulmonary HypertensionM.L. Bochenek, C. Leidinger, N.S. Rosinus, M. Lankeit, E. Mayer, T. Münzel, S. Konstantinides, M. Bosmann, K. Schäfer (Germany)

10:15 – 10:30 OC 03.4

Aspirin Therapy Reduces the Ability of Platelets to Promote Colon and Pancreatic Cancer Cell Proliferation: Implications for the Oncoprotein c-MYCA. Mitrugno, J.L. Sylman, A.T.P. Ngo, J. Pang, R.C. Sears, C.D. Williams, O.J.T. McCarty (United States)

10:30 – 10:45 OC 03.5

Platelet Releasate Promotes Breast Cancer Growth and Angiogenesis via VEGF-integrin Cooperative SignalingL. Jiang1, Y. Luan2, X. Miao1, C. Sun2, K. Li2, Z. Huang1, D. Xu1, M. Zhang2, F. Kong2, N. Li1 (1Sweden, 2China)

Ora

ls



118 119

Mon

day

09:30 – 10:45 A6

Mechanisms of (Pro)Platelet Production

Chairs: Katya Ravid, United States Alessandra Balduini, Italy 09:30 – 09:45 OC 04.1

Ultrastructural Characterization of the Cellular Contacts between Megakaryocytes and Endothelial Cells in the Bone MarrowA. Eckly, J.-Y. Rinckel, F. Proamer, F. Lanza, H. de la Salle, C. Gachet (France)

09:45 – 10:00 OC 04.2

Loss of the Hematopoietic Adaptor Protein ADAP Impairs Megakaryocyte Polarization and Induces Ectopic Platelet ReleaseM. Spindler, J.M.M. van Eeuwijk, Y. Schurr, D. Stegner, B. Nieswandt, A. Reinhold, M. Bender (Germany)

10:00 – 10:15 OC 04.3

Centrosome Destabilization through the Ubiquitin-proteasome Pathway Regulates Proplatelet ProductionK. Machlus, P. Vijey, T. Soussou, J. Italiano (United States)

10:15 – 10:30 OC 04.4

Scalable Production of Human Platelets in a BioreactorL. Beaulieu, B. Dykstra, C. Peters, J. Italiano, Jr, J. Thon (United States)

10:30 – 10:45 OC 04.5

Platelet Release from Infused Megakaryocytes is Largely Limited to the Pulmonary VasculatureI. Johnston, D. Jarocha, V. Hayes, L. Rauova, M. Poncz (United States)

09:30 – 10:45 A7

Protease-Activated ReceptorsChairs: Justin Hamilton, Australia Patricia Liaw, Canada 09:30 – 09:45 OC 05.1

The Lipid-raft Organizer Tetherin Negatively Regulates Platelet Receptor FunctionX. Zhao, D. Alibhai, J.L. Hutchinson, S. Cross, C.M. McKinnon, R. Aungraheeta, A. Poole, G. Banting, S.J. Mundell (United Kingdom)

09:45 – 10:00 OC 05.2bPAR-1 Protects Mice from Influenza A Virus Infection by Regulating Vascular Permeability and the Innate Immune ResponseS. Antoniak1, K. Tatsumi2, N. Mackman1 (1United States, 2Japan)

10:00 – 10:15 OC 05.3

PAR-1 Limits Coxsackievirus B3 Hepatitis in vivo and in vitroS. Antoniak1, K. Burkey1, K. Tatsumi2, N. Mackman1 (1United States, 2Japan)

10:15 – 10:30 OC 05.4

Protease Activated Receptor-1 (PAR-1) Impedes Tumor Progression by Promoting Tumor Cell ApoptosisG. Adams, E. Laws, L. Rosenfeldt, M. Frederick, A. Remiker, E. Mullins, M. Flick, K. Steinbrecher, J. Palumbo (United States)

10:30 – 10:45 OC 05.5

PAR2 Mutant Mice Provide New Insights into Protease Signaling Specificity in the Tumor MicroenvironmentC. Graf, P. Wilgenbus, W. Ruf (Germany)

09:30 – 10:45 New York

Rare Bleeding DisordersChairs: Flora Peyvandi, Italy Nigel Key, United States 09:30 – 09:45 OC 07.1

ThromboGenomics: HTS Diagnosis of Inherited Bleeding, Thrombotic, Coagulation and Platelet DisordersK. Downes1, K. Freson2, K. Gomez1, on behalf of ThromboGenomics and the Genomic Medicine Centre at Cambridge University Hospitals (GMC@CUH) (1United Kingdom, 2Belgium)

09:45 – 10:00 OC 07.2An International Prospective Cohort of Rare Bleeding Disorders: Results of a Follow-up Study on Patients with Factor XIII Deficiency (PRO-RBDD)M. Menegatti1, R. Palla1, M. Boscarino1, S. Halimeh2, M.A. Daoud2, M. Borhany3, N. Fatima3, N. Ozdemir4, S.M. Siboni1, D. Mikovic5, M. Saracevic5, A. Mumford6, A. Harvey6, R.E. Schutgens7, M. van Haaften-Spoor7, C. McGuinn8, M. Ly8, H. Platokouki9, H. Pergantou9, A. Yimaz4, A.D. Shapiro8, A. Williamson8, P. De Moerloose10, A. Casini10, J. Payne6, L. Muszbek11, F. Peyvandi1 (1Italy, 2Germany, 3Pakistan, 4Turkey, 5Serbia, 6United Kingdom, 7the Netherlands, 8United States, 9Greece, 10Switzerland, 11Hungary)

Ora

ls



120 121

Mon

day

10:00 – 10:15 OC 07.3Profile of Mutations Identified in the 3Winters-IPS Project on a Cohort of European Patients with Previously Diagnosed Type 3 von Willebrand DiseaseA. Goodeve1, R. Schneppenheim2, L. Crookes1, N. Niksic1, F. Oyen2, L. Baronciani3, J. Batlle4, E. Berntorp5, I. Bodo6, U. Budde2, G. Castaman3, J. Eikenboom7, C. Ettorre3, J. Goudemand8, W. Hassenpflug2, C. Hay1, R. Lassila9, F. Leebeek7, M.F. Lopez Fernandez4, P.M. Mannucci3, M.G. Mazzucconi3, M. Morfini3, J. Oldenburg2, R. Parra Lòpez4, I.R. Peake1, F. Peyvandi3, A. Tiede2, A. Tosetto3, M. Trossaert8, E. Zetterberg5, A.B. Federici3, 3WiNTERS (1United Kingdom, 2Germany, 3Italy, 4Spain, 5Sweden, 6Hungary, 7the Netherlands, 8France, 9Finland)

10:15 – 10:30 OC 07.4

Endoplasmic Reticulum Stress and the Unfolded Protein Response in Congenital FVII DeficiencyE. Andersen1, M.E. Chollet1, C.F. Myklebust1, M. Pinotti2, F. Bernardi2, E. Skarpen1, P.M. Sandset1, G. Skretting1 (1Norway, 2Italy)

10:30 – 10:45 OC 07.5

Characterization of GGCX Mutations Identified in VKCFD1 PatientsS. Ghosh, K.J. Czogalla, J. Müller, K. Hoening, V. Hornung, M. Watzka, J. Oldenburg (Germany)

09:30 – 10:45 London

VWF: Biosynthesis and Mechanisms of ActionChairs: Simon De Meyer, Belgium Laura L. Swystun, Canada 09:30 – 09:45 OC 08.1

A Discontinuous Autoinhibitory Module Masks the A1 Domain of VWFW. Deng, Y. Wang, S.A. Druzak, J.F. Healey, A.K. Syed, P. Lollar, R. Li (United States)

09:45 – 10:00 OC 08.2Allele-specific Inhibition of von Willebrand Factor p.Cys2773Ser Restores a Severe Multimerization DefectA. de Jong, R.J. Dirven, J.A. Oud, D. Tio, J. Eikenboom (the Netherlands)

10:00 – 10:15 OC 08.3

Altered Sialylation in Patiens with Low von Willebrand Factor LevelsS. Aguila1, M. Lavin1, N. Dalton1, M. Byrne1, T. Brophy1, A. Chion1, J. Di Paola2, J. O'Donnell1 (1Ireland, 2United States)

10:15 – 10:30 OC 08.4The N-terminal TIL'-E' Domains of von Willebrand Factor Requires a Structurally Intact VWD3 Domain for Optimal Factor VIII BindingM. Przeradzka, H. Meems, C. van der Zwaan, M. van der Biggelaar, K. Mertens, A.B. Meijer (the Netherlands)

10:30 – 10:45 OC 08.5

The Redox State of the von Willebrand Factor A2 Domain Disulphide Bond Controls Platelet GPIbα BindingD. Butera, F. Passam, L. Ju, P. Hogg (Australia)

09:30 – 10:45 Helsinki 1

ADAMTS 13 and TTP Basic

Chairs: Johanna Kremer Hovinga, Switzerland Karen Vanhoorelbeke, Belgium 09:30 – 09:45 OC 09.1

Conformation of ADAMTS13 is Altered in Acquired TTP PatientsE. Roose1, A.-S. Schelpe1, B. Joly2, A. Vandenbulcke1, J. Caron1, I. Pareyn1, N. Vandeputte1, M. Peetermans1, P. Verhamme1, H. Deckmyn1, S.F. De Meyer1, P. Coppo2, A. Veyradier2, K. Vanhoorelbeke1 (1Belgium, 2France)

09:45 – 10:00 OC 09.2

PAD4 Citrullination of ADAMTS13: A New Link between NETosis and ThrombosisN. Sorvillo, K. Martinod, C. Staudinger, D. Wagner (United States)

10:00 – 10:15 OC 09.3

The Role of ADAMTS13 Exosites in VWF Recognition and ProteolysisA. Petri, R. de Groot, Y. Xu, J. Crawley (United Kingdom)

10:15 – 10:30 OC 09.4Autoantibody Binding to 'Open' and 'Closed' ADAMTS13 in Patients with Acquired Immune Thrombotic Thrombocytopenic PurpuraM.I. Underwood, M.R. Thomas, M.A. Scully, J.T.B. Crawley (United Kingdom)

10:30 – 10:45 OC 09.5

Parallel Profiling of ADAMTS13-derived Peptide Repertoires on HLA-DR and HLA-DQJ. Hrdinová1, F. Verbij1, P.H.P. Kaijen1, R.B. Hartholt1, F.P.J. van Alphen1, N. Lardy1, A. ten Brinke1, K. Vanhoorelbeke2, J. Voorberg1, A.B. Meijer1, I. Peyron1 (1the Netherlands, 2Belgium)

Ora

ls



122 123

Mon

day

09:30 – 10:45 Helsinki 2

Future Biotherapeutics for Hemophilia A and BChairs: Michael Laffan, United Kingdom Johnny Mahlangu, South Africa 09:30 – 09:45 OC 10.1

An Engineered Serpin for the Treatment of HaemophiliaS. Polderdijk1, T. Adams1, L. Ivanciu2, R. Camire2, T. Baglin1, J. Huntington1 (1United Kingdom, 2United States)

09:45 – 10:00 OC 10.2

Antithrombin Resistance and Heparosan Conjugation Synergistically Extend the in vivo Half-life of FVIIaM.B. Hermit1, P.S. Gandhi1, C. Behrens1, M. Dainiak1, O.H. Olsen1, A.A. Pedersen1, G. Andersen1, K. Lamberth1, J.J. Hansen1, M.A. Zundel1, P.L. Deangelis2, F.M. Haller2, E. Cló1, J. Breinholt1, M. Åkesson1, M.S. Jensen1, H. Pelzer1, L. Hansen1, H. Stennicke1, I. Hilden1, H. Østergaard1 (1Denmark, 2United States)

10:00 – 10:15 OC 10.3

Pharmacokinetic and Activity Levels Achieved with Daily Subcutaneously Administered CB 2679d/ISU304 in Hemophilia B DogsH. Levy, T. Nichols, E. Merricks, R. Raymer, A. Hetherington (United States)

10:15 – 10:30 OC 10.4

FcRn Mediated Recycling of Recombinant VWF D'D3-albumin Fusion Protein /rVIII-SingleChain Complex Is a Mechanism for FVIII Half-life ExtensionJ. Chia1, I. Glauser1, A. Andrews1, T. Weimer2, M. Wilson1, A. Verhagen1 (1Australia, 2Germany)

10:30 – 10:45 OC 10.5Half-life Extension of FVIII by Coadministration of a Recombinant D´D3 Albumin Fusion ProteinS. Pestel1, E. Raquet1, M. Mischnik1, P. Claar1, A. Andrews2, E. Herzog1, T. Weimer1 (1Germany, 2Australia)

09:30 – 10:45 Budapest

Pediatric ThrombosisChairs: M. Patricia Massicotte, Canada Elizabeth Chalmers, United Kingdom

09:30 – 09:45 OC 11.1Development of a Predictive Risk Model for Deep Vein Thrombosis in Pediatric Oncology PatientsL. Mitchell1, F. Ruehle2, L. Brandão1, J. Halton1, S. Israels1, K. Dietrich1, M. Spavor1, M. Stoll2, ABLE Investigators (1Canada, 2Germany)

09:45 – 10:00 OC 11.2

External Validation of a Venous Thromboembolism Risk Prediction Tool for Critically Ill Children - The Cleveland ScoreR. Talati, M. Tran, S.L. Shein, X. Ji, K. Chagin, H. Ding, S.P. Ahuja (United States)

10:00 – 10:15 OC 11.3

External Validation of Risk Prediction Models for Catheter-associated Thrombosis in Critically Ill ChildrenJ. Rutgers1, S. Jones1, P. Monagle1, F. Newall1, E.V. Faustino2 (1Australia, 2United States)

10:15 – 10:30 OC 11.4

Thrombophilia in Children to Predict Recurrent Line-related Thrombosis: Time to Choose WiselyM.L. Avila, N. Amiri, K. Barron, T. Vu, P. Krol, N. Yue, S. Williams, L.R. Brandão (Canada)

10:30 – 10:45 OC 11.5

Predictive Factors for Central Venous Catheter-related Thrombosis and Long Term SequelaeS. Jones, J. Rutgers, W. Butt, F. Newall, P. Monagle (Australia)

Ora

ls



124 125

Mon

day

09:30 – 10:45 Berlin

Predictors of ThromboembolismChairs: Francesco Dentali, Italy Marc Rodger, Canada 09:30 – 09:45 OC 12.1

Prevalence of Major Medical Illnesses Associated with Venous Thromboembolism Risk in US HospitalsA.T. Cohen1, W. Huang2, R.A. Harrington2, S.Z. Goldhaber2, R.D. Hull3, A.F. Hernandez2, C.M. Gibson2, F.A. Anderson2 (1United Kingdom, 2United States, 3Canada)

09:45 – 10:00 OC 12.2

Venous Thromboembolism and Physical Function in the Nurses' Health StudyK. Hagan, L. Harrington, J. Kim, F. Grodstein, C. Kabrhel (United States)

10:00 – 10:15 OC 12.3

Catheter-related Venous Thromboembolism in Hospitalized Pediatric Patients with Inflammatory Bowel Disease: A Retrospective Study Assessing Prevalence, Characteristics and Role of Anticoagulant Thromboprophylaxis with EnoxaparinJ. Meldau, C. Hennessey, C. Guelcher, D. Carrie, M. Guerrera, Y. Diab (United States)

10:15 – 10:30 OC 12.4

External Validation and Comparison of the Improve Risk Assessment Model with the Geneva Risk Assessment Model in the ESTIMATE CohortM. Blondon, D. Spirk, N. Kucher, D. Aujesky, D. Hayoz, J. Beer, M. Husmann, B. Frauchiger, W. Korte, W. Wuillemin, H. Bounameaux, M. Righini, M. Nendaz (Switzerland)

10:30 – 10:45 OC 12.5

Genetics InFormatics Trial (GIFT) of Warfarin to Prevent Deep Venous Thrombosis: Improvement in Time Spent in the Therapeutic INR RangeB. Gage, A.R. Bass, H. Lin, S. Woller, S. Stevens, N. Al-Hammadi, T. Rodriguez Jr., J.P. Miller, G. McMillin, R. Pendleton, A. Jaffer, C. King, B. DeVore, R. Porche-Sorbet, L. Napoli, K. Merritt, A. Joykutty, G. Hyun, J. Anderson, W. Hollomon, R. Barrack, R. Nunley, G. Moskowitz, V. Davila-Roman, C. Eby (United States)

10:45 – 11:15 Coffee break in Exhibition Halls

Plenary

11:15 – 12:00 Hall B

Marion I. Barnhart Memorial Lecture: Platelet SignalingChairs: Bernhard Nieswandt, Germany 11:15 – 12:00 PL 01 Snakes and Ladders: New Roles for Platelets in Health and Disease

Stephen Watson, United Kingdom

12:00 – 13:15 Lunch, Poster Session and Industry Exhibition in Exhibition Halls

Product Theaters12:15 – 13:00 See page 535

Supported Symposia13:15 – 14:30 See page 529

Abstract Symposia

14:45 – 16:15 Hall B

Clinical Research and Outcomes in HemophiliaChairs: Donna DiMichele, United States Christoph Königs, Germany 14:45 – 15:15 ASY 01 Outcomes in Hemophilia

Marilyn Manco-Johnson, United States 15:15 – 15:30 ASY 01.1

Efficacy, Safety and Pharmacokinetics (PK) of Emicizumab (ACE910) Prophylaxis (Px) in Persons with Hemophilia A with Inhibitors (PwHAwI): Randomized, Multicenter, Open-label, Phase 3 Study (HAVEN 1)J. Oldenburg1, J. Mahlangu2, B. Kim3, C. Schmitt4, M. Callaghan3, G. Young3, E. Santagostino5, R. Kruse-Jarres3, C. Negrier6, C. Kessler3, N. Valente3, E. Asikanius4, G. Levy3, J. Windyga7, M. Shima8 (1Germany, 2South Africa, 3United States, 4Switzerland, 5Italy, 6France, 7Poland, 8Japan)

Abs

trac

ts



126 127

Mon

day

15:30 – 15:45 ASY 01.2Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Interim Results from a Phase 2 Extension Study in Patients with Hemophilia A or B with and without InhibitorsK.J. Pasi1, P. Georgiev2, T. Mant1, M.D. Creagh1, T. Lissitchkov2, D. Bevan1, S. Austin1, C. Hay1, I. Hegemann3, R. Kazmi1, P. Chowdary1, S. Rangarajan1, C.-H. Soh4, A. Monpara4, H.V. Nguyen4, K. Madigan4, M.V. Ragni4 (1United Kingdom, 2Bulgaria, 3Switzerland, 4United States)

15:45 – 16:00 ASY 01.3

Musculoskeletal Ultrasound for Intra-articular Bleed Detection: A Highly Sensitive Imaging Modality Compared to Conventional Magnet Resonance ImagingS. Nguyen, X. Lu, Y. Ma, J. Du, E.Y. Chang, A. von Drygalski (United States)

16:00 – 16:15 ASY 01.4The Thunder Study: Haemophilia Epidemiology Treatment, Outcome and Unmet Needs in the UK: An Analysis from the UK National Haemophilia DatabaseC.R. Hay1, B.P. Palmer1, M. Scott1, H. Xiang1, C. Sima2, D.P. Hart1, P.W. Collins1 (1United Kingdom, 2United States)

14:45 – 16:15 A1

Structural Biology in CoagulationChairs: James Huntington, United Kingdom Jonas Emsley, United Kingdom 14:45 – 15:15 ASY 02 Structural Correlates of Function in Coagulation

Sriram Krishnaswamy, United States 15:15 – 15:30 ASY 02.1

Human-snake Chimeras of Cofactor V Reveal Allostery between the A- and C-domainsD. Verhoef1, G.A.F. Nicolaes1, R. Schrijver1, R.M. Camire2, P.H. Reitsma1, M.H.A. Bos1 (1the Netherlands, 2United States)

15:30 – 15:45 ASY 02.2

Uncovering the Unique Functional APC-resistant Modifications of Snake Venom FVM. Schreuder, D. Verhoef, K.L. Cheung, P.H. Reitsma, M.H.A. Bos (the Netherlands)

15:45 – 16:00 ASY 02.3X-ray Crystallographic Studies of the Factor VIII C2 Domain in Complex with O-phospho-L-serine Indicate that Arg 2320 Contributes to the Phospholipid Membrane Binding SiteP.C. Spiegel, S. Wo (United States)

16:00 – 16:15 ASY 02.4

Full Length Activated Plasma Prekallikrein Crystal Structure reveals Autoactivation Model Involving the Apple DomainsC. Li, J. Emsley (United Kingdom)

14:45 – 16:15 A2

Microbiota as an Environmental Risk FactorChairs: Tobias A. Fuchs, Germany Matthew Rondina, United States 14:45 – 15:15 ASY 03 Microbiota and Thrombosis

Christoph Reinhardt, Germany 15:15 – 15:30 ASY 03.1

Platelet Necrosis Induces Neutrophil Macro-aggregation and Pulmonary Thrombosis Following Gut IschemiaY. Yuan, I. Alwise, M. Wu, Z. Kaplan, K. Ashworth, A. Pham, J. Mcfadyen, S. Schoenwaelder, E. Josefsson, B. Kile, S. Jackson (Australia)

15:30 – 15:45 ASY 03.2

Going against the Flow: How Staphylococcus Aureus and Staphylococcus Lugdunensis Adhere to the Heart Valves and Initiate Endocarditis by Binding to von Willebrand FactorL. Liesenborghs, J. Claes, M. Peetermans, R.T. Veloso, M. Criel, M. Lox, G. Vande Velde, T. Vanassche, M. Hoylaerts, P. Verhamme (Belgium)

15:45 – 16:00 ASY 03.3

Soluble Short Fractions of β-1,3 Glucans Derived from Candida albicans Act as a Shield for Pathogenic Yeasts and Modulate the Activation of PlateletsH. Vancraeyneste1, R. Charlet1, Y. Guerardel1, L. Choteau1, A. Bauters1, M. Tardivel1, N. Francois1, L. Dubuquoy1, D. Soloviev2, D. Poulain1, B. Sendid1, S. Jawhara1 (1France, 2United States)

16:00 – 16:15 ASY 03.4

VWF and ADAMTS-13 Modulate the Outcome of Staphylococcus aureus SepsisM. Peetermans, L. Liesenborghs, J. Claes, M. Jacquemin, K. Vanhoorelbeke, M.F. Hoylaerts, S. De Meyer, T. Vanassche, P. Verhamme (Belgium)

Abs

trac

ts



128 129

Mon

day

14:45 – 16:15 A3

Platelet DiagnosticsChairs: Kerstin Jurk, Germany Keith Neeves, United States 14:45 – 15:15 ASY 04 Platelet Diagnostics - Critical Appraisal of Current Methodology

Paolo Gresele Italy 15:15 – 15:30 ASY 04.1

A Microfluidic Model of Hemostasis Sensitive to Platelet Function and CoagulationR.M. Schoeman, N. Danes, K. Leiderman, K.B. Neeves (United States)

15:30 – 15:45 ASY 04.2Introduction of a National Protocol for Light Transmission Aggregometry in the Netherlands: Results of More than 80 Healthy Volunteers Before and after StandardisationY. Henskens, F. van der Graaf, H. Hopman-Kerkhoff, C. Hudig, M. de Maat, M. Schoorl, J. Slomp, A. Stroobants (the Netherlands)

15:45 – 16:00 ASY 04.3

Three-Dimensional Fluorescence Emission Computed Tomography (FLECT) with a Newly Generated Activated Platelet-specific Fluoroprobe: A Unique Technology for the Diagnosis of Thrombotic DiseasesB. Lim1, Y. Yao1, A.L.-I. Huang1, M.L. Yap1, U. Flierl2, J. Palasubramaniam1, X. Wang1, K. Peter1 (1Australia, 2Germany)

16:00 – 16:15 ASY 04.4

Novel Integrin αIIbβ3 and GPIbα Coatings that Feature Anti-fouling Properties for Platelet Research and Clinical DiagnosticsM.A.D. Neves, Y. Wang, G. Zhu, R.C. Gallant, T.W. Stratton, M. Thompson, H. Ni (Canada)

14:45 – 16:15 A5

Autoimmune ThrombocytopeniaChairs: Cindy E. Neunert, United States Douglas Cines, United States 14:45 – 15:15 ASY 05 Immune Thrombocytopenia (ITP): New Insights From Clinical Studies


15:15 – 15:30 ASY 05.1Enhancing Autophagy Protects Platelets in Immune Thrombocytopenia PatientsS. Ma, C. Wang, J. Miao, M. Hou, J. Peng (China)

15:30 – 15:45 ASY 05.2

Antibody Mediated Glycan Modification: A Potential Role in Platelet Destruction in Autoimmune ThrombocytopeniaR. Jouni, I. Marini, J. Alex, L. Janzen, A. Greinacher, T. Bakchoul (Germany)

15:45 – 16:00 ASY 05.3Fc-independent Immune Thrombocytopenia via Mechanomolecular Signaling in PlateletsM. Quach1, M. Dragovich1, W. Chen1, A. Syed1, X. Liang1, W. Deng1, H. Ni2, S. De Meyer3, J. Ware1, H. Deckmyn3, F. Zhang1, R. Li1 (1United States, 2Canada, 3Belgium)

16:00 – 16:15 ASY 05.4Induction of Immune Thrombocytopenia in Mice Expressing Human Fcy Receptors: An Improved Experimental Model that Better Reflects the Inflammatory State Associated with ITPM. Davila, T. Meyer, L. Robles-Carrillo, H. Desai, M. Rivera-Amaya, J. Francis, A. Amirkhosravi (United States)

14:45 – 16:15 A6

Antiphospholipid SyndromeChairs: Karen Schreiber, United Kingdom Karl Lackner, Germany 14:45 – 15:15 ASY 06 Antiphospholipid Syndrome 2017 Update

Doruk Erkan, United States 15:15 – 15:30 ASY 06.1

IgM Antibodies against Oxidation-specific Epitopes Identify Patients with a Lupus Anticoagulant at Risk for Thrombotic Complications: The Vienna Lupus Anticoagulant and Thrombosis StudyF. Posch, L. Alic, S. Koder, J. Gebhart, C. Ay, C.J. Binder, I. Pabinger (Austria)

15:30 – 15:45 ASY 06.2

Differences in the Platelet Proteome Between Lupus Anticoagulant Positive Individuals with or without Thrombotic Manifestations and Healthy ControlsL. Hell, K. Lurger, J. Gebhart, S. Koder, C. Ay, I. Pabinger, M. Zellner (Austria)

Abs

trac

ts



130 131

Mon

day

15:45 – 16:00 ASY 06.3Antiphospholipid Antibody Induced Cellular Signal Transduction Depends on Antigen SpecificityA. Hollerbach, N. Müller-Calleja, K. Lackner (Germany)

16:00 – 16:15 ASY 06.4

Complement-dependent Monocyte TF Activation Triggers Antiphospholipid Antibody Internalization and ROS SignalingN. Müller-Calleja, K. Lackner, W. Ruf (Germany)

14:45 – 16:15 A7

FXIIIChairs: Robert A.S. Ariëns, United Kingdom Nicola Mutch, United Kingdom 14:45 – 15:15 ASY 07 Recent Advances in FXIII

Robert A.S. Ariëns, United Kingdom 15:15 – 15:30 ASY 07.1

Deriving the Full Atom Structure for the Coagulation Factor XIII A2B2 Hetero-tetrameric Complex by Molecular Modeling Using Guiding Constraints Based on Mass Spectrometric Analysis of the ComplexS. Singh1, A. Nazabal2, V. Ivaskevicius1, J. Dodt1, H. Philippou3, J. Oldenburg1, A. Biswas1 (1Germany, 2Switzerland, 3United Kingdom)

15:30 – 15:45 ASY 07.2

Reciprocal Inter-tissue Regulation of Factor XIII-A and -B Subunits Determines Factor XIII Levels in PlasmaJ.R. Byrnes, A.S. Wolberg (United States)

15:45 – 16:00 ASY 07.3

Plasma-, but Not Platelet-factor XIII Promotes Red Blood Cell Retention in Contracted Clots and Mediates Clot Size during Venous ThrombosisS. Kattula, J.R. Byrnes, S.M. Martin, B.C. Cooley, M.J. Flick, A.S. Wolberg (United States)

16:00 – 16:15 ASY 07.4

FXIII on Cold-stored Platelet Surface Enhance Clot Contraction and Anti-fibrinolysisP.M. Nair, X. Wu, J.D. Keesee, L. Bin, A.P. Cap, A.K. Ramasubramanian (United States)

14:45 – 16:15 A8

Platelet Receptor SignalingChairs: Lucia Stefanini, Italy Stephen Watson, United Kingdom 14:45 – 15:15 ASY 08 GPVI: More Than a Collagen Receptor and More Than an Antithrombotic Target

Pierre Mangin, France 15:15 – 15:30 ASY 08.1

CLEC2 Contributes to Hemostasis Independently of Classical HemiTAM Signaling in MiceE.J. Haining1, D. Stegner1, D. Cherpokova1, K. Wolf1, S.P. Watson2, B. Nieswandt1 (1Germany, 2United Kingdom)

15:30 – 15:45 ASY 08.2

Desialylation of O-glycans on GPIbα Drives Receptor Signaling and Platelet ClearanceY. Wang, W. Chen, C. Casari, S.A. Druzak, W. Bergmeier, J. Ware, R. Li (United States)

15:45 – 16:00 ASY 08.3

Impaired GlycoproteinVI-mediated Signaling and Platelet Functional Responses in CD45 Knockout MiceV. Inamdar, J. Kostyak, R. Badolia, C. Dangelmaier, B.K. Manne, A. Patel, S. Kim, S. Kunapuli (United States)

16:00 – 16:15 ASY 08.4

Visualizing Cooperative Mechanosensing of GPIb and GPIIb-IIIa on a Single Aspirated PlateletL. Ju1, Y. Chen2, S. Jackson1, C. Zhu2 (1Australia, 2United States)

14:45 – 16:15 New York

Regulation of Vascular Function by Noncoding RNAsChairs: Margitta Elvers, Germany Leon J. Schurgers, the Netherlands 14:45 – 15:15 ASY 09 Regulation of Vascular Function by Noncoding RNAs

Stefanie Dimmeler Germany

Abs

trac

ts



132 133

Mon

day

15:15 – 15:30 ASY 09.1Thrombin-reduced miR-27b Attenuates Platelet Angiogenic Activities via Enhancing Platelet de Novo Synthesis of Anti-angiogenic Thrombospondin-1X. Miao, M.F.-U. Rahman, L. Jiang, S. Tan, H. Xie, W.-O. Lui, N. Li (Sweden)

15:30 – 15:45 ASY 09.2

Human Endothelial Cells Infected with Staphylococcus aureus Leads to an Up-regulation of miR-330, Resulting in Loss of Barrier Integrity in an ex vivo Model of SepsisR.L. Watkin, O. Piskereva, S. Das, S. Madden, R. Stallings, S.W. Kerrigan (Ireland)

15:45 – 16:00 ASY 09.3

Identification of Eight Oestrogen-sensitive miRNAs that Regulate Coagulation Factors, One of which (miR-365a-3p) Inhibits Tissue Factor ExpressionJ. Tian, J. Tay, Q. Hughes, J. Tiao, R. Baker (Australia)

16:00 – 16:15 ASY 09.4

Everolimus Eluting Coronary Stenting Elicits Less Cellular Activation via Altered miRNA Levels in Plasma and Endothelial CellsZ. Fejes, T. Szük, Z. Czimmerer, S. Póliska, E. Balogh, V. Jeney, I. Édes, J. Kappelmayer, B. Nagy Jr. (Hungary)

14:45 – 16:15 London

Bleeding Management Under Oral AnticoagulationChairs: Walter Ageno, Italy Elaine Hylek, United States 14:45 – 15:15 ASY 10 Bleeding Under Direct Oral Anticoagulants

Jeffrey I. Weitz, Canada 15:15 – 15:30 ASY 10.1

Mortality in Patients with Intracerebral Hemorrhage Associated with Vitamin K Antagonists, Direct Oral Anticoagulants, Antiplatelets or No Antithrombotic TherapyL. Franco1, M. Paciaroni1, L. Latte1, A. Chiti1, S. Mazzoli1, S. Vanni1, F. Guideri1, A. Giossi1, D. Consoli1, V. Terruso1, M. Romoli1, G. Manina1, C. Nitti1, R. Re1, S. Sacco1, R. Cappelli1, J. Beyer-Westendorf2, S. Cattinelli1, F. Pomero1, M. Giuntini1, F. Corea1, G. Agnelli1, C. Becattini1 (1Italy, 2Germany)

15:30 – 15:45 ASY 10.2Rates, Management and Outcome of Bleeding Complications during Apixaban and Edoxaban Therapy in Daily Care - Results from the Dresden NOAC Registry (NCT01588119)S. Marten, S. Helmert, I. Beyer-Westendorf, M. Göbelt, L. Tittl, J. Beyer-Westendorf (Germany)

15:45 – 16:00 ASY 10.3

Prevention of Exsanguination under Apixaban Anticoagulation Using Andexanet Alfa in a Polytrauma ModelO. Grottke1, T. Braunschweig1, N. Akman1, R. Rossaint1, P.B. Conley2, J.M. Leeds2, M. Honickel1 (1Germany, 2United States)

16:00 – 16:15 ASY 10.4Reduction of Hepatic Factor XII Expression in Mice by ALN-F12 Inhibits Thrombosis without Increasing Bleeding RiskJ. Liu, J. Qin, B. Cooley, J. Butler (United States)

14:45 – 16:15 Helsinki 1

Safety of Blood Components and Blood Transfusions Chairs: Hermann Eichler, Germany Thomas Thiele, Germany

14:45 – 15:15 ASY 11 Safety and Inactivation of Blood Components

Michael Schmidt, Germany 15:15 – 15:30 ASY 11.1

Synthesis of the First GMP Grade Biotin 3-sulfo N-Hydroxysuccimide Is now Available to Label Blood Cells Intended for Human Transfusion Studies, but not ExclusivelyG. Kemperman1, J. Basten1, M.-C. Viaud-Massuard2, C. Ravanat2, P. Ohlmann2 (1the Netherlands, 2France)

15:30 – 15:45 ASY 11.2

French Lyophilized Plasma versus Fresh Frozen Plasma for the Initial Management of Trauma Induced Coagulopathy: A Randomized Open-label TrialD. Garrigue-Huet, A. Godier, A. Glacet, J. Labreuche, E. Kipnis, E. Resch, P. Goldstein, A. Bauters, B. Tavernier, A. Sailliol, S. Susen (France)

Abs

trac

ts



134 135

Mon

day

15:45 – 16:00 ASY 11.3The Neutralization of CD40/CD40L Complex Inhibits TRALI Development in a Mouse Model Induced through Lipopolysaccharide and Anti-MHC I mAb InjectionS. Tariket, C.-A. Arthaud, A. Meneveaux, H. Hamzeh-Cognasse, O. Garraud, F. Cognasse (France)

16:00 – 16:15 ASY 11.4

Controlling Hydrophobicity to Minimize Thrombogenic Risk on Medical Devices in an Arterial EnvironmentD. Bark Jr. (United States)

14:45 – 16:15 Helsinki 2

Rare Bleeding DisordersChairs: Amy Shapiro, United States Raimondo De Cristofaro, Italy 14:45 – 15:15 ASY 12 Lessons Learned From RBD Databases

Danijela Mikovic, Serbia 15:15 – 15:30 ASY 12.1

Next Generation Sequencing in Patients with No Apparent Laboratory Platelet Defect Despite Having an Extensive Bleeding HistoryA. Maclachlan, S.P. Watson, N.V. Morgan (United Kingdom)

15:30 – 15:45 ASY 12.2An International Prospective Cohort Study of Patients with Fibrinogen Deficiency (PRO-RBDD Study)R. Palla1, M. Menegatti1, M. Boscarino1, J. Blatny2, O. Zapletal2, J.F. Schved3, M. Giansily-Blaizot3, S. Halimeh4, M.A. Daoud4, H. Platokouki5, H. Pergantou5, S.M. Siboni1, P. Brons6, B. Laros Van Gorkom6, E. van Pinxten6, R.E.G. Schutgens6, M. van Haaften-Spoor6, M. Borhany7, N. Fatima7, D. Mikovic8, M. Saracevic8, P. De Moerloose9, A. Casini9, N. Ozdemir10, Y. Ay10, S.K. Austin11, P. Quartey11, M. Makris11, C. Lockley11, A.D. Shapiro12, A. Williamsonn12, C. McGuinn12, M. Ly12, F. Peyvandi1 (1Italy, 2Czech Republic, 3France, 4Germany, 5Greece, 6the Netherlands, 7Pakistan, 8Serbia, 9Switzerland, 10Turkey, 11United Kingdom, 12United States)

15:45 – 16:00 ASY 12.3

Studying Adaptor Protein 3 Dependent Trafficking to Weibel-Palade Bodies Using Hermansky-Pudlak Syndrome Type 2 Blood Outgrowth Endothelial CellsE. Karampini, M. Hofman, F.P.J. van Alphen, T. Kuijpers, S. Meijer, J. Voorberg, R. Bierings (the Netherlands)

16:00 – 16:15 ASY 12.4Involvement of OCRL, a Phosphoinositide 5-phosphatase, in Cytoskeleton Reorganization and Megakaryocyte MaturationS. Poirault-Chassac, E. Dreano, M. Egot, D. Pidard, R. Salomon, G. Baujat, D. Lasne, P. Gaussem, C. Bachelot-Loza (France)

14:45 – 16:15 Budapest

Risk Factors for Carotid Atherosclerosis and StrokeChair: Robert Medcalf, Australia H.M.H. Spronk, the Netherlands 14:45 – 15:15 ASY 13 Risk Factor for Stroke

Gregory Lip, United Kingdom 15:15 – 15:30 ASY 13.1

Impact of Venous Thromboembolism on Formation and Progression of Carotid Atherosclerosis - The Tromsø StudyC. Lind1, B. Småbrekke1, L. Balteskard Rinde1, K. Hindberg1, E. B. Mathiesen1, S.H. Johnsen1, K.A. Arntzen1, I. Njølstad1, W. Lijfering2, S. Brækkan1, J.-B. Hansen1 (1Norway, 2the Netherlands)

15:30 – 15:45 ASY 13.2

Carotid Atherosclerotic Plaque Matrix Metalloproteinase-2 Content Predicts Adverse Outcome in Patients Undergoing EndarterectomyG. Gubbiotti, G. Isernia, E. Falcinelli, G. Guglielmini, M. Lenti, P. Gresele (Italy)

15:45 – 16:00 ASY 13.3

Vascular Matrix Metalloproteinase-9 Enhances Blood Brain Barrier Breakdown and Ischemic Brain Injury in Experimental Thromboembolic StrokeS. Singh, T. Zhao, A. Houng, S. Saleem, G. Reed (United States)

16:00 – 16:15 ASY 13.4

High Risk of Ischemic Stroke in Patients with Acute Pulmonary Embolism and Patent Foramen Ovale: Paradoxical Embolism Confirmed as an Important Mechanism. The EPIC FOP Prospective Multicentre Study (Clinical Trials.gov Number NCT01216423)E. Le Moigne, Y. Jobic, S. Timsit, D. Ben Salem, N. Paleiron, C. Tromeur, T. Joseph, C. Hoffmann, A. Dion, G. Le Gal, F. Couturaud, D. Mottier (France)

Abs

trac

ts



136 137

Mon

day


Plenary

16:45 – 17:30 Hall B

Kenneth M. Brinkhous Memorial Lecture: Hemophilia Therapy - From Disease to CureChair: Ingrid Pabinger, Austria 16:45 – 17:30 PL 02 Hemophilia: From Royal Gene to Gene Therapy

H. Marijke van den Berg, the Netherlands

Oral Communications

17:45 – 19:00 Hall B

Gene Therapy for Hemophilia: ClinicalChair: Robert Klamroth, Germany Paul Monahan, United States 17:45 – 18:00 OC 13.1

SPK-9001: Adeno-associated Virus Mediated Gene Transfer for Haemophilia B Achieved Durable Endogenous Prophylaxis at Levels of Activity Sufficient to Achieve Significant Mean Reduction in Annual Bleeding and Infusions Rates in Preliminary Data from an On-going Phase 1/2a TrialL. George1, A. Giermasz1, S. Sullivan1, J. Ducore1, J. Rasko2, J. Teitel3, C. Mcguinn1, A. Galvao1, B. Samelson-Jones1, R. Camire1, A. Luk1, F. Wright1, K. Wachtel1, M. Carr1, X. Anguela1, K. High1 (1United States, 2Australia, 3Canada)

18:00 – 18:15 OC 13.2

Updated Results from a Dose-escalation Study in Adults with Severe or Moderate-severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy: up to 1.5 Years Follow-upW. Miesbach1, M. Tangelder2, K. Meijer2, M. Coppens2, P. Kampmann3, R. Klamroth1, R. Schutgens2, G. Castaman4, E. Seifried1, J. Schwaeble1, H. Bonig1, F. Cattaneo4, F. Leebeek2 (1Germany, 2the Netherlands, 3Denmark, 4Italy)

18:15 – 18:30 OC 13.3

An Analysis of Bleeding Rates and Factor IX Consumption in the Phase I/II BAX 335 Gene Therapy Trial in Subjects with Hemophilia BJ. Chapin1, H. Rottensteiner2, F. Scheiflinger2, P.E. Monahan1 (1United States, 2Austria)

18:30 – 18:45 OC 13.4Immunogenicity and Efficacy of FIX-Padua in Distinct Canine Models of Severe Hemophilia B Following AAV Gene Therapy to Skeletal Muscle or LiverB.J. Samelson-Jones, R.A. French, N.B. Martin, T.C. Nichols, R.M. Camire, V.R. Arruda (United States)

18:45 – 19:00 OC 13.6

Development of SHP654, a Highly Efficient AAV8-based BDD-FVIII Gene Therapy Vector for Treatment of Hemophilia AF.G. Falkner1, F. Horling1, J. Lengler1, M. Weiller1, J. Mayrhofer1, M. Turecek1, P.E. Monahan2, W. Hoellriegl1, H. Rotteinsteiner1, F. Scheiflinger1 (1Austria, 2United States)

17:45 – 19:00 A1

Anticoagulant Regulators (Protein C, TFPI, AT)Chair: Esteban C. Gabazza, Japan Anne Angelillo-Scherrer, Switzerland 17:45 – 18:00 OC 14.1

Revisiting Antithrombotic Therapeutics; Sculptin a Novel Class of Specific, Competitive, Reversible, Scissile and Tight Binding Inhibitor of ThrombinA. Iqbal, M. Barbugiani Goldfeder, R. Marques-Porto, H. Asif, J. Gabriel de Souza, F. Faria, A.M. Chudzinski-Tavassi (Brazil)

18:00 – 18:15 OC 14.2

Study of the Antithrombin Folding through the N-glycosylationS. Águila, G. Luengo-Gil, N. Bohdan, S. Espín, V. Vicente, J. Corral, I. Martínez Martínez (Spain)

18:15 – 18:30 OC 14.3

Palmitoylation of the Cytoplasmic Domain of Tissue Factor Regulates its Encryption, Mediated through Alteration in the Orientation of the Transmembrane DomainC. Ettelaie, M. Collier, J. Greenman, A. Maraveyas (United Kingdom)

18:30 – 18:45 OC 14.4

Characterization of the p.Arg393Cys Variant of Antithrombin. Extracellular Formation of Antithrombin-albumin Disulphide Linked Dimers through a Conformational Dependent Mechanism and Role in ThrombosisM. Toderici, M.E. de la Morena-Barrio, C. de Cos, A. Miñano, S. Espín, J. Padilla, V. Vicente, J. Corral (Spain)

Ora

ls



138 139

Mon

day

18:45 – 19:00 OC 14.5Involvement of Heparanase Procoagulant Domain in Bleeding and Wound HealingY. Crispel, S. Ghanem, J. Attias, E. Peled, I. Kogan, B. Brenner, Y. Nadir (Israel)

17:45 – 19:00 A2

Contact Pathway Chairs: Thomas Renné, Germany Alvin Schmaier, United States 17:45 – 18:00 OC 15.1

Proteolytic Activity of Single-chain PrekallikreinI. Ivanov, M.-F. Sun, A. Matafonov, D. Gailani (United States)

18:00 – 18:15 OC 15.2

The Proline Rich Domain of Factor XII Mediates Contact ActivationC. Naudin1, A. Di Gennaro1, E.X. Stavrou2, T. Renné1 (1Sweden, 2United States)

18:15 – 18:30 OC 15.3

Physiological Activation of Factor XII Occurs on the Platelet Surface in a Zinc-dependent MannerP. Bendapudi, K. DeCeunynck, S. Koseoglu, R. Bekendam, R. Flaumenhaft (United States)

18:30 – 18:45 OC 15.4

Neutralizing Blood-borne Polyphosphate In vivo Provides Safe ThromboprotectionA. Di Gennaro1, L. Labberton1, E. Kenne1, A.T. Long2, K.F. Nickel2, R.A. Rigg1, J.S. Hernandez3, L. Butler1, C. Maas4, E.X. Stavrou3, T. Renné1 (1Sweden, 2Germany, 3United States, 4the Netherlands)

18:45 – 19:00 OC 15.5

Essential role of High-molecular-Weight Kininogen in EndotoxemiaA. Yang1, B. Wang1, Z. Xie1, R.W. Colman2, J. Dai2, Y. Wu1 (1China, 2United States)

17:45 – 19:00 A3

FVIII/IXChairs: Koen Mertens, the Netherlands Mettine Bos, the Netherlands 17:45 – 18:00 OC 16.1

Expression Patterns of F8 Promoter-binding-TFs and F8 Promoter Methylation in Different Endothelial CellsM.A. Jamil, N. Nuesgen, J. Oldenburg, O. El-Maarri (Germany)

18:00 – 18:15 OC 16.2

Different N-glycosylation of Factor VIII: Similarities and Differences of Plasma Derived and Recombinant Factor VIII ProductsM. Malisauskas, J. Anzengruber, P. Bärnthaler, M. Feichtinger, F. Scheiflinger, B. Reipert (Austria)

18:15 – 18:30 OC 16.3

Factor VIII with 237 Amino Acids B-domain Has Extended Half-life in MiceE. Bloem, D.M. Karpf, P.L. Nørby, P.B. Johansen, M. Loftager, H.H. Petersen, G.E. Blouse, L. Thim, G. Bolt, M. Kjalke (Denmark)

18:30 – 18:45 OC 16.4

Altered Cleavage of Human Factor VIII at the B-domain and Acidic Region 3 Interface Enhances in vitro and in vivo FunctionG.N. Nguyen, C.M. Wood, D.E. Sabatino (United States)

18:45 – 19:00 OC 16.5

Probing Changes in Activated Factor VIII Upon Complex Formation with Activated Factor IX on Phospholipid MembranesJ. van Galen, E.H.T.M. Ebberink, N. Freato, C. van der Zwaan, M.G. Boon-Spijker, K. Mertens, M. van den Biggelaar, A.B. Meijer (the Netherlands)

17:45 – 19:00 A5

Platelets in ThrombosisChairs: Beate E. Kehrel, Germany Martine Jandrot-Perrus, France 17:45 – 18:00 OC 17.1

Convection Denied: Platelet Packing Density is an Independent Regulator of the Hemostatic Response to InjuryS. Mirramezani, B. Herbig, T. Stalker, L. Nettey, M. Cooper, J. Weisel, S. Diamond, T. Sinno, S. Shadden, L. Brass, M. Tomaiuolo (United States)

Ora

ls



140 141

Mon

day

18:00 – 18:15 OC 17.2Platelet Margination and Activation Are Essential for Thrombus Propagation in an in vitro Model of Venous ThrombosisM. Lehmann, P. Krohl, K. Neeves (United States)

18:15 – 18:30 OC 17.3

Coactosin-like 1 is a Novel Regulator of Arterial Thrombosis and HemostasisI. Birkholz, S. Stritt, S. Beck, K.G. Heinze, G. Krohne, B. Nieswandt (Germany)

18:30 – 18:45 OC 17.4

Clathrin-mediated Endocytosis is Required for Normal Platelet Hemostatic FunctionS. Giannini1, H.F.G. Heijnen2, K.M. Hoffmeister1, H. Falet1 (1United States, 2the Netherlands)

18:45 – 19:00 OC 17.5

Platelet-mediated Activation of FasR and Subsequent Phosphatidylserine Exposure of Red Blood Cells is Substantial for Thrombus Formation and HemostasisK.J. Krott, C. Klatt, S. Zey, N.S. Gowert, A. Oberhuber, M. Schaller, M. Kelm, H. Schelzig, M. Elvers (Germany)

17:45 – 19:00 A6

Platelet Life Span and Clearance Chairs: Karin M. Hoffmeister, United States Markus Bender, Germany

17:45 – 18:00 OC 18.1Platelet GPIba Is Important for Liver Thrombopoietin (TPO) ProductionM. Xu1, G. Zhu1, J. Li1, N. Carrim1, S. Kunishima2, J. Ware3, Z. Ruggeri3, J. Freeman1, H. Ni1 (1Canada, 2Japan, 3United States)

18:00 – 18:15 OC 18.2

Intravital Microscopy Reveals Key Role of Kupffer Cells in Clearance of Desialylated PlateletsC. Deppermann, P. Kubes (Canada)

18:15 – 18:30 OC 18.3

Twinfilin 2a Is a Central Regulator of Platelet Reactivity and Turnover in MiceI. Becker1, S. Stritt1, S. Beck1, T. Vögtle1, M. Hakala2, K.G. Heinze1, X. Du3, M. Bender1, A. Braun1, P. Lappalainen2, B. Nieswandt1 (1Germany, 2Finland, 3United States)

18:30 – 18:45 OC 18.4Investigating the Mechanisms of Clearance of Pre-activated Platelets in Mice Lacking Function of the Rap1 GAP Rasa3R.H. Lee1, C. Casari1, D.S. Paul1, L. Stefanini2, L.L. Peters1, W. Bergmeier1 (1United States, 2Italy)

18:45 – 19:00 OC 18.5

TNF-α is an Important Factor for Platelet Hyperreactivity in AgingP. Davizon-Castillo1, S. Aguila2, K. Higa1, K.J. Ashworth1, G. Hernandez1, D. Bark1, R.A. Campbell1, M. Rondina1, J. DeGregori1, E.M. Pietras1, J. Di Paola1 (1United States, 2Ireland)

17:45 – 19:00 A7

Thrombolysis in DiseaseChairs: Alessandro Casini, Switzerland Anetta Undas, Poland 17:45 – 18:00 OC 19.1

Fibrinolysis with Clot-specific Thrombin-cleavable Microplasminogen is a Potential Alternative to Plasminogen ActivatorsT. Bonnard, Z. Tennant, B. Niego, R. Kanojia, K. Alt, S. Jagdale, L. Soon Law, S. Rigby, R.L. Medcalf, K. Peter, C.E. Hagemeyer (Australia)

18:00 – 18:15 OC 19.2Coagulation Factor XIIIa Is Inactivated during Thrombolytic TreatmentW. Hur, L. Machan, C. Kastrup (Canada)

18:15 – 18:30 OC 19.3

Fibrinolytic System Components Uniquely Affect the Resolution of Deep Vein Thrombosis: Comparison of α2-antiplasmin and Tissue Plasminogen ActivatorS. Singh, A. Houng, G. Reed (United States)

18:30 – 18:45 OC 19.4

CVD-risk Associated Lipid Levels Associate Not Only with Increased Fibrinogen Concentration but also with Altered Plasma Clot Properties in a Healthy PopulationZ. De Lange, B. Kahler, C.M. Smuts, M. Pieters (South Africa)

18:45 – 19:00 OC 19.5

Recombinant ADAMTS-4 Enhances tPA-mediated Fibrinolysis in Ischemic StrokeS. Martinez de Lizarrondo1, M. Pruvost1, A. Anfray1, C. Ali1, J. Montaner2, M. Rubio1, M. Gauberti1, D. Vivien1 (1France, 2Spain)

Ora

ls



142 143

Mon

day

17:45 – 19:00 A8

Immune Aspects of Venous ThrombosisChairs: Maria M. Aleman, United States Johannes Thaler, Austria 17:45 – 18:00 OC 20.1

Contributions of Complement-Dependent Membrane Perturbations to Myeloid Cell TF Activation in Venous ThrombosisS. Subramaniam, K. Jurk, L. Hobohm, S. Jäckel, M. Saffarzadeh, K. Schwierczek, P. Wenzel, F. Langer, C. Reinhardt, W. Ruf (Germany)

18:00 – 18:15 OC 20.2

Deep Vein Thrombosis Suppresses Peripheral T Cell Effector FunctionJ. Prochaska, N. Luther, M. Brähler, A. Schulz, P. Wild, C. Becker (Germany)

18:15 – 18:30 OC 20.3

IFNγ Induces the Formation of NETs in Venous ThrombosisF.-R. Bertin, S. Laurance, C. Lemarie, M. Blostein (Canada)

18:30 – 18:45 OC 20.4

Natural IgM Binding Oxidation-specific Epitopes Protect from Microvesicle-driven ThrombosisG. Obermayer, T. Afonyushkin, F. Puhm, M. Schwameis, W. Schrottmaier, B. Jilma, A. Assinger, C. Binder (Austria)

18:45 – 19:00 OC 20.5

Hemodynamic Force Triggers NETosis within Sterile Thrombotic OcclusionsS. Diamond, X. Yu (United States)

17:45 – 19:00 New York

Cancer Associated Thrombosis: Risk PredictionChairs: Alessandro Squizzato, Italy Marc Carrier, Canada 17:45 – 18:00 OC 21.1

Development and External Validation of a Risk Assessment Model for Cancer-associated Venous ThromboembolismI. Pabinger1, N. van Es2, G. Heinze1, F. Posch1, N. Kraaijpoel2, H.R. Büller2, C. Ay1, on behalf of the contributors to the Vienna Cancer and Thrombosis Study (CATS) and the Multinational Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism (MICA) (1Austria, 2the Netherlands)

18:00 – 18:15 OC 21.2Comparison of Risk Prediction Scores for Cancer-Associated Venous Thromboembolism: A Prospective Cohort StudyN. van Es1, M. Di Nisio2, G. Cesarman3, A. Kleinjan1, H.-M. Otten1, I. Mahé4, I.T. Wilts1, D.C. Twint1, E. Porreca2, O. Arrieta3, A. Stépanian4, K. Smit1, M. De Tursi2, S.M. Bleker1, R. Nieuwland1, P.W. Kamphuisen1, P.M. Bossuyt1, H.R. Büller1 (1the Netherlands, 2Italy, 3Mexico, 4France)

18:15 – 18:30 OC 21.3

External Validation of a Risk Score for Occult Cancer in Patients with Unprovoked Venous Thromboembolism: Results from an Individual Patient Data Meta-AnalysisN. van Es1, L. Bertoletti2, L. Jara-Palomares3, G. Le Gal4, H.-M. Otten1, A. Piccioli5, P. Religa6, R. Lecumberri3, V. Rieu2, M. Rondina7, M. Beckers8, P. Robin2, P. Prandoni5, M. Di Nisio5, P.M. Bossuyt1, H.R. Büller1, M. Carrier4, P.-Y. Salaun2 (1the Netherlands, 2France, 3Spain, 4Canada, 5Italy, 6Sweden, 7United States, 8Belgium)

18:30 – 18:45 OC 21.4

External Validation of a Prognostic Score for Occult Cancer in Patients with Venous ThromboembolismL. Jara-Palomares1, R. Otero1, D. Jimenez1, J.M. Praena-Fernandez1, C. Font1, C. Falgá1, S. Soler1, D. Riesco1, P. Verhamme2, M. Monreal1, RIETE Registry (1Spain, 2Belgium)

18:45 – 19:00 OC 21.5

Thrombin Generation Predicts for Early Cancer Recurrence in Breast Cancer Patients Undergoing Post-surgical Adjuvant Therapy: A Prospective StudyC. Giaccherini, M. Marchetti, C. Verzeroli, G. Masci, L. Celio, B. Merelli, R. Sarmiento, S. Brevi, S. Gamba, V. Milesi, L. Russo, C.J. Tartari, P. Malighetti, D. Spinelli, F. De Braud, R. Labianca, G. Gasparini, A. Santoro, A. Falanga (Italy)

17:45 – 19:00 London

VWF: Functional Implications in Health and DiseaseChairs: Caterina Casari, France Maria Alexandra Brehm, Germany 17:45 – 18:00 OC 22.1

CRISPR/Cas9-engineered VWF Knockout BOECs Have Increased Angiogenic PropertiesM. Schillemans, M. Hofman, J. Westeneng, M. Fernandez-Borja, C. Margadant, R. Bierings (the Netherlands)

Ora

ls



144 145

Mon

day

18:00 – 18:15 OC 22.2Von Willebrand Factor Free-thiols Are Critical for Function under High Shear StressH. O'Brien1, S. Shapiro1, F. Zhang2, P. Henne1, A. Doerr1, M. Laffan1, T. McKinnon1 (1United Kingdom, 2United States)

18:15 – 18:30 OC 22.3

Mouse VWF Propeptide Regulates Platelet Thrombus Formation in vitroO. Rawley, C. Brown, C. Dwyer, J. Mewburn, C. Zhang, J.W. Dennis, D. Lillicrap (Canada)

18:30 – 18:45 OC 22.4

Protein Kinase C Signaling Dysfunction in von Willebrand Disease Type 2B PlateletsC. Casari1, D.S. Paul2, R.H. Lee2, R. Piatt2, O.D. Christophe1, P.J. Lenting1, C.V. Denis1, W. Bergmeier2 (1France, 2United States)

18:45 – 19:00 OC 22.5

Silent von Willebrand Factor Variant c.4146G>T (p.Leu1382=) Causes Type 1 von Willebrand Disease via Disruption of an Exonic Splice Enhancer MotifA.H. Mufti, N.H. Alyami, I.R. Peake, A.C. Goodeve, D.J. Hampshire (United Kingdom)

17:45 – 19:00 Helsinki 1

Hemophilia: Animal Models of Inhibitor FormationChairs: David Scott, United States Paul Batty, United Kingdom 17:45 – 18:00 OC 23.1

A Novel Platform for Immune Tolerance Induction in Hemophilia A MiceS. Merlin1, E. Borroni1, V. Bruscaggin1, W. Tulalamba2, M. Chuah2, V. Arruda3, T. Vandendriessche2, M. Prat1, A. Follenzi1 (1Italy, 2Belgium, 3United States)

18:00 – 18:15 OC 23.2

Cellular and transcriptional immune profiling of early factor VIII responses in hemophilia A miceJ.D. Lai1, C. Hough1, R. Hartholt2, I. Peyron2, D. Cartier1, K. Nesbitt1, B. Vidal1, A. van Velzen2, J. den Haan2, J. Voorberg2, D. Lillicrap1 (1Canada, 2the Netherlands)

18:15 – 18:30 OC 23.3

Interleukin-6 Inhibition Reduces Factor VIII Inhibitor Formation in Factor VIII-deficient MiceM.R. Rollins, J.A. Taylor (United States)

18:30 – 18:45 OC 23.4Inhibition of the bruton's tyrosine kinase alters the anti-FVIII memory B-cell response in mice with severe hemophilia AS. Delignat, J. Russick, B. Gangadharan, M. Ing, S. Kaveri, S. Lacroix-Desmazes (France)

18:45 – 19:00 OC 23.5Targeted Depletion of Gut Microbes Increases Factor VIII Inhibitor Development in Hemophilia A MiceJ.L. Tarrant, M.C. Cormier, K. Nesbitt, C. Dwyer, C. Hough, D. Lillicrap (Canada)

17:45 – 19:00 Budapest

Hemorrhagic Disorders: Pediatric AspectsChairs: Christoph Male, Austria Gili Kenet, Israel

17:45 – 18:00 OC 24.1Efficacy, Safety and Pharmacokinetics (PK) of Once-weekly Prophylactic (Px) Emicizumab (ACE910) in Pediatric (< 12 years) Persons with Hemophilia A with Inhibitors (PwHAwI): Interim Analysis of Single-arm, Multicenter, Open-label, Phase 3 Study (HAVEN 2)G. Young1, J. Oldenburg2, R. Liesner3, V. Jiménez-Yuste4, M.E. Mancuso5, T. Chang1, M. Uguen6, C. Dhalluin6, C. Schmitt6, S. Fuerst-Recktenwald6, M. Shima7, R. Kruse-Jarres1 (1United States, 2Germany, 3United Kingdom, 4Spain, 5Italy, 6Switzerland, 7Japan)

18:00 – 18:15 OC 24.2

Non-neutralizing FVIII Antibodies after Successful ITI Influence FVIII PharmacokineticsC. Heller, S. Schultze-Strasser, D. Stichel, A. Orlowski, D. Schwabe, C. Königs (Germany)

18:15 – 18:30 OC 24.3

Intracranial Haemorrhage in Neonates with Haemophilia - Vaginal or Caesarean Section?N.G. Andersson1, E. Chalmers2, G. Kenet3, R. Ljung1, A. Mäkipernaa4, H. Chambost5, PedNet Group (1Sweden, 2United Kingdom, 3Israel, 4Finland, 5France)

18:30 – 18:45 OC 24.4

Thai Pediatric Bleeding Assessment Tool (BAT) for the Screening of Mild Bleeding DisordersS. Pakdeeto1, R. Natesirinilkul1, P. Komwilaisak1, S. Arj-Ong Vallipakara1, M. Rand2, V. Blanchette2, N. Sirachainan1 (1Thailand, 2Canada)

Ora

ls



146 147

Tues

day

18:45 – 19:00 OC 24.5Tranexamic Acid in Adolescent Girls with Heavy Menstrual BleedingS. Saini, H. Ziegler, M. Christian-Rancy, S. Ahuja, K. Hege, S. Savelli, S. Vesely, S. O'Brien (United States)

17:45 – 19:00 Berlin

Long-Term VTE Outcomes and Complications of TreatmentChair: Francis Couturaud, France Susan R. Kahn, Canada 17:45 – 18:00 OC 25.1

The Impact of Residual Pulmonary Obstruction on the Long-term Outcome of Patients with Pulmonary EmbolismR. Pesavento, L. Filippi, P. Prandoni, for The Scope Investigators group (Italy)

18:00 – 18:15 OC 25.2

The Impact of Increased Systolic Pulmonary Artery Pressure on the Late Outcome of Patients with Pulmonary EmbolismR. Pesavento, L. Filippi, P. Prandoni, for the Scope Investigators Group (Italy)

18:15 – 18:30 OC 25.3High Sensitivity of a Non-invasive Screening Strategy for Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary EmbolismY.M. Ende-Verhaar, D. Ruigrok, H.J. Bogaard, M.V. Huisman, L. Meijboom, A. Vonk Noordegraaf, F.A. Klok (the Netherlands)

18:30 – 18:45 OC 25.4

Residual Vein Thrombosis and Serial D-Dimer for the Long-term Management of Patients with Deep Venous ThrombosisP. Prandoni, The Morgagni Investigators (Italy)

18:45 – 19:00 OC 25.5

Site and Mortality of Major Bleedings in Patients Treated with Individual DoacsL. Franco1, C. Becattini1, J. Beyer-Westendorf2, R. Re1, S. Espinoza Tofalos1, C. Nitti1, F. Pomero1, L. Masotti1, R. Cappelli1, G. Manina1, S. Cattinelli1, G. Agnelli1 (1Italy, 2Germany)

Scientific Program

Tuesday, July 11, 2017



Legend

Plenary Sessions




Supported Symposia




148 149

Tues

day

Tuesday, July 11, 2017Scientific Program

State of the Art

08:00 – 09:15 Hall B

Novel Therapies for HemophiliaChairs: David Lillicrap, Canada Midori Shima, Japan 08:00 – 08:25 SOA 08.1 Gene Therapy Replacement

Katherine High, United States 08:25 – 08:50 SOA 08.2 Small Molecules in the Treatment of Hemophilia

Steven Pipe, United States 08:50 – 09:15 SOA 08.3 Nanobody Based Therapy

Peter Lenting, France

08:00 – 09:15 A1

Stem Cell EngineeringChairs: Erhard Seifried, Germany Toni Cathomen, Germany 08:00 – 08:25 SOA 09.1 System of 300B In Vitro Platelet Biogenesis From iPS Cells

Koji Eto, Japan 08:25 – 08:50 SOA 09.2 Megakaryocyte Matrix Interactions and Platelet Production

Alessandra Balduini, Italy 08:50 – 09:15 SOA 09.3 Large-Scale Production of Platelets: A Clinical Perspective

Cedric Ghevaert, United Kingdom

08:00 – 09:15 A2

Novel Regulatory Mechanisms of CoagulationChairs: Elisabetta Castoldi, the Netherlands Edward M. Conway, Canada 08:00 – 08:25 SOA 10.1 Zymogen Transition of Clotting Factors - Therapeutic Potential

Rodney Camire, United States

08:25 – 08:50 SOA 10.2 FV-Short/TFPI/Protein S in Regulation of Coagulation

Björn Dahlbäck, Sweden 08:50 – 09:15 SOA 10.3 New Coagulant Mechanisms

John Griffin, United States

08:00 – 09:15 A3

Coagulation SignalingChairs: Marvin T. Nieman, United States Agneta Siegbahn, Sweden 08:00 – 08:25 SOA 11.1 Biased Agonism of PAR Signaling in Infection

Laurent Mosnier, United States 08:25 – 08:50 SOA 11.2 PAR Signaling in Viral Infection

Nigel Mackman, United States 08:50 – 09:15 SOA 11.3 Homeostatic Effects of PAR Signaling

Berend Isermann, Germany

Sta

te o

f th

e A

rt



150 151

Tues

day

08:00 – 09:15 A6

Current Pathophysiological Concepts of Thrombotic MicroangiopathiesChairs: Bernhard Lämmle, Germany Masanori Matsumoto, Japan 08:00 – 08:25 SOA 12.1 Pathophysiology of TTP and HUS

Johanna Kremer Hovinga, Switzerland 08:25 – 08:50 SOA 12.2 New Treatments of TTP

Spero Cataland, United States 08:50 – 09:15 SOA 12.3 TMA: Current Insight Into Clinical Manifestations

Elie Azoulay, France

08:00 – 09:15 A7

Platelets In Development and Vascular Integrity Chairs: Denisa Wagner, United States Ulrich Walter, Germany

08:00 – 08:25 SOA 13.1 How Do Platelets Prevent Bleeding?

Bernhard Nieswandt, Germany 08:25 – 08:50 SOA 13.2 CLEC-2 and Podoplanin in the Regulation of Vascular Integrity

Lijun Xia, United States 08:50 – 09:15 SOA 13.3 Platelet and Vascular Integrity: Role of GP6 in Securing Inflamed Vessels

Benoît Ho-Tin-Noé, France

08:00 – 09:15 A8

Venous Thromboembolism: Have We Made Progress Since the Last Guidelines? Chairs: Giancarlo Agnelli, Italy James Douketis, Canada

08:00 – 08:25 SOA 14.1 Incidence and Case Fatality Rates Related to VTE: Can They be (Further)

Improved?Suzanne Cannegieter the Netherlands

08:25 – 08:50 SOA 14.2 Diagnosis of Pulmonary Embolism

Marc Righini Switzerland 08:50 – 09:15 SOA 14.3 Antithrombotic Treatment

Patrick Mismetti France

Oral Communications

09:30 – 10:45 Hall B

Late Breaking Abstract Session

Chairs: Johannes Oldenburg, Germany Sam Schulman, Canada 09:30 – 09:48 LB 01.1 Interim Results from a Phase 1/2 AAV5-FVIII Gene Transfer in Patients with

Severe Hemophilia AJ. Pasi1, S. Rangarajan1, L. Walsh2, W. Lester1, D. Perry1, B. Madan1, H. Yu2, G.F. Pierce2, W.Y. Wong2 (1United Kingdom, 2United States)

09:48 – 10:06 LB 01.2 Evaluation of Safety and Establishment of a PK/PD Relationship of Concizumab

in Hemophilia A PatientsH. Eichler1, P. Angchaisuksiri2, K. Kaan Kavakli3, P. Knoebl4, J. Windyga5, V. Jiménez-Yuste6, U. Friedrich7, A. Hyseni7, P. Chowdary8 (1Germany, 2Thailand, 3Turkey, 4Austria, 5Poland, 6Spain, 7Denmark, 8United Kingdom)

Ora

ls



152 153

Tues

day

10:06 – 10:24 LB 01.3 The IDEAL DVT Study, Individualised Duration of Elastic Compression Therapy

against Long-term Duration of Therapy for the Prevention of Post-thrombotic Syndrome: A Randomised Controlled TrialA.J. ten Cate-Hoek, the IDEAL DVT investigators (the Netherlands)

10:24 – 10:42 LB 01.4 Final Results of RE-VERSE AD Study: Reversal of Dabigatran by its Specific

Reversal Agent Idarucizumab in Patients with Uncontrolled Bleeding or Requiring Urgent Surgery/ProceduresC. Pollack1, P. Reilly1, J. van Ryn2, J. Eikelboom3, S. Glund2, R.A. Bernstein1, R. Dubiel1, M.V. Huisman4, E.M. Hylek1, C.-W. Kam5, P.W. Kamphuisen4, J. Kreuzer2, J.H. Levy1, G. Royle6, F.W. Sellke1, J. Stangier2, T. Steiner2, P. Verhamme7, B. Wang1, L. Young6, J.I. Weitz3 (1United States, 2Germany, 3Canada, 4Netherlands Antilles, 5Hong Kong, 6New Zealand, 7Belgium)

09:30 – 10:45 A1

Animal Models in HemostasisChairs: Peter L. Gross, Canada Mario Colucci, Italy 09:30 – 09:45 OC 26.1

A Novel Mouse Model of Carotid Artery Thrombosis for the Evaluation of Thrombolytic TherapiesJ. Maclean, A. Samson, S. Sturgeon, A. Tomkins, L. Ju, S. Jackson, S. Schoenwaelder (Australia)

09:45 – 10:00 OC 26.2

Development of an Inducible Mouse Model for Factor X DeficiencyO.D. Christophe, A. Hamieh, V. Muczynski, C. Loubière, C.V. Denis, P.J. Lenting (France)

10:00 – 10:15 OC 26.3

Gene-based FVIIa Prophylaxis Modulates the Spontaneous Bleeding Phenotype of Hemophilia A RatsS.M. Zintner1, J.C. Small1, M.J. Kjelgaard-Hansen2, B. Wiinberg2, P. Margaritis1 (1United States, 2Denmark)

10:15 – 10:30 OC 26.4

Distinct Pathogenesis of Cancer-associated Venous Thrombosis Identifies Tissue Factor-phospholipid Interactions as Selective Antithrombotic Target in vivoK. Stark1, I. Schubert1, U. Joshi1, S. Pfeiler1, T. Schmidergall1, S. Stockhausen1, N. Mackman2, B. Engelmann1, S. Massberg1 (1Germany, 2United States)

10:30 – 10:45 OC 26.5Recombinant Destabilase-isopeptidase Stimulates Destruction of Preformed Cross-linked (Old) Thrombi in RatsS. Kalabushev, V. Lazarev, V. Manuvera, D. Akhaev, I. Baskova (Russian Federation)

09:30 – 10:45 A2

Platelets and Extracellular Compounds in AtherothrombosisChairs: Françoise Dignat-George, France Philip Wenzel, Germany 09:30 – 09:45 OC 27.1

Hypertension Upregulates Tissue Factor Expression in Bone Marrow Megakaryocytes and in Circulating PlateletsM. Brambilla, L. Rossetti, P. Gelosa, L. Castiglioni, P. Canzano, C. Zara, L. Sironi, E. Tremoli, M. Camera (Italy)

09:45 – 10:00 OC 27.2

Elevated Mean Platelet Volume is Associated with Lower Risk of Death in a General Population, but is a Predictive Marker of Death in Patients with History of Cardiovascular DiseaseM. Bonaccio, A. Di Castelnuovo, S. Costanzo, A. De Curtis, M. Persichillo, C. Cerletti, M.B. Donati, G. de Gaetano, L. Iacoviello, Moli-sani Study Investigators (Italy)

10:00 – 10:15 OC 27.3

Acute Phase Serotonin-mediated Neutrophil Trafficking is Independent of Endothelial Adhesion MoleculesC. Schönichen1, F. Glatzki1, M. Mauler1, V. Ollivier2, N. Herr1, C. Starz1, D. Stallmann1, I. Ahrens1, C. Bode1, I. Hilgendorf1, B. Ho-Tin-Noé2, D. Duerschmied1 (1Germany, 2France)

10:15 – 10:30 OC 27.4Circulating Microparticles in Cardiovascular Disease: Predictive Value in CABG PatencyM. Brambilla, P. Canzano, L. Lodi, L. Rossetti, C. Tedesco, L. Cavallotti, A. Parolari, F. Veglia, E. Tremoli, M. Camera (Italy)

10:30 – 10:45 OC 27.5

Proteomic Analysis of Premature Myocardial Infarction Subjects Indicates Impairment in 'Hedge Hog' Signaling Protein DYNC2H1M. Ghatge, A. Sharma, R.K. Vangala (India)

Ora

ls



154 155

Tues

day

09:30 – 10:45 A3

Coagulation and CancerChairs: Matthew Flick, United States Henri Versteeg, the Netherlands 09:30 – 09:45 OC 28.1

Blocking of Tissue Factor Signaling in Breast Cancer Inhibits Tumor MetastasisB. Ünlü1, B. Kocatürk1, W. Ruf2, H.H. Versteeg1 (1the Netherlands, 2United States)

09:45 – 10:00 OC 28.2

Thrombin Cleavage of Osteopontin Plays an Important Role in Melanoma Growth and ProgressionS. Peraramelli, Q. Zhou, J. Kim, T. Myles, J. Morser, L. Leung (United States)

10:00 – 10:15 OC 28.3

Thrombin-PAR-1 Promotes Pancreatic Ductal Adenocarcinoma Through Tumor Cell Expression of Urokinase Plasminogen Activator and ReceptorM. Flick, A. Smith, J. Palumbo, J. Luyendyk, Y. Yang, S. Konieczny (United States)

10:15 – 10:30 OC 28.4

Mechanisms Linking Fibrin(ogen) Structure/Function to Tumor MetastasisA.S. Remiker, L.A. Rosenfeldt, G.N. Adams, M.J. Flick, M.D. Frederick, J.S. Palumbo (United States)

10:30 – 10:45 OC 28.5

Biomarkers of Inflammation and Coagulation in Long-term Survivors of an Adult Cancer - Results from the Gutenberg Health StudyM. Panova-Noeva1, A. Schulz1, N. Arnold1, M.I. Hermanns1, J.H. Prochaska1, D. Laubert-Reh1, H.M. Spronk2, M. Blettner1, M. Beutel1, N. Pfeiffer1, T. Münzel1, K.J. Lackner1, H. ten Cate2, P.S. Wild1 (1Germany, 2the Netherlands)

09:30 – 10:45 A5

Platelet Function in InflammationChairs: Yotis A. Senis, United Kingdom Patricia Maguire, Ireland 09:30 – 09:45 OC 29.1

Platelet-dependent Leukocyte Adhesion and Fate in Whole Blood Thrombus FormationM. Nagy1, S. Montague2, M.A.H. Feijge1, T.G. Mastenbroek1, K. Egan3, F.N. Ainle3, R.R. Koenen1, S.P. Watson2, J.M.E.M. Cosemans1, J.W.M. Heemskerk1 (1the Netherlands, 2United Kingdom, 3Ireland)

09:45 – 10:00 OC 29.2The Contribution of Platelet Adhesion Receptors to Vascular Integrity during Inflammation Is Stimulus and Organ DependentJ. Rayes1, S. Lax1, A. Gros2, S. Wichaiyo1, S. Jadoui2, V. Ollivier2, J. Ware3, B. Nieswandt4, M. Jandrot-Perrus2, S. Watson1, B. Ho Tin Noé2 (1United Kingdom, 2France, 3United States, 4Germany)

10:00 – 10:15 OC 29.3

Human Endoglin as a Potential New Partner Involved in Platelet-Endothelium InteractionsE. Rossi1, M. Pericacho2, C. Bachelot-Loza1, D. Pidard1, P. Gaussem1, S. Poirault-Chassac1, F.J. Blanco2, C. Langa2, C. Gonzalez-Manchon2, J.M. Lopez-Novoa2, D.M. Smadja1, C. Bernabeu2 (1France, 2Spain)

10:15 – 10:30 OC 29.4

VWF-Mediated Platelet ´Priming´ Potentiates Novel Leukocyte Interactions under FlowA. Constantinescu-Bercu, I.I. Salles-Crawley, K.J. Woollard, J.T.B. Crawley (United Kingdom)

10:30 – 10:45 OC 29.5

Platelets Protect Cardiomyocytes from Ischaemic DamageT. Walsh, A. Poole (United Kingdom)

09:30 – 10:45 A6

Platelet Signaling 2Chairs: Jonathan Gibbins, United Kingdom Paola van der Meijden, the Netherlands 09:30 – 09:45 OC 30.1

NOX2 as an Anti-thrombosis Target: Small Molecule Targeting of Rac1-p67phox Signaling Prevents NOX2 Mediated GPVI- and Non-GPVI Dependent ROS Generation and Platelet ActivationH. Akbar, X. Duan, S. Saleem, A.K. Davis, Y. Zheng (United States)

09:45 – 10:00 OC 30.2

Evidence from Protein Kinase C δ Y155F Knock-in Mice Reveal Positive Regulatory Role of Y155 in GPVI-mediated Platelet ActivationA. Patel, D. Bhavanasi, J. Kostyak, R. Turaga, R. Badolia, C. Dangelmaier, S. Kim, S. Kunapuli (United States)

Ora

ls



156 157

Tues

day

10:00 – 10:15 OC 30.3Implications of eNOS-signaling Heterogeneity within Human Platelets on Adhesion and AggregationG. Lesyk, A. Radziwon-Balicka, P. Jurasz (Canada)

10:15 – 10:30 OC 30.4

Differential Roles of Paraoxonase-2 (PON2) and NADPH Oxidase-2 (NOX2) in Murine PlateletsV. Petermann, J. Ebert, K. Jurk, S. Horke, I. Witte, H. Kleinert (Germany)

10:30 – 10:45 OC 30.5

Alox12 Regulates Syk in FcγRIIA and Integrin αIIbβ3 Signaling in PlateletsS. Abraham, Y. Zhou, M. Whitley, J. Yeung, D.J. Maloney, T.R. Holman, M. Holinstat, S.E. McKenzie (United States)

09:30 – 10:45 A7

VWF: Mechanisms of Clearance Chairs: James O'Donnell, Ireland Peter Lenting, France 09:30 – 09:45 OC 31.1

The Common VWF Variants p.T789A/p.Y795= Modify VWF Expression and Half-life in a Murine ModelL.L. Swystun1, K. Ogiwara1, A. Mufti2, C. Notley1, K. Nesbitt1, J. Eikenboom3, A. Goodeve2, D.J. Hampshire2, D. Lillicrap1 (1Canada, 2United Kingdom, 3the Netherlands)

09:45 – 10:00 OC 31.2

Macrophage Scavenger SR-AI Mediates von Willebrand Factor ClearanceA. Mohamadi, N. Wohner, V. Muczynski, G. Ayme, C. Denis, O.D. Christophe, P. Lenting (France)

10:00 – 10:15 OC 31.3Real-time Intravital Imaging and Quantification of VWF Clearance by Endothelial Cells and Macrophages in the Murine LiverL.L. Swystun1, C. Notley1, J. Mewburn1, I. Georgescu1, K. Nesbitt1, K. Schledzewski2, C. Géraud2, S. Goerdt2, D. Lillicrap1 (1Canada, 2Germany)

10:15 – 10:30 OC 31.4

A Novel Macrophage-mediated Pathway Regulates Enhanced Clearance of Hyposialylated von Willebrand Factor In vivoS. E. Ward, J.M. O'Sullivan, C. Drakeford, S. Aguila Martinez, M. Lavin, R. Preston, A. Chion, J.S. O'Donnell (Ireland)

10:30 – 10:45 OC 31.5Genetic Variability and Glycans Modulate the Interaction between VWF and the Sinusoidal Endothelial Clearance Receptor Stabilin-2L.L. Swystun1, A.S. Paine1, C. Notley1, J. Lai1, K. Nesbitt1, K. Schledzewski2, C. Géraud2, S. Goerdt2, W. Hopman1, R.R. Montgomery3, P.D. James1, D. Lillicrap1 (1Canada, 2Germany, 3United States)

09:30 – 10:45 A8

Genetic Thrombotic Risk FactorsChairs: David-Alexandre Tregouet, France José Manuel Soria, Spain 09:30 – 09:45 OC 32.1

Genetic Associations of a Clinical Pulmonary Embolism among Those with a Venous Thromboembolism: The INVENT ConsortiumN.L. Smith1, T. Bartz1, H.G. de Haan2, P. Suchon3, M.-H. Chen1, N. Pankratz1, E.N. Smith1, D.I. Chasman1, M. Crous Bou1, J.A. Heit1, M. Germain3, K.L. Wiggins1, K. Taylor1, A. van Hylckama Vlieg2, M. Puurunen1, W. Tang1, K.A. Frazer1, L.M. Rose1, S. Lindstrom1, S.M. Armasu1, J.-F. Deleuze3, J.S. Brody1, S.R. Heckbert1, C.J. O'Donnell1, S.K. Brækkan4, P. Kraft1, B. McKnight1, B.M. Psaty1, F.R. Rosendaal2, P.-E. Morange3, A. Johnson1, A. Folsom1, J.-B. Hansen4, P.M. Ridker1, C. Kabrhel1, M. de Andrade1, D.-A. Trégouët3, INVENT Consortium (1United States, 2the Netherlands, 3France, 4Norway)

09:45 – 10:00 OC 32.2

Genetic Footprint of Endothelial Cells in Chronic Thromboembolic Pulmonary HypertensionM.L. Bochenek, K. Saar, F. Marini, A. Gerhold-Ay, N. Hübner, T. Münzel, E. Mayer, S. Konstantinides, K. Schäfer (Germany)

10:00 – 10:15 OC 32.3

Genetic Associations with Recurrent Venous Thromboembolism: A Meta-analysis of Candidate SNPs in 4 StudiesM. Blondon1, M. Germain1, S. Armasu2, A. van Hylckama Vlieg1, K. Wiggins2, P.-E. Morange3, F. Rosendaal2, D.-A. Tregouët3, M. de Andrade2, N. Smith2 (1Switzerland, 2United States, 3France)

10:15 – 10:30 OC 32.4

A New Genetic Risk Score for Predicting Venous Thromboembolism Events in Cancer Patients Receiving ChemotherapyA. Muñoz, I. Ortega, C. Font, V. Pachón, V. Castellón, V. Martinez, M. Salgado, E. Martinez, J. Calzas, J.C. Souto, E. Salas, J.M. Soria (Spain)

Ora

ls



158 159

Tues

day

10:30 – 10:45 OC 32.5Prothrombotic Genotypes and the risk of Major Bleeding Events in the First Year after Incident Venous ThromboembolismH.S. Johnsen1, E. Bjøri1, K. Hindberg1, E.N. Smith2, F.R. Rosendaal1, S.K. Brækkan1, K.A. Frazer1, J.B. Hansen1 (1Norway, 2United States)

09:30 – 10:45 New York

Progress in Atrial Fibrillation Management Chairs: Cihan Ay, Austria Sabine Eichinger, Austria

09:30 – 09:45 OC 33.1The Role of Time in Therapeutic Range on Bleeding Risk Prediction in Atrial Fibrillation Patients under Vitamin K Antagonist TherapyJ.M. Rivera-Caravaca1, F. Marín1, M.A. Esteve-Pastor1, M. Valdés1, V. Vicente1, G.Y.H. Lip2, V. Roldán1 (1Spain, 2United Kingdom)

09:45 – 10:00 OC 33.2

Persistence of Oral Anticoagulant Treatment for Atrial Fibrillation in the Netherlands: A Surveillance StudyW. Lijfering, M. Teichert, N. van Rein, F. Klok, F. Rosendaal, F.J.M. van der Meer, M. Huisman, S. Cannegieter (the Netherlands)

10:00 – 10:15 OC 33.3

Atrial Fibrillation, Stroke, and Mortality in Patients on Hemodialysis - Prospective Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in HemoDIalysis Patients (VIVALDI)O. Königsbrügge, E. Grilz, S. Schmaldienst, M. Auinger, M. Lorenz, R. Klauser-Braun, J. Kletzmayr, M. Antlanger, F. Posch, I. Pabinger, M. Säemann, C. Ay (Austria)

10:15 – 10:30 OC 33.4

Direct Oral Anti-coagulants (DOACs) Are Associated with Decreased Mortality Compared to Warfarin among Hospitalized Patients with Non-valvular Atrial FibrillationA. Israel, Y. Schwarz, O. Salomon, Y. Sidi (Israel)

10:30 – 10:45 OC 33.5Perioperative Outcomes of Direct Oral Anticoagulants vs. Warfarin in Atrial Fibrillation: A Meta-analysis of Phase III TrialsB. Nazha, B. Pandya, J. Cohen, M. Zhang, A.C. Spyropoulos (United States)

09:30 – 10:45 London

HITChairs: Michael Nagler, Switzerland Ulrich J. Sachs, Germany 09:30 – 09:45 OC 34.1

Platelet Factor 4: von Willebrand Factor Complexes: An Important Antigenic Target in Heparin-induced Thrombocytopenia?I. Johnston, J. Lopez, D. Cines, L. Rauova, M. Poncz (United States)

09:45 – 10:00 OC 34.2

A New Mechanism of Autoimmune HIT Caused by a Subset of AntibodiesT.-H. Nguyen, N. Medvedev, M. Delcea, A. Greinacher (Germany)

10:00 – 10:15 OC 34.3

A Standardized Functional Assay for Routine Reliable HIT Diagnosis: A Potential Alternative to the Serotonin Release AssayB. Tardy-Poncet, A. Montmartin, M. Piot, F. Alkhalfioui, H. Maes, B. Tardy, GFHT-HIT Study Group (France)

10:15 – 10:30 OC 34.4

Soluble Glycoprotein VI (sGPVI) Measurement Is a Useful Biomarker of Platelet Activation in Heparin-induced Thrombocytopenia (HIT) and Correlates with Thrombotic EventsC.W. Tan, E. Duncan, S. McRae, R.K. Andrews, E.E. Gardiner (Australia)

10:30 – 10:45 OC 34.5

Identification of Clinical Parameters for Heparin Induced Thrombocytopenia: An International Multicenter Prospective StudyB. Tardy1, E. De Maistre1, D. Lasne1, C. Pouplard1, M. Alhenc-Gelas1, A. Serre-Sapin1, C. Lavenu-Blombed1, J. Perrin1, F. Mullier2, M.-H. Horellou1, I. Elalamy1, T. Lecompte3, A. Greinacher4, B. Tardy-Poncet1, GFHT-HIT Study Group (1France, 2Belgium, 3Switzerland, 4Germany)

09:30 – 10:45 Helsinki 1

New Approaches in Research and Diagnostics Chairs: Marguerite Neerman-Arbez, Switzerland Barbara A. Konkle, United States

09:30 – 09:45 OC 35.1Exome Sequencing as a First Tier Genetic Test for Hemostatic DiseasesW. van Heerde, A. Simons, S. Schoormans, S. Krouwel, M.R. Nijziel (the Netherlands)

Ora

ls



160 161

Tues

day

09:45 – 10:00 OC 35.2A Role for Chromatin Architecture in the Expression of the Fibrinogen Gene ClusterC. Espitia, R.J. Fish, M. Neerman-Arbez (Switzerland)

10:00 – 10:15 OC 35.3

A Survey of F8 and F9 Variants in my Life, our Future for Evidence of Alternative Splicing in HemophiliaJ. Johnsen, M. Kircher, S. Fletcher, H. Huston, K. Lannert, S. Roberge, B. Martin, N. Josephson, J. Shendure, S. Ruuska, M. Koerper, J. Morales, G. Pierce, D. Aschman, B. Konkle (United States)

10:15 – 10:30 OC 35.4

Development of an Antidote-controlled RNA Probe for Molecular Thrombi ImagingB. Powell Gray, K.-A. Steen-Burrell, B. Sullenger, Diagnostics and OMICs (United States)

10:30 – 10:45 OC 35.5

The Design of a Novel Catheter to Deliver and Monitor Heparin Anticoagulation Therapy: Validation in a Small CohortJ. Wang, J. Jokerst (United States)

09:30 – 10:45 Helsinki 2

Acquired Bleeding Disorders and DICChairs: Bernd Jilma, Austria Christine Kempton, United States 09:30 – 09:45 OC 36.1

Results from Italian Registry of Activated Prothrombin Complex Concentrate in Acquired Hemophilia A: The FAIR StudyE. Zanon, M. Milan, G. Gamba, G. Giuffrida, A. Falanga, A.B. Federici, I. Cantori, S. Siragusa, M.G. Mazzucconi, G. Piseddu, A. Rocino, R.C. Santoro, S. Pasca, C. Lodigiani (Italy)

09:45 – 10:00 OC 36.2

Low Dose of aPCC as Short-term Prophylaxis after the End of Initial Treatment of Acquired Hemophilia a to Reduce Bleeding Recurrences: Data from the FAIR RegistryE. Zanon, S. Pasca, G. Gamba, G. Giuffrida, A. Falanga, A.B. Federici, I. Cantori, S. Siragusa, M.G. Mazzucconi, G. Piseddu, A. Rocino, R.C. Santoro, C. Lodigiani (Italy)

10:00 – 10:15 OC 36.3Blood Pump Hemocompatibility: in vitro and in vivo Evaluation of von Willebrand Factor DegradationP.A. Coghill, Z. Azartash-Namin, J.R. Stanfield, T.A. Snyder, J.W. Long (United States)

10:15 – 10:30 OC 36.4

Relationship of Markers of Inflammation, Infection, and Endothelial Function to Mortality and Severity of Coagulopathy in Patients with Sepsis-associated DICA. Walborn, P. Patel, D. Hoppensteadt, M. Mosier, M. Rondina, J. Fareed (United States)

10:30 – 10:45 OC 36.5

Angiopoietin-2 Levels in the Risk Stratification and Mortality Outcome Prediction of Sepsis Associated CoagulopathyS. Statz, A. Walborn, M. Williams, D. Hoppensteadt, M. Mosier, M. Rondina, J. Fareed (United States)

09:30 – 10:45 Budapest

Hemophilia: Clinical ScienceChairs: Roger Schutgens, the Netherlands Margareth Ozelo, Brazil 09:30 – 09:45 OC 37.1

Influence of Phospholipid Configuration of APPT Reagents in the Diagnosis of Mild Haemophilia A with DiscrepancyB. Gillet, M. Sigaud, M. Fouassier, C. Ternisien, M. Trossaërt (France)

09:45 – 10:00 OC 37.2

Desmopressin in Hemophilia: The Need for a Clinical Response Definition and Individualized Test Regimen Based on FVIII:C Values One Hour after InfusionS.C.M. Stoof, L.M. Schütte, F.W.G. Leebeek, M.H. Cnossen, M.H.J.A. Kruip (the Netherlands)

10:00 – 10:15 OC 37.3The Role of Vascular Remodeling and Clotting Factor Thresholds in the Context of Hemophilic Joint Bleeding: Results from a Prospective Imaging Study in Patients with Hemophilia and Advanced ArthropathyR.F. Barnes1, E.J. Cooke1, T.J. Cramer1, J.Y. Zhou1, G. Foster2, A. Iorio2, A. von Drygalski1 (1United States, 2Canada)

Ora

ls



162 163

Tues

day

10:15 – 10:30 OC 37.4Development and Validation of the “Joint Activity and Damage Exam” (JADE) for Quantitation of Structural Abnormalities by Musculoskeletal Ultrasound (MSKUS) in Hemophilic Joints: Intra- and Inter-rater ReliabilityL. Volland, J.Y. Zhou, R.F.W. Barnes, R. Kruse-Jarres, B. Steiner, D.V.Q. Quon, C. Bailey, M. Brackman, E.Y. Chang, A. von Drygalski (United States)

10:30 – 10:45 OC 37.5

Evaluation of the Hemostatic Effect of the Combination of Factor Concentrate with Tranexamic Acid (TXA) in vitro Using Global AssaysM. Janbain1, J.C. Bordet2, C. Leissinger1, C. Negrier2, Y. Dargaud2 (1United States, 2France)

09:30 – 10:45 Berlin

Future Therapies for Hemophilia and VWDChairs: Alok Srivastava, India Jim Crawley, United Kingdom 09:30 – 09:45 OC 38.1

Correcting the Bleeding Phenotype in Hemophilia A Using Lentivirally FVIII-corrected Endothelial Cells Differentiated from Hemophilic Induced Pluripotent Stem Cells (iPSCs)C. Olgasi1, S. Merlin1, A. Lombardo1, A. Raya2, M. Messina1, P.C. Schinco1, A. Follenzi1 (1Italy, 2Spain)

09:45 – 10:00 OC 38.2

Inhibitory Nanobodies against Antithrombin Correct Thrombin Generation and Reduce Bleeding in FVIII-deficient MiceG. Aymé, C.V. Denis, A. Mohamadi, O.D. Christophe, P.J. Lenting (France)

10:00 – 10:15 OC 38.3

Exploring Chaperone-like Compounds as Innovative Therapeutic Strategy for Hemophilia BS. Pignani, M. Ferrarese, S. Lombardi, S. Marchi, A. Todaro, P. Pinton, F. Bernardi, M. Pinotti, A. Branchini (Italy)

10:15 – 10:30 OC 38.4

Development of Nanobodies Fused to Albumin Binding Peptide: A Tool to Increase Plasmatic Levels of Endogenous ProteinsC. Kawecki, G. Ayme, C. Casari, P. Legendre, O.D. Christophe, P.J. Lenting, C.V. Denis (France)

10:30 – 10:45 OC 38.5Development of a Gene Therapy Strategy for von Willebrand Disease Based on Dual Adeno-associated Virus VectorsE. Barbon, C. Kawecki, F. Collaud, M. Simon-Sola, S. Charles, O.D. Christophe, C.V. Denis, P.J. Lenting, F. Mingozzi (France)


Plenary

11:15 – 12:00 Hall B

Fritz Koller Plenary Lecture: Vascular Diseases and Metabolism Chair: Klaus T. Preissner, Germany

11:15 – 12:00 PL 03 Angiogenesis Revisited: Role and (Therapeutic) Implications of Endothelial

MetabolismPeter Carmeliet, Belgium


Product Theaters12:15 – 13:00 See page 536

Supported Symposia13:15 – 14:30 See page 531

Abstract Symposia

14:45 – 16:15 Hall B

VTE - Difficult Decisions Chairs: Cecilia Becattini, Italy Alicia N. Blanco, Argentina

14:45 – 15:15 ASY 14 Restart of Anticoagulants After Bleeding

Sam Schulman, Canada

Abs

trac

ts



164 165

Tues

day

15:15 – 15:30 ASY 14.1Two Years versus Six Months of Oral Anticoagulation after a First Episode of Unprovoked Proximal Depp Vein Thrombosis: the PADIS DVT Multicenter, Double-blind, Randomized Trial (Clinical Trials. Gov Number NCT00740493)F. Couturaud, G. Pernod, C. Tromeur, E. Duhamel, P. Jego, K. Provost, C. Bal Dit Solier, E. Presles, L. Bressollette, P. Lorillon, P. Girard, E. Le Moigne, S. Melac, S. Laporte, K. Lacut, D. Mottier (France)

15:30 – 15:45 ASY 14.2Odds of Pharmacologic Prophylaxis by Venous Thromboembolism and Bleeding Risk GroupsS. Kaatz, D. Paje, A. Conlon, S. Bernstein, B. Almasri, P. Patel, G. Salem, M. Hettiarachchi, V. Hereford, M. Cerasale (United States)

15:45 – 16:00 ASY 14.3

VTE in Acute Leukemia: Improved Survival with AnticoagulationT. Cox, M. Khan, W. Qiao, M. Nassif, M. Alzubaidi, N. Garg, T. Oo, C. Rojas-Hernandez (United States)

16:00 – 16:15 ASY 14.4

Incidence of Fatal Thromboembolic and Bleeding Events in over Ninety Year-old Patients on Treatment with Oral Anticoagulants for Non-valvular Atrial FibrillationM. Giustozzi, M.C. Vedovati, M. Verso, P. Verdecchia, G. Bogliari, S. Conti, L. Pierpaoli, E. Marchesini, G. Agnelli, C. Becattini (Italy)

14:45 – 16:15 A1

TAFI and Other Inhibitors of FibrinolysisChairs: Paul Kim, Canada Dorien Leenaerts, Belgium 14:45 – 15:15 ASY 15 TAFI

Joost C.M. Meijers, the Netherlands 15:15 – 15:30 ASY 15.1

The Antithrombotic Protein C Activator E-WE Thrombin Supports Fibrinolysis by Inhibiting TAFI ActivationB. Markway, M. Wallisch, N. Verbout, C. Lorentz, M. Carris, O. McCarty, A. Gruber, E. Tucker (United States)

15:30 – 15:45 ASY 15.2

Plasminogen Activator Inhibitor 1 is Retained on the Surface of Activated Platelets in a αIIbβ3 and Fibrin Dependant MannerG.B. Morrow, N.J. Mutch, C.S. Whyte (United Kingdom)

15:45 – 16:00 ASY 15.3The Signaling Lipid Sphingosine-1-Phosphate (S1P) Regulates Expression and Secretion of the Plasminogen Activator Inhibitor-1 (PAI-1) in Differentiated Fat CellsV. Witschel, A. Böhm, C. Joseph, E. Moritz, B.H. Rauch (Germany)

16:00 – 16:15 ASY 15.4

CPU Inhibition with AZD9684: Effects on Fibrinolytic Rate in Different in vitro ModelsD. Leenaerts1, S. Loyau2, J.C. Mertens1, M. Jandrot-Perrus2, D. Hendriks1 (1Belgium, 2France)

14:45 – 16:15 A2

Coagulation System and AtherothrombosisChairs: Steen Dalby Kristensen, Denmark Hugo ten Cate, the Netherlands

14:45 – 15:15 ASY 16 ADAMTS-13 and Thrombosis

Jim Crawley, United Kingdom 15:15 – 15:30 ASY 16.1

bApolipoprotein C-III is a Predictor of Activated Factor VII-antithrombin Complex Levels: A New Link between Plasma Lipids and Coagulation PathwayN. Martinelli1, F. Tosi1, M. Baroni1, A. Castagna1, F. Stefanoni1, F. Pizzolo1, A. Bassi1, P. Pattini1, B. Lunghi1, D. Girelli1, B. Woodhams2, F. Bernardi1, O. Olivieri1 (1Italy, 2United Kingdom)

15:30 – 15:45 ASY 16.2

Markers of Vascular Function Are Associated with Procoagulation Factors in the General PopulationI. Dekkers, R. de Mutsert, A. de Vries, F. Rosendaal, S. Cannegieter, T. Rabelink, H. Lamb, W. Lijfering (the Netherlands)

15:45 – 16:00 ASY 16.3

TFPI in Human Atherosclerotic PlaquesB. Stavik, S. Espada, S. Holm, V. Bjerkeli, P.M. Sandset, T. Børresdatter Dahl, M. Skjelland, T. Espevik, N. Iversen, G. Skretting, B. Halvorsen (Norway)

16:00 – 16:15 ASY 16.4

Protease-activated Receptor 2 Deficiency Attenuates the Formation of AtherosclerosisS. Jones, N. Robbins, K. Saum, J. Thompson, N. Mackman, P. Owens (United States)

Abs

trac

ts



166 167

Tues

day

14:45 – 16:15 A3

Stem Cells, Heterogeneity, Differentiation and ReprogrammingChairs: Morayma Reyes Gil, United States Johannes A. Schmid, Austria 14:45 – 15:00 ASY 17 Stem Cells, Heterogeneity, Differentiation and Reprogramming of Cells in the

VasculatureShahin Rafii, United States

15:00 – 15:15 ASY 17.1

Vascular Endothelial Cells Derived from Human PAI-1 Deficient iPS Cells Reveal Physiological Functions of PAI-1 in AngiogenesisH. Sano, M. Otsu, Y. Suzuki, H. Tanaka, K. Nagahashi, T. Iwaki, N. Kanayama, T. Urano (Japan)

15:15 – 15:30 ASY 17.2Perivascular Progenitor Cells Regulate the Balance between Regeneration vs. Fibrosis via PDGFRa SignallingM. Reyes Gil (United States)

15:30 – 15:45 ASY 17.3

Co-injection of Mesenchymal Stem Cells with Endothelial Progenitor Cells Accelerates Muscle Recovery in Hind Limb Ischemia by an Endoglin-dependent MechanismE. Rossi1, C. Goyard1, A. Cras1, B. Dizier1, N. Bacha1, A. Lokajczyk1, C.L. Guerin1, B. Planquette1, V. Mignon1, C. Bernabeu2, O. Sanchez1, D.M. Smadja1 (1France, 2Spain)

15:45 – 16:00 ASY 17.4

Thromboembolic Events in Patients with BCR-ABL1-negative Myeloproliferative Neoplasms Are Not Related to in vitro Endothelial Cells Adhesiveness Nor JAK2-V617F ExpressionB.K.L. Duarte, S. Ospina, G.G. Yamaguti-Hayakawa, R.C. Saez, K.B.B. Pagnano, F.F. Costa, M.C. Ozelo (Brazil)

14:45 – 16:15 A5

Extracellular Nucleosomes and NETs in ThrombosisChairs: Bernd Engelmann, Germany Manuel Mayr, United Kingdom

14:45 – 15:15 ASY 18 Contribution of NETs to Thrombosis

Tobias A. Fuchs, Germany

15:15 – 15:30 ASY 18.1Citrullinated Histone H3, a Biomarker of Neutrophil Extracellular Trap Formation, is Associated with Increased Risk of Venous Thromboembolism in Patients with CancerL.-M. Mauracher1, J. Thaler1, F. Posch1, K. Martinod2, E. Grilz1, T. Däullary1, L. Hell1, S. Koder1, C. Brostjan1, C. Zielinski1, C. Ay1, D.D. Wagner2, I. Pabinger1 (1Austria, 2United States)

15:30 – 15:45 ASY 18.2

Elucidation of the Role of Neutrophils in Human Pancreatic Cancer-associated Thrombosis Using a Humanized NSG Mouse ModelM.-N. Fan, C.-T. Yen, T.-Y. Cheng, S.-F. Yang, Y.-L. Yang, S.-C. Chou, C.-Y. Chang, S.-W. Lin (Taiwan)

15:45 – 16:00 ASY 18.3

Neutrophils Prothrombotic Characteristics during Myeloproliferative NeoplasmsA. Guy, L. Deloison, V. Gourdou-Latyszenok, C. James (France)

16:00 – 16:15 ASY 18.4

Mice Lacking the Novel Venous Thromboembolism Susceptibility Gene Slc44a2 Have Normal Hemostasis, but Reduced Fibrin Accumulation upon Vascular InjuryJ. Tilburg1, R. Adili2, T.S. Nair2, M.E. Hawley2, B.J.M. van Vlijmen1, D.C. Tuk1, H.M. Spronk1, M. Holinstat2, T.E. Carey2, C.X. Maracle1 (1the Netherlands, 2United States)

14:45 – 16:15 A6

Platelets From Bench to ClinicChairs: Meinhard Gawaz, Germany Chris Ward, Australia

14:45 – 15:00 ASY 19 Novel Approaches to Target Platelets in Cardiovascular Disease

Karlheinz Peter, Australia 15:00 – 15:15 ASY 19.1

The Platelet COX-1 Knockout Mouse as a Model to Study the Effects of Aspirin in the Cardiovascular SystemM. Crescente1, P.C. Armstrong1, M.V. Chan1, J. Jiao2, C. Gaston-Massuet1, G.S. Cottrell1, N.S. Kirkby1, J.A. Mitchell1, H.R. Herschman2, T.D. Warner2 (1United Kingdom, 2United States)

Abs

trac

ts



168 169

Tues

day

15:15 – 15:30 ASY 19.2Low Platelet Count is an Independent Risk Factor for Infection in Patients with Primary Immune ThrombocytopeniaA.J.G. Jansen1, M. Qu2, Q. Liu2, H.-G. Zhao2, J. Peng2, H. Ni3, M. Hou2 (1the Netherlands, 2China, 3Canada)

15:30 – 15:45 ASY 19.3

Increased Circulating T Follicular Helper Cells in Patients with Chronic Immune ThrombocytopeniaL. Dai, M. Zhu, X. Bai, Z. Wang, C. Ruan (China)

15:45 – 16:00 ASY 19.4

Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Acquired TTP PatientsE. Roose1, G. Vidarsson2, O. Verhagen2, R. Visser2, M. Berkowska2, J. Caron1, I. Mancini3, L. Desender1, I. Pareyn1, N. Vandeputte1, A. Vandenbulcke1, M.-A. Azerad1, H. Deckmyn1, S.F. De Meyer1, F. Peyvandi3, K. Vanhoorelbeke1 (1Belgium, 2the Netherlands, 3Italy)

14:45 – 16:15 A7

Inherited Platelet Disorders Chairs: Alan Nurden, France Irina Pleines, Australia 14:45 – 15:15 ASY 20 From Genes to Systems Biology

Kathleen Freson, Belgium 15:15 – 15:30 ASY 20.1

Mutations in Tropomyosin 4 Underlie a Rare Form of Human MacrothrombocytopeniaI. Pleines1, J. Woods2, S. Chappaz1, V. Kew2, N. Foad2, J. Ballester-Beltrán2, K. Aurbach3, C. Lincetto2, R.M. Lane1, G. Schevzov1, W.S. Alexander1, D.J. Hilton1, W.J. Astle2, K. Downes2, P. Nurden4, S.K. Westbury2, A.D. Mumford2, S.G. Obaji2, P.W. Collins2, N. BioResource2, F. Delerue1, L.M. Ittner1, N.S. Bryce1, M. Holliday1, C.A. Lucas1, E.C. Hardeman1, W.H. Ouwehand2, P.W. Gunning1, E. Turro2, M.R. Tijssen2, B.T. Kile1 (1Australia, 2United Kingdom, 3Germany, 4France)

15:30 – 15:45 ASY 20.2

A Human Germ Line Mutation in the Ephrin Receptor B2 Gene Associated with a Bleeding Syndrome, Affects Platelet Functions and GPVI SignalingE. Berrou1, C. Soukaseum1, R. Favier1, A. Kauskot1, F. Adam1, Z. Elaib1, K. Dias1, J.-C. Bordet1, W.H. Ouwehand2, J.-P. Rosa1, P. Nurden1, M. Bryckaert1 (1France, 2United Kingdom)

15:45 – 16:00 ASY 20.3Cytokine Receptor-like Factor 3 (CRLF3): A Novel Regulator of Platelet Biogenesis and Potential Drug Target for ThrombocythaemiaC. Bennett1, J. Guerrero1, S. Stritt2, Y. Yan1, R. Mifsud1, D. Adams1, A. Baig2, W. Erber3, B. Nieswandt2, R. Read1, C. Ghevaert1 (1United Kingdom, 2Germany, 3Australia)

16:00 – 16:15 ASY 20.4

RNA Sequencing of Roifman Syndrome Megakaryocytes Reveals a Role for a Small Nuclear RNA in Platelet and Granule BiologyJ. Heremans1, E. Turro2, C. Thys1, C. Wouters1, C. Van Geet1, I. Meyts1, K. Freson1, BRIDGE-BPD consortium (1Belgium, 2United Kingdom)

14:45 – 16:15 A8

Regulation of CoagulationChairs: Steven Lentz, United States Bernd Pötzsch, Germany 14:45 – 15:00 ASY 21 Aptamers Targeting Coagulation Factors

Bruce A. Sullenger, United States 15:00 – 15:15 ASY 21.1

Functional Characterization of Three Novel Activated Protein C (APC) Binding AptamersN. Shahidi Hamedani, S. Gasper, J. Oldenburg, J. Müller, B. Pötzsch (Germany)

15:15 – 15:30 ASY 21.2

Inhibition of Activated Protein C Aspartyl Beta-hydroxylation Restricts Anticoagulant Function but Enhances Cytoprotective Signaling ActivityO. Willis Fox, E. Gleeson, H. Rushe, A. Rehill, R. Preston (Ireland)

15:30 – 15:45 ASY 21.3

TFPIα Protects FV-short from Rapid Inactivation by Activated Protein CF. Ayombil, T. Petrillo, R.M. Camire (United States)

15:45 – 16:00 ASY 21.4

Factor V-Short and Protein S as Synergistic TFPIα-cofactorsB. Dahlbäck1, L.J. Guo1, R. Livaja-Koshiar1, S. Tran1, R. Camire2 (1Sweden, 2United States)

Abs

trac

ts



170 171

Tues

day

14:45 – 16:15 New York

Women's Issues in Venous ThromboembolismChairs: Fionnuala Ni Ainle, Ireland Saskia Middeldorp, the Netherlands 14:45 – 15:15 ASY 22 Women's Issues in Venous Thromboembolism

Shannon M. Bates, Canada 15:15 – 15:30 ASY 22.1

Sex-specific Incidence Rates of Deep Vein Thrombosis and Pulmonary Embolism in the NetherlandsL.J.J. Scheres, D. Kort, N. van Rein, N. Wiersma, H.W. Vermaas, F.J.M. van der Meer, W.M. Lijfering, S.C. Cannegieter (the Netherlands)

15:30 – 15:45 ASY 22.2

Incidence Rate and Factors Influencing Occurrence of Unprovoked Venous Thrombosis during Long Term Period of Follow-up in Women with Previous Pregnancy Related ThromboembolismJ. Bodrozic, P. Miljic, D. Lekovic, M. Mitrovic, M. Gojnic Dugalic (Serbia)

15:45 – 16:00 ASY 22.3

Aspirin, Heparin or Both to Improve Live Birth in Women with Antiphospholipid Syndrome and Recurrent Pregnancy LossM.C. Marijnen, L.J.J. Scheres, S. Middeldorp (the Netherlands)

16:00 – 16:15 ASY 22.4

Induced Delivery and Neuraxial Anesthesia in Pregnant Women Using Thromboprophylaxis: Data from the Highlow StudyI. Bistervels1, A. Buchmüller2, S. Bleker1, C. Chauleur2, F. Ní Aínle3, J. Donnelly3, P. Verhamme4, A.F. Jacobsen5, H. Décousus2, S. Middeldorp1, for the Highlow investigators (1the Netherlands, 2France, 3Ireland, 4Belgium, 5Norway)

14:45 – 16:15 London

Factor VIII Inhibitors in Congenital and Acquired HemophiliaChairs: H. Marijke van den Berg, the Netherlands Andreas Tiede, Germany 14:45 – 15:15 ASY 23 Factor VIII Inhibitors in Congenital and Acquired Hemophilia

Peter Collins, United Kingdom

15:15 – 15:30 ASY 23.1Product Type and the Risk of Inhibitor Development in Nonsevere Hemophilia A PatientsA. Van Velzen1, C. De Groot-Eckhardt1, M. Peters1, J. Oldenburg2, M. Cnossen1, R. Liesner3, M. Morfini4, G. Castaman4, S. McRae5, R. Keenan3, A. Van der Bom1, K. Fijnvandraat1, INSIGHT consortium (1the Netherlands, 2Germany, 3United Kingdom, 4Italy, 5Australia)

15:30 – 15:45 ASY 23.2

Risk Factors for the Progression From Low- to High-titers In 260 Children with Severe Hemophilia A and Newly Developed InhibitorsM.E. Mancuso1, K. Fischer2, E. Santagostino1, J. Oldenburg3, H. Platokouki4, C. Königs3, C. Escuriola-Ettingshausen3, G.E. Rivard5, A. Cid6, M. Carcao5, R. Ljung7, P. Petrini7, C. Altisent6, G. Kenet8, R. Liesner9, K. Kurnik3, G. Auerswald3, H. Chambost10, A. Mäkipernaa11, A.C. Molinari1, M. Williams9, H.M. van den Berg2 (1Italy, 2the Netherlands, 3Germany, 4Greece, 5Canada, 6Spain, 7Sweden, 8Israel, 9United Kingdom, 10France, 11Finland)

15:45 – 16:00 ASY 23.3

Antigen-specific Regulatory T Cells Generated by Factor VIII-CAR Retrovirus Ttransduction Suppress Anti-factor VIII Immune ResponsesR.Y. Fu, M.J. Lyle, X. Cai, I. Khan, X. Wang, D.J. Rawlings, C.H. Miao (United States)

16:00 – 16:15 ASY 23.4

Stabilin-2 Deficiency or Competitive Inhibition Reduces Human FVIII Immunogenicity in a VWF-dependent MannerJ.D. Lai1, L.L. Swystun1, I. Georgescu1, K. Nesbitt1, K. Schledzewski2, C. Géraud2, S. Goerdt2, D. Lillicrap1 (1Canada, 2Germany)

14:45 – 16:15 Helsinki 1

Gene Editing and Cellular Therapy Chairs: Koji Eto, Japan Torsten Tonn, Germany 14:45 – 15:15 ASY 24 Gene Editing and Cellular Therapy

Toni Cathomen, Germany

Abs

trac

ts



172 173

Tues

day

15:15 – 15:30 ASY 24.1Sequential Mesenchymal Stromal Cell Treatment of Thrombocytopenia after Allogeneic Stem Cell Transplant: Results from a Multicenter Phase II TrialA. Veiga, A. Redondo, E. Villarón, J.M. Bastida, M. López-Parra, O. López-Villar, N. Arratibel, M. Baile, F. López, E. Pérez, M. Cabrero, L. López-Corral, L. Vázquez, J.A. Pérez-Simón, F. Prósper, M.D. Caballero, M.C. Del Cañizo, J.R. González-Porras, F. Sánchez-Guijo (Spain)

15:30 – 15:45 ASY 24.2

Optimization of in vitro Megakaryocyte and Platelet Production by Inducible Overexpression of Supporting FactorsK. Cullmann, K. Blokland, A. Mucci, F. Schenk, K. Boller, S. Kohlscheen, L. Latorre, T. Moritz, N. Heinz, U. Modlich (Germany)

15:45 – 16:00 ASY 24.3

Endothelial and Cancer Cell Gene Silencing by Platelet-vehiculated siRNAsM. Malvestiti, G. Manni, A. Marturano, L. Bury, P. Gresele (Italy)

16:00 – 16:15 ASY 24.4

Targeting Peripheral Blood Mononuclear Cells to Activated Platelets Preserves Cardiac Function after Ischemia-reperfusion InjuryM. Ziegler, X. Wang, B. Lim, E. Leitner, V. Ching, K. Alt, H. Kiriazis, C.E. Hagemeyer, I. Ahrens, K. Peter (Australia)

14:45 – 16:15 Helsinki 2

Micoparticles Chairs: Leonard Edelstein, United States Alain Brisson, France 14:45 – 15:15 ASY 25 The Diversity of Extracellular Vesicles

Eric Boilard, Canada 15:15 – 15:30 ASY 25.1

Microparticles as a Biomarker to Detect Thrombosis in Patients with Implanted Ventricular Assist DevicesT. Torres, J. Walenga, B. Menapace, E. Coglianese, W. Jeske, E. Kumar, V. Escalante, J. Schwartz, M. Bakhos (United States)

15:30 – 15:45 ASY 25.2

Inflammatory Activities of rRNA-containing Microparticles from Mast CellsA.-K. Elsemüller, V.Y. Tomalla, K.T. Preissner, S. Fischer (Germany)

15:45 – 16:00 ASY 25.3Analysis of Platelet PolyphosphateZ. Pons Vila, L. Labberton, T. Renné (Sweden)

16:00 – 16:15 ASY 25.4

NETosis Markers Predict Adverse Events in Anticoagulated Patients with Atrial FibrillationA.B. Arroyo Rodríguez, J.M. Rivera Caravaca, A.M. De los Reyes García, P. Valledor, R. Teruel Montoya, V. Vicente, C. Martínez, R. González Conejero, V. Roldán (Spain)

14:45 – 16:15 Budapest

Pediatric Thrombosis and Bleeding Chairs: Leonardo Brandão, Canada Ulrike Nowak-Göttl, Germany 14:45 – 15:15 ASY 26 Cerebral Sinovenous Thrombosis

Anthony Chan, Canada 15:15 – 15:30 ASY 26.1

Unravelling Pediatric Pulmonary Embolism: Outcomes and Severity PredictorsM.-C. Pelland-Marcotte, L.M. Avila, A. Amid, S. Williams, L.R. Brandao (Canada)

15:30 – 15:45 ASY 26.2

Congenital Antithrombin Deficiency Increases 43-fold the Risk of Pediatric Thrombosis and 200-fold the Risk of Neonatal Thrombosis. Results from 468 Patients with Antithrombin Deficiency from 176 Unrelated FamiliesB. de la Morena-Barrio1, M.E. de la Morena-Barrio1, E. Wypasek2, Á. Palomo1, I. Tirado1, M.F. López-Fernández1, T. Sevivas3, C. de Cos1, L. Entrena1, J. Cuesta1, A. Rodríguez-Alen1, I. Peláez1, N. Revilla1, U. Abigaard1, A. Undas1, P. Marco1, J. Fontcuberta1, V. Vicente1, J. Corral1 (1Spain, 2Poland, 3Portugal)

15:45 – 16:00 ASY 26.3

A Polymorphism in the Transcriptional Repressor Growth Factor Independence-1 Gene GFI136N is Associated with DVT Risk in Pediatric Oncology Patients: Results from a Genome-wide Association AnalysisF. Ruehle1, M. Stoll1, L. Brandão2, J. Halton2, S. Israels2, K. Dietrich2, M. Spavor2, L.G. Mitchell2, ABLE Study Investigators (1Germany, 2Canada)

Abs

trac

ts



174 175

Tues

day

16:00 – 16:15 ASY 26.4Haemostatic Monitoring and Thresholds for Blood Product Replacement Therapy during Treatment of Acute Lymphoblastic Leukaemia in Children and Young People Vary between Centres in the UKT.T. Biss, K.R. Sibson, J.D. Grainger, C. Macartney, J.H. Payne, R.E. Hough, E.A. Chalmers (United Kingdom)


Plenary

16:45 – 17:30 Hall B

Hanns Gotthard Lasch Plenary Lecture: Management of ThromboembolismChairs: Stavros Konstantinides, Germany 16:45 – 17:30 PL 04 Treatment of Venous Thromboembolism in 2017

Harry Büller, the Netherlands

Oral Communications Oral Communications

17:45 – 19:00 Hall B

Extending Anticoagulation: Benefits Versus RisksChairs: Pantep Angchaisuksiri, Thailand Marianne Brodmann, Austria OC 39.1 Long-term Risk of Recurrent Venous Thromboembolism with and without

Effective Antithrombotic TherapyM.H. Prins1, A.W.A. Lensing2, P. Prandoni3, J. Beyer-Westendorf2, B. van Bellen4, A.F. Pap2, M. Gebel2, P. Verhamme5, P.S. Wells6, J.I. Weitz6 (1the Netherlands, 2Germany, 3Italy, 4Brazil, 5Belgium, 6Canada)

OC 39.2 External Validation of the DASH Prediction Model: The TRIP (Thrombosis

Research Italian Partnership) CollaborationA. Tosetto, E. Antonucci, W. Ageno, E. Banfi, L. Barcella, F. Bartolomei, P. Bucciarelli, B. Cosmi, F. Dentali, V. De Stefano, A. Falanga, C. Lodigiani, C. Legnani, I. Martinelli, I. Nichele, O. Paoletti, D. Poli, S. Testa, G. Palareti (Italy)

OC 39.3 Extended Anticoagulation with Two Doses of Rivaroxaban (20 mg and 10 mg) for Preventing Recurrent Venous Thromboembolism: A Benefit-risk Analysis of EINSTEIN CHOICEJ.I. Weitz1, A.W.A. Lensing2, P.S. Wells1, M. Gebel2, A.F. Pap2, M. Homering2, J. Beyer-Westendorf2, H. Bounameaux3, P. Prandoni4, M.H. Prins5 (1Canada, 2Germany, 3Switzerland, 4Italy, 5the Netherlands)

OC 39.4 Prediction of Major Bleeding (MB) Risk in 2514 High Recurrence Risk

Venous Thromboembolism Patients Treated Beyond 3 to 6 Months with Oral Anticoagulation Therapy (OAT)P. Wells1, M. Rodger1, M. Kovacs1, D. Anderson1, S. Kahn1, S. Solymoss1, C. Kearon1, V. Shah2, D. Keeling3, I. Chagnon1, R. Zide2, M. Carrier1, R. Mallick1, D. Corsi1, G. Le Gal1, S. Schulman1, S. Kaatz2 (1Canada, 2United States, 3United Kingdom)

OC 39.5 External Validation of the VTE-BLEED Score for Predicting Major Bleeding in

Stable Anticoagulated Patients with Venous ThromboembolismF.A. Klok, S. Barco, S. Konstantinides (Germany)

17:45 – 19:00 A1

Intrinsic Coagulation PathwayChairs: Cihan Ay, Austria Jens Müller, Germany

17:45 – 18:00 OC 40.1Cleaved Kininogen as a Biomarker for Bradykinin ProductionZ.L.M. Hofman1, S. de Maat1, C. Suffritti2, C.L.R. van Doorn1, D. Csuka3, A. Zanichelli2, N. Veszeli3, G. Pasterkamp1, T. Renné4, M. Cicardi2, H. Farkas3, E. Hack1, C. Maas1 (1the Netherlands, 2Italy, 3Hungary, 4Sweden)

18:00 – 18:15 OC 40.2

The Pharmacokinetic Profiles of Intravenously and Subcutaneously Administered Recombinant Factor IX Fc-XTEN in Cynomolgus MonkeysA. van der Flier, A. Ismail, N. Moore, Z. Liu, S. Bardan, L. Kurt, B. Yang, C. Liu, V. Schellenberger, J. Salas, R. Peters (United States)

18:15 – 18:30 OC 40.3

Activated FXI Regulates the Catalytic Activity of ADAMTS13 by Removing the CUB DomainsC. Puy, K.S. Garland, T. Shirai, S.E. Reitsma, J. Zilberman-Rudenko, A. Gruber, O.J.T. McCarty (United States)

Ora

ls



176 177

Tues

day

18:30 – 18:45 OC 40.4A Small-Molecule and Direct Inhibitor of Factor Xia Provides Strong Antithrombotic Activity with Low Bleeding in Non-Human Primate Model of Arterial ThrombosisP. Wong, M. Quan, C. Watson (United States)

18:45 – 19:00 OC 40.5

New Implications of the Deleterious Role of Furin Processing on Factor VIII BiologyB.J. Samelson-Jones, J.I. Siner, T.V. Daniel, V.R. Arruda (United States)

17:45 – 19:00 A2

Novel Pathways in AtherosclerosisChairs: Elena Tremoli, Italy Katerina Akassoglou, United States 17:45 – 18:00 OC 41.1

Role of Endothelial NF-κB Signalling in AtherosclerosisM. Mussbacher, M. Salzmann, H. Volek, M. Kuttke, B. Hoesel, J. Basilio, A. Assinger, J. Schmid (Austria)

18:00 – 18:15 OC 41.2

Autophagy Is Required for Endothelial Cell Alignment and Atheroprotective Signaling Under Physiological Blood FlowA.-C. Vion1, M. Kheloufi1, A. Hammoutene1, J. Poisson1, J. Lasselin1, C. Devue1, I. Pic1, N. Dupont1, J. Busse2, K. Stark2, J. Lafaurie-Janvore1, A. Barakat1, X. Loyer1, M. Souyri1, B. Viollet1, P. Julia1, A. Tedgui1, P. Codogno1, C.M. Boulanger1, P.-E. Rautou1 (1France, 2Germany)

18:15 – 18:30 OC 41.3

Immune Regulation by Oral Tolerance Induces Alternative Activation of Macrophages and Reduces Markers of Plaque Vulnerability in Apobtm2Sgy/Ldlrtm1Her/J MiceL.N.R. Thota, L. Mundkur, T. Ponnusamy, R.K. Vangala (India)

18:30 – 18:45 OC 41.4

IL-33 Stimulates the Release of Procoagulant Microvesicles from Human Monocytes and Differentially Increases Tissue Factor in Human Monocyte SubsetsS. Stojkovic1, Å. Thulin2, L. Hell1, B. Thaler1, S. Rauscher1, J. Baumgartner1, M. Gröger1, C. Ay1, S. Demyanets1, C. Neumayer1, I. Huk1, A. Spittler1, K. Huber1, A. Siegbahn2, J. Wojta1, M. Åberg2 (1Austria, 2Sweden)

18:45 – 19:00 OC 41.5Mir-146a from the Hematopoietic Compartment is Not Involved in Atherosclerosis Development Despite Provoking an Increased Inflammation and NET FormationA.B. Arroyo Rodríguez, A. del Monte, A.M. De los Reyes García, N. García Barberá, M.S. Caleprico, M.J. Andrés Manzano, V. Roldán, R. Teruel Montoya, V. Vicente, R. González Conejero, V. Andrés, C. Martínez (Spain)

17:45 – 19:00 A3

Innate Immune CellsChairs: Bjarne Osterud, Norway Silvio Antoniak, United States 17:45 – 18:00 OC 42.1

Functional Characterization of Characterization of RIG-I Like Receptors (RLRs) in Megakaryocytes and PlateletD. Pandey, C. Heuer, J. Tossounidis, S. Endres, S. Rothenfusser (Germany)

18:00 – 18:15 OC 42.2

SERPINE2 Expression and Function in NeutrophilsK. Aymonnier, L. Venisse, Y. Boulaftali, V. Arocas, M.-C. Bouton (France)

18:15 – 18:30 OC 42.3

Biophysical Regulation of Leukocyte Recruitment by the 3-Dimentional Structure of Platelet ThrombiI. Alwis, Y. Yuan, Z. Kaplan, F. Tovar-Lopez, W. Nesbitt, A. Ju, S. Jackson (Australia)

18:30 – 18:45 OC 42.4

Plasmin and Plasminogen Induce Macrophage Reprogramming and Regulate Key Steps of Inflammation Resolution via Annexin A1M. Sugimoto1, A.L. C. Ribeiro1, B. R. C. Costa1, J. P Vago1, K. Maciel Lima1, F. S Carneiro1, M. Maira O. Ortiz1, G.L. Negreiros Lima1, A. A. F. Carmo1, R. M. Rocha1, D. A. Perez1, A. C Reis1, V. Pinho1, L. A Miles2, C. C Garcia1, M. M Teixeira1, L. P Sousa1 (1Brazil, 2United States)

18:45 – 19:00 OC 42.5

Alternative Proteolytic Activation of Human Prothrombin by a Bacterial Serine ProteaseG. Pontarollo, L. Acquasaliente, D. Peterle, I. Artusi, V. De Filippis (Italy)

Ora

ls



178 179

Tues

day

17:45 – 19:00 A5

Coagulation Proteins Beyond Hemostasis Chairs: J. Evan Sadler, United States Laurent Mosnier, United States

17:45 – 18:00 OC 43.1A Non-circulating Pool of Factor XIB.M. Mohammed, Q. Cheng, A. Matafonov, C. Puy, A. Gruber, O.J.T. McCarty, D. Gailani (United States)

18:00 – 18:15 OC 43.2Complex Formation with Pentraxin-2 Regulates Factor X Plasma Levels and Macrophage InteractionsV. Muczynski, G. Aymé, V. Regnault, M. Vasse, D. Borgel, P. Legendre, A. Bazaa, A. Harel, C. Loubière, P.J. Lenting, C.V. Denis, O.D. Christophe (France)

18:15 – 18:30 OC 43.3

Role of the Thrombomodulin - Endothelial Protein C Receptor System in New Vessel Formation Following IschemiaM.L. Bochenek1, J. Orth1, S. Reyda1, H. Spronk2, T. Münzel1, W. Ruf1, K. Schäfer1 (1Germany, 2the Netherlands)

18:30 – 18:45 OC 43.4

Protective Function of Tissue Factor in Diabetic NephropathyJ. Manoharan, S. Ghosh, M.M. Al-Dabet, K. Shahzad, B. Isermann (Germany)

18:45 – 19:00 OC 43.5

Factor XII Protects Neurons from Serum Deprivation-induced ApoptosisS. Martinez de Lizarrondo, E. Garnier, C. Ali, A. Chevilley, D. Vivien, F. Docagne (France)

17:45 – 19:00 A6

Megakaryopoiesis and Platelet Biogenesis In VivoChairs: Paquita Nurden, France Jonathan Thon, United States 17:45 – 18:00 OC 44.1

Thrombopoiesis is Spatially Regulated by the Bone Marrow VasculatureD. Stegner, J.M.M. van Eeuwijk, O. Angay, M. Gorelashvili, J. Pinnecker, H. Schulze, B. Nieswandt, K.G. Heinze (Germany)

18:00 – 18:15 OC 44.2Rap1a/b Isoforms Differentially Regulate Megakaryocyte BiologyD. Ghalloussi1, E. O'Shaughnessy1, D.S. Paul1, K. Hahn1, R. Piatt1, L. Stefanini2, R.H. Lee1, K. Eto3, W. Bergmeier1 (1United States, 2Italy, 3Japan)

18:15 – 18:30 OC 44.3

A Cdc42/RhoA Regulatory Circuit Downstream of Glycoprotein Ib Guides Transendothelial Platelet BiogenesisS. Dütting1, I. Pleines1, M. Popp1, A. Antkowiak2, J.M.M. van Eeuwijk1, P. Nurden1, S. Stritt1, O. Angay1, D. Cherpokova1, N. Heinz1, A.A. Baig1, M. Gorelashvili1, F. Gerner1, K.G. Heinze1, J. Ware3, G. Krohne1, D. Stegner1, A.T. Nurden2, H. Schulze1, U. Modlich1, F. Gaits-Iacovoni2, C. Brakebusch4, B. Nieswandt1 (1Germany, 2France, 3United States, 4Denmark)

18:30 – 18:45 OC 44.4Megakaryocyte-Specific Sin1 Deficiency Leads to Thrombocytopenia and Defective Platelet Activation in Thrombosis and Myocardial InfarctionC. Xue, Y. Xu, L. Zhang, K. Wang, J. Liu (China)

18:45 – 19:00 OC 44.5

CK2β Deficiency Results in Severe Macrothrombocytopenia due to Premature Megakaryocyte FragmentationP. Münzer1, B. Walker-Allgaier1, S. Geue1, D. Eißler1, D. Stegner1, D. Semeniak1, M. Chatterjee1, L. Quintanilla-Martinez de Fend1, D. Litchfield2, F. Lang1, B. Nieswandt1, H. Schulze1, M. Gawaz1, O. Borst1 (1Germany, 2Canada)

17:45 – 19:00 A7

Platelet AntagonistsChairs: Karlheinz Peter, Australia Timo Voegtle, United Kingdom 17:45 – 18:00 OC 45.1

A Small Molecule Ligand for CLEC-2 Blocking Podoplanin Binding Inhibits Experimental Tumor Metastasis and Thrombus Formation in MiceK. Suzuki-Inoue, H. Shinmori, M. Osada, T. Shirai, C. Mochizuki, S. Kojima, T. Saito, T. Sasaki, O. Inoue, Y. Ozaki (Japan)

18:00 – 18:15 OC 45.2

Pharmacological Characterization of the Functional Role of Calcium-activated Potassium Channels in PlateletsV. Back, G. Lesyk, F. Plane, P. Jurasz (Canada)

Ora

ls



180 181

Tues

day

18:15 – 18:30 OC 45.3Pharmacological Inhibition of the Class II PI3K, PI3KC2α, Provides Marked Anti-thrombotic Effects in Mice and Humans via a Unique Anti-platelet MechanismM. Selvadurai, M. Moon, S. Mountford, Z. Zheng, I. Jennings, P. Thompson, J. Hamilton (Australia)

18:30 – 18:45 OC 45.4

Quercetin and its Metabolites Inhibit Platelet Function and Thrombus Formation both in vitro and in vivo, and Combine with Aspirin to Increase Anti-platelet EffectsA. Stainer, L. Holbrook, P. Sasikumar, A. Bye, A. Unsworth, J. Lovegrove, M. Tindall, J. Gibbins (United Kingdom)

18:45 – 19:00 OC 45.5

Putative, Novel Mechanisms of Action for Citalopram-induced Platelet InhibitionH.G. Roweth, N. Fowler, A. Chauhan, N. Habib, S.O. Sage, R.W. Farndale, G.E. Jarvis (United Kingdom)

17:45 – 19:00 A8

Cancer Associated ThrombosisChairs: Marina Marchetti, Italy Florian Langer, Germany 17:45 – 18:00 OC 46.1

Combined Effects of GP6 rs1613662 and Pre-cancer Platelet Count on the Risk of Cancer-related Venous ThromboembolismH. Skille1, O.V. Gran1, B. Paulsen1, E.N. Smith2, T. Solomon2, S.K. Braekkan1, F.R. Rosendaal1, K.A. Frazer1, J.-B. Hansen1 (1Norway, 2United States)

18:00 – 18:15 OC 46.2

Incidence and Risk Factors for Central Venous Catheter-related Venous Thromboembolism in Breast Cancer Patients under (Neo)adjuvant Chemotherapy: The CAVECCAS StudyP. Debourdeau, M. Espié, S. Chevret, J. Gligorov, A. Elias, P.F. Dupré, J. Lelong, S. Lavau-Denes, P.Y. Dubois, M.A. Sevestre, L. Bastit, I. Kalidi, S. Villiers, A. Hij, S. Giachetti, C. Frere, D. Farge (France)

18:15 – 18:30 OC 46.3

Statin Use and Venous Thromboembolism in Cancer: A Large, Propensity Score Matched Cohort Study in the United StatesJ. Brown, S. El-Refai, V. Adams, P. Black, J. Talbert (United States)

18:30 – 18:45 OC 46.4Arterial Thromboembolism in Patients with Cancer: Frequency, Risk Factors and MortalityE. Grilz, O. Königsbrügge, F. Posch, I. Lang, I. Pabinger, C. Ay (Austria)

18:45 – 19:00 OC 46.5

Effect of Low Molecular Weight Heparin on Survival of Patients with Resected Non-small Cell Lung Cancer: The Tinzaparin in Lung Tumors (TILT) Randomized Phase III TrialG. Meyer, B. Besse, H. Doubre, A. Charles-Nelson, S. Aquilanti, A. Izadifar, R. Azarian, I. Monnet, C. Lamour, R. Descourt, G. Oliviero, L. Taillade, C. Chouaid, P.-E. Falcoz, M.-P. Revel, V. Westeel, M. Alifano, G. Chatelier, P. Girard (France)

17:45 – 19:00 New York

Factor VIIIa Mimetic Drugs: Pharmacodynamics and MonitoringChairs: John Pasi, United Kingdom Pier Mannuccio Mannucci, Italy 17:45 – 18:00 OC 47.1

Pharmacodynamic Data and Coagulation Biomarkers in Persons with Hemophilia A (PwHA) with Inhibitors: Results from the HAVEN 1 Emicizumab (ACE910) Phase 3 StudyJ.I. Adamkewicz1, C. Schmitt2, A. Calatzis2, G. Young1, C. Negrier3, M. Callaghan1, J.M. Venstrom1, E. Asikanius2, G. Levy1, B. Kim1 (1United States, 2Switzerland, 3France)

18:00 – 18:15 OC 47.2

Synergistic Interplay of A Sequence Identical Analog of ACE910, a Bispecific Antibody, and a Bypassing Reagent and its ComponentsR. Hartmann1, T. Feenstra1, S. Knappe1, L.A. Valentino2, F. Scheiflinger1, M. Dockal1 (1Austria, 2United States)

18:15 – 18:30 OC 47.5

Identification of FIXa- and FX-specific Antibodies for the Generation of Bispecific Antibodies with FVIIIa-like ActivityN. Leksa, B. Pearse, A. Goodman, T. Wang, L. Culyba, D. Rabinovich, O. Mercury, L. Liu, C. Graff, J. Kulman, R. Peters (United States)

18:30 – 18:45 OC 47.4

Mode of Enhancement in the Global Hemostatic Potentials with Concomitant Use of Bypassing Agents and Emicizumab in Hemophilia A Patients with Inhibitor Evaluated by ROTEMK. Yada, K. Nogami, T. Kitazawa, K. Hattori, M. Shima (Japan)

Ora

ls



182 183

Tues

day

18:45 – 19:00 OC 47.3Challenges in Quantifying FVIIIa-mimetic Bispecific Antibody Activity Relative to FVIII for Hemophilia A TreatmentA. Goodman, D. Rabinovich, M. Aleman, E. Kistanova, B. Pearse, N. Leksa, R. Peters (United States)

17:45 – 19:00 London

ThrombophiliaChairs: Sigrid Braekkan, Norway Paul Kyrle, Austria 17:45 – 18:00 OC 48.1

Venous Thromboembolism Risk Assessment in 2214 Relatives from 651 Families with Known Thrombophilia DefectsP. Suchon, M. Ibrahim, A. Robin, N. Resseguier, M.-C. Barthet, D. Brunet, N. Saut, M.-C. Alessi, D.A. Trégouët, P.E. Morange (France)

18:00 – 18:15 OC 48.2

Coagulation Factor 12 and the Risk of Recurrent Venous Thromboembolism: A Prospective Cohort StudyL. Eischer, S. Eichinger, P. Kyrle (Austria)

18:15 – 18:30 OC 48.3

Indications and Outcomes after IVC Filter Insertion for Primary Prophylaxis of Pulmonary Embolism: A Population-based Cohort StudyM. Gurney, A. Ashrani, T.M. Petterson, D.J. Crusan, K.R. Bailey, J.A. Heit (United States)

18:30 – 18:45 OC 48.4

Derivation and Validation of a Prognostic Model for VTE Development in Outpatients Setting: A Nested Case-control StudyF. Dentali, A. Fontanella, G. Gussoni, M. Campanini, G. Agnelli, F. Lapi, FADOI-SIMG (Italy)

18:45 – 19:00 OC 48.5

Increased Incidence of Venous Thromboembolism in Californians with Severe AsthmaA. Mahajan, A. Brunson, B. Kuhn, T. Keegan, T. Wun (United States)

17:45 – 19:00 Helsinki 1

Management of Bleeding and Trauma Chair: Wolfgang Korte, Switzerland Jerrold Levy, United States

17:45 – 18:00 OC 49.1VKA-related Major Bleeding in VTE Patients is Associated with a High Mortality Rate and is Rarely Treated with Prohemostatic Agents: Results from the RIETE RegistryA. Stehouwer1, F. Moustafa2, P. Kamphuisen1, J.C. Sahuquillo3, A. Samperiz3, M. Alfonso3, F. Pace4, J.M. Surinach3, A. Blanco-Molina3, M. Monreal3, RIETE Investigators (1Netherlands Antilles, 2France, 3Spain, 4Italy)

18:00 – 18:15 OC 49.2

Hypofibrinolysis on ROTEM Early after Traumatic Injury Represents a Heterogenous Group with Significant Variation in Both Fibrinolytic Activity and MortalityL.S. Gall1, K. Brohi1, C. Gaarder2, J.C. Goslings3, N.P. Juffermans3, M. Maegele4, P.I. Johansson5, R.A. Davenport1, on behalf of the International Trauma Research Network (INTRN) (1United Kingdom, 2Norway, 3the Netherlands, 4Germany, 5Denmark)

18:15 – 18:30 OC 49.3

Data-driven ROTEM and TEG Algorithms for the Management of Trauma HaemorrhageK. Baksaas-Aasen1, S. van Dieren2, K. Balvers2, N.P. Juffermans2, P.A. Næss1, C. Rourke3, S. Eaglestone3, S.R. Ostrowski4, J. Stensballe4, S. Stanworth3, M. Maegele5, J.C. Goslings2, P.I. Johansson4, K. Brohi3, C. Gaarder1 (1Norway, 2the Netherlands, 3United Kingdom, 4Denmark, 5Germany)

18:30 – 18:45 OC 49.4

Management of Hemorrhage Using Self-propelling Particles to Deliver Thrombin or Tranexamic AcidJ.R. Baylis1, A.E. St. John2, M.M. Lee1, X. Wang2, E.B. Lim2, M.L. Statz2, D. Chien2, E. Simonson1, J.S.J. Yoon1, A. Kazerooni1, M.H. Thomson1, R.T. Liggins1, S.A. Stern2, N.J. White2, C.J. Kastrup1 (1Canada, 2United States)

18:45 – 19:00 OC 49.5

A Chimeric Factor VIIa Molecule Shows Reduced Thrombogenicity in Animal ModelsD. Stafford1, B. Cooley1, W. Bergmeier1, Y. Boulaftali2, D. Feng1, V. Zachary1, R. Jenny1, D. Monroe1, M. Griffith1 (1United States, 2France)

Ora

ls



184 185

Tues

day

17:45 – 19:00 Helsinki 2

Hemophilia: Basic ScienceChairs: Kathleen P. Pratt, United States Jan Voorberg, the Netherlands 17:45 – 18:00 OC 50.1

Modulation of F8 Secretion by Autophagy Related ProteinsH. Singer, N. Nüsgen, B. Pezeshkpoor, J. Oldenburg, O. El-Maarri (Germany)

18:00 – 18:15 OC 50.2

Clustered F8 Missense Mutations Cause Hemophilia A Phenotypic Heterogeneity by Combination of Altered Splicing, Protein Secretion and ActivityI. Donadon1, J. McVey2, I. Garagiola1, M. Mortarino1, A. Branchini1, F. Peyvandi1, F. Bernardi1, M. Pinotti1 (1Italy, 2United Kingdom)

18:15 – 18:30 OC 50.3

Vascular Remodeling in Hemophilic Arthropathy is Exacerbated by Defective TAFIa-mediated Inactivation of SDF1α (CXCL12)T.L. Wyseure1, J.Y. Zhou1, E.J. Cooke1, P.J. Declerck2, J.C.M. Meijers3, A. von Drygalski1, L.O. Mosnier1 (1United States, 2Belgium, 3the Netherlands)

18:30 – 18:45 OC 50.4

90-bp Insertion of Deep Intron between E18 and E19 (E18ins90bpE19) May Be a Hot-spot Mutation for Mild Hemophilia A Patients without Found DNA MutationC.-Y. Chang, S.-N. Cheng, S.-H. Hu, T.-Y. Wu, S.-Y. Lin, Y.-C. Chen (Taiwan)

18:45 – 19:00 OC 50.5

Imbalance between Wound Healing and Inflammation in HemophiliaL.M. Knowles, D. Lessig, M. Bernard, E.C. Schwarz, H. Eichler, J. Pilch (Germany)

17:45 – 19:00 Budapest

Thrombo-Embolic Disease - Risk Factors and BiomarkersChairs: Walter A. Wuillemin, Switzerland Suzanne Cannegieter, the Netherlands 17:45 – 18:00 OC 51.1

Impact of Genetic Variation on the Plasma Proteome in the Tromsø StudyE.N. Smith1, T. Solomon1, J. Lapek1, S.B. Jensen2, K. Hindberg2, N. Latysheva2, S.K. Brækkan2, D.J. Gonzalez1, K.A. Frazer1, J.B. Hansen2 (1United States, 2Norway)

18:00 – 18:15 OC 51.2Effect of Endogenous Sex Hormone Levels Overall, and as Markers for Polycystic Ovary Syndrome and Primary Ovarian Insufficiency on Risk of Venous ThromboembolismL.J.J. Scheres, A. van Hylckama Vlieg, B.E. Ballieux, B.C.J.M. Fauser, S. Middeldorp, S.C. Cannegieter (the Netherlands)

18:15 – 18:30 OC 51.3

Risk Prediction of Recurrent Venous Thrombosis in All Patients with a First Venous Thrombotic Event: Results from the MEGA Follow-up StudyJ. Timp, S. le Cessie, L. Flinterman, A. van Hylckama Vlieg, F. Rosendaal, S. Cannegieter (the Netherlands)

18:30 – 18:45 OC 51.4

Discovery of Plasma Biomarkers of Future Incident Venous Thromboembolism by Untargeted MS-Based ProteomicsS.B. Jensen1, K. Hindberg1, E.N. Smith2, T. Solomon2, J. Lapek2, N. Latysheva1, S.K. Brækkan1, D.J. Gonzalez2, K.A. Frazer2, J.-B. Hansen1 (1Norway, 2United States)

18:45 – 19:00 OC 51.5

D-dimer Measured at Diagnosis Improves the Prediction of Major Bleeding Events during the 1-yr after an Incident VTEH.S. Johnsen, E. Bjøri, K. Hindberg, S.K. Brækkan, J.B. Hansen (Norway)

Ora

ls



186 187

Wed

nesd

ay

Wednesday, July 12, 2017Scientific Program

State of the Art

08:00 – 09:15 Hall B

Risk Factors of Venous ThromboembolismChairs: Paolo Prandoni, Italy Alexander Cohen, United Kingdom

08:00 – 08:25 SOA 15.1 Contribution of Factor XIII to Thrombosis

Nicola Mutch, United Kingdom 08:25 – 08:50 SOA 15.2 Microvesicles and Thrombosis

Romaric Lacroix, France 08:50 – 09:15 SOA 15.3 Genetic Risk Factors of Venous Thromboembolism in Humans and Mice

Toshiyuki Miyata, Japan

08:00 – 09:15 A2

Neurobiology and Stroke Chairs: Ton Lisman, the Netherlands Malgorzata Wygrecka, Germany

08:00 – 08:25 SOA 16.1 Coagulation and Fibrinolysis at the Neurovascular Interface

Katerina Akassoglou, United States 08:25 – 08:50 SOA 16.2 Stroke Models: Time for a Compromise

Denis Vivien, France 08:50 – 09:15 SOA 16.3 Fibrinolysis and Brain Injury

Robert Medcalf, Australia

Scientific Program

Wednesday, July 12, 2017



Legend

Plenary Sessions




Supported Symposia


Sta

te o

f th

e A

rt



188 189

Wed

nesd

ay

08:00 – 09:15 A3

Factor XI and XII in Blood Clotting and BeyondChairs: Alvin Schmaier, United States Coen Maas, the Netherlands 08:00 – 08:25 SOA 17.1 Factor XII and the Contact System

Thomas Renné, Sweden 08:25 – 08:50 SOA 17.2 An Update on Factor XI Function

David Gailani, United States 08:50 – 09:15 SOA 17.3 Contact Pathway Under Flow

Owen McCarty, United States

08:00 – 09:15 A5

Sepsis and ImmunityChairs: Florea Lupu, United States Cheng-Hock Toh, United Kingdom 08:00 – 08:25 SOA 18.1 Proteolytic Processing of Platelet Receptors in Inflammation

Elizabeth Gardiner, Australia 08:25 – 08:50 SOA 18.2 Platelet Dynamics in Systemic Infections

Matthew Rondina, United States 08:50 – 09:15 SOA 18.3 Regulation of Coagulation Signaling by Factor V

Hartmut Weiler, United States

08:00 – 09:15 A6

Platelets Beyond Thrombosis Chairs: Peter Bugert, Germany Wolfgang Bergmeier, United States 08:00 – 08:25 SOA 19.1 Focus on Platelet-Tumor Crosstalk

Thomas Würdinger, the Netherlands

08:25 – 08:50 SOA 19.2 Platelets and Their Role as Mediators of Immunity

John W. Semple, Sweden 08:50 – 09:15 SOA 19.3 Platelets at the Vascular Interface


08:00 – 09:15 A7

Metabolic Regulation and Vascular Growth ControlChairs: Marc Hoylaerts, Belgium Anna Randi, United Kingdom 08:00 – 08:25 SOA 20.1 Regulation of Angiogenesis by Endothelial Metabolism

Michael Potente, Germany 08:25 – 08:50 SOA 20.2 Role of HIF-Oxygen Sensing Metabolic Pathways in Disease

Julián Aragonés López, Spain 08:50 – 09:15 SOA 20.3 S1P Signaling in the Vasculature

Tim Hla, United States

08:00 – 09:15 A8

Hereditary Platelet Disorders Chairs: Harald Schulze, Germany Kerstin Jurk, Germany 08:00 – 08:25 SOA 21.1 Inherited Thrombocytopenias Predisposing to Other Disorders

Alessandro Pecci, Italy 08:25 – 08:50 SOA 21.2 Update on Congenital Thrombocytopenias

Shinji Kunishima, Japan 08:50 – 09:15 SOA 21.3 Identifying the Genetic Determinants of Bleeding and Platelet Disorders

Ernest Turro, United Kingdom

Sta

te o

f th

e A

rt



190 191

Wed

nesd

ay

Oral Communications

09:30 – 10:45 Hall B

Advances in ThromboprophylaxisChairs: Ajay Kakkar, United Kingdom Jean M. Connors, United States 09:30 – 09:45 OC 52.1

Evaluation of Interventions for Implementation of Thromboprophylaxis in Hospitalized Patients at Risk for Venous Thromboembolism (VTE): An Updated Cochrane Systematic Review and Meta-analysis of Randomized Controlled Trials (RCT)S.R. Kahn, D.R. Morrison, A. Piché, K.B. Filion, G. Diendere, A. Klil-Drori, J. Douketis, J. Emed, A. Roussin, V. Tagalakis, M. Morris, W. Geerts (Canada)

09:45 – 10:00 OC 52.2

Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip or Knee Arthroplasty (EPCAT II)D. Anderson1, M. Dunbar1, S. Kahn1, S. Pleasance1, P.-A. Vendittoli1, J. Murnaghan1, D. Zukor2, P. Gross1, M. Forsythe1, S. Pelet1, W. Fisher1, E. Belzile1, S. Dolan1, M. Crowther1, E. Bohm1, S. MacDonald1, W. Gofton1, P. Kim1, P. Andreou1, S. Doucette1, C. Theriault1, A. Abianui1, M. Carrier1, D. Coyle1, M. Kovacs1, M. Rodger1, P. Wells1 (1Canada, 2Cameroon)

10:00 – 10:15 OC 52.3

A landmark analysis of the APEX study comparing extended duration betrixaban with standard duration enoxaparin in hospitalized medically ill patientsA.T. Cohen1, M. Yee2, D. Arbetter2, R.A. Harrington2, S.Z. Goldhaber2, R.D. Hull3, A.F. Hernandez2, A. Gold2, C.M. Gibson2 (1United Kingdom, 2United States, 3Canada)

10:15 – 10:30 OC 52.4

Rivaroxaban Use in Extensive Superficial ThrombophlebitisA. Webster, E. Millen, V. Frimpong, J. Eggleston, D. Thornton, H. Briggs, T. Stewart, R. Clarke-Drury, K. Coultas, J. Strong (United Kingdom)

10:30 – 10:45 OC 52.5

Relationship between DOAC Levels and Subsequent Thromboembolic EventsS. Testa, O. Paoletti, C. Dellanoce, A. Banzato, B. Cosmi, R. Morandini, V. Pengo, D. Poli, L. Salomone, M. Tala, R. Testa, A. Tripodi, G. Palareti (Italy)

09:30 – 10:45 A1

Platelet Activation and SecretionChairs: Herve Falet, United States Carsten Deppermann, Canada 09:30 – 09:45 OC 53.1

Defective Arterial Thrombosis and Thrombo-inflammation in Mice Lacking Bridging Integrator 2 (Bin2)J. Volz, M. Popp, D. Cherpokova, M.K. Schuhmann, T. Premsler, K. Wolf, S. Beck, D. Stegner, G. Stoll, A. Braun, B. Nieswandt (Germany)

09:45 – 10:00 OC 53.2

SNAP23 is Critical for Platelet Granule SecretionC. Williams, A. Poole (United Kingdom)

10:00 – 10:15 OC 53.3

14-3-3ζ Regulates the Mitochondrial Respiratory Reserve Linked to Platelet Phosphatidylserine Exposure and Procoagulant FunctionR. Darbousset, S.M. Schoenwaelder, S.L. Cranmer, H.S. Ramshaw, S.L. Orive, S. Sturgeon, Y. Yuan, Y. Yao, J.R. Krycer, J. Woodcock, E.E. Gardiner, D.E. James, A.F. Lopez, S.P. Jackson (Australia)

10:15 – 10:30 OC 53.4

Kinesin-1 Regulates Platelet Secretion and Thrombus Stability Through the Interaction with the Granular Slp4/Rab27b Effector ComplexF. Adam1, A. Kauskot1, M. Kurowska1, N. Goudin1, I. Munoz1, J.-C. Bordet1, J.-D. Huang2, A. Fischer1, D. Borgel1, G. de Saint Basile1, O. Christophe1, G. Ménasché1 (1France, 2Hong Kong)

10:30 – 10:45 OC 53.5

Secretory Granules and Molecular Interaction of DOCK7, VAC14 and SEC16A with NBEAL2L. Mayer, M. Jasztal, J. Collins, S. Meacham, M. Pardo, J. Choudhary, W. Ouwehand, J. Guerrero (United Kingdom)

Ora

ls



192 193

Wed

nesd

ay

09:30 – 10:45 A2

Structural Aspects of Fibrinogen and FibrinChairs: Leonid Medved, United States Alisa Wolberg, United States 09:30 – 09:45 OC 54.1

Intermolecular Interactions in Double-stranded Half-staggered Fibrin OligomersA. Zhmurov1, A.D. Protopopova2, R.I. Litvinov2, P. Zhukov1, A.R. Mukhitov2, J.W. Weisel2, V. Barsegov2 (1Russian Federation, 2United States)

09:45 – 10:00 OC 54.2

Role of Fibrinogen αC Domain in Fibrin Fibre Lateral Aggregation and αC Connector Region In Longitudinal Fibre Growth; Complex Interactions of the αC Region that Regulate Clot Structure and FunctionH. McPherson1, C. Duval1, N. Asquith1, M. Domingues2, S. Baker1, V. Ridger1, S. Connell1, H. Philippou1, R. Ajjan1, R. Ariëns1 (1United Kingdom, 2Portugal)

10:00 – 10:15 OC 54.3

Pharmacologic Enhancement of the Fibrin(ogen)-integrin αMβ2 Interaction Reduces Acetaminophen-induced Liver Injury in Mice through Induction of Matrix Metalloproteinase 12A. Kopec, N. Joshi, A. Pant, H. Cline-Fedewa, M. Flick, J. Luyendyk (United States)

10:15 – 10:30 OC 54.4

Functional Characterisation of Fibrinogen γ' TruncationsH. McPherson1, C. Duval1, M. Domingues2, S. Baker1, V. Ridger1, S. Connell1, H. Philippou1, R. Ajjan1, R. Ariëns1 (1United Kingdom, 2Portugal)

10:30 – 10:45 OC 54.5

Interaction of Fibrin with the VLDL Receptor: Mapping the VLDL Receptor-binding Site in Fibrin βN-domainsL. Medved, S. Yakovlev (United States)

09:30 – 10:45 A3

Regulation of Coagulation Chairs: Sandip Kanse, Norway Paris Margaritis, United States 09:30 – 09:45 OC 55.1

Multi-ethnic Genome-wide Association Study Identifies New Loci Regulating Factor VIII and von Willebrand FactorM. Sabater-Lleal1, P.S. de Vries2, J.E. Huffman2, J. Marten3, A. Martinez4, P.E. Morange5, M.E. Kleber6, C. Hayward3, X. Guo2, H.G. de Haan7, S. Trompet7, L.R. Yanek2, A.V. Smith8, A.B. Ozel2, W. Tang2, N. Pankratz2, D.P. Strachan3, C.J. Lowenstein2, C.J. O’Donnell2, N.L. Smith2, CHARGE Hemostasis Working Group (1Sweden, 2United States, 3United Kingdom, 4Spain, 5France, 6Germany, 7the Netherlands, 8Iceland)

09:45 – 10:00 OC 55.2

Exome Enriched Genome-wide Association Analysis Identifies Novel Influence from The ADCY2 Locus on Circulating Levels of Factor VII Activating Protein (FSAP) ActivityM. Olsson1, T.M. Stanne1, A. Pedersén1, E. Lorentzen1, E. Kara2, A. Martinez-Palacian2, G. Engström1, O. Melander1, S.M. Kanse2, C. Jern1 (1Sweden, 2Norway)

10:00 – 10:15 OC 55.3

High Levels of Latent Antithrombin in Plasma from Patients with Antithrombin Deficiency. New Conformational Mutations and Pleiotropic DeficiencyM.E. de la Morena-Barrio1, E. Sandoval1, P. Llamas1, E. Wypasek2, M. Toderici1, J. Navarro-Fernández1, A. Rodríguez-Alen1, N. Revilla1, R. López-Gálvez1, A. Miñano1, J. Padilla1, B. de la Morena-Barrio1, J. Cuesta1, J. Corral1, V. Vicente1 (1Spain, 2Poland)

10:15 – 10:30 OC 55.4

Spatio-temporal Analysis of Hemostasis by Immunofluorescence Microscopy Following Transection of the Murine Caudal VeinV. Muczynski, O.D. Christophe, P.J. Lenting, C.V. Denis (France)

10:30 – 10:45 OC 55.5

Water Channel Aquaporin-1 Regulates the Platelet Procoagulant Response and in vivo Thrombus FormationE.O. Agbani1, C.M. Williams1, M.T.J. VanDenBosch2, S.F. Moore1, A. Mauroux1, L. Hodgson1, A.S. Verkman3, I. Hers1, A.W. Poole1 (1United Kingdom, 2Canada, 3United States)

Ora

ls



194 195

Wed

nesd

ay

09:30 – 10:45 A5

Sepsis and Hemostatic FactorsChairs: Craig Morrell, United States Heiko Herwald, Sweden 09:30 – 09:45 OC 56.1

Different Roles for Platelet Glycoprotein VI and CLEC2 during Gram Negative Pneumonia Derived SepsisT.A.M. Claushuis1, A.F. de Vos1, B. Nieswandt2, L. Boon1, J.J.T.H. Roelofs1, O.J. de Boer1, C. van 't Veer1, T. van der Poll1 (1the Netherlands, 2Germany)

09:45 – 10:00 OC 56.2

Inhibition of Factor XI Activation by Factor XIIa Blocks Coagulopathy and Provides Organ Protection and Survival Benefit in a Baboon Model of S. aureus SepsisR. Silasi1, R.S. Keshari1, W.J. van Rensburg2, G. Regmi1, C. Lupu1, C.U. Lorentz1, E.I. Tucker1, D. Gailani1, A. Gruber1, O.J.T. McCarty1, F. Lupu1 (1United States, 2South Africa)

10:00 – 10:15 OC 56.3

Targeting Coagulase Activity in S. aureus Bacteremia: A Prospective Randomized Controlled Trial of Staphylothrombin InhibitionM. Peetermans, T. Vanassche, L. Liesenborghs, O. Gheysens, M. Jacquemin, J. Verhaegen, M.F. Hoylaerts, W. Peetermans, P. Verhamme (Belgium)

10:15 – 10:30 OC 56.4

PF4 Binds and Stabilizes Neutrophil Extracellular Traps: Implications in SepsisK. Gollomp, I. Johnston, G. Zhao, F. Diarra, L. Zhai, M. Poncz, M.A. Kowalska (United States)

10:30 – 10:45 OC 56.5

Utility of Cell-free DNA, Protein C, and Multiple Organ Dysfunction Score (MODS) Components in the Assessment of Mortality Risk in Septic PatientsP. Liaw, A. Fox-Robichaud, E. McDonald, D. Dwivedi, K.-L. Liaw, L. Pepler, T. Gould, M. Xu, N. Zytaruk, L. McIntyre, J. Marshall, J. Tsang, P. Dodek, B. Winston, C. Martin, D. Fraser, J. Weitz, F. Lellouche, D. Cook, Canadian Critical Care Translational Biology Group & Canadian Critical Care Trials Group (Canada)

09:30 – 10:45 A6

Regulation and Function of Platelet IntegrinsChairs: Timothy J. Stalker, United States Kenneth Clemetson, Switzerland 09:30 – 09:45 OC 57.1

Blocking the b´x Domain of PDI Interferes with its Interaction with αIIbβ3 and Prevents Thrombus FormationL. Lin, C. Garnier, J. Dilks, R. Bekendam, G. Merrill-Skoloff, R. Flaumenhaft (United States)

09:45 – 10:00 OC 57.2

Profilin 1 is a Central Regulator of Integrin Turnover and Function in Mouse PlateletsS. Beck1, S. Stritt1, S. Sorrentino2, I. Birkholz1, K.T. Sapra2, H. Schulze1, X. Du3, J.H. Hartwig3, M. Bender1, A. Braun1, O. Medalia2, B. Nieswandt1 (1Germany, 2Switzerland, 3United States)

10:00 – 10:15 OC 57.3

The Platelet Oxidoreductase ERp5 Modulates Fibrinogen Binding to Α2bβ3 Integrin by Cleaving a βI Domain Disulphide BondF. Passam1, J. Chiu1, L. Ju1, K. Kolsek2, F. Graeter2, P. Hogg1 (1Australia, 2Germany)

10:15 – 10:30 OC 57.4

Synergistic Inside-out and Outside-in Activation of Integrin αIIbβ3L. Ju1, Y. Chen2, C. Zhu2 (1Australia, 2United States)

10:30 – 10:45 OC 57.5

IκB Kinase 2 impairs GPIIb/IIIa Activation in PlateletsM. Salzmann, M. Mussbacher, W.C. Schrottmaier, J.B. Kral-Pointner, B. Hoesel, A. Assinger, J.A. Schmid (Austria)

09:30 – 10:45 A7

Platelets in Infection and Immunity Chairs: Heyu Ni, Canada Thomas Vanassche, Belgium 09:30 – 09:45 OC 58.1

Platelets Kill Bacteria after Bridging Innate and Adaptive Immunity via PF4 and FcγRIIAR. Palankar, T.P. Kohler, K. Krauel, M. Medvidov, J. Wesche, S. Hammerschmidt, A. Greinacher (Germany)

Ora

ls



196 197

Wed

nesd

ay

09:45 – 10:00 OC 58.2Aging-Associated Increases in Platelet Granzyme A Regulates Pro-inflammatory Gene Synthesis by Target MonocytesR. Campbell, A. Bhatnagar, Z. Franks, J. Rowley, B. Manne, M. Supiano, H. Schwertz, A. Weyrich, M. Rondina (United States)

10:00 – 10:15 OC 58.3

Mature Murine Megakaryocytes Process and Present Both Exogenous and Endogenous Antigens to CD8+ T Cells and Transfer this Ability to PlateletsJ.W. Semple1, A. Zufferey2, E.R. Speck2, K.R. Machlus3, R. Aslam2, L. Guo2, M.J. McVey2, M. Kim2, R. Kapur2, E. Boilard2, J.E. Italiano, Jr3 (1Sweden, 2Canada, 3United States)

10:15 – 10:30 OC 58.4

Platelet Desialylation: Novel Mechanism of Immune ToleranceJ. Li, Y. Wang, Y. Yucel, J. Freedman, H. Ni (Canada)

10:30 – 10:45 OC 58.5

Platelets Promote Monocyte Polarization to a M1 Phenotype upon LPS StimulationM. Schattner, A. Carestia, H.A. Mena, A.E. Errasti, S. Negrotto, E.A. Carrera Silva (Argentina)

09:30 – 10:45 A8

Translational Aspects in Inherited Platelet DisordersChairs: Walter Kahr, Canada Ernest Turro, United Kingdom

09:30 – 09:45 OC 59.1Phenotyping and Genotyping Inherited Platelet Disorders: The Iberian Peninsula Multicenter Project ExperienceV. Palma-Barqueros, J.M. Bastida, K. Janusz, J.R. Gonzalez-Porras, J.M. Hernández-Rivas, V. Vicente, M.L. Lozano, J. Rivera (Spain)

09:45 – 10:00 OC 59.2

Homozygous Frameshift in ABCC4 Causes a Novel Inherited Platelet Disorder Characterised by Increased cAMP Levels and Excessive BleedingT.K. Bariana, on behalf of the BRIDGE Consortium (United Kingdom)

10:00 – 10:15 OC 59.3

A New Dominant Platelet P2RY12 Variant Affecting Receptor Function Identified in a Family with Severe Bleeding HistoryM.-C. Morel-Kopp1, D. Rabbollini1, S. Mundell2, R. Aungraheeta2, S. Gabrielli1, Q. Chen1, T. Kilo1, J. Mackay1, W. Stevenson1, C. Ward1 (1Australia, 2United Kingdom)

10:15 – 10:30 OC 59.4Characterisation of Two Novel FLI1 Variants Causing Substitution of Arginine 340 in the ETS Domain of FLI1 in Patients with Dense Granule Secretion DefectsM. Aldossary1, V. Leo1, M. Makris1, C. Thornburg2, D. Masser-Frye2, N. Morgan1, M. Daly1 (1United Kingdom, 2United States)

10:30 – 10:45 OC 59.5

A Novel Splice-specific GFI1B-p32 Mutation in a Family with Recessive MacrothrombocytopeniaH. Schulze1, A. Schlagenhauf2, G. Manukjan1, O. Andres1, E. Klopocki1, E.-M. König1, S. Panzer2, C. Beham-Schmid2, K. Althaus1, A. Greinacher1, T. Bakchoul1, M. Seidel2 (1Germany, 2Austria)

09:30 – 10:45 New York

Predicting and Managing the Post-Thrombotic Syndrome Chairs: Arina ten Cate-Hoek, the Netherlands Sebastian Schellong, Germany

09:30 – 09:45 OC 60.1Short and Long Term Incidence of and Risk Factors for Post Thrombotic Syndrome after a First Deep Vein ThrombosisY.M. Ende-Verhaar, L.W. Tick, F.A. Klok, M.V. Huisman, F.R. Rosendaal, S.C. Cannegieter (the Netherlands)

09:45 – 10:00 OC 60.2

Rivaroxaban Reduces the Rate of Post-Thrombotic Syndrome After DVT - a Cross-Sectional Study Comparing Rivaroxaban to WarfarinK.K. Utne, A. Dahm, H.S. Wik, L.-P. Jelsness-Jørgensen, P.M. Sandset, W. Ghanima (Norway)

10:00 – 10:15 OC 60.3

Development and Validation of a Practical Two-step Prediction Model for Post-thrombotic SyndromeE. Amin, S.M.J. van Kuijk, M.A. Joore, H. ten Cate, A.J. ten Cate-Hoek (the Netherlands)

10:15 – 10:30 OC 60.4

Development of a Clinical Prediction Model for the Post-Thrombotic Syndrome in a Prospective Cohort of Patients with Proximal DVT: The SOX-PTS IndexA. Rabinovich1, T. Ducruet2, S.R. Kahn2 (1Israel, 2Canada)

Ora

ls



198 199

Wed

nesd

ay

10:30 – 10:45 OC 60.5No Compression, Multilayer Compression Bandaging or Compression Hosiery in the Acute Phase of Deep Vein Thrombosis in Relation to the Villalta Score, Health-related Quality of Life, and Costs at 3 Months after the DiagnosisE. Amin, M.A. Joore, H. ten Cate, A.J. ten Cate-Hoek, the IDEAL DVT investigators (the Netherlands)

09:30 – 10:45 London

Hemophilia: Risk of Inhibitor FormationChairs: Shannon Meeks, United States Jan Astermark, Sweden 09:30 – 09:45 OC 61.1

Mutational Repertoire in the SIPPET Cohort and Prediction of FVIII Inhibitor RiskS. Spena1, I. Garagiola1, A. Cannavò1, M. Mortarino1, A. El-Beshlawy2, M. Elalfy2, V. Ramanan3, P. Eshghi4, S. Hanagavadi3, R. Varadarajan3, M. Karimi4, M.V. Manglani3, C. Ross3, G. Young5, T. Seth3, S. Apte3, D.M. Nayak3, E. Santagostino1, M.E. Mancuso1, A.C. Sandoval Gonzales6, J.N. Mahlangu7, S. Bonanad8, M. Cerqueira9, N.P. Ewing5, C. Male10, T. Owaidah11, V. Soto Arellano12, N.L. Kobrinsky5, S. Majumdar5, R. Perez Garrido8, A. Sachdeva3, M. Simpson5, M. Thomas3, E. Zanon1, B. Antmen13, K. Kavakli13, M.J. Manco-Johnson5, M. Martinez14, E. Marzouka12, M.G. Mazzucconi1, D. Neme14, A. Palomo Bravo8, R. Paredes Aguilera6, A. Prezotti9, K. Schmitt10, B.M. Wicklund5, B. Zulfikar13, P.M. Mannucci1, F.R. Rosendaal15, F. Peyvandi1 (1Italy, 2Egypt, 3India, 4Iran, Islamic Republic of, 5United States, 6Mexico, 7South Africa, 8Spain, 9Brazil, 10Austria, 11Saudi Arabia, 12Chile, 13Turkey, 14Argentina, 15the Netherlands)

09:45 – 10:00 OC 61.2

Improved Immunogenicity Prediction Using Composite Variables that Incorporate the Known Patient, Product and Therapy Related Risk Factors for Inhibitor Development with Immunologic Parameters from the HLA-class-II (HLAcII)-factor (F)VIII PeptidomeB. Luu1, M. Hofmann2, V. Diego1, M. Almeida1, J. Hernandez1, A. Morelli3, A. Ameri1, R. Rajalingam1, J. Powell1, J. Blangero1, E. Maraskovsky3, T. Howard1 (1United States, 2Germany, 3Australia)

10:00 – 10:15 OC 61.3

Immune Monitoring by Epigenetic Cell Counting - Application in the Hemophilia Inhibitor PUP Study (HIPS)B. Gangadharan1, B.M. Reipert1, C.J. Hofbauer2, F. Scheiflinger1, J. Bowen2, E. Donnachie2, K. Fijnvandraat3, J. Klintman4, R. Gruppo2, C. Male1, S. Meeks2, C. McGuinn2, M. Recht2, M.V. Ragni2, H. Yaish2, E. Santagostino5, D.L. Brown2 (1Austria, 2United States, 3the Netherlands, 4Sweden, 5Italy)

10:15 – 10:30 OC 61.4Comparative Profiling of HLA-DR and HLA-DQ Associated FVIII Peptides Presented by Monocyte-derived Dendritic CellsI. Peyron, R.B. Hartholt, L. Pedro-Cos, F.P.J. van Alphen, N. Lardy, A.B. Meijer, J. Voorberg (the Netherlands)

10:30 – 10:45 OC 61.5Differential Effects of von Willebrand Factor on Processing and Presentation of Factor VIII-derived PeptidesC. Lubich, K. Steinitz-Trost, B. Binder, T. Prenninger, F. Scheiflinger, B.M. Reipert (Austria)

09:30 – 10:45 Helsinki 1

Gene Therapy for Hemophilia: Preclinical Chairs: Thierry VandenDriessche, Belgium Lindsey George, United States 09:30 – 09:45 OC 62.1

Platelet-targeted Hyperfunctional FIX Gene Therapy of Hemophilia B MiceJ. Schroeder, M. Jozwiak, P. Monahan, Q. Shi (United States)

09:45 – 10:00 OC 62.2SHP648: A High Performing Next Generation FIX Gene Therapy Vector Based on AAV8F. Horling1, F.G. Falkner1, M. Chuah2, J. Lengler1, J. Mayrhofer1, M. Klugmann1, S. Coulibaly1, W. Hoellriegl1, P.E. Monahan3, T. Vandendriessche2, F. Scheiflinger1, H. Rotteinsteiner1 (1Austria, 2Belgium, 3United States)

10:00 – 10:15 OC 62.3

Preventive Immune Suppression Using CTLA-4 IgGs Enables Re-administration in AAV8 Gene TherapyM. Frentsch1, A. Sada Japp1, N. Matzmohr1, A. Thiel1, F. Scheiflinger2, B.M. Reipert2, M. de la Rosa2 (1Germany, 2Austria)

10:15 – 10:30 OC 62.4

Modulation of AAV Vector Dosing and Avoidance of Capsid Immune Responses via Repeated Co-administration of Vector with Tolerogenic Rapamycin NanoparticlesA. Meliani1, F. Boisgerault1, S. Marmier1, R. Hardet1, G. Ronzitti1, F. Collaud1, S. Charles1, L. van Wittenberghe1, B. Marolleau1, P. Ilyinskii2, C. Roy2, A. Michaud2, C. Leborgne1, O. Christophe1, T.K. Kishimoto2, F. Mingozzi1 (1France, 2United States)

Ora

ls



200 201

Wed

nesd

ay

10:30 – 10:45 OC 62.5CRISPR/Cas9-mediated Genome Editing via Postnatal Injection of AAV Vector Cures Hemophilia B in MiceT. Ohmori, Y. Nagao, H. Mizukami, A. Sakata, S.-I. Muramatsu, K. Ozawa, S.-I. Tominaga, Y. Hanazono, S. Nishimura, O. Nureki, Y. Sakata (Japan)

09:30 – 10:45 Budapest

ADAMTS 13 and TTP Clinical Chairs: Paul Knöbl, Austria Ross Ian Baker, Australia 09:30 – 09:45 OC 63.1

Childhood-onset Congenital Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman syndrome): The French Reference Center for Thrombotic MicroAngiopathies ExperienceB. Joly, P. Boisseau, A. Stepanian, C. Garrec, C. Desconclois, G. Deschênes, N. Biebuyck, C. Berger, L. Mansuy, J.-P. Vannier, S. Bezieau, P. Coppo, A. Veyradier, French Reference Center for Thrombotic MicroAngiopathies, Paris, France (France)

09:45 – 10:00 OC 63.2

Hereditary Thrombotic Thrombocytopenic Purpura - Incidence of Acute Events under Plasma ProphylaxisJ. Kremer Hovinga1, Z. Cermakova2, Y. Fujimura3, K. Friedman4, J. George4, I. Hrachovinova2, P. Knöbl5, A.S. von Krogh6, B. Lämmle7, M. Matsumoto3, R. Schneppenheim7 (1Switzerland, 2Czech Republic, 3Japan, 4United States, 5Austria, 6Norway, 7Germany)

10:00 – 10:15 OC 63.3

Clinical and Laboratory Characteristics of Patients Affected with Acquired Thrombotic Thrombocytopenic Purpura Enrolled in the Milan TTP RegistryI. Mancini, S. Pontiggia, A. Cannavò, B. Ferrari, A. Artoni, C. Valsecchi, S.M. Trisolini, S. Capria, L. Facchini, K. Codeluppi, E. Rinaldi, A. Melpignano, S. Campus, R.A. Podda, C. Caria, A. Caddori, E. Di Francesco, G. Giuffrida, V. Agostini, U. Roncarati, C. Mannarella, A. Fragasso, G.M. Podda, E. Bertinato, A.M. Cerbone, A. Tufano, G. Loffredo, V. Poggi, M. Pizzuti, G. Re, M. Ronchi, A. De Fanti, S. Amarri, L. Aprile, M. Bocchia, S. Cerù, F. Peyvandi (Italy)

10:15 – 10:30 OC 63.4

ML355, a Selective 12-LOX Inhibitor, Prevents Immune-mediated Thrombocytopenia and ThrombosisJ. Yeung, B. Tourdot, M. Jackson, R. Adili, S. Abraham, Y. Zhou, D. Maloney, T. Holman, M. Holinstat (United States)

10:30 – 10:45 OC 63.5Rituximab Use Is Associated with Longer Relapse Free Survival in Patients with Acquired Thrombotic Thrombocytopenic PurpuraA. Artoni, E. Canavesi, I. Mancini, S. Pontiggia, A. Cannavò, B. Ferrari, S.M. Trisolini, C. Saveria, L. Facchini, K. Codeluppi, E. Rinaldi, A. Melpignano, S. Campus, R.A. Podda, C. Caria, A. Caddori, E. Di Francesco, G. Giuffrida, V. Agostini, U. Roncarati, C. Mannarella, A. Fragasso, G.M. Podda, E. Bertinato, A.M. Cerbone, A. Tufano, G. Loffredo, V. Poggi, M. Pizzuti, G. Re, M. Ronchi, A. De Fanti, S. Amarri, L. Aprile, M. Bocchia, S. Cerù, F. Peyvandi (Italy)

09:30 – 10:45 Berlin

Coagulation in Extracorporal Circulation Chairs: Barbara Zieger, Germany Heleen Van Ommen, the Netherlands 09:30 – 09:45 OC 64.1

Extracorporeal Membrane Oxigenation (ECMO) in Neonates and Children: Prospective Single Center Study of ArgentinaC. Cervio, G. Sciuccati, M. Hepner, J.P. Frontroth, G. Pieroni, S.E. Annetta, A. Feliu Torres, M. Bonduel (Argentina)

09:45 – 10:00 OC 64.2

Can Coagulation Parameters Guide the Way in Neonatal and Pediatric Extracorporeal Membrane Oxygenation?Ö. Erdem, J.W. Kuiper, R.J.M. Houmes, D. Tibboel, C.H. van Ommen, E.D. Wildschut (the Netherlands)

10:00 – 10:15 OC 64.3

Intraoperative ROTEM Predicts Excessive Bleeding in Infants on Cardiopulmonary BypassR. Bercovitz, E. Stuth, J. Scott, R. Niebler, P. Simpson, K. Yan, R. Woods, D. Newman (United States)

10:15 – 10:30 OC 64.4

Antithrombotic Guideline for the PumpKIN Trial: Design and RationaleM.P. Massicotte1, D. Rosenthal2, W. Mahle2, R. Jaquiss2, S. Siami2, T. Baldwin2, C. Almond2 (1Canada, 2United States)

10:30 – 10:45 OC 64.5

Platelet Secretion Defects and Acquired von Willebrand Syndrome in Patients with Ventricular Assist DevicesU. Geisen1, K. Brehm1, G. Trummer1, M. Berchtold-Herz1, C. Heilmann1, F. Beyersdorf1, J. Schelling1, A. Schlagenhauf2, B. Zieger1 (1Germany, 2Austria)

Ora

ls



202 203

Wed

nesd

ay


Plenary

11:15 – 12:00 Hall B

Oscar D. Ratnoff Memorial Lecture: Tissue Factor Biology Chair: John Griffin, United States

11:15 – 12:00 PL 05 Tissue Factor Flip-Flopping Between Coagulation and Signaling

Wolfram Ruf, Germany


Product Theaters12:15 - 13:00 See page 537

Supported Symposia13:15 - 14:30 See page 533

Abstract Symposia

14:45 – 16:15 Hall B

Clinical Management of Bleeding Disorders Chairs: Charles Hay, United Kingdom Guy Young, United States 14:45 – 15:15 ASY 27 Tailored Treatment of Bleeding Disorders: Where Do We Stand?

Claude Negrier, France 15:15 – 15:30 ASY 27.1

A Sparse Sampling Method for FVIII Population Pharmacokinetic (PK) Analyses in Males with Severe Hemophilia A (SHA)V. Blanchette1, S. Jackson1, L. Tiseo1, V. Bouskill1, S. Ito1, D. Lillicrap1, M. Morfini2, M. Rand1, D. Stephens1, K. Usuba1, C. Wakefield1, E. Zapotocka1, M. Carcao1 (1Canada, 2Italy)

15:30 – 15:45 ASY 27.2Factor VIII Concentration and the Risk of Spontaneous Bleeding Following Treatment with rFVIII (Turoctocog Alfa) in Patients with Severe Haemophilia AA. Tiede1, F. Abdul Karim2, V. Jiménez-Yuste3, R. Klamroth1, S. Lejniece4, T. Suzuki5, A.V. Groth6, N. Tripkovic7, E. Santagostino8 (1Germany, 2Malaysia, 3Spain, 4Latvia, 5Japan, 6Denmark, 7Switzerland, 8Italy)

15:45 – 16:00 ASY 27.3

Current PK Tools Differ in Prophylactic Dosing Advice of Factor VIII Concentrate in Hemophilia A PatientsI. van Moort, T. Preijers, K. Fijnvandraat, F.W.G. Leebeek, R.A.A. Mathot, M.H. Cnossen, 'OPTI-CLOT' study group (the Netherlands)

16:00 – 16:15 ASY 27.4

Preoperative Screening for Bleeding Disorders: A Comprehensive Laboratory Assessment of Clinical PracticeM.J.A. Vries1, P.E.J. van der Meijden1, G.J.A.J.M. Kuiper1, P.J. Nelemans1, R.J.H. Wetzels1, R.G.M. van Oerle1, M.D. Lance2, H. ten Cate1, Y.M.C. Henskens1 (1the Netherlands, 2United Arab Emirates)

14:45 – 16:15 A1

New Aspects of FibrinogenChairs: Helen Philippou, United Kingdom Shirley Uitte de Willige, the Netherlands 14:45 – 15:15 ASY 28 Fibrinogen: What's New?

Marguerite Neerman-Arbez, Switzerland 15:15 – 15:30 ASY 28.1

Fibrin Protofibril Structure at the Atomic LevelV. Barsegov1, A. Zhmurov2, A.D. Protopopova1, R.I. Litvinov1, P. Zhukov2, A.R. Mukhitov1, J.W. Weisel1 (1United States, 2Russian Federation)

15:30 – 15:45 ASY 28.2

Extended D-E Interaction Sites Near the Classical Knob-hole Binding Site Play an Important Role in Fibrin Polymerisation and Clot FormationN. Asquith1, C. Duval1, M. Domingues2, H. McPherson1, F. Macrae1, S. Connell1, V. Barsegov3, R. Ariens1 (1United Kingdom, 2Portugal, 3United States)

Abs

trac

ts



204 205

Wed

nesd

ay

15:45 – 16:00 ASY 28.3The Factor VII Activating Protease (FSAP) Accelerates Fibrinolysis by Altering Fibrin Clot StructureM. Etscheid1, S. Subramaniam2, G. Lochnit1, M. Zabczyk3, K.-M. Hanschmann1, A. Undas3, S. Kanse4 (1Germany, 2United States, 3Poland, 4Norway)

16:00 – 16:15 ASY 28.4

Relevance of Fibrinogen α-chain Cross-linking in Clot Formation, Structure, and StabilityC. Duval1, M. Gold1, H. McPherson1, N. Asquith1, S. Baker1, M. Domingues2, R. Ajjan1, V. Ridger1, S. Connell1, H. Philippou1, R. Ariens1 (1United Kingdom, 2Portugal)

14:45 – 16:15 A2

Pathogenesis in Thrombosis: Basic Chairs: Jose A. Diaz, United States Roopen Arya, United Kingdom

14:45 – 15:15 ASY 29 Protein Disulfide Isomerase and Thrombosis

Robert Flaumenhaft, United States 15:15 – 15:30 ASY 29.1

Variety of Activators and Intracellular Sources Determine the Structural Diversity of Platelet-derived MicroparticlesR.I. Litvinov1, A.A. Ponomareva2, T.A. Nevzorova2, E.R. Mordakhanova2, I.A. Andrianova2, L. Rauova1, J.W. Weisel1 (1United States, 2Russian Federation)

15:30 – 15:45 ASY 29.2

Tissue Factor-Positive Microvesicles from a Human Pancreatic Tumor Grown Orthotopically Enhance Venous Thrombosis in MiceY. Hisada1, C. Ay2, B. Cooley1, N. Mackman1 (1United States, 2Austria)

15:45 – 16:00 ASY 29.3

SerpinE2 Deficiency Accentuates Coagulation and Inflammation and Promotes Pulmonary FibrosisL. Venisse, D. François, Y. Boulaftali, K. Aymonnier, M. Jandrot-Perrus, E. Camerer, V. Arocas, M.-C. Bouton (France)

16:00 – 16:15 ASY 29.4

Von Willebrand Factor Regulates Deep Vein Thrombosis in a Mouse Model of Diet-induced ObesityA. Michels, C. Dwyer, L.L. Swystun, D. Lillicrap (Canada)

14:45 – 16:15 A3

Signaling Mechanisms in the Vasculature Chairs: Florence Sabatier, France Rafal Pawlinski, United States

14:45 – 15:15 ASY 30 Signaling Mechanisms in the Vasculature

Ingrid Fleming, Germany 15:15 – 15:30 ASY 30.1

Targeting the Angiopoietin-Tie2 Axis to Regulate Microvascular Thrombosis in SepsisK. De Ceunynck, S.J. Higgins, S.A. Chaudhry, S.M. Parikh, R. Flaumenhaft (United States)

15:30 – 15:45 ASY 30.2

AMPK Promotes VEGF-induced Angiogenesis via GFAT1 InhibitionD. Zibrova1, F. Vandermoere2, O. Göransson3, M. Peggie4, K.V. Mariño5, A. Knierim1, K. Spengler1, C. Weigert1, B. Viollet2, N.A. Morrice4, K. Sakamoto4, R. Heller1 (1Germany, 2France, 3Sweden, 4United Kingdom, 5Argentina)

15:45 – 16:00 ASY 30.3

Endothelial Primary Cilia Coordinate Vascular Regression During DevelopmentA.-C. Vion, T. Zheng, A. Klaus, E. Bartels-Klein, I. Hollfinger, H. Gerhardt (Germany)

16:00 – 16:15 ASY 30.4

Nterm-Phosphatase of Soluble Epoxide Hydrolase (sEH) in the Regulation of Vascular Endothelial InflammationE. Suzuki, H. Hirosaki, M. Tajima, M. Kaseda, J. Abe, N. Matsumoto, K. Hasumi (Japan)

14:45 – 16:15 A5

Ischemic Injury in Heart and BrainChairs: Lina Badimon, Spain Elizabeth Gardiner, Australia 14:45 – 15:15 ASY 31 Protection From Ischemic Injury in Heart and Brain

Derek Hausenloy, Singapore

Abs

trac

ts



206 207

Wed

nesd

ay

15:15 – 15:30 ASY 31.1Targeted Termination of Plasminogen Activation after Tissue Plasminogen Activator Therapy Reduces Ischemic Brain Injury and Hemorrhage in Experimental Ischemic StrokeT. Zhao, S. Lane, Y. Zhang, A. Houng, G. Reed (United States)

15:30 – 15:45 ASY 31.2

A Novel and Effective Fibrinolytic Approach in a Murine Model of Diabetes-associated Ischemic StrokeM. Navarro-Oviedo, C. Roncal, B. Zandio, J.A. Rodríguez, J.A. Páramo, R. Muñoz, J. Orbe (Spain)

15:45 – 16:00 ASY 31.3

Late Administration of a new Antifibrinolytic Strategy (CM352) Reduces Lesion Size and Improves Functional Outcome in a Collagenase-Induced Rat Model of Intracerebral HemorrhageM. Navarro-Oviedo, T. Sobrino, J.A. Rodriguez, F. Campos, J. Oyarzabal, J. Castillo, J.A. Páramo, J. Orbe (Spain)

16:00 – 16:15 ASY 31.4

Restoring Cardiac Function after Myocardial Infarction by Targeting CD39 to Activated PlateletsM. Ziegler, J.D. Hohmann, A.K. Searle, M.-K. Abraham, H. Nandurkar, X. Wang, K. Peter (Australia)

14:45 – 16:15 A6

The Role of Platelets in ImmunocompetenceChairs: John W. Semple, Sweden Eric Boilard, Canada 14:45 – 15:15 ASY 32 The Role of Platelets in Immune Regulation

Craig Morrell, United States 15:15 – 15:30 ASY 32.1

Platelets Modulate the Proinflammatory Phenotype of Macrophages via the Interaction of CLEC-2 and PodoplaninJ. Rayes, S. Lax, M. Zuidscherwoude, S. Wichaiyo, B. Grygielska, S. Watson, S.P. Watson, Birmingham platelet group (United Kingdom)

15:30 – 15:45 ASY 32.2Activation of Circulating Platelets Leads to Innate-like Delivery of Potent Antiviral AntibodiesW.C. Schrottmaier1, A.-L. Luik1, M. Salzmann2, S. Badrnya2, S. Morava2, J.B. Kral-Pointner2, M. Karlsson1, A. Assinger2, M. Forsell1 (1Sweden, 2Austria)

15:45 – 16:00 ASY 32.3

Platelets Orchestrate Bleomycin-induced Lung Fibrosis in Circuitry with NETsM. Bosmann1, D.R. Riehl1, J. Roewe1, S. Klebow1, N.L. Esmon2, S. Eming1, G. Colucci3, M. Gunzer1, A. Waisman1, K. Schäfer1, C.T. Esmon2, W. Ruf1 (1Germany, 2United States, 3Switzerland)

16:00 – 16:15 ASY 32.4

Platelets Interact with Neutrophils and Promote Intravascular Neutrophil Activation in Acute GlomerulonephritisM. Finsterbusch, M.J. Hickey (Australia)

14:45 – 16:15 A7

New Technology to Study PlateletsChairs: Lawrence Brass, United States David Stegner, Germany 14:45 – 15:15 ASY 33 Superresolution Microscopy

Steven G. Thomas, United Kingdom 15:15 – 15:30 ASY 33.1

Differential Signaling through Platelet Collagen Receptors Investigated Using MetabolomicsA. Bussey, Z. Ament, J.-D. Malcor, J. Griffin, R.W. Farndale (United Kingdom)

15:30 – 15:45 ASY 33.2

Characterization of the Gp1ba-Cre Transgenic Mouse: A Novel Approach for Generating Megakaryocyte/Platelet-specific Knockout MiceZ. Nagy1, T. Vögtle1, G. Di Nunzio1, J. Mori1, M. Geer1, S. Heising1, R. Gareus2, A. Mazharian1, Y.A. Senis1 (1United Kingdom, 2United States)

15:45 – 16:00 ASY 33.3

Real-time Platelet Production from Human iPS-derived Megakaryocytes in a Micropillar-textured Microfluidic ChipG. Sicot, K. Khelloufi, A. Magniez, A. Legoff, S. Corbineau, A. Nivau, F.S. Hamdi, B. Teste, N. Debili, M. Reyssat, D. Baruch (France)

Abs

trac

ts



208 209

Wed

nesd

ay

16:00 – 16:15 ASY 33.4Quantification of Platelet Contractile Movements during Thrombus FormationK. Claesson, N. Boknäs, T. Lindahl, L. Faxälv (Sweden)

14:45 – 16:15 A8

Coagulation and Immune Responses Chairs: Björn Dahlbäck, Sweden Madhusudhan Thati, Germany

14:45 – 15:15 ASY 34 Immunothrombosis

Bernd Engelmann, Germany 15:15 – 15:30 ASY 34.1

Tissue Factor-PAR2 Signaling Promotes Cutaneous Inflammation in MiceM.I. Schmidgen, T. Schmidt, N. Lorenz, V. Raker, J. Haub, G. Carlino, S. Reyda, W. Ruf, K. Steinbrink (Germany)

15:30 – 15:45 ASY 34.2

Protease Activated Receptor 2 Cleavage by Coagulation Factor VIIa Contributes to Lung InflammationM. Zelaya, C. Graf, W. Ruf (Germany)

15:45 – 16:00 ASY 34.3

Effector-memory T cells Attenuate Thrombus ResolutionF. Shahneh, N. Luther, B. Kleis-Fischer, C. Reinhardt, H.C. Probst, P. Wenzel, K. Schäfer, C. Becker (Germany)

16:00 – 16:15 ASY 34.4

Caveolin-1 is a Novel Key Player in the Crosstalk between Tissue Factor and the IGF-1RM. Åberg, A. Siegbahn (Sweden)

14:45 – 16:15 New York

Management Strategies in Acute VTE Chairs: Guy Meyer, France David Jiménez, Spain

14:45 – 15:15 ASY 35 Evidence for Interventional Treatment of Acute VTE and Beyond

Akhilesh K. Sista, United States

15:15 – 15:30 ASY 35.1No Further Reduction in the Number of Required CT Pulmonary Angiograms When Implementing the ADJUST (Age Adjusted) D-dimer Cut-off Level in the YEARS AlgorithmL.M. van der Pol, T. van der Hulle, Y.W. Cheung, T. van Bemmel, J. van Es, L.M. Faber, M. ten Wolde, H. Hofstee, M.M.C. Hovens, M. Nijkeuter, R.C.J. van Klink, M.J.H.A. Kruip, A.T.A. Mairuhu, S. Middeldorp, M.V. Huisman, F.A. Klok (the Netherlands)

15:30 – 15:45 ASY 35.2

Mean Bilateral Proximal Extension of the Clot - A New Score for Risk Stratification of Pulmonary EmbolismJ.P. Ghanima, F. Bremptum, M. Schnitzkewitz, M. Tavoly, J. Gleditich, W. Ghanima (Norway)

15:45 – 16:00 ASY 35.3

Disease Prevalence Dependent Failure Rate in Diagnostic Management Studies in Suspected Deep Vein ThrombosisC.E.A. Dronkers1, Y.M. Ende-Verhaar1, P.A. Kyrle2, M. Righini3, S.C. Cannegieter1, M.V. Huisman1, F.A. Klok1 (1the Netherlands, 2Austria, 3Switzerland)

16:00 – 16:15 ASY 35.4

Clinical characteristics and management of 10,329 patients with a confirmed diagnosis of venous thromboembolism: the GARFIELD-VTE registryW. Ageno1, P. McCallum2, S. Haas3, J.I. Weitz4, P. Angchaisuksiri5, H. Bounameaux6, S.Z. Goldhaber7, S. Goto8, G. Kayani2, J. Dalsgaard Nielsen9, L.G. Mantovani1, S. Schellong3, A.G.G. Turpie4, P. Prandoni1, A.K. Kakkar2 (1Italy, 2United Kingdom, 3Germany, 4Canada, 5Thailand, 6Switzerland, 7United States, 8Japan, 9Denmark)

14:45 – 16:15 London

VTE - Gaps of EvidenceChairs: Menno Huisman, the Netherlands Alex Spyropoulos, United States 14:45 – 15:15 ASY 36 Calf Deep Vein Thrombosis

Jan Beyer-Westendorf, Germany

Abs

trac

ts



210 211

Wed

nesd

ay

15:15 – 15:30 ASY 36.1Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical ExtentM.P.A. Brekelmans1, H.R. Buller1, M.F. Mercuri2, W. Ageno3, C.Z. Chen2, A.T. Cohen4, N. van Es1, M.A. Grosso2, A.P. Medina2, G. Raskob2, A. Segers1, T. Vanassche5, P. Verhamme5, P.S. Wells6, G. Zhang2, J.I. Weitz6 (1the Netherlands, 2United States, 3Italy, 4United Kingdom, 5Belgium, 6Canada)

15:30 – 15:45 ASY 36.2Validation of the IMPROVE Bleeding Risk Assessment Model in Hospitalized Medical Patients: A Multi-center StudyS. Kaatz, D. Paje, S. Bernstein, B. Almasri, M. Hettiarachchi, P. Patel, G. Salem, V. Hereford, M. Cerasale (United States)

15:45 – 16:00 ASY 36.3

Tinzaparin for Treatment of Fetal Growth Retardation: A Randomized Multicenter-trialA.T. Hansen, P. Sandager, M. Ramsing, J.D. Salvig, N. Uldbjerg, A.-M. Hvas (Denmark)

16:00 – 16:15 ASY 36.4

Puerperium But Not Pregnancy Is a Risk Factor for Cerebral Venous ThrombosisS.M. Silvis1, L.J.J. Scheres1, S. Hiltunen2, E. Lindgren3, K. Jood3, S.M. Zuurbier1, S. Middeldorp1, J. Putaala2, S.C. Cannegieter1, T. Tatlisumak2, J.M. Coutinho1 (1the Netherlands, 2Finland, 3Sweden)

14:45 – 16:15 Helsinki 1

Women's Issues in Thrombosis and Hemostasis Chairs: Claire McLintock, New Zealand Rochelle Winikoff, Canada

14:45 – 15:15 ASY 37 Hormonal Therapy-Related Thrombosis

Marc Blondon, Switzerland 15:15 – 15:30 ASY 37.1

Adverse Pregnancy Outcomes in Women with Persistent Lupus Anticoagulant - Experiences from the Prospective Vienna Lupus Anticoagulant and Thrombosis Study (LATS)S. Koder, J. Gebhart, F. Posch, P. Quehenberger, C. Ay, I. Pabinger (Austria)

15:30 – 15:45 ASY 37.2

Identification of Gene-environment Interactions in Pregnancy-related Venous ThromboembolismM. deAndrade1, S.M. Armasu1, B.M. McCauley1, T.M. Petterson1, H.G. de Haan2, J.A. Heit1 (1United States, 2the Netherlands)

15:45 – 16:00 ASY 37.3Cancer and Venous Thromboembolism in PregnancyV. Barros, E. Hase, A.M. Igai, R. Francisco, M. Zugaib (Brazil)

16:00 – 16:15 ASY 37.4Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism: A Case-Only StudyJ. Hugon-Rodin, M.H. Horellou, J. Conard, A. Gompel, G. Plu-Bureau, COREVE investigators (France)

14:45 – 16:15 Helsinki 2

miRNA as Diagnostic Biomarkers Chairs: John-Bjarne Hansen, Norway Astrid van Hylckama Vlieg, the Netherlands

14:45 – 15:15 ASY 38 miRNA as Diagnostic Biomarkers

Manuel Mayr, United Kingdom 15:15 – 15:30 ASY 38.1

Plasma miRNA Expression as Risk Marker of Stroke in Patients with Atrial FibrillationR. Teruel-Montoya, A.B. Arroyo, P. Valledor, M.A. de los Reyes-García, N. García-Barbera, V. Vicente, F. Marin, V. Roldán, R. González-Conejero, C. Martínez (Spain)

15:30 – 15:45 ASY 38.2

Identification of a microRNA Profile for Predicting the Thrombotic Risk of Biliopancreatic Cancer PatientsJ. Oto1, A.C. Larsen2, E. Plana1, D. Hervás1, L. Martos1, L.A. Ramón1, M.J. Solmoirago1, Á. Fernández-Pardo1, F. España1, S. Navarro1, S.R. Kristensen2, O. Thorlacius-Ussing2, P. Medina1 (1Spain, 2Denmark)

15:45 – 16:00 ASY 38.3

Septic Conditions Modulate the Level of miRNAs in Platelets and Megakaryocytes that May Contribute to Abnormal Platelet ReactivityZ. Fejes, T. Orosz, S. Póliska, Z. Czimmerer, G. Nagy, B. Fülesdi, J. Kappelmayer, B. Nagy Jr. (Hungary)

16:00 – 16:15 ASY 38.4

miR-125a-5p Regulates Megakaryocyte Differentiation and Proplatelet FormationS. Bhatlekar, S. Nagalla, C. Lindsey, L. Ma, X. Kong, I. Basak, R. Pellegrino da silva, L. Yichuan, M. Rondina, A. Weyrich, L. Edelstein, P. Bray (United States)

Abs

trac

ts



212 213

Wed

nesd

ay

14:45 – 16:15 Budapest

HITChairs: Theodore Warkentin, Canada Tamam Bakchoul, Germany 14:45 – 15:15 ASY 39 Management of the Multiple Phases of HIT

Adam Cuker, United States 15:15 – 15:30 ASY 39.1

Elevated Plasma Soluble GPVI (sGPVI) Can Aid Detection of Platelet-activating Autoantibodies in Heparin-induced Thrombocytopenia (HIT)C. Lee1, M. Al-Tamimi2, M. Berndt1, R. Baker1, R. Andrews1, P. Choi1, A. Cuker3, E. Gardiner1 (1Australia, 2Jordan, 3United States)

15:30 – 15:45 ASY 39.2

Pathogenic Antibodies in Heparin-induced Thrombocytopenia (HIT) Activate Monocytes and Induce Profound Membrane RemodelingI.A. Andrianova1, V. Hayes2, R.I. Litvinov2, D.B. Cines2, M. Poncz2, J.W. Weisel2, L. Rauova2 (1Russian Federation, 2United States)

15:45 – 16:00 ASY 39.3

Dynamic Redistribution of Platelet Factor 4 on Vascular and Intravascular Cell Surfaces: Implications for Heparin-induced Thrombocytopenia (HIT)J. Dai, V. Hayes, I. Johnston, K. Golomp, G.M. Arepally, D.B. Cines, M. Poncz, L. Rauova (United States)

16:00 – 16:15 ASY 39.4

Neutrophils and Released Neutrophil Extracellular Traps (NETs) Contribute to the Prothrombotic State in HITK. Gollomp, V. Hayes, I. Johnston, G. Zhao, L. Rauova, M. Poncz (United States)


Plenary

16:45 – 17:30 Hall B

Erwin Deutsch Plenary Lecture: Transfusion Medicine and Cell Therapies Chairs: Andreas Greinacher, Germany 16:45 – 17:30 PL 06 From HSC to Megakaryocytes: The Uncovered Role of Glycans in

HematopoiesisKarin M. Hoffmeister, United States

Ple

nary



214 215

Thur

sday

Thursday, July 13, 2017Scientific Program

State of the Art

08:00 – 09:15 A1

MegakarypoiesisChairs: Mortimer Poncz, United States Catherine Léon, France 08:00 – 08:25 SOA 22.1 Regulation of Hematopoietic Stem Cell Quiescence by Megakaryocytes

Paul Frenette, United States 08:25 – 08:50 SOA 22.2 Emergency Megakaryopoiesis Under Inflammation

Marieke A.G. Essers, Germany 08:50 – 09:15 SOA 22.3 Visualization of Platelet Life: Thrombopoiesis and Thrombus Formation

Satoshi Nishimura, Japan

08:00 – 09:15 A2

Epigenetic and Genetic Determinants of Hemostasis and Thrombosis Chairs: Pierre Emmanuel Morange, France Sven Danckwardt, Germany

08:00 – 08:25 SOA 23.1 Genetics of Pediatric Bleeding Disorders

Jorge Di Paola, United States 08:25 – 08:50 SOA 23.2 Epigenetics and Platelet Function

Chris Van Geet, Belgium 08:50 – 09:15 SOA 23.3 New Approaches to Understand Genetic Risk of Venous Thrombosis

John-Bjarne Hansen, Norway

Scientific Program

Thursday, July 13, 2017



Legend

Plenary Sessions




Supported Symposia


Sta

te o

f th

e A

rt



216 217

Thur

sday

08:00 – 09:15 A3

Nanotechnology and Microfluidics in Diagnostic Approaches Chairs: John Weisel, United States Mihaela Delcea, Germany

08:00 – 08:25 SOA 24.1 Microfluidic Analysis of Whole Blood Hemostasis

Scott Diamond, United States 08:25 – 08:50 SOA 24.2 Diagnostic Approaches for Polyphosphate

James H. Morrissey, United States 08:50 – 09:15 SOA 24.3 Pico Newtons and Nanometers: Single Molecule Analysis in Thrombosis and

HemostasisMihaela Delcea, Germany

08:00 – 09:15 A5

Managing Thrombosis in Children Chairs: Manuela Albisetti, Switzerland Paul Monagle, Australia 08:00 – 08:25 SOA 25.1 Which Risk Groups of Children Should Receive Thromboprophylaxis?

Brian Branchford, United States 08:25 – 08:50 SOA 25.2 Challenges of Anticoagulant Therapy in Children: Which Agent, Intensity,

Duration?Fiona Newall, Australia

08:50 – 09:15 SOA 25.3

Direct Oral Anticoagulant: Are We Ready to Use Them in Children? Christoph Male, Austria

08:00 – 09:15 A6

Inflammation and Atherothrombosis Chairs: Steffen Massberg, Germany Rory R. Koenen, the Netherlands

08:00 – 08:25 SOA 26.1 Oxidation-Specific Epitopes and Atherosclerosis

Christoph Binder, Austria 08:25 – 08:50 SOA 26.2 Clotting Factors and Atherothrombosis

Hugo ten Cate, the Netherlands 08:50 – 09:15 SOA 26.3 NETosis and Cardiovascular Disease

Denisa Wagner, United States

08:00 – 09:15 A7

ISTH-EHA Joint Session: Cancer-Associated ThrombosisChairs: Per Morten Sandset, Norway Francesco Rodeghiero, Italy 08:00 – 08:25 SOA 27.1 Mechanisms of Cancer-Associated Thrombosis

Anna Falanga, Italy 08:25 – 08:50 SOA 27.2 Etiology and Risk Assessment of Thrombosis in Cancer

Cihan Ay, Austria 08:50 – 09:15 SOA 27.2 Managing Thrombosis in Cancer Patients

David Garcia, United States

Sta

te o

f th

e A

rt



218 219

Thur

sday

08:00 – 09:15 A8

Inhibitors in Hemophilia Chairs: Roshni Kulkarni, United States Alfonso Iorio, Canada 08:00 – 08:25 SOA 28.1 Immune Tolerance Induction in Hemophilia

David Lillicrap, Canada 08:25 – 08:50 SOA 28.2 Therapeutic Potential of Engineered Regulatory T Cells: From CARs to BARS

David Scott, United States 08:50 – 09:15 SOA 28.3 Product Type and Other Environmental Risk Factors for Inhibitor Formation


Oral Communications

09:30 – 10:45 Hall B

Proficiency Testing and Quality ControlChairs: Isobel D. Walker, United Kingdom Michael Spannagl, Germany 09:30 – 09:45 OC 65.1

Commutability - The Importance of Valid Material for Proficiency Testing PurposesI. Jennings, D. Kitchen, S. Munroe-Peart, S. Kitchen, T. Woods, I. Walker (United Kingdom)

09:45 – 10:00 OC 65.2

Chromogenic and One Stage FIX Assays in the Presence of Idelvion (rFIX-FP), Alprolix (rFIXFc) Benefix and Replenine: Data from a UK NEQAS for Blood Coagulation SurveyS. Kitchen, I. Jennings, M. Makris, D. Kitchen, T. Woods, I. Walker (United Kingdom)

10:00 – 10:15 OC 65.3

The ECAT External Quality Assessment Programme: Larger Variation in FVIII Activity < 0.05 IU/ml with One-stage Assay Compared to Chromogenic AssayI. van Moort, P. Meijer, F.W.G. Leebeek, M.H. Cnossen, M.P.M. de Maat (the Netherlands)

10:15 – 10:30 OC 65.4North American Special Coagulation Laboratories (NASCOLA): Laboratory Practices for aPTT Based One-stage Factor Assays and their Outcomes on Results: A SurveyD. Castellone1, K. Moffat2, E. Plumhoff1 (1United States, 2Canada)

10:30 – 10:45 OC 65.5

Efficiency of Bayesian Logic in Detecting and Characterizing Loss of Precision, and or Loss of Accuracy: Application to aPTT Statistical Process ControlF. Sobas1, K. Bourazas2, E. Jousselme1, C. Nougier1, C. Négrier1, P. Tsiamyrtzis2 (1France, 2Greece)

09:30 – 10:45 A1

Platelet ReceptorsChairs: Renhao Li, United States Andrew L. Frelinger III, United States 09:30 – 09:45 OC 66.1

Platelet Collagen Receptor GPVI-dimer Binds to Fibrinogen D-fragment and D-dimer and May Contribute to Platelet Activation and Adhesion during Thrombus FormationI. Induruwa, M. Moroi, A. Bonna, J.-D. Malcor, J.-M. Howes, E.A. Warburton, R. Farndale, S.M. Jung (United Kingdom)

09:45 – 10:00 OC 66.2

Gp6 Signaling is Compromised in Early Young Platelets in MiceS. Gupta, D. Cherpokova, M. Morowski, M. Bender, B. Nieswandt (Germany)

10:00 – 10:15 OC 66.3

Dissecting PAR1 Specific Signaling in Platelets Using Quantitative Mass Spectrometry Based PhosphoproteomicsS.B.G. Jansen, F.P.J. van Alphen, A.B. Meijer, M. van den Biggelaar (the Netherlands)

10:15 – 10:30 OC 66.4

Perlecan: a Physiological Ligand for the Inhibitory Platelet Receptor G6b-BT. Vögtle, S. Rajesh, M.R. Douglas, Y.A. Senis (United Kingdom)

10:30 – 10:45 OC 66.5

Structural Analysis of Protease Activated Receptor 4 (PAR4) with Histidine Hydrogen Deuterium ExchangeM. de la Fuente, M. Miyagi, M. Nieman (United States)

Ora

ls



220 221

Thur

sday

09:30 – 10:45 A2

Vessel Wall and Angiogenesis Chairs: Judith Cosemans, the Netherlands Annette von Drygalski, United States 09:30 – 09:45 OC 67.1

Endothelial Cells Are Important Players in the Pathogenesis of Thrombosis in Myeloproliferative NeoplasmsA. Guy, V. Gourdou-Latyszenok, N. Le-Lay, J. Vieira Dias, B. Kilani, C. Peghaire, C. Duplaa, C. Denis, J.-L. Villeval, M. Jandrot-Perrus, T. Couffinhal, C. James (France)

09:45 – 10:00 OC 67.2

Modification of the VEGF165 C-terminus by Activated Thrombin-activatable Fibrinolysis Inhibitor (TAFIa) Inhibits Neuropilin-1 (Nrp1)-dependent Induction of Angiogenesis in vitro and in vivoT.L. Wyseure1, R.K. Sinha1, P.J. Declerck2, J.C.M. Meijers3, A. von Dryglaski1, L.O. Mosnier1 (1United States, 2Belgium, 3the Netherlands)

10:00 – 10:15 OC 67.3

Deficiency of Androgen Dependent TFPI-Regulating Protein (ADTRP) Promotes Vascular Malformations via Wnt-mediated up-regulation of MetalloproteasesC. Lupu, M.M. Patel, A. Behar, R.S. Keshari, R. Silasi, G. Regmi, F. Lupu (United States)

10:15 – 10:30 OC 67.4

The von Willebrand Factor-binding Protein Bridges the Bacterial Cell Wall via Clumping Factor A and Endothelial von Willebrand Factor Allowing Shear-resistant Binding of Staphylococcus aureus to Inflamed or Damaged EndotheliumJ. Claes1, L. Liesenborghs1, M. Peetermans1, T.R. Veloso1, D. Missiakas2, O. Schneewind2, S. Mancini3, J.M. Entenza3, M.F. Hoylaerts1, R. Heying1, P. Verhamme1, T. Vanassche1 (1Belgium, 2United States, 3Switzerland)

10:30 – 10:45 OC 67.5

Cadherin 6 (cdh6) is Required for Thrombus Formation in vivoE. Bouck, M. de la Fuente, W. Li, M. Mumaw, M. Nieman (United States)

09:30 – 10:45 A3

Platelet Proteomics and GenomicsChairs: Willem H. Ouwehand, United Kingdom Ángel García, Spain

09:30 – 09:45 OC 68.1Platelet Transcriptome Analysis of Mice with Altered Thrombin RegulationS. Schubert, F. Marini, C. Santos, H. Binder, W. Ruf (Germany)

09:45 – 10:00 OC 68.2

Identification of eQTLs for Platelet and Hemostasis Related Genes in Platelets and Leukocytes within the Framingham Heart StudyJ.E. Huffman, J.D. Eicher, K. Tanriverdi, J.E. Freedman, A.D. Johnson (United States)

10:00 – 10:15 OC 68.3

The First Quantitative Phosphoproteome after Selective cGMP/PKG Stimulation by Riociguat In Human Platelets and Comparison to the cAMP/PKA PhosphoproteomeO. Pagel1, E. Walter1, S. Makhoul1, H. Gonczarowska-Jorge1, A. Smolenski2, S. Gambaryan1, U. Walter1, K. Jurk1, R. Zahedi1 (1Germany, 2Ireland)

10:15 – 10:30 OC 68.4

Reversible Protein Lysine Acetylation as a Novel Regulatory Modality Orchestrating Platelet FunctionJ.E. Aslan, R.A. Rigg, A.T.P. Ngo, J.W. Nelson, J. Burchard, Ö. Babur, E. Demir, U. Shinde, L.L. David, O.J.T. McCarty (United States)

10:30 – 10:45 OC 68.5

The Platelet Releasate is a 'Barcode' for the Health Status of an IndividualP.B. Szklanna, M.E.M. Parsons, K. Wynne, H. O'Connor, K. Egan, F. Ni Ainle, P.B. Maguire (Ireland)

Ora

ls



222 223

Thur

sday

09:30 – 10:45 A5

Inherited Platelet Disorders Chairs: Kathleen Freson, Belgium Tadbir K. Bariana, United Kingdom 09:30 – 09:45 OC 69.1

New Insights in Pathogenesis, Diagnosis and Phenotype of FLI1-associated ThrombocytopeniaP. Saultier, L. Vidal, M. Canault, D. Bernot, C. Falaise, K. Pouymayou, J.-C. Bordet, N. Saut, A. Rostan, V. Baccini, F. Peiretti, M. Favier, P. Lucca, P.E. Morange, C. Gachet, S. Fauré, A. Eckly, D.-A. Trégouët, M. Poggi, M.-C. Alessi (France)

09:45 – 10:00 OC 69.2

Identification of the DIAPH1 R1213* Variant in a Family with Macrothrombocytopenia and Hearing LossN. Mota-Pérez1, V. Palma-Barqueros1, J.M. Bastida1, C. Martínez1, J. Padilla1, V. Vicente1, B. Johnson2, S.P. Watson2, N. Morgan2, M.L. Lozano1, J. Rivera1 (1Spain, 2United Kingdom)

10:00 – 10:15 OC 69.3

Genotype-phenotype Correlation in Wiskott-Aldrich Syndrome: Four Novel Mutations in WAS GeneS.S. Medina, L.H. Siqueira, M.P. Colella, M.M.S. Vilela, M.C. Ozelo (Brazil)

10:15 – 10:30 OC 69.4Identification of Two Novel Mutations in RASGRP2 Affecting Platelet CalDAG-GEFI Expression and Function in Patients with Bleeding DiathesisT. Sevivas1, J.M. Bastida2, D.S. Paul3, E. Caparros-Pérez2, V. Palma-Barqueros2, M. Coucelo1, D. Marques1, F. Ferrer-Marín2, J.R. González-Porras2, V. Vicente2, J.M. Hernández-Rivas2, S.P. Watson4, M.L. Lozano2, W. Bergmeier3, J. Rivera2 (1Portugal, 2Spain, 3United States, 4United Kingdom)

10:30 – 10:45 OC 69.5Phenotyping of Platelets of Patients with Inherited Platelet Disorders on Blood Smears by Immunofluorescence Microscopy - Experience of the Greifswald LaboratoryK. Althaus, C. Blumentritt, U. Strobel, T. Bakchoul, A. Greinacher (Germany)

09:30 – 10:45 A6

Platelets and InflammationChairs: Sidney Whiteheart, United States Peter Presek, Germany 09:30 – 09:45 OC 70.1

Von Willebrand Factor-platelet Microthrombi Phagocytosis by Macrophages as a New Homing Mechanism for Tissue Entry and FibrosisR. Fortna1, N. Prévost2 (1United States, 2Japan)

09:45 – 10:00 OC 70.2

Interferon-induced Transmembrane 3 (IFITM3) on Megakaryocytes and Platelets Regulates Fibrinogen Endocytosis and Thrombosis During InflammationR. Campbell, B. Manne, S. Saperstein, H. Schwertz, J. Rowley, A. Weyrich, M. Rondina (United States)

10:00 – 10:15 OC 70.3Platelet exosomes Promote Vaso-occlusive Thrombosis in Sickle Cell DiseaseM. Jimenez, M. Bennewitz, T. Brzóska, M. Scott, M. Neal, M. Gladwin, P. Sundd (United States)

10:15 – 10:30 OC 70.4

Visualising LPS-induced Platelet Adhesion and Activation in Lungs Using Immunohistochemistry and Intravital MicroscopyS.J. Cleary1, E. Lefrançais2, B. Mallavia2, M.R. Looney2, C.P. Page1, S.C. Pitchford1 (1United Kingdom, 2United States)

10:30 – 10:45 OC 70.5

PLD1 Regulates TNF-mediated Protection against Responses to LPSR. Steubing, C. Kaup, M.-A. Urbahn, I. Krüger, P. Lang, M. Elvers (Germany)

09:30 – 10:45 A7

Regulation of Thrombosis and Beyond Chairs: Benjamin Brenner, Israel Robert Flaumenhaft, United States 09:30 – 09:45 OC 71.1

The Phosphate Transporter XPR1 Regulates Platelet Polyphosphate MetabolismM. Allende1, S. Gambaryan2, D. Firsov3, T. Renné1 (1Sweden, 2Russian Federation, 3Switzerland)

Ora

ls



224 225

Thur

sday

09:45 – 10:00 OC 71.2Lack of FXI on Top of Platelet Depletion Does Not Increase Gastrointestinal Bleeding in MiceM.V. Schmidt, J. Mueller, S. Heitmeier, F. Buehning, U. Lange, A. Buchmueller, V. Laux (Germany)

10:00 – 10:15 OC 71.3

Defining Differential Effects of Direct fXa versus FIIa Inhibition on Coagulation and InflammationS. Nazir, K. Shahzad, I. Gadi, M. Al-Dabet, S. Kohli, S. Ranjan, B. Isermann (Germany)

10:15 – 10:30 OC 71.4

Characterization of Activated Protein C (APC) Antibodies: Preferential Inhibition of APC's Anticoagulant Activity over Cytoprotective ActivityL.O. Mosnier, C. Patel, X.-Y. Zhao, S. Yegneswaran (United States)

10:30 – 10:45 OC 71.5

Establishment of a Reporter Cell Line for the Functional Screening of Vitamin K Cycle EnzymesJ.-K. Tie, D.-Y. Jin, D. Stafford (United States)

09:30 – 10:45 A8

Coagulation Factors and Inhibitors Chairs: Tilman Hackeng, the Netherlands Hartmut Weiler, United States 09:30 – 09:45 OC 72.1

The Role of Fibrinogen's αC Regions in the Early Stages of Fibrin PolymerizationA.D. Protopopova1, R.I. Litvinov1, D.K. Galanakis1, N.A. Barinov2, A.R. Mukhitov1, D.V. Klinov2, J.W. Weisel1 (1United States, 2Russian Federation)

09:45 – 10:00 OC 72.2

The Role of Thrombin Exosites 1 and 2 in the Activation of Factor XI by ThrombinV. Patel, K. Chen, B. Leslie, A. Stafford, J. Fredenburgh, J. Weitz (Canada)

10:00 – 10:15 OC 72.3

Clot-bound Thrombin Characterization of Plasma Clots in a Flow ReactorL.M. Haynes, T. Orfeo, K.E. Brummel-Ziedins (United States)

10:15 – 10:30 OC 72.4Thrombospondin 1 is Required for Fibrin Accumulation during Thrombus FormationS. Grover, R. Flaumenhaft, B. Furie (United States)

10:30 – 10:45 OC 72.5

A Critical Role of Factor XI Feedback Activation for Placental HemostasisA. Jämsä1, H.M.H. Spronk2, D. Gailani3, N. Mackman3, T. Renne´1 (1Sweden, 2the Netherlands, 3United States)

09:30 – 10:45 New York

Anticoagulation in the Real World Chairs: Philipp Wild, Germany Bettina Kemkes-Matthes, Germany

09:30 – 09:45 OC 73.1VTE Risk Factors in an Irish Urban Obstetric PopulationF. O'Shaughnessy, K. Bennett, F. Ní Áinle, B. Cleary (Ireland)

09:45 – 10:00 OC 73.2

Low Persistence to Direct Oral Anticoagulants at Routine Treatment for Acute Venous ThromboembolismC.E.A. Dronkers, W.M. Lijfering, M. Teichert, F.J.M. van der Meer, F.A. Klok, S.C. Cannegieter, M.V. Huisman (the Netherlands)

10:00 – 10:15 OC 73.3

Management Strategies and Long-term Outcomes in Patients with Isolated Distal Deep Vein Thrombosis: Findings from the XALIA StudyW. Ageno1, L.G. Mantovani1, S. Haas2, R. Kreutz2, D. Monje2, J. Schneider2, M. van Eickels2, M. Gebel2, A.G.G. Turpie3 (1Italy, 2Germany, 3Canada)

10:15 – 10:30 OC 73.4

Impact of BMI on Clinical Outcomes in Daily Care DOAC Recipients - Results of the Prospective Dresden NOAC Registry (NCT01588119)L. Tittl, S. Marten, E. Sebastian, A. Reitter, T. Schreier, J. Beyer-Westendorf (Germany)

10:30 – 10:45 OC 73.5

Risk Factors for Death Following Major Bleeding Whilst on Warfarin or Direct Oral Anticoagulants: Results from a Prospective UK Study (ORANGE)L. Green, J. Tan, R. Alikhan, N. Curry, T. Everington, R. Maclean, K. Saja, S. Stanworth, C. Tait, J. Morris, P. MacCallum (United Kingdom)

Ora

ls



226 227

Thur

sday

09:30 – 10:45 Helsinki 1

Platelet Disorders, Acquired Chairs: Donald Arnold, Canada Yves Gruel, France 09:30 – 09:45 OC 74.1

Low-dose Decitabine Improves Platelet Recovery in Patients with Isolated Thrombocytopenia Following SCTY. Han, Y. Tang, Y. Zhao, M. Huang, J. Qi, J. Chen, X. Wu, X. Ma, F. Chen, X. Feng, C. Ruan, D. Wu (China)

09:45 – 10:00 OC 74.2

Circulating Histone-associated Thrombocytopenia Has a Significant Adverse Impact on Outcome in Critically Ill PatientsY. Alhamdi, S. Abrams, I. Welters, G. Wang, C.-H. Toh (United Kingdom)

10:00 – 10:15 OC 74.3

Lack of Effect of Inhaled Nitric Oxide on Platelet Function or Bioenergetics in Patients with Acute Submassive Pulmonary Embolism: Results of a Randomized, Placebo-controlled TrialJ. Kline, M. Puskarich, A. Jones, R. Mastouri, T. Lahm, E. Gundert, C. Hall (United States)

10:15 – 10:30 OC 74.4

The Hypercoagulable State in Patients with Immune Thrombocytopenia (ITP) and its Association with Bleeding SymptomsT. Chiasakul, B. Akkawat, P. Rojnuckarin (Thailand)

10:30 – 10:45 OC 74.5

Effects of the Btk Inhibitor Ibrutinib on Platelet Function during Inflammation and in Primary HemostasisR.H. Lee, R. Piatt, P.B. Conley, W. Bergmeier (United States)

09:30 – 10:45 Budapest

Future Gene and Cell Based Therapies for HemophiliaChairs: Federico Mingozzi, France Qizhen Shi, United States 09:30 – 09:45 OC 75.1

Pharmacological Intervention and Improved Platelet-factor VIII Functionality Enhanced Efficacy of in vivo Platelet-targeted Gene Therapy of Murine Hemophilia A via Intraosseous DeliveryX. Wang, R. Fu, C. Miao (United States)

09:45 – 10:00 OC 75.2Persistent Expression of FVIII Following Intravenous Administration of Lenti-viral Vectors in Neonatal Hemophilia A Mouse and Dog ModelsT. Liu1, D. Drager1, S. Patarroyo-White1, A. Seregin1, A. Cantore2, L. Harpell3, D. Lillicrap3, L. Naldini2, R. Peters1 (1United States, 2Italy, 3Canada)

10:00 – 10:15 OC 75.3

Vector Dose-dependent Delayed CD8+ T Cell-mediated Clearance of AAV Encoded Antigen in the LiverR.W. Herzog, G.Q. Perrin, S. Kumar (United States)

10:15 – 10:30 OC 75.4

Prophylactic Platelet Factor (F) VIII Infusions Established from Induced Pluripotent Stem Cell (iPSC)-derived Megakaryocytes in Hemophilia AR. Lyde, H. Ahn, K. Vo, D. Jarocha, L. Zhai, S. Sullivan, V. Arruda, D. Sabatino, R. Camire, D. French, M. Poncz (United States)

10:30 – 10:45 OC 75.5

Targeted FVIII Expression under the Control of its Native Promoter for Hemophilia A Gene and Cell TherapyR. Famà, S. Merlin, E. Borroni, V. Bruscaggin, S. Zucchelli, A. Follenzi (Italy)

09:30 – 10:45 Berlin

DOACs and Beyond: Translational Aspects Chairs: Jeffrey I. Weitz, Canada Stefano Barco, Germany 09:30 – 09:45 OC 76.1

High Affinity FXII Inhibitor Macrocycle Peptide for Safe Anticoagulation TherapyR. Prince, J. Wilbs, S.J. Middendorp, C. Heinis, A. Angelillo-Scherrer (Switzerland)

09:45 – 10:00 OC 76.2

Improving the Therapeutic Index with JNJ-375: A Novel Long Acting Exosite-1 Thrombin Inhibitor In Animal ModelsM. Chintala1, Q. Li1, Z. Huang Devine1, P. Andrade-Gordon1, J. Verbeeck2, T. Baglin2, J. Huntington2, D. Grainger2, R. Mason2, K. Conde-Knape2 (1United States, 2United Kingdom)

10:00 – 10:15 OC 76.3

Different Effects of Heparin and Bilvalirudin on Thrombin-induced Platelet Activation via PAR1 and PAR4N. Boknäs, L. Faxälv, M. Wallstedt, T.L. Lindahl (Sweden)

Ora

ls



228 229

Thur

sday

10:15 – 10:30 OC 76.4Pharmacokinetic and Pharmacodynamic Modeling of Andexanet Alfa Dose to Reverse the Anticoagulant Activity of Factor Xa Inhibitors in Patients with Acute Major BleedingJ.M. Leeds1, J.W. Mandema1, G. Lu1, J.T. Curnutte1, T.J. Milling1, M. Crowther2, S.J. Connolly2, P.B. Conley1 (1United States, 2Canada)

10:30 – 10:45 OC 76.5

Plasma Level of Apixaban is Inversely Correlated with Hemoglobin Level due to Apixaban Binding to Deoxy-hemoglobinR. De Cristofaro, M. Sacco, F. Berruti, S. Lancellotti (Italy)

10:45 – 11:15 Coffee break

Plenary

11:15 – 12:30 Hall B

Sol Sherry Memorial Lecture: From Genomes to Stem CellsChairs: Christine Mannhalter, Austria Paul Frenette, United States

11:15 – 11:53 PL 07 The 100,000 Genomes Project: Which Results Do I Share With My Patient and Why?

Willem H. Ouwehand, United Kingdom 11:53 – 12:30 PL 08 Bone Marrow Niches

Sean Morrison, United States

12:30 – 13:45 Hall B

Highlights of ISTH Chairs: Johannes Oldenburg, Germany Robert Medcalf, Australia

12:30 – 13:00 Highlights of the Basic Science at the ISTH 2017Klaus T. Preissner, Germany

13:00 – 13:30 Highlights of the Clinical Science at ISTH 2017

Anne Angelillo-Scherrer, Switzerland 13:30 - 13:45 Closing Remarks

Posters

POSTER SESSIONSPOSTER SESSIONS


230 231

Mon

day

Pos

ter

Ses

sion

s

Monday, July 10, 2017Poster Sessions

Poster Session12:00 – 13:15 Exhibition Hall 2.2

Atherothrombosis & Stroke

PB 001 ErbB Signaling Gene EGFR Centric Network Plays an Important Role in Coronary Artery DiseaseM. Ghatge, J. Nair, A. Sharma, R.K. Vangala (India)

PB 002 Immunization with Recombinant Atherosclerosis Vaccine Candidate

(AHhHmR) Does Not Promote Melanoma Lung Metastasis in B6;129S-Ldlrtm1herApobtm2sgy/J MiceM. Xia1, V. Endresz2, I. Lantos2, K. Buzas2, X. Lu1 (1United Kingdom, 2Hungary)

PB 003 Pro-inflammatory and Pro-thrombotic Phenotype of Spontaneously

Differentiated Human Monocyte-derived Macrophages in Coronary Heart Disease Patients: Implications for Plaque Morphology and ActivityS. Eligini, N. Cosentino, S. Fiorelli, F. Fabbiocchi, G. Niccoli, H. Refaat, M. Camera, G. Calligaris, S. De Martini, A. Bonomi, F. Veglia, F. Fracassi, F. Crea, G. Marenzi, E. Tremoli (Italy)

PB 004 Regression of Atherosclerosis in ApoE Null Mice through Targeting Coagulation

Factor XaJ.J. Posthuma1, J.J.N. Posma1, R. van Gorp1, A. Jaminon1, R. van Oerle1, S. Heitmeier2, L.J. Schurgers1, H. ten Cate1, H.M.H. Spronk1 (1The Netherlands, 2Germany)

PB 005 The Effect of Factor XIII on the Proliferation and Migration of Vascular Smooth

Muscle CellsR. Bogáti, É. Katona, A.H. Shemirani, E. Balogh, V. Jeney, L. Muszbek (Hungary)

PB 006 Insights Into the Genetic Architecture of Coronary Artery Disease in Asian IndiansJ. Nair, J. Shanker (India)

PB 007 Oral Anticoagulants as Modulators of Arterial Calcification

R. van Gorp1, A. Jaminon1, M. Bauwens1, J. Bucerius1, V. Brandenburg2, W. Jahnen-Dechent2, H.M.H. Spronk1, C.P. Reutelingsperger1, L.J. Schurgers1 (1The Netherlands, 2Germany)

PB 008 Involvement of PAR Signaling in Thrombin Generation on Vascular Smooth Muscle Cells from Abdominal Aortic AneurysmsM. Didelot, J.B. Michel, P. Lacolley, V. Regnault (France)

PB 009 Commensal Microbiota Contribute to Atherosclerotic Plaque Formation and Thrombogenicity in the Carotid Artery of Ldlr-/- MiceS. Jäckel1, K. Kiouptsi1, E. van der Vorst1, C. Neideck1, M. Kuijpers2, K. Jurk1, S. Ascher1, S. Subramaniam1, D. Tsiantoulas3, J. Heemskerk2, C.J. Binder3, C. Weber1, Y. Döring1, C. Reinhardt1 (1Germany, 2The Netherlands, 3Austria)

PB 010 C3-Complement Activation is Found in Human Severe Atherosclerotic Plaques

T. Padro, M. Garcia-Arguinzonis, A. Deya, L. Badimon (Spain) PB 011 Relationship of Elevated Levels of Visfatin with Insulin Resistance and

Prothrombotic State in Coronary Artery DiseaseO. Korzh, E. Lavrova, O. Pavlova (Ukraine)

PB 012 Parameters of Complete Blood Count Do Not Predict On-treatment Platelet

Reactivity in Acute Coronary Syndrome PatientsL. Bonello, M. Laine, V. Baccini, C. Frere (France)

PB 013 Impairment of Weight Gain and Lipoprotein Lipase Mediated-triglyceride

Clearance in Integrin β3 (CD61) Deficient MiceB. Xiao, J. Mao, W. Zhang, Z. Ruan, X. Shi, X. Xi (China)

PB 014 Platelet Acetyl-CoA Carboxylase Phosphorylation: A Potential Marker for

Atherothrombotic Coronary Artery DiseaseS. Kautbally, S. Lepropre, A. Lerigoleur, B. Gerber, J. Kefer, D. Castanares, S. Eeckhoudt, C. Oury, J.-L. Vanoverschelde, L. Bertrand, S. Horman, C. Beauloye (Belgium)

PB 015 Recombinant Atherosclerosis Vaccine Candidate Antigen (AHhHmR)-induced

Tregs in B6;129S-Ldlrtm1herApobtm2sgy/J Mice Do Not Promote Melanoma Cell (MC) ProliferationM. Xia1, V. Endresz2, I. Lantos2, X. Lu1 (1United Kingdom, 2Hungary)

PB 016 Peripheral Immune Changes and Persistence of Tolerance to Atherosclerosis by Immune Modulation with Multi-antigenic Construct in Apobtm2Sgy Ldlrtm1Her/J MiceL.N.R. Thota, L. Mundkur, T. Ponnusamy, M. Ghatge, R.K. Vangala (India)

PB 017 Association of vWF Antigen/ADAMTS13 Activity Ratio with Gensini Score in

Type 2 Diabetes MellitusS. Lasom, N. Komanasin, N. Settasatian, C. Settasatian, U. Kukongviriyapan, P. Intharapetch, V. Senthong (Thailand)



232 233

Mon

day

Pos

ter

Ses

sion

s

PB 018 Activated Protein C Protects against Accelerated Atherosclerosis in Diabetes by Epigenetically Restricting p66Shc Expression in MacrophagesK. Shahzad1, I. Gadi2, S. Nazir2, M. Aldabet2, S. Kohli2, S. Ranjan2, B. Isermann2 (1Pakistan, 2Germany)

PB 019 Restoration of Blood Flow Contributes to the Regression of Atherosclerosis Plaque in MiceL. Ren, Y. Liu, Y. Wang, Y. Cao, F. Wu, L. Wang, T. You, L. Zhu, C. Tang (China)

PB 020 Nanoliposomes for Transfection Of CD39 mRNA: A Step towards

Nanotheranostics for Delivery of Anti-inflammatory Therapeutics against ThrombosisM.-K. Abraham1, K. Peter2, T. Michel1, H.P. Wendel1, S. Krajewski1, X. Wang2 (1Germany, 2Australia)

PB 021 Association of Plasma Soluble Thrombomodulin and HDL-C with Coronary

Artery StenosisN. Komanasin, N. Sittidedpachone, N. Settasatian, C. Settasatian, U. Kukongwiriyapan, P. Intharapetch, V. Senthong (Thailand)

PB 022 Protective Auto Antibodies and their Inverse Correlation with Antigen Levels in

Indian Patients with Acute Coronary SyndromeT. Ponnusamy, L. Mundkur, S.K. Venkatachala, R.K. Vangala (India)

PB 024 Role of RhoA/Rho Kinase Pathway Activation in Cocaine-induced Leukocyte

Transendothelial MigrationJ. Pereira, C.G. Sáez, M. Palominos, G. Valenzuela, A. Pastore, I. Solar-Costabal, D. Mezzano (Chile)

PB 025 High Circulatory Level of Inflammatory Cells and their Relation to Recurrent

Cardiac Events tn Indian PopulationT. Ponnusamy, L. Mundkur, S.K. Venkatachala, R.K. Vangala (India)

PB 026 Lipoprotein a [Lp(a)] and Hemostatic Variables in Young and Post Menopausal Women: Are their Levels Affected by Hormones Use?M.G. Carvalho, D.B. Serenini, C.N. Ferreira, E. Reis, I.F. Silva (Brazil)

PB 027 Selected Factors of Haemostasis and Some Clinical Parameters in Patients with Peripheral Arterial Disease with Regard to AtherosclerosisR. Wieczór, D. Rość, K. Stankowska, A.M. Wieczór, B. Ruszkowska-Ciastek, J. Fabisiak, K. Suppan, J. Budzyński, G. Pulkowski (Poland)

PB 028 MicroRNA Target Prioritization to Identify Potential Therapeutic Candidate in

Cardiovascular DiseaseV. Deshpande, A. Sharma, L.N. Thota, R. Vangala (India)

PB 029 Plasminogen Deficiency Attenuates Atherosclerosis in a Murine Model of Type IIa Familial HypercholesterolemiaC. Miyajima1, T. Iwaki1, V. Ploplis2, K. Umemura1, F. Castellino2 (1Japan, 2Armenia)

PB 030 Integrated microRNA and mRNA Expression Profiling to Identify mRNA Targets of Dysregulated miRNAs in Coronary Artery Disease ConditionJ. Nair, J. Shanker (India)

PB 032 Predictive Value of Neutrophil to Lymphocyte Ratio in Long-term Outcomes

of Left Main and/or Three-Vessel Disease in Patients with Acute Myocardial InfarctionN. Xu, X.-F. Tang, Y. Yao, J.-J. Xu, Y. Song, L. Jiang, P. Jiang, R. Liu, J.-Q. Yuan, R.-L. Gao (China)

PB 034 Myocardial Infarction is a Risk Factor for Venous Thromboembolism (VTE)

Recurrence in Women with a First VTEN. Arshad1, W. Lijfering2, S. Cannegieter2, J.B. Hansen1, F. Rosendaal1, S.K. Braekkan1 (1Norway, 2The Netherlands)

PB 035 Lack of Tissue Factor Cytoplasmic Tail Attenuates Cardiac Injury after

Myocardial InfarctionV.S. Garlapati, M. Brandt, S. Kossmann, J. Lagrange, W.-S. Rudi, W. Ruf, P. Wenzel (Germany)

PB 036 Free Ubiquitin Promotes Cardiomyocytes Proliferation and Survival In vitro and

In vivo via CXCR4 PathwayJ. Yao, K. Lv, Q. Zhang, M. Tong, W. Chen (China)

PB 037 Development of a Novel Flow Cytometric Immunobead Array to Quantify von

Willebrand Factor Antigen and Ristocetin Cofactor Activity and its Application in Acute Myocardial InfarctionY. Zhao (China)

PB 039 Post-infarct Survival and Cardiac Remodeling Depends on the Interplay of

Neutrophils, Monocytes and Interferon Gamma in a Mouse Model of Myocardial InfarctionS. Finger, M. Knorr, S. Kossmann, R. Schüler, M. Molitor, S. Karbach, T. Münzel, P. Wenzel (Germany)

PB 040 Control of Thrombosis and Inflammation by Platelet p38α in Acute Myocardial

InfarctionP. Shi, X. Fan, Y. Xu, X. Chen, L. Zhang, K. Wang, J. Liu (China)



234 235

Mon

day

Pos

ter

Ses

sion

s

PB 041 Identification of a Plasma microRNAs Profile Related to Arterial ThrombosisL. Martos, A. Fernández-Pardo, D. Hervás, L.A. Ramón, J. Oto, E. Plana, J. Rueda, E. Zorio, P. Medina, F. España, S. Navarro (Spain)

PB 042 Platelet Serotonin Aggravates Myocardial Reperfusion Injury via Degranulation

M. Mauler1, N. Herr1, C. Schoenichen1, T. Witsch1, T. Marchini1, C. Haerdtner1, C. Koentges1, M. Schell1, L. Dorner1, D. Stallmann1, H. Bugger1, P. Walther1, D. Wolf1, I. Ahrens1, K. Ley2, C. Bode1, I. Hilgendorf1, D. Duerschmied1 (1Germany, 2United States)

PB 043 Smoking and Fibrinogen Levels Modify the Risk of MI due to FXIII V34L:

Results from the MAMI StudyJ. Debattista1, R. Attard1, C. Tabone1, T. Lisman2, K. Cassar1, C.J.M. Doggen2, S. Bezzina Wettinger1, R. Farrugia1 (1Malta, 2The Netherlands)

PB 044 Levels of Beta-thromboglobulin and Platelet Factor 4 Are Different between

NSTEMI and STEMI: Results from the MAMI StudyJ. Bonaci1, R. Attard1, P. Dingli1, T. Lisman2, K. Cassar1, C.J.M. Doggen2, S. Bezzina Wettinger1, R. Farrugia1 (1Malta, 2The Netherlands)

PB 045 CD41 Distribution within Platelet-Monocyte Complexes in Patients with Acute

Myocardial InfarctionM. Loguinova1, N. Pinegina1, M. Vagida1, A. Shpektor1, L.B. Margolis2, E. Vasilieva1 (1Russian Federation, 2United States)

PB 046 Cardiomyocyte Extracellular Vesicles Increase after Experimental Myocardial

Infarction and Promote Endothelial Dysfunction in vitroC. Roncal, J.A. Rodriguez, J. Orbe, G. Abizanda, F. Prosper, J.A. Paramo (Spain)

PB 047 T Lymphocyte Microparticles Are the Major Determinant of Acute Coronary

SyndromeS. Howhan, N. Komanasin, A. Jumnainsong, B. Pussadhamma, V. Senthong, P. Makarawate, K. Anutarapongpan, D. Kaewkes (Thailand)

PB 049 Specificity of Various Haemostatic Markers in Young and Elderly Patients with

Myocardial InfarctionN. Antonijevic, L. Jovanovic, I. Veljic, D. Matic, S. Obradovic, J. Dubljanin, J. Perunicic, D. Vucelic, D. Vukosavljevic, A. Beletic (Serbia)

PB 050 Soluble P-selectin Levels Are higher in Patients with NSTEMI vs STEMI

C. Agius1, R. Attard1, P. Dingli1, T. Lisman2, K. Cassar1, C.J.M. Doggen2, S. Bezzina Wettinger1, R. Farrugia1 (1Malta, 2The Netherlands)

PB 051 On-treatment Platelet Reactivity in Peripheral and Coronary Blood in Patients Undergoing Primary PCI for ST-segment Elevation Myocardial Infarction (STEMI)L. Spiezia, A. Al Mamary, E. Campello, D. Piazza, S. Maggiolo, F. Dalla Valle, M. Napodano, P. Simioni (Italy)

PB 052 Ultrasound Elastography: A New Technique to Distinguish between Acute and

Chronic Deep Vein ThrombosisF. Dentali, N. Mumoli, R. Pesavento, M. Mochi, W. Ageno (Italy)

PB 053 General Practitioner-performed Compression Ultrasound for Deep Vein Thrombosis (Practicus Study): A Prospective, Multicenter Cohort StudyF. Dentali, D. Mastroiacovo, M. Giorgi-Pierfranceschi, R. Tulino, N. Mumoli (Italy)

PB 054 Targeted MiR126 Therapy of Abdominal Aortic Aneurysm

X. Wang, A.K. Searle, Y.C. Chen, A. Liu, K. Peter (Australia) PB 056 Risk Prediction Model for Peripheral Arterial Disease Patients Undergoing

Revascularization within Two Years of DiagnosisR. Olie, S. Petersohn, B. Ramaekers, S. van Kuijk, A.J. ten Cate-Hoek, M.-C. Kleinegris, M. Joore, H. ten Cate (The Netherlands)

PB 057 Repetitive Intravenous Thrombin Injections Result in Pulmonary Arterial

Endothelial Dysfunction in a Mouse Model of Sublethal Acute Pulmonary EmbolismV.S. Garlapati, M. Brandt, E. Giokoglu, T. Schoenfelder, S. Kossmann, M. Knorr, T. Muenzel, P. Wenzel (Germany)

PB 058 Lack of Association between Candidate Gene Polymorphisms and Ischemic

Events in Patients with Peripheral Arterial DiseaseV. Boc, M. Bozic Mijovski, M. Pohar Perme, A. Blinc (Slovenia)

PB 059 Restenosis is a Predictor of Poor Outcome in Patients Undergoing Endovascular

Intervention for Peripheral Arterial DiseaseM. Sartori, A. Pacelli, E. Favaretto, E. Conti, B. Cosmi (Italy)

PB 061 Venous Thromboembolism Following Hantaviral Infection

A.-M. Connolly-Andersen1, H. Whitaker2, J. Klingström1, C. Ahlm1 (1Sweden, 2United Kingdom)

PB 062 Abdominal Aortic Calcification in Patients with Peripheral Arterial Disease:

Hemostasis Changes in Relation to Calcinosis GradeV. Zelinskiy, A. Svetlikov, V. Andreev (Russian Federation)



236 237

Mon

day

Pos

ter

Ses

sion

s

PB 063 Thrombophilic and Cardiovascular Risk Factors for Retinal Vein OcclusionP. Bucciarelli, S.M. Passamonti, F. Gianniello, A. Artoni, F. Peyvandi, I. Martinelli (Italy)

PB 064 Patients with Cryptogenic Acute Limb Ischemia Have High Recurrence Rates

Off Anticoagulation: Results of a Single Institution Retrospective Cohort StudyD. Mart, J. Shatzel, T. Deloughery (United States)

PB 065 Gene-sodium Interaction on the Developing of Hypertension: A Cohort-based Case-control StudyM.-L. Chen, T.-P. Huang, B.-F. Hwang (Taiwan)

PB 066 Drug Induced Venous ThrombosisF. Saïd, M.S. Hamdi, M. Khedher, I. Ben Ghorbel, M. Lamloum, T. Ben Salem, M. Smiti, M.H. Houman (Tunisia)

PB 067 Retinal Vascular Occlusions: A Retrospective Study

F. Saïd, S. Hamrouni, Z. Meddeb, M. Lamloum, I. Ben Ghorbel, T. Ben Salem, M. Khanfir, M.H. Houman (Tunisia)

PB 068 Thrombosis Events in Antiphospholipid Syndrome

F. Saïd, M. Khedher, M.S. Hamdi, I. Ben Ghorbel, M. Lamloum, T. Ben Salem, M. Khanfir, M.H. Houman (Tunisia)

PB 069 Mean Platelet Volume (MPV) as a Predictor of Venous Thromboembolism (VTE)

in Colorectal CancerC. Wilasrusmee, B. Siribumrungwong, N. Poprom (Thailand)

Coagulant & Anticoagulant Mechanisms

PB 071 The Chimeric Monoclonal Antibody MHCSZ-123 against Human von Willebrand Factor A3 Domain Inhibits High Shear Arterial Thrombosis Model in Rhesus MonkeysS. Ji, M. Jiang, F. Shen, Y. Zhao, C. Ruan (China)

PB 072 Effects of Two Plant Protein Inhibitors on Haemostasis and Thrombosis

M.L. Vilela Oliva1, B. Salu1, S.C. Pando1, M. Vilela de Brito1, F. Odei-Addo2, C. Frost2, R. Johannes Naude2, J. Emsley1, M. Uemura Sampaio1, F. Humberto de Abreu Maffei1 (1Brazil, 2South Africa)

PB 073 Slounase, a Modified Snake Venom Hemocoagulase Combined with FXa,

Enhances Hemostasis and Limits Bleeding in Both Normal and Hypocoagulant ConditionsR. Adili1, X. Dai2, B.X. Li2, M. Holinstat1 (1United States, 2China)

PB 074 Platelet Defects Upon Surgical Liver Disease Models iin MiceF. Reusswig, N.S. Gowert, M. Klier, M. Reich, L. Donner, V. Keitel, D. Häussinger, M. Elvers (Germany)

PB 075 D-Insight - An Integrated Animal and Cell Model System to Interrogate the

Expression and Secretion Dynamics of F2 Real-time in vivoS. Khokhar, L.K. Schott, K. Mühlbach, S. Tolakov, S. Danckwardt (Germany)

PB 076 Role of Disruptive Hydrodynamic Forces in Determining Occlusive and Non-

occlusive Arterial Thrombosis ScenariosA. Yakusheva1, N. Receveur2, D. Nechipurenko1, A. Eckly2, F. Ataullakhanov1, C. Gachet2, P. Mangin2, M. Panteleev1 (1Russian Federation, 2France)

PB 077 Sickle Cell Red Blood Cells Alter Properties of Mouse and Human ClotC. Faes, E.M. Sparkenbaugh, S. Wang, K.I. Ataga, A.S. Wolberg, N.S. Key, R. Pawlinski (United States)

PB 078 Porcine Model of Methicillin-resistant Staphylococcus Aureus (MRSA) Sepsis-induced Disseminated Intravascular Coagulation (DIC) and Multiple Organ Dysfunction Syndrome (MODS)T. Nguyen, J. Marini, B. Guillory, C. Valladolid, D. Cohen, Q. Da, S. Cirlos, M. Martinez-Vargas, F. Lam, Y. Yuan, B. Stoll, D. Bashir, M. Desai, E. Mason, S. Kaplan, J. Vallejo, L. Lamberth, K. Hulten, V. Vijayan, M. Cruz (United States)

PB 079 Role of bone morphogenetic protein receptor type II in vascular remodeling

during thrombosisS. Sharma, A. Alimohammadi, A. Panzenboeck, I.M. Lang (Austria)

PB 080 In Vivo Neutralization of Unfractionated Heparin (UFH) and a Bioengineered

Heparin Dodecasccharide (12-mer) by Protamine Sulfate in a Primate ModelA. Kouta, R. Duff, D. Hoppensteadt, W. Jeske, S. Abro, J. Fareed (United States)

PB 081 Hemostatic Profile in Mouse Models of Advanced Chronic Liver Disease

N.C. Dewarrat, C. Quarroz, J. Jankovic, M.D. Reina Caro, R. Prince, A. De Gottardi, S. Calzavarini, A. Angelillo-Scherrer (Switzerland)

PB 082 A Dual Antiplatelet (AP) and Anticoagulant (AC) Compound - APAC - Inhibits

Collagen-induced Platelet Aggregation in Mice and Protects against Arterial ThrombosisN.R. Bonetti1, A. Jouppila2, S. Gobbato1, S. Stivala1, G.G. Camici1, R. Lassila2, J.H. Beer1 (1Switzerland, 2Finland)

PB 083 Blood Microsampling as a Refined Model of Platelet Thromboembolism in vivo

F. Rauzi, E. Smyth, K. Taylor, M. Emerson (United Kingdom)



238 239

Mon

day

Pos

ter

Ses

sion

s

PB 084 Thromboelastography in Mice: Impact of Blood Collection MethodH. Kaur, M. Othman (Canada)

PB 085 Quantitative Proteomics of Plasma-derived Macrovesicles Identifies Early

Systemic Protein Markers of a Hemophilic Bleed in RatsI.R. León, K. Roepstorff, B. Vandahl, M.R. Larsen, M. Kjelgaard-Hansen (Denmark)

PB 086 Improved Anticoagulant Effect of Fucosylated Chondroitin Sulfate Orally

Administered as Gastro-resistant TabletsR.J. Fonseca, I.D. Sucupira, S.-N.M.C.G. Oliveira, G.R.C. Santos, P.A.S. Mourão (Brazil)

PB 087 Three Point Ligation of Inferior Vena Cava in Rats: Experimental Approach to

Study Mechanism of Venous ThrombosisN. Gupta, A. Sahu, M.Z. Ashraf (India)

PB 088 Activated factor VII for Hemostasis Enhancement in Factor XI and XIa Inhibitor-

treated PrimatesM. Wallisch1, A. Buchmüller2, J. Johnson1, E.I. Tucker1, M.T. Hinds1, A. Wilmen2, V. Laux2, A. Gruber1 (1United States, 2Germany)

PB 089 The Electrolytic IVC Model of Venous Thrombosis (EIM): A Cost-effective,

Highly Reproducible, and Easily Controlled Tool to Investigate Venous Thrombosis under Flow ConditionsO.R. Palmer, M.E. Shaydakov, J.M. Greve, J.A. Diaz (United States)

PB 090 A Functional and Thromboelastometric-based Micromethod for Assessing

Crotoxin Anticoagulant Activity and Antiserum Relative Potency against Crotalus Durissus Terrificus VenomB. Prezoto, A. Tanaka-Azevedo, J. Kapronezai, J. Marcelino, J. Mota, M. Rocha, C. Silva, N. Oguiura (Brazil)

PB 091 Hemostasis and Fibrinolysis during Learning in Rats

K. Nikolskaya, L. Podorolskaya (Russian Federation) PB 092 In the Cath Lab - A Novel Rabbit Bleeding Model

I. Meyer, J. Strassburger, A. Trabandt, A. Gaefke (Germany)

PB 093 Von Willebrand Factor Effects Vessel Conformation and the Expression of Integrin αVβ3 and Ang-2 in the Porcine Female Reproductive TractH. Allerkamp, S. Lehner, M. Ekhlasi-Hundrieser, C. Detering, C. Pfarrer, M. von Depka (Germany)

PB 094 Antithrombotic In-vivo Effects of Quercetin-tetra-sulphate (QTS) Isolated from Flaveria bidentis in an Experimental Thrombosis Model in MiceH.A. Guglielmone, A.M. Agnese, S.G. Nuñez-Montoya, J.L. Cabrera, G.R. Cuadra (Argentina)

PB 095 Increase of Fibrinolytic and Anticoagulant Activity by Per Os Administration of

Proteinase Complex Longolytin in RatsT. Sharkova, L. Podorolskaya (Russian Federation)

PB 096 The Anti-factor XIa Antibody BAY 1213790 is a Novel Anticoagulant that

Shows Strong Antithrombotic Efficacy without an Increased Risk of Bleeding in Rabbit ModelsA. Buchmueller, A. Wilmen, J. Strassburger, M.V. Schmidt, V. Laux (Germany)

PB 097 Concomitant Administration of Factor IX Replacement Therapy with Immunosuppression Decreases Immunogenicity in Hemophilia B Mice Expressing a Human Major Histocompatibility ComplexY. Abajas, J. Sun, G. Hu, S. Vanleeuwen, P. Monahan (United States)

PB 098 Factor VIII Memory Immune Responses, von Willebrand Factor Makes a

DifferenceJ. Chen, J. Schroeder, X. Luo, Q. Shi (United States)

PB 099 New Insights into FV-short Function and Interaction with TFPIα

T. Petrillo, R.M. Camire (United States) PB 100 Structural and Functional Characterization of Anticoagulant TIX-5, the Specific

Inhibitor of the Activation of FV by FXaA. Maag, P. Sharma, T. Schuijt, W. Kopatz, D. Kruijswijk, A. Marquart, T. van der Poll, T. Hackeng, G. Nicolaes, J. Meijers, M.H.A. Bos, C. van 't Veer (The Netherlands)

PB 101 Inhibition of Contact Activation by Histidine Rich Glycoprotein is Mediated by

its Histidine-rich DomainT. Truong, A. Stafford, B. Leslie, J. Fredenburgh, J. Weitz (Canada)

PB 102 Dabigatran and Rivaroxaban Inhibit Thrombin Generation Much Stronger than

the Growth of a Fibrin ClotN. Dashkevich, E. Pivovarova, R. Ovsepyan, Y. Kotova, D. Ayusheev, A. Bernakevich, F. Ataullakhanov (Russian Federation)

PB 103 Factor VII Activating Protease (FSAP) and Marburg I (G534E) Polymorphism;

How One Amino Acid Determines FunctionN.V. Nielsen1, D. Manna1, E. Roedel2, J.P. Morth1, S. Kanse1 (1Norway, 2Germany)



240 241

Mon

day

Pos

ter

Ses

sion

s

PB 104 Acquired Hemophilia A in Dutch Patients, a Single Center ExperienceW.E.M. van Dijk, A. Huisman, K.P.M. van Galen, E.P. Mauser-Bunschoten, P.R. van der Valk, K. Fischer, R.E.G. Schutgens (The Netherlands)

PB 105 Salvianolic Acids Inhibit Blood Coagulation and Platelet Aggregation: A New

Class of Herb Derived Dabigatran AnalogsY. Wang1, M. Neves1, D. Zhang1, X. Xu1, X. Lei1, G. Zhu1, Y. Wang2, L. Xuan2, J. Ding2, H. Ni1 (1Canada, 2China)

PB 106 Fusion to Albumin Extends the Circulatory Half-life and Antithrombotic Effects

of the Kunitz Protease Inhibitor Domain of Protease Nexin 2 in MiceW. Sheffield, L. Eltringham-Smith, V. Bhakta (Canada)

PB 107 Immunogenicity Assessment of OBIZUR, a Recombinant B-domain Deleted Porcine- sequence FVIII, in Patients with Acquired Hemophilia AF. Horling1, H. Koppensteiner1, S. Dorn1, M. Malisauskas1, B. Hartlieb1, P. Allacher1, A. Novack2, F. Scheiflinger1, B.M. Reipert1 (1Austria, 2United States)

PB 108 Affimers as a Tool to Understand Mechanistic Pathways that Control Fibrin Clot

Structure and LysisN. Pechlivani, R. King, C. Tiede, K. Simmons, K. Kearney, K. Smith, F. Phoenix, R. Cheah, R.A.S. Ariens, D. Tomlinson, R.A. Ajjan (United Kingdom)

PB 109 The Most Significant Physiological Function of Protein S is Inhibition of

Thrombin GenerationE. Goldfeld, W. Plautz, A. Dorsey, D. Monroe, R. Majumder (United States)

PB 110 Immunogenicity of BAX 855 in Previously Treated Patients with Congenital

Severe Hemophilia AF.M. Horling, P. Allacher, H. Koppensteiner, W. Engl, F. Scheiflinger, B. Abbühl, B.M. Reipert (Austria)

PB 111 Validation of a FVIII Nijmegen Bethesda Assay for the Detection of Inhibitors to

Porcine FVIIIM. Robinson1, S. Tiefenbacher1, D.M. Adcock1, M. Schlager2, H. Gritsch2 (1United States, 2Austria)

PB 112 Single-dose Safety and Toxicological Studies of Long-acting FVIIa (MOD-5014)

in Rats and Monkeys Support the Initiation of Clinical Phase 1 Subcutaneous (SC) Study in Healthy VolunteersL. Israeli Yagev, A. Bar-Ilan, M. Hoffmann, G. Hart (Israel)

PB 113 Low Plasma FVII:C and Activated FVII as Predictive Markers for Overt

Disseminated Intravascular CoagulationS. Lertthammakiat, N. Anantasit, U. Anurathapan, N. Sirachainan, P. Kadegasem, A. Chuansumrit (Thailand)

PB 114 imabalance of Factor VIII/Protein C System as Major Determinant of Hypercoagulability in Cushing´s SyndromeS. Maggiolo, E. Campello, C. Bulato, C.M. Radu, S. Gavasso, L. Spiezia, P. Simioni (Italy)

PB 115 Anti-Hemostatic Compounds Isolated from Coral Snake Micrurus tener tener

VENOMA.M. Salazar1, B. Guerrero1, K. Perez1, J. Vivas1, C. Ibarra1, E. Salazar1, E. Sanchez2, A. Rodríguez-Acosta1 (1Venezuela, 2United States)

PB 116 Zinc Binds and Regulates the Activity of the Natural Anticoagulant Protein Z

T. Sengupta1, W. Plautz2, N. Manoj1, R. Majumder2 (1India, 2United States)

PB 117 Effects of SERPINC1, PROC, PROS1 and EPCR Polymorphisms on the Plasma Levels of Natural Anticoagulants in Healthy IndividualsG. Balla, T. Miklós, J. Kállai, S. Kovács, B. Kovács, É. Katona, É. Molnár, Z. Bereczky (Hungary)

PB 118 Identification of a Novel Factor VII Activating Protease (FSAP) Zymogen-activating Peptide by Phage DisplayS. Seidel1, G. Åge Løset1, N.V. Nielsen1, P. Declerck2, S. Kanse1 (1Norway, 2Belgium)

PB 119 Stability of Plasma for Add-on Coagulation Tests

M. Blois, F. Fischer, A. Appert-Flory, D. Jambou, P. Toulon (France) PB 120 Microplate-based Method for Quantifying Polyphosphate in Biological

Samples S. Smith, R. Breitenfeld, K. Mcevoy, J. Morrissey (United States) PB 121 Differential Investigation of Post-translational Modifications in Recombinant

and Plasma-Derived Human Coagulation FIXP. Soupourmas, S. Ow, M. Pelzing (Australia)

PB 122 Clinical Significance of Prothrombin G20210A Mutation in Homozygous

PatientsA. Shemesh1, R. Hoffman1, Y. Nadir1, A. Keren-Politansky1, M. Monreal2, B. Brenner1, I. Tzoran1 (1Israel, 2Spain)

PB 123 Impact of Reagents on FVIII Inhibitor Titration

C. Nougier, C. Pouplard, 'Club des Biologistes' on behalf of the 'French Study Group on Haemostasis and Thrombosis' (France)

PB 124 Evaluation of endogenous thrombin potential among patients with antithrombin

deficiency-Serbian AT deficiency study group resultsM. Kovac1, G. Mitic1, S. Lalic-Cosic1, V. Djordjevic1, B. Tomic1, Z. Bereczky2 (1Serbia, 2Hungary)



242 243

Mon

day

Pos

ter

Ses

sion

s

PB 125 Anti-FVIII IgG1 Antibody in Previously Untreated Patients with Hemophilia A Might Be Protective Against Inhibitor Development: Preliminary Results from the Hemfil Cohort StudyD. Gonçalves Chaves, A. Cardoso Oliveira Silveira-Cassette, L. Lemos Jardim, M. Antônio Portugal Santana, M. Hermida Cerqueira, A. Prezotti, C. Lorenzato, V. Franco, S. Meireles Rezende (Brazil)

PB 126 Cost-effectiveness of Recombinant Porcine Factor VIII (OBIZUR) for Treatment

of Hemorrhagic Events in Acquired Hemophilia A (AHA)M. Najafzadeh, A.O. Oladapo, B.M. Ewenstein, T. Raj, R.L. Bohn, J. Avorn (United States)

PB 128 APC-Resistance Testing Based on Genetic or Functional Assays: To Be or Not to Be ?

A.C. Brisset1, C. Stocker1, M. Janssen1, F. Prüller2 (1Switzerland, 2Austria) PB 129 Alteration of the Hemostatic System in Cirrothic Patients

C. Duboscq, J. Ceresetto, M. Rodriguez Grazi, G. Stemmelin, F. Villamil (Argentina)

PB 130 In vitro Antithrombin is the Main Inhibitor of Thrombin Generation at the

Surface of Endothelial Cells Acting Independently to Heparan SulfatesB. Catieau, S. Chtourou, J.-L. Plantier (France)

PB 131 Pregnancy and Delivery Experiences in a Patient with Severe Factor X

(FX) Deficiency Treated with a High-purity Plasma-derived Factor X (pdFX) ConcentrateG. Auerswald, M. Bührlen (Germany)

PB 132 Impact of Thrombin (Dabigatran) and FXa Inhibitors (Rivaroxaban, Apixaban,

Edoxaban) on Hemostasis AssaysJ. Hammelburger, R. Bottenus, M. Triscott (United States)

PB 133 Role of Factor-Xa Inhibitor Treatment on Platelet Function and Thrombus

FormationT. Petzold, M. Thienel, T. Czermak, J. Pircher, C. Schulz, S. Massberg (Germany)

PB 134 Prolonged Targeted Temperature Management Causes an Impaired Coagulation: A Randomised Clinical TrialA. Jeppesen, H. Kirkegaard, S. Ilkjær, A.-M. Hvas (Denmark)

PB 135 Features of Clinical and Laboratory Diagnostics of Disturbance of Hemostasis

System in Patients with Retinal Vein Occlusion on the Background of FV Leiden Mutation and LAS. Tatyana (Russian Federation)

PB 136 Causes of Isolated Prolonged Activated Partial Thromboplastin Time in a Haemostasis Reference HospitalN. Vilalta, M. Carrasco, J.A. Millón, H. Cerdà, D. Llobet, C. Vallvé, J. Fontcuberta (Spain)

PB 137 Evaluation of Lupus Anticoagulant and Anti Cardiolipin Antibodies in Poly

Transfused Beta Thalassemia Major Patients at HyderabadI. Ujjan, A. Memon, A. Naz (Pakistan)

PB 138 Reference Ranges for Hemostasis Parameters in Pregnant Women from the

Krasnoyarsk AreaV. Potylitsina1, S. Lobanova1, I. Olkhovsky1, P. Toulon2 (1Russian Federation, 2France)

PB 139 Recombinant FVIIIFc-VWF-XTEN Promotes Normal Fibrin Formation, Structure

and StabilityM. Aleman, E. Kistanova, E. Seth-Chhabra, R. Peters, J. Salas (United States)

PB 140 Dissecting the Catalytic Enhancement of Activated Factor IX via Foot-printing

Mass SpectrometryN. Freato, E.H.T.M. Ebberink, F.P.J. van Alphen, C. van der Zwaan, M.G. Boon-Spijker, M. van den Biggelaar, A.B. Meijer, K. Mertens (The Netherlands)

PB 141 Characterization of Interactive Sites of the Blood Coagulation Factor VIII and

the Low-density Lipoprotein Receptor using Macromolecular Docking Prediction AlgorithmsB. Fochtman, S. Shestopal, V. Simonyan, T. Lee, A. Sarafanov (United States)

PB 142 Comparison of Bleeding Efficacy of FIX-FC and FIXWT 7 Days Post-infusion

B. Cooley, F.-C. Lin, D. Stafford (United States) PB 143 rFVIIIFc-VWF-XTEN Demonstrates Comparable Efficacy to Recombinant Human

FVIII in Mice by Acute Bleeding and Intravital Microscopy ModelsM. Demers, Z. Liu, A. van der Flier, E. Seth Chhabra, T. Liu, R. Peters, J. Salas (United States)

PB 144 How Full-length FVIII Benefits from its Heterogeneity - Insights into the Role of

the B DomainJ. Anzengruber, M. Feichtinger, P. Bärnthaler, N. Haider, J. Ilas, F. Scheiflinger, B.M. Reipert, M. Malisauskas (Austria)

PB 145 Monoclonal Antibodies to FcγRIIB (CD32) Modulate FVIII-specific Recall

Response in vitroN. Vollack1, J. Friese1, S. Bergmann1, M. Cragg2, A. Tiede1, S. Werwitzke1 (1Germany, 2United Kingdom)



244 245

Mon

day

Pos

ter

Ses

sion

s

PB 146 Factor VIII A1 Residues 346-349 is a Novel Thrombin-binding Site Responsible for cleavage at Arg372 in the Heavy ChainH. Minami, K. Nogami, K. Sasai, S. Furukawa, M. Takeyama, M. Shima (Japan)

PB 147 Recombinant FVIIIFc-VWF-XTEN (BIVV 001) Demonstrates Equivalent

Thrombin Generation and Whole Blood Clotting Profiles to Advate®Y. Buyue, E. Seth Chhabra, J. Sommer, J. Salas, R. Peters (United States)

PB 148 Altering FIX Zymogenicity Extends Procoagulant Function and Improves

Hemostatic Function in Murine Hemophilia BL. Ivanciu, V.R. Arruda, R.M. Camire (United States)

PB 149 Evaluation of Recombinant FVIIIFc-VWF-XTEN (BIVV 001) Activity in One-stage Clotting and Chromogenic Assays and its Correlation with in vivo Efficacy in Hemophilia A MiceY. Buyue, A. van der Flier, D. Rabinovich, S. Bardan, Z. Liu, E. Seth Chhabra, J. Salas, J. Sommer, R. Peters (United States)

PB 150 Evaluation of Impact of Codon-Optimization on the Functional Activity of

the Blood Coagulation Factor VIII by Clotting, Chromogenic and Thrombin Generation AssaysS. Shestopal1, Y. Liang1, M. Lin1, M. Ovanesov1, T. Lee1, J. McVey2, A. Sarafanov1 (1United States, 2United Kingdom)

PB 151 An In silico and In vitro Approach to Elucidate the Impact of Residues Flanking

the Cleavage Scissile Bonds of FVIIIB. Pezeshkpoor, U. Schreck, A. Biswas, J. Driesen, A.-C. Berkemeier, A. Pavlova, J. Müller, J. Oldenburg (Germany)

PB 152 In vitro Characterization of the Factor 8 Gene Mutations Associated with Assay

DiscrepancyB. Pezeshkpoor, M. Gazorpak, A.-C. Berkemeier, J. Müller, A. Biswas, A. Pavlova, J. Oldenburg (Germany)

PB 153 Corn Trypsin Inhibitor Mediates Differential Effects on Thrombin Generation

Parameters in Hemophilic Patients Compared with Healthy VolunteersB. Tardy-Poncet, M. Piot, A. Montmartin, P. Chelle (France)

PB 154 Influence of Pharmacodynamics of Factor VIII on Bleeding Phenotype of

Children under Long-term Prophylactic RegimenI. Fernandez-Bello1, F. Rode2, M.T. Alvarez-Roman1, N.V. Butta1, S. Rivas-Muñoz1, A.L. Hernandez-Moreno3, H. de la Corte Rodriguez1, M. Martin-Salces1, L.F. Larsen2, V. Jimenez-Yuste1 (1Spain, 2Denmark, 3Mexico)

PB 155 Influence of Neighbourhood Socioeconomic Status on Mortality Is Mediated by Factor VIII: Results from a Cohort StudyB. Vučković1, A. Eikenboom2, L. Doetsch2, F. Rosendaal2, S. Cannegieter2, W. Lijfering2 (1Serbia, 2The Netherlands)

PB 156 Novel F9 Gene Variants in Hemophilia B Patients from Turkey

S. Colakoglu, B. Koc, E. Berber, B. Zulfikar (Turkey) PB 157 Evaluations of the Activated Partial Thromboplastin Time-based One-stage Clot

Assays for Monitoring of Half-life Extended Factors VIII and IX FormulationsY. Fujimori, S. Madoiwa, N. Shinohara, C. Eda, S. Shinohara, N. Arai, M. Wakui, M. Murata (Japan)

PB 158 Population Pharmacokinetic Analysis of Perioperative Factor IX Dosing in

Hemophilia BT. Preijers1, H.C.A.M. Hazendonk1, R. Liesner2, P. Chowdary2, M.H.E. Driessens1, D. Hart2, D. Keeling2, B.A.P. Laros-van Gorkom1, F.J.M. van der Meer1, K. Meijer1, K. Fijnvandraat1, F.W.G. Leebeek1, P.W. Collins2, M.H. Cnossen1, R.A.A. Mathôt1, for the OPTICLOT-Study Group (1The Netherlands, 2United Kingdom)

PB 159 Which Tests Can Better Indicate Clinical Phenotype of Pediatric Patients with

Hemophilia on Prophylaxis?Y. Ay, E. Toret, S. Gozmen, D. Cubukcu, T.H. Karapinar, Y. Oymak, R.C. Vergin (Turkey)

PB 160 Acquired Haemophilia and Eosinophilic Fasciitis

M. Mrouki, S. Hamrouni, F. Ben Dahmen, Y. Cherif, M. Abdallah (Tunisia)

Fibrinolysis & Proteolysis

PB 161 Affimers for Modulation of Fibrinolysis: An Alternative Approach for Bleeding DisordersK. Kearney, C. Tiede, K. Smith, F. Phoenix, N. Oxley, R. Ariëns, N. Pechlivani, D. Tomlinson, R. Ajjan (United Kingdom)

PB 162 A Novel Tick Salivary Protein Modulates Fibrinolysis by Interacting with

Plasminogen and Tissue Plasminogen Activator, and Prevents Arterial Thrombosis in vivoI. Francischetti1, T. Assumpcao1, D. Mizurini2, D. Ma1, R. Monteiro2, H. Kaneku1, M. Reyes1, M. Kotsyfakis3, J. Andersen1, J. Lukszo1, J. Ribeiro1 (1United States, 2Brazil, 3Czech Republic)



246 247

Mon

day

Pos

ter

Ses

sion

s

PB 163 Comparison and Characterization of Two Assays (TAFIa/ai ELISA vs. Activity Based Selective CPU Assay) for the Monitoring of Carboxypeptidase U (CPU, TAFIa, CPB2) Levels in PatientsJ.C. Mertens, D. Leenaerts, L. Yperzeele, Y. Sim, P. Van Der Veken, D. Hendriks (Belgium)

PB 164 Optimising the Degradation of NETs to Destabilise Fibrin Clot Structure and

Promote FibrinolysisM. Locke, C. Longstaff (United Kingdom)

PB 165 Extracellular Histones Enhance Fibrin Degradation by Prourokinase in a Factor

Seven Activating Protease (FSAP)-dependent MannerF. Semeraro, M. Colucci, N. Semeraro, C.T. Ammollo (Italy)

PB 166 Localization of the C-terminal Cleavage Site of Human Alpha-2-antiplasmin

S. Abdul1, D.H. Dekkers1, J.J. Demmers1, R.A. Ariëns2, F.W. Leebeek1, D.C. Rijken1, S. Uitte de Willige1 (1The Netherlands, 2United Kingdom)

PB 167 PAI-1 Inhibition with MDI-2001: Towards a Safer and More Effective Treatment

for Deep Vein ThrombosisM.E. Shaydakov, M. Warnock, D.A. Lawrence, J.A. Diaz (United States)

PB 168 A Phase 2/3, Open-label, Repeat-Dose Study of the Pharmacokinetics, Efficacy,

and Safety of Prometic Plasminogen Intravenous Infusion in Subjects with Hypoplasminogenemia (HPLG)C. Nakar1, B. Hardesty1, N. Thurkal1, G. Albert1, M. Rubinacci1, K. Thibaudeau2, J. Parker1, J. Moran1, A. Shapiro1 (1United States, 2Canada)

PB 169 Colistin Dampens Fibrinolysis and Endothelial Activation during Endotoxemia:

A Randomized, Double Blind TrialC. Schoergenhofer, P. Matzneller, M. Mußbacher, J. Schmid, P. Jilma-Stohlawetz, B. Jilma (Austria)

PB 170 A Novel Fluorescent Assay for the Measurement of Activated Thrombin-

activatable Fibrinolysis Inhibitor (TAFIa) ActivityT. Marar, K. Picco, M. Boffa (Canada)

PB 171 Global Assay of Fibrinolysis in Sickle Cell Disease: Contrasting Results in

Plasma and Whole BloodA. Ilich, M. Piegore, R. Pawlinski, N. Key (United States)

PB 174 Generation and Characterization of Monoclonal Antibodies against the

N-terminus of Alpha-2-antiplasminS. Abdul1, M. Peeters2, E. Brouwers2, J.J. Malfliet1, F.W. Leebeek1, P.J. Declerck2, D.C. Rijken1, S. Uitte de Willige1 (1The Netherlands, 2Belgium)

PB 175 Stretching Fibrin Fibers Hampers their LysisM. Guthold, W. Li, T. Lucioni, R. Li, S. Cho (United States)

PB 176 Performance and Determinants of whole Blood and Plasma Fibrinolysis Assays

in Patients with Mild Bleeding SymptomsM.J.A. Vries1, F. Macrae2, P.J. Nelemans1, G.J.A.J.M. Kuiper1, R.J.H. Wetzels1, P. Bowman2, P.W.M. Verhezen1, H. ten Cate1, R.A.S. Ariens2, Y.M.C. Henskens1 (1The Netherlands, 2United Kingdom)

PB 177 Characterisation of the Different Pathways of Neutrophil Extracellular Trap

(NET) Formation Triggered by Treatment with phorbol-12-myristate-13-acetate (PMA) or Calcium IonophoresM. Locke, R. Francis, C. Longstaff (United Kingdom)

PB 178 Effect of Alpha-2 Plasmin Inhibitor p.Arg6Trp Polymorphism and Antigen Level

on the Risk of Myocardial Infarction in Young PatientsÉ. Katona, A. Orosz, Z. Mezei, L. Balogh, R. Bogáti, I. Édes, L. Muszbek (Hungary)

PB 179 Effect of PAI-1 on Vascular Smooth Muscle Cells PhenotypeX. Deng, M. Luo, J. Wu (China)

PB 180 Study of Fibrinolytic Factors along with Thrombophilia Screening Gives a

Comprehensive Picture of the Cause of Venous Thrombosis in Indian PatientsA. Prabhudesai, S. Shetty, K. Ghosh, B. Kulkarni (India)

PB 181 Impaired Plasminogen Binding in Patients with Venous Thromboembolism:

Association with Protein CarbonylationJ. Siudut, J. Natorska, M. Zabczyk, D. Zajac, K. Seweryn, M. Rapala-Kozik, A. Undas (Poland)

PB 182 Ligneous Gingivitis due to Severe Plasminogen Deficiency: Results of a

Prophylactic Protocol for Dental CareM.T. Sartori, S. Sivolella, I. Di Pasquale, G. Saggiorato, F. Boscaro, M. De Biagi (Italy)

PB 183 Effect of Polyamidoamine (PAMAM) Dendrimers on the Activity of the Fibrinolytic System in vitroR. Aisina, L. Mukhametova, E. Ivanova, K. Gerchkovich, E. Zakharyan, S. Varfolomeyev (Russian Federation)

PB 184 Fibrinolytic Markers in Patients Undergoing Total Hip Replacement with and

without Administration of Tranexamic AcidI.P. Antropova, T.A. Zhirova, A.N. Varaksin, B.G. Yushkov (Russian Federation)



248 249

Mon

day

Pos

ter

Ses

sion

s

PB 185 Hyperfibrinolysis during Liver Transplantation Detected by Classical Parameters and ThromboelastometryS. Maggiolo, E. Campello, L. Spiezia, A. Tredese, G. Saggiorato, S. Gavasso, P. Feltracco, P. Simioni (Italy)

PB 186 The Use of Antiplasmin-Specific Affimer as a Tool to Modulate Fibrin Clot

Properties and Thrombosis RiskM. Almutairi, C. Tiede, K. Kearney, N. Pechlivani, F. Phoenix, N. Oxley, D. Tomlinson, R. Ajjan (United Kingdom)

PB 187 Application of the CloFAL Assay, a Global Assay which Evaluates Coagulation

and Fibrinolysis in a Cohort of Venous Thromboembolism (VTE)B.M. Martinelli, S. Montalvão, S.C. Huber, J.L. Cunha, M.P. Collela, F.A. Orsi, E.V. de Paula, J.M. Annichino-Bizzacchi (Brazil)

PB 188 Simultaneous Thrombin Plasmin Generation Assay in Haemorragic and Non

Haemorragic Caesarean Section: Pilot StudyE. Jeanpierre, I. Saidi, A.-S. Ducloy-Bouthors, B. Hennart, A.-S. Baptiste, S. Giovannoni, E. Simon, D. Lannoy, D. Allorge, A. Duhamel, S. Susen (France)

PB 189 Simultaneous Thrombin Plasmin Generation Assay: Effect of Tranexamic Acid

Concentration in vitroE. Jeanpierre, I. Saidi, A.-S. Ducloy-Bouthors, B. Hennart, A.-S. Baptiste, S. Giovannoni, E. Simon, D. Lannoy, D. Allorge, A. Duhamel, S. Susen (France)

PB 190 Association of Fibrinolytic Parameters with Coagulation Activity and Fibrin Clot

Permeability in Patients with Hemophilia AM. Milos1, D. Coen Herak1, S. Zupancic-Salek1, J. Pavic2, N. Mahmoud Hourani Soutari3, J.P. Antovic3, R. Zadro1 (1Croatia, 2Bosnia and Herzegovina, 3Sweden)

PB 191 Consequences of Tranexamic Acid on Fibrinolysis in Patients with Hereditary

Bleeding Disorders Compared with Healthy ControlsI. Goncalves, D. Draxler, B. Niego, V. Sonia, R. Medcalf, H. Tran (Australia)

PB 192 Association of TAFI Polymorphisms and Fibrinolytic Status with Obesity in

Subjects Suspected for Coronary Artery DiseaseC. Rattanawan, N. Komanasin, N. Settasatian, C. Settasatian, U. Kukongviriyapan, P. Intharapetch, V. Senthong (Thailand)

PB 193 Nattokinase Easily Hydrolyzed Fish Elastin and Collagen, and Produced Anti-

platelet Aggregation ActivityH. Sumi, M. Maruyama, T. Ito, N. Toki (Japan)

PB 195 A New Functional Food “Coix-Natto” for Fibrinolysis

H. Sumi, S. Naito, C. Yatagai, T. Ohsugi, E. Yoshida (Japan)

PB 197 Fibrinolytic Effects of Regulatory Leucine-containing Peptides in the OrganismL. Lyapina, T. Obergan (Russian Federation)

PB 198 Very High Production of Nattokinase by D-amino Acids

Y. Yanagisawa, T. Ito, H. Sumi (Japan) Hemorrhagic Disorders, Hemophilia

PB 199 Evaluation of the Ankle Brachial Index in Persons with Hemophilia: Unexpected FindingsH. Hop, P.W. Kamphuisen, A.M. van Roon, J.D. Lefrandt, K. Meijer (The Netherlands)

PB 200 A Single Center Cross-sectional Study of the Age Related Effects of Intensive Prophylactic Therapy on Annual Bleed Rate and Joint Arthropathy in 338 Patients with Severe Haemophilia AJ. Oldenburg, C. Causemann, H.-H. Brackmann, N. Marquardt, G. Goldmann (Germany)

PB 201 Patient, Regional and Center-level Variation in Utilization of Arthroplasty and Arthrodesis Interventions in Persons with Hemophilia: An Analysis of the American Thrombosis and Hemostasis Network (ATHN) DatasetT. Buckner, D. Cheng, A. Ginde, M. Manco-Johnson (United States)

PB 202 New Tools for the Optimization of the Primary and Secondary Prophylaxis in

Pediatric Patients with Severe Hemophilia: Ultrasound Thromboelastography (UT) and Joint EchotomographyF. Lionti, V. Dicembre, F. Gagliano, G. Corsello (Italy)

PB 203 Responsiveness and Construct Validity of Goal Attainment Scaling for

Hemophilia (GAS-Hēm): A Novel, Personalised, Patient-reported Outcome for HaemophiliaM. Recht1, J. Roberts1, S. Jackson2, V. Price2, S. Robinson2, S. Lattimore1, D. Gue2, S. Squire2, S. Richardson1, M. Denne1, K. Rockwood2 (1United States, 2Canada)

PB 204 Compartmental High Resolution 3D Imaging by XtremeCT Reveals Low Bone

Mineral Density in Hemophilia Patients is Attributed to Loss of Trabecular BoneA. Lee, D. Raymond, S. Jackson, G. Kline, S. Boyd, M.-C. Poon (Canada)

PB 205 No Association between HFE and HMOX1 Polymorphisms, Important in Iron

and Heme Handling, and the Severity of Haemophilic ArthropathyL. van Vulpen, W. Foppen, K. Fischer, S. Mastbergen, F. Lafeber, R. Schutgens (The Netherlands)



250 251

Mon

day

Pos

ter

Ses

sion

s

PB 206 Factors Associated with Perception of Functional Abilities in US Adults with Hemophilia Beyond Joint Status: Analysis of the Pain, Functional Impairment, and Quality of Life (P-FiQ) StudyC. Kempton, T. Buckner, M. Fridman, N. Iyer, D. Cooper (United States)

PB 207 Long-term Treatment with Human-cl rhFVIII in Previously Treated Children with

Severe Haemophilia AR. Liesner1, A. Klukowska2, V. Vdovin3, T. Szczepański2, J. Bichler4, I. Dzhunova4 (1United Kingdom, 2Poland, 3Russian Federation, 4Switzerland)

PB 208 Realworld Health Care Utilization and Costs of Extended and Standard Half-life

Recombinant Factor IX Products in Hemophilia B PatientsA. Chhabra1, J. Alvir1, B. Tortella1, D. Spurden2, P. Fogarty1, M. McDonald1, A. Pleil1 (1United States, 2United Kingdom)

PB 209 Three-year Bleeding Frequency in >1000 Haemophilia A Patients on

Prophylaxis: A Reliable Effectiveness BenchmarkK. Khair1, J. Oldenburg2, C. Santoro3, K. Kurnik2, R. Parra4, A. Huth-Kühne2, R. Klamroth2, K. Steinitz-Trost5, H. Brondke2, A. Gringeri5, on behalf of the AHEAD Study Groups (1United Kingdom, 2Germany, 3Italy, 4Spain, 5Austria)

PB 210 Bleeding Phenotype In Non-severe Hemophilia A Has a Better Association with the One-stage Than the Chromogenic AssayL.M. Schütte, I. Van Moort, S.C.M. Stoof, J.S. Biedermann, M.H. Cnossen, F.W.G. Leebeek, M.P.M. De Maat, M.J.H.A. Kruip (The Netherlands)

PB 211 Inhibitor Development and Efficacy in Previously Untreated Patients with

Severe Haemophilia A Treated with Human-cl rhFVIII, a 4th Generation Recombinant FVIII of Human OriginR. Liesner1, M. Jansen2, L. Belyanskaya3, E.J. Neufeld4 (1United Kingdom, 2Austria, 3Switzerland, 4United States)

PB 212 Long-term Impact of rFVIIIFc Prophylaxis in Paediatric, Adolescent, and Adult

Subjects with Target Joints and Severe Haemophilia AK.J. Pasi1, I. Pabinger2, M. Wang3, B. Kerlin3, R. Kulkarni3, B. Nolan4, R. Liesner1, S. Brown5, E. Tsao3, B. Winding6, S. Lethagen6, N. Jain3 (1United Kingdom, 2Austria, 3United States, 4Ireland, 5Australia, 6Sweden)

PB 213 Administration of Recombinant Factor VIII by Continuous Infusion (CI) versus

Intermittent Bolus Infusion (BI) in the Intra- and Post-operative SettingI. Pabinger1, G. Spotts2, W. Engl1, B. Pavlova1, J. Doralt1, L.A. Valentino2 (1Austria, 2United States)

PB 214 Assessment of Clot Kinetics of Recombinant Human Factor VIII (rhFVIII), Recombinant Porcine Factor VIII (rpFVIII) Recombinant Factor VIIa (rFVIIa) and Activated Prothrombin Complex Concentrate (APCC) Utilizing Thromboelastography in Patients with Severe Hemophilia A and InhibitorsR. Carmona, E. Marquez, H.S. Lee, G. Young (United States)

PB 215 Obesity in Patients with Hemophilia: Prevalence by Age, Clinical Correlates and

Impact on Joint BleedingC.-Y. Chang, T.-Y. Li, S.-N. Cheng, R.-Y. Pan, H.-J. Wang, S.-H. Hu, Y.-C. Chen (Taiwan)

PB 216 Influence of Genetic Polymorphisms of Biological Mediators on the Phenotypic

Heterogeneity in Hemophilic ArthropathyY.-C. Chen, S.-N. Cheng, T.-Y. Li, R.-Y. Pan, S.-H. Hu (Taiwan)

PB 217 Joint Status and Other Factors Associated with Pain Severity and Interference

in US Adults with Hemophilia Beyond Joint Status: Analysis of the Pain, Functional Impairment, and Quality of Life (P-FiQ) StudyT. Buckner, C. Kempton, M. Fridman, N. Iyer, D. Cooper (United States)

PB 218 Ranges of Risk Associated with Sports/Recreational Activities in People with

Hemophilia: Results of the Activity-Intensity-Risk (AIR) Consensus Survey of US Physical TherapistsG. Hernandez, K. Baumann, S. Knight, H. Purrington, M. Gilgannon, M. Karelus, J. Newman, P. Tobase, D. Basoff, S. Mathew, D. Cooper (United States)

PB 219 The Impact of Switching Recombinant Factor VIII Product Concentrates on

Inhibitor Development among Haemophilia A Patients in AustraliaH. Tran, S. Parikh, S. McRae (Australia)

PB 220 Sociodemographic, Clinical and Psychosocial Characteristics of People with

Haemophilia (PWH) in Portugal: Preliminary Results of the First National SurveyA.C. Paredes, S. Pedras, P. Costa, M. Carvalho, M. Lopes, S. Fernandes, M. Crato, A. Almeida, P.R. Pinto (Portugal)

PB 221 Understanding Burden of Illness of People with Hemophilia A with or without a

Current InhibitorW.E. Owens, Y. Xu, A. Cyhaniuk, E. Chan, P. Kuebler, R.H. Ko, P.G. Solari, J. Chupka (United States)

PB 222 The Continued Use of Cryoprecipitate and Plasma to Treat Bleeding Disorders

M. Brooker, C. Herr, F. Robinson, D. Coffin (Canada)



252 253

Mon

day

Pos

ter

Ses

sion

s

PB 223 Anti-CD20 and Sirolimus for Immune Tolerance in Congenital Hemophilia A with InhibitorsB. Doshi, V.R. Arruda, L.J. Raffini, L.A. George (United States)

PB 224 A Prospective Surveillance Study of Inhibitor Formation in Quebec Hemophilia A Patients Following a Population Switch to a Third-generation B-Domain-deleted Recombinant Factor VIIIE. Dubé, A. Bonnefoy, C. Merlen, J.-F. Castilloux, S. Cloutier, C. Demers, J. St-Louis, C. Vezina, M. Warner, G.-E. Rivard (Canada)

PB 225 Evaluation of Reagent Substitutions in the Centers for Disease Control and

Prevention Modified Nijmegen-Bethesda Assay (CDC-NBA) for Factor VIII (FVIII) Inhibitors in Hemophilia AC.H. Miller, A.B. Payne, J. Driggers, D. Ellingsen, B. Boylan, C. Bean (United States)

PB 226 Evaluation of an Optimized Thrombin Generation Assay for Measurement of

rFVIIa in Haemophilia A Patient PlasmaI. Fernandez-Bello1, N.V. Butta1, V. Jimenez-Yuste1, L.F. Larsen2, V. Lind2, M. Ezban2 (1Spain, 2Denmark)

PB 227 Efficacy and Safety of Human-cl rhFVIII in Patients with Severe Hemophilia A

Undergoing Surgical ProceduresN. Zozulya1, J. Bichler2, A. Klukowska3 (1Russian Federation, 2Switzerland, 3Poland)

PB 228 Comparison of Biomarkers and Immunological Parameters between Hemophilia Patients, Rheumatoid Arthritis Patients, and Control SubjectsR. Toenges, A. Wittenbrink, S. Gundermann, W. Miesbach (Germany)

PB 229 Frozen Autologous Platelet Gel and Fibrin Glue in Hemophilia A, B and von

Willebrand Surgical PatientsA. Misiak, E. Lachert, B. Ceglarek, A.J. Sikorska, K. Bykowska, A. Szczepanik (Poland)

PB 230 Safety and Efficacy Of Moroctocog Alfa (AF-CC) in Patients with Hemophilia A:

Results of a Post-authorization Study in Usual Care Settings in ChinaR. Yang1, R. Wu1, J. Sun1, C. Jin1, F. Sun1, P. Rendo2, J. Rupon2, F. Huard3, J.M. Korth-Bradley2, L. Xu1, B. Luo1, Y. Liu1 (1China, 2United States, 3France)

PB 231 Post-authorization Study to Evaluate Pharmacokinetics of FVIII after

Moroctocog Alfa (AF-CC), as Well as Safety and Efficacy in Previously Treated Pediatric Patients with Severe Hemophilia AL. Rusen1, J.M. Korth-Bradley2, J. Rupon2, F. Huard3, A. Borodin4, C. Alvey2, L. Smith2, J. Fuiman2, M. Kuzmanovic5, P. Rendo2 (1Romania, 2United States, 3France, 4Ukraine, 5Serbia)

PB 232 Understanding Care Utilization and Perceptions of People with Hemophilia A with or without a Current InhibitorW.E. Owens, Y. Xu, A. Cyhaniuk, E. Chan, P. Kuebler, R.H. Ko, P.G. Solari, J. Chupka (United States)

PB 233 Utilisation of Smartphone Technology in Managing Prophylaxis for Patients with

HaemophiliaM. Lavin, E. Singleton, R. Bird, F. Mc Groarty, K. Ryan, J.S. O'Donnell, B. White, N.M. O'Connell (Ireland)

PB 234 Retrospective Analysis of Hemostatic Efficacy by Continuous Infusion of

Recombinant Factor VIIa: A Single Institution StudyN. Suzuki, M. Kishimoto, T. Kanematsu, A. Suzuki, M. Ogawa, H. Kiyoi, T. Matsushita (Japan)

PB 235 An Evaluation of the Pharmacokinetics of Turoctocog Alfa in Relation to Body

Mass Index (BMI) in Patients with Haemophilia A (HA)S. Zupančić-Šalek1, M.C. Ozelo2, L. Korsholm3, I. Matytsina3 (1Croatia, 2Brazil, 3Denmark)

PB 236 Pharmacokinetic Studies of FVIII in Chinese Boys with Severe Hemophilia AZ. Chen, P. Li, G. Li, L. Tang, Y. Zhen, X. Wu, R. Wu (China)

PB 237 Preliminary Results of a Personalized One-year Program to Individualize the

Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Hemophilia A PatientsJ.E. Megías Vericat, M.R. Marqués Miñana, S. Haya, A.R. Cid, F. Querol, E. Monte, M. García Dasí, P. Caunedo, P. Bosch, R. Curats, J.L. Poveda, S. Bonanad (Spain)

PB 238 International Clinical Study Investigating the Incidence of Inhibitors in

Previously Untreated Patients with Severe Haemophilia A Treated with a High Purity FVIII/VWF Concentrate in a 1:1 RatioM. Jansen1, T. Andreeva2, V. Vdovin2 (1Austria, 2Russian Federation)

PB 239 Magnitude of Dosing Adjustment of AFSTYLA in Clinical TrialsS. Yan1, R. Wang1, A. Veldman2, M. Fries1, G. Krishnarajah1 (1United States, 2Germany)

PB 240 Validity of Angiography and Therapeutic Embolization in the Treatment of

Acute Bleeding in Hemophilia PatientsY.S. Park, M. Kim (Republic of Korea)

PB 241 Postraumatic Anterior and Posterior Thigh Pseudotumor in Young and

Adolescent with HemophiliaR. Silva, J. Marun, D. Perez (Colombia)



254 255

Mon

day

Pos

ter

Ses

sion

s

PB 242 Vitamin D Deficiency in Patients with Haemophilia: Initial Workup and Follow-up of SupplementationB. Krammer-Steiner, C. Schneider, R. Toenges, M. Steiner (Germany)

PB 243 Severe Haemophilia A Patients Born between 2000- 2015 at a Single

Haemophilia Centre: Characteristics and Inhibitor DevelopmentM. Martorell, S. Alonso, R. Parra, M. Constans, C. Altisent (Spain)

PB 244 The Effectiveness of PK-Tailored Tertiary Prophylaxis for Severe Hemophilia A

Children: A Pilot Study from BCHP. Li, Z. Chen, X. Cheng, Y. Wang, N. Zhang, Y. Zhen, X. Wu, R. Wu (China)

PB 245 Korea Hemophilia Foundation Registry Trends 1991-2015: Patient Registry,

Demographics, Health Services UtilizationS.K. Kim, S.K. Park, K.Y. Yoo (Republic of Korea)

PB 246 Safety and Efficacy of Nonacog Alfa in Patients with Hemophilia B: Results of

a Post-authorization Study in Usual Care Settings in ChinaR. Yang1, R. Wu1, J. Sun1, F. Sun1, J. Rupon2, F. Huard3, J.M. Korth-Bradley2, L. Xu1, B. Luo1, Y. Liu1, P. Rendo2 (1China, 2United States, 3France)

PB 247 Spinal & Cranial Neurosurgical Procedures in Patients with Hemophilia

C. Nakar, B. Hardesty, M. Karimi, A. Greist, R. Thukral, A. Shapiro (United States)

PB 248 Pseudotumors in Hemophilia: Effective Surgery with Application of Frozen Autologous Platelet GelA. Misiak, B. Ceglarek, A.J. Sikorska, K. Bykowska, J. Swornóg, E. Lachert, A.J. Meissner, A. Szczepanik (Poland)

PB 249 Rationale and Study Design for a Prospective, Non-interventional Phase 4

Study Evaluating the Effectiveness of Recombinant Factor VIII Fc Compared with Conventional Factor VIII Concentrates in the Prophylactic Treatment of Haemophilia A: The A-SURE StudyB. Winding1, J. Oldenburg2, C. Hay3, F. Peyvandi4, F.R. Rosendaal5, V. Jiménez-Yuste6, J. Szamosi1, S. Lethagen1 (1Sweden, 2Germany, 3United Kingdom, 4Italy, 5The Netherlands, 6Spain)

PB 250 Outcomes in Acquired Hemophilia A Based on the Choice of Hemostatic Agent:

A Single Institution Retrospective Cohort StudyM. Daughety, J. Shatzel, T. Deloughery (United States)

PB 251 The Use of Multiple Drugs in a Sample of Adult Patients with Hemophilia:

Considerations and Perspectives on AgingS. Riva, A. Nobili, E. Mancuso, G. Pravettoni, L. Cortesi, P.M. Mannucci, E. Santagostino (Italy)

PB 252 Sudden Decrease of High-titer Anti-FVIII Antibodies with Anti-inhibitor Coagulant Complex in a Patient with Severe Hemophilia A and Poor Response to Immune Tolerance InductionI. Soto, L.F. Ávila, D. Martínez, Á. Bernardo (Spain)

PB 253 Projecting Product Consumption of AFSTYLA vs. ADVATE in the United States

G. Krishnarajah1, S. Yan1, L. Stern1, R. Hutcheson2 (1United States, 2Canada) PB 254 Correlation between Pharmacokinetic of Factor VIII and Bleeding Frequency of

Children withsevere Hemophilia A in China - A Single Center Data AnalysisX. Cheng, Z. Chen, P. Li, Y. Wang, N. Zhang, Y. Zhen, X. Wu, R. Wu (China)

PB 255 Assessment of the Quality of Life in Korean Hemophiliacs: Impact of Disease-

related Factors, Social Status and Treatment Factors on the Quality of Life of Korean HemophiliacsC.W. You, H. Shin, S. Lee, M.K. Kim (Republic of Korea)

Management of Thromboembolism

PB 256 Relevance of Polypharmacy for the Clinical Outcome of Patients Receiving Oral Anticoagulation Therapy - Results from the thrombEVAL StudyL. Eggebrecht, M. Nagler, S. Göbel, H. Lamparter, K. Keller, C. Bickel, M. Lauterbach, C. Espinola-Klein, R. Hardt, T. Münzel, P.S. Wild, J.H. Prochaska (Germany)

PB 257 Thromboembolic and Bleeding Risk of Patients with Left-sided Mechanical Heart Prosthesis: The FCSA-START-Valvole StudyD. Poli, R. De Caterina, V. Pengo, E. Antonucci, L. Migliaccio, E. Grifoni, N. Maggini, M. Moia, S. Testa, G. Palareti, FCSA-START group (Italy)

PB 258 Warfarin Binds to a Hydrophobic Pocket within the Oxidized Open State

Human VKORC1 ConformationK.J. Czogalla, A. Biswas, K. Höning, V. Hornung, K. Liphardt, M. Watzka, J. Oldenburg (Germany)

PB 259 The Contribution of Genetic Variants that Are Associated with Venous

Thrombosis or with Vitamin K Antagonist Dosage, alone or Combined, to the Risk of Major Bleeding in Patients Treated with Vitamin K AntagonistsN. van Rein, W.M. Lijfering, M.H.A. Bos, J.J. Swen, F.J.M. van der Meer, P.H. Reitsma (The Netherlands)

PB 260 Assessment of the Efficacy of a Novel Tailored Vitamin K Dosing Regimen in

Lowering INR in Over-anticoagulated PatientsE. Kampouraki, P.J. Avery, H. Wynne, T. Biss, J. Hanley, K. Talks, F. Kamali (United Kingdom)



256 257

Mon

day

Pos

ter

Ses

sion

s

PB 261 Clinical Usefulness of the SAMe-TT2R2 Score: A Systematic Review and Meta-analysisJ.H.A. van Miert, S. Bos, N.J.G.M. Veeger, K. Meijer (The Netherlands)

PB 262 Safety of Long Term Warfarin Therapy in Real Clinical Practice: Predictors of

Major and Non-Major Clinically Relevant BleedingsE. Kropacheva, O. Zemlyanskaya, A. Dobrovolsky, E. Panchenko (Russian Federation)

PB 263 Decreased Bone Mineral Density in Fontan Patients Receiving Long-term

WarfarinC. Attard, P. Monagle, V. Ignjatovic, P. Simm, C. Munns, A. Timmi, K. Du Plessis, J. Chapman, Y. d'Udekem (Australia)

PB 264 Predicting Recurrent Venous Thromboembolism in Patients with Deep-vein

Thrombosis: Development and Internal Validation of an Simply Applicable Prediction Model (Continu-8)M. Nagler1, S.M. van Kuijk2, H. ten Cate2, M.H. Prins2, A.J. ten Cate-Hoek2 (1Switzerland, 2The Netherlands)

PB 266 Anticoagulation Control in Premenopausal Women with Mechanical Heart Valves Using Vitamin K Antagonists: Room for ImprovementC.S.B. Veen, J.S. Biedermann, F.W.G. Leebeek, M.J.H.A. Kruip (The Netherlands)

PB 267 Involvement of Antithrombotic Therapy in Intracranial Bleeding: A Tertiary

Hospital ExperienceV. Pons, P. Raheja, K.J. Flores, P. Olivera, T. Canals, E. Johansson, V. Cortina, M. Constans, F. Bosch, A. Santamaria (Spain)

PB 268 One-year Medical Costs and Predictors of Costs of Pulmonary Embolism: A

Prospective StudyJ.-P. Galanaud, A. Ternisien-Payerols, V. Georgescu, D. Pontal, P. Aubas, I. Quéré, G. Mercier (France)

PB 269 The Impact of Antiphospholipid Syndrome and Related Comorbidities in the

Quality of Oral AnticoagulationG.G. Yamaguti-Hayakawa, M.P. Colella, E.V. de Paula, J.M. Annichino-Bizzacchi, F.A. Orsi (Brazil)

PB 270 Predicting Recurrent Venous Thromboembolism in Patients with Deep-vein

Thrombosis: External Validation of a Prediction ModelM. Nagler1, S.M. van Kuijk2, H. ten Cate2, M.H. Prins2, A.J. ten Cate-Hoek2 (1Switzerland, 2The Netherlands)

PB 271 Clinical Characteristics Associated with Diagnostic Delay of Pulmonary Embolism in Primary Care: A Retrospective Observational StudyJ. Hendriksen, M. Koster- van Ree, M. Morgenstern, R. Oudega, R. Schutgens, K. Moons, G.-J. Geersing (The Netherlands)

PB 272 Variability in Calculation of Time in Therapeutic Range for Quality Control

Measurement of WarfarinS. Siddiqui, C. De Remer, J. Waller, R. Abraham, J. Gujral (United States)

PB 273 D-dimer Levels Predict Clinical Outcomes in Patients with Mechanical Heart

Valve Replacement during Oral Anticoagulation TherapyL. Zhang, L. Yanli, J. Yang, Z. Zhang (China)

PB 274 Prevention of Recurrent Gastrointestinal Bleeding in Anticoagulated Patients with Vitamin K Antagonists: Randomized Study Comparing Warfarin with BemiparinJ. Mateo Arranz, M. Carrasco Exposito, A. Ardevol Ribalta, E. Alvarado Tapias, N. Vilalta Seto, J.A. Millon Caño, C. Villanueva Sanchez, J. Fontcuberta Boj (Spain)

PB 275 Has the Introduction of the DOACs Moved Patients with Labile INRs from

Warfarin Therapy?T. O Halloran, D. O Keeffe, J. Conway, O. Power, C. Holt, M. Watts (Ireland)

PB 276 Risk of Recurrence after Stopping Anticoagulation in Patients with a First Episode of Unprovoked Venous Thromboembolism: A Systematic Review and Meta-AnalysisF. Khan1, A. Rahman1, M. Carrier1, C. Kearon1, S. Schulman1, F. Couturaud2, P. Prandoni3, S. Eichinger4, C. Becattini3, G. Agnelli3, H. Buller5, E. Sabri1, B. Hutton1, G. Wells1, M. Rodger1 (1Canada, 2France, 3Italy, 4Austria, 5Netherlands Antilles)

PB 277 Outcome of Vitamin K Antagonist Associated Bleeding in Patients Treated with

Prothrombin Complex Concentrate: The ROVAP StudyM.P.A. Brekelmans, R.A. Abdoellakhan, L.J.J. Scheres, J.S. Biedermann, B.A. Hutten, K. Meijer, H. ten Cate, M.V. Huisman, M.J.H.A. Kruip, S. Middeldorp, M. Coppens (The Netherlands)

PB 278 Association of 5'-untranslated Region / Exonic VKORC1 Mutations with Vitamin

K Antagonist Resistance: Results of the GFHT Cohort StudyE. Lesteven, J. Fréchaud, C. Moreau, M. Babayan, A. Veyradier, P. Gaussem, J.-L. Golmard, M.-A. Loriot, V. Siguret, on behalf of the GFHT (France)



258 259

Mon

day

Pos

ter

Ses

sion

s

PB 279 Repeated Serial D-Dimer (DD) Measurement after Anticoagulation Therapy (AT) withdrawal to Identify Patients (PTS) at Risk for Venous Thromboembolism (VTE) RecurrenceB. Cosmi, C. Legnani, M. Cini, G. Guazzaloca, G. Rodorigo, G. Palareti (Italy)

PB 280 Safety and Efficacy of Warfarin in Patients with Thrombocytopenia

Y.F. Lai, C.W. Tan, D.Y.T. Goh, S.Y. How, K.Y. Lee, V.W.P. Tham, M.C. Kong, H.J. Ng (Singapore)

PB 281 AF Patients on VKAs: Heart Failure is Associated with Worst Quality of

Anticoagulation and Higher Bleeding Risk. Results from the START RegisterD. Poli, E. Antonucci, L. Migliaccio, S. Testa, V. Pengo, F. Marongiu, A. Tripodi, G. Palareti, START-Register participants (Italy)

PB 282 Thrombotic Complication Rates Following Anticoagulation Reversal: A Retrospective Evaluation of Prothrombin Complex ConcentratesJ. Shaw, R. Buyting, M. Latrous, M. Tokessy, N. Cober, E. Saidenberg, G. Le Gal, M. Carrier, L. Castellucci (Canada)

PB 284 Assessment of the Quality of Oral Anticoagulation Control at Two Hospital-

based Clinics in BrazilM.A.P. Martins, R.G.L. Silva, I.G. Ferreira, L.C. Brant, C.M. Bertollo (Brazil)

PB 285 Factors Associated with Postoperative Hemorrhage in Patients Undergoing

Dental SurgeryM.A.P. Martins, A.L. Rocha, A.F. Souza, M.G. Fraga, D.V. Travassos, A.C.B. Oliveira, D.D. Ribeiro, T.A. Silva (Brazil)

PB 287 Thrombin Generation Test: A Reliable Tool to Evaluate the Pharmacodynamics of Vitamin K Antagonist Rodenticides in RatsG. Jourdi, S. Lefebvre, B. Le Bonniec, E. Curis, P. Gaussem, V. Lattard, V. Siguret (France)

PB 288 The Efficacy of 3-mg versus 5-mg Warfarin Initiating Dose and Corresponding

Dosing Schedule in Thai Patients Diagnosed with Venous ThromboembolismB. Suwanawiboon, W. Rotchanapanya, K. Mahaprom, N. Sermsathanasawadi, Y. Lalerd, W. Thongnoppakhun, C. Limwongse (Thailand)

PB 289 Barriers to Implementing an Extended INR Testing Interval Policy for Stable

Warfarin Patients: A Mixed Methods Study in Five Anticoagulation ClinicsG. Barnes, S. Misirliyan, S. Kaatz, E. Jackson, B. Haymart, E. Kline-Rogers, J. Kozlowski, G. Krol, J. Froehlich, A. Sales (United States)

PB 290 Vitamin K Antagonists Compared to Low-molecular-weight Heparins for Treatment of Cancer-associated Venous Thromboembolism: An Observational Study in Routine Clinical PracticeP. den Exter, J. Hooijer, T. van der Hulle, J.P. van Oosten, O.M. Dekkers, F.A. Klok, M.V. Huisman (The Netherlands)

PB 291 External Quality Assessment of the POCT Prothrombin Time Determination -

the 6-Year Experience with the Evaluation of the Postanalytical PhaseP. Kessler, M. Budina (Czech Republic)

PB 292 The Incidence of Thromboembolic and hEMorrhagic (ITEM) Complications in

Patients on Anticoagulant Therapy. A Dynamic Parallel-group Cohort StudyS. Testa, G. Palareti, O. Paoletti, G. Castaman, F. Catalano, F. Cora', M. Di Paolo, P. Esteban, S. Mannino, R. Morandini, A. Maroni, I. Nichele, M. Tala, A. Tosetto (Italy)

PB 293 Specific Inhibition of Endogenous VKOR Enzymes by Oral Anticoagulants

Reveals Lower VKORC1L1 Susceptibility due to Different Binding SiteK. Liphardt, K.J. Czogalla, K. Höning, V. Hornung, M. Watzka, J. Oldenburg (Germany)

PB 294 A comparison of management strategies for patients with warfarin-induced

bleedingP. Dobesh, B. Trevarrow, C. Duncan, P. Malinowski, K. Guiliano, K. Gundabolu (United States)

PB 295 Provision of External Quality Assurance for Post Analytical Assessment of Point

of Care Haemostasis TestsD.P. Kitchen, S. Munroe-Peart, L. Brown, S. Kitchen, I. Jennings, T. Woods, I. Walker (United Kingdom)

PB 296 Warfarin Toxicities: Risk Factors and Management - Data from a Developing

CountryS.A. Ali, A. Rashid, B. Moiz (Pakistan)

PB 297 Use of a 4-factor Prothrombin Complex Concentrate for Warfarin Reversal prior

to Urgent SurgeryB. Trevarrow, P. Dobesh, M. Wolfe, K. Gundabolu (United States)

PB 298 Can Results Be Improved on Vitamin K Antagonists (AVKs) Therapy ?

A.B. Vilaseca, G. Vidmar, R. Barbera, H. Beccari (Argentina)



260 261

Mon

day

Pos

ter

Ses

sion

s

PB 299 Genetically Determined Hypersensitivity to Vitamin K Antagonists Caused by a c.109G>A (p.Ala37Thr) Mutation in the Factor IX Propeptide: The First Case Identified in PolandE. Odnoczko, J. Falkowska, B. Baran, A. Buczma, E. Stefanska-Windyga, J. Windyga (Poland)

PB 300 Vkorc1 and cyp2c9 Gene Polymorphisms in the Healthy Russian and Buryat

Respondents in Trans-Baikal RegionO. Bolshakova, B. Pushkarev, A. Emelyanov, Y. Vitkovsky (Russian Federation)

PB 301 The Use of Prothrombinex Alone to Reverse Warfarin in Orthopaedic Patients

Requiring Emergency SurgeryR. Stokes, H. Seymour, P. Kruger, S. P'ng (Australia)

PB 303 Utility of a new Point of Care system, Coag S, for Vitamin K Antagonist Therapy in a Rural Family PracticeF. Kiss, J. Antal (Hungary)

PB 304 Duration of Anticoagulation in First Venous Thromboembolism (VTE) in the

Newcastle upon Tyne Hospitals NHS Foundation Trust (NUTH): A Quality Improvement ProjectL. Tafesh, K. Talks (United Kingdom)

PB 305 Out of Range INR Values Increase Healthcare Interaction Time in Four Large

Anticoagulation ClinicsG. Barnes, X. Gu, E. Kline-Rogers, C. Graves, E. Puroll, K. Townsend, E. McMahon, T. Craig, J. Froehlich (United States)

PB 306 Evaluation of Time in Therapeutic Range in Anticoagulated Patients with

Venous Thromboembolism. A Single-center, Retrospective, Observational StudyZ. Tazi Mezalek, M. Bourkia, W. Ammouri, W. Mounfaloti, F.Z. Iraqi, M. Maamar, H. Harmouche, R. Razine, M. Adnaoui (Morocco)

Transfusion & Biotherapeutics

PB 307 Plasma Derived FVIII Concentrates Induce Neutrophil Extracellular Trap (NET) FormationM.F. Brodde, A. Bertling, B.E. Kehrel (Germany)

PB 308 Vlidation of Hemostatic Impairment Induced by Hydroxyethyl Starch in vivo

R. Azumaguchi, Y. Tokinaga, M. Kimizuka, S. Kazuma, S. Hayashi, M. Yamakage (Japan)

PB 309 Ex Vivo Haemostatic Capacity of Thawed Plasma Beyond 24 Hours: Comparison between FFP and RTFP24A.L. Ang, W.H. Wong, W.C. Tan, S. Lam, P. Kuperan, H.J. Ng, J. Chay, H.H. Tan, C.W. Tan, S.S. Chua (Singapore)

PB 310 Effect of Handling on the Functional Utility of Stored Platelet Units

J. Zilberman-Rudenko, F.Z. Zhao, S.E. Reitsma, J. Pang, C. Tyrrell, W. Hasan, M.A. Schreiber, O.J.T. McCarty, OHSU (United States)

PB 311 Coagulations Parameters and Need for Transfusion in Patients with Veno-

arterial Extracorporeal Membrane Oxygenation in Clinical Hospital Center RijekaN. Vukelic-Damijani, N. Katalinic, A. Starcevic, J. Sokolic, Z. Zupan, S. Balen (Croatia)

PB 312 Blood Loss and Transfusion of Blood Products in Children Undergoing

Craniofacial SurgeryA.L. d'Amore, N. Juul, C. Fenger-Eriksen, M. Rasmussen, L. Krogh, G. von Oetting, A.-M. Hvas (Denmark)

PB 313 Inappropriate Fresh Frozen Plasma Transfusion in ChildrenY. Guzin, Y. Oymak, T.H. Karapınar, S. Gözmen, Y. Ay, C. Vergin (Turkey)

PB 314 Knowledge, Attitude and Practice Regarding the Voluntary Blood Donation

among the Young Student Population of KarachiB. Nepal (Pakistan)

PB 315 Burden of Hemoglobinopathies on the Blood Bank of a Tertiary Care Setting

R. Akbar (Pakistan) PB 316 Major Blood Groups and A2 Sub-group in Mixed Pakistani Population of

KarachiB. Nepal1, N. Nusrat2 (1Nepal, 2Pakistan)

PB 317 New Tools for the Delivery of RNA to PlateletsS. Novakowski, S. Romani, G. Prakash, C. Kastrup (Canada)

PB 318 Effects of Activated Human Platelet Releasates on Wound Healing of

Immunodeficient Mice: Comparison with Basic FGFK. Tozawa, Y. Ono-Uruga, T. Mori, N. Takizawa, M. Murata, S. Okamoto, Y. Ikeda, Y. Matsubara, M. Yazawa (Japan)

PB 320 SAG Mediated Therapy Leads to a Predominant Th1 during Visceral Leishmaniasis on Triggering CD2 EpitopeS. Sinha, S. Sundaram (India)



262 263

Mon

day

Pos

ter

Ses

sion

s

PB 321 Characterization of a Universal Reversal Agent for AnticoagulantsK. Bakhtiari1, S.L.M. Peters1, D.M. Monroe2, J.C.M. Meijers1 (1The Netherlands, 2United States)

PB 322 Antiaggregant Effect of Rubia tinctorum Butanolic Extract on Human Platelets

M. Fatimazahra1, Z. Younes2, K. Haouach1, C. Abderahim1, B. Abdellah1, B. Hicham1 (1Morocco, 2Canada)


Hemorrhagic Disorders, Hemophilia

PB 323 Extracellular Nucleosome Levels in the Etiopathogenesis of Sepsis-associated CoagulopathyA. Walborn, P. Patel, D. Hoppensteadt, M. Mosier, M. Rondina, J. Fareed (United States)

PB 324 Mediators of Inflammation and Infection in Sepsis Associated Disseminated

Intravascular Coagulation and Their Prognostic RoleP. Patel, A. Walborn, D. Hoppensteadt, M. Mosier, M. Rondina, J. Fareed (United States)

PB 325 Crotoxin, a phospholipase A2 from Crotalus durissus terrificus rattlesnake

venom, attenuates coagulation and inflammatory parameters in endotoxin-induced DICM.A. Sartim, G.N. Cezarette, S.V. Sampaio (Brazil)

PB 326 Evaluation of the Diagnostic Utility of Individual Parameters in the

Disseminated Intravascular Coagulation (DIC) Panel for Use in Under-resourced SettingsS. Louw, E.S. Mayne, A. Mayne (South Africa)

PB 327 Circulating Nucleosomes and Neutrophil Activation Predict for Disseminated

Intravascular Coagulation but Not for Mortality in Patients with Severe Sepsis or Septic ShockM.N. Lauw1, W.A. Wuillemin2, G.J. Van Mierlo1, S. Zeerleder1 (1The Netherlands, 2Switzerland)

PB 328 A Prospective Observational Study for the Evaluation of New Diagnostic

Criteria for Disseminated Intravascular Coagulation by the Japanese Society on Thrombosis and HemostasisY. Kondoh, H. Satoh, H. Takeda, S. Funakoshi, K. Watanabe, K. Sasao, K. Sekine, J. Nozaki, M. Kawamura, S. Madoiwa (Japan)

PB 329 A comparison of Disseminated Intravascular Coagulation (DIC) Screening Parameters with and without Human Immunodeficiency Virus Infection in an African Academic Hospital SettingE. Mayne, A. Mayne, S. Louw (South Africa)

PB 330 International Normalized Ratio Relevance to the Observed Coagulation

Abnormalities in Warfarin Treated and Those with Disseminated Intravascular CoagulationD. Hoppensteadt, A. Walborn, S. Abro, J. Walenga, M. Mosier, K. Tsuruta, J. Fareed (United States)

PB 331 Epidemiological Evaluation of Patients Presenting with Disseminated

Intravascular Coagulation (DIC) at an Academic Hospital in an African Middle-income CountryE. Mayne, A. Mayne, S. Louw (South Africa)

PB 332 Real Word Difficulties in the Diagnosis and Management of Hyperfibrinolysis

W. Thomas, J. Russell, E. Symington, M. Besser (United Kingdom) PB 333 Fulminant Disseminated Intravascular Coagulation as Initial Manifestation of

Pulmonary AdenocarcinomaS. Teixeira, C. Monteiro, M. Carvalho, L. Gonçalves, C. Koch (Portugal)

PB 334 Platelet-mimicking Synthetic Nanoparticles (SynthoPlateTM) Improve

Hemostasis and Survival Following Uncontrolled HemorrhageM. Dyer, C. Pawlowski, S. Haldeman, A. Gutierrez, W. Alexander, U. Sekhon, E. Niedoba, D. Hickman, A. Sen Gupta, M. Neal (United States)

PB 335 Early Fibrinolytic Activation and Hypofibrinogenaemia Are Associated with

Mortality in Isolated Traumatic Brain InjuryP. Vulliamy, S.E. Breukers, S. Gillespie, T. Walton, V. Carneiro Gimenez, C. Uff, K. Brohi, R.A. Davenport (United Kingdom)

PB 336 Platelets Loaded with Thrombin-encapsulated Liposomes Have Increased

CoagulabilityV. Chan, M. Sarkari, R. Sunderland, C. Kastrup (Canada)

PB 337 S100B in Suspected Intracranial Hemorrhage in Patients after Minor Head

Injury Older than 65 Years and on Antiplatelet TherapyH.W. Thaler, J. Schmidsfeld (Austria)

PB 338 Antifibrinolytic Therapy to Prevent Oral Bleeding in People on Anticoagulants

Undergoing Oral or Dental Procedures: A Cochrane Systematic ReviewE.T. Engelen, R.E.G. Schutgens, E.P. Mauser-Bunschoten, R.J.J. Van Es, K.P.M. Van Galen (The Netherlands)



264 265

Mon

day

Pos

ter

Ses

sion

s

PB 339 Management of Rivaroxaban or Apixaban Associated Major Bleeding with Prothrombin Concentrate: A Prospective Cohort StudyA. Majeed1, A. Ågren1, M. Bruzelius1, R. Chaireti1, J. Odeberg1, M. Holmström1, E.L. Hempel1, M. Magnusson1, T. Frisk1, S. Schulman2 (1Sweden, 2Canada)

PB 340 Favorable Thrombogenicity Profile of a Prothrombin Complex Concentrate

(4F-PCC) in Animal Models of Venous and Arterial ThrombosisF. Kaspereit, W. Krege, E. Raquet, F. Musch, M. Mischnik, E. Herzog (Germany)

PB 341 fProthrombin Complex Concentrate for Major Bleeding on Factor Xa InhibitorsS. Schulman, P. Gross, B. Ritchie, S. Nahirniak, Y. Lin, L. Lieberman, M. Carrier, M. Crowther, I. Ghosh, A. Lazo-Langner, M. Zondag (Canada)

PB 342 Reversal of Dabigatran-associated Major Bleeding with Activated Prothrombin

Concentrate: A Prospective Cohort StudyS. Schulman1, B. Ritchie1, S. Nahirniak1, P. Gross1, M. Carrier1, A. Majeed2, H.-G. Hwang3, M. Zondag1 (1Canada, 2Sweden, 3Korea, Republic of)

PB 343 A randomized study of 4-factor prothrombin complex concentrate and tranexamic acid on bleeding, thrombin generation, and pharmacodynamics after punch biopsies in rivaroxaban treated subjects with supratherapeutic drug levelsJ. Levy1, K.T. Moore1, M. Neal1, D. Schneider1, V. Marcsisin1, J. Ariyawansa1, J. Weitz2 (1United States, 2Canada)

PB 344 Idarucizumab for Dabigatran Reversal in Daily Practice - First Experiences from

SloveniaN. Vene, A. Mavri, M. Bozic Mijovski, P. Gradisek, M. Gregoric, S. Frol, J. Pretnar (Slovenia)

PB 345 The Influence of Histones on the Generation of Factor XIa in Trauma Patient BloodS. Prior, N. Dow, K. Freeman, C. Esmon, K. Mann, S. Butenas (United States)

PB 346 Markers of Platelet Activation Are Elevated Specifically on Leukocytes after Major InjuryS. Gillespie, P. Vulliamy, J. Shepherd, R. Davenport, K. Brohi (United Kingdom)

PB 347 Evaluation of Early Metrics of Clot Amplitude from New Generation

Thromboelastogram (TEG6s) in Capturing Trauma Induced CoagulopathyB. Mathew, C. Lopez-Espina, J. O‘Mara (United States)

PB 348 Implementation and Migration of Haemophilia-treatment-diaries from Paper Based to Electronic Documentation at Haemophilia CCC at the University of BonnJ. Oldenburg, R. Langenkamp, G. Goldmann (Germany)

PB 349 Development and Validation of the Warfarin-Aspirin Bleeding Assessment Tool

(WA-BAT)C. Attard, P. Monagle, Y. d‘Udekem, V. Ignjatovic (Australia)

PB 350 Prothrombin Concentrate Complex for Major Bleeding in Patients Receiving

Direct Oral Anti-coagulants: A Single Center Retrospective StudyM. Barzilai, D. Salzer Gotler, I. Avivi, I. Kirgner (Israel)

PB 351 Chemical Composition of Malian Medicinal Plants Used to Treat Bleeding EventsY.L. Diallo, A. Togola, I. Sanogo, D. Traore, A.H. Babana, R. Sanogo, D. Diallo (Mali)

PB 352 First Italian Experience of Clinical Use of Obizur, Recombinant Porcine Sequence Factor VIII (RPFVIII), for Acquired Haemophilia A (AHA)C. Lodigiani, P. Ferrazzi, L. Libre‘, V. Pacetti, A. Colombo, M.C. Beltrametti, I. Quaglia (Italy)

PB 353 The Effect of PCC on ROTEM Parameters in Patients with Coagulopathy of

Liver DiseaseC. Hamid1, J. McVey1, A. Riddell1, T. Fox1, E. Brodkin1, A. Gatt2, R. Morris1, P. Chowdary1 (1United Kingdom, 2Malta)

PB 354 Factor VIII and von Willebrand levels at Desmopressin (DDAVP) Challenge Test: A Single Center ResultsC. Casas, M.H. Solano, M.L. Parra, D. Espinosa, V. Abello, A. Palacios (Colombia)

PB 355 Correlation between Platelet Count and Platelet Component in ThromboelastometryM. Milic, J. Jonjic, V. Seric (Croatia)

PB 356 Favorable Effect of Combined Use of Prothrombin Complex Concentrate and

Plasma in in vitro-Induced CoagulopathyH.J.M. Brinkman1, M. Zuurveld1, R. Lassila2, J.C.M. Meijers1 (1The Netherlands, 2Finland)

PB 357 Towards a Clinically Relevant Hybrid Adenovirus-Sleeping Beauty Transposon

Vector for Gene Therapy for von Willebrand DiseaseI. Portier1, M. Solanki2, H. Deckmyn1, K. Vanhoorelbeke1, A. Ehrhardt2, S.F. De Meyer1 (1Belgium, 2Germany)



266 267

Mon

day

Pos

ter

Ses

sion

s

PB 358 Comprehensive Functional and Structural Studies to Characterize von Willebrand Factor Propeptide Novel Missense Variants with Unknown Pathological SignificanceH. Yadegari1, A. Biswas1, S. Ahmed2, A. Naz2, J. Oldenburg1 (1Germany, 2Pakistan)

PB 359 Triggering Receptor Expressed on Myeloid Cells Like Transcript-1 (TLT-1) is a

Novel Ligand for von Willebrand FactorA. Doerr, C. Gardiner, M. Laffan, T. McKinnon (United Kingdom)

PB 360 A2 Domain Unfloding Might Significantly Increase Shear and Elongation-

meadiated vWF Unfolding in the BloodstreamD. Nechipurenko1, I. Krauz1, K. Vladislav1, I. Gudich1, V. Alferov2, C. Cardona2, V. Isidorova2, T. Kurakina2, E. Morales2, D. Yarotskiy2 (1Russian Federation, 2Spain)

PB 361 Acquired von Willebrand Disease (aVWD) in Plasma Cell Dyscrasias (PCD): Variable Underlying Pathophysiology as Evidenced by the Analysis of Proteolytic von Willebrand Factor (VWF) Cleavage FragmentsJ. Irle1, F. Langer1, C.C. Dicke1, J. Fuchs1, C. von Auer1, S. Schneppenheim1, H. Rossmann1, Z. Ruggeri2, B. Lämmle1, K. Jurk1 (1Germany, 2United States)

PB 362 Axial Structure and Collagen Binding of the von Willebrand Factor Multimer

M.C. Csanyi, T. Feller, T. Bozo, M.S.Z. Kellermayer, J. Harsfalvi (Hungary) PB 363 Safety and Efficacy of Recombinant von Willebrand Factor (rVWF) in Patients

with Severe von Willebrand Disease (VWD) Undergoing Major and Minor Elective Surgical Procedures: A Prospective Clinical TrialF. Peyvandi1, A. Mamaev2, J.-D. Wang3, C.A.M. von Auer4, O. Stasyshyn5, M. Timofeeva2, N. Curry6, A.R. Cid7, T.T. Yee6, K. Kavakli8, M. Chapman9, A. Grigorian9, B. Ploder10, A. Sytkowski9 (1Italy, 2Russian Federation, 3Taiwan, 4Germany, 5Ukraine, 6United Kingdom, 7Spain, 8Turkey, 9United States, 10Austria)

PB 364 Recombinant Activated Factor VII-Induced Correction of Bleeding Tendency in

Genetically-engineered von Willebrand Disease Type 2B Mice Evaluated Using New Tail Transection Bleeding ModelsV. Proulle, C. Auditeau, H. Petit, F. Adam, A. Kauskot, F. Moreau, O.D. Christophe, P.J. Lenting, C.V. Denis (France)

PB 365 VWF D‘D3 Mutations Associated with Type 1 von Willebrand Disease

Demonstrate Impaired Gp1B⍺-VWF Binding under High Shear StressN. Christopher, K. Ashworth, T. White-Adams, J. Di Paola (United States)

PB 366 Diagnostic Challenges of Acquired von Willebrand SyndromeS. Schneppenheim, R. Dittmer, U. Budde (Germany)

PB 367 Multimer Size Distribution and Multimerization Defects of von Willebrand Factor Investigated at the Single-molecule Level by AFM ImagingA. Löf, G. König, S. Schneppenheim, T. Obser, R. Schneppenheim, M. Benoit, U. Budde, J.P. Müller, M.A. Brehm (Germany)

PB 368 Exploration of Interim Bleeding Scores in VWD Subjects from Irish LoVIC,

Canada and the US Zimmerman ProgramP. Christopherson1, M. Lavin2, J. Grabell3, T. Abshire1, V. Flood1, J. Gill1, S. Haberichter1, J. O‘Donnell2, R. Montgomery1, P. James3, Zimmerman Program Investigators (1United States, 2Ireland, 3Canada)

PB 369 Does Ageing Modify Hemostatic Parameters in Type 1 von Willebrand Disease

(VWD-1)?G. Guglielmini, M. Borghi, A.M. Mezzasoma, E. Falcinelli, P. Gresele (Italy)

PB 370 Common Single Nucleotide Variants in the von Willebrand Factor Gene

Associate with “Mutation Negative” Type 1 VWDC. Notley, M. Bowman, C. Brown, K. Tyryshkin, L. Swystun, P. James, D. Lillicrap (Canada)

PB 371 Functional Polymorphisms of the von Willebrand Factor Gene in Patients with

Mild to Moderate Bleeding Tendency and Low von Willebrand Factor Antigen or von Willebrand Factor Ristocetin CofactorS. Hofer, J. Gebhart, J. Rejtö, G. Hörmann, I. Pabinger, R. Sunder-Plassmann (Austria)

PB 372 Expression of the von Willebrand Factor C-domains in E.coli

H. O‘Brien, F. Hansen, T. Tuddenham, M. Laffan, T. McKinnon (United Kingdom) PB 373 Quantitative ELISA Assay for in vivo Proteolysis of von Willebrand Factor

andBbleeding: A Pilot Study in Type 2A (IIA) von Willebrand DiseaseA. Rauch, B. Pan Petesch, K. Pouymayou, S. Castet, D. Desprez, L. Rugeri, N. Itzhar, E. Jeanpierre, C. Caron, C. Ternisien, A. Borel-Derlon, P. Boisseau, E. Fressinaud, P. Lenting, A. Veyradier, J. Goudemand, S. Susen (France)

PB 374 Bleeding Symptoms in Patients Previously Diagnosed as Type 3 von Willebrand Disease: Results from a Multicenter, Multinational Cross-sectional StudyA. Tosetto1, Z. Badiee2, M.-R. Baghaipour2, L. Baronciani1, J. Battle3, E. Berntorp4, I. Bodo5, U. Budde6, G. Castaman1, J. Eikenboom7, P. Eshghi2, C. Ettorre1, A. Goodeve8, J. Goudemand9, C. Hay8, H. Hoorfar2, M. Karimi2, B. Keikhaei2, R. Lassila10, F. Leebeek7, M.F. Lopez Fernandez3, P.M. Mannucci1, M.G. Mazzucconi1, M. Morfini1, J. Oldenburg6, R. Parra Lòpez3, I. Peake8, F. Peyvandi1, R. Schneppenheim6, A. Tiede6, G. Toogeh2, M. Trossaert9, S.O.R. Zekavat2, E. Zetterberg4, A.B. Federici1 (1Italy, 2Iran, Islamic Republic of, 3Spain, 4Sweden, 5Hungary, 6Germany, 7The Netherlands, 8United Kingdom, 9France, 10Finland)



268 269

Mon

day

Pos

ter

Ses

sion

s

PB 375 Fluorescence Intensity-based Analysis of the Shear-dependent Internalization of Von Willebrand Factor Mutants by MacrophagesU. Klemm, G. Ahmari, T. Obser, G. König, R. Schneppenheim, M. Brehm (Germany)

PB 376 Von Willebrand Factor Multimer Analysis in 255 Patients Previously Diagnosed

as VWD Type 3 from the Iranian Republic and Nine European Countries (3WINTERS-IPS Study)U. Budde1, S. Schneppenheim1, Z. Badiee2, M.-R. Baghaipour2, L. Baronchiani3, J. Battle Fonrodona4, E. Berntorp5, I. Bodo6, G. Castaman3, J. Eikenboom7, P. Eshghi2, C. Ettore3, A. Goodeve8, J. Goudemand9, C. Hay8, H. Hoofar2, M. Karimi2, B. Keikhaei2, R. Lassila10, F. Leebeek7, M.F. Lopez Fernandez4, P.M. Mannucci3, M.G. Mazzucconi3, M. Morfini3, J. Oldenburg1, R. Parra Lopez4, I.R. Peake8, F. Peyvandi3, R. Schneppenheim1, A. Tiede1, G. Toogeh2, A. Tosetto3, M. Trossaert3, S.O.R. Zekavat2, E. Zetterberg5, A.B. Federici3 (1Germany, 2Iran, Islamic Republic of, 3Italy, 4Spain, 5Sweden, 6Hungary, 7The Netherlands, 8United Kingdom, 9France, 10Finland)

PB 377 Interaction between the A3 and A2 Domains of von Willebrand Factor Reduces

the Binding of the A1 Domain to Glycoprotein IbαS. Cirlos, M. Auton, M. Cruz (United States)

PB 378 Incidence and Economic Burden of Thromboembolic Events (TEEs) among

US Patients with von Willebrand Disease (VWD) - A Large Claims Database AnalysisM. Lu, A. Oladapo, E. Fadli, A. Khachatryan, E. Brouwer, M. Bron, T. Kauf (United States)

PB 379 oPerioperative Management of Replacement Therapy in von Willebrand

Patients: Steps towards Individualization of Treatment?H.C.A.M. Hazendonk, H.C. Veerman, J.M. Heijdra, J. Boender, I. van Moort, R.A.A. Mathôt, K. Meijer, B.A.P. Laros-van Gorkom, J. Eikenboom, K. Fijnvandraat, F.W.G. Leebeek, M.H. Cnossen, WIN and OPTI-CLOT study group (The Netherlands)

PB 380 Deficiency of von Willebrand Factor (VWF) High Molecular Weight Multimers (HMWM) in the Presence of Normal/Increased Activity of both VWF Cofactor Activity (VWF:RCo) and VWF Antigen (VWF:Ag) in Patients with Severe Aortic StenosisK. Bykowska, D. Zakrzewski, B. Baran, P. Kunicki, T. Hryniewiecki, J. Windyga (Poland)

PB 381 Usefulness of VWF Propeptide in the Differential Diagnosis between Patients

with VWD and AVWSF. Stufano, M. Boscarino, L. Baronciani, P. Bucciarelli, G. Cozzi, F. Peyvandi (Italy)

PB 382 Lack of Discontinuous von Willebrand Factor Multimer Organization Associated with the c.2269_2270del Mutation in the von Willebrand Factor GeneV. Daidone, E. Galletta, A. Casonato (Italy)

PB 383 Surgeries in adults and Children with von Willebrand‘s Disease - Results from

the Ongoing Study Wilate-STATES. Halimeh, M. Daoud, M. Rieke, T. Lang, J. Kadar, S. Alesci, J. Koscielny, J. Feddern, S. Seeger (Germany)

PB 384 Laboratory Diagnosis of von Willebrand Disease Type 2A versus LVAD-Induced

Acquired von Willebrand SyndromeS. Deconinck1, C. Tersteeg1, E. Bailleul1, L. Delrue1, N. Vandeputte1, I. Pareyn1, H. Deckmyn1, S.F. De Meyer1, N. Itzhar-Baikian2, M. Vanderheyden1, K. Vanhoorelbeke1 (1Belgium, 2France)

PB 385 Elevated Levels of vWF Antigen and Activities, Factor VIII and Fibrinogen Inversely Correlated with the Estimated Glomerular Filtration Rate in Patients with Non-dialysis Chronic Kidney DiseaseB. Suwanawiboon, R. Chainarongsiriporn, Y. Nakkinkun, R. Chawanasuntorapoj (Thailand)

PB 386 Measurement of Platelet von Willebrand Factor (VWF) Antigen Concentration

and Activity Using Automated Latex-immunoturbidometric (LIA) AssaysH. Rühl, K.M. Orschulik, J. Müller, J. Oldenburg, B. Pötzsch (Germany)

PB 387 Impact of Changes in Laboratory Diagnostic Criteria in the Classification of von

Willebrand DiseaseP. Batty, J.N. Hodgetts, J. Uprichard (United Kingdom)

PB 388 Combined Lenalinomide and Dexamethasone Treatment of Multiple Myeloma

Cures Acquired von Willebrand Syndrome: A Case ReportC. Paris, A. Rauch, C. Herbaux, C. Caron, E. Jeanpierre, C. Zawadzki, V. Tintillier, N. Trillot, B. Wibaut, J. Goudemand, S. Susen (France)

PB 389 Profile of Mutations Identified in the 3WINTERS-IPS Project on Iranian

Patients with Previously Diagnosed Type 3 von Willebrand DiseaseL. Baronciani1, F. Peyvandi1, F. Stufano1, P. Eshghi2, Z. Badiee2, M.-R. Baghaipour2, U. Budde3, J. Eikenboom4, A. Goodeve5, J. Goudemand6, H. Hoorfar2, M. Karimi2, B. Keikhaei2, P.M. Mannucci1, I.R. Peake5, R. Schneppenheim3, G. Toogeh2, A. Tosetto1, S.O.R. Zekavat2, A.B. Federici1 (1Italy, 2Iran, Islamic Republic of, 3Germany, 4The Netherlands, 5United Kingdom, 6France)



270 271

Mon

day

Pos

ter

Ses

sion

s

PB 390 Self-reported Experiences with Menorrhagia in Women with von Willebrand Disease: A Patient-oriented Survey StudyA. Marshall, H. Dasari, N. Warner, D. Grill, A. Ashrani, W. Nichols, R. Pruthi (United States)

PB 391 Primary Hemostasis in Severe von Willebrand Disease Patient‘s Blood Is

Reconstituted in vitro by Ultralarge von Willebrand Factor MultimersT. Kragh, I. Pekrul, M. Spannagl (Germany)

PB 392 Ristocetin Cofactor Latex Immunoassay, High Sensibility to Acquired von

Willebrand Disease with Subtle Loss of High Molecular Weight MultimersB. Montaruli, P. Sivera, D. Cosseddu, C. Fornelli, I. Canta, N. Renzi, O. Ruggia, M. Migliardi (Italy)

PB 393 Von Willebrand Factor Antigen Levels in 255 Patients Previously Diagnosed as VWD Type 3 from the Iranian Republic and Nine European Countries (3WINTERS-IPS Study)B. Ulrich1, S. Schneppenheim1, Z. Badiee2, M.-R. Baghaipoor2, L. Boronchiani3, J. Battle Fonrodona4, E. Berntorp5, I. Bodo6, G. Castaman3, J. Eikenboom7, P. Eshghi2, C. Ettore3, A. Goodeve8, J. Goudemand9, C. Hay8, H. Hoofar2, M. Karimi2, B. Keikhaei2, R. Lassila10, F. Leebek7, M.F. Lopez Fernandez4, P.M. Mannucci3, M.G. Mazzuconi3, M. Morfini3, J. Oldenburg1, R. Parra Lopez4, I.R. Peake8, F. Peyvandi3, R. Schneppenheim1, A. Tiede1, G. Toogeh2, A. Tossetto3, S.O.R. Zekavat2, M. Trossaert9, E. Zetterberg5, A.B. Federici3 (1Germany, 2Iran, Islamic Republic of, 3Italy, 4Spain, 5Sweden, 6Hungary, 7The Netherlands, 8United Kingdom, 9France, 10Finland)

PB 394 Clinical Characterization of 76 Families with von Willebrand Disease

M.S.S. Namen-Lopes, D.G. Chaves, S. Brener, D.D. Ribeiro, C. Velloso-Rodrigues, S.M. Rezende (Brazil)

PB 395 Clinical Evaluation of the Sebia Hydragel von Willebrand Factor Assay in

Comparison to Electophoresis and Blotting Based Multimer AnalysisH. Seidel1, P. Westhofen1, H. Bautista2, G. Beaulieu2, G. Nouadje2, J.P. Kruppenbacher1 (1Germany, 2France)

PB 396 Can a One-time von Willebrand Testing Rule out Type 1 von Willebrand Disease

in Young Women with Menorrhagia?E. Morita, E. Soundar, K. Bruzdoski, V. Kostousov, J. Teruya, S.-K. Hui (United States)

PB 397 Screening of von Willebrand´s Disease in a Region of High Consanguinity

Y. Ouarhlent, H. Laiadhi, M.R. Makhloufi, R. Chafai, S. Chichoune (Algeria)

PB 398 Management of a Spontaneous Ileo-psoas Haematoma in a Girl with Type 3 von Willebrand Disease and Alloantibodies to von Willebrand FactorC. Ambaglio, G. Giorgiani, N. Decembrino, F. Zane, M. Russo, C. Sacco, E. Genini, P.S. Preti, M. Zecca, G. Gamba (Italy)

Diagnostics and OMICs

PB 399 Failure of Wells Score and D-dimer to Safely Exclude Diagnosis of Deep Vein Thrombosis: A Single Centre Experience of over 3500 PatientsS. Badle, E. Friedman, L. Bowles, P. MacCallum (United Kingdom)

PB 400 Residual Vein Thrombus Does Not Predict for Recurrent Vein Thrombosis in the

ASPIRE StudyT. Brighton1, A. Bosco1, K. Robedo1, R. Mister1, W. Hague1, A. Kirby1, J. Eikelboom2, J. Simes1 (1Australia, 2Canada)

PB 401 Utility of Thromboelastometry Analysis in Patients with Mild Bleedings Disorders

A. Wieland Greguare-Sander, W.A. Wuillemin, M. Nagler (Switzerland)

PB 402 Increased Maximum Lysis of ROTEM in Pregnancy: It Is Not HyperfibrinolysisJ. Teryua, A. Shamshirsaz, H. Erfani, K. Fox, K. Bruzdoski, S.K. Hui, V. Kostousov (United States)

PB 403 Significant von Willebrand Disease Can Be Missed if a von Willebrand Factor

Activity Assay Is Not PerformedS. Platton (United Kingdom)

PB 404 Validation of Flow Cytometric Mepacrine Uptake and CD63 Expression in the

Diagnosis of Storage Pool DiseaseI. van Asten, M. Blaauwgeers, L. Granneman, A. Huisman, G. Pasterkamp, H. Heijnen, S. Korporaal, R. Schutgens, R. Urbanus (The Netherlands)

PB 405 Post-analytical External Quality Assessment - Interpretation of UK NEQAS

(Blood Coagulation) ResultsI. Jennings, D. Kitchen, S. Kitchen, T. Woods, I. Walker (United Kingdom)

PB 406 Different D-dimer Assays Have Similar Performance Using the Age-adjusted

Threshold for the Diagnosis of Pulmonary EmbolismN. Kraaijpoel, N. van Es, F.A. Klok, M.V. Huisman, P.M. Bossuyt, H.R. Büller (The Netherlands)

PB 407 Safety of Multidetector Computed Tomography Pulmonary Angiography to Exclude Pulmonary Embolism in Patients with a Likely Pretest Clinical ProbabilityH. Robert-Ebadi1, G. Le Gal2, M. Righini1 (1Switzerland, 2Canada)



272 273

Mon

day

Pos

ter

Ses

sion

s

PB 408 Familial Multiple Coagulation Factor Deficiencies - Need for Deeper Clinical and Scientific AssessmentB. Preisler, B. Pezeshkpoor, I. Schwarze, R. Kuhlemann, J. Junen, R. Maurer, I. Radermacher, L. Rothbrust, J. Beckedahl, J. Oldenburg, A. Pavlova (Germany)

PB 409 Performance of Anti-factor Xa Heparin Assays in External Quality Control

SurveysC. Bon, G. Matar, R. Meley, C. Sotta, J.C. Eynard, B. Poggi (France)

PB 410 Ex-vivo Plasma Clot Formation and Lysis as a Universal Measure for

Anticoagulation in Patients on Vitamin-K-antagonist, Dabigatran, Rivaroxaban, Apixaban, or Low-molecular-Weight HeparinO. Königsbrügge, G. Weigel, P. Quehenberger, I. Pabinger, C. Ay (Austria)

PB 411 Thrombin Generation Response of rFVIIa in Haemophilia A Patient Plasma

when Using Different Triggers and PhospholipidsL.F. Larsen, H. Østergaard, M.B. Hermit, V. Lind, M. Ezban (Denmark)

PB 412 Performances of the Hydragel 5 von Willebrand Multimers - A New within-Day von Willebrand Factor (VWF) Multimer Screening MethodA.E. Bowyer1, K.J. Goodfellow1, G. Nouadje2, G. Beaulieu2, S. Kitchen1, M. Makris1 (1United Kingdom, 2France)

PB 413 The Selective Use of Computer-assisted Strain Gauge Plethysmography as

an Additional Screening Test for Suspected DVT Can Decrease the Need for Compression Ultrasonography: A Validation StudyA. Hughes, B. Hall, C. Smith, V. Webb, J. King, K. Jennings, G. Page, S. Macdonald, F. Charova (United Kingdom)

PB 414 Semi-automated Platelet Aggregometry Employing the Sysmex CS-2x00;

Preliminary Findings in a Multi-centre StudyA.N. McCormick, S. Platton, M. Bukht, D.A. Gurney, G.W. Moore (United Kingdom)

PB 415 The Impact of Repeated Freeze-thaw Cycles on Antiphospholipid Antibody Titer

K. Maelegheer, M. Luypaert, K. Devreese (Belgium) PB 416 Suitability of a Liquid High-sensitivity Recombinant Human Prothrombin Time

Reagent with Two Year Helf Life on an Automated Coagulation Laboratory PlatformK. Cawthern, C. Kung, R. Bottenus, V. Sarquella (United States)

PB 417 Discrepancy in Optical and Impedance Platelet Count in Platelet Rich Plasma Prepared for Light Transmission Aggregation as a Possible Sample Quality IndicatorA. Mlinaric, D. Coen Herak, M. Milos, D. Rogic (Croatia)

PB 418 Thrombophilia: Women-specific Reference Ranges May Prevent OverdiagnosisC.S.B. Veen, M.J.H.A. Kruip, M.F. Durian, J.G. van Asten, M. Ahmadi, S. Petronia, W. Visser, M.P.M. de Maat (The Netherlands)

PB 419 A New Chromogenic DTI Assay for the Quantitative Determination of Dabigatran

in Human PlasmaJ. Mueller, A. Hesse, I. Kieper-Rupp, D. Koch, J. Kurz, S. Vollmerhausen, D. Bussfeld (Germany)

PB 420 Comparison of Thrombin Generation Profiles among Patients Treated with Three

Different Direct Oral Anticoagulants and WarfarinO. Paoletti, C. Dellanoce, A. Zimmermann, R. Morandini, E. Cancellieri, S. Zambelli, M. Tala, C. Beati, M. Stramezzi, S. Testa (Italy)

PB 421 Multicenter Evaluation of D-Dimer on Two New Coagulation Systems

T. Wissel1, D. Christie2, V. Janssen1, K. Purr1, U.-P. Schobel1 (1Germany, 2United States)

PB 422 Innovative Method for the Description of Human Platelets PopulationA. Litvinenko, V. Nekrasov, A. Moskalensky, D. Strokotov, V. Maltsev (Russian Federation)

PB 423 Thromboelastometry to Detect Anticoagulant Effect of Apixaban in Patients

with Non Valvular Atrial FibrillationM.C. Vedovati, M.G. Mosconi, F. Isidori, G. Agnelli, C. Becattini (Italy)

PB 424 Assessment of Single-factor Deficiency Sensitivty of Three Thromboplastin

ReagentsV. Juif, P.O. Sevenet, M. Lubineau, N. Masset (France)

PB 425 Genetic Analysis for Investigation of Heritable Bleeding Disorders - Update on

the UK NEQAS (Blood Coagulation) ProgrammeI. Jennings, S. Kitchen, A. Goodeve, M. Hill, B. Theophilus, T. Cumming, I. Walker, D. Perry (United Kingdom)

PB 426 Platelet Reactivity in Patients on Aspirin and Clopidogrel Therapy Measured by

a New Bed-side Whole Blood AssayA. Polzin, C. Helten, S. Rehder, A. Mohring, L. Dannenberg, K. Görlinger, T. Zeus, M. Kelm, T. Hoffmann (Germany)

PB 427 Usefulness of Waveform Analysis of APTT on the ACL-TOP® When

Troubleshooting Unexpected Abnormal APTTN. Tokunaga, C. Inoue, T. Sakata, Y. Inoue, S. Akaiwa, H. Yoshida, T. Nakao, T. Doi (Japan)



274 275

Mon

day

Pos

ter

Ses

sion

s

PB 428 Evaluating the Analytical Performance of Six New Coagulation Assays S. Kitchen1, U. Geisen2, J. Kappelmayer3, P. Quehenberger4, R. Jones1, A. Lowe1, J. Boehm2, G. Miles5, G. Rozsnyai6 (1United Kingdom, 2Germany, 3Hungary, 4Austria, 5United States, 6Switzerland)

PB 429 Performance Evaluation of the microINR® Point-of-Care INR-testing System

J. Joubert, M.C. Van Zyl, J. Raubenheimer (South Africa) PB 430 Statistical Evaluation of APTT Clot Waveform Patterns (CWP) in Sequential

Samples of Severe Haemophilia A Patients Receiving Long Acting Clotting Factor Concentrates (CFC) - An Observational StudyR. Phatale, S. Apte, S. Kannan, A. Raiyyani, D. Vaghasiya, H. Balar, B.C. Mahadev, D. Patel, N. Chaturvedi (India)

PB 431 Divergence of Normal Ranges Using Thromboelastography as Measured by Clot

Viscosity versus Clot Harmonic ResonanceG. Wool, K. Mikrut, J. Miller (United States)

PB 432 Identification of Triple Positivity Patients with Major Risk for Thromboses Is Dependent of Methodology Applied at the Lab InvestigationS.A.L. Montalvao, M.C.G.L. Fernandes, S. Soares, A.A. Oliveira, S.C. Huber, E.V. De Paula, F.L.A. Orsi, M.P. Collela, J.M. Annichinno-Bizzachi (Brazil)

PB 433 Performance Evaluation of the ZL 6000i Cone Plate Viscometer

J. Lee, S. Yu, S. Song, S. Oh, J. Shin, H. Kim, K. Jun, J. Lee (Republic of Korea) PB 434 Standardization and Automation of Thrombin Generation Assay: on the Way to

the Clinical LabJ. Douxfils, J. Baudar, M. Guldenpfennig, B. Chatelain, J.-B. Nicolas, F. Mullier (Belgium)

PB 435 Accurate Recovery of N9-GP in a One-stage Ellagic Acid Based Clot Assay on

the ACL Top AnalyzerA. Khan, M. Doyle, M. Triscott (United States)

PB 436 A Performance Evaluation of a New Lupus Sensitive APTT Reagent

C. Gardiner1, E. Kinoshita2, K. Akatsuchi2, P. Lane1, I. Patel1, S.J. Machin1, I.J. Mackie1 (1United Kingdom, 2Japan)

PB 437 Standardization and Automation of Thrombin Generation (TG) Assay Measured in Presence and Absence of Thrombomodulin: TG on its Way to the Clinical LabC. Bulato, S. Gavasso, E. Campello, D. Tormene, L. Spiezia, P. Simioni (Italy)

PB 438 Establishment of Oral Anticoagulant Monitoring Facility at Tertiary Care

Teaching Hospital in Western India: Four Years ExperienceA. Kelkar, A. Nisal, P. Doshi, A. Moses, N. Gaikwad, R. Nimbargi, N.S. Mani (India)

PB 439 Do Chinese Patients with Heart Valve Replacement Benefit from Warfarin Pharmacogenetic Test: A Pilot Retrospective StudyY. Hao, Y. Hu, X. Yan, S. Cao, Z. Zhang, X. Zheng (China)

PB 440 Analytical Performance of an Anti Xa Assay with Rivaroxaban Specific CalibratorsC. Duboscq, J. Ceresetto, C. Shanley, O. Rabinovich, S. Palmer, G. Stemmelin (Argentina)

PB 441 Multicenter Study on the Interference of Spontaneous Hemolysis at Blood

Sampling on Five Main Hemostasis TestsC. Novelli, B. Morelli, M. Vidali, Study Group of Hemostasis and Thrombosis of Italian Society of Clinical Biochemistry and Molecular Biology (SIBioC) (Italy)

PB 442 Performance Evaluation of the Coag-Sense® Point-of-Care INR-testing System

J. Joubert, M.C. Van Zyl, J. Raubenheimer (South Africa)

PB 443 Thrombin Generation in Patients with Coronary Complications during the First Year after Percutaneous InterventionT. Vavilova, V. Udina, O. Napalkova, E. Vasilieva, M. Karpenko (Russian Federation)

PB 444 Prediction of Partial Thromboplastin Time (PTT) and Prothrombin Time (PT) on

the Basis of Factor Assay Activities Using Data from a Clinical Data WarehouseA. Obstfeld, M. Lambert (United States)

PB 445 Use of a Synthetic Collagen to Monitor Platelet Function in Patients Receiving

Dual Antiplatelet TherapyW. Jeske, V. Escalante, W. Klein, C. Kartje, J. Walenga, M. Bakhos (United States)

PB 446 Stability of TGA Parameters in Patients Treated with Anticoagulants Using the

Fully Automated ST-Genesia SystemJ. Douxfils, J.-B. Nicolas, A.-S. Larock, B. Devalet, Y. Vandermeeren, V. Gérard, M. Guldenpfennig, K. De Fays, J. Baudar, F. Mullier (Belgium)

PB 447 First European Evaluation of ClarityCor Plasma Set for Instrument to

Instrument Reproducibility AssessmentM.M.W. De Sloovere, K.M. Devreese (Belgium)

PB 448 Comparison of Activated Clotting Time Measured by I-STAT, Sonoclot and

ACTPlus and Correlation with Anti-Xa during Cardiopulmonary Bypass ProceduresS. Vandendriessche, F. De Somer, H. Laverge, K. Devreese (Belgium)



276 277

Mon

day

Pos

ter

Ses

sion

s

PB 449 Presence of Residual Venous Thrombus at Warfarin Withdrawal: A Predictor for Recurrence After a First Episode of Symptomatic Provoked Proximal Deep Venous Thrombosis in an Asian Population?N. Sermsathanasawadi (Thailand)

PB 450 Hemolyzed Samples: Should Be Accepted in Hemostasis Laboratories?

M.L. Iglesias Varela, M. Siracusa, C. Val, S. Gatti, D. Jacobsen, N. Salguero, L. Maggi (Argentina)

PB 451 Coag S: A Professional INR Monitoring Device. Comparison with the Laboratory

INR TestingE. Pap, L. Nagy, Z. Vajda (Hungary)

PB 452 Evaluation of the New Tcoag Pre-calibrated TriniLIATM D-Dimer II Assay

H. Lewis, K. Harrison, J. Needham (United Kingdom)


PB 453 Safety and Efficacy of Edoxaban Compared with Warfarin for the Treatment of Acute Symptomatic Deep-vein Thrombosis in the Outpatient SettingA. Medina1, G. Raskob1, W. Ageno2, A.T. Cohen3, M.P.A. Brekelmans4, C.Z. Chen1, M.A. Grosso1, M.F. Mercuri1, A. Segers4, P. Verhamme5, T. Vanassche5, P.S. Wells6, M. Lin1, S.M. Winters1, J.I. Weitz6, H.R. Büller4 (1United States, 2Italy, 3United Kingdom, 4Netherlands Antilles, 5Belgium, 6Canada)

PB 454 Reliability and Validity of a Point of Care Test from Urine Samples of Patients

on Therapy with Apixaban, Rivaroxaban and DabigatranJ. Harenberg, U. Warttinger, S. Hetjens, R. Schreiner, C. Giese, H.-J. Roth, R. Krämer, C. Weiss (Germany)

PB 456 XALIA-LEA, a Non-interventional Study Comparing Rivaroxaban with Standard

Anticoagulation for Initial and Long-term Therapy in Deep Vein ThrombosisA.G.G. Turpie1, L.G. Mantovani2, S. Haas3, R. Kreutz3, D. Monje3, J. Scheinder3, M. van Eickels3, M. Gebel3, M. Tamm3, W. Ageno2 (1Canada, 2Italy, 3Germany)

PB 457 Rivaroxaban for Initial Therapy in Patients with Pulmonary Embolism. A Real-

life StudyP. Di Micco1, J. Trujillo-Santos2, A. Merah3, A. Fidalgo2, J.R. Vela2, I. Mahe3, A. Bura-Riviere3, J. Bascunana2, B. Valero2, M. Monreal2, RIETE Investigators (1Italy, 2Spain, 3France)

PB 458 Impact of Age, Comorbidity and Polypharmacy on the Efficacy and Safety of Edoxaban for the Treatment of Venous Thromboembolism: An Analysis of the Randomized, Double-blind Hokusai-VTE StudyT. Vanassche1, P. Verhamme1, P.S. Wells2, A. Segers3, W. Ageno4, M.P.A. Brekelmans3, C.Z. Chen5, A.T. Cohen6, M.A. Grosso5, A.P. Medina5, M.F. Mercuri5, S.M. Winters5, G. Zhang5, J.I. Weitz2, G. Raskob5, H.R. Büller3 (1Belgium, 2Canada, 3The Netherlands, 4Italy, 5United States, 6United Kingdom)

PB 459 Prothrombin Complex Concentrate for Reversal of XA Inhibitors - Real Life DataG. Spectre, A. Steimatzky, A. Shacham, V. Yahalom, S. Nakav, Y. Belnick (Israel)

PB 460 Clinical Characteristics and Treatment of Patients with Cancer-associated

Venous Thromboembolism: Results from the GARFIELD-VTE RegistryJ.I. Weitz1, A.G.G. Turpie1, S. Haas2, W. Ageno3, P. Angchaisuksiri4, H. Bounameaux5, S.Z. Goldhaber6, S. Goto7, G. Kayani8, J. Dalsgaard Nielsen9, S. Schellong2, L.G. Mantovani3, P. Prandoni3, A.K. Kakkar8 (1Canada, 2Germany, 3Italy, 4Thailand, 5Switzerland, 6United States, 7Japan, 8United Kingdom, 9Denmark)

PB 461 Rivaroxaban for Scheduled Work-up of Patients with Suspected Deep Venous Thrombosis: A Prospective Interventional Outcome Study - The Ri-Schedule studyW. Ghanima, M. Qarboush, C. Tøvik Jørgensen, N. Raouf, J. Gleditich, A. Dahm, P.M. Sandset (Norway)

PB 462 Real-world Adherence with Direct Oral Anticoagulants in Adults with Atrial

FibrillationB.S. Manzoor, S.M. Walton, T.A. Lee, L.K. Sharp, W.L. Galanter, E.A. Nutescu (United States)

PB 463 Oxygen Saturation to Improve Risk Stratification in Hemodynamically Stable

Patients with Acute Pulmonary Embolism C. Becattini1, M.C. Vedovati1, P. Pruszczyk2, S. Vanni1, M. Cotugno3, V. Stefanone1, M.G. De Natale1, M. Kozlowska2, F. Mannucci1, L. Guirado Torrecillas3, G. Agnelli1 (1Italy, 2Poland, 3Spain)

PB 464 Direct Anticoagulants and Vitamin K-antagonists Exert Differential Effects on

Markers of Subclinical Cardiovascular Disease: Results from the MyoVasc StudyL. Eggebrecht1, A. Schulz1, S.-O. Tröbs1, M. Dib1, S. Schwuchow1, S. Göbel1, S. Dieselmeier1, N. Arnold1, T. Gori1, K.J. Lackner1, H. ten Cate2, T. Münzel1, P.S. Wild1, J.H. Prochaska1 (1Germany, 2The Netherlands)



278 279

Mon

day

Pos

ter

Ses

sion

s

PB 465 Lifelong Apixaban Treatment Is Cost-effective for Idiopathic Venous ThromboembolismL. de Jong, M. Huisman, M. Postma (Netherlands Antilles)

PB 466 Factors Associated with the Anticoagulant Regimen and Duration of

Hospitalization in Patients with Acute Pulmonary Embolism: FOCUS, a Prospective Multicenter Cohort StudyS. Barco, H. Binder, L. Bruch, R. Ewert, M. Faehling, F. Gerhardt, H.-A. Ghofrani, E. Grünig, M. Halank, M. Held, M.M. Hoeper, M. Lankeit, H.H. Leuchte, E. Mayer, F.J. Meyer, C. Neurohr, C. Opitz, S. Rosenkranz, H.-J. Seyfarth, R. Wachter, H. Wilkens, P.S. Wild, S.V. Konstantinides (Germany)

PB 467 Real-life Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Cancer Associated Venous Thromboembolism: Data from a Prospective CohortA. Mancuso, M.C. Vedovati, L. Pierpaoli, U. Paliani, S. Conti, E. Filippucci, A. Ascani, S. Radicchia, G. Galeotti, G. Agnelli, C. Becattini (Italy)

PB 468 The YEARS Algorithm for Suspected Pulmonary Embolism Leads to Much

Shorter Diagnostic Turnaround Time than Conventional AlgorithmsC.E.A. Dronkers, L.M. van der Pol, T. van der Hulle, C. Tromeur, C. Heringhaus, A.T.A. Mairuhu, M.V. Huisman, F.A. Klok (The Netherlands)

PB 469 The Assessment of Apixaban Reversal in a Porcine Trauma Mmodel by

Thrombelastography (TEG)M. Honickel, N. Akman, O. Grottke (Germany)

PB 471 Plasma Fibrin Clot Properties in the G20210A Prothrombin Mutation Carriers

Following Venous Thromboembolism: The Effect of RivaroxabanJ. Siudut, A. Janion-Sadowska, J. Natorska, M. Zabczyk, A. Stanisz, A. Undas (Poland)

PB 472 A Cross-Sectional, Multinational, Multidisciplinary Survey of Physicians

Surrounding the Management of Bleeding Complications in the Setting of Direct Oral Anticoagulant UseJ. Shaw, L. Castellucci, D. Siegal, I. Stiell, S. Syed, J. Lampron, P. Dorian, H. Dhaliwal, G. Stotts, P. Wells, M. Carrier (Canada)

PB 473 Apixaban in Mechanical Circulatory Support - Evaluation in a Mock Circulatory

Loop with Human BloodS. Rao, D. Connor, K. Nicholas, J. Joseph, P. Jansz, C. Hayward (Australia)

PB 474 Management of Major Bleeding and Outcomes in Patients Treated with DOACs: Results from the START SSC Event RegisterS. Testa1, W. Ageno1, E. Antonucci1, V. Pengo1, D. Poli1, J. Beyer-Westendorf2, M. Righini3, T.-F. Wang4, P. Verhamme5, P. Rojnuckarin6, B. Caramelli7, P. Angchaisuksiri6, M. Paciaroni1, E. Grifoni1, G. Guazzaloca1, P. Sivera1, D. Colaizzo1, A. Turrini1, S. Rupoli1, A. Tosetto1, P. Michela1, G. Palareti1, START SSC Event Register (1Italy, 2Germany, 3Switzerland, 4United States, 5Belgium, 6Thailand, 7Brazil)

PB 475 High Recanalization Rate in Patients with Proximal-vein Thrombosis Treated

with the New Direct Oral AnticoagulantsP. Prandoni, W. Ageno, N. Mumoli, N. Zanatta, D. Imberti, A. Visonà, M. Ciammaichella, L. Simioni, R. Cappelli, E. Bucherini, M. Di Nisio, G. Avruscio, R. Parisi, S. Cuppini, F. Noventa, L. Sarolo (Italy)

PB 476 Clot Waveform Analysis of Activated Partial Thromboplastin Time Measurement Curves Reveals How Direct Oral Anticoagulants Impact In Vitro CoagulationY. Fujimori, M. Wakui, H. Katagiri, Y. Kondo, S. Nakamura, N. Shimizu, M. Murata (Japan)

PB 477 Concentration Correlation of Direct Oral Anticoagulants as Measured by the

TEG® 6s Oral Anticoagulant AssayF. Zaman, B. Matthew, C. Lopez-Espina, M. Doubleday, A. Muresan (United States)

PB 478 Self-poisoning with Direct Oral Anticoagulants: A Series of Five Cases Admitted to the Intensive Care UnitA. Stepanian, A. Dragoni, I. Malissin, N. Deye, B. Joly, A. Hadj-Ali, J. Oliary, A. Veyradier, B. Mégarbane, V. Siguret (France)

PB 479 New Insights in Interindividual Variability of Pharmacodynamic (PD) Response

to Rivaroxaban through Thrombin Generation in the Presence of an Active Protein C Pathway: DRIVING Study Results in Healthy VolunteersV. Siguret1, X. Delavenne1, J. Abdoul1, E. Curis1, A. Carlo1, A. Blanchard1, J.-E. Salem1, P. Gaussem1, C. Funck-Brentano1, M. Azizi1, P. Mismetti1, M.-A. Loriot1, T. Lecompte2, I. Gouin-Thibault1 (1France, 2Switzerland)

PB 480 DTI/DXI Interferences with Global Coagulation Tests in Daily Care

Emergency Admissions - Results of the Prospective Dresden NOAC Registry (NCT01588119)L. Wunder, U. Hänsel, S. Hauswald-Dörschel, K. Daschkow, L. Tittl, J. Beyer-Westendorf (Germany)



280 281

Mon

day

Pos

ter

Ses

sion

s

PB 481 No Additional Diagnostic Value of Chest X-ray Prior to the YEARS Algorithm in the Diagnostic Management of Suspected Pulmonary EmbolismL.M. van der Pol, T. van der Hulle, C. Tromeur, L.J.M. Kroft, A. de Roos, L.M. Faber, A.T.A. Mairuhu, M.V. Huisman, F.A. Klok (The Netherlands)

PB 482 Rivaroxaban Levels in Patients Plasmas Are Comparable by Measuring through

Two Different Calibrators in Two Different SystemsM. Martinuzzo, R. Forastiero, C. Duboscq, M.S. Campana, M.S. López, L.H. Barrera, D. Penchasky, S. Viñuales, J. Ceresetto, J. Oyhamburu (Argentina)

PB 483 Multicenter Observational Study to Evaluate TEG®6s Oral Anticoagulant (OAC)

Assay in Apixaban-treated PatientsK. Bliden, F. Zaman, H. Taheri, L. Ilkhanoff, C. Sandesara, M. Blessy, U. Tantry, P. Gurbel (United States)

PB 484 Management Strategies and Long-term Outcomes in Patients with Upper

Extremity Deep Vein Thrombosis: Findings from the XALIA StudyW. Ageno1, L.G. Mantovani1, S. Haas2, R. Kreutz2, D. Monje2, J. Schneider2, M. van Eickels2, M. Gebel2, A.G.G. Turpie3 (1Italy, 2Germany, 3Canada)

PB 485 Measurement of Apixaban and Rivaroxaban Levels in Real Life Clinical

Practice: An Instrument to Improve Anticoagulation Management?C. Kartsios, M. Kaparou, R. Payne, L. Philpotts, K. Beale, M. Fowler, A. Lokare, N. Smith (United Kingdom)

PB 486 Comparison of Bleeding and Thromboembolic Event Rates in Atrial Fibrillation

Patients with Good and Poor Warfarin Control before and after Switching to Direct Oral AnticoagulantsB. Haymart, X. Kong, X. Gu, S. Almany, J. Kozlowski, G. Krol, M. McNamara, M. Dahu, E. Kline-Rogers, J. Froehlich, G. Barnes, S. Kaatz (United States)

PB 487 Measurement of Direct Oral Anticoagulant Drug Levels Following Bariatric

SurgeryE. Tseng, L. Sardo, J. Bayadinova, M. Crowther, D. Siegal (Canada)

PB 488 Use of a 4-factor Prothrombin Complex Concentrate for Management of Direct

Xa Inhibitor-induced Major BleedingP. Dobesh, B. Trevarrow, P. Malinowski, K. Guiliano, C. Duncan, K. Gundabolu (United States)

PB 489 Is Rivaroxaban Associated with Headache and Dizziness? A Retrospective Study

S. Piran, S. Schulman (Canada)

PB 490 Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment Naïve Atrial Fibrillation Patients: 2013-2014J. Brown, J. Talbert (United States)

PB 491 Determination of Rivaroxaban, Apixaban, Edoxaban and Dabigatran by Ultra-performance Liquid Chromatography-tandem Mass-Spectrometry and Chromogenic Assays from Urine Samples of PatientsR. Schreiner, S. Hetjens, C. Giese, H.-J. Roth, C. Weiss, R. Krämer, J. Harenberg (Germany)

PB 492 Length of Hospital Stays Following Acute Pulmonary Embolism in England:

Observational Cohort Study Using the CPRD-HES DatabasesR. Alikhan, M. Lumley, S. Lister, N. Hill, C. Lefevre (United Kingdom)

PB 493 Early Uptake of Edoxaban: A Danish Nationwide Cohort Study

M. Hellfritzsch, E. Grove, A. Pottegård (Denmark) PB 494 Fibrin Monomer Complex and Dilute Prothrombin Time as a Marker for

Thrombotic Tendency in Anti-Xa DOAC TherapyT. Suzuki, M. Ieko, S. Naito, M. Yoshida, Y. Komiyama, D. Hatanaka, O. Kumano, T. Suetake, N. Takahashi, I. Sakuma (Japan)

PB 495 Adherence to Rivaroxaban for the Management of Acute Venous

Thromboembolism (VTE) - Early Results from the ‚Follow-up in Rivaroxaban Patients in Setting of Thromboembolism‘ (FIRST) RegistryV. Speed, V. Auyeung, J. Patel, L. Roberts, J. Czuprynska, J. Samuel, R. Patel, R. Arya (United Kingdom)

PB 496 Level of Fatigue after Initiation of Rivaroxaban for Treatment of Venous

ThromboembolismT.M. Karlsvik, K.K. Utne, T.L. Borgenvik, E. Førsund, C. Jørgensen, W. Ghanima (Norway)

PB 497 The Combination of Rivaroxaban and Dabigatran Is Superior to Either Agent

Alone in Suppressing Mechanical Heart Valve-induced Thrombin GenerationI. Jaffer, A. Stafford, J. Fredenburgh, R. Whitlock, J. Weitz (Canada)

PB 498 Oral Rivaroxaban for the Treatment of Antiphospholipid Syndrome (APS)

Y. Du, X.-X. Yan, K. Sun, T.-Y. Lian, Z.-C. Jing (China) PB 499 Improving Appropriate Use of NOACs: Success of Online CME

J. Spyropoulos, J. Marko, A. Spyropoulos (United States)



282 283

Mon

day

Pos

ter

Ses

sion

s

PB 500 Influence of Anthropometric, Hematological and Biochemical Parameters on Plasma Levels of Direct Oral AnticoagulantsS. Lancellotti, M. Sacco, E. De Candia, R. De Cristofaro (Italy)

PB 501 Non Vitamin-k Oral Anticoagulants (NOAC) Dose Reduction and Adverse

Outcomes - A Single Center ExperienceA. Lubetsky, M. Misgav, S. Lalezari, J. Luboshitz, O. Salomon, G. Kenet (Israel)

PB 502 Reversal of Rivaroxaban Using Prothromplex Total, a 4-Factor Prothrombin ComplexH. Kaur, S.H. Yeang, E. See, D. Grant, C.W. Tan, W.H. Wong, D. Tan, H.J. Ng, L.H. Lee (Singapore)

PB 503 Similar Rivaroxaban Plasma Concentrations Induce Different Anticoagulant

Effects in Individual Obese PatientsD. Bertaggia Calderara, D. Kröll, C. Gerschheimer, N. Nicolas, G. Stirnimann, L. Alberio (Switzerland)

PB 504 Reversal of Dabigatran in Emergency Situations

A. Fernandez, T. Arias, J. Zanabili (SpainPB 505 Can we Successfully Reverse a “Massive Overdose” of Dabigatran?

I. Freire, T. Gago, A.P. Azevedo (Portugal) PB 506 Routine Coagulation Tests for Assess Anticoagulant Activity of Direct Oral

AnticoagulantsH. Cruz Gomes, L. Gonçalves, C. Monteiro, V. Cunha, M. Carvalho, C. Koch (Portugal)

PB 507 Direct Oral Anticoagulants in the Treatment of Deep Vein Thrombosis: The Experience of a Hemostasis UnitE. Papadakis, N. Petridis, A. Banti, V. Papadopoulos, S. Efremidou, A. Kioumi (Greece)

PB 508 Reversal of Dabigatran with Idarucizumab in Five Patients Admitted to the

Emergency Department of Centro Hospitalar São João, PortoL. Gonçalves, M. Carvalho, F. Correia, G. Oliveira, C. Koch (Portugal)

PB 509 Do All Patients Respond to Treatment with Direct Oral Anticoagulants?

J. Janukonyte, D. Svenstrup Moeller, G. Dahlmann Oddershede, J. Refsgaard (Denmark)

PB 510 Measurement of Direct Factor Inhibitors Concentration in Practice Laboratory

T. Vavilova, A. Bekoeva, P. Zubkova, Y. Skorobogatova, I. Yurinok, E. Vasilieva (Russian Federation)

Pediatrics

PB 511 Safety, Efficacy and PK/PD of Rivaroxaban Tablets in Children with VTE. An Einstein Junior Phase II EvaluationP. Monagle1, D. Kubitza2, R. Kumar3, S. Holzhauer2, G. Grangl4, J. Robertson1, G. Young3, A.C. Molinari5, U. Nowak-Goettl2, S. Willmann2, K. Thelen2, M. Becka2, J.F. Heubach2, A.W.A. Lensing2 (1Australia, 2Germany, 3United States, 4Austria, 5Italy)

PB 512 Safety, Efficacy and PK/PD of a Rivaroxaban Suspension in Children with VTE.

An Einstein Junior Phase II EvaluationA. Chan1, D. Kubitza2, A. Santamaría3, E. Samochatova4, I. Martinelli5, P. Connor6, G. Young7, C. Male8, G. Kenet9, P. Massicotte1, S. Willmann2, S. Kraff2, M. Becka2, J.F. Heubach2, A.W.A. Lensing2 (1Canada, 2Germany, 3Spain, 4Russian Federation, 5Italy, 6United Kingdom, 7United States, 8Austria, 9Israel)

PB 514 Long-term Outcome in Children on Anticoagulant Therapy after Extracardiac

Conduit Fontan Operation (FO)M. Agazzoni, S.S. Meschengieser, W. Conejeros-Parodi, M.L. Romero, M. Barrenechea, A.J. Schlichter, G.O. Kreutzer, R. Pellicciari, H. Vazquez, M.I. Grippo, A. Sánchez-Luceros (Argentina)

PB 516 e-Health Usefulness in Oral Anticoagulation Therapy in Children: Point of Care

Instruments and Mobile APPsR. Berrueco, C. Benedicto, S. Gassiot, A. Ruiz-Llobet, A. Català, M. Torrebadell, M. Camós, S. Rives (Spain)

PB 517 Feasibility and Safety of Full Dose Anticoagulation Therapy in the Context of

Thrombocytopenia in Children with Symptomatic Thromboembolism during Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma TreatmentM. Bhatt, N. Parmar, J. Fowler, A. Chan, U. Athale (Canada)

PB 518 Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical TrialsH. Maas1, S. Gropper1, F. Huang2, J. Stangier1, I. Tartakovsky1, M. Brueckmann1, J. Halton3, L. Mitchell3 (1Germany, 2United States, 3Canada)

PB 519 Factor Levels in Heparinized Critically Ill Pediatric Patients

J. Byrnes, J. Palumbo (United States) PB 520 Dosing and Therapeutic Drug Monitoring of Tinzaparin in the Pediatric

Intensive Care Unit (PICU)P.P. Roeleveld, D. Hartwich, R. de Wilde, F. Smiers, J. Eikenboom, H. Bunker-Wiersma (The Netherlands)



284 285

Mon

day

Pos

ter

Ses

sion

s

PB 521 Safety and PK/PD of a Single Rivaroxaban Administration in Children. An Einstein Junior Phase I EvaluationC. Male1, K. Thelen2, L.R. Brandao3, G. Young4, A. Santamaría5, I. Martinelli6, P. Saracco6, A. Chan3, J. Halton3, P. Monagle7, S. Willmann2, M. Becka2, J.F. Heubach2, A.W.A. Lensing2, D. Kubitza2 (1Austria, 2Germany, 3Canada, 4United States, 5Spain, 6Italy, 7Australia)

PB 522 Neonatal Portal Vein Thrombosis: Characteristics and Role of Anticoagulation

E. Zapotocka1, V. Labarque2, L.R. Brandao1, S. Williams1 (1Canada, 2Belgium) PB 523 The Incidence, Assessment and Management of Mental Health Issues in

Young People on Anticoagulation Therapy Secondary to Idiopathic Venous ThromboembolismL. Seneviratna, J. Hislop, S. Jones, F. Newell (Australia)

PB 524 Investigating the Experience of Parents who Have Given their Children

Enoxaparin at HomeS. Monagle, H. Gilmore, S. Lima, F. Newall (Australia)

PB 525 A Pilot Feasibility and Safety Multicenter Trial of Administering Weight

Adjusted FIXed Dose of Low Molecular Weight Heparin (Enoxaparin) to Neonates with Thrombosis (FIXET): Study ProtocolM. Bhatt1, K. Hamilton1, S. Shivananda1, K. Kulkarni1, L. Raffini2, A. Chan1 (1Canada, 2United States)

PB 526 Secondary Antithrombotic Prophylaxis in Children with Right Atrium

ThrombosisP. Zharkov, N. Ershov, A. Pshonkin, D. Fedorova (Russian Federation)

PB 527 Thrombotic Storm in an 11 Year Old Boy

S. Singh, A. Jindal, J. Ahluwalia (India)

PB 528 Variation in Practice in Relation to Antithrombotic Therapy and Monitoring After Paediatric Cardiac Surgery: Results of a United Kingdom SurveyT. Biss, J. Alamelu, D. Arachchillage, E. Chalmers, M. Mathias, M. Richards, M. Williams, O. Tunstall (United Kingdom)

PB 529 Successful Endovascular Thrombectomy of an Extensive Cerebral Venous

Thrombosis with Bilateral Thalamic Infarction in A 16 Year Old Girl: Case Report and Therapeutic AlgorithmS. Holzhauer, B. Weschke, M. Nikolaus, T. Liebig, A. Gratopp (Germany)

PB 530 Management of Henoch-Shönlein Purpura in Children with Heparin. Russian

Long-term ExperienceN. Sokolova, N. Vaynyunskaya (Russian Federation)

PB 531 Inherited Antithrombin Deficiency in Children: Treatment of Massive Cerebral Sinus Venous Thrombosis in a Neonate with a Mutation in Gene SERPINC1 (Exon 3 C481c>t)S. Izquierdo Sebastiá, B. Argilés Aparicio, C. García Blanes, J. Corral de la Calle, M.Á. Dasí Carpio (Spain)

PB 532 Venous Thromboembolism Prevention in Children

A.M. Pizzini, V. Montemaggiori, D. Galimberti, M.C. Leone, A. Ghirarduzzi (Italy)

PB 533 Development of a Thrombus in Giant Coronary Aneurysm of a Child with

Kawasaki Disease - An Unusual Clinical ManifestationS. Singh, A. Jindal, M. Singhal (India)

PB 534 Management of Anticoagulation Therapy in Patients with Thromboembolism in

The Context of Renal Diseases: Case Series and Practical SuggestionsA. Bahabri, V. Belostotsky, A. Chan, M. Bhatt (Canada)

PB 535 Successful Use of Low Molecular Weight Heparin (LMWH) in Intracardiac

Thrombus of a Premature Infant: Case ReportA.M. Vélez Escobar, A. Jaramillo Yepez, C. Jimenez Alvarez, L.N. Builes Restrepo (Colombia)

PB 536 Petechial Rash and Thrombocytopenia with Unfractionated Heparin (UFH)

Use: Heparin Induced Thrombocytopenia (HIT) in a Child with Non-vegetative Infective EndocarditisM.-P. Schlosser, J. Chan, J. Halton, L. Abbott (Canada)

PB 537 Resolution of Cerebral Sino-venous Thrombosis (CSVT) without Anticoagulation in

a Neonate with Co-existing Protein C and Anti-thrombin Deficiency: A Case ReportV. Khatri, A. Chan, N. Stein, M. Bhatt (Canada)

Platelets - Basic

PB 538 Selected Expression and Functional Importance of alpha4a-Tubulin in Platelet BiogenesisC. Strassel1, A. Hovasse1, S. Moog1, M. Mageira1, M. Batzenschlager1, C. Schaeffer-Reiss1, B. Kile2, C. Gachet1, C. Janke1, F. Lanza1 (1France, 2Australia)

PB 539 Redundant and Non-redundant Roles of RhoA and Cdc42 in Platelet

Biogenesis and FunctionD. Cherpokova1, M. Popp1, S. Dütting1, P. Nurden2, I. Pleines1, M. Morowski1, A. Baig1, K. Aurbach1, G. Krohne1, C. Brakebusch3, B. Nieswandt1 (1Germany, 2France, 3Denmark)



286 287

Mon

day

Pos

ter

Ses

sion

s

PB 540 PDK1 is Crucial to Proplatelets Formation and ThrombopoiesisB. Walker-Allgaier, P. Münzer, S. Geue, D. Eißler, F. Lang, H. Schulze, M. Gawaz, O. Borst (Germany)

PB 541 Inhibition of MAP Kinase-interacting Kinase-1 (Mnk1) Regulates Platelet

Functional Responses and Protein Synthesis in MegakaryocytesB. Manne, R. Campbell, R. Badolia, S.P. Kunapuli, A. Weyrich, M. Rondina (United States)

PB 542 On-track to Producing Commercially-Feasible cGMP-Compliant Human

Platelets from induced Pluripotent Stem Cells at Clinical ScaleJ. Thon, B. Dykstra, L. Beaulieu, C. Peters, J. Italiano (United States)

PB 543 Disruption of the Cholesterol Efflux Transporters ABCA1 and ABCG1 Alters Megakaryocyte Proplatelet ProductionA.B. Ouweneel1, M. van der Stoep1, H.F. Heijnen1, C. Strassel2, M. Van Eck1, S.J.A. Korporaal1 (1The Netherlands, 2France)

PB 544 Environmental Chronic Stress Induces Abnormal Megakaryopoiesis

Predisposing to Thrombosis: Protective Effects of ApocyninL. Sandrini, A. Ieraci, P. Amadio, M. Popoli, E. Tremoli, S.S. Barbieri (Italy)

PB 546 CCalcium/calmodulin-dependent Protein Kinase II (CamKII) Regulates Platelet

FormationR. Campbell, D. Shi, J. Winters, S. Bhatlekar, B. Manne, A. Jiang, S. Saperstein, M. Rondina, P. Bray, A. Weyrich (United States)

PB 547 Presence and Absence of Platelet Proteins in Differentiating Megakaryocytes

J.M. Koornneef, F.P.J. van Alphen, C. van der Zwaan, M. Hansen, E. van den Akker, K. Mertens, M. van den Biggelaar, A.B. Meijer (The Netherlands)

PB 548 Platelet Factor 4 (PF4) Levels Correlate with Platelet Count and Ability to

Inhibit Megakaryopoiesis in Pediatric Patients with ITPE. Tkaczynski, A. Arulselvan, M. Lambert (United States)

PB 549 Role of NOD-like receptors (NLRs) in Megakaryo/thrombopoiesis

L.P. D‘Atri, M. Centurión, S. Negrotto, M. Schattner (Argentina) PB 550 In vitro Generation of Functional Megakaryocytes Derived from Induced

Pluripotent Stem Cells of Parahaemophilia PatientsC. Radu, M. Trevisan, C. Bulato, E. Campello, F. Sartorello, L. Spiezia, L. Barzon, P. Simioni (Italy)

PB 553 The Application of High throughput Sequencing to the Diagnosis of

ThrombocytopeniaR. Wheeler, J. Cutler, M. Mitchell (United Kingdom)

PB 554 PEAR1 Methylation Is a Determinant of Platelet and Plasma P-selectin Levels, Platelet-leukocyte Aggregates and Platelet Distribution WidthB. Izzi1, F. Gianfagna2, K. Cludts1, A. De Curtis2, P. Verhamme1, A. Di Castelnuovo2, C. Cerletti2, G. de Gaetano2, M. Hoylaerts1, L. Iacoviello2, Moli-family investigators (1Belgium, 2Italy)

PB 555 Single Cell Transcriptome Analysis in Living Human Platelets

C. Zara, R. D‘Alessandro, M. Brambilla, E. Tremoli, M. Camera (Italy)

PB 556 Uncovering GEnetic NEtworks Underlying Platelet Response to Thienopyridines by EXome Sequencing of Extreme Phenotype Patients: Discovery and Validation ResultsJ.-L. Reny1, M. Ibberson1, B. Stevenson1, Y. Daali1, M. Docquier1, I. Xenarios1, T. Cuisset2, M.-C. Alessi2, P. Fontana1 (1Switzerland, 2France)

PB 557 Poorly Controlled Diabetes Mellitus Is Associated with Decreased Aspirin-

mediated Acetylation of Platelet Cyclooxygenase-1 (COX-1) at Serine 529F. Finamore, J.-L. Reny, S. Malacarne, P. Fontana, J.-C. Sanchez (Switzerland)

PB 559 A Combination of Biochemical and Functional Approaches Shows a

Hyperactivation of Src Family Kinases-mediated Signaling Pathways in Platelets from Obese PatientsM.N. Barrachina, A.M. Sueiro, F.F. Casanueva, M. Pardo, Á. García (Spain)

PB 560 First Quantitative Proteomic Approaches of Platelet Protein Expressions and

Networks in Human MYH9-Related DisordersN. Schlegel, M. Le Gall, A. Vincenot, O. René, V. Salnot, M. Leduc, C. Broussard, M.-F. Hurtaud-Roux, S. Binard, S. Crosnier, M. Canton, P. Ohlmann (France)

PB 562 Platelets in Severe Aortic Stenosis Have an Altered Protein Profile and Are

More Vulnerable upon Activation Compared to Coronary Artery DiseaseC. Christersson, A. Dimberg, U. Alström, E. Ståhle (Sweden)

PB 563 Characterization of Large and Small Platelets

S. Handtke, J. Conrad, L. Steil, R. Palankar, M. Ferrara, S. Cauhan, U. Völker, A. Greinacher, T. Thiele (Germany)

PB 564 TREM-like Transcript-1: A More Sensitive Marker of Platelet Activation than

P-selectin Detectable in the Core and Shell of ThrombiC.W. Smith, Z. Raslan, P. Patel, Y.A. Senis, A. Mazharian (United Kingdom)

PB 565 WASH-complex Subunit Strumpellin Selectively Regulates Integrin αIIbβ3

ExpressionY. Schurr1, L. Reil1, B. Nieswandt1, L. Machesky2, M. Bender1 (1Germany, 2United Kingdom)



288 289

Mon

day

Pos

ter

Ses

sion

s

PB 566 Mechanisms of Platelet Adhesive-receptor Shedding in Platelet Populations in Thrombus FormationC.C.F.M.J. Baaten1, F. Swieringa1, T. Misztal1, T.G. Mastenbroek1, M.A.H. Feijge1, P.E. Bock2, M.M.P.C. Donners1, P.W. Collins3, P.E.J. van der Meijden1, J.W.M. Heemskerk1 (1The Netherlands, 2United States, 3United Kingdom)

PB 567 The GYPSIE (GlYcoProtein Six in Stroke) Study: GPVI-dimer Level is Increased

in Ischaemic Stroke Patients, But Total GPVI Is NotH. McKinney1, P. Thomas1, I. Induruwa1, J. Batista1, C. Kempster1, A. Bonna1, K. Soejima2, W.H. Ouwehand1, E.A. Warburton1, K. Downes1, R.W. Farndale1, M. Moroi1, S.M. Jung1 (1United Kingdom, 2Japan)

PB 568 Gradient-dependent Modulation of Platelet Stimulatory G-protein Coupled

Receptors (GPCR) SignalingA. Macwan, N. Boknäs, S. Ramström, S. Berg, L. Faxälv, T. Lindahl (Sweden)

PB 569 Activation of αIIbβ3 Integrin Involves the Cys608-Cys655 Disulfide Bond and

the Electrostatic Network of the β-tail DomainR. Mor-Cohen, L. Levin, E. Nachliel, M. Gutman, Y. Tsfadia, Y. Einav (Israel)

PB 570 Clathrin Mediated αIIbβ3 Endocytosis Plays an Important Role in Platelet

ActivationX. Fan, W. Gao, P. Shi, X. Chen, L. Zhang, K. Wang, X. Luo, J. Liu (China)

PB 571 An Inhibitory Mutant of Snake Venom Rhodocytin Blocks CLEC-2/Podoplanin

Interaction-dependent Platelet Aggregation and Experimental Lung MetastasisT. Sasaki, T. Shirai, N. Tsukiji, S. Otake, S. Tamura, M. Osada, K. Satoh, Y. Ozaki, K. Suzuki-Inoue (Japan)

PB 572 Human and Murine Neonatal Platelets Display Reduced CLEC-2 and GPVI Expression and Function Profiles Compared with Adult PlateletsV. Palma-Barqueros1, A.T. Hardy2, R. Teruel-Montoya1, J.E. Blanco1, E. Caparros-Pérez1, R. Guijarro-Campillo1, V. Vicente1, M.L. Lozano1, S.K. Watson2, Y. Senis2, S.P. Watson2, F. Ferrer-Marin1, J. Rivera1 (1Spain, 2United Kingdom)

PB 573 DCBLD2 but Not GARP Has A Minor Role in Thrombus Formation in Mice

which is Not in Line with the Findings in ZebrafishE. Vermeersch1, B. Nuyttens1, K. Broos1, W. Maes1, S.F. De Meyer1, K. Vanhoorelbeke1, D. Unutmaz2, H. Fujii3, C. Tersteeg1, H. Deckmyn1 (1Belgium, 2United States, 3Japan)

PB 574 The Association of PAR4 Polymorphism with Human Platelet Reactivity in

JapaneseY. Morikawa, H. Kato, N. Nishiura, K. Akuta, H. Kashiwagi, S. Honda, Y. Kanakura, Y. Tomiyama (Japan)

PB 575 Engineering scFvs (Single Chain Variable Fragments) to Platelet Glycoprotein VIS. Hamaia, M. Moroi, R.W. Farndale, S.M. Jung (United Kingdom)

PB 576 Activation of Human Blood Platelets through CLEC2 is Slackened due to the

Diffusion of Receptors into the Signalosome Region, but Still Can Induce Cytosolic Calcium Spiking in Single PlateletsA. Martyanov, M.A. Panteleev, A.N. Sveshnikova (Russian Federation)

PB 577 Decompensated Heart Failure Patients Demonstrate Shedding of Platelet

Receptors Glycoprotein (GP) Ibα and GPVI in Contrast to Stable Heart Failure PatientsJ.M.L. Casan, J.F. Arthur, R.K. Andrews, E.E. Gardiner, J. Shaw, A.K. Davis (Australia)

PB 578 Switching Integrin Alpha IIb-beta3 Conformations under Physiological and

Stress ConditionsU. Janke, M. Delcea (Germany)

PB 579 C-Type Lectin-like Receptor 2 Promotes Hematogenous Tumor Metastasis and

Prothrombotic State in Tumor-bearing MiceT. Shirai, O. Inoue, S. Tamura, N. Tsukiji, T. Sasaki, H. Endo, K. Satoh, M. Osada, H. Sato-Uchida, H. Fujii, Y. Ozaki, K. Suzuki-Inoue (Japan)

PB 580 αIIb or Not IIb: Novel Insights into the Regulation of αIIb Expression and

Localization in Activated PlateletsA. Mitrugno, A.T.P. Ngo, J. Pang, M.L.D. Thierheimer, O.J.T. McCarty (United States)


Coagulation Signaling & Immunity

PB 581 Complement Factor H, Extracellular Nucleosomes, ADAMTS13 and the Regulation of von Willebrand Factor Size in Young Patients with Ischemic Stroke and Myocardial InfarctionB.M. Luken, T. Hoppenbrouwers, M.A. Sonneveld, G.J. van Mierlo, S. Zeerleder, F.W.G. Leebeek, D. Wouters, M.P. de Maat (The Netherlands)

PB 582 The Effect of Short Chained Polyphosphates on Complement Activation in

Plasma and Human Whole BloodI. Høiland1, R.A. Liang1, N. Latysheva1, S. Beck Jensen1, S.A. Smith2, J.H. Morrissey2, B. Østerud1, O.-L. Brekke1, T.E. Mollnes1, J.-B. Hansen1, K. G. Jebsen – Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø (1Norway, 2United States)



290 291

Mon

day

Pos

ter

Ses

sion

s

PB 583 Extracellular Histones Can Inhibit Complement Activation through C4 BindingJ. Qaddoori, S. Abrams, D. Su, T. Liu, Y. Alhamdi, G. Wang, C.-H. Toh (United Kingdom)

PB 584 Complement Activation in Patients with Venous Thromboembolism

M. Efthymiou, I. Mackie, A. Chitolie, P. Lane, T. Gkouleli, H. Cohen (United Kingdom)

PB 585 C5B9 Deposits on Endothelial Cells for the Evaluation of Complement Function

in Thrombotic Microangiopathies of Different Origin and Therapy MonitorizationM. Palomo, M. Blasco, P. Molina, G. Escolar, J. Campistol, M. Diaz-Ricart (Spain)

PB 586 The Complement Lectin Pathway in Post Cardiac Arrest Patients: A

Randomized Clinical StudyS. Haugaard, A.N. Jeppesen, A. Troldborg, H. Kirkegaard, S. Thiel, A.-M. Hvas (Denmark)

PB 587 The Effect of Platelets and Extracellular Vesicles on Complement Activation in

Human PlasmaR.A. Liang, I.I. Høiland, N. Latysheva, B. Østerud, T.E. Mollnes, J.-B. Hansen (Norway)

PB 588 Fibrinogen and Clot Structure is Affected by Eculizumab in Patients with

Paroxysmal Nocturnal HaemoglobinuriaF. Macrae, P. Bowman, E. Linton, B. Peacock-Young, D. Newton, R. Ariëns, A. Hill (United Kingdom)

PB 589 Hemocompatibility Analysis of Silk Nanoparticles Leads to Different Results under Static and Flow ConditionsM.F. Maitz, F.P. Seib, M. Herklotz, C. Sperling, C. Werner (Germany)

PB 590 Character of Haemostatic System in Preterm Labor in Women with

ThrombophyliaB. Kurbanov (Uzbekistan)

PB 591 Role of Protease-activated Receptor-1 in Poly I:C Induction of Tissue Factor

Expression in Endothelial Cells and in the Activation of Coagulation in MiceS. Subramaniam, S. Antoniak, C. Fletcher, N. Mackman (United States)

PB 592 Role of Helicobacter Pylori Eradication Therapy in Platelet Recovery in Chronic

Immune Thrombocytopenic PurpuraI. Ujjan, S. Khan, A. Memon, A. Naz, F. Naz, I. Sheikh (Pakistan)

PB 593 Intravascular Parasitic Worms and HemostasisA. Da‘darah1, R. Bhardwaj1, B. Figueiredo2, S. Oliveira2, A. de Laforcade1, P. Skelly1 (1United States, 2Brazil)

PB 594 Comparative Functional Studies of Thrombin and Staphylocoagulase in Terms

of Clotting Kinetics and Properties of the Resultant FibrinC. Thelwell1, Á.Z. Farkas2, V.J. Farkas2, K. Kolev2 (1United Kingdom, 2Hungary)

PB 595 Liver Fibrosis and Thrombophilia: Is There a Real Connection? Preliminary

Results among HIV/HCV Co-infectionS. Perés, F. Aranda, M. Moiana, C. Julian, A. Lucero, K. Bendezu, G. de Larrañaga (Argentina)

PB 596 Anticoagulants Increase Alveolar Hemorrhage after Influenza A Infection in

MiceK. Tatsumi1, S. Antoniak1, S. Subramaniam1, B. Gondouin1, S. Neidich1, M. Beck1, J. Mickelson1, D. Monroe1, J. Bastarache1, H. Kaji2, N. Mackman1 (1United States, 2Japan)

PB 597 Comparison of Fibrin Generation Markers in Septic Shock

G. Lissalde-Lavigne, E. Cochery-Nouvellon, S. Bouvier, E. Mercier, J.-C. Gris, Sepsi-Coag Group (France)

PB 598 Thoracic Manifestations in Behcet‘s Disease

L. Belhadj, A. Hariz, I. Boukhris, I. Kechaou, S. Azzabi, L. Ben Hassine, E. Cherif, N. Khalfallah (Tunisia)

PB 599 Macrophages Release Tissue Factor-bearing Microparticles upon Stimulation

with Histophilus somniJ.J. Rivera Rivas, C. Czuprynski (United States)


PB 600 A Systems Biology Approach to Elucidate the Post-translational Regulome of Coronary Artery DiseaseA. Sharma, V. Deshpande, M. Ghatge, R.K. Vangala (India)

PB 601 A Translational Approach for Identifying Shared Molecular Function and

Pathways between CAD and its Risk FactorsA. Sharma, V. Deshpande, M. Ghatge, R.K. Vangala (India)

PB 602 Electronic Alerts, Comparative Practitioner Metrics, and Education Effect on

Thromboprophylaxis and Thrombosis in Community HospitalsS. Woller, S. Stevens, R.S. Evans, D. Wray, J. Christensen, V. Aston, M. Wayne, J. Lloyd, E. Wilson, C.G. Elliott (United States)



292 293

Mon

day

Pos

ter

Ses

sion

s

PB 603 Efficiency of Bayesian Logic in Reagent Batch Change Management: Application to aPTTF. Sobas1, K. Bourazas2, E. Jousselme1, C. Nougier1, C. Négrier1, P. Tsiamyrtzis2 (1France, 2Greece)

PB 604 aPTT as an Independent Risk Factor for 30-day Survival for Patients on

Extracorporeal Membrane Oxygenation (ECMO): 8-year Experience at Albert Einstein College of Medicine, Montefiore Medical CenterI. Francischetti, J. Szymanski, D. Rodriguez, M. Heo, L. Wolgast (United States)

PB 605 Sensitivity of Spatial Thrombin Generation and Fibrin Clot Growth to Clotting

Factors DeficiencyA. Kuprash1, A. Balandina1, R. Vijay2, S. Nair2, F. Ataullakhanov1, A. Srivastava2, M. Panteleev1 (1Russian Federation, 2India)

PB 606 In-cardiome: A Knowledgebase Integrating Molecular and Clinical Worlds for

Translational Research and Drug Development in Coronary Artery DiseaseA. Sharma, V. Deshpande, M. Ghatge, R.K. Vangala (India)

PB 607 Addressing Reproducibility Concerns for Mechanistic Models of Clot Formation

M. Anand, M. Susree (India) PB 608 Epigenetic Regulation of PAR-4-mediated Platelet Activation Underlies

Smoking-related Cardiovascular DiseaseC.M. Williams1, L.J. Corbin1, S.J. White1, M. Van Den Bosch1, A. Taylor1, M.T. Harper1, M.L. Jones1, M. Bond1, G. Davey Smith1, C.L. Relton1, L. Falk1, A. Groom1, B.G. Nordestgaard2, A. Tybjaerg-Hansen1, S. Egil Bojesen1, A.D. Mumford1, A.W. Poole1, N.J. Timpson1 (1United Kingdom, 2Denmark)

PB 609 Polymorphic Variation in Glutathione-S-transferase Genes among Chronic Myeloid Leukemia Patients in PakistanA. Shahni, S.N. Mukry, T. Farzana, M. Nadeem, T.S. Shamsi (Pakistan)

PB 610 Gene Expression Profile of Schistosoma Mansoni Adult Worms after Treatment

with an Anti-schistosomicidal Drug that Inhibits Lysine Demethylase LSD1H. Asif, D.D.S. Pires, E.J.R. Vasconcelos, M.S. Amaral, V. Coutinho, J.C. Setubal, M. Fantappié, S. Verjovski-Almeida (Brazil)

PB 611 Nanoscale Measurement of Force Generation during Platelet-driven Clot

Formation in Platelet Rich PlasmaT. Feller, J. Harsfalvi, G. Domján, K. Gado, K. Varnai, M. Kellermayer (Hungary)

PB 612 Analysis of Platelet Activation by Stable Isotope-resolved Metabolomics (SIRM)

S. Joshi, M. Banerjee, Z. Qi, P. Lin, M.O. Warmoes, Q. Sun, H.N.B. Moseley, R.M. Higashi, A.N. Lane, T.W.M. Fan, S.W. Whiteheart, Q.J. Wang (United States)

PB 613 Metabolites Associated with Massive versus Submassive Pulmonary Embolism - A Pilot StudyO. Zeleznik1, E. Poole1, S. Lindstrom1, P. Kraft1, A. Van Hylckama Vlieg2, B. Parry1, N. Giordano1, C. Kabrhel1 (1United States, 2The Netherlands)

Pathogenesis of Thromboembolism

PB 614 Efficacy of Dabigatran Etexilate in a Cancer Associated Thrombosis Murine ModelY. Kassim1, C. Lemarie1, J. Van Ryn2, M. Blostein1 (1Canada, 2Germany)

PB 615 Incidence of Venous Thromboembolism in Cancer Survivors: The Scandinavian

Thrombosis and Cancer (STAC) CohortI.L. Gade1, S.K. Brakkan2, I.A. Naess2, J.-B. Hansen2, F.R. Rosendaal3, S.C. Cannegieter3, K. Overvad1, H. Jensvoll2, J. Hammarstrom2, O.V. Gran2, H.H. Eriksen1, S.R. Kristensen1, M.T. Severinsen1 (1Denmark, 2Norway, 3The Netherlands)

PB 616 Incidence of Occult Cancer in the Year Following a Second Unprovoked Venous

Thromboembolism EventA. Delluc, S. Rezig, J.-C. Ianotto, C. Tromeur, M. Gouillou, F. Couturaud, K. Lacut, D. Mottier (France)

PB 617 Risk Factors of Occult Malignancy in Patients with Unprovoked Venous

Thromboembolism: Results from the MVTEP StudyP. Robin1, P.-Y. Le Roux1, C. Tromeur1, B. Planquette1, N. Prévot-Bitot1, C. Lavigne1, J. Pastre1, A. Merah1, G. Le Gal2, P.-Y. Salaun1, MVTEP study group (1France, 2Canada)

PB 618 Impact of Tumor Grade on the Risk of Venous Thromboembolism in Cancer; the Scandinavian Thrombosis and Cancer (STAC) CohortI.L. Gade1, S.K. Brakkan2, I.A. Naess2, J.-B. Hansen2, F.R. Rosendaal3, S.C. Cannegieter3, K. Overvad1, H. Jensvoll2, J. Hammarstrom2, O.V. Gran2, H.H. Eriksen1, S.R. Kristensen1, M.T. Severinsen1 (1Denmark, 2Norway, 3The Netherlands)

PB 619 Thromboembolic Events in Cancer Patients on Active Treatment with Cisplatin-

based Chemotherapy; Another Look!H. Abdel-Razeq, A. Mansour, A. Alshwayat, H. Abdulelah, M. Ibrahim, M. Abu Nasser, A. Rabhaiah, R. Alfar, A. Abufara, A. Ibrahim, M. Ma‘koseh, Y. Ismael (Jordan)



294 295

Mon

day

Pos

ter

Ses

sion

s

PB 620 Low Discriminating Power of the Modified Ottawa VTE Risk Score in a Cohort of Patients with Cancer from The RIETE RegistryA. Alatri1, L. Mazzolai1, C. Font2, A. Tafur3, R. Valle2, M. Monreal2, RIETE Investigators (1Switzerland, 2Spain, 3United States)

PB 621 End of Life Management of Venous Thromboembolism in Metastatic Cancer:

Current Practice, Place of Death and ComplicationsS. Banerjee, N. Pease, S. Noble (United Kingdom)

PB 622 Outcomes of Extended Anticoagulant Treatment of Venous Thromboembolism

in Patients with CancerM. Stalc, U. Cvajnar, A. Mavri (Slovenia)

PB 623 Joint Effects of Body Height and Cancer on the Risk of Incident Venous

Thromboembolism: The Tromsø StudyH. Skille, O.V. Gran, B. Paulsen, S.K. Braekkan, J.-B. Hansen (Norway)

PB 624 Patients with Cancer-associated Thrombosis Benefit from Anticoagulant

Treatment Beyond 6 MonthsI.T. Wilts1, J. Trujillo-Santos2, P.W. Kamphuisen1, L. Hernández-Blasco2, M. Lumbierres2, M.D.C. Díaz-Pedroche2, M.A. Lorente2, J.B. López-Sáez2, M. Ciammaichella3, M. Monreal2, the RIETE Investigators (1The Netherlands, 2Spain, 3Italy)

PB 625 Impact of Time Since Diagnosis and Mortality Rate on Cancer-associated

Venous Thromboembolism in a General Population - The Scandinavian Thrombosis and Cancer (STAC) CohortK. Blix1, M.T. Severinsen2, S.C. Cannegieter3, H. Jensvoll1, K. Overvad2, O.V. Gran1, J. Hammerstrøm1, A. Tjønneland2, I.A. Naess1, F.R. Rosendaal3, S.R. Kristensen2, S.K. Braekkan1, J.-B. Hansen1 (1Norway, 2Denmark, 3The Netherlands)

PB 626 Quality of Life Related to Health in Cancer Associated Thrombosis. Pilot of Qca StudyL. Jara-Palomares, M.I. Asensio-Cruz, E. Ríos Herranz, C. Font, E. Oncala Sibajas, A. Revuelta Rodríguez, C. Beato, M.D.C. Areses, I. Garcia-Escobar, M. Serrano Moyano, J. Lima Álvarez, P. Estévez, M.D.l.Á. Moreno Santos, A.J. Muñoz Martín, M. Gómez Rosa, J.L. Gálvez San Román, S. Fernández Arrojo, A. Illan Varella, L. Marin Barrera, T. Elías Hernández, R. Otero (Spain)

PB 627 Differential Impact of Triggers on the Risk of Venous Thromboembolism in

Subjects with and without Cancer - Results from a Population-based Case-crossover StudyO.V. Gran, H. Skille, B. Paulsen, T. Isaksen, S.K. Braekkan, J.-B. Hansen (Norway)

PB 628 Venous Thromboembolism in Patients with LymphomaS. Phusanti, P. Angchaisuksiri (Thailand)

PB 629 Cancer Associated Thrombosis in Cancer Patients Receiving Chemotherapy or

Hormonal Therapy in an Ambulatory SettingS. Rhodes, S. Bond, L. Moore, F. Rozycki, S. Abrook (United Kingdom)

PB 630 Long-term Impact on Mortality of Isolated Superficial Vein Thrombosis in

Patients with Active CancerJ.-P. Galanaud1, H. Rerrisse1, M.A. Sevestre1, G. Pernod1, S. Kahn2, I. Quéré1, J.-L. Bosson1 (1France, 2Canada)

PB 631 Prediction of Venous Thromboembolism in Newly Diagnosed Patients Treated

for Lymphoid Malignancies - Validation of the Khorana Risk Score among Patients with Diffuse Large B-cell Lymphoma and Hodgkin LymphomaJ. Rupa-Matysek, L. Gil, M. Kaźmierczak, M. Barańska, M. Komarnicki (Poland)

PB 632 High Real-life Incidence of Venous Thromboembolism in Multiple Myeloma:

A Need for More Effective Thromboprophylaxis at a Lower Thrombosis Risk ThresholdE. De Waal, M. Hoogendoorn, L. Snetselaar, R. Tjeerdsma, H. Kluin-Nelemans, E. Vellenga, K. Meijer (The Netherlands)

PB 633 The Procoagulant Fingerprint of Breast Cancer Cells Varies in Function of Their

Aggressiveness and the Tissue Factor ExpressionA. Camara, M. Sabah, E. Mbemba, A. Rousseau, P. Van Dreden, H. Mokrani, A. Khaterchi, A. Larsen, I. Elalamy, G. Gerotziafas (France)

PB 634 Joint Effect between Smoking Status and Cancer on the Risk of Venous Thromboembolism: The Scandinavian Thrombosis and Cancer CohortB. Paulsen1, O.V. Gran1, M.T. Severinsen2, J. Hammerstrøm1, S.K. Braekkan1, S.R. Kristensen2, S.C. Cannegieter3, H. Skille1, A. Tjønneland2, F.R. Rosendaal1, K. Overvad2, I.A. Næss1, J.B. Hansen1 (1Norway, 2Denmark, 3The Netherlands)

PB 635 The Impact of Traditional Triggers on the Risk of Venous Thromboembolism in

Cancer - Results from a Population-based Case-crossover StudyO.V. Gran, B. Paulsen, H. Skille, T. Isaksen, S.K. Braekkan, J.-B. Hansen (Norway)

PB 636 Impact of a Novel Version 2.0 of an Electronic Alert System for Venous

Thromboembolism (VTE) Prevention in Hospitalised Cancer PatientsR. Figueroa, A. Alfonso, S. Villar, N. Martínez-Calle, M. Marcos, J. López-Picazo, I. Gil-Bazo, A. García-Mouriz, J. Páramo, J. Hermida, R. Lecumberri (Spain)



296 297

Mon

day

Pos

ter

Ses

sion

s

PB 637 Platelet-related Thrombin Generation in Adult Survivors of Childhood CancerM. Panova-Noeva1, F. Haydl1, M. Nagler1, S. Eckerle1, M. Michler-Abo Mustafa1, M. Paul1, D. Laubert-Reh1, H.M. Spronk2, H. Merzenich1, J. Faber1, K.J. Lackner1, H. ten Cate2, P.S. Wild1 (1Germany, 2The Netherlands)

PB 639 Clinical History of Thrombosis before Diagnosis of Overt Myeloproliferative Neoplasms in Triple Negative PatientsM. Napolitano, S. Siragusa, S. Mancuso, M. Santoro, F. Di Piazza, A. Perez, A. Russo, V. Accurso (Italy)

PB 640 Importance of the Association Cancer Cells and Microparticles on the

Hypercoagulable Power of CancerA. Rousseau, R. Amrane, P. Van Dreden, A. Larsen, I. Elalamy, G. Gerotziafas (France)

PB 641 Variability of Khorana Score and its Validity after First Chemotherapy in

Patients with Gastric CancerH. Fuentes, L. Paz, X. Andrade, D. Oramas, A. Tafur (United States)

PB 642 Venous Thromboembolism in Patients Undergoing Allogeneic Stem Cell

Transplantation with Umbilical Cord BloodG. Moyer, J. Gutman, J. Di Paola, T. Buckner (United States)

PB 643 Joint Effects of FGG rs2066865 and Pre-cancer Fibrinogen Level on Cancer-

related Venous ThromboembolismB. Paulsen1, O.V. Gran1, H. Skille1, S.K. Braekkan1, E.N. Smith2, T. Solomon2, F.R. Rosendaal1, K.A. Frazer1, J.B. Hansen1 (1Norway, 2United States)

PB 644 Performance of Current Risk Assessment Models for Prediction of Venous Thromboembolism in Patients with Gastric CancerH. Fuentes, L. Paz, D. Oramas, Y. Wang, A. Tafur (United States)

PB 645 Clinical Course of Venous Thromboembolism in Patients with Pancreatic

Cancer: Insights from the RIETE RegistryC. Frere1, J. Trujillo-Santos2, C. Fernández-Capitán2, J. Del Toro2, V. Rosa2, L. Lopez-Jimenez2, J.M. Pedrajas2, C. Tolosa2, D. Farge1, M. Monreal2 (1France, 2Spain)

PB 646 Mean Platelet Volume (MPV) and MPV/Platelet (plt) Identify Essential

Thrombocythemia (ET) Patients at High Thrombotic RiskC. Verzeroli, M. Marchetti, C. Giaccherini, S. Gamba, A. Vignoli, L. Russo, G. Finazzi, A. Rambaldi, A. Falanga (Italy)

PB 647 Interleukin Profile in Polycythemia Vera and its Correlation with the Risk of ThrombosisP. Deo, P. Malhotra, S. Varma, N. Varma, M.U.S. Sachdeva, P. Jeeyaraman, G. Prakash, A. Khadwal, D. Lad (India)

PB 648 Joint Modeling of Longitudinal Haemostatic and Inflammatory Biomarker

Trajectories and Mortality in Patients with CancerF. Posch, E.-M. Reitter, J. Riedl, P. Quehenberger, C. Ay, I. Pabinger (Austria)

PB 649 LMWH First Dose Program to treat Cancer-associated Thrombosis in a Pharmacy SettingJ. Easaw, S. McCall, A. Azzim (Canada)

PB 650 Biomarkers for Venous Thromboembolism (VTE) in Newly Diagnosed Multiple

Myeloma (NDMM): Early Results from the Thromboprophylaxis in Multiple Myeloma (TiMM) Trial at King‘s College HospitalZ. Sayar, J. Czuprynska, R. Benjamin, J.P. Patel, L.N. Roberts, R.K. Patel, R. Arya (United Kingdom)

PB 651 The CATs out of the Bag: Alternatives to Low Molecular Weight Heparin

(LMWH) in Patients with Cancer Associated Thrombosis (CAT)M.P. Crowley, D. McClinton, K.A. Breen, V. McDonald (United Kingdom)

PB 652 Additional Testing Following Screening Strategies for Occult Malignancy

Diagnosis in Patients with Unprovoked Venous ThromboembolismP. Robin1, P.-Y. Le Roux1, E. Le Moigne1, B. Planquette1, N. Prévot-Bitot1, P.-M. Roy1, J. Pastre1, A. Merah1, F. Couturaud1, G. Le Gal2, P.-Y. Salaun1, MVTEP study group (1France, 2Canada)

PB 653 Assessing the Effects of Pre-analytical Variables on Thrombosis Biomarkers in Cancer Patients: Study Planning and LaunchR. Agarwal, E.J. Greenspan, J.H. Bavarva, C. Soria, L. Agrawal, T.H. Mondoro, A.L. Kindzelski, C. Andry, D. Remick, D. Stearns-Kurosawa, S. Kurosawa, E. Duffy, M. Sloan, J. Henderson, J. Kim, F. Sun, M. Thompson, C. Spencer, M.A. Berny-Lang (United States)

PB 654 Predictors of Prolonged Hospitalization Deep Vein Thrombosis Patients

A. Kurniawan, N.P.H. Lugito (Indonesia) PB 655 Incidence of Central Venous Catheter-related Venous Thrombosis in Japanese

Inpatients with Hematological Malignancies: Single Center ExperienceK. Miyazaki, T. Ishida, M. Danbara, M. Higashihara (Japan)

PB 656 Inaugural Thrombotic Events in Myeloproliferative Neoplasms

H. Baccouche, D. Bahri, A. Chakroun, Z. Manai, S. Mahjoub, N. Ben Romdhane (Tunisia)



298 299

Mon

day

Pos

ter

Ses

sion

s

PB 657 Biological Pro-coagulant and Pro-inflammatory Effect of Interferon Alpha in Myeloproliferative NeoplasmsN. Ajzenberg, D. Faille, L. Lamrani, S. Loyau, M.-G. Huisse, M. Jandrot-Perrus, S. Alkhaier, B. Cassinat, C. Chomienne, C. Dosquet (France)

PB 659 Audit: Use of Khorana Score in Oncology Patients in Belfast Trust

C. Carson, G. Benson (United Kingdom) PB 660 Treatment Tactics of Ulcerous Hemorrhage in Patients with Coronary Disease

R. Rakhimov (Uzbekistan) PB 661 Venous Thrombosis and Thromboembolic Risk Factors in Outpatients with

Lymphoma on ChemotherapyM.E. Mingot-Castellano, I. Sánchez Bazán, J. Díaz Pastor, O.M. Benítez Hidalgo, M. Espeso de Haro (Spain)

PB 662 Investigation of Plasma Microparticles in Patients with Type 1 Diabetes May Be

Interfered by Elevated Endogenous Lactadherin Levels in this Patient GroupK. Bergen, F. Mobarrez, G. Jörneskog, H. Wallén, S. Tehrani (Sweden)

PB 663 Circulating Platelet Microparticles with Regards to Microvascular Complications

and Sex Differences in Patients with Type 1 DiabetesK. Bergen, F. Mobarrez, G. Jörneskog, H. Wallén, S. Tehrani (Sweden)

PB 664 Effects of Low- and High-dose Doxorubicin and Paclitaxel on Tumorigenic,

Thrombogenic and Angiogenic Properties of Extracellular Vesicles Derived from Breast Cancer Cell Lines

A. Aharon, A. Rebibo-Sabbah, L. Issman, Y. Abboud, Y. Talmon, B. Brenner (Israel)PB 665 Functional Tissue Factor Activity on Endothelial Cells Conveyed by Bloodcell

MicroparticlesA. Brandtner, G.F. Lehner, A.-M. Mokina, B. Zassler, S. Klein, M. Joannidis (Austria)

PB 666 Impact of All Trans Retinoic Acid on the Plasmin Generation of Leukemic Cells

and Microparticles in Acute Promyelocytic LeukemiaD. Franckel1, C. Judicone1, R. Lacroix1, I. Weiss2, A. Muller1, C. Chareyre1, S. Cointe1, F. Dignat-George1, H.C. Kwaan2 (1France, 2United States)

PB 667 Circulating Microparticles Trend in Patients with HCV-related Liver Cirrhosis

who Underwent Direct-acting Antiviral TherapyE. Campello, A. Zanetto, C. Radu, L. Spiezia, C. Bulato, S. Shalaby, M. Senzolo, P. Burra, F.P. Russo, P. Simioni (Italy)

PB 668 P2Y1 and P2Y12 Antagonists Mediate the Release and Composition of Platelet Extracellular VesiclesA. Gasecka1, E. van der Pol2, A.N. Böing2, N. Hajji2, A. Sturk2, P. Siljander3, P. Harrison4, K.J. Filipiak1, G. Opolski1, R. Nieuwland2 (1Poland, 2The Netherlands, 3Finland, 4United Kingdom)

PB 669 Characterization of Plasma Microvesicles in Patients with Diabetic Nephropathy

M. Uil, C.M. Hau, M. Ahdi, V. Gerdes, S. Florquin, R. Nieuwland, J.J.T.H. Roelofs (The Netherlands)

PB 670 Coagulo-fibrinolytic Properties of Circulating Microparticles, and Subsequent Intravascular Coagulation, in Women with Ovarian Hyper Stimulation for In vitro FertilizationS. Cointe, E. Dos Santos, R. Lacroix, F. Vialard, C. Judicone, P. Poncelet, V. Serazin, B. Wainer, A. Fauconnier, F. Dignat-George, F. Boitrelle, F. Sabatier, A. Torre (France)

PB 671 Immune Response Favors the Release of Leukocyte-derived Microparticles

Mediating Endothelial Senescence, and Pro-coagulant and Pro-inflammatory PhenotypeA. El Habhab, M. Abbas, G. Kreutter, M. Kassem, S. Khemais, F. Zobairri, B. Yver, V. Schini-Kerth, L. Kessler, F. Toti (France)

PB 672 Increase in Microparticles TF/TFPI Procoagulant Ratio in Carriers of Inherited Bleeding DisordersE. Campello, L. Spiezia, C. Radu, C. Bulato, G. Saggiorato, F. Sartorello, S. Maggiolo, P. Simioni (Italy)

PB 673 Factor Xa Inhibitors Apixaban and Rivaroxaban Suppress the Release of TF-

bearing Microvesicles from Cancer Cell LinesS. Featherby, C. Ettelaie, A. Maraveyas (United Kingdom)

PB 674 Endothelial Nitric Oxide Synthase Gene Polymorphisms Influence on Endothelial Microparticles Levels in Renal TransplantationS.R. Martins, L.S. Dusse, F.F. Campos, L.V. Alves, F.C.G. Evangelista, R.C.F. Duarte, A.C. Simões e Silva, P.N. Alpoim, A.P.l. Mota (Brazil)

PB 675 Effects of Chemotherapy on Extracellular Vesicles and Coagulation Activation in

Colorectal Cancer PatientsL. Traby, H. Pur, M. Kollars, M. Kammer, G. Prager, W. Scheithauer, G. Kornek, P.A. Kyrle, S. Eichinger (Austria)

PB 676 The Impact of the Eculizumab on the Thrombogenicity Induced by Extracellular

Vesicles in Paroxysmal Nocturnal Hemoglobinuria PatientsA. Wannez, B. Devalet, C. Bouvy, B. Bihin, J. Douxfils, J.-M. Dogné, F. Mullier (Belgium)



300 301

Mon

day

Pos

ter

Ses

sion

s

PB 677 Magnetic Capture of Extracellular Vesicles: A Quantitative Flow Cytometry StudyA. Brisson, R. Linares, Y. Boucaud, C. Gounou, S. Tan, L. Adumeau, S. Mornet (France)

PB 678 Procoagulant Extracellular Vesicles in Amniotic Fluid

J. Thaler1, L. Hell1, L. Wisgrill1, C. Ay1, A. Spittler1, M. Schwameis1, B. Jilma1, P. Altevogt2, I. Pabinger1 (1Austria, 2Germany)

PB 679 Thrombin Generation Associated with Extracellular Vesicles is Increased Two

Weeks Post-partumC.E. Henriksson, M. Hellum, S. Sandberg, A.-H. Kristoffersen (Norway)

PB 680 Enumeration of Circulating Microparticles in Healthy Medical Workers

Occupationally Exposed to Low Doses of Ionizing RadiationG. Al Massarani, F. Najjar (Syrian Arab Republic)

PB 681 A High Throughput Flow Cytometry Assay for the Detection of Platelet

MicroparticlesC.J. Reddel, G.J. Pennings, V.M.Y. Chen, L. Kritharides (Australia)

PB 682 Visualization of Tissue Factor-positive Microvesicles from Patients with

Pancreatic Cancer Using Laser Scanning Confocal MicroscopyY. Hisada1, A. Auriemma1, W. Alexander1, C. Ay2, N. Mackman1 (1United States, 2Austria)

PB 683 New Specific and Highly Sensitive Procoagulant Test to Measure Tissue Factor

Activity on MicroparticlesL. Vallier, T. Bouriche, A. Bonifay, J. Bez, R. Lacroix, P. Poncelet, F. Dignat-george (France)

PB 684 Circulating Microparticles in Women with Polycystic Ovary Syndrome:

Preliminary ResultsE. Campello, R. Mioni, A. Dalla Cà, S. Maggiolo, C. Radu, C. Bulato, P. Simioni (Italy)

PB 685 Plasma Platelets Microparticles Evaluation in Thrombotic Thrombocytopenic

PurpuraL. Tahmasbi, S. Amini Kafiabadi, M. Karimi, M. Nikougoftar, S. Haghpanah (Islamic Republic of Iran)

PB 686 Endothelial and Platelet Microparticles in Kidney Transplanted Recipients:

Influence of Time Post Transplantation and Donor TypeS.R. Martins, P.N. Alpoim, F.F. Campos, L.V. Alves, F.C.G. Evangelista, R.C.F. Duarte, A.C. Simões e Silva, M.G. Carvalho, L.S. Dusse, A.P.L. Mota (Brazil)

PB 687 The Relation between Circulating Endothelial Microparticles and Asymetric Dimethylarginine in Vitamin B12 DeficientM.A. Dundar, Y. Altuner Torun, F. Cetin, S. Celik, C. Karakukcu (Turkey)

PB 688 Circulating Microparticles as Predictive Biomarkers for Tumor Progression in

Advanced Non-small Cell Lung CancerF. Najjar, M. Alammar, G. Al Massarani (Syrian Arab Republic)

PB 689 Microparticles with Platelet Pro-aggregation Potential Are Present in Patients with Acute Coronary Syndrome and No Perfusion (TIMI-0)A. De la Peña Díaz1, M. Flores Garcia1, A. Candia Ramirez1, O. Zepeda García1, R. Botello Maraver1, C. García Meré1, E.J. Guerrero Casillas1, M.A. Peña Duque1, M.A. Martínez Ríos1, A.M. Mejia Dominguez1, E. Anglés-Cano2, Genetica Intervencionista (1Mexico, 2France)

Platelets - Clinical

PB 690 Obesity and ADAMTS13 Deficiency as Risk Factors for TTPL. Geys, E. Roose, I. Scroyen, C. Tersteeg, K. Vanhoorelbeke, R. Lijnen (Belgium)

PB 691 Acute Thrombotic Thrombocytopenic Purpura (TTP) - Diagnostic and

Prognostic Implications of Highly Sensitive Troponin Assays, ECG and ECHOI. Karpha, T. Dutt (United Kingdom)

PB 692 Plasmin Cleavage of ADAMTS-13 Enhances its Activity

M.M. Mebius, C.C. Clark, S. de Maat, A.G.M. Tielens, P.G. de Groot, R.T. Urbanus, R. Fijnheer, J.J. van Hellemond, C. Maas (The Netherlands)

PB 694 Unraveling Immunoprofiles of Acquired TTP Patients Using Anti-idiotypic

AntibodiesA.-S. Schelpe1, E. Roose1, F. Peyvandi2, B. Joly3, I. Pareyn1, H. Deckmyn1, J. Voorberg4, P. Coppo3, A. Veyradier3, S.F. De Meyer1, K. Vanhoorelbeke1 (1Belgium, 2Italy, 3France, 4The Netherlands)

PB 695 The in vitro and in vivo Effects of Streptokinase in a Papio ursinus Baboon Model of Acquired Thrombotic Thrombocytopenic Purpura (TTP) - A Pilot StudyJ. Joubert1, W.J. Janse van Rensburg1, S.M. Meiring1, C. Tersteeg2, K. Vanhoorelbeke2 (1South Africa, 2Belgium)

PB 696 mRNA Identification of a Novel Isoform (ISF) and ISF3 from ADAMTS13 in

Different Types of CellsJ. Paiva, A.C. Kempfer, M.F. Alberto, A.I. Woods, C. Dos Santos, A. Sánchez-Luceros, M.A. Lazzari (Argentina)



302 303

Mon

day

Pos

ter

Ses

sion

s

PB 698 Splenic Anti-ADAMTS13 Response in Relapsing Thrombotic Thrombocytopenic Purpura (iTTP) Patients Mirrors the Acute Immune Response in PlasmaM. Skowronska, J.A. Kremer Hovinga, M. Schaller (Switzerland)

PB 699 The Incidence of Thrombotic Thrombocytopenic Purpura in Israel, as

Determined by ADAMTS-13 Activity and Anti-ADAMTS-13 Antibody LevelsA. Keren-Politansky, E.J. Dann, G. Tennenbaum, B. Brenner, G. Sarig (Israel)

PB 700 A Rapid and Simple Assay for the Determination of ADAMTS-13 Activity

M. Griffiths, H. Vetr, N. Binder (Austria) PB 701 Retrospective Analysis of the Relapse Rate in Patients Surviving Acute

Acquired Thrombotic Thrombocytopenic Purpura (TTP) Treated with or without RituximabS. Herold, T. Falter, V. Schmitt, V. Weyer, H. Roßmann, C. von Auer, K. Lackner, B. Lämmle, P. Wild, I. Scharrer (Germany)

PB 702 Epidemiology of Thrombotic Microangiopathy in Malaysia

Y.Y. Yap, P.A. Zulkarnain, K.B. Law, S. Carlo, J. Sathar, K.M. Chang (Malaysia)

PB 703 Highly Sensitive Fully Automated Chemiluminescent Immunoassay for Rapid Quantification of ADAMTS13 ActivityM. Mirabet, S. Blanch, J. Puig, J. Serra (Spain)

PB 704 Clinical Characteristics and Outcome of Patients with Thrombotic

Thrombocytopenic Purpura at Siriraj HospitalY. Chinthammitr, W. Wangchinda (Thailand)

PB 705 Characteristic of ADAMTS13 in Patients with Acute Phase of Kawasaki Disease

N. Tsujii, K. Nogami, M. Matsumoto, H. Yoshizawa, T. Takase, I. Tanaka, T. Sakai, A. Isonishi, K. Matsuura, Y. Fujimura, M. Shima (Japan)

PB 706 Acquired TTP in Prague: More than 20 Years Single Centre Experience

P. Salaj, J. Louzil, V. Pohlreichova, V. Geierova, I. Capova, I. Hrachovinova (Czech Republic)

PB 707 Complements are Activated to a Similar Level in both Thrombotic

Thrombocytopenic Purpura and Atypical Hemolytic Uremic SyndromeD. Oh1, S.J. Lee1, J.O. Kim1, N.K. Kim1, S.Y. Chong1, J.Y. Huh1, R.I. Baker2 (1Republic of Korea, 2Australia)

PB 708 aPreliminary Report on the Genetic Background and Clinical Course of

Upshaw-Schulman Syndrome in Polish PatientsJ. Windyga1, M. Gorska-Kosicka1, K. Bykowska1, E. Odnoczko1, B. Baran1, M. Letowska1, E. Stefanska-Windyga1, J.A. Kremer Hovinga Strebel2 (1Poland, 2Switzerland)

PB 709 A Murine Anti-ADAMTS13 Monoclonal Antibody against the Disintegrin-like Domain Inhibit the Enzyme ActivityZ. Ma, F. Shen, J. Su, J. Ling, J. Yin, C. Ruan (China)

PB 710 Relationship between ADAMTS13 Antigen (Ag) and Free IgG Anti-ADAMTS13

Antibody (Free IgG ab), Functional ADAMTS13 Inhibitor (FI) and Circulating Immune Complexes (CIC) Using two ELISA Techniques, in Patients (P) with Acquired Thrombotic Thrombocytopenic Purpura (aTTP)A.C. Kempfer, J. Paiva, A. Sanchez-Luceros, A. Woods, M.M. Casinelli, M.A. Lazzari (Argentina)

PB 711 ‚Predisposed‘ Hemophagocytosis in a Patient with Thrombotic Thrombocytopenic PurpuraT. Shimomura, T. Takafuta, H. Niimi, S. Munemasa, M. Kadono, Y. Tachiyama (Japan)

PB 712 Technozym® ADAMTS-13 Activity Assay for Determination of Inhibitory

Antibodies against ADAMTS-13L. Wagner, M. Kafka, F. Nasufi, N. Binder (Austria)

PB 713 Evolution of ADAMTS13 Activity in Patients with Relapsing Acquired Thrombotic Thrombocytopenic PurpuraF. García-Candel, J.J. Cerezo, A. Moret, D. Iyú, A. Martinez, E. Fernandez Poveda, M. Moya Armao, E. Salido Fierrez, V. Cabañas Perianes, R. Pérez López, M. Berenguer Piqueras, N. Marin, J.M. Moraleda (Spain)

PB 714 Evaluation of Sample Interferences on ADAMTS-13 Activity Measurement

L. Wagner, M. Griffiths, H. Vetr, S. Geiter, N. Binder (Austria) PB 715 Early Detection of Refractoriness and Silent Relapse in Acquired Thrombotic

Thrombocytopenic PurpuraP. Manresa Manresa, F. López Castaño, H. Sarmiento Palao, I. Molina Pomares, L. Hernández Mateo, P. Marco Vera (Spain)

PB 716 Upshaw-Schulman Syndrome: The Importance of the Modulating Effect of the

Different Genetic VariationsP. Manresa Manresa, H. Sarmiento Palao, F. López Castaño, I. Molina Pomares, L. Hernández Mateo, P. Marco Vera (Spain)

PB 717 Characterization of a Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

Misdiagnosed as HELLP SyndromeX. Bai, J. Su, L. Cao, Z. Yu, C. Ruan (China)

PB 718 The Next Case Report of Thrombotic Thrombocytopenic Purpura (TTP) after

Influenza VaccinationD. Kaspřák, Z. Kořístek, M. Navrátil, P. Richterová, J. Gumulec (Czech Republic)



304 305

Mon

day

Pos

ter

Ses

sion

s

PB 719 Thrombotic Thrombocytopenic Purpura as an Initial Presentation of Systemic Lupus Erythematosus in a Thai Child: A Case ReportR. Natesirinilkul, W. Padungmaneesub, P. Charoenkwan, S. Reungrongrat, W. Chartapisak (Thailand)

PB 720 A Case of SLE with Different Types of Thrombotic Microangiopathy during the

CourseE. Tatsumi, M. Miyamoto, F. Kamitani, S. Oono, N. Yada, K. Yoshimoto, M. Hayakawa, M. Matsumoto, Y. Akai, K. Nishio (Japan)

PB 721 Congenital Thrombotic Thrombocytopenic Purpura without Nephropathy and NeuropathyC. Albayrak, D. Albayrak (Turkey)

PB 722 Thrombotic Microangiopathies (TMA): First Report of 250 Cases from a Single

Institution Experience in Latin AmericaC. Dos Santos, M. Agazzoni, M. Barrenechea, J. Paiva, M.M. Casinelli, A.C. Kempfer, M.L. Romero, M.A. Lazzari, A. Sánchez-Luceros (Argentina)

PB 723 Successful International Standardisation of the ADAMTS13 Assays - Results from the APMAT (Asia Pacific Microangiopathic Thrombocytopenia) NetworkJ.Y. Tiao1, D. Oh2, P. Angchaisuksiri3, J. Sathar4, M. Yap4, C. Ruan5, Z. Yu5, K. Dai5, R. Yang5, M. Smith6, E. Merriman6, S. McRae1, R. Wong7, A. Enjeti1, J. Curnow1, J. Joseph1, A. Davies1, G. Chan6, C. McLintock6, L. Young6, P. Meijer8, N. Binder9, M. Matsumoto10, T.S. Leng11, S.C. Nair12, M.-C. Shen13, R. Bird1, T. Brighton1, G.V. D’Aulerio1, G. Gilmore1, J. Tay1, Q. Hughes1, R.I. Baker1, (on behalf of the Asia Pacific Microangiopathic Thrombocytopenia (APMAT) Network Investigators of the APSTH and THANZ) (1Australia, 2Korea, Republic of, 3Thailand, 4Malaysia, 5China, 6New Zealand, 7Hong Kong, 8The Netherlands, 9Austria, 10Japan, 11Singapore, 12India, 13Taiwan)

PB 724 Treatment of Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome in Pediatric Patients - A Single Center ExperienceO. Serbic, B. Andric, Z. Radonjic, N. Stajic, D. Jevtic, D. Djokic, M. Kuzmanovic (Serbia)

PB 725 Successful Treatment of Renal Infiltration Complicated by Atypical Hemolytic

Uremic Syndrome in a Child with Acute LeukemiaZ. Kaya, E.Ö. Özmen, M. Akgül, B. Topuz, E. Akkuzu, N. Alıcı, N. Buyan (Turkey)

PB 726 Transplant/Imunosupressor Related Thrombotic Microangiopathy

F. Mousinho, A.P. Azevedo, C. Pimenta da Silva, C. Jorge, E. Cacheira, P. Sousa e Santos, A.M. Batalha Reis, J. Viana (Portugal)

PB 727 A Heterozygous Mutation of G-protein-Coupled Receptor 25 in a Family with

inherited Thrombocytopenia and ThrombosisJ. Yamanouchi, T. Hato, Y. Ikeda, H. Takeda, M. Yasukawa (Japan)

PB 728 Seven Years‘ Experience of Healthcare Cards Delivery from the French Reference Center on Inherited Platelet Disorders (CRPP)M. Fiore, A. Dupuis, R. Favier, P. Sie, M.-F. Hurtaud, C. Lavenu-Bombled, D. Desprez, C. Pouymayou, C. Falaise, R. D‘oiron, C. James, N. Trillot, V. Latger-Cannard, Y. Gruel, N. Schlegel, P. Chamouni, C. Negrier, M. Fouassier, A. Nurden, P. Nurden, M.-C. Alessi (France)

PB 729 Novel RUNX1 Mutations in Families with Inherited Thrombocytopenia

P. Noris1, D. De Rocco1, F. Melazzini1, C. Marconi1, A. Pecci1, R. Bottega1, C. Gnan1, F. Palombo1, P. Giordano1, M.S. Coccioli1, A.C. Glembotsky2, E. Cigalini1, P. Heller2, M. Seri1, A. Savoia1 (1Italy, 2Argentina)

PB 730 A Novel Mutation in TBXA2R Impairs the Expression of the TPβ Isoform of the

Platelet Thromboxane Receptor and Associates with Bleeding DiathesisL. Bury, E. Falcinelli, A.M. Mezzasoma, G. Manni, E. Cesari, P. Gresele (Italy)

PB 731 Spontaneous Loss of Mitochondrial Potential and Phosphatidylserine Exposure

in Fibrinogen-bound Platelets of Patients with Wiskott-Aldrich SyndromeS. Obydennyi, D. Pershin, A. Maschan, A. Shcherbina, M. Panteleev (Russian Federation)

PB 732 ACTN1 Macrothrombocytopenia: Deleterious Effects of Rod-domain ACTN1 Variants

A. Vincenot1, M. Poggi1, N. Schlegel1, O. René1, S. Binard1, P. Saultier1, S. Kunishima2, M.C. Alessi1 (1France, 2Japan)

PB 733 Complete Failure of Integrin αIIbβ3 Activation in Kinetic Assay Associates with

Severe Bleeding Problems in a Patient with Kindlin-3 DeficiencyH. Kato, Y. Ito, H. Kashiwagi, Y. Morikawa, K. Akuta, N. Nishiura, S. Honda, K. Kokame, T. Miyata, Y. Kanakura, Y. Tomiyama (Japan)

PB 734 Identification of Two New P2RY12 Heterozygous Mutations Responsible for Hemorrhagic Diathesis in Two Unrelated FamiliesA. Dupuis1, V. Heim1, D. Desprez1, P. Ohlmann1, A. Lorenzo2, C. Gachet1 (1France, 2Switzerland)

PB 735 Glanzmann‘s Thrombasthenia in China: New Insights into its Pathogenesis

Z. Lu, M. Jiang, Z. Yu, Z. Wang, L. Xia, C. Ruan (China) PB 736 A New Form of Inherited Thrombocytopenia (IT) Due to Monoallelic Loss-of-

function Mutation in the Thrombopoietin (THPO) GeneP. Noris, C. Marconi, D. De Rocco, F. Melazzini, T. Pippucci, G. Loffredo, T. Giangregorio, A. Pecci, E. Cigalini, M. Seri, A. Savoia (Italy)



306 307

Mon

day

Pos

ter

Ses

sion

s

PB 737 MYH9 Variants Defined by Next-generation Sequencing: Predicting Variants Likely Causing MYH9-related DisorderL. Bury1, I. Simeoni2, P. Gresele1, on behalf of the BRIDGE-BPD and the ThromboGenomics Consortia (1Italy, 2United Kingdom)

PB 738 Aberrant Gsalpha Signalling in Platelets from AHO Patients Linked to Impaired Platelet FunctionF. Swieringa1, F.A. Solari1, M.A.H. Feijge2, N.J.A. Mattheij2, O. Pagel1, F. Beck1, C.T.R.M. Stumpel2, J. Pohlenz1, J. Faber1, A. Russo1, O. Schwab1, B. Zieger1, K. Jurk1, A. Sickmann1, P.E.J. van der Meijden2, I.M.L.W. Körver-Keularts2, R.P. Zahedi1, J.W.M. Heemskerk2 (1Germany, 2The Netherlands)

PB 739 Pseudo-Glanzmann Thrombasthenia due to Mutation in RasGRP2 Gene

Encoding for CalDAG-GEFIN. Rosenberg, R. Dardik, H. Hauschner, S. Nakav, O. Barel, J. Luboshitz, J. Yacobovich, H. Tamary (Israel)

PB 740 GATA1 T296P Mutation Causes a Severe Bleeding Disorder due to Platelet

Α-Granule and Partial δ-Storage Pool DeficiencyK. Jurk, S. Sollfrank, O. Pagel, K. Groß, A. Czwalinna, J. Erkel, K.J. Lackner, U. Walter, H. Rossmann, R.P. Zahedi, F. Bergmann (Germany)

PB 741 Detection and Analysis of Gene Mutations in Patients with Glanzmann

Thrombasthenia by Next Generation SequencingD. Zhang, Y. Jia, L. Zhang, L. Qin, Y. Lin, F. Xue, R. Yang, K. Ru (China)

PB 743 Refined Detection and Characterization of Delta Storage Pool Disorders: A

Cohort Study on Pediatric PatientsG. Manukjan, J. Eilenberger, O. Andres, C. Schambeck, S. Eber, H. Schulze (Germany)

PB 744 Multiplex PCR and Cycle Sequencing for Detection of Mutations in ACTN1,

TUBB1 and ANKRD 26L. Dai, J. Cutler, M. Mitchell (United Kingdom)

PB 745 Delta Storage Pool Deficiency in a Patient with a R216Q Mutation of GATA1

M. Blaauwgeers, I. van Asten, A. Huisman, S. Korporaal, E. Beckers, M. Coppens, J. Eikenboom, M. Kruip, M. Nijziel, R. Tamminga, R. Urbanus, R. Schutgens (The Netherlands)

PB 746 Genetic Heterogeneity in Familiar Macrothrombocytopenia with Decreased

Expression of GpIIbIIIaC. Lau, J. Oliveira, M. Sampaio, A. Gonçalves, M. Pereira, M. Gonçalves, E. Cruz, R. Santos, M. Lima, S. Morais (Portugal)

PB 747 Pseudodominance in a Family with Bernard-Soulier Syndrome due to a Homozygous Variant in the Platelet Glycoprotein IX (GP9) GeneC. Lau, J. Oliveira, A. Gonçalves, M. Gonçalves, M. Pereira, E. Cruz, R. Santos, M. Lima, S. Morais (Portugal)

PB 748 Highly Significant Bleeding Diathesis in Patients with Platelet Dysfunction due to a Novel Mutation in RASGRP2, Encoding CalDAG-GEFI (p.Gly305Asp)E. Bermejo1, M.F. Alberto1, P. David S.2, P. Nurden3, A. Sanchez Luceros1, A.T. Nurden3, W. Bergmeier2 (1Argentina, 2United States, 3France)

PB 749 Positive Impact of Social Media as a Support Group for Females with

Glanzmann Thrombasthenia in Saudi Arabia - A Mother‘s InitiativeM. Saleh, T. Owaidah, A. Aljefri, H. Alzahrani, S. Parween, R. Barmada, M. Zulfiqar, S. Jose, V. Mohammed (Saudi Arabia)

PB 750 Five New Cases of Hermansky-Pudlak Syndrome: Identification of Novel Genetic Variants in HPS4 and HPS3 Associated to Relevant Clinical ComplicationsJ.M. Bastida1, J.R. Gonzalez-Porras1, M.L. Lozano1, M. del Rey1, R. Benito1, N. Bermejo1, M. Karkukak2, M. Trapero1, K. Janusz1, Y. Yucel2, J.M. Hernandez-Sanchez1, V. Palma-Barqueros1, V. Vicente1, J.M. Hernandez-Rivas1, J. Rivera1 (1Spain, 2Turkey)

PB 751 Quality of Life Is Reduced in Patients with (Suspected) Congenital Platelet

Function DisordersM. Blaauwgeers, K. Fischer, I. van Asten, S. Korporaal, A. Huisman, M. Kruip, M. Coppens, M. Nijziel, J. Eikenboom, R. Tamminga, E. Beckers, R. Urbanus, R. Schutgens (The Netherlands)

PB 752 The Diagnostic Performance of Impedance Aggregometry and Platelet

Function Analyzer Regarding Platelet Function Disorders as Detected by Light Transmission AggregometryF. Moenen, M. Vries, H. ten Cate, P. Verhezen, R. Wetzels, E. Beckers, Y. Henskens (The Netherlands)

PB 753 Evaluation of the Platelet Function in Different Inherited Thrombocytopenias. Correlation of Platelet Response Measured by Flow Cytometry with Bleeding Scores and Clinical PhenotypesM.A. Alberelli, A. Savoia, E. De Candia (Italy)

PB 754 Management of a Patient with Glanzmann Thrombasthenia during a Coronary

Artery Bypass Graft Surgery: A Case StudyM. Kurdi, A. Ankri, J. Amour, C. Brumpt, J. Delort, G. Lebreton, L. Croisille, R. D‘orion, I. Martin-Toutain (France)



308 309

Mon

day

Pos

ter

Ses

sion

s

PB 755 Compound Heterozygosity for Mutations in ITGA2B Including a Novel p.Cys198Ser in Glanzmann ThrombastheniaE. Hashimoto, S. Kunishima, Y. Takagi, S. Suzuki, N. Kawamura, A. Makiyama, H. Sakane, A. Fujioka, T. Uehara, S. Tamura, A. Takagi, T. Kojima (Japan)

PB 756 Quantitative Evaluation of Bleeding due to Platelet Disorders Associated with

Dense Granule Deficiency and/or Impaired Aggregation ResponsesJ. Iyer1, M. Badin1, J. Brunet1, L. Graf2, G. Pare1, A.D. Paterson1, G.E. Rivard1, C.P.M. Hayward1 (1Canada, 2Switzerland)

PB 757 MYH9 Disorders Are the Most Common Cause of Macrothrombocytopenia in

Australia: Importance of Mean Platelet Diameter Measurement and Döhle Body Detection for Improved DiagnosisM.-C. Morel-Kopp1, D. Rabbollini1, Y. Chun1, K. Fixter1, S. Kunishima2, S. Gabrielli1, Q. Chen1, W. Stevenson1, P. Tan1, K. Radhakrishnan1, R. Bird1, O. Paul3, L.P. Chew4, C. Ward1 (1Australia, 2Japan, 3New Zealand, 4Malaysia)

PB 758 Hemorrhagic Diathesis in Four Patients with the Heterozygous Pro258Thr Mutation of the P2RY12 GeneM. Blaauwgeers, I. van Asten, A. Huisman, S. Korporaal, E. Beckers, M. Coppens, J. Eikenboom, M. Kruip, M. Nijziel, R. Tamminga, R. Urbanus, R. Schutgens (The Netherlands)

PB 759 Nine-year Effective Management of an LAD III Patient with Conventional Pro-

hemostatic and Immunological TreatmentP. Saultier, S. Szepetowski, C. Falaise, L. Vidal, M. Canault, V. Barlogis, M.-C. Alessi, H. Chambost (France)

PB 760 Assessment of the Severity of the Epistaxis by Epistaxis Severity Score in the

Inherited Platelet DisordersR. Messaoudi, M. Lahmer, D. Saidi, Z. Zouaoui, H. Touhami, M.A. Bekkadja, A. Arabi, N. Sidi-Mansour (Algeria)

PB 762 A Study of Comparison of Platelet Aggregation Response Obtained on Sysmex CS-2000i with Chrono-log Light Transmission AggregometerA. Abraham1, S.C. Nair1, T. Geevar1, P. Tavkar2, S. Singh1, H.F. Margaret1, R. V1 (1India, 2Japan)

PB 763 Minor Dental Surgery in Patients with Glanzmann Thrombasthenia Patients

A.J. Sikorska, B. Ceglarek, K. Bykowska, K. Maślanka, B. Baran, J.M. Teliga Czajkowska, J. Windyga (Poland)

PB 764 Flow Cytometric Mepacrine Uptake Related to Platelet Size in Patients with Moderate MacrothrombocytopeniaS.J. Rodriguez Moreno, M.F. Alberto, E. Bermejo, M.L. Romero, S. Meschengieser, A. Sachez Luceros (Argentina)

PB 765 Circumcision in Children with Inherited Bleeding Disorders - A Tertiary Care Centre Experience in Saudi ArabiaM. Saleh, Z. Habib, A. Aljefri, H. Musallam, L. Tuleimat, S. Jose, M. Zulfiqar, V. Mohammed, N. Alshaikh (Saudi Arabia)

PB 766 Patient Experiences with Hereditary Thrombotic Thrombocytopenic Purpura (hTTP): A Conceptual Framework of Patient-reported Outcomes (PROs)A. Oladapo, D. Ito, C. Hibbard, S.E. Bean, R.N. Krupnick, B.M. Ewenstein (United States)

PB 767 Application of ISTH - Bleeding Assessment Tools to Inherited Platelet Disorders

R. Messaoudi, M. Lahmer, L. Zatla, Z. Zouaoui, H. Touhami (Algeria) PB 768 Post Platelet Transfusion Flow Cytometry Analysis as an Ancillary Test Guiding

Treatment of Glanzmann Thrombastenia Patients Undergoing Surgical ProceduresA. Barg, H. Hauschner, A. Lubetsky, S. Levy Mendelovich, M. Misgav, N. Rosenberg, G. Kenet (Israel)

PB 769 Successful Management of Severe Bleeding with Combined Platelet

Transfusion, rFVIIa and Tranexamic Acid Therapy in Glanzmann Thrombasthenia PatientB. Ceglarek, A.J. Sikorska, K. Bykowska, K. Maślanka, A. Misiak, A. Szczepanik, J.M. Teliga Czajkowska, J. Windyga (Poland)

PB 770 Immature Platelets Fraction and its Application in the Differential Diagnosis of

Congenital and Acquired TrombocytopeniaJ. Neves, C. Faria Coelho, C. Teixeira, E. Cruz, C. Lau, S. Morais, I. Freitas (Portugal)

PB 771 A Case of Acquired, Transient Bleeding Diathesis Associated with Platelet

DysfunctionE.A. Femia, G.M. Podda, V. Caroppo, C. Cheng, M. Cattaneo (Italy)



310 311

Mon

day

Pos

ter

Ses

sion

s

Late Breaking Abstracts12:00 – 13:15 Exhibition Hall 6.2

LB 02 A Large-scale Exome-wide Association Study of Venous Thromboembolism: Meta-analysis from the INVENT ConsortiumS. Lindstroem1, M. Germain2, T. Bartz1, C. Turman1, E.N. Smith1,3, M.-H. Chen1, M. Puurunen1, J.S. Brody1, P. Suchon2, J.-P. Empana2, R. Olaso2, S.K. Brækkan3, B. McKnight1, J.-F. Deleuze2, C.J. O'Donnell1, X. Jouven2, J.-B. Hansen3, B.M. Psaty1, K.L. Wiggins1, K.T. Taylor1, S.R. Heckbert1, K.A. Frazer1,3, A.D. Johnson1, P. Kraft1, P.-E. Morange2, D.-A. Trégouët2, N. Smith1, C. Kabrhel1, The INVENT Consortium (1United States, 2France, 3Norway)

LB 03 Anticoagulant Effects of Rosuvastatin in Patients with a History of Venous Thromboembolism: The STAtins Reduce Thrombophilia (START) TrialJ. Biedermann, M. Kruip, F. van der Meer, F. Rosendaal, F. Leebeek, S. Cannegieter, W. Lijfering (The Netherlands)

LB 04 rFVIIIFc for Immune Tolerance Induction in Severe Hemophilia A Patients with Inhibitors - A Retrospective AnalysisM. Carcao1, A. Shapiro2, J. Staber2, N. Hwang2, C. Druzgal2, K. Lieuw2, M. Belletrutti1, C. Thornburg2, S. Ahuja2, J. Morales-Arias2, J. Dumont2, K. Jaworski2, G. Miyasato2, E. Tsao2, N. Jain2, S. Pipe2 (1Canada, 2United States)

LB 05 Analysis of VTE Prophylaxis Therapy among Hospitalized General Medical and Cancer Patients: Is There an Opportunity to Benefit from Reduced Use of VTE Thromboprophylaxis?A. Budd, M. Rhodes, P. Wells (Canada)

LB 06 Prospective Randomized Placebo-controlled Trial of Simvastatin in the Prevention of COPD Exacerbations (STATCOPE) - Effects on Tissue Factor Pathway of Blood CoagulationA.K. Rao, F. Del Carpio-Cano, S. Janapati, H. Zhao, G. Criner, NIH COPD Clinical Research Network and Canadian Institute of Health Research Investigators (United States)

LB 07 Effect of Pregnancy on the Course of ITP Pregnant Women and their Offspring. Results of a Spanish Case-Series of 230 Primary ITP PregnanciesT.J. González-López, P. Olivera, I. Jarque, B. Sánchez González, S. Bernat, E. Bolaños, G. Pérez-Rus, A.R. Huerta, V. Martinez Robles, M.P. Martínez-Badas, R. Pérez Montes, M.J. Peñarrubia, M.T. Alvarez, V. Conesa, N. Bermejo, C. Fernández-Miñano, G. Hermida (Spain)

LB 08 The Association between Genetic Variants Involved in Immune Response and Inhibitors among Persons with Hemophilia A: A Systematic Review and Meta-analysisA.B. Payne, J.M. Soucie, C.J. Bean, J.G. Mulle (United States)

LB 09 Perioperative Hemostasis with an Extended Half-life, Full-length, Pegylated, Recombinant Factor VIII in Patients with Hemophilia AR. Gruppo1, T. Wynn1, M. López-Fernández2, W. Engl3, M. Sharkhawy3, S. Tangada1 (1United States, 2Spain, 3Austria)

LB 10 Prospective Observational Registry for Acquired Autoimmune Thrombotic Thrombocytopenic Purpura (iTTP) of the University Medical Center MainzC. v. Auer-Wegener1, T. Falter1, X. Messmer1, A. Trinchero1, C. Graf1, I. Scharrer1, K. Jurk1, L. Bach1, V. Weyer-Elbrich1, H. Rossmann1, K. Lackner1, B. Lämmle1,2 (1Germany, 2Switzerland)

LB 11 Platelet Count and Central Venous Catheter-related Thrombosis in Critically Ill Children: An Observational StudyJ. Rutgers, F. Newall, P. Monagle, S. Jones (Australia)

LB 12 Fibrinolysis in Sepsis-related Disseminated Intravascular CoagulationJ.B. Larsen, M.A. Laursen, C.L. Hvas, L. Kim Michael, A.-M. Hvas (Denmark)

LB 14 Effect of Dabigatran on Bleeding after a Standardized Cut and the Potency of Reversal by Prothrombin Complex Concentrate (Beriplex): A Randomized Double-blind Placebo-controlled Crossover StudyA. Stehouwer1, H. Hop1, T. Lisman1, J. Adelmeijer1, J. van Ryn2, P.W. Kamphuisen1 (1The Netherlands, 2Germany)



312 313

Tues

day

Pos

ter

Ses

sion

s

Tuesday, July 11, 2017Poster Sessions



PB 772 Regular Physical Activity and Risk of Incident Venous Thromboembolism in the General PopulationL.H. Evensen, T. Isaksen, S.K. Braekkan, J.B. Hansen (Norway)

PB 773 Impact of Regular Physical Activity on the Risk of Recurrent Venous

Thromboembolism and All-cause MortalityL.H. Evensen, T. Isaksen, S.K. Braekkan, J.B. Hansen (Norway)

PB 775 Associations between Serum Levels of Calcium, Parathyroid Hormone and

Future Risk of Venous Thromboembolism - The Tromsø StudyG. Lerstad, E.E. Brodin, J. Svartberg, R. Jorde, J. Brox, S.K. Braekkan, J.-B. Hansen (Norway)

PB 776 Repeated Measures of Fish Consumption, n-3 PUFA Intake and Future Risk of

Incident VTET. Isaksen, H. Kristian, E. Line Holtet, B. Sigrid, H. John-Bjarne (Norway)

PB 777 Residual Vein Thrombosis in Subjects with Proximal DVT: An Association with

Subclinical Atherosclerosis. The VERITAS StudyP. Prandoni, M. Ciammaichella, N. Mumoli, N. Zanatta, A. Visonà, G. Avruscio, E. Bucherini, C. Bova, D. Imberti, V. Rossetto, G. Camporese, F. Noventa, M. Milan (Italy)

PB 778 Elevated Circulating CD40-L in Atrial Fibrillation and its Modulation by

AblationA. Otto, J. Fareed, S. Statz, J. Liles, A. Walborn, D. Hoppensteadt, T. Rowe, S. Jabati, M. Syed (United States)

PB 779 Elevated Cellular Fibronectin is a Modifier of Clot Properties in Type 2

Diabetes: Association with Cardiovascular DiseaseA.H. Bryk, M. Konieczyńska, K.P. Malinowski, K. Draga, A. Undas (Poland)

PB 780 Thrombin Generation Potential is Increased in Anabolic Androgenic Steroid

Abuse Years after CessationS. Chang, J. Rasmussen, M. Frandsen, M. Schou, J. Faber, J.J. Sidelmann, C. Kistorp (Denmark)

PB 781 The CHA2DS2-VASc Score Predicts Bleeding Risk in a Cohort with Implantable Cardiac Monitoring Devices without Atrial FibrillationF. Shamoun, C. Parson, S. Cha, A. Tseng, F. Al-saffar, H. Esser, F. Mookadam (United States)

PB 782 PCSK9 Promotes Arterial Thrombosis in Mice

J. Wu, Y. Liu, M. Ren, N. Chen (China) PB 783 Plasma Lipoprotein(a) Predicts Bleeding and Long-term Adverse Events in

Patients with Chronic Kidney Disease who Underwent Percutaneous Coronary InterventionN. Xu, Y. Yao, X.-F. Tang, J.-J. Xu, Y. Song, L. Jiang, R. Liu, P. Jiang, J.-Q. Yuan, R.-L. Gao (China)

PB 784 Effects of HAART on Fibrinogen, D-dimer and Protein C Levels in Patients with

HIV at the University of Benin Teaching Hospital Benin City, NigeriaO. Awodu, A. Onunu, E. Chukwuka (Nigeria)

PB 785 Persistent Thrombin Generation at 24 Months after Acute Coronary Syndrome

C. Yip, A. Seneviratna, S.H. Tan, S.C. Poh, Z.L. Teo, J.P.Y. Loh, E.S. Yap, M. Richards, M. Chan (Singapore)

PB 786 A Chemical Screen for Small Molecule Modulators of Fibrinogen Production

R. Vilar, M. Neerman-Arbez, R.J. Fish (Switzerland) PB 787 The Novel 2MACE Score Predicts Cardiovascular Events in Atrial Fibrillation

PatientsJ.M. Rivera-Caravaca1, F. Marín1, M.A. Esteve-Pastor1, M. Valdés1, V. Vicente1, G.Y.H. Lip2, V. Roldán1 (1Spain, 2United Kingdom)

PB 788 Altered Platelet Lipidome Influences Thrombotic Disposition: Implications in

Acute Coronary Syndrome and Modulation by the CXCL12-CXCR4-CXCR7 AxisM. Chatterjee, D. Rath, J. Schlotterbeck, J. Rheinlaender, B. Walker-Allgaier, T.E. Schäffer, M. Lämmerhofer, T. Geisler, M. Gawaz (Germany)

PB 789 A Time-course Analysis of Activated Factor VII-antithrombin Complex Plasma

Concentration in the Follow-up of Patients with Angiographically-demonstrated Coronary Artery DiseaseF. Stefanoni1, A. Castagna1, M. Baroni1, F. Tosi1, G. Poli1, B. Lunghi1, S. Gaino1, B. Woodhams2, G. Lippi1, D. Girelli1, O. Olivieri1, F. Bernardi1, N. Martinelli1 (1Italy, 2United Kingdom)

PB 791 Up-Regulation of HO-1 by CORM-2 Attenuates Thrombin-Induced COX-2

Expression and Hypertrophy in Human CardiomyocytesC.-M. Yang (Taiwan)



314 315

Tues

day

Pos

ter

Ses

sion

s

PB 792 High Antithrombin Levels in Women Are Associated with a Lower Risk of Recurrent Arterial Thromboembolism or Death. Results from the Observational ATTAC-StudyF.N. Croles, M.P.M. De Maat, F. Leebeek (The Netherlands)

PB 793 The Role of Fasting Glucose Levels and Self-reported Diabetes in the Risk of a

First Event of Venous Thrombosis: The MEGA Case-control StudyR. Li-Gao, V.M. Morelli, W.M. Lijfering, S.C. Cannegieter, F.R. Rosendaal, A. van Hylckama Vlieg (The Netherlands)

PB 794 Urinary 11-dehydrothromboxane B2 Measurement Assays and their Clinical

CorrelationU. Tantry, R. Chaudhary, L. Lopez, K. Bliden, P. Gurbel (United States)

PB 795 The Value of sPESI for Risk Stratification in Patients with Pulmonary Embolism

P. Wells1, W.F. Peacock2, G.J. Fermann2, C.I. Coleman2, L. Wang2, O. Baser2, J. Schein2, C. Crivera2 (1Canada, 2United States)

PB 796 D-Dimer but Not Platelet Function Testing Improves Risk Stratification in

Patients Treated with Elective PCIA. Komarov, E. Guskova, E. Novikova, A. Samko, A. Deev, A. Dobrovolsky, E. Panchenko (Russian Federation)

PB 797 Increased Extracellular Nucleosome Levels, Biomarkers of Cell Death, in Atrial

Fibrillation Patients Compared to the Normal PopulationD. Hoppensteadt, S. Jabati, T. Phan, J. Liles, T. Rowe, J. Fareed, M. Syed (United States)

PB 798 vWF Thr789Ala Genetic Variants Correlates with the Type of Myocardial

Ischemia in Egyptian PatientsN. Osman, R. Yaseen (Egypt)

PB 799 The Incidence and Prognosis of Venous Thromboembolism (VTE) and Arterial

Thromboembolism (ATE) Associated with Oral Contraceptives by Age Groups in JapanK. Sugiura, T. Kobayashi, T. Ojima (Japan)

PB 800 Implementation of CHA2DS2-VASc and HAS-BLED Scoring E-tool for Aatrial

Ffibrillation Patients into Routine Clinical Practice in North Estonia Medical CentreJ. Arjakse, R. Berner, H. Ilumets, S. Kaarna, J. Kostjuk, M. Märk, T. Marandi (Estonia)

PB 801 Heightened Thrombogenicity in Women with Myocardial Infraction No

Obstructive Coronary Artery Disease: The Difference between the SexesP. Gurbel, R. Chaudhary, H. Tran, K. Bliden, A. Fitzgerald, U. Tantry (United States)

PB 802 Role of Matrix Metalloproteinase-2 and Correlation with the Anticoagulant System in DiabetesK. Nishihama, T. Yasuma, A. Takeshita, T. Totoki, Y. Takahashi, K. Fujiwara, C.N. D'Alessandro-Gabazza, M. Toda, T. Kobayashi, Y. Yano, E.C. Gabazza (Japan)

PB 804 Extracellular Nucleosomes, Markers of Cell Death, are Elevated in End-Stage

Renal Disease Independent of Circulating Microparticle-associated Tissue FactorT. Phan, R. Mcmillan, A. Walborn, D. Hoppensteadt, J. Fareed, V. Bansal (United States)

PB 805 Stroke Prevalence in Patients with Different Patterns of Atrial Fibrillation:

Cross-sectional Study of Moscow RegistryA. Melekhov, G. Gendlin, E. Dadashova, E. Alekseeva, I. Zaigraev, I. Nikitin (Russian Federation)

PB 806 Validation of a Patient-completed Caprini Risk Assessment Tool in a Spanish-

speaking PopulationH. Fuentes, L. Paz, D. Oramas, C. Acob, X. Andrade, A. Tafur, J. Caprini (United States)

PB 807 The Procoagulant Contribution of Tissue Factor Expressing Platelets in

HypertensionM. Brambilla, L. Rossetti, L. Lodi, P. Canzano, E. Tremoli, M. Camera (Italy)

PB 808 Patients with Multiple Cardiovascular Risk Factors Show a Characteristic

Decrease in Circulating MAIT CellsS. Fujii, K. Akasaka (Japan)

PB 809 Protein Z Deficiency: A Reliable Risk Factor for Acute Coronary Syndrome

D. Samir Eissa, M. Fawzy Ghozlan, A. Abd El-Hameed Mohamed, H. Shehata Eldawy (Egypt)

PB 810 Cardiac and Inflammatory Biomarkers and their Role in the Pathogenesis of

Heart Failure in End-Stage Renal DiseaseR. Mcmillan, V. Bansal, D. Hoppensteadt, J. Fareed (United States)

PB 811 Risk Factors for Recurrent Venous Thromboembolism in the Elderly

M. Al Subieg, F. Al-Eidan (Saudi Arabia) PB 812 Increased von Willebrand Factor Platelet Interactions in Patients with Chronic

PainI. Scharrer, M. Hoffmann (Germany)



316 317

Tues

day

Pos

ter

Ses

sion

s

PB 813 Routine Care Data in Prediction ResearchS. van Doorn, T. Brakenhoff, G.-J. Geersing, A.W. Hoes, K.G.M. Moons (The Netherlands)

PB 814 Markers of Plasma and Platelet Hemostasis Function as the Risk Factors for

Leg Amputation in Patients with Critical Limbs IschemiaJ. Budzyński, D. Rość, R. Wieczór, A.M. Wieczór, K. Stankowska, B. Ruszkowska-Ciastek, J. Kubiak, J. Fabisiak, K. Suppan, G. Pulkowski (Poland)

PB 815 Validation of a Patient-completed Caprini Risk Assessment Tool

H. Fuentes, L. Paz, A. Al-Ogaili, D. Oramas, C. Acob, A. Tafur, J. Caprini (United States)

PB 816 Patients with Diabetes Mellitus 2 on Treatment, with or without Previous

Cardiovascular Events, Have Delayed Clot Lysis, but Not Hyperactive Platelets Nor Increased Thrombin GenerationO. Panes, L. Quiñiñir, J. Pereira, R. Corbalán, D. Mezzano (Chile)

PB 817 Haemorrheologic and Fibrinolytic Activities in Diabetic Patient with

Hypertension in Calabar, NigeriaM.S. Edem, D.C. Okpokam, A.O. Emeribe (Nigeria)


PB 818 Efficacy, Safety, and Pharmacokinetics of a High-purity Plasma-derived Factor X (pdFX) Concentrate in the Prophylaxis of Bleeding Episodes in Children < 12 Years with Moderate to Severe Congenital Factor X Deficiency (FXD)R. Liesner, M. Gattens, C. Akanezi, J. Payne (United Kingdom)

PB 819 Characterization of an Aptamer Inhibiting Coagulation Factor XIa Identified

through in vitro Screening of a Single-stranded DAN LibraryD. Donkor, V. Bhakta, L. Eltringham-Smith, A. Stafford, J. Weitz, W. Sheffield (Canada)

PB 820 Three Dimensional Thrombus Architecture Formed under Flow Conditions

L. Hardy, F. Macrae, E. Hethershaw, R. Ariens, R. Foster, H. Philippou (United Kingdom)

PB 821 Administration of Dexamethasone during Initial Exposure to Factor VIII

Reduces Inhibitor Development in Hemophilia A Mice Via Thymic Tolerance Induction MechanismsM.T. Georgescu, P.C. Moorehead, K. Nesbitt, C. Hough, D.P. Lillicrap (Canada)

PB 822 Dual Mode of Interaction of Fibrinogen with the Staphylocoagulase•Prothrombin* ComplexA.A. Maddur, M. Voehler, P.R. Panizzi, J. Sheehan, I.M. Verhamme, J. Meiler, P.E. Bock (United States)

PB 823 Sensitive, Functional Assay for Detecting Polyphosphate in Plasma

C. Baker1, S. Smith1, M. Kalathottukaren2, C. Haynes2, J. Kizhakkedathu2, J. Morrissey1 (1United States, 2Canada)

PB 824 Combined IV and SC administration of Long-acting FVIIa (MOD-5014)

Significantly Improves the Pharmacokinetics (PK), Pharmacodynamics (PD) and Pharmacological Long-term Outcome in Preclinical and Toxicological Models, Supporting the Initiation of a Clinical Study Combining Prophylactic and On-demand TreatmentsM. Hoffmann, L. Israeli Yagev, A. Bar-Ilan, G. Hart (Israel)

PB 825 Factors Influencing the Recanalization of Deep and Superficial Venous

Thrombosis of Lower LimbsA. Spirkoska, P. Poredos (Slovenia)

PB 826 Effect of Platelet Depletion and Thrombin Inhibition on Tail Bleeding in Wild

Type and FXI-deficient MiceJ. Mueller, M.V. Schmidt, S. Heitmeier, C. Luecker, V. Laux (Germany)

PB 827 Interrelation between Levels of Hemostatic Factors, Lipids and C-reactive

Protein in Population ControlsV.M. Morelli, R. Li-Gao, W.M. Lijfering, F.R. Rosendaal, S.C. Cannegieter, A. van Hylckama Vlieg (The Netherlands)

PB 828 Selective Inhibition of Protein S Anti-coagulant Functions Restores in vitro

Thrombin Generation in Haemophilia A and B PlasmaJ. Lund, E. Waters, L.M. Andersen, G. Røder, B. Olsen Krogh, H. Demuth, M. Brunsgaard Hermit, H. Lindgreen Holmberg (Denmark)

PB 829 Treatment of a Subdural Hematoma and Long-term Secondary Prophylaxis in a

Patient with Severe Factor X (FX) Deficiency Treated with a High-purity Plasma-derived Factor X (pdFX) ConcentrateK. Kavakli, C. Balkan, D. Yilmaz Karapinar (Turkey)

PB 830 Differential Coagulotoxic Effects of Asian Pitviper Snake Venoms: Evolutionary,

Pathophysiology and Biodiscovery ImplicationsJ. Debono, B. Fry (Australia)

PB 831 The Effect of Histone H4 on Coagulation Enzymes and Complexes in Purified

SystemsS. Prior, S. Butenas (United States)



318 319

Tues

day

Pos

ter

Ses

sion

s

PB 832 CP-5-001: A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics Profile of a Long-acting Recombinant Factor VIIa (MOD-5014) in Adult Men with Hemophilia A or BG. Young1, D.V. Quon1, M.A. Escobar1, L.N. Boggio1, M.E. Eyster1, M.V. Ragni1, N.P. Ewing1, A. Shapiro1, M.D. Tarantino1, G. Hart2, G. Kenet2 (1United States, 2Israel)

PB 833 Age-related Variation in the Glycosylation of Alpha-2-Macroglobluin

L. Calvert, H. Atkinson, J. Macri, L. Berry, A. Chan (Canada) PB 834 First Evaluation of the Safety, Pharmacokinetics and Pharmacodynamics of

BAY 1213790, a Full Human IgG1 Antibody Targeting Coagulation Factor XIa, in Healthy Young MenD. Thomas, K. Thelen, D. van der Mey, S. Schwers, S. Schiffer, S. Unger, J. Heubach, A. Yassen, S. Boxnick (Germany)

PB 835 Case Study of Successful Transition to Human Cell Line Fc Fusion Factor

IX Replacement without Premedication in an Adolescent Male with Severe Hemophilia B, Anaphylactoid Reaction to FIX Replacement, and Previous History of Inhibitor and Nephrotic SyndromeA. Federizo (United States)

PB 836 Estimates of within-subject Biological Variation of Factor VIII, von Willebrand

Factor Antigen, Fibrinogen, Prothrombin Time, INR and APTT in Pregnant WomenA.H. Kristoffersen, P. Hyltoft Petersen, T. Roraas, S. Sandberg (Norway)

PB 837 A Snake-venom Enzyme (Noscarin)-based Assay for APC-resistance Is Not

Influenced by Non-vitamin K Antagonist Oral Anticoagulants (NOAC)A.C. Brisset1, C. Stocker1, M. Janssen1, W. Renner2, H. Mangge2, F. Prüller2 (1Switzerland, 2Austria)

PB 838 APC and TFPI Cofactor Activities of Thrombin-cleaved Protein S and C4BP-

protein S ComplexN. Alshaikh, J. Rosing, T. Hackeng (The Netherlands)

PB 839 Anticoagulants Differentially Affect Procoagulant Platelet Formation

S. Wang, H. Campbell, G. Pennings, C. Reddel, L. Pasalic, V. Chen (Australia) PB 840 A Novel Hypoxia Response Element Regulates Oxygen-related Repression of

Tissue Factor Pathway Inhibitor ExpressionX. Cui, G. Skretting, B. Stavik, M. Tinholt, A.E.A. Dahm, S. Kanse, N. Iversen, P.M. Sandset (Norway)

PB 841 Impact of Thrombomodulin on Spatial Clot Growth and Fibrin Polymerization in Cirrhotic PatientsA. Lebreton1, T. Sinegre1, C. Duron1, A. Abergel1, A. Casini2 (1France, 2Switzerland)

PB 842 Biomechanisms of a Severe Hypersensitivity Reaction Induced by Factor IX in

Hemophilia B Complicated by Factor IX InhibitorM. Cugno, M.E. Mancuso, A. Tedeschi, E. Santagostino, M. Lorini, V. Carbonelli, F. Peyvandi, P.M. Mannucci (Italy)

PB 843 The Thrombomodulin Resistance in Prothrombin Belgrade Mutation Carriers

V. Djordjevic1, P. Miljic1, Y. Takagi2, A. Takagi2, M. Gvozdenov1, I. Pruner1, J. Bodrozic1, B. Tomic1, D. Radojkovic1, T. Kojima2 (1Serbia, 2Japan)

PB 844 Hereditary Factor X (FX) Deficiency in Females: Treatment with a High Purity

Plasma-derived Factor X ConcentrateR. Kulkarni1, A. James1, M. Norton2, A. Shapiro1 (1United States, 2United Kingdom)

PB 845 Factor VII Deficiency: A Center Experience

A.R. Fernandes, M. Antunes, M.J. Diniz (Portugal) PB 846 ADP and ATP Inhibit Factor X Activation by Factor VIIa/Tissue Factor

Y. Wang, J. Morrissey (United States) PB 847 Intracranial Hemorrhage in Neonates and Infants with Congenital Bleeding

Disorders: The Experience of Çukurova University Hemophilia CenterB. Antmen, I. Sasmaz, B. Karagun, G. Leblebisatan, Y. Kilinc (Turkey)

PB 848 A Novel Mutation in the F7 Gene in a Tunisian Patient with Factor VII

DeficiencyH. Elmahmoudi, C. Ouardani, M. Achour, A. Jlizi, H. Ben Neji, K. Zahra, B. Meddeb, E. Gouider (Tunisia)

PB 849 A Rat-human Cross-species Compatibility Study: Catalytic Efficiency for

Activation of Rat FX Is Decreased for Human FVIIa Compared to Rat FVIIaI. Tuneew, M. Kjelgaard-Hansen, J. Lund, L. Moreau Andersen (Denmark)

PB 851 Investigations of Plasma-soluble Fibrin: Implications of Enhanced Functionally-

assayed Fibrinogen Level, Erythrocyte Sedimentation, Fibrin Self-assembly, and Clot LysisD.K. Galanakis, C. Marmorat, L. Zhang, M. Golightly, M. Rafailovich (United States)



320 321

Tues

day

Pos

ter

Ses

sion

s

PB 852 Correlation Analysis of Standard Bethesda Method versus Modified Nijmegen Assay in Detecting Factor VIII Inhibitors, and Impact of Marginal Titer Inhibitors on FVIII Pharmacodynamics and Pharmacokinetics in Patients with Hemophilia AA. Batorova, A. Morongova, D. Jankovicova, T. Prigancova, M. Mistrik (Slovakia)

PB 853 Differences in Levels of Markers of Inflammation and Endotelial Damage

between the Blood from Varicose Veins and Systemic BloodA. Spirkoska, P. Poredos, M.K. Jezovnik (Slovenia)

PB 854 Intracranial Hemorrhage in an Infant with Factor V Deficiency

E. Turkkan, F. Aygun, Y. Turkmenoglu (Turkey) PB 855 Detection of Specific and Non-specific Inhibitors in Patients of Hemophilia A

A. Naz, F. Ahmed, S. Ansari, T. Shamsi (Pakistan) PB 856 Interim Safety of a Long-acting Recombinant Factor VIIa (MOD-5014): A Phase

1 Study in Adult Subjects Following Subcutaneous AdministrationG. Hart, R. Arison, L. Binder, G. Kenet (Israel)

PB 857 Replacement Therapy in ALL Patients Treated with L-asparaginase

A. Freixo, P. Chorão, C. Monteiro, M. Carvalho, L. Gonçalves, F. Principe, J.E. Guimarães, M.C. Koch (Portugal)

PB 858 Hemarthrosis in Rare Factor Deficiencies

Z. Salcioglu, H. Şen, G. Aydoğan, F. Akıcı, Z. Başlar (Turkey) PB 859 Amyloidosis Induced Abnormal Coagulopathy Associated with Multiple

Coagulation Factor DeficienciesU.Y. Malkan, H. Demiroglu, S. Aksu, I.C. Haznedaroglu, N. Sayinalp (Turkey)

PB 860 Protein S Inhibits Apoptosis of Islet β Cells via Regulating BIRC3 Expression

and AKT SignalingT. Yasuma, A. Takeshita, K. Nishihama, C.N.D. Gabazza, M. Toda, K. Fujiwara, E. Harada, T. Kobayashi, Y. Yano, E.C. Gabazza (Japan)

PB 861 Spatiotemporal Modulation of the Protease Activated Receptors Signaling

Protects against Diabetic NephropathyS. Ghosh1, T. Madhusudhan1, H. Wang2, J. Manoharan1, D. Gupta1, B. Isermann1 (1Germany, 2China)

PB 862 Overexpression of Protein S Exacerbates Carbon Tetrachloride-induced Liver

Injury and Fibrosis in MiceT. Totoki, C.N. D'Alessandro-Gabazza, R. Mifuji-Moroka, K. Nishihama, A. Takeshita, T. Yasuma, Y. Takahashi, K. Fujiwara, M. Toda, M. Nakamura, N. Horiki, M. Iwasa, T. Kobayashi, Y. Takei, E.C. Gabazza (Japan)

PB 863 Signal through the Regulatory Subunits of PI3Kinase Endows Coagulation Protease Activated Protein C with Hormone Like FunctionM. Thati, H. Wang, S. Ghosh, W. Dong, W. Ruf, B. Isermann (Germany)

PB 864 Rivaroxaban Ameliorates Neuroinflammation

M. Merker, S. Eichler, A.M. Herrmann, H. Wiendl, C. Kleinschnitz, K. Göbel, S.G. Meuth (Germany)

PB 865 Novel Role of Protein S in Clot Retraction: Induction of Apoptosis in Activated

PlateletsV. Pilli, A. Datta, E. Lazartigues, R. Majumder (United States)

PB 866 Thrombomodulin Dependent PC Activation Protects from a Senescence-like

Tubular Phenotype in Diabetic Nephropathy (dNP)M.M.A. Al-Dabet, K. Shahzad, I. Gadi, S. Kohli, F. Bock, S. Nazir, B. Isermann (Germany)

PB 867 Coagulation Proteases are Potential Regulators in the Development of Exercise-

associated arterial EndofibrosisJ.J. Posthuma, J.J.N. Posma, G. Schep, M. Bender, R. van Oerle, H. ten Cate, H.M.H. Spronk (The Netherlands)

PB 868 Biochemical and Pharmacological Differentiation of APC and Recombinant

Thrombomodulin with Reference to the Effect on the Hemostatic and Fibrinolytic ProcessesJ. Fareed, D. Hoppensteadt, W. Jeske, O. Iqbal, S. Abro, D. Clarizio, S. Raghuvir, R. Wasmund, K. Tanaka, K. Tsuruta (United States)

PB 869 Plasminogen-deficient Patients

H. Kızılocak1, G.N. Özdemir1, G. Dikme1, B. Koç1, G. İskeleli1, B. Dönmez Demir1, N.M. Christiansen2, M. Ziegler2, H. Özdağ1, V. Schuster2, T. Celkan1 (1Turkey, 2Germany)

PB 870 Direct Factor Xa Inhibitor Apixaban Prevents Endothelial Activation and

Damage Associated with Chronic Kidney DiseaseS. Torramade-Moix, M. Palomo, M. Vera, A. Cases, G. Escolar, M. Diaz-Ricart (Spain)

PB 871 A Factor X Activator from Caterpillar Triggers Cell Survival on Fibroblasts in

Response to Serum Deprivation by Inhibition of ApoptosisM.P. Alvarez-Flores, R.V. Bosch, D.A. Maria, A.M. Chudzinski-Tavassi (Brazil)

PB 872 Protective Effect of Protein S against the Development of Diabetic Nephropathy

in MiceA. Takeshita, K. Nishihama, T. Yasuma, K. Fujiwara, E. Harada, C.N. D'Alessandro-Gabazza, M. Toda, T. Kobayashi, Y. Yano, E.C. Gabazza (Japan)



322 323

Tues

day

Pos

ter

Ses

sion

s

PB 873 A Significant Change in Laboratory Markers of Thrombosis Very Early in the First Trimester of Pregnancy May be Linked to a Concurrent Increase in EstradiolC.N. Bagot, E. Leishman, C.C. Onyiaodike, F. Jordan, D.J. Freeman (United Kingdom)

PB 874 Analysis of Estrogen Mediated Expression of TFPI-2 by miRNAs in Breast

Cancer CellsM.S. Andresen, N. Iversen, M. Tinholt, C.F. Myklebust, K.K. Sahlberg, B. Stavik, P.M. Sandset, G. Skretting (Norway)

PB 875 Comparative Studies on the Inhibition of Thrombin by Recombinant

Thrombomodulin in Activated Protein C and Whole Blood PlasmaJ. Fareed, W. Jeske, D. Hoppensteadt, J. Walenga, P. Maia, K. Tanaka, K. Tsuruta (United States)

PB 876 Activation of the Hepatocyte Growth Factor/c-met Pathway during Experimental

Envenomation of Rats with Bothrops Jararaca or Crotalus Durissus Terrificus Snake VenomsB. Prezoto, L. Gonçalves, S. Sampaio, I. Sano-Martins (Brazil)

PB 877 Targeted Inhibition of Activated Protein C by an Exosite Antibody to Treat

HemophiliaX.-Y. Zhao1, A. Wilmen2, X. Wang3, L. Linden2, U. Egner2, J. Glueck2, K. McLean1, S. Yegneswaran1, X. Jiang1, V. Evans1, I. Ivens1, Y. Xu1, A. Hesslein1, V. Laux2, C. Patel1 (1United States, 2Germany, 3China)

PB 878 Silencing of Anticoagulant Protein C Evokes Low Incident but Spontaneous

Atherothrombosis in Apolipoprotein E Deficient MiceM. Heestermans, A.B. Ouweneel, R.A.F. Verwilligen, M. Gijbels, P.H. Reitsma, M. van Eck, B.J.M. van Vlijmen (The Netherlands)

PB 879 Protection of the Endothelial Protein C Receptor (EPCR) against Inactivation by

P. falciparum Erythrocyte Membrane Protein 1 (PfEMP1) Domains with a Non-inhibitory Anti-EPCR AntibodyJ. Barber-Singh1, E.A.M. Bouwens1, J.E.V. Petersen2, K.F.E. Lee3, P. Cowan3, H. Gock3, H. Weiler1, K. Fukudome4, L. Turner2, T. Lavstsen2, L. Mosnier1 (1United States, 2Denmark, 3Australia, 4Japan)

PB 880 Characterization of an In vivo Mouse Model for the Binding of P. falciparum

Erythrocyte Membrane Protein 1 (PfEMP1) Domains to the Endothelial Protein C Receptor (EPCR)J. Barber-Singh1, L. Turner2, K.F.E. Lee3, P. Cowan3, H. Gock3, H. Weiler1, T. Lavstsen2, L. Mosnier1 (1United States, 2Denmark, 3Australia)

PB 881 Antithrombin and Protein C Plasma Levels at Admission Are Associated to Mortality at Six Months in Patients with Pulmonary Embolism with and without Malignant DiseaseS. Obradovic, B. Dzudovic, B. Subotic, M. Stavric, V. Subota, D. Mikovic (Serbia)

PB 882 Positive Correlation of Plasma Protein S Levels to Apolipoprotein C-II in

Middle-aged Obese Women and Non-obese Young WomenY. Otsuka, M. Ueda, E. Nakazono, T. Tsuda, X. Jin, K. Noguchi, H. Miyazaki, S. Nakano, H. Tsuda (Japan)

PB 883 Hepatocyte Growth Factor Reduces Protein C Inhibitor Expression in HepG2

Cells via MEK and PI3 KinaseT. Hayashi, N. Akita, T. Okamoto, J. Nishioka, K. Suzuki (Japan)

PB 884 Differential Modulation of Plasminogen Activator Mediated Thrombolysis by

Recombinant Thrombomodulin and Activated Protein CJ. Fareed, Z. Siddiqui, S. Raghuvir, R. Wasmund, O. Iqbal, W. Jeske, D. Hoppensteadt, K. Tanaka, K. Tsuruta (United States)

PB 885 G-quadruplex-Directed Aptamer Selection against Activated Protein C (APC)

N. Shahidi Hamedani, S. Gasper, J. Oldenburg, G. Mayer, B. Pötzsch, J. Müller (Germany)

PB 886 The Protective Effect of Activated Protein C as the Baised Agonism in

Activation of Protease-activated Receptor 1L. Gorbacheva, S. Strukova (Russian Federation)

PB 887 Function and Prevalence of Host-derived Coagulation Factors on the Virus

SurfaceB.H. Lin, M.R. Sutherland, E.L.G. Pryzdial (Canada)

PB 888 Decryption of Hepatocyte Tissue Factor Procoagulant Activity by Bile Acids

Requires Non-apoptotic Phosphatidylserine ExternalizationK. Baker, A. Kopec, N. Joshi, H. Cline-Fedewa, J. Luyendyk (United States)

PB 889 Clustering of CD98 on Monocytic THP1 Cells Increases Tissue Factor

Procoagulant ActivityF. Langer, B. Spath, C. Lehr, B. Sievers, W. Ruf (Germany)

PB 890 A First-in-Human (FIH) Study of the Safety, Tolerability, Pharmacokinetics

(PK) and Pharmacodynamics (PD) of PF-06741086, an anti-TFPI Monoclonal Antibody, Following Administration of Single Subcutaneous or Intravenous Doses in Healthy Adult Male VolunteersM. Cardinal1, C. Kantaridis2, T. Zhu1, P. Sun1, D. Pittman1, J. Murphy1, S. Arkin1 (1United States, 2Belgium)



324 325

Tues

day

Pos

ter

Ses

sion

s

PB 891 Hypoxia Augments Tissue Factor Expression in Inflammatory Stimulated Macrophages but Not in Smooth Muscle Cells or in Endothelial CellsK. Maekawa, A. Yamashita, K. Hatakeyama, K. Nishihira, Y. Asada (Japan)

PB 892 BAY 1093884 Binds to the Kunitz 1 and 2 Domain Interface of Tissue Factor

Pathway Inhibitor and Inhibits its FunctionS. Yegneswaran1, V. Evans1, X. Jiang1, L. Leong1, H. Steuber2, U. Egner2, M. Koellnberger2, C. Patel1 (1United States, 2Germany)

PB 893 mTOR Inhibitors Reduce Expression of Tissue Factor Isoforms in

Neuroendocrine Tumors of the PancreasC.S. Lewis1, H. Elnakat Thomas1, M. Orr-Asman1, L.C. Green1, F.V. Lucas1, N. Mackman1, H.H. Versteeg2, V.Y. Bogdanov1 (1United States, 2The Netherlands)

PB 894 High Plasma Concentration of Activated Factor VII-antithrombin Complex is

Associated with an Increased Activated Factor X GenerationF. Stefanoni1, M. Baroni1, B. Lunghi1, A. Castagna1, N. Ziliotto1, F. Tosi1, D. Minguzzi1, S. Udali1, B. Woodhams2, D. Girelli1, O. Olivieri1, N. Martinelli1, F. Bernardi1 (1Italy, 2United Kingdom)

PB 895 Renin-angiotensin System Blockade Downregulates Tissue Factor Expression

Induced by γ-Glutamyltransferase in Human Peripheral Blood Mononuclear Cells Exposed to High GlucoseV. Scalise, C. Balia, S. Cianchetti, T. Neri, V. Carnicelli, R. Zucchi, A. Celi, R. Pedrinelli (Italy)

PB 896 Over-activation of Src1 Mediates Tissue Factor-induced Apoptosis in

Endothelial CellsA. Ethaeb, J. Greenman, C. Ettelaie (United Kingdom)

PB 897 Indoleamine 2,3-dioxygenase 1 Enhances Tissue Factor Expression in Coronary

Atherosclerotic PlaqueA. Yamashita, Y. Watanabe, K. Maekawa, K. Kitamura, Y. Asada (Japan)

PB 898 Application of a Quantitative Systems Pharmacology (QSP) Model of Human

Blood Coagulation to Understand the Response of Clinical Biomarkers from a Recent Anti-TFPI Trial in Healthy SubjectsS. Nayak1, T. Zhu1, C.N. Lim1, D.D. Pittman1, M.H. Cardinal1, S.W. Martin1, L.O. Harnisch2, S. Arkin1, J. Murphy1 (1United States, 2United Kingdom)

PB 899 Coagulation and Angiogenesis Parameters in Essential Thrombocythemia

D. Rość, G. Gadomska, K. Stankowska, J. Boinska, J. Filipiak (Poland) PB 900 Simulation of Factor X Activation by Extrinsic Tenase on Phospholipid Vesicles:

Size Matters!T. Kovalenko, M. Panteleev, A. Sveshnikova (Russian Federation)

PB 901 Rutin (quercetin-3-rutinoside) Modulates Hemostatic Disturbances and Reactive Species Levels in Experimental Bothrops jararaca EnvenomationM.L. Santoro, A.T.A. Sachetto (Brazil)

PB 902 Measurement of Tissue Factor Molecules and Factor Xa Generation on Vascular

CellsM. Rosas, C.P. Thomas, D.A. Slatter, V. Jenkins, V.B. O'Donnell, P.W. Collins (United Kingdom)

PB 903 Tissue Factor Pathway Inhibitor Polymorphism 399C>T Predisposes to

Idiopathic DVT in Young IndiansR. Saxena, K. Kishor, A. Sharma, R. Ranjan, P. Mishra, M. Mahapatra (India)

PB 904 Role of Tissue Factor 603A>G and 5466A>G Polymorphisms in the

Development of DVT in Young IndiansK. Kishor, A. Sharma, R. Ranjan, H. Pandey, P. Mishra, R. Saxena (India)

PB 905 Tissue Factor Gene Polymorphisms (A603G, C1322T, C1812T, G1442C) in

Healthy Individuals and Patients with Erysipelas in Transbaikalian RegionA. Emelianov, A. Emelianova, Y. Vitkovsky (Russian Federation)


PB 906 Thrombin-activable Fibrinolysis Inhibitor (Procarboxypeptidase B2) Deficiency Protects from Carbon Tetrachloride-induced Liver FibrosisT. Totoki, C.N. D'Alessandro-Gabazza, R. Mifuji-Moroka, K. Nishihama, A. Takeshita, T. Yasuma, Y. Takahashi, K. Fujiwara, M. Toda, M. Nakamura, N. Horiki, M. Iwasa, T. Kobayashi, Y. Takei, E.C. Gabazza (Japan)

PB 907 Transcriptional Regulation of the Tissue Factor Gene is Mediated by the

Androgen ReceptorB. Hoesel1, M. Mussbacher1, M. Salzmann1, H. Paar1, A. Assinger1, N. Mackman2, J. Schmid1 (1Austria, 2United States)

PB 908 Factor V Expression in Aggressive Breast Cancer Modifies Patient Survival,

Tumor Cell Growth and Response to TreatmentM. Tinholt, M. Sletten, Ø. Garred, K.K. Sahlberg, P.M. Sandset, N. Iversen (Norway)

PB 909 Low Phosphatase Activity Mediates L-selectin Shedding in B-CLL

I. Beke Debreceni, R. Szász, Z. Kónya, F. Erdődi, G. Vereb, J. Kappelmayer (Hungary)



326 327

Tues

day

Pos

ter

Ses

sion

s

PB 910 Platelet-dependent von Willebrand Factor Activity in Acute Myeloid Leukemia Patients: Role in Haemostatic AlterationsB. Farweez, H. Abaza, S. Samaan (Egypt)

PB 911 Fibronectin Supports Glioma Invasion and Colonization of Fibrin in Co-

operation with Slug/Snail2L.M. Knowles, C. Wolter, A. Burkardt, S. Urbschat, R. Ketter, D. Lessig, I. Müller, H. Eichler, J. Pilch (Germany)

PB 912 Altered Fibrin Clot Properties in Advanced Lung Cancer: Impact of

ChemotherapyM. Zabczyk, G. Krolczyk, G. Czyzewicz, A. Undas (Poland)

PB 913 The Effect of Neoadjuvant Chemotherapy on the Activated Protein C (aPC)

Pathway in High Grade Serous Ovarian Cancer PatientsM.P. Ward, F.A. Saadeh, J.J. O'Leary, N. Gleeson, S.A. O'Toole, L.A. Norris (Ireland)

PB 914 Inhibition of Tumour Cell-induced Platelet Aggregation by a Novel Stat3

Inhibitor in Podoplanin Positive Cancer CellsK.-Y. Chong, P.-S. Lu, P.-Y. Lin, Y.-W. Chang, T.-T. Huang (Taiwan)

PB 915 Cancer Stromal Targeting Therapy Using MMAE Conjugated Anti-insoluble

Fibrin AntibodyH. Fuchigami, S. Manabe, T. Obonai, M. Yasunaga, Y. Matsumura (Japan)

PB 916 A Linkage between ERBB2 Expression and the Pro-coagulant Properties of

Breast Cancer Cells is Mediated by the PI3k/Akt Signaling PathwaysC. Yunliang, M. Scully, A. Kakkar (United Kingdom)

PB 917 Exosomes from Heparin-treated Cancer Cells Exhibit Transferable Anti-

tumorigenic ActivityC. Yunliang, M. Scully, A. Kakkar (United Kingdom)

PB 918 Sonic Estimation of Elasticity via Resonance (SEER) Sonorheometry to Identify

Hypercoagulability in Patients with CancerE. McLoughlin, E. Ferrante, F. Viola, H. Maitland (United States)

PB 920 Direct Oral Anticoagulants Do Not Inhibit Growth and Metastasis of

Orthotopically Growing Claudin-low MDA-MB-231 Human Breast Cancer Cells in Immunodeficient miceJ.T. Buijs, C. Tieken, K. van der Molen, J. Crooijmans, C. Kroone, N. Swier, G. van der Pluijm, S.E. le Dévédec, H.H. Versteeg (The Netherlands)

PB 921 Does Remote Ischemic Preconditioning Increase Fibrinolysis in Head and Neck Cancer Surgery? Preliminary Results from a Randomized Controlled TrialA.E. Krag, B.J. Kiil, C.L. Hvas, A.-M. Hvas (Denmark)

PB 922 The Role of asTF in Glioblastoma Multiforme

M.Y. Kapteijn, B. Ünlü, H.H. Versteeg (The Netherlands) PB 923 Tumoral Factor VII Expression Changes TGF-β-mediated Intercellular

Communication in Breast CancerM. Paauwe, R. Hikmet, E.H. Laghmani, H.H. Versteeg (The Netherlands)

PB 924 Chemotherapy as a Factor in the Pathogenesis of Thrombosis in Patients with

Ovarian CancerA. Vorobev, A. Makatsariya, A. Solopova (Russian Federation)

PB 925 Preoperative Panel Scores of CA 19-9, FVIII and D-dimer Predict Postoperative

Survival in Pancreatic Ductal AdenocarcinomaN. Mattila, H. Seppänen, C. Haglund, R. Lassila (Finland)

PB 926 Expression of Coagulation Proteases from the Activated Protein C Pathway in

Ovarian TumoursC. Spourquet, M.P. Ward, F.A. Saadeh, J.J. O'Leary, N. Gleeson, S.A. O'Toole, L.A. Norris (Ireland)

PB 927 Mucin1 Acts as a Potential Mediator of the Pro-coagulant Properties of Breast

Cancer Cells by Altering the Activity of Key Phosphokinase PathwaysC. Yunliang, M. Scully, A. Kakkar (United Kingdom)

PB 928 Coagulation Factor Xa Promotes Melanoma Metastasis

M. Arce, M. Galleguillos, C. Ramirez, R. Erices, L. Lobos, L. Leyton, A. Quest, G. Owen (Chile)

PB 929 Identification of Novel Molecular Targets of the Kunitz-type Molecule

Amblyomin-X Using Immuno-fishing Interactomics ApproachA.M. Chudzinski-Tavassi, A. Iqbal, K.L.P. Morais, M.B. Goldfeder (Brazil)

PB 930 Dissolution of Platelet-rich Thrombus by Perfusion of N-acetyl Cysteine

S.M. Hastings, D.N. Ku (United States)

PB 931 Thrombolysis by rt-PA Combinated with Anticoagulant and Antiaggregant Molecules under Flow ConditionsS. Loyau, Y. Boulaftali, N. Ajzenberg, B. Ho Tin Noe, M. Jandrot-Perrus (France)



328 329

Tues

day

Pos

ter

Ses

sion

s

PB 932 Systematic Review and Meta-analysis of Treatments for Massive and Submassive Pulmonary EmbolismL.A. Castellucci, S. Gupta, M. Carrier (Canada)

PB 933 Structure and Function of Trypsin-loaded Fibrinolytic Liposomes

A. Tanka-Salamon, A. Bóta, A. Wacha, L. Szabó, J. Mihály, M. Lovas, K. Kolev (Hungary)

PB 934 Changes in Treatments and Outcomes after Creation of a Pulmonary Embolism

Response Team (PERT)R. Rosovsky, Y. Chang, K. Rosenfield, R. Channick, M. Jaff, I. Weinberg, T. Sundt, A. Witkin, J. Rodriguez-Lopez, B. Parry, S. Harshbarger, P. Hariharan, C. Kabrhel (United States)

PB 935 Comparing Emergency Department Patients to Inpatients Receiving a

Pulmonary Embolism Response Team (PERT) ActivationE. Deadmon, N. Giordano, K. Rosenfield, R. Rosovsky, B. Parry, R. Al-Bawardi, C. Kabrhel (United States)

PB 936 Indications and Results of Treatment with Ultrasound Assisted Cathether

Thrombolysis in Patients with Pulmonary EmbolismS. Obradovic, B. Subotic, B. Dzudovic, M. Stavric, V. Subota, N. Antonijevic (Serbia)

PB 937 In vitro Thrombolytic Action of New Fibrinolytic Enzyme Complexes -

Strictoliase and LilasynE.I. Kornienko, A.A. Bobrovskaya , N.S. Fokichev, A.A. Osmolovskiy, T.S. Sharkova (Russian Federation)

PB 938 A Case Series of Low Dose Alteplase for Submassive Pulmonary Embolism (PE)

J. Lozier, A. Suffredini, D. Rosing, J. Elinoff, R. Sherry, A. Metwalli, R. Chang (United States)

PB 939 Successful Thrombolysis of Huge Right Atrial Thrombus in a Patient with

Primary Repair of Atrial Septal DefectB. Shakerian, N. Razavi (Iran, Islamic Republic of)

PB 940 Thrombolytic Properties of Longolytin - Proteinase Complex from Impertfect

Fungi Arthrobotrys Longa - in Dependence on its Fibrinolytic ActivityT. Sharkova, L. Podorolskaya, I. Pavlova (Russian Federation)

PB 941 Sub-massive PE - A Role for Low Dose Thrombolysis?

M.P. Crowley, T. Mason, K.A. Breen, B.J. Hunt, N. Karunanithy, B. Lams, A. West (United Kingdom)

PB 942 A Complex Non-invasive Assessment of the Effect of Hirudotherapy on Structural and Functional State of Vascular BedI. Pavlova, Pavlova I.B., Parfenov A.S. (Russian Federation)


PB 943 Genetic Risk Stratification to Minimize Inhibitor Risk with the Use of Recombinant Factor VIII Concentrates: A SIPPET AnalysisF.R. Rosendaal1, R. Palla2, I. Garagiola2, P.M. Mannucci2, F. Peyvandi2, SIPPET Study group (1The Netherlands, 2Italy)

PB 944 Pharmacokinetics of Recombinant Fusion Protein Linking Activated Factor VIIa

to Human Albumin (rVIIa-FP), Eptacog Alfa and Plasma-derived Factor VII in Patients with Congenital FVII DeficiencyP.A. Holme1, B. Laros-van Gorkom2, W. van Heerde2, C. Joch3, S. Puli3, J. Roberts3 (1Norway, 2The Netherlands, 3United States)

PB 945 Bone Properties in Children with Hemophilia A: Influence of Target Joint and

FVIII InhibitorP. Xafaki, A. Balanika, H. Pergantou, O. Papakonstantinou, H. Platokouki (Greece)

PB 946 Longitudinal Modified Hemophilia Joint Health Scores (mHJHS) in Children,

Adolescents, and Adults with Severe Hemophilia A with Long-term rFVIIIFc ProphylaxisJ. Oldenburg1, R. Kulkarni2, A. Srivastava3, J. Mahlangu4, E. Tsao2, B. Winding5, N. Jain2 (1Germany, 2United States, 3India, 4South Africa, 5Sweden)

PB 947 Obesity and Dosing of Replacement Therapy in Hemophilia; How to Optimize?

H.C.A.M. Hazendonk, T. Preijers, I. van Moort, K. Meijer, B.A.P. Laros-van Gorkom, F.J.M. van der Meer, K. Fijnvandraat, F.W.G. Leebeek, R.A.A. Mathôt, M.H. Cnossen, OPTI-CLOT study group (The Netherlands)

PB 948 Safety of Nonacog Beta Pegol (N9-GP): Results from the paradigm™ Clinical

TrialsP. Collins1, M. Carcao2, M. Simonsen3, S. Ehrenforth4, S. Lentz5, J.N. Mahlangu6, M.E. Mancuso7, J. Oldenburg8, C. Negrier9 (1United Kingdom, 2Canada, 3Denmark, 4Switzerland, 5United States, 6South Africa, 7Italy, 8Germany, 9France)



330 331

Tues

day

Pos

ter

Ses

sion

s

PB 949 Perioperative Replacement Therapy in Hemophilia B: Should We “B” More Precise?H.C.A.M. Hazendonk1, R. Liesner2, P. Chowdary2, M.H.E. Driessens1, D. Hart2, D. Keeling2, B.A.P. Laros-van Gorkom1, F.J.M. van der Meer1, K. Meijer1, R.A.A. Mathôt1, K. Fijnvandraat1, F.W.G. Leebeek1, P.W. Collins2, M.H. Cnossen1, OPTI-CLOT Study Group (1The Netherlands, 2United Kingdom)

PB 950 Identification of Patient and Disease-related Characteristics Influencing the

Risk of Bone Fracture in Individuals with HaemophiliaP. Miljic, J. Bodrozic, D. Miljic, D. Lekovic, M. Mitrovic (Serbia)

PB 951 Post-partum Bleeding in Women who Are Carriers of and Who Have Bleeding

Disorders: A Case-Control StudyS. Wolf, S. Montes-Otalvaro, B. Shohreh, J. Pasi, H. Daniel, C. Foley, K. Forsyth, A. Morris, W. Maposa, B. Louise (United Kingdom)

PB 952 Prophylaxis with rIX-FP Reduces Consumption Compared with Previous FIX in

Both Adult and Pediatric PatientsM. Escobar1, E. Santagostino2, C. Lessinger1, A. Shapiro1, J. Oldenburg3, B. Pan-Petesch4, W. Seifert3, the PROLONG-9FP Investigators (1United States, 2Italy, 3Germany, 4France)

PB 953 Dosing of rVIII-SingleChain Based on Clinical Bleeding Phenotypes Results in

Low Bleeding Rates in Pediatric Patients Treated with Prophylaxis Two or Three Times WeeklyM. Simpson1, K. Fischer2, J. Oldenburg3, M.T. Álvarez-Román4, T. Lambert5, M. Wang1, D. Bensen-Kennedy1, O. Stasyshyn6 (1United States, 2The Netherlands, 3Germany, 4Spain, 5France, 6Ukraine)

PB 954 Factor VIII (FVIII) Inhibitor Testing Using a Validated Chromogenic Bethesda

Assay (CBA) in HAVEN 1 (BH29884), a Phase 3 Trial of Emicizumab in Persons with Hemophilia A (PwHA) with InhibitorsJ.I. Adamkewicz1, C. Schmitt2, E. Asikanius2, J. Xu1, G. Levy1, B. Kim1, A. Calatzis2 (1United States, 2Switzerland)

PB 955 Recombinant FVIII Product Type and the Risk of Inhibitor Development in

Previously Treated Patients with Hemophilia A: Preliminary Results of a Systematic Review and Meta-analysisA. Cannavo`1, S. Hassan2, S. Gouw2, F.R. Rosendaal2, J. van der Bom2 (1Italy, 2The Netherlands)

PB 956 Preliminary Observations from a Prospective, Dose Escalating, Prophylaxis Study in Young Boys with Severe Hemophilia A in China: The China Hemophilia Individualized Prophylaxis Study (CHIPS)R. Wu1, W. Yao1, X. Luo1, L. Tang1, M. Zhou1, Y. Wang1, P. Ding1, N. Zhang1, S. Yang1, P. Hilliard2, K. Usuba2, N.L. Young2, A.S. Doria2, A. Audrey2, Z. Chen1, Y. Peng1, J. Wu1, K.H. Luke2, V.S. Blanchette2, X. Li1 (1China, 2Canada)

PB 957 Pilot Study to Determine the Frequency of Cerebral Microbleeds among Adult

Patients with Hemophilia a or BH. Husseinzadeh1, T. Chiasakul2, B. Pukenas1, R. Wolf1, M. Kelty1, P. Gimotty1, E. Chiang1, P.F. Fogarty1, A. Cuker1 (1United States, 2Thailand)

PB 958 Thrombo-Embolic Events Reported with the Use of Activated Prothrombin

Complex Concentrate (APCC) in Congenital Haemophilia: A Cumulative Review on Four DecadesR. Crea1, A. Novack2, J. Kennedy2, S. Raff2, N. Bajwa2, A. Gringeri1 (1Austria, 2United States)

PB 959 Effects of Acute Moderate Physical Activity on Haemostatic Parameters in

Severe Haemophilia A Subjects Using a Third Generation B-Domain Deleted Recombinant Factor VIIIC. Merlen, N. Zourikian, C. Thibeault, E. Dubé, A. Bonnefoy, T. Nava, J. St-Louis, G.-E. Rivard (Canada)

PB 960 Clinical Characteristics of Patients with Hemophilia A and B: Preliminary

Results of the Hemfil Cohort StudyC.C. Brommonschenkel, L.L. Jardim, D.G. Chaves, M.P. Santana, M.H. Cerqueira, A. Prezotti, C.S. Lorenzato, V. Franco, S.M. Rezende (Brazil)

PB 961 Target Joint Outcomes with Prophylaxis with rFIXFc in Adults and Adolescents

with Hemophilia B: Updated Results from B-YONDR. Kulkarni1, K.J. Pasi2, J. Feng1, B. Winding3, A. Ramirez-Santiago1, N. Jain1 (1United States, 2United Kingdom, 3Sweden)

PB 962 Pressure Pain Thresholds Hint at Structural Findings in Knees of Patients with

HaemophiliaS. Krüger, M. Hoffmeister, T. Hilberg (Germany)

PB 963 Once-weekly Prophylaxis with GlycoPEGylated Recombinant Factor VIII (N8-

GP) in Severe Haemophilia A: Safety and Efficacy Results from a Randomised Phase 3 Trial (pathfinder™2)N. Curry1, C. Albayrak2, M. Escobar3, P.A. Holme4, S. Kearney3, R. Klamroth5, M. Misgav6, C. Négrier7, E. Santagostino8, M. Shima9, A. Wheeler3, S.M. Tønder10, A. Landorph10, S. Lentz3 (1United Kingdom, 2Turkey, 3United States, 4Norway, 5Germany, 6Israel, 7France, 8Italy, 9Japan, 10Denmark)



332 333

Tues

day

Pos

ter

Ses

sion

s

PB 964 End-of-trial Results from a Large Multinational Extension Trial (guardian™2) Using Turoctocog Alfa for Prophylaxis and Treatment of Bleeding in Patients with Severe Haemophilia AS. Lentz1, D. Janic2, M.C. Ozelo3, A. Tiede4, I. Matytsina5, L. Korsholm5, S. Zupančić-Šalek6, J. Oldenburg4 (1United States, 2Serbia, 3Brazil, 4Germany, 5Denmark, 6Croatia)

PB 965 rVIII-SingleChain in Surgical Prophylaxis: Efficacy and Safety in 35 Surgeries

F. Abdul Karim1, C. Djambas Khayat2, J. Mahlangu3, R. Baker4, C. Male5, J. Oldenburg6, J. Ong7, S. P'ng4, M.E. Mancuso8, C. Leissinger9, A. Veldman6, S. Lucas9, I. Pabinger5 (1Malaysia, 2Lebanon, 3South Africa, 4Australia, 5Austria, 6Germany, 7Philippines, 8Italy, 9United States)

PB 966 Platelet Aggregation and Clinical Phenotype in Pediatric Patients with Severe Hemophilia A (SHA)M. Rand, H. Wang, E. McMillan-Ward, V.S. Blanchette, S.J. Israels (Canada)

PB 967 Characterisation of the Inhibitor Status of Patients with Haemophilia A in

AustraliaS. McRae, S. Parikh, H. Tran (Australia)

PB 968 Long-term Quality-of-Life Outcomes with rFIXFc in Adults with Hemophilia B:

Results from B-LONG and B-YONDJ. Su1, J. Feng1, K.-J. Myren2, C. Barnowski1 (1United States, 2Sweden)

PB 969 Lower Risk of Factor VIII Inhibitors among Severe Hemophilia A Patients with

Indigenous Background from BrazilA. Tucunduva, A.N. Prezotti, L.H. Siqueira, S.A.L. Montalvão, C. Lorenzatto, D. Fujimoto, A. Streva, S. Thomas, M.C. Della-Piazza, C.S. Costa-Lima, S.S. Medina, M.C. Ozelo (Brazil)

PB 970 Surgery with Turoctocog Alfa: Efficacy and Safety in Bleeding Prevention

During Surgery in Patients with Severe Haemophilia a - Results from the Guardian™ TrialsE. Santagostino1, M. Misgav2, P. Chowdary3, F. Abdul Karim4, S. Lejniece5, S. Zupančić-Šalek6, P.S. Miljic7, B. Brand8, I. Matytsina8 (1Italy, 2Israel, 3United Kingdom, 4Malaysia, 5Latvia, 6Croatia, 7Serbia, 8Denmark)

PB 971 Improved Pharmacokinetics of BAY 81-8973 versus Sucrose-formulated

Recombinant Factor VIII (rFVIII-FS): Noncompartmental and Population PK Assessment Based on a Single-dose, Randomized, Crossover, Pharmacokinetics Study in Patients with Severe Hemophilia AA. Solms1, D. Garmann1, A. Shah2 (1Germany, 2United States)

PB 972 Towards the Development of a Core Set of Outcome Measures for Standardized Assessment of Outcomes in Persons with HemophiliaB. Feldman1, A. Srivastava2, S. Dover1, A. Abad1, V. Blanchette1 (1Canada, 2India)

PB 973 Low-dose Factor VIII Infusion in Chinese Adult Haemophilia A Patients:

Pharmacokinetics Evidence that Daily Infusion Results in Higher Trough Level than with Every-other-day Infusion with Similar Factor VIII ConsumptionB. Hua1, A. Lee2, J. Gu1, K. Li1, M.-C. Poon2, Y. Zhao1 (1China, 2Canada)

PB 974 Association of Factor VIII and Factor IX Mutations, HLA Class II, Tumor

Necrosis Factor-Alpha and Interleukin-10 on Inhibitor Development among Thai Hemophilia A and BA. Chuansumrit, W. Sasanakul, N. Sirachainan, P. Kadegasem, P. Wongwerawattanakoon, L. Mahaklan, O. Nathalang (Thailand)

PB 975 Participation of Clinical Psychologist in a Non-hemophilia Treatment CenterA. Nakao, J. Yamanouchi, T. Hato, E. Ishii, M. Yasukawa (Japan)

PB 976 Continuous Infusion of Recombinant Factor IX Fc Fusion Protein during Major

SurgeryT. Kanematsu, N. Suzuki, M. Ogawa, M. Kishimoto, A. Suzuki, H. Kiyoi, T. Kojima, T. Matsushita (Japan)

PB 977 United States Post-marketing Safety (PMS) Study of rpFVIII in Patients with

Acquired Hemophilia A: Preliminary Enrollment DataR. Crea1, J.-F. Huang2, J. Jiang2, A. Gringeri1, N. Bajwa2 (1Austria, 2United States)

PB 978 Initial Safety Results from a Prospective Post-marketing Surveillance Study

Using rFVIIIFc in the Real World Setting in Japanese Hemophilia A PatientsM. Taki, K. Fukutake, M. Kobayashi, A. Nagao, H. Makioka, M. Shiraishi (Japan)

PB 979 Factor Utilization and Costs in Patients with Hemophilia B Using Standard and

Extended Half-life Recombinant Factor IX Replacement Products: Real-world Analysis in JapanT. Karumori1, S. Hiro1, A. Chhabra2, D. Spurden3, A. Pleil2, J. Alvir2, B. Tortella2 (1Japan, 2United States, 3United Kingdom)

PB 980 Long Term Hemostatic Efficacy of Once a Week Administration with a

Combination Medicine of Plasma Derived Factor Viia and Factor X for a Hemophilia B Patient with InhibitorT. Suzuki, Y. Chikasawa, T. Hagiwara, M. Bingo, Y. Yamamoto, K. Amano, K. Fukutake (Japan)



334 335

Tues

day

Pos

ter

Ses

sion

s

PB 981 Economic Impact of Recombinant FVIII (rFVIII) vs Plasma-derived FVIII with von Willebrand Factor (pdFVIII/VWF) and Low-dose vs High-dose Immune Tolerance Induction in Previously Untreated Hemophilia A Patients (PUPs) in GermanyJ. Oldenburg1, E. Neufeld2, M.C. Runken2, K. O'Day2, K. Meyer2, J. Spears2 (1Germany, 2United States)

PB 982 Low Dose Long Acting CFC (Eloctate, Biogen) Replacement during Bilateral

Total Knee Replacement Surgery (TKA) for Hemophilia A - Feasible and Extremely Cost Effective ApproachS. Apte, M. Swamy, A. Raiyani, A. Joshi, K. Subramanian, D. Vagasiya, H. Balar, R. Phatale, R. Dange (India)

PB 983 Improving Care in Haemophilia: A Qualitative Study

E. van Balen1, M. Krawczyk2, D. Gue2, S. Jackson2, S. Gouw1, J. van der Bom1, R. Sawatzky2 (1The Netherlands, 2Canada)

PB 984 Improving the Survival for Life-threatening Hemorrhage with Hemophilia Patient in One Hemophilia Treatment Center for 34 YearsK. Lee, J. Kim, J. Seo, S. Hyun, H.-J. Yoon (Republic of Korea)

PB 985 Single Centre Experience of Obstetric Management of Women with Inherited

Bleeding Disorders (IBD) in a Multidisciplinary Joint Women's Bleeding Disorders / Obstetric ClinicB. Madan, F. Al-Fararjeh, G. Gray (United Kingdom)

PB 986 At Home PK to Tailor Prophylaxis

M. Morfini (Italy) PB 987 Bayesian Approach to Individualize Prophylaxis of Simoctocog Alfa in

HaemophiliaX. Delavenne, J. Mercy, S. Dantin, C. Négrier (France)

PB 988 Sports/Recreational Activity-specific Risks and Drivers of Risk in People with

Hemophilia: Results of the Activity-intensity-Risk (AIR) Consensus Meeting of US Physical TherapistsK. Baumann, G. Hernandez, S. Knight, H. Purrington, M. Gilgannon, M. Karelus, J. Newman, P. Tobase, D. Basoff, S. Mathew, D. Cooper (United States)

PB 989 Preferences of Hemophilic Patients and their Parents on the Characteristics of

Replacement Treatment Used in ProphylaxisM.E. Mancuso, E. Santagostino, L. Scalone, P.A. Cortesi, P. Cozzolino, G. Cesana, L.G. Mantovani, P.M. Mannucci (Italy)

PB 990 Evaluation of Unmet Medical Needs of Hemophilia Patients in BavariaH. Lechner, A. Schleiermacher, K. Berger, D. Schopohl, W. Schramm (Germany)

PB 991 The Occurence of Inhibitors in PUPs Treated with Octocog α in Polish

Haemophilia Care CentersA. Koltan, W. Badowska, W. Balwierz, H. Bobrowska, L. Dakowicz, G. Dobaczewska, A. Janik-Moszant, G. Karolczyk, A. Klukowska, M. Kostrzewska, P. Laguna, T. Ociepa, D. Pietrys, M. Radwanska, T. Urasinski, D. Wasiński, M. Wlazlowski, I. Woznica, M. Wysocka (Poland)

PB 992 The Impact of a Comprehensive Hemophilia Management Programme in

Vulnerable PopulationC.A. Montano Mejia, S. Sarmiento (Colombia)

PB 993 The Impact of Long-term Secondary Prophylaxis on Health-related Quality of Life

in Adolescents and Adults with Severe Haemophilia A treated with rFVIII-FSA. Tagliaferi1, A. Coppola1, C. Santoro1, S. Amoresano1, S. von Mackensen2 (1Italy, 2Germany)

PB 994 FEIBA Global Outcome Study (FEIBA GO) First Data Read-Out: Real-world

Bleeding Frequency in Patients with Inhibitors on Prophylaxis with APCCC. Escuriola-Ettingshausen1, J. Windyga2, P.A. Holme3, C. Hermanns4, C. Negrier5, A.R. Cid6, S. Rangarajan7, A. Rocino8, A. Gringeri9, R. Crea9 (1Germany, 2Poland, 3Norway, 4Belgium, 5France, 6Spain, 7United Kingdom, 8Italy, 9Austria)

PB 996 Prevalence of Adult-onset Medical Comorbidities and Active Intervention via

Web-based Monitoring in Korean HemophliacsH.C. Kim, S. Jeon, H.J. Kim (Republic of Korea)

PB 997 Prevalence of Inhibitors in Tunisian Hemophiliac B

H. Elmahmoudi, M. Achour, H. Ben Neji, W. Lahouel, F. Ben Lakhal, R. Benlakhal, K. Zahra, W. Hosni, B. Meddeb, E. Gouider (Tunisia)

PB 998 Pharmacokinetics and Annual Bleeding Rate (ABR) during Prophylaxis with a

Full-length Recombinant FVIII: One Center ExperienceD. Neme, L. Elhelou, E. Honnorat, A. Cocca, M. Tezanos Pinto (Argentina)

PB 999 A Unique Case Involving Delivery of Bolus rFVIIa via an Innovative Syringe Pump

to a Patient with Haemophilia and Inhibitors Undergoing a Kidney TransplantJ. Stanley, S. Austin (United Kingdom)



336 337

Tues

day

Pos

ter

Ses

sion

s


PB 1000 The Prevalence of Concomitant Deep Vein Thrombosis, Symptomatic or Asymptomatic, in the Patients with Symptomatic Pulmonary EmbolismJ. Hirmerova, J. Seidlerova, Z. Chudacek (Czech Republic)

PB 1001 Predicting Post-thrombotic Syndrome with Ultrasonographic Measurements

after Proximal Deep Vein ThrombosisC.E.A. Dronkers1, G.C. Mol1, G. Maraziti2, M.A. van de Ree1, M.V. Huisman1, C. Becattini2, F.A. Klok1 (1The Netherlands, 2Italy)

PB 1002 Can Ultrasonographic and Laboratory Measurements One Year after Proximal

Deep Vein Thrombosis Predict Post-thrombotic Syndrome?G.C. Mol, C.E.A. Dronkers, M.A. van de Ree, F.A. Klok, M.V. Huisman (The Netherlands)

PB 1003 Patient-reported Reasons for and Predictors of Non-compliance with Elastic

Compression Stockings in the SOX TrialS.R. Kahn1, A. Akaberi1, J.-P. Galanaud2, D. Morrison1, S. Shapiro1, for the SOX Trial Investigators (1Canada, 2France)

PB 1004 External Validation of the Patient Reported Form of the Villalta ScaleK.K. Utne, A. Dahm, H.S. Wik, L.-P. Jelsness-Jørgensen, P.M. Sandset, W. Ghanima (Norway)

PB 1005 High Accuracy and Reproducibility of CT Right-to-left Ventricular Diameter

Measurement by Non-radiologists in Patients with Acute Pulmonary EmbolismY.M. Ende-Verhaar, I.C. Mos, L.J.M. Kroft, M.V. Huisman, F.A. Klok (The Netherlands)

PB 1006 Nationwide Study on the Management and Outcomes of Patients with

Superficial Vein Thrombosis under Real-life Conditions (INSIGHTS-SVT)R. Bauersachs, H.E. Gerlach, U. Hoffmann, F. Langer, A. Heinken, E. Rabe, D. Pittrow, J. Klotsche, T. Noppeney (Germany)

PB 1007 Post-Thrombotic Syndrome in Patients Treated with Rivaroxaban or Warfarin for

Venous ThromboembolismC.I. Coleman, T.J. Bunz (United States)

PB 1009 Possible Predictors of Long-term Dyspnea in Patients with Pulmonary

Embolism - A Cross Sectional StudyM. Tavoly1, H. Skuterud Wik1, L.-P. Jelsness-Jørgensen1, J. Ghanima1, F.A. Klok2, P.M. Sandset1, W. Ghanima1 (1Norway, 2The Netherlands)

PB 1010 Reliability Testing of the CAPTSureTM Pediatric Post-thrombotic Syndrome ToolM.L. Avila, C.M. Lumia, M.I. Montoya, J. Vincelli, S. Williams, L.R. Brandão (Canada)

PB 1011 Measuring Limb Edema in Children at Risk of Post Thrombotic Syndrome: Do I

See what You Feel?M.L. Avila, M.I. Montoya, J. Vincelli, S. Williams, C.M. Lumia, L.R. Brandão (Canada)

PB 1012 Laboratory and Clinical Parameters at Diagnosis of Venous Thromboembolism

(VTE) Are Not Associated to the Presence of Residual Vein Thrombosis (RVT)S.M.S. Soares, F.M. Hasseman, A.V.C. Romano, L.F.B. Sckayer, F.A. Orsi, E.V. de Paula, J.M. Annichino-Bizzacchi (Brazil)

PB 1013 An Innovative Approach to an Age-old Problem: Piloting a Smart Compression

Garment DeviceM.L. Avila, K.L. Tam, T. Chau, M.I. Montoya, S. Stephens, C.M. Lumia, L.R. Brandão (Canada)

PB 1014 Post-Pulmonary Embolism Syndrome Development among Patients who Needed Pulmonary Embolism Response Team AssessmentK. Smart, A. Ahsan, O. Iftikhar, A. Tafur (United States)

PB 1015 Patients Treated with Rivaroxaban Presented Low Prevalence of Post-

thrombotic SyndromeT. Ferreira, L.F. Bittar, S. Cares Huber, S. Soares, A.V. Calazans Romano Marina Pereira Colella, F. Andrade Orsi, E.V. de Paula, J. M. Annichino-Bizzacchi (Brazil)

PB 1016 Non-invasive Detection of Fresh Deep Vein Thrombosis with Diffusion Weighted

Magnetic Resonance ImagingY. Kuroiwa, A. Yamashita, T. Gi, Y. Konishi, T. Asanuma, T. Miyati, T. Imamura, Y. Asada (Japan)

PB 1017 Patients' Experience of Post-thrombotic Syndrome: A Qualitative Study with

Focus Groups Aiming at a More Accurate DiagnosisM. Engeseth, T.R. Enden, M.H. Andersen, P.M. Sandset, H.S. Wik (Norway)

PB 1018 Optimizing Treatment for Post-thrombotic Syndrome (PTS): A Systematic

ReviewS. Abegunde, I. Ajayi (Nigeria)

PB 1020 Comparison of Trans-popliteal Reflux in the Limb with Deep Vein Thrombosis

and the Limb without ThrombosisL. Sarolo, G. Turatti, M. Milan, F. Bilora, P. Prandoni (Italy)



338 339

Tues

day

Pos

ter

Ses

sion

s

PB 1022 Inferior Vena Cava Filters: Experience of 133 Patients in a Tertiary Referral CenterA. Riera-Mestre, J. Ribas Sola, E. Cuevas Sales, E. Alba Rey, E. Escalante Porrua, X. Corbella Virós, J. Dorca Sargatal (Spain)

PB 1023 Sex Specific Prevalence and Performance of Diagnostic Algorithms for

Pulmonary EmbolismT.E. van Mens, L.M. van der Pol, N. van Es, I.M. Bistervels, A.T.A. Mairuhu, T. van der Hulle, F.A. Klok, M.V. Huisman, S. Middeldorp (The Netherlands)

PB 1024 Clinical Course of Lemierre Syndrome: An Individual-Patient Data Meta-

Analysis of 518 SubjectsS. Barco1, F. Zane2, C. Sacco2, S. Granziera2, S.V. Konstantinides1, M. Di Nisio2, A. Pecci2, Lemierre Study Group (1Germany, 2Italy)

PB 1025 Comparison of Pulmonary Embolism Severity Index Score and Hestia Criteria to

Identify Pulmonary Embolism Patients for Outpatient TreatmentP. Nona, A. Tawney, D. Tirunagari, C. Klochko, S. Ahsan, V. Shah, S. Ellsworth, S. Kaatz (United States)

PB 1026 Clinical Courses of Portal Vein Thrombosis (PVT) in ChildrenP. Komvilaisak, S. Sutra, R. Komvilaisak, N. Tewattanarat, K. Wichajarn (Thailand)

PB 1027 The Incidence and of Catheter-related-Thrombosis during Induction

Chemotherapy and Follow-up in Chinese Acute Lymphocytic Leukemia ChildrenY. Wei, R. Wu (China)

PB 1028 Behcet and Thrombosis in Children: Hacettepe Experience

S. Aytac, I. Altan, I. Yaman Bajin, M. Cetin, S. Ozen, F. Gumruk (Turkey) PB 1029 Relevance of the Pulmonary Embolism with and without Cancer of for 3 Years

in an Academic Medical CenterC. Yasuda, M. Shiina (Japan)

PB 1030 Pulmonary Thromboembolism in Children: Tuberculosis May Be the Underlying

ProblemM. Çetin, İ. Yaman Bajin, S. Aytaç, İ. Altan, E. Yalçın, A.B. Cengiz, F. Gümrük (Turkey)

PB 1031 Inherited Prothrombotic Risk Factors in Turkish Children with Hereditary

Anjioedema. Single Center ExperienceT. Patiroglu, M. Cansever, A. Ozcan, F. Tahan, Y. Ozkul (Turkey)

Transfusion & Biotherapeutics

PB 1032 Intraoperative Patient Blood Management: A Role for Very-low-Dose Recombinant Activated Factor VIIT. Hoffmann, S. Sixt, A. Albert, A. Dierksen, E. Roussel, A. Lichtenberg, A. Assmann (Germany)

PB 1033 Preoperative Assessment of Bleeding Risk - Implementing Strategies in the

Pursuit of Effective Patient Blood ManagementJ. Joseph, D. Behan, G. Mills, G. Lepar, E. Bean (Australia)

PB 1034 Indications for the Use of Fresh Frozen Plasma in Neonatal Intensive Care Unit

in a Tertiary Care HospitalR. Akbar, A. Khan (Pakistan)

PB 1035 Intermittent Intravenous Deferoxamine for the Treatment of Transfusional Iron

OverloadM. Varma (United States)

PB 1036 Reasons for Blood Donor Deferral among Voluntary Blood Donors in a Tertiary

Care Hospital in Kathmandu, NepalB. Nepal, B. Gautam (Nepal)

PB 1037 Haemovigilance Reports of Adverse Blood Donor Reaction among Voluntary

Blood Donors in Tertiary Care Hospital in Kathmandu, NepalB. Nepal, B. Gautam (Nepal)

PB 1038 Re-infusion of Heparinized Shed Blood in Aortic Surgery to Maintain

Hemostatic Levels of FibrinogenM. Reyes, O. Preventza, C. Letheridge, J. Coselli, J. Anton, A. Bracey (United States)

PB 1039 Use of Molecular Biology to Reveal the Mechanism of Non-hemolytic Febrile

Transfusion Reaction to Enhance the Transfusion SafetyD.-P. Chen, Y.-H. Wen, C.-P. Tseng (Taiwan)

PB 1041 Pseudomyxoma Peritonei Surgery: Potential for Predicting Fibrinogen Use using

ThromboelastometryC. Rea, S. Stanford, J. Needham, A. Roy, N. Sargant, S. Rangarajan (United Kingdom)

PB 1042 Comparison of Arterial and Venous Coagulation Parameters Measured with the

QuantraTM System in Cardiac SurgeryF. Viola, D. Winegar, L. Fernandez, D. Groves, J. Huffmyer (United States)



340 341

Tues

day

Pos

ter

Ses

sion

s

PB 1043 The Quantra Surgical Cartridge: A Novel Assay for the Rapid Assessment of Coagulation Function from Whole BloodF. Viola, C. Lloyd, T. Higgins, A. Homyk, D. Bryant, T. Givens, P. Braun (United States)

PB 1044 Five Years of Hemovigilance Reports of Complications of the Blood Donation

Reported at a Tertiary Care Centre in KarachiB. Nepal (Pakistan)

PB 1046 Performance Evaluation of the Quantra Surgical Cartridge for Rapid Point-of-

Care (POC) Assessment of Coagulation FunctionP. Braun, C. Wang, V. Sekaran, M. Koren, C. Lloyd, F. Viola (United States)

PB 1047 ABO Discrepancies and Errors in a Routine Blood Bank

B. Nepal (Pakistan) PB 1048 Is the Thrombin Generation Test, a Useful Research Tool, Suitable to

Characterize Therapeutic Plasmas?C. Ravanat, A. Dupuis, N. Marpaux, C. Naegelen, G. Mourey, H. Isola, M. Laforêt, P. Morel, C. Gachet (France)

PB 1049 Viral Inactivation and Enrichment of Factor VIII, Factor XIII, Fibrinogen and

von Willebrand Factor (VWF) Multimers from Fresh Frozen Plasma (FFP)using, ”VIPS Plasma, Virus Inactivation Treatment System”B. Nepal (Pakistan)

PB 1050 Prolonged Platelet Storage Associated with Increased Incidence of Platelet

Transfusion Adverse EventsJ. Chen, L. Blower, D. Hamed, S. Yang, S. Cataland (United States)

Nurses and Allied Health

PB 1051 Remote 'Bridging Clinics' Maximise Efficiency and Patient Satisfaction in the Perioperative Management of AnticoagulationS. Brookman (United Kingdom)

PB 1052 Expanding the Role of the Anticoagulation Nurse

S. Rivera, E. Gee (United Kingdom) PB 1053 Nurse-led Clinic Initiative for Patients Commencing Direct Oral Anticoagulants

(DOACs) in the National Coagulation Centre, Dublin, IrelandL. Solomon, M. Blake, R. Diaz, N. Flynn, V. Graham, J. Benson, N. O Connell (Ireland)

PB 1054 Haemorrheologic and Fibrinolytic Activities of Sickle Cell Subjects in Steady and Crisis States in Abuja Metropolis, NigeriaD.C. Okpokam, G. Izuwa, J. Akpotuzor, P. Akpan (Nigeria)

PB 1055 Social Work Research and Funding Opportunities: The Canadian Experience

Claude Bartholomew, St. Paul´s Hospital, Vancouver, Canada Neale Smith, University of British ColumbiaC. Bartholomew, N. Smith (Canada)

PB 1056 Scapular Injection of Low Molecular Weight Heparin in Neonates Receiving

Treatment for ThormobosisR. Goldsmith, K. Hamilton, B. Paes, A. Chan (Canada)

PB 1057 Empowering a Link Practitioner Network to Enhance Venous Thromboembolism

(VTE) Prevention and Anti-coagulation CareR. Greenall, E. Gee, L. Bonner, C. Doyle, G. Mulla (United Kingdom)

PB 1059 Has the Introduction of the Direct Oral Anticoagulants (DOACs) Made Any

Difference to Telephone Calls to A Secondary Care Led Anticoagulant Clinic?S. Bond, S. Rhodes (United Kingdom)

PB 1061 When the Absence of Prophylaxis in Patients with Hemophilia, Surgery is

InevitableL. Rakic (Serbia)



PB 1062 Abnormal Plasma Clot Formation and Stability Distinguish Bleeding Risk in Patients with Severe or Partial Factor XI DeficiencyG. Pike1, L. Holle2, J. Burthem1, P. Bolton-Maggs1, F.-C. Lin2, A. Wolberg2 (1United Kingdom, 2United States)

PB 1063 Anti FIXa/FX Bispecific Antibody (Emicizumab) Enhances Plasma Procoagulant

Activity In Hemophilia B in the Presence of Very Low Level of Factor IXK. Ogiwara, H. Minami, K. Nogami, T. Matsumoto, T. Kitazawa, K. Hattori, M. Shima (Japan)

PB 1064 Abrogating Fibrinolysis Does Not Markedly Affect the Bleeding Phenotype or

Response to rFVIII Therapy in Mice with Haemophilia AR. Stagaard1, M.J. Flick2, B. Bojko3, K. Goryński3, P.Z. Goryńska3, C.D. Ley1, L.H. Olsen1, T. Knudsen1 (1Denmark, 2United States, 3Poland)



342 343

Tues

day

Pos

ter

Ses

sion

s

PB 1065 Vascular Remodeling in Hemophilic Joint Bleeding is Associated with Vascular Leak: A Possible Mechanism for Re-bleedingE.J. Cooke, J.Y. Zhou, T.L. Wyseure, V. Bhat, S. Joshi, D.L. Durden, L.O. Mosnier, A. von Drygalski (United States)

PB 1066 Development of a Pharmacokinetic-Pharmacodynamic (PK-PD) Model of

Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia in Patients with and without InhibitorsH. Attarwala, V. Goel, K. Madigan, A. Akinc, G.J. Robbie (United States)

PB 1067 Electrostatic Analysis of Hemophilia B Causative Mutations

M. Meireles, E. Bandinelli, G. Vieira, F. Salzano (Brazil) PB 1068 Identification of Regulatory B Cells in Severe Hemophilia A Patients

D. Matino1, M. Gargaro1, A. Turco1, G. Scalisi1, S. Linari1, P. Puccetti1, A. Iorio2, G. Castaman1, F. Fallarino1 (1Italy, 2Canada)

PB 1069 Prophylactic Treatment with Turoctocog Alfa Pegol (N8-GP), a GlycoPEGylated

Recombinant Factor VIII, Completely Prevents Development of Arthropathy in a F8 - Knockout Mouse Model of Induced Knee BleedingJ.B. Hebsgaard, M. Petersen, K. Roepstorff, M. Ezban, C.D. Ley (Denmark)

PB 1070 Two Large F8 Deletions Possibly Related to the Mechanism of Microhomology-

mediated Break-induced Replication (MMBIR) as a Cause of Severe Haemophilia a and InhibitorsM.M. Abelleyro, V.D. Marchione, C.P. Radic, T. Tetzlaff, D. Neme, M. Tezanos Pinto, I.B. Larripa, L.C. Rossetti, C.D. De Brasi (Argentina)

PB 1071 Measurement of Basal Levels of TF, FVII, FVIIa, Free and Total TFPI and FVIIa.AT Complex Levels in Patients with Haemophilia A and BE. Fosbury (United Kingdom)

PB 1072 F8-deficiency in Mice is Associated with Increased von Willebrand Factor

(VWF) Content in the Hepatic Endothelium and with Increased VWF Plasma LevelsK. Kiouptsi, M. Döhrmann, M. Lillich, S. Subramaniam, I. Scharrer, S. Jäckel, U. Walter, K. Jurk, C. Reinhardt (Germany)

PB 1073 Feasibility of Prospective Transcriptome Profiling in Previously Untreated

Patients with Severe Hemophilia A: NuProtect Gene Expression Satellite StudyP. Batty, E. Wozniak, E. Savage, C.A. Mein, D.P. Hart (United Kingdom)

PB 1074 The Bone Disease in Haemophilia: A Possible Role of Coagulation Factors?

M. Sacco, S. Lancellotti, A. Arcovito, G. Battafarano, A. Del Fattore, R. De Cristofaro (Italy)

PB 1075 Determinants of Thrombin Generation in Haemophilia A and BB. Tardy-Poncet, P. Chelle, A. Montmartin, M. Piot, M. Cournil, C. Morin (France)

PB 1076 Unusual Genomic Rearrangement Combined with Inv22 and Wild-type

X-chromosome in Severe Hemophilia A PatientsS. Tamura, M. Kakihara, Y. Hattori, E. Hashimoto, H. Sakane, Y. Takagi, M. Ogawa, T. Kanematsu, N. Suzuki, A. Takagi, T. Matsushita, T. Kojima (Japan)

PB 1077 Biochemical and Biophysical Characteristics of Commercially Available FVIII

ProductsR. De Cristofaro, M. Sacco, S. Lancellotti, I. Garagiola, C. Valsecchi, G. Scaglione, M. Basso, E. Di Stasio, F. Peyvandi (Italy)

PB 1078 Global Assays of Hemostasis among Severe Hemophilia A Boys Detects

VariationF. Pluthero, M. Rand, V. Blanchette, W. Kahr (Canada)

PB 1079 A Bispecific Antibody Lacks Measurability in Routine Coagulation Assays and

Comparability to Factor VIIIR. Hartmann1, S. Knappe1, G. Schrenk1, L.A. Valentino2, F. Scheiflinger1, M. Dockal1 (1Austria, 2United States)

PB 1080 Efficacy of Anti-TFPI Antibody PF-06741086 Compared to rFactor VIIa in

Mouse Hemophilia A Bleeding ModelsR. Jasuja, J.E. Murphy, D.D. Pittman (United States)

PB 1081 X Chromosome Inactivation and Plasma Level of Factor VIII and IX in Carriers

of Hemophilia A and BI. Garagiola, M. Mortarino, M. Biganzoli, M.E. Mancuso, E. Santagostino, F. Peyvandi (Italy)

PB 1082 Turoctocog AlfaPegol (N8-GP) Is Cleared from Subcutaneous Injection Sites

without Local DegradationM. Petersen, L.F. Larsen, H. Pelzer, G. Bolt, A.L. Nielsen, F. Rode, K. Almholt (Denmark)

PB 1083 Thrombin Generation Profiling in Amish Factor IX Carriers and Controls: Plasma

Composition and Bleeding PhenotypeM.C. Bravo, S. Gupta, C. Nakar, M. Heiman, A. Shapiro, K. Brummel-Ziedins (United States)

PB 1084 The Global Annual Bleed Rate in Haemophilia: A 2015 Estimate

C. Thompson1, A. Srivastava2, M. Skinner1, J. Stonebraker1, J. Epstein1, T. Kauf1, L. Valentino1 (1United States, 2India)



344 345

Tues

day

Pos

ter

Ses

sion

s

PB 1085 Mortality of Hemophilia in Brazil: First ReportL. Lemos Jardim1, J. van der Bom2, C. Caram Deelder2, S. Claudia Gouw2, M. Leal Cherchiglia1, S. Meireles Rezende1 (1Brazil, 2The Netherlands)

PB 1086 Alternative Payment Models in Hemophilia

B. Jönsson1, G. Dolan2 (1Sweden, 2United Kingdom) PB 1087 Rapid and Cost-effective FVIII Intron Inversion 22 Screening of the Central

South African Haemophilia A PopulationW. Janse van Rensburg, J. Kloppers (South Africa)

PB 1088 Patient Satisfaction of Home Delivery Program in Haemophilia through an

Association of PatientsM. Martín-Cerezuela, J.E. Megías-Vericat, E. Monte-Boquet, P. Pérez-Huertas, M.J. Cuéllar-Monreal, M.V. Tarazona-Casany, J.L. Poveda-Andrés, S. Bonanad-Boix (Spain)

PB 1089 Contribution to the Molecular Study of Hemophilia B in an Algerian Population

A. Zidani1, Y. Ouarhlent1, M. Yahia1, N. Lannoy2, K. Belhadi1 (1Algeria, 2Belgium)

PB 1090 A Hand-held Electronic Patient Diary for Haemophilia Home Care-pilot Study in

PolandP. Laguna, H. Bobrowska, A. Janik-Moszant, A. Klukowska, A. Koltan, T. Urasinski, I. Woznica –Karczmarz (Poland)

PB 1091 Induction of FVIII Tolerance by Gene Transfer of IL2 and Factor VIII Plasmids

in Hemophilia A MiceM.J. Lyle, R.Y. Fu, C.H. Miao (United States)

PB 1092 Therapeutic Expression of Factor VIII Following Ultrasound-mediated Gene

Delivery of High-expressing FVIII Variant Plasmids and Immunomodulation in Hemophilia A MiceM.J. Lyle, J. Harrang, D. Tran, R.Y. Fu, C.H. Miao (United States)

PB 1094 Integration Site Analysis in Mice Demonstrates Excellent Biosafety Profile of a

Recombinant (R) FVIII Adeno-associated Virus (AAV8) Gene Therapy ProductW. Hoellriegl1, F.G. Falkner1, M. Weiller1, M. Schmidt2, F. Scheiflinger1, H. Rotteinsteiner1 (1Austria, 2Germany)

PB 1095 A Novel Strategy for Liver Cell-based Therapy in a Hemophilia B Model

Y.C. Hsu, Y.J. Huang, I.S. Yu, Y.M. Wu, S.W. Lin (Taiwan) PB 1096 Immunity to AAV8 and Other AAV Serotypes in Healthy Individuals

A. Kruzik, D. Fetahagic, B. Hartlieb, F.M. Horling, F. Scheiflinger, B.M. Reipert, M. de la Rosa (Austria)

PB 1097 Development and Application of Methods for the Selective Measurement of the Human Single Amino Exchange Variant Factor IX PaduaA. Weber, A. Engelmaier, D. Voelkel, R. Pachlinger, F. Scheiflinger, H. Rottensteiner (Austria)

PB 1098 Biological Significance of Neutralizing Antibodies to AAV8

A. Kruzik, D. Fetahagic, B. Hartlieb, H. Koppensteiner, S. Coulibaly, A. Weber, W. Hoellriegl, F.M. Horling, F. Scheiflinger, B.M. Reipert, M. de la Rosa (Austria)

PB 1099 Nonclinical Safety Evaluation of a FVIII Gene Therapy Construct in Mice

W. Hoellriegl, M. Weiller, T. Ruthsatz, K. Benamara, H. Gritsch, A. Weber, B. Gangadharan, F.G. Falkner, P.E. Monahan, H. Rottensteiner, F. Scheiflinger, M. Turecek (Austria)

PB 1100 Preliminary Results of SPK-9001 Gene Transfer Demonstrate Statistical

Improvements on the Health-related Quality-of-Life in Adults with Haemophilia BS. von Mackensen1, L.A. George2, A.M. Galvao2, A.Y. Luk2, K.A. High2 (1Germany, 2United States)

PB 1101 Dose Response and Long-term Expression of a FVIII Gene Therapy Construct in

Hemophilia A MiceW. Hoellriegl, M. Weiller, A. Kopić, K. Benamara, H. Gritsch, B. Gangadharan, F.G. Falkner, P.E. Monahan, H. Rottensteiner, F. Scheiflinger, M. Turecek (Austria)

PB 1102 Pre-existing Anti-AAV5 Neutralizing Antibodies Measured Using a Highly Sensitive Assay in Sera of Hemophilia B Patients in a Phase I/II Clinical Trial of AMT-060 Do Not Predict Efficacy of AAV5-mediated Liver-directed Gene TransferA. Majowicz, M. Lampen, H. Petry, C. Meyer, V. Ferreira, B. Nijmeijer, M. Tangelder (The Netherlands)

PB 1103 Manufacturing Scale AAV Vectors: Quantification Strategy for Clinical Trials

M. Bendik, R. Necina, M. Graninger, E. Böhm, C. Fiedler, B. Kraus, D. Mittergradnegger, J. Hernandez Bort, S. Reuberger, W. Herok, R. Raim, J. Lengler, J. Mayrhofer, F.G. Falkner, W. Hoellriegl, C. Konetschny, C. Tauer, M. Löflund (Austria)

PB 1104 Gold Nanoparticles: A New Approach for Non-viral Gene Therapy of Hemophilia

M.-K. Holz, L. Gamrad, K. Roellecke, K. Waack, A. Heinemann, C. Rehbock, S. Barcikowski, D. Reinhardt, H. Hanenberg (Germany)

PB 1105 Health-related Quality of Life in Pediatric Hemophilia B Patients Treated with

rIX-FPS. von Mackensen, W. Seifert (Germany)



346 347

Tues

day

Pos

ter

Ses

sion

s

PB 1106 Hyperfibrinolysis in Children. Prevalence of Hyperfibrinolysis in Mucocutaneous Bleeders of Unknown Cause in a Pediatric CohortP. Zuñiga, N. Orellana, O. Panes, D. Mezzano (Chile)

PB 1107 Pregnancy in Factor XI-deficient women

R. Santoro, P. Iannaccaro, S. Morgione, M.T. Paparo (Italy) PB 1108 Factor XIII Deficiency and Noonan Syndrome: A Tricky Association

M. Albisetti, T. Boesten, K. Steindl, V. Schröder, S. Kroiss Benninger (Switzerland)

PB 1109 Dysprothrombinemia Caused by the Homozygote Mutation Ala563Val in the

F2 Gene Was Associated with Reduced Thrombin Generation in a Patient with Bleeding DisorderH. Glosli, N. Iversen, M.S. Le, M. Sletten, G.K. Halvorsen, P.A. Holme, C.E. Henriksson (Norway)

PB 1110 Severe Acquired Hemophilia A, B and C Associated with Lupus Anticoagulant

in a Child. A Case ReportS. Arghirescu, E. Ursu, D. Savescu, L. Cernat, C. Jinca, M. Serban (Romania)

PB 1111 A Novel Thrombin-activable Factor X Corrects Acquired Hemophilia A in Rabbit

T. Abache, A. Fontayne, C. Bourdon, A.-S. Dezetter, D. Grenier, E. Jacque, A. Longue, V. Pochet-Beghin, B. Souilliart, G. Chevreux, D. Bataille, S. Chtourou, J.-L. Plantier (France)

PB 1112 Recombinant Factor VIIa-Albumin Fusion Protein Undergoes Endothelial Cell Protein C Receptor Mediated Internalization and RecyclingI. Glauser1, J. Chia1, S. Cattepoel2, S. Dower1, A. Verhagen1 (1Australia, 2Switzerland)

PB 1113 Treatment of Hemophilia A by Injection of FVIII-encoding mRNA

J. Russick1, S. Delignat1, K. Kariko2, S. Lacroix-Desmazes1 (1France, 2Germany) PB 1114 Clinically-relevant Bioavailability of rIX-FP after Subcutaneous Administration

to Rodent and Non-rodent SpeciesM.W. Nolte1, S. Herrmann1, E. Raquet1, F. Kaspereit1, W. Krege1, B. Doerr1, S. Zollner2, E. Herzog1 (1Germany, 2Switzerland)

PB 1115 Rescue of Multiple Hemophilia B-causing Mutations in F9 Exon 3 by a Unique

ExSpeU1D. Balestra, D. Scalet, F. Bernardi, M. Pinotti (Italy)

PB 1116 Dose-response and Duration of Effect of a Half-life Extended Recombinant Factor VIIa in the Tail Vein Transection Bleeding Model in Haemophilia A RatsT. Elm, C. Behrens, M. Dainiak, M. Åkesson, J.J. Hansen, M.S. Jensen, I. Hilden, H. Østergaard, M.B. Hermit (Denmark)

PB 1117 Defining Extended Half-life rFVIII: A Critical Review of the Evidence

J. Mahlangu1, E. Santagostino2, G. Young3, C. Hermans4, V. Blanchette5, E. Berntorp6 (1South Africa, 2Italy, 3United States, 4Belgium, 5Canada, 6Sweden)

PB 1118 Nonclinical Immunogenicity and Safety of SHP656 (BAX826), a Next

Generation Extended Half-life Recombinant Factor VIII ProductV. Ehrlich, M. Malisauskas, B. Hartlieb, P. Leidenmuehler, F. Horling, B. Dietrich, G. Hoebarth, T. Ruthsatz, S. Dorn, K. Benamara, M. Wolfsegger, A. Weber, H. Gritsch, W. Hoellriegl, M. Turecek (Austria)

PB 1119 Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered

Marzeptacog Alfa (Activated) in Hemophilia B MiceH. Levy, A. Hetherington, N. Usman (United States)

PB 1120 Underestimation of N-glycoPEGylated Factor IX (N9-GP) Activity in One-stage

Clotting Assay Owing to Contact Activator Impairment of N9-GP ActivationE. Persson, C. La Cour Christoffersen (Denmark)

PB 1121 Analysis of the Novel Recombinant Factor VIII-SingleChain Protein Predicts A

Lower Immunogenic Potential as Compared to Full-length Recombinant FVIIIM. Hofmann1, A. Verhagen2, H. Huyhn2, A. Baz Morelli2, S. Schmidbauer1, S. Zollner3, J. Powell4, A. Veldman1, T. Howard4, E. Maraskovsky2 (1Germany, 2Australia, 3Switzerland, 4United States)

PB 1122 Identification of Amino Acid Substitutions in the D´D3 Region of von

Willebrand Factor that Increase the Binding Affinity for FVIIIA. Andrews1, M. Hardy1, K. Emmrich1, C. Panousis1, T. Weimer2, S. Dower1, M. Wilson1 (1Australia, 2Germany)

PB 1123 Administration of rFVIIa to Concizumab-dosed Monkeys Is Safe and

Concizumab Does Not Affect the Potency of rFVIIa in Haemophilic RabbitsB. Lauritzen, J. Olling, K. Abel, C. Augustsson, K. Balling, I. Hilden (Denmark)

PB 1124 A Monoclonal Antibody with TFPI Neutralizing Activity, Improves the Coagulation

Parameters of Hemostatic Assays Performed with Hemophilic Whole BloodS. Patel-Hett, E.J. Martin, S. Rakhe, P. Sun, D.D. Pittman, M. Nolte, J. Kuhn, J.C. Barrett, D.F. Brophy, J.E. Murphy (United States)



348 349

Tues

day

Pos

ter

Ses

sion

s

PB 1125 Protein Engineering of Factor X to Restore Coagulation: Building an Alternate Amplification LoopG.E. Blouse, K.W. Balling, F. Stavenuiter, C. Dan Ley, P.B. Johansen, H. Østergaard, P.S. Gandhi, J.J. Hansen, A.K. Seresht, P. Tiainen, T.N. Krogh (Denmark)

PB 1126 Pharmacodynamic Efficacy of a Recombinant Fusion Protein Linking Activated

Factor VIIa to Human Albumin (rVIIa-FP) in FVIII and FIX Depleted Plasma with or without InhibitorsE. Raquet, P. Niebl, B. Doerr, E. Herzog (Germany)

PB 1127 Effect of Phospholipid Vesicle Composition on Activity of FVIIIa-mimetic

Bispecific AntibodiesM. Aleman, A. Goodman, E. Kistanova, N. Leksa, R. Peters (United States)

PB 1128 A New Long-acting Pegylated Recombinant Factor VIII Derived from Single-

Chain Factor VIII Engineered to Be Highly Expressed in CHO Cell LineK.-Y. Kang, S.-H. Lee, I.-J. Oh, J.-H. Ryu, E.-C. Jo, M.-S. Oh, S.-A. Yang, K.-N. Lee, J.-S. Kim (Republic of Korea)

PB 1129 Pharmacodynamic Efficacy of a Recombinant Fusion Protein Linking Activated

Factor VIIa to Human Albumin (rVIIa-FP) in FVII Depleted PlasmaE. Raquet, P. Niebl, B. Doerr, E. Herzog (Germany)

PB 1130 Extended Hemostatic Efficacy of rIX-FP is Confirmed in a Hemophilia B Mouse

Model of Arterial InjuryE. Raquet, F. Musch, M. Mischnik, M. Nolte, E. Herzog (Germany)

PB 1131 A Model of the Minimum Half-life Extension Ratio Needed to Reduce the

Dosing Frequency of Extended Half-life Recombinant FVIII ProductsJ. Booth1, H. Schütz2, K. Steinitz-Trost2, H.-Y. Lee3, A. Bauer2, M. Wolfsegger2 (1United States, 2Austria, 3Switzerland)

PB 1132 The Safety and Efficacy of IB1001 in Previously Treated Children 12 Years of Age or Younger with HemophiliaR. Liesner1, R. Fritz2, B. MacPherson2, D. Schaaf2 (1United Kingdom, 2United States)


PB 1133 A Single Analysis for Simultaneous Measurement of All 4 DOACsJ. Emmerechts, S. Ameye, V. Engelrelst, D. Borrey (Belgium)

PB 1134 Interest of PERC Rule (Pulmonary Embolism Rule-out Criteria) to Exclude Pulmonary Embolism in European Patients with Low Implicit Clinical Probability: PERCEPIC StudyA. Penaloza1, C. Soulie-Chavignon2, A. Ghuysen1, D. El Kouri2, C. Brice2, N.S. Marjanovic2, A. Trinh-Duc2, T. Moumneh2, Q. Delmez1, P.-M. Roy2 (1Belgium, 2France)

PB 1135 Validation of STA-Liatest D-Di Assay for Exclusion of Deep Vein Thrombosis

According to the Latest Clinical and Laboratory Standard Institute/Food and Drug Administration Guideline. Results of a Multicenter Management StudyC. Aguilar1, M. Sartori2, A. D'Angelo2, D. Richardson3, C. Kabrhel3, J. Groce3, E. Demaistre4, S. Rathbun3, J. Kassis5, J. Lazarchick3, C. Kaide3, P. Marco Vera1, J. Kline3, M. Courtney3, M. Sharafuddin3, A. Rubin3, G. Pernod4 (1Spain, 2Italy, 3United States, 4France, 5Canada)

PB 1136 Variation in Practice for FVIII and FIX Inhibitor Investigations - Results from a

UK NEQAS (Blood Coagulation) and UK HCDO Multicentre ExerciseI. Jennings, D. Kitchen, S. Kitchen, A. Riddell, D. Hart, T. Woods, I. Walker (United Kingdom)

PB 1137 Improving aPTT Test and Resource Utilisation in Manitoba, Canada - A

Successful Provincial ExperienceC.T. Musuka, P. Sun, C. Mc Mahon, C. Morales (Canada)

PB 1138 Prediction of Coagulation Testing in Underfilled Patient Samples

A. Cloe, K. Mikrut, G. Wool, J. Miller (United States) PB 1139 Thrombin Generation Based Factor VIII Assay is Sensitive to Low FVIII Levels

in HemophiliaR. Kremers, C. Bai, J. Remijn, I. van Moort, D. Huskens, M. Ninivaggi, B. de Laat, M. de Maat (The Netherlands)

PB 1140 Novel Biochip Detects Drug Effects in Patients with Cardiovascular Disease in

a Near Patient SettingA. Hall, M. Somers, J. Cowman, P. McCluskey, D. Kenny, N. Kent, N. Gilmartin (Ireland)

PB 1141 Microfluidic Systems with Vascular Biomimetic Surfaces for Assessment of

Platelets and Fibrin Components of Hemostasis: Comparison with a Classic Annular Device in the Evaluation of the Antithrombotic Effects of ApixabanI. Lopez-Vilchez, E. Mir-Fuertes, J. Casals-Terre, M. Pegueroles, E. Arellano-Rodrigo, M. Diaz-Ricart, G. Escolar (Spain)



350 351

Tues

day

Pos

ter

Ses

sion

s

PB 1142 Automated CH50-like Assays for Assessment of the Complement System and Complement Inhibitor DrugsI. Mackie1, C. Gardiner1, P. Lane1, A. Chitolie1, H. Kurono2, M. Nunn1, S. Machin1 (1United Kingdom, 2Japan)

PB 1143 Prenatal diagnosis for Inherited Bleeding Disorders in India

E.S. Edison, R.V. Shaji, G. Sankari Devi, S.V. Rajkumar, M. Kamath, T.K. Aleyamma, N.A. Fouzia, A. Korula, A. Abraham, B. George, S.C. Nair, V. Mathews, A. Srivastava (India)

PB 1144 Availability of Age-specific Coagulation Laboratory Values in Pediatric Hospitals

vs. Combined Pediatric/Adult Hospitals: An International PerspectiveZ. Solh1, R. Rajagopal2, J. Thachil3, A. Chan1, N. Heddle1, P. Monagle2 (1Canada, 2Australia, 3United Kingdom)

PB 1145 The Use of the ADJUST (Age Adjusted) D-dimer Cut-off in Screening Patients

Aged over 50 Years Presenting with Suspected DVTs Can Decrease the Need for Compression UltrasonographyA. Hughes, B. Hall, C. Smith, J. King, G. Page, K. Jennings, S. Macdonald, V. Webb, F. Charova (United Kingdom)

PB 1146 Is the Application of a Single Conversion Factor Suitable for the Laboratory

Monitoring of Single Chain rFVIII by One-stage FVIII:C Assay?A.E. Bowyer1, S. Kitchen1, D. Dalton2, N.S. Key2, M. Makris1 (1United Kingdom, 2United States)

PB 1147 Impact of Pneumatic Tube System Transportation for the Monitoring of Heparin

TherapyA. Lebreton, A. Casini, O. Bulla, P. Fontana (Switzerland)

PB 1148 Comparison of von Willebrand Factor Collagen Binding Activity (VWF:CB)

Determined by a Chemiluminescent Assay on AcustarTM to an ELISA KitE. Jousselme, L. Rugeri, C. Nougier (France)

PB 1149 Validation of a Flow Cytometric Platelet Function Test in a Cohort of Patients

with a Suspected Platelet Function DisorderI. van Asten, M. Baaij, J. Zandstra, A. Huisman, G. Pasterkamp, R. Schutgens, S. Korporaal, R. Urbanus (The Netherlands)

PB 1150 Comparison of light transmission aggregometry and multiple electrode

aggregometry for the evaluation of platelet aggregation in patients with mucocutaneous bleedingS.J. Israels, E. McMillan-Ward, R. Mian, D. Murariu, P. Sun (Canada)

PB 1151 Clot Waveform Analysis Has the Potential to Detect Fibrinogen Abnormalities

A. Suzuki, N. Suzuki, M. Kishimoto, T. Kanematsu, T. Matsushita (Japan)

PB 1152 Effect of Anticoagulant Adjustment on Prothrombin Time Test Using 2 Different Thromboplastins in Patients with Elevated HematocritV.M. Silva, C. Cavalheiro Filho, D.C. Rezende, C.C. Strunz (Brazil)

PB 1153 Methodology of Thrombogenicity Assessment Intended for Biomaterials Utilized

in Blood PumpsM. Gawlikowski, K. Janiczak, B. Zawidlak-Wegrzynska, R. Kustosz (Poland)

PB 1154 LC-MS/MS Nonradioactive Serotonin Release Assay for Platelet Function

Analysis in Whole BloodS.L. Chan, X. Yi, E. Wysocki, R. Bridgman, K. Mikrut, J. Gutierrez, E.K.-Y. Leung, K.-T.J. Yeo, J. Miller (United States)

PB 1155 Thromboelastometry can Generate Significant Disagreement in the

Management of Patients after Cardiopulmonary Bypass due to Analytical VariabilityB. Bachellerie, H. Charbonneau, S. Voisin, F. Labaste, A. Caussanel, F. Guerrero (France)

PB 1156 Establishing of Therapeutic Range for Unfractionated Heparin Therapy:

Activated Partial Thromboplastin Time vs. Anti-Xa MeasurementL. Zhang1, P. Toulon2, X. Zheng1, J. Yang1, Q. Fan1, C. Liu1, Z. Zhang1 (1China, 2France)

PB 1157 Impact of Rivaroxaban and Dabigatran on Clotting Screens as Performed Using

the Roche Cobas t 711 AnalyserA. Lowe1, R. Jones1, A. Stankiewicz2, S. Kitchen1 (1United Kingdom, 2United States)

PB 1158 Genotypic Characteristics of Polish Patients with Antithrombin, Protein C and

Protein S DeficiencyE. Odnoczko1, E. Stefanska-Windyga1, A. Buczma1, B. Baran1, J. Oldenburg2, A. Pavlova2, V. Ivaskevicius2, J. Windyga1 (1Poland, 2Germany)

PB 1159 Assessment of Overall Coagulation and Fibrinolytic Activity in Hemophilia A

Patients by Using Global Hemostatic Laboratory Methods: Overall Hemostasis Potential, aPTT-waveform Analysis and Endogenous Thrombin PotentialM. Milos1, D. Coen Herak1, S. Zupancic-Salek1, J. Pavic2, N. Mahmoud Hourani Soutari3, J.P. Antovic3, R. Zadro1 (1Croatia, 2Bosnia and Herzegovina, 3Sweden)

PB 1160 Thrombin Generation in Patients with Systemic Lupus Erythematosus (SLE)N.K. Tóth, T. Tarr, P. Soltész, L. Muszbek, Z. Bagoly (Hungary)

PB 1161 Comparison of Three Different Anti-Xa Assays in Major Orthopedic Surgery

Patients Treated with EdoxabanH. Wada (Japan)



352 353

Tues

day

Pos

ter

Ses

sion

s

PB 1162 Assessment of Two Chromogenic FVIII Assays In Haemophilia A Patients Infused with B-domain Truncated or Deleted Products: Results from a French Multicentric StudyE. De Maistre, V. Le Cam-Duchez, C. Biron, D. Bouchot, A. Deshaye, P. Jouve, C. Ternisien, V. Barbay, V. Proulle, D. Lasne, A. Ryman, N. Hezard, C. Pouplard, P. Suchon, C. Flaujac, F. Pineau-Vincent, C. Caron (France)

PB 1163 Effects of Interfering Substances on Factor Assays Performed Using Q Smart

Analyser and DG-PT RecombiLIQ or DG-APTT Synth ReagentsA. Woolley, S. Kitchen (United Kingdom)

PB 1164 Comparison of Point-of-Care Instruments I-STAT, ACTPlus and Hemochron

Signature Plus for Measurement of Activated Clotting Time (ACT)S. Vandendriessche, H. Laverge, K. Devreese (Belgium)

PB 1165 Extracellular Proteases of Micromicetes as New Agents for Protein C, Factor X

and Plasma Prekallikrein DiagnosticsA.A. Osmolovskiy, A.V. Orechova , E.S. Zvonareva , V.G. Kreyer , N.A. Baranova , N.S. Egorov (Russian Federation)

PB 1166 Laboratory Expert System in the Field of Hemostasis and Thrombosis: A Pilot

Project for the Diagnosis of von Willebrand DiseaseH. Seidel, B. Pötzsch, U. Budde, R. Dittmer, S. Schneppenheim, D. Peetz, P. Lodemann, M. Hägele, M.-O. Link, M. Takla, R. Groh, W.A. Scherbaum, F. Strasding, P. Westhofen, J.P. Kruppenbacher (Germany)

PB 1167 A New and Improved Euglobulin Clot Lysis Time Assay (iECLT)

A. Ilich, N. Key (United States) PB 1168 Platelet Estimation from Peripheral Blood Smear: Does it Really Works?

I. Bachiri, Z.Yahiaoui , N.Fenni (Algeria) PB 1169 Comparison of Rotational Thromboelastometry Reference Ranges with

Normative Ranges across Trimesters in PregnancyA.A. Shamshirsaz, K.A. Fox, H. Erfani, K. Brudozski, V. Kostousov, H. Rocky, J. Teruya (United States)

PB 1170 Enhanced Coagulation Decreases Probability of Positive Outcome during in

vitro FertilizationA. Balandina, E. Koltsova, T. Teterina, A. Yakovenko, E. Simonenko, A. Poletaev, I. Zorina, S. Yakovenko, F. Ataullakhanov (Russian Federation)

PB 1171 Development and Implementation of a Coagulation Factor Testing Method

Utilizing Autoverification in a High Volume Clinical Reference Laboratory EnvironmentP. Riley1, A. Valcour1, B. Gallea2 (1United States, 2France)

PB 1172 Factors VII and VIII Assays: Analytical Performance and Reference Ranges for Argentinian PopulationR. Raimondi, V. Monserrat, S. Aguirre, L. Herrera, S. Pons, A. Grinspon, A. Scazziota (Argentina)

PB 1173 Can Thromboelastography Accurately Assess Coagulation in Anemic Patients?

A.A. Kuperman, E. Shaoul, R. Pollack, A. Braester (Israel) PB 1174 Standardization of a Cytometry Test to Measure the von Willebrand Factor

Collagen Binding ActivityL. Maira Moura de Oliveira, M.V. de Almeida Amorim, D. Gonçalves Chaves (Brazil)

PB 1175 Implementing Autoverification of Coagulation Screen Tests in Universitary

Hospital Laboratory in BrazilM.L. Pereira Gonçalves, P. Orlandi Mourão (Brazil)

PB 1176 Assessment of a Pre-analytical Check System on ACL TOP 750 CTS®

K. Kanouchi, T. Sakata, Y. Takahama, R. Ohta, M. Sato, A. Suzuki, K. Morikane (Japan)

PB 1177 Results of Implemented Postanalytical Quality Indicator - Turnaround Time

(TAT) Monitoring for Urgent Coagulation TestsS. Margetic, I. Vukasovic, N. Vrkic (Croatia)

PB 1178 Is it Helpful for Physicians the Laboratory Post Analytical Comments on a

Prolonged APTT?M.D.V. Arias, R.E. Sueldo, M. Avalos, M. Gurfinkiel (Argentina)

PB 1179 Sensitive Method for Determination of Blood Hypercoagulation

V. Sukhanov, O. Petrova (Russian Federation) PB 1180 Variants of FVII Deficiency at an Elderly Care Hospital

R.E. Sueldo1, G. Guerrero1, P. Do Nascimento1, A. Baques1, A. Girolami2, G. Scoles1, M.D.V. Arias1 (1Argentina, 2Italy)

PB 1181 Towards Harmonization of Critical International Normalized Ratio Values

Reporting: The Croatian SurveyA. Bronic, D. Coen Herak, S. Margetić, M. Milic Gall (Croatia)

PB 1182 Improving Laboratory Operational Efficiency with the Implementation of a

Specialized Hemostasis Lab AutomationV. Cortina, A. Marín, F. Bosch, A. Santamaría (Spain)



354 355

Tues

day

Pos

ter

Ses

sion

s

PB 1183 In Search of a Sensitive and Reliable Laboratory Tool to Assess HypercoagulabilityD. Bertaggia Calderara, D. Kröll, P. Nett, A. Aliotta, D. Pratte, N. Weiland-Jäggi, G. Stirnimann, L. Alberio (Switzerland)

PB 1184 HIL Interferences in Coagulation Testing: Evaluation of Automatic Check with

the New ACL TOP 550 CTS AnalyzerA. Skibowska-Bielińska, E. Wierszyło, E. Czajkowska, K. Lewandowski (Poland)

PB 1185 Comparison of Clot Waveform Analysis from Sepsis Patients and Healthy

Control GroupN. Zamalek (Indonesia)

PB 1186 Impact of New Oral Anticoagulants on Routine Coagulation Assays

A. Bronic, M. Pavic, L. Milevoj Kopcinovic (Croatia)


PB 1187 Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation: An Ancillary Analysis from the Edoxaban versus Warfarin in Subjects UndeRgoing Cardioversion of Atrial Fibrillation (Ensure-AF) StudyG.Y. Lip1, J.L. Merino2, A.G. Dan3, S. Themistoclakis4, K.A. Ellenbogen5, R. De Caterina4, A. Goudev6, J. Jin5, M. Melino5, S.M. Winters5, B. Merkely7, A. Goette8 (1United Kingdom, 2Spain, 3Romania, 4Italy, 5United States, 6Bulgaria, 7Hungary, 8Germany)

PB 1188 Anticoagulation Treatment Patterns of Venous Thromboembolism in GARFIELD-

VTE PatientsS. Haas1, A.G.G. Turpie2, J.I. Weitz2, W. Ageno3, P. Angchaisuksiri4, H. Bounameaux5, S.Z. Goldhaber6, S. Goto7, G. Kayani8, J. Dalsgaard Nielsen9, S. Schellong1, L.G. Mantovani3, P. Prandoni3, A.K. Kakkar8 (1Germany, 2Canada, 3Italy, 4Thailand, 5Switzerland, 6United States, 7Japan, 8United Kingdom, 9Denmark)

PB 1189 Clinical Outcomes in Fragile Patient with Venous Thromboembolism

F. Moustafa1, M. Giorgi Pierfranceschi2, P. Di Micco2, E. Bucherini2, A. Lorenzo3, A. Villalobos3, J.A. Nieto3, B. Valero3, A.L. Samperiz3, M. Monreal3, RIETE Investigators (1France, 2Italy, 3Spain)

PB 1190 Comprehensive Characteristics of the Anticoagulant Activity in Relationship to

the Plasma Concentration of DabigatranW.J. Comuth1, L.Ø. Henriksen1, D. van de Kerkhof2, S. Husted1, S.D. Kristensen1, M.P.M. de Maat2, A.-M.B. Münster1 (1Denmark, 2The Netherlands)

PB 1191 Menstrual Bleeding Patterns in Women Treated with Rivaroxaban: Data from the EINSTEIN CHOICE TrialK. Boonyawat1, A.W. Lensing2, M.H. Prins3, P. Prandoni4, J.I. Weitz1, M. Crowther1 (1Canada, 2Germany, 3Netherlands Antilles, 4Italy)

PB 1192 Absence of Interaction between Rivaroxaban, Tacrolimus and Everolimus in

Renal Transplant Recipients Anticoagulated for Proximal Deep Vein Thrombosis or Atrial FibrillationG. Camporese, M.T. Sartori, D. Bernardi, F. Marchini, G. Avruscio (Italy)

PB 1193 Impact of Evolving ACCP Guidelines on Estimates of Venous Thromboembolism

Risk in US HospitalsW. Huang1, A. Cohen2, Z. Maksim1, A. Wyman1, F. Anderson1 (1United States, 2United Kingdom)

PB 1194 Healthcare Resource Use in the Non-interventional XALIA Study of Rivaroxaban

versus Standard Anticoagulation for Deep Vein ThrombosisL.G. Mantovani1, S. Cano2, M. Gebel1, K. Sahin1, K. Folkerts1, S. Haas1, R. Kreutz1, D. Monje1, J. Schneider1, M. van Eickels1, W. Ageno3, A.G.G. Turpie4 (1Germany, 2United Kingdom, 3Italy, 4Canada)

PB 1195 Oral Anticoagulation with Direct Thrombin Inhibitors Prevents the Early Events

of Atrial Remodeling and the Thrombin-activated ErbB Signaling in a Rat Model of Atrial DilationC. Jumeau, F. Loisel, G. Dilanian, N. Mougenot, N. Villeneuve, S. Hatem, M. David-Dufilho (France)

PB 1196 6-months Outcomes of Patients: Results from GARFIELD-VTE

A.G.G. Turpie1, S. Haas2, J.I. Weitz1, W. Ageno3, P. Angchaisuksiri4, H. Bounameaux5, S.Z. Goldhaber6, S. Goto7, G. Kayani8, J. Dalsgaard Nielsen9, S. Schellong2, L.G. Mantovani3, P. Prandoni3, A.K. Kakkar8 (1Canada, 2Germany, 3Italy, 4Thailand, 5Switzerland, 6United States, 7Japan, 8United Kingdom, 9Denmark)

PB 1197 Outcomes, Interventions and DOAC Plasma Concentration Assay Utility in

DOAC-treated Patients Presenting with Major Haemorrhage or Thrombosis - Results from the Anticoagulant Reversal and Events Study Collaborative (ARES1)R.I. Baker1, J. Curnow1, L. Young2, S.R. McGregor1, T. Brighton1, P. Harper2, J. Joseph1, A. Hugman1, G.V. D'Aulerio1, A. Gallus1, Thrombosis and Haemostasis Society of Australia and New Zealand (1Australia, 2New Zealand)

PB 1198 Direct Oral Anticoagulants in Patients with Venous Thromboembolism Usually Excluded for Clinical TrialsF. Moustafa1, R. Pesavento2, P. Di Micco2, J. Gonzalez-Martinez3, R. Quintavalla2, L. Peris3, J.A. Porras3, N. Falvo1, P. Banos3, M. Monreal3, RIETE investigators (1France, 2Italy, 3Spain)



356 357

Tues

day

Pos

ter

Ses

sion

s

PB 1199 A New Method for Determining Concentrations of Direct Oral Anticoagulants

S. Bloemen1, S. Zwaveling1, J. Douxfils2, T. Peters1, R. Wagenvoord1, H.C. Hemker1, F. Mullier2, B. de Laat1, M. Roest1, R. Kremers1 (1The Netherlands, 2Belgium)

PB 1200 Patients with Dabigatran Circulating Concentration above 200 ng/ml Have a

Rebound after Neutralization by a Single Dose of IdarucizumabN. Gendron, J. Gay, M. Lemoine, A. Lillo-Le Louët, D. Smadja (France)

PB 1201 Patient-reported Treatment Satisfaction with Oral Rivaroxaban: Results from

the Non-interventional XALIA Study of Deep Vein ThrombosisL.G. Mantovani1, S. Cano2, M. Gebel3, K. Sahin3, K. Folkerts3, S. Haas3, R. Kreutz3, D. Monje3, J. Schneider3, M. van Eickels3, W. Ageno1, A.G.G. Turpie4 (1Italy, 2United Kingdom, 3Germany, 4Canada)

PB 1202 Comparison of Applying TTR Proportion of Tests and TTR Rosendaal to a

Sample Population Attending a Warfarin ClinicT. O Halloran, D. O Keeffe, O. Power, J. Conway, M. Watts (Ireland)

PB 1204 Development and Characterization of Neutralizing Monoclonal Antibodies

Targeting the Direct Oral Anticoagulant ApixabanE. Maurer, S. Crosnier, C. Baltus, M.-C. Viaud-Massuard, M. Canton, P. Ohlmann (France)

PB 1205 Pulmonary Embolism Rule-out Criteria (PERC) Has No Added Value to the

YEARS Algorithm to Rule out Pulmonary EmbolismL.M. van der Pol, T. van der Hulle, A.T.A. Mairuhu, M.V. Huisman, F.A. Klok (The Netherlands)

PB 1206 Evaluation of Different Coagulation Laboratory Methods to Monitor Apixaban,

Rivaroxaban and Dabigatran TreatmentA. Rasmuson, M. Berndtsson, L. Söderblom, M. Skeppholm, R.E. Malmström, J.P. Antovic (Sweden)

PB 1207 Effect of Rivaroxaban on Expression of Monocyte Platelet Aggregates and P Selectin in Patients with Atrial FibrillationR.C.F. Duarte, E.L. Figueiredo, L.G. Freitas, E. Reis, C.N. Ferreira, F.F.M. Campos, M.G. Carvalho (Brazil)

PB 1208 Gastrointestinal Bleeding in Patients on Warfarin and Direct Oral Anticoagulant

Therapy: An Observational Study in a District General HospitalA. McSorley, C. Dinning, M.D. Creagh, J. Blundell (United Kingdom)

PB 1209 Select-d Trial Qualitative Sub-study: Patient and Carer Experience of Anticoagulation for Cancer-Associated ThrombosisA. Hutchinson, S. Rees, K. Date, A. Young, A. Maraveyas, M.J. Johnson (United Kingdom)

PB 1210 TRAP-induced Platelet Aggregation is Reduced in Patients Receiving

DabigatranJ. Sokol, F. Nehaj, M. Mokan, J. Ivankova, J. Stasko (Slovakia)

PB 1211 An Oral Factor Xa Inhibitor Edoxaban Ameliorates Neointima Formation

Following Vascular Injury in ApoE KO MiceY. Morishima, Y. Honda (Japan)

PB 1212 Thrombelastography (TEG) for Assessing Dabigatran Reversal in a Preclinical

Trauma ModelM. Honickel, N. Akman, O. Grottke (Germany)

PB 1213 Lower Prevalence of Isolated Subsegmental Pulmonary Embolism in the YEARS

Diagnostic Algorithm Compared with the Conventional Algorithm for Suspected Pulmonary EmbolismL.M. van der Pol, T. van der Hulle, P.L. den Exter, J.M. van Werkhoven, T.E. van Mens, I.M. Bistervels, M. ten Wolde, A.T.A. Mairuhu, S. Middeldorp, M.V. Huisman, F.A. Klok (The Netherlands)

PB 1214 Renal Clearance is Able to Predict Drug Discontinuation in Patients with Atrial

Fibrilation Treated with Direct Oral AnticogulantsB. Navarro-Almenzar, J.J. Cerezo-Manchado, A. Maritnez-Marin, E. Fernandez, M. Moya-Arnau, F. Garcia-Candel, N. Marin, D. Iyu, V. Cabañes, M. Berenguer, S. Eduardo, R. Perez-Lopez, F. Labbadia, M. Blanquer, A.M. Garcia-Hernandez, D. Sanchez, J. Sanchez-Garcia, N. Garcia-Iniesta, F. Iniesta, J.M. Moraleda (Spain)

PB 1215 What's the Optimal Cut-off Value of the Prothrombin Time (PT) Assay for

Determining Overdose Status of Rivaroxaban?B. Kim, S. Jang, Y.-U. Cho, C.-J. Park (Republic of Korea)

PB 1216 DOAC Reversal with Low (< 20 Units/kg) or Moderate Dose (≥20 Units/kg)

FEIBA in the Urgent Management of Major BleedingW. Dager, A. Roberts (United States)

PB 1217 Treatment Effect Estimates for Extended Treatment of VTE Using Network

Meta-analysis from Clinical Trials with Rivaroxaban, Aspirin or PlaceboÁ.F. Pap1, A.W.A. Lensing1, M.H. Prins2, P. Prandoni3, U. Krahn1 (1Germany, 2The Netherlands, 3Italy)



358 359

Tues

day

Pos

ter

Ses

sion

s

PB 1218 Is LMWH-calibrated Anti-Xa Assay Useful to Estimate Apixaban Concentration in Patients Undergoing Apixaban Treatment?M.D.L. Herrera, A. Scazziota, A. Grinspon, S. Aguirre, R. Raimondi, A. Brodsky, S. Pons (Argentina)

PB 1219 Calibrated Automated Thrombogram II: A New Thrombin Generation Test Able

to Measure in the Presence of a Direct Thrombin InhibitorP.L.A. Giesen, A.J.W. Gulpen, R. van Oerle, H. ten Cate, H.M. Spronk (The Netherlands)

PB 1220 Inability of Idarucizumab 5gm to Completely Reverse Excessively High

Dabigatran ConcentrationsW. Dager, A. Roberts (United States)

PB 1221 The Direct Rivaroxaban: Direct Measurement of Plasma Rivaroxaban

Concentration through Prothrombin Time (PT) AssayB. Kim, S. Jang, Y.-U. Cho, C.-J. Park (Republic of Korea)

PB 1222 Management of Pulmonary Embolism in a Short Stay Medical Unit: A Cohort

StudyM. Donadini, A. Squizzato, M. Caprioli, N. Macchi, W. Ageno (Italy)

PB 1223 The Safety of a Nurse Led Pathway to Transition Patients with Acute Venous

Thromboembolism (VTE), Treated with Rivaroxaban, into the CommunityT. Indran, A. Cummins, H. Tran, S. Brown, A. Bennett, E. Wood, Z. McQuilton, N. Chan, S. Chunilal (Australia)

PB 1224 Performance of a Chromogenic Assay for the Measurement of Edoxaban

Concentration in PlasmaC. Hamon, C. Godefroy (France)

PB 1225 The Perioperative Anticoagulant Use Surgery Evaluation (PAUSE) Study

J. Douketis1, A. Spyropoulos2, S. Bates1, M. Blostein1, J. Caprini2, M. Carrier1, P.L. Gross1, J. Kassis1, S. Kowalski1, A. Lee1, G. Le Gal1, G. Le Templier1, E. MacKay1, S. Shivakumar1, V. Shah2, F. Spencer1, S. Solymoss1, S. Syed1, A. Tafur2, C. Wu1, E. Yeo1, S. Schulman1 (1Canada, 2United States)

PB 1226 Assay Availability for Measurement the Anticoagulant Effect of Direct and

Indirect Xa InhibitorsS. Platton, M. Dave (United Kingdom)

PB 1227 Evaluation of Prescribing Practices and Medication Persistence in Patients

Initiated on Direct Oral Anticoagulant Therapy at a Tertiary Care Academic Medical CenterB. Lai, E. Peterson, P. Klem, G. Woodhouse, E. Fields, T. Trujillo, K. Hassell, C. Thienelt (United States)

PB 1228 Selection of Long-term Anticoagulation Therapy after Acute Pulmonary Embolism in Real LifeV. Ģībietis, D. Kigitoviča, B. Vītola, S. Strautmane, A. Skride (Latvia)

PB 1229 Impact Analysis of Prognostic Stratification for Pulmonary Embolism: The iAPP

StudyM. Donadini1, W. Ageno1, M. Cei1, F. Dentali1, P. Fenu1, N. Mumoli1, F. Pomero1, R. Re1, G. Palmiero1, L. Spadafora1, D. Aujesky2, A. Squizzato1 (1Italy, 2Switzerland)

PB 1230 Do the Direct Oral Anticoagulants (Doacs) Make Managing Anticoagulant

Therapy during the Peri-operative Period Easier?K. Kittoe, J. Patel, R. Arya (United Kingdom)

PB 1231 Limits of Sensitized Rotational Thromboelastometry for Rivaroxaban and

Apixaban DetectionC. Pailleret Ringuier, G. Jourdi, V. Siguret, I. Gouin-Thibault, S. Gandrille, A. Stepanian, J.-L. Golmard, P. Gaussem, C.-M. Samama, B. Le Bonniec (France)

PB 1232 Choice of Anticoagulation in the Obese

G. McCaughan, H. Crowther, J. Curnow (Australia) PB 1233 Antithrombotic Effects of Edoxaban, a Direct Factor Xa Inhibitor, and

Antiplatelet Agents and their Combination Effects on Stent Thrombosis in RatsY. Morishima, C. Kamisato, Y. Honda (Japan)

PB 1234 Dental Extractions on NOACs withouT Stopping Therapy (DENTST) Study:

Interim AnalysisY. Brennan, Y. Gu, E.J. Favaloro, H. Crowther, E. Kelly, H. Zoellner, M. Schifter, J. Curnow (Australia)

PB 1235 Patients on a Fixed Dose of DOAC: What Percentage is in the Therapeutic

Window?H.C. Hemker1, S. Bloemen1, R. Kremers1, H. Kelchtermans1, J. Douxfils2, F. Mullier2, B. de Laat1 (1The Netherlands, 2Belgium)

PB 1236 Comparing the Performance of Different Assays for Monitoring Dabigatran

Plasma Concentrations in Real-practiceL. Gonçalves, M. Carvalho, V. Cunha, C. Monteiro, C. Koch (Portugal)

PB 1237 Total Thrombus-formation Analysis System (T-TAS) as a Potential Tool for

Assessing Comprehensive Hemostatic Function in Patients Taking DabigatranT. Ito, T. Nagasato, T. Nakashima, H. Matsuoka, K. Hosokawa, I. Maruyama (Japan)



360 361

Tues

day

Pos

ter

Ses

sion

s

PB 1238 Evaluation of Dabigatran Concentrations in Patients Plasma. Comparison of Four Commercially Available AssaysP. Toulon, N. DePooter, A. Appert-Flory, D. Jambou, F. Fischer (France)

PB 1239 Comparison of the LMWH Tinzaparin and the Direct Inhibitors of Factor Xa and

Thrombin on the Kinetics and Qualitative Characteristics of Blood Clot. An in vitro Thromboelastometric StudyS. Salta, C. Soulier, P. Van Dreden, L. Papageorgiou, A. Larsen, I. Elalamy, G. Gerotziafas (France)

PB 1240 Measurement of Direct Oral Anticoagulants Levels in Patients Admitted for

Bleeding Events: A Prospective StudyA.-L. Sennesael, A.-S. Larock, J. Douxfils, J.-M. Dogné, A. Spinewine, F. Mullier (Belgium)

PB 1241 Direct Oral Anticoagulants for Pulmonary Embolism in Patients Initially

Admitted to Sub Intensive Care Unit for Intermediate High Risk Index EventD. Arioli, M. Casella, M. Calzolari, A. Casali, L. Morini, M.C. Leone, M. Granito, A. Ghirarduzzi, G. Tortorella, E.A. Negri (Italy)

PB 1242 Oral Anticoagulant Associated Bleeding Events - A Single Centre Experience

S. McNeill, J. Tan, S. MacBride-Stewart, L. Green, P. MacCallum, C. Bagot, R.C. Tait (United Kingdom)

PB 1243 Influence of Direct Oral Anticoagulants in Fibrinolysis Testing

M. Pereira, R. Matos, E. Cruz, S. Morais (Portugal)

Pediatrics

PB 1244 The Incidence and Assessment of Post-thrombotic Syndrome in Critically Ill Children Two Years Post-central Venous Catheter PlacementS. Jones, J. Rutgers, W. Butt, F. Newall, P. Monagle (Australia)

PB 1245 Venous Thromboembolism (VTE) in Pediatric Recipients of Hematopoietic Stem

Cell Transplant (HSCT): Principal Findings from a Multicenter Cohort StudyR. Kumar, J. Stanek, H. Rangarajan, S. O'Brien (United States)

PB 1246 Chronic Blood Transfusion Therapy Corrects Abnormalities of Coagulation and

Fibrinolysis in Children with Sickle Cell DiseaseS. Williams1, C. Segbefia2, F. Pluthero1, W. Kahr1 (1Canada, 2Ghana)

PB 1247 Evaluating the Relationship between von Willebrand Factor, ABO Blood Group and Circulating Lymphoblasts in the Development of ALL-associated Thromboembolism in ChildrenT. Mizrahi, C. Laverdière, M. David, J.-M. Leclerc, Y.-L. Delva, L. Thabane, A. Chan, U. Athale (Canada)

PB 1248 Central Venous Catheter Associated Thrombosis in Congenital Heart Disease

Patients: A Preliminary Analysis of the Children's Hospital Acquired Thrombosis (CHAT) RegistryM. Silvey, B. Branchford, E. Krava, J. Jaffray, A. Mahajerin, S. Carpenter (United States)

PB 1249 Neutrophil Extracelular Traps (NETs) and Inflammatory Biomarkers in Patients

with Hereditary Spherocytosis. Influence of SplenectomyC. García, A. Moscardó, S. Izquierdo, A.M. Latorre, B. Argiles, M.T. Santos, J. Vallés, M.Á. Dasí (Spain)

PB 1250 Paget-Schroetter Syndrome in Children and Young Adults: The Bane of Athletes

of Either GenderD. Warad, A. Nageswara Rao, R. Pruthi, V. Rodriguez (United States)

PB 1251 The Association between Central Venous Catheter Placement and Central

Venous Catheter Related ThrombusS. Jones, J. Rutgers, P. Monagle, W. Butt, F. Newall (Australia)

PB 1252 Acute Ischemic Stroke in Children on Left Ventricular Assist Device. Is There a

Role For Endovascular Treatment?M. Hunfeld, H. van Ommen, B. Emmer, A. van Es, U. Kraemer, R.J. Houmes, D. Tibboel (The Netherlands)

PB 1253 Thrombotic and Hemorrhagic Complications in Pediatric Recipients of

Hematopoietic Stem Cell Transplant (HSCT): Mayo Clinic ExperienceD. Kaur, A. Ashrani, R. Pruthi, S. Khan, K. Bailey, V. Rodriguez (United States)

PB 1254 Venous Thromboembolism in Children with Hodgkin´s Lymphoma

D. Evstratov, P. Zharkov, L. Potapenko, A. Pshonkin, N. Myakova (Russian Federation)

PB 1255 Thrombin Generation in Venous Thromboembolism, Arterial Ischaemic Stroke

and Bleeding Events in ChildrenV. Ignjatovic1, S. Thedieck2, P. Monagle1, U. Nowak-Goettl2 (1Australia, 2Germany)

PB 1256 Paroxysmal Nocturnal Hemoglobinuria Spectrum among Pediatric Age Group of

Patients: Single Center Experience without Any Thrombotic EventsS. Unal, F. Gumruk, M. Cetin (Turkey)



362 363

Tues

day

Pos

ter

Ses

sion

s

PB 1257 Incidence and Risk Factors for Childhood Thrombosis: Ten Years Experience of a Paedatric Hematology Center from TurkeyA. Meral Güneş, B. Baytan, M. Sezgin Evim, T. Ersoy Kuzucu (Turkey)

Platelets - Basic

PB 1258 A Default in Acetyl-CoA Carboxylase Phosphorylation Increases Thrombus Growth in vitro and in vivo, and in a Collagen-dependent MannerS. Lepropre1, S. Kautbally1, L. Bertrand1, G.R. Steinberg2, B.E. Kemp3, A. Hego1, O. Wéra1, S. Brouns4, F. Swieringa4, J. Heemskerk4, C. Oury1, C. Beauloye1, S. Horman1 (1Belgium, 2Canada, 3Australia, 4The Netherlands)

PB 1260 Fibrin Activation and Not GPCR Activation Induces Shedding of Platelet GPVI:

Soluble GPVI is Elevated in Thermal Injury and ICU PatientsS.J. Montague1, C. Delierneux2, C. Lecut2, N. Layios2, R.J. Dinsdale3, N.S. Poulter3, R.K. Andrews1, P. Hampson3, C.M. Wearn3, C. Lee1, N. Maes2, J. Bishop3, A. Bamford3, C. Gardiner3, N. Moiemen3, S.P. Watson3, C. Oury2, E.E. Gardiner1, P. Harrison3 (1Australia, 2Belgium, 3United Kingdom)

PB 1261 A Humanized Monoclonal Antibody that Inhibits Platelet-surface ERp72

Reveals a Role for ERp72 in Platelet Function and Thrombus FormationL.-M. Holbrook, G. Sandhar, P. Sasikumar, M. Schenk, A. Bye, A. Stainer, K. Sahli, G. Flora, A. Bicknell, J. Gibbins (United Kingdom)

PB 1262 Patient Derived HLA Monoclonal Antibodies Induce Fcγriia Dependent Platelet

ActivationM. Rijkers, F.H.J. Claas, A. Mulder, L. Porcelijn, F.W.G. Leebeek, J. Voorberg, A.J.G. Jansen, M. de Haas (The Netherlands)

PB 1263 Platelet PN-1 Regulates Clot Structure and Retraction

S. Loyau, Y. Boulaftali, L. Venisse, V. Arocas, M.-C. Bouton (France) PB 1264 Statins Inhibit Platelet Function and Attenuate Clot Structure

M.M. Jalal, F.P. Coxon, N.J. Mutch (United Kingdom) PB 1265 Cyclophilin D Restricts the Lytic Susceptibility of Fibrin via Modulation of

Platelet FunctionsV.J. Farkas, L. Kőhidai, L. Szabó, C. Chinopoulos, L. Polgár, K. Kolev, I. Varjú (Hungary)

PB 1266 Biomechanical Mechanisms of Platelet-fibrin Interactions as a Basis of Blood

Clot ContractionR.I. Litvinov, O.V. Kim, M.S. Alber, J.W. Weisel (United States)

PB 1267 Non-genomic Effects of the Pregnane X Receptor: Inhibition of Platelet FunctionsG.D. Flora, K.A. Sahli, A.R. Stainer, A.J. Unsworth, P. Sasikumar, L.M. Holbrook, T. Sage, J.M. Gibbins (United Kingdom)

PB 1268 A Potential Role of Platelet Activation in the Progression of Atrial Fibrillation

S. Dolleman, H. de Boer, A.J. van Zonneveld (The Netherlands) PB 1269 Analysis of Microparticles Associated with Procoagulant Platelets by Imaging

Flow CytometryE.C. Reddy, H. Wang, S.J. Israels, K.W.A. Bang, M.L. Rand (Canada)

PB 1270 Controlled Adhesion of Endothelial Cell and Platelets onto Patterned CoCr Alloy

Surfaces by Direct Laser Interference Patterning Technique for Cardiovascular ApplicationsM. Pino1, R. Schieber1, F. Lasserre2, M. Hans2, M. Fernández-Yagüe1, M.P. Ginebra1, F. Mücklich2, M. Pegueroles1, G. Escolar1, M. Diaz-Ricart1 (1Spain, 2Germany)

PB 1271 Authophagy of Microparticles by Platelets is Partially Mediated through TLR-4

and Enhances ThrombogenicityI. Lopez-Vilchez, R.M. Hernandez, P. Molina, M. Pino, M. Diaz-Ricart, G. Escolar (Spain)

PB 1272 Analysis of Venous and Arterial Hemostatic Plugs Reveals Strikingly Similar

Composition and a Gradient of Platelet ActivationC. Matzko, M. Tomaiuolo, I. Poventud-Fuentes, L. Nettey, J. Weisel, L. Brass, T. Stalker (United States)

PB 1273 Platelet Reactivity and Receptor Density in Platelets with Different MPV

A. Södergren, S. Ramström (Sweden) PB 1274 Connexin 62 Hemichannels and Gap Junctions Regulate Platelet Function

K.A. Sahli, G.D. Flora, A. Bye, A. Stainer, S.K. Alouda, P. Sasikumar, L.M. Holbrook, M. AboHassan, T. Sage, J.M. Gibbins (United Kingdom)

PB 1275 Chloride Intracellular Channel 1 Cooperates with Integrins to Promote

Thrombus Formation and AngiogenesisL.M. Knowles, E. Ampofo, P. Niewald, A. Drawz, I. Müller, H. Eichler, J. Pilch (Germany)

PB 1276 A Novel Role for the Membrane Protein G6f in Platelet Activation Induced by

Weak StimulationA. Amirkhosravi, M. Davila, L. Robles-Carrillo, M. Brodie, J. Francis (United States)



364 365

Tues

day

Pos

ter

Ses

sion

s

PB 1277 Biomimetic Surfaces for Studying Neutrophil-platelet InteractionsL. Erpenbeck1, J. Spatz1, R.K. Andrews2, M.P. Schön1, S. Kruß1 (1Germany, 2Australia)

PB 1278 Heparin Decreases Thrombin Induced Procoagulant Platelet Formation via a

Direct Platelet EffectS. Wang, M. Bourcy, H. Campbell, V. Chen (Australia)

PB 1279 Changes in Platelet Surface Receptor Expression upon Activation Are Mainly

Contributed by Large PlateletsM. Moroi, S.M. Jung (United Kingdom)

PB 1280 Autophagy Inhibitors Reduce Platelet Function by Preventing Granule

ExocytosisD. Groeneveld, J. Adelmeijer, T. Lisman (The Netherlands)

PB 1281 Kinetics of Prothrombin Interaction with Subpopulations of Activated Platelets

N. Podoplelova1, S. Obydennyi1, M. Canault2, F. Ataullakhanov1, M.-C. Alessi2, M. Panteleev1 (1Russian Federation, 2France)

PB 1282 Inhibition of MRP4 Mediated Transport Reduces Platelet Function in a cAMP-

cGMP Independent MannerL. Alemanno1, V. Klaus2, I. Massimi1, G. Maria1, D. Angiolillo3, F.M. Pulcinelli1 (1Italy, 2Germany, 3United States)

PB 1283 Single Platelet Screening Platform Based on Cytoskeletal Adhesion Morphology

S. Lickert, I. Schön, V. Vogel (Switzerland) PB 1284 Systemic Alteration of Platelet Activity during Each Trimester of Normal

PregnancyS. Cullen, M.A. Alobaidly, C. Regan, N. Moran (Ireland)

PB 1285 The Inhibitory Effect of Protamine on Arterial Thrombosis and Platelets in Rats

J. Miklosz, B. Kalaska, D. Pawlak, A. Mogielnicki (Poland) PB 1286 The Role of Neuraminidases in Platelet Function

D.E. van der Wal, A.M. Davis, M. Mach, D.C. Marks (Australia) PB 1287 Platelet Procoagulant Activity Development and Thrombin Generation in

Recalcified ADP-supplemented Platelet-rich PlasmaE. Artemenko, F. Ataullakhanov, M. Panteleev (Russian Federation)

PB 1288 Role of HSP47 in Platelet Collagen Interaction

S. Alouda, K. Sahli, P. Sasikumar, L. Holbrook, J. Gibbins (United Kingdom)

PB 1289 Assessment of Platelet Procoagulant State - Significance of Different MethodsS.A. Fiedler, A.-C. Junker, G.J. Praefcke, C. Grundmann, R. Seitz, U. Salge-Bartels (Germany)

PB 1290 Exploration of additional parameters of multiple electrode aggregometry is

encouragedM.T. Skipper, P. Rubak, O.H. Larsen, A.-M. Hvas (Denmark)

PB 1293 Nicotine Suppresses the Collagen-induced Platelet Aggregation

Y. Suganuma, T. Kano, K. Ikemoto, C. Ichinose, T. Matsui, K. Kondo (Japan) PB 1294 Platelets Enhance Freshly Isolated Lymphocytes Adhesion to Fibrin

O. Solpova, A. Solpov (Russian Federation) PB 1295 Synergistic Inhibitory Effect of Capsaicin and Dihydrocapsaicin on the

Arachidonic Acid Pathway of Platelet AggregationS. Almaghrabi, K. Ahuja, D. Geraghty, M. Adams (Australia)

PB 1296 Crosstalk between PI3K Pathway and MAPK Pathway Regulates Platelet

Activation and Protein Synthesis via Phosphoinositide-dependent Kinase-1B. Manne1, P. Munzer2, R. Badolia1, R. Campbell1, S. Kunapuli1, O. Borst2, A. Weyrich1, M. Rondina1 (1United States, 2Germany)

PB 1298 Diacylglycerol Kinase Zeta is a Negative Regulator for GPVI-Mediated Platelet

ActivationA. Moroi, H. Zhi, M. Riese, P. Newman (United States)

PB 1299 ELMO1 Negatively Regulates Glycoprotein VI-mediated Signaling by RhoG in

PlateletsA. Patel, J. Kostyak, R. Badolia, D. Bhavanasi, C. Dangelmaier, S. Kim, J. Aslan, S. Merali, S. Kunapuli (United States)

PB 1300 All Roads Lead to Filamin A: Ligand Binding and Shear Force Signal to

Calpain-mediated Cleavage of Filamin A upon Platelet ActivationC.L. Buitrago, B. Coller (United States)

PB 1301 Kindlin-3 identified as a key negative regulator of the small Rho GTPase,

Cdc42 during platelet spreadingD. Ghalloussi, L. Vidal, M. Poggi, P. Saultier, F. Peiretti, L. Limozin, H. Chambost, M.-C. Alessi, M. Canault (France)

PB 1302 RGS-insensitive G Proteins as a Model to Study G Protein-dependent Signaling

S. Gupta, D. DeHelian, L. Brass, P. Ma (United States)



366 367

Tues

day

Pos

ter

Ses

sion

s

PB 1303 Arp2/3 is Critical for Platelet Homeostasis but Dispensable for Hemostatic Plug FormationD.S. Paul, C. Casari, C. Wu, R. Piatt, S. Pasala, R. Campbell, R.H. Lee, B.C. Cooley, K.R. Machlus, J.E. Italiano Jr., A. Weyrich, J.E. Bear, W. Bergmeier (United States)

PB 1304 Cold-induced Binding of von Willebrand Factor Facilitates Fast Clearance of

Refrigerated PlateletsW. Chen, S.A. Druzak, K.M. Hoffmeister, J. Ware, R. Li (United States)

PB 1305 RGS Proteins Shape the Hemostatic Response by Regulating the Platelet

Signaling NetworksS. Gupta, S. Sampietro, D. Dehelian, L. Brass, P. Ma (United States)

PB 1306 A Spatial Systems Approach to Identifying Roles for the Rho-specific Guanine

Nucleotide Dissociation Inhibitor (RhoGDI) Ly-GDI in Platelet FunctionA.T.P. Ngo, M.L.D. Thierheimer, Ö. Babur, A.D. Rocheleau, T. Huang, R.A. Rigg, A. Mitrugno, J. Burchard, X. Nan, E. Demir, O.J.T. McCarty, J.E. Aslan (United States)

PB 1307 RhoGAP6 and RhoGEF2 Are Novel Regulators of RhoA in Platelets

S. Comer1, Z. Nagy2, S. Gambaryan3, U. Walter4, R. Zahedi4, K. Jurk4, A. Smolenski1 (1Ireland, 2United Kingdom, 3Russian Federation, 4Germany)

PB 1308 A Role of TNF Receptor-associated Factor 3 in Platelets A and Thrombosis

R. Zhang, G. Zhang, B. Xiang, P. Xie, Z. Li (United States) PB 1309 Annexin A7 (ANX7) Regulates Collagen-dependent Platelet Ca2+ Increase and

ActivationS. Geue, B. Walker-Allgaier, D. Eißler, P. Münzer, F. Lang, M. Gawaz, O. Borst (Germany)

PB 1310 Four-receptor Platelet Signaling Computational Model Reveals a New Role of

Protein Kinase A in the Control of Platelet ResponseA. Sveshnikova1, F. Balabin1, E. Shylov1, S. Shakhidzhanov1, J. Dunster2, J. Gibbins2, M. Panteleev1 (1Russian Federation, 2United Kingdom)

PB 1311 Disabled-2 Controls Platelet Activation Through a Regulatory Circuit Involving

Multiple Interacting ProteinsH.-J. Tsai, K.-Y. Chien, H.-R. Liao, Y.-H. Chiang, J.-C. Cheng, C.-P. Tseng (Taiwan)

PB 1312 Sustained Inhibition of Acetyl-CoA Carboxylase Decreases Platelet Dense

Granules Secretion and AggregationS. Lepropre1, M. Octave1, S. Kautbally1, G. Muccioli1, V.M. Darley-Usmar2, L. Bertrand1, C. Beauloye1, S. Horman1 (1Belgium, 2United States)

PB 1313 The G12/13 Signaling Pathway Contributes to the Racial Difference in PAR4 SignalingB. Tourdot, H. Stoveken, D. Trumbo, P. Bray, G. Tall, M. Holinstat (United States)

PB 1314 Changes in Gene Expression Levels in Immune Thrombocytopenia Patients

Treated with EltrombopagJ.M. Bastida, J.M. Hernández-Sánchez, A.E. Rodríguez, D. Alonso-López, E. Lumbreras, A. Díaz, R. Bueno, V. Gutiérrez, J.M. Hernández-Rivas, J.R. González-Porras (Spain)

PB 1315 Calcium Homeostasis in Platelets in Pregnancy Women with Preeclampsia

V.D. Bichan, A.V. Bakunovich, A.A. Krivolap, V.N. Sidorenko, L.M. Lobanok, K.Y. Bulanova (Belarus)

PB 1316 PDK1 Regulates Platelet Activation through Phosphorylating of S6K on Thr229

W. Gao, K. Wang, L. Zhang, J. Liu, X. Luo, X. Chen (China) PB 1317 Reverse Phosphorylation of the Protein Phosphatase 2A Inhibitor α-endosulfine

(ENSA) at Two Distinct Sites (S67, S109) in Activated and Inhibited Human PlateletsE. Walter1, O. Pagel1, S. Makhoul1, R.P. Zahedi1, A. Smolenski2, S. Gambaryan1, U. Walter1, K. Jurk1 (1Germany, 2Ireland)

PB 1318 Integration of Platelet Agonist Signaling during the Hemostatic Response in

vivoJ. Shen1, S. Sampietro2, J. Wu2, J. Tang1, C. Matzko2, C. Tang1, Y. Yu1, L.F. Brass2, T.J. Stalker2 (1China, 2United States)

PB 1319 The Identification and Characterization of a Novel, Selective Platelet-surface

ERp57 Inhibitor that Modulates Platelet Function Independently of Outside-in Signaling through Integrin αIIbβ3L.-M. Holbrook1, E. Brunt1, A. Stainer1, A. Bye1, A. Feldenzer2, C. Galinski2, D. Kennedy2, J. Gibbins1 (1United Kingdom, 2United States)

PB 1320 Platelet Proteomic Profiling in a Patient with Severe Platelet Dysfunction

Associated to an Anti-αIIbβ3 Autoantibody Triggering Outside-in SignalingM. Fiore, X. Pillois, M. Jandrot-Perrus, F. Cognasse, A. Debesset, A. Chansavang, S. Claverol, B. Payrastre, S. Laradi (France)

PB 1321 STAT3 Phosphorylation Is Regulated by Thromboxane A2 Receptor in Platelets

A.M. Latorre, J. Vallés, M.T. Santos, S. Bonanad, A. Moscardó (Spain) PB 1322 Guanosine Exerts Antiplatelet and Antithrombotic Properties through cAMP-

PKA Signaling and Independently of Platelet Adenosine ReceptorsE. Fuentes1, M.A. Alarcón1, I. Palomo1, L. Badimon2, G. Vilahur2, T. Padro2, K.-N. Klotz3, S. Kachler3, M. Fuentes1 (1Chile, 2Spain, 3Germany)



368 369

Tues

day

Pos

ter

Ses

sion

s

PB 1323 Anti-thrombotics from Snake Venom as Selective Inhibitor of αIIbβ3 Outside-in SignalingY.-J. Kuo, W.-J. Chuang, T.-F. Huang (Taiwan)

PB 1324 The Involvement of αIIbβ3 Integrin on the Release of Extracellular Vesicles and

the Chemokines CXCL4 and CCL5 by PlateletsA.C.A. Heinzmann, T. Vajen, J.W.M. Heemskerk, J.M. Cosemans, T.M. Hackeng, R.R. Koenen (The Netherlands)

PB 1325 Neuromedin U Potentiates ADP and Epinephrine Activation of Human Platelets

C. Grippi1, B. Izzi2, F. Gianfagna1, A. Di Pardo1, M.B. Donati1, G. de Gaetano1, M.F. Hoylaerts2, L. Iacoviello1, C. Cerletti1 (1Italy, 2Belgium)

PB 1326 Real-time Flow Cytometry Can Identify Differences in the Kinetics of Platelet

Activation in Response to Different AgonistsJ.L. Mitchell, C.I. Jones (United Kingdom)

PB 1327 Interplay between Calcium and Zinc: Implications for Platelet Activation

K. Taylor, N. Pugh (United Kingdom) PB 1329 Btk Kinase Activity is Not Critical for Platelet Activation by GPVI

P.L.R. Nicolson, S. Watson, C.E. Hughes, A.P. Bye, J.M. Gibbins, A.T. Hardy, C.N. Watson, S. Montague, M.G. Tomlinson, G.E. Pratt, S.P. Watson (United Kingdom)

PB 1330 ERK5 Associates Casein Kinase II to Regulate GPIb-IX-mediated Platelet

Activation via PI3K/Akt PathwayZ. Cheng, X. Fan, X. Chen, H. Mei, J. Liu, Y. Hu (China)

PB 1331 Agonist-induced Protein Disulfide Isomerase Activity in Platelets: Different

Effect of Different AgonistsR. Mor-Cohen, J. Mostafa, U. Seligsohn (Israel)

PB 1332 Dose-dependent Inhibitory and Stimulatory Effects of Sphingosine-1-phosphate

on Platelet Adhesion to EndotheliumB. Knoop, B. Levkau, A. Ayhan, A. Mohring, L. Dannenberg, M. Kelm, T. Zeus, A. Polzin (Germany)

PB 1333 Calcium Signalling Patterns in Adherent Single Platelets during Activation with Collagen-related PeptideS. Obydennyi, F. Ataullakhanov, M. Panteleev (Russian Federation)

PB 1334 Reelin Modulates PLCγ2 Phosphorylation upon Platelet Activation and Integrin

Outside-in SignalingI. Krüger, N.S. Gowert, H.H. Bock, M. Elvers (Germany)

PB 1335 Calcium Monitoring in Platelets: Tool for Diagnosing Platelet Function DefectsA. Aliotta, D. Bertaggia Calderara, L. Alberio (Switzerland)

PB 1336 Modelling Intracellular Zinc Release in Platelets

N.S. Ahmed, N. Pugh (United Kingdom) PB 1337 Role of Heterotrimeric G Proteins in Platelet Activation and Clot Formation in

Platelets Treated with Integrin αIIbβ3 InhibitorI. Budnik1, B. Shenkman2, H. Hauschner2, U. Martinowitz2, N. Savion2 (1Russian Federation, 2Israel)

PB 1338 In vitro Assessment of Catecholamines to Restore Platelet Aggregation in the

Presence of Ticagrelor and AspirinA.-C. Martin, T. Nunes, B. Decouture, P. Gaussem, A. Godier, C. Bachelot-Loza (France)

PB 1339 Emerging Role for TLT-1 at the Interception of Inflammation and Hemostasis

J. Morales, F. Reyes, F. Staback, O. Santiago, A. Pacheco, C. Con Yost, M. Rondina, A. Washington (United States)

PB 1340 Uptake of Influenza Virus by Platelets Occurs via Sialic Acid Binding

A.J.G. Jansen1, H. Low2, J. van den Brand1, D. van Riel1, A. Osterhaus2, E. van der Vries2 (1The Netherlands, 2Germany)

PB 1341 Platelets Express and Release Immune-modulatory CXCL14 upon Activation

A. Witte, J. Lu, M. Gawaz (Germany) PB 1342 CD8 T Cells Are Important Mediators of Platelet Refractoriness

C. Maier, S. Patel, C. Arthur, A. Bennett, A. Duncan, S. Stowell (United States) PB 1343 Endothelial Expression of TLT-1 Binding Pockets Mediate Platelet-endothelial

Interaction, Leukocyte Transmigration, and AngiogenesisY. Ferrer-Acosta1, J. Morales1, K. Lugo-Citron1, J. Thon2, B. Madera1, A.V. Washington1 (1Puerto Rico, 2United States)

PB 1344 Extracellular Vesicles from Activated Platelets: A Quantitative Cryo-electron

Microscopy and Immuno-Gold Labeling StudyA. Brisson, S. Tan, R. Linares, C. Gounou, S. Mornet (France)

PB 1345 Renal Denervation Decreases the Platelet Activation Status in Hypertensive

PatientsM.T.K. Zaldivia, D. Hering, P. Marusic, Y. Sata, R. Lee, M. Esler, N. Htun, J. Duval, L. Hammond, U. Flierl, M. Schlaich, K. Peter (Australia)



370 371

Tues

day

Pos

ter

Ses

sion

s

PB 1346 Upregulation of Inflammatory Transcripts in Platelets of Patients with Nonalcoholic Fatty Liver Disease (NAFLD): Role of Platelets in the "Inflammatory Network" of NAFLDM.A. Alberelli, L. Miele, G. Marrone, A. Liguori, M. Biolato, R. Landolfi, A. Gasbarrini, A. Grieco, E. De Candia (Italy)

PB 1347 Characterization of PF4-heparin Complexes by Photon Correlation Spectroscopy

and Zeta PotentialS. Bertini1, J. Fareed2, L. Madaschi1, G. Risi1, G. Torri1, W. Jeske2, A. Naggi1 (1Italy, 2United States)

PB 1348 Acetylsalicylic Acid Differentially Limits Activation and Apoptosis of Human

Platelets Exposed to Various Staphylococcus aureus StrainsA. Chabert, P. Damien, P.O. Verhoeven, F. Grattard, P. Berthelot, F. Zeni, L. Panicot-Dubois, S. Robert, F. Dignat-George, M.-A. Eyraud, B. Pozzetto, B. Payrastre, F. Cognasse, O. Garraud, H. Hamzeh-Cognasse (France)

PB 1349 Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in

vitro and in Renal Cell Carcinoma PatientsB.M.E. Tullemans, M. Nagy, S. Sabrkhany, M.G.A. Oude Egbrink, M.J. Aarts, J.W.M. Heemskerk, M.J.E. Kuijpers (The Netherlands)

PB 1350 Tunable Activation of Therapeutic Platelet-Rich Plasma by Pulse Electric

Fields: Differential Effects on Clot Formation, Growth Factor Release and Platelet MorphologyA.J. Gerrits, V.B. Neculaes, T. Gremmel, A.S. Torres, A. Caiafa, S.L. Carmichael, A.D. Michelson, A.L. Frelinger III (United States)

PB 1351 Bacteria Educated Platelets (BEPs) - Altered RNA expression in Human

Platelets Induced by Gram Negative BacteriaA.V. Fejes1, W.A. van der Heijden2, M.G. Best2, A. Vancura2, Q. de Mast2, T. Wurdinger2, C. Mannhalter1 (1Austria, 2The Netherlands)

PB 1352 Ascorbic Acid on Platelet Activation. New Functions for an Old Drug

R.G. Pozner, P.C. Ivani, S. Suarez, M.A. Martí (Argentina) PB 1353 Lipopolysaccharide Do Not Affect Platelet Activation in vitro

A.S. Maiorov, A.N. Sveshnikova (Russian Federation) PB 1354 Intercellular Signalling between Platelets and a Myeloid Leukemic Cell Line

T. Iftikhar, C. Vial, M.P. Mahaut-Smith (United Kingdom) PB 1355 An Optimized Protocol for Platelet Rich Plasma Preparation to Improve its

Angiogenic and Regenerative PropertiesJ. Etulain, H.A. Mena, R.P. Meiss, S. Negrotto, M. Schattner (Argentina)

PB 1357 Treatment of Patients with Autologous Platelet Rich Fibrin is Dependent on the Composition of Peripheral Blood Cells: Dental Implant Stability is Associated with Red Blood Cells and Not with PlateletsJ.A. Remijn, S. Buis, A. Karanzai, J. Konings, P.G. de Groot, B. de Laat, J.E.I.G. Brouwers (The Netherlands)

Poster Session 12:00 – 13:15 Exhibition Hall 6.2


PB 1358 Identification of a Novel Regulator Platelet P2Y12 Receptor Function: Tetherin, a Lipid-raft Organizing Protein Negatively Regulates Receptor ActivityX. Zhao, D. Alibhai, J.L. Hutchinson, S. Cross, R. Aungraheeta, C.M. McKinnon, A. Poole, G. Banting, S.J. Mundell (United Kingdom)

PB 1359 Platelet Endocytosis in Immune Responses to Viral Infection

M. Banerjee, S. Whiteheart (United States) PB 1360 Pharmacologic Blockade of Platelets Reduces Neuroinflammation in an Animal

Model of Multiple SclerosisS. Eichler, H. Böhnlein, K. Loser, H. Wiendl, B.E. Kehrel, K. Göbel, S.G. Meuth (Germany)

PB 1361 Exploring Pro-thrombotic HMGB-1 Release from Platelets

J. Davies, M. Harper (United Kingdom) PB 1362 Platelets Enhance Distinct Dynamics of Effector Cell Responses of Naive and

Effector Memory CD4+ T cellsS. Tan, C.-L. Liu, Y. Min, X. Liu, N. Li (Sweden)

PB 1363 The Staphylococcal Toxin Panton-Valentine Leukocidin (PVL) Induces

Neutrophil Extracellular Trap (NET) Formation that Leads to Platelet ActivationA. Bertling, S. Niemann, M.F. Brodde, F. Anke C., H. Van de Vyver, B. Schlott, C. Heilmann, G. Peters, B. Löffler, B.E. Kehrel (Germany)

PB 1364 Platelets Play a Protective Role in the Host Defense against Burkholderia

pseudomallei (Melioidosis)E. Birnie1, T.A.M. Claushuis1, G.C.K.W. Koh2, J. Ware3, A.F. de Vos1, T. van der Poll1, C. van 't Veer1, W.J. Wiersinga1 (1The Netherlands, 2United Kingdom, 3United States)



372 373

Tues

day

Pos

ter

Ses

sion

s

PB 1365 Plant Food Cyanidin-3-glucoside Attenuates Atherosclerosis via Inhibiting Platelet-derived Chemokines and Chemokine Receptors in ApoE-/- MiceY. Yan, Y. Yanling, Z. Xiandan, Y. Fuli, C. Binlin, L. Qing, L. Dan, L. Wenhua (China)

PB 1366 Platelets Promote Immunosuppression and Colorectal Tumor Formation: Inhibition by ClopidogrelL. Servais, C. Delierneux, O. Wéra, A. Gothot, A. Nchimi, P. Lancellotti, C. Oury (Belgium)

PB 1367 Interplay between Platelets, Neutrophils and Coagulation in Bleeding in a

Mouse Model of Inflammatory Bowel DiseaseO. Wéra, C. Delierneux, L. Servais, A. Hego, C. Lecut, P. Delvenne, A. Nchimi, P. Lancellotti, C. Oury (Belgium)

PB 1368 Platelet-leukocyte Interactions after Major Trauma Primarily Involve Platelet-

derived Microvesicles and Are More Frequent in Patients with Poor Clinical OutcomesP. Vulliamy, P.C. Armstrong, S. Gillespie, H.E. Allan, T.D. Warner, K. Brohi (United Kingdom)

PB 1369 Complete Attenuation of PrP(106-126)-mediated Pathological Responses by

Flufenamic Acid in PlateletsR.L. Mallick1, S.N. Chaurasia2, D. Dash2 (1Nepal, 2India)

PB 1370 Platelet Functional Activity Is Altered in Multiple Sclerosis

L. Schüngel, S. Eichler, M.F. Brodde, C. Korsukewitz, S.G. Meuth, K. Göbel, B.E. Kehrel (Germany)

PB 1371 Contributions of von Willebrand Factor to the Development of Angiotensin II-

induced Vascular InflammationJ. Lagrange1, S. Kossmann1, T. Münzel1, Z. Ruggeri2, W. Ruf1, P. Wenzel1 (1Germany, 2United States)

PB 1372 Platelets Are Effectors of Articular Degradation in Rheumatoid Arthritis

E. Petito, E. Falcinelli, A. Alunno, S. Momi, E. Bartoloni, A. Marturano, F. Luccioli, G. Mirabelli, R. Gerli, P. Gresele (Italy)

PB 1373 Procoagulant Extracellular Vesicles Impair Trophoblast Function by a Thrombo-

inflammatory PathwayS. Kohli, M.M. Al-Dabet, F. Lochmann, P. Marmeyer, S. Ranjan, K. Shahzad, B. Isermann (Germany)

PB 1374 Procoagulant Platelets as a Biomarker in Suspected Sepsis - A Pilot Study

L. Pasalic, A. Shetty, E. Lau, S. Sparenberg, V. Chen, J. Iredell (Australia)

PB 1375 Contraction of Blood Clots is Promoted by Tissue Factor-expressing Activated MonocytesA. Peshkova1, L.M. Giang1, V. Tutwiler2, I. Andrianova1, J. Weisel2, R. Litvinov2 (1Russian Federation, 2United States)

PB 1376 Different Cytokine and Chemokine Patterns in Pediatric Patients with Acute

and Chronic Immune Thrombocytopenia (ITP) Compared with Healthy ChildrenN. Gölz1, J.M. Eekels1, M.L. Rand2, M. Schmugge1, O. Speer1 (1Switzerland, 2Canada)

PB 1377 Therapeutics of Multiple Ssclerosis, Eexcept of Gglatiramer Acetate, Are

Unlikely to Alter Platelet Functional ActivityL. Schüngel, S. Eichler, S.G. Meuth, B.E. Kehrel, K. Göbel (Germany)

PB 1378 Anticoagulant and Anti-inflammatory Properties of the Novel Antimicrobial

Peptide Centrocin 1 from Green Sea UrchinE. Andreassen, B. Østerud, K.-E. Eilertsen (Norway)

PB 1379 Deficiency of Sirtuin 3 Elevates Mitochondrial ROS in Neutrophils and

Platelets but Does not Exacerbate NETosis or Venous ThrombosisH. Hayashi, D. Cherpokova, K. Martinod, T. Witsch, S.L. Wong, M. Gallant, S.M. Cifuni, L.P. Guarente, D.D. Wagner (United States)

PB 1380 Neutrophil Extracellular Traps (NETs) in Septic and Burn Patients

T. Kaufman, D. Magosevich, C. Moreno, A. Guzman, P. D´Atri, A. Carestia, F. Palizas, C. Fondevila, M. Schattner (Argentina)

PB 1382 Platelets Release Pathogenic Serotonin in Response to Immune Complexes

N. Cloutier1, I. Allaeys1, G. Marcoux1, B. Mailhot1, T. Levesque1, Y. Becker1, M. Rondina2, S. Mckenzie2, F. Cote3, B. Nieswandt4, W. Khan1, F. Matthew2, P. Newman2, S. Lacroix1, P. Fortin1, E. Boilard1 (1Canada, 2United States, 3France, 4Germany)

PB 1383 Influence of Intravenous Immunoglobulin and Methylprednisolone on Cytokines

Secreted by T Lymphocyte in Children ITPM. Jingyao, C. Zhenping, W. Runhui (China)


PB 1384 Evaluation of a New D-dimer Concept for Venous Thrombosis Exclusion: A Prospective Study (FSET Study) ClinicalTrials.gov ID: NCT02523937I. Mahé, E. Peynaud-Debayle, H. Helfer, J. Chidiac, B. Dumont, R. Omezzine, M. Pinson, N. Javaud (France)



374 375

Tues

day

Pos

ter

Ses

sion

s

PB 1385 A New D-dimer concept for More Specific Detection of Venous ThromboembolismG. Contant, S.S. Mirshahi, F. Depasse, J. Soria (France)

PB 1386 GDF-15 Alters the expression of Actin Associated Protein, Increases Migration

and the Phosphorylation of Smad2 is Mediated via TGFβRIIL. Kask, K. Hörneaus, M. Åberg, A. Jorsback, J. Bergquist, A. Siegbahn (Sweden)

PB 1387 Validation of Plasma Marker Candidates for VTE Using Affinity and Mass

Spectrometry-based Proteomics Indicate a Link to Alternative Complement PathwayL. Sanchez-Rivera1, M.J. Iglesias1, M. Bruzelius1, M.-G. Hong1, L. Butler1, J. Schwenk1, P. Morange2, D.-A. Trégouët2, J. Odeberg1 (1Sweden, 2France)

PB 1388 Proteomic Profiling to Find Candidate Biomarkers Associated with the Risk of

First and Recurrent Venous ThrombosisA. van Hylckama Vlieg1, C. Kabrhel2, S.C. Cannegieter1, F.R. Rosendaal1 (1The Netherlands, 2United States)

PB 1389 Clinical Determinants of Thrombin Generation Measured in Presence and

Absence of Platelets - Results from the Gutenberg Health StudyM. Panova-Noeva1, M.-A.M. Miriam1, M. Paul1, A. Schulz1, H.M. Spronk2, D. Laubert-Reh1, F. Haydl1, N. Arnold1, J.H. Prochaska1, M. Beutel1, N. Pfeiffer1, T. Münzel1, K.J. Lackner1, H. ten Cate2, P.S. Wild1 (1Germany, 2The Netherlands)

PB 1390 Metabolomic Study in Plasma Samples to Identify a Metabolite Profile

Associated to Venous ThromboembolismA. Fernández-Pardo, L. Martos, D. Hervas, L.A. Ramón, J. Oto, A.R. Cid, S. Haya, S. Bonanad, Y. Pico, P. Medina, F. España, S. Navarro (Spain)

PB 1391 Prevalence of Deep Vein Thrombosis and Wells Score Accuracy for Inpatient

with Suspected Deep Vein ThrombosisM. Sartori, F. Gabrielli, E. Favaretto, M. Filippini, E. Conti, B. Cosmi (Italy)

PB 1392 Impact of Chronic Inflammation, Assessed by C-reactive Protein, on the

Association between Red Cell Distribution Width and Risk of Incident Venous ThromboembolismT.S. Ellingsen, J. Lappegård, S.K. Brækkan, P. Aukrust, T. Ueland, J.-B. Hansen (Norway)

PB 1393 Improved Exclusion of the Pulmonary Embolism Diagnosis in the Emergency

Department Using a New D-dimer-Based AssayB. Planquette, S. Jumel, J. Pastre, P. Aelion, H. Pereria, J. Marey, A. Roche, G. Chatelier, O. Sanchez, G. Meyer (France)

PB 1394 Plasma Leptin is Not a Mediator of the Association between Obesity and Risk of Venous ThromboembolismL.D. Horvei, T. Sovershaev, N. Latysheva, L. Wilsgård, S.K. Brækkan, P. Aukrust, T. Ueland, J.-B. Hansen (Norway)

PB 1395 Identifying a Common Biochemical Background for Thrombotic Events in

Patients with Deep Vein Thrombosis (DVT) and Peripheral Artery Disease (PAD)A.J. ten Cate-Hoek1, S. Birocchi2, R. van Oerle1, S. Zeerleder1, H. Spronk1, B. Luken1, H. ten Cate1 (1The Netherlands, 2Italy)

PB 1396 Plasma Levels of miRNAs Are Associated with Risk of Cancer-related Venous ThromboembolismI. Starikova1, K. Hindberg1, J. Oto2, F. España2, S. Navarro2, S. Brækkan1, P. Medina Badenes2, J.-B. Hansen1 (1Norway, 2Spain)

PB 1397 A Global Metabolomic Analysis Comparing Low-risk and High-Risk Pulmonary

EmbolismO. Zeleznik1, E. Poole1, S. Lindstrom1, P. Kraft1, A. Van Hylckama Vlieg2, B. Parry1, N. Giordano1, C. Kabrhel1 (1United States, 2The Netherlands)

PB 1398 Changes in the Fibrinolytic Status and Cardiovascular Profile in Obese Patients

Undergoing Bariatric SurgeryA. Marco, P. Marco (Spain)

PB 1399 Evaluation of Risk Factors for Postpartum Hemorrhage after Vaginal Delivery in

Uncomplicated PregnancyK. Nishioka, N. Furukawa, K. Horie (Japan)

PB 1400 Analysis of the Substrate Specificity of Factor VII Activating Protease (FSAP)

and Design of a Specific and Sensitive Peptide SubstrateE. Kara1, D. Manna1, G. Åge Løset1, E. Schneider2, C. Craik2, S. Kanse1 (1Norway, 2United States)

PB 1401 Von Willebrand Factor Propeptide May Identify the Patients Susceptible for

Renal Dysfunction in Collagen DiseaseN. Yada, M. Matsumoto, K. Sakai, M. Hayakawa, T. Fujimura, T. Fujimoto, S. Ono, K. Yoshimoto, Y. Urizono, K. Nishio (Japan)

PB 1402 Age-related Diagnostic Value of D-dimer Testing and the Role of Inflammation

in Patients with Suspected Deep Vein Thrombosis - Results from the VTEval StudyJ. Prochaska1, B. Frank1, M. Nagler1, H. Lamparter1, G. Weißer1, A. Schulz1, L. Eggebrecht1, S. Göbel1, N. Arnold1, M. Panova-Noeva1, I. Hermanns1, A. Pinto1, S. Konstantinides1, H. ten Cate2, K. Lackner1, T. Münzel1, C. Espinola-Klein1, P. Wild1 (1Germany, 2The Netherlands)



376 377

Tues

day

Pos

ter

Ses

sion

s

PB 1404 Characterization of a Transient Procoagulant Phenotype Induced by Recombinant Activated Factor VII (rFVIIa)H. Rühl, C. Berens, F.I. Winterhagen, J. Müller, J. Oldenburg, B. Pötzsch (Germany)

PB 1405 The Effects of Shear Stress on Platelet Activation and Incipient Clot

Characteristics: Exploring the Mechanisms of Shear Induced Clot FormationR. Hambly, B. Thomas, C. Thornton, P.R. Williams, K. Hawkins (United Kingdom)

PB 1406 VWF and ADAMTS13 Levels in Early Onset Preeclampsia: Prothrombotic

Mechanisms in Mothers with Elevated Risk of Venous ThromboembolismT. McKinnon1, K. Egan2, L. Belmokhtar1, P. Henne1, H. O'Conner2, J. Donnelly2, C. Monteith2, P. Maguire2, P. Szklanna2, S. Allen2, F. Ní Áinle2 (1United Kingdom, 2Ireland)

PB 1407 Changes in Thrombin Generation in Obese Patients Undergoing Bariatric

Surgery: Improvement in the Hypercoagulable StatusA. Marco, P. Marco (Spain)

PB 1408 Combined Detection of Factor XIII and D-Dimer Is Helpful for Differential

Diagnosis in Patients with Suspected Pulmonary EmbolismN. Tang (China)

PB 1409 Clinical Significance of Circulating Endothelial-derived Microparticles and

Coagulation Profiles in Patients with Advanced Solid TumorsS. Der Sheng, H.K. Lee, Y. Kim, H.S. Won, Y.H. Ko, H. Kim (Republic of Korea)

PB 1410 Markers of Neutrophil Extracellular Traps in Patients with Thrombosis and

SepsisL. Cavanaugh, K. Lee, H. Leung, F. Yan, Z. Ahmadi, B. Chong, F. Passam (Australia)

PB 1411 A Quantitative Clot-based Assay for Antithrombin Activity

B. Woodhams1, S. Gavasso2, W. Calhoon3, L. Spiezia2, E. Campello2, M. Morris3, P. Simioni2 (1United Kingdom, 2Italy, 3United States)

PB 1412 Identification of microRNAs as Biomarkers for Predicting the Risk of Venous

ThromboembolismJ. Gabler, O. Steinbrecher, M. Kollars, P. Kyrle, S. Eichinger (Austria)

PB 1413 Platelet Counts and Plateletcrit are Associated with an Increased Risk of

Venous Thrombosis in Females. Results from the RETROVE StudyM. Vázquez-Santiago, N. Vilalta, A. Ziyatdinov, B. Cuevas, R. Macho, N. Pujol-Moix, M. Carrasco, J. Mateo, J. Fontcuberta, J.M. Soria, J.C. Souto (Spain)

PB 1414 Plasma Levels of miRNAs Are Associated with Future Risk of Incident Venous

ThromboembolismI. Starikova1, K. Hindberg1, L. Martos2, F. España2, S. Navarro2, S. Brækkan1, P. Medina Badenes2, J.-B. Hansen1 (1Norway, 2Spain)

PB 1415 The Blood Components Strongly Affect Thrombus Structure Formed in a Novel

Microfluidic DeviceN. Sugita, H. Hirakata, K. Inoue, K. Tatsumi, S. Ii, H. Niioka, S. Wada (Japan)

PB 1416 D-dimer in Acute Medically Ill Adults: A Multicenter Observational Study

Evaluating the Prevalence of Elevated D-dimer in Acute Medically Ill, Hospitalized Adults: The DAMIACT Study, Initial ResultsC.L. Clark, A.H. Shams, W.F. Peacock, G.J. Fermann, B. Kea, A.M. Chang, S.E. Mace, B.C. Hiestand, J.A. Welker, R.A. Swor, K.N. Sawyer, A. Bastani, on behalf of the DAMIACT Study Investigators (United States)

PB 1417 Down-regulation of Protein C Pathway Associated with Increased Inflammation

in Patients with Implanted Ventricular Assist Devices as a Potential Cause of Pump ThrombosisT. Torres, J. Walenga, W. Jeske, V. Escalante, E. Coglianese, J. Schwartz, M. Bakhos (United States)

PB 1418 Impact of Iron Status, Assessed by Ferritin Light Chain and Soluble Transferrin

Receptor, on the Association between Red Cell Distribution Width and VTE. The Tromsø StudyJ. Lappegård, T.S. Ellingsen, S.K. Brækkan, P. Aukrust, T. Ueland, J.-B. Hansen (Norway)

PB 1419 Utility of Novel Biomarkers of DIC—TAT (Thrombin-antithrombinIII Complex),

PIC (alpha2plasmin Inhibitor-plasmin Complex), tPAIc (Tissue Plasminogen Activator-plasminogen Activator Inhibitor Complex) and TM (Thrombomodulin) in Predicting the Worsening of Coagulopathy and/or Mortality in Acute Promyelocytic Leukaemia (APL) and Sepsis: A Prospective Observational StudyA. Janaki Krishnamoorthi1, S.C. Nair1, S. David1, A.M. Varghese1, V. Mathews1, P. John Victor1, P. Tavkar2, J. Matsui2, M. Baliwag2, J.J. Mammen1 (1India, 2Japan)

PB 1420 Measurement of Thrombin Generation in Conditions of Low Antithrombin

P. Giesen1, R. van Oerle1, A. Sehgal2, A. Akinc2, H.M.H. Spronk1 (1The Netherlands, 2United States)



378 379

Tues

day

Pos

ter

Ses

sion

s

PB 1421 Sensitivity of Different D-dimer Cut-off Levels In Unselected Patients with Confirmed Acute Pulmonary Embolism: FOCUS, a Prospective Multicenter Cohort StudyS. Barco, H. Binder, L. Bruch, R. Ewert, M. Faehling, F. Gerhardt, A. Gerhold-Ay, H.-A. Ghofrani, E. Grünig, M. Halank, M. Held, M.M. Hoeper, M. Lankeit, H.H. Leuchte, E. Mayer, F.J. Meyer, C. Neurohr, C. Opitz, S. Rosenkranz, H.-J. Seyfarth, R. Wachter, H. Wilkens, P.S. Wild, S.V. Konstantinides (Germany)

PB 1422 Assessment of Endothelial and Inflammatory Markers in Brazilian Renal

Transplant RecipientsS.R. Martins, K.B. Gomes, I.F.O. Silva, P.N. Alpoim, C.X. Lima, A.C. Simões e Silva, L.S. Dusse, A.P. Mota (Brazil)

PB 1423 Remote Platelet Function Testing Using Platelet-Bound P-selectin as a Marker

of Platelet ActivationS. Heptinstall (United Kingdom)

PB 1424 Endothelial Microparticles, Thrombomodulin and D dimer in Women with

Systemic Lupus Erythematosus under treatmentF. Campos, W. Cicarini, K. Ferreira, C. Loures, L. Alves, T. Guimarães, V. Toledo, R. Consoli, C. Neiva, P. Pádua, E. Reis, M.G. Carvalho (Brazil)

PB 1425 Chronic Lymphocytic Leukemia: Is there a Role for Circulating Microparticles or

Trombin Generation in Clinical Heterogeneity?M.G. Carvalho, A. Ferrão, F. Evangelista, F. Campos, R. Duarte, T. Braga, L. Gomes, M. Santiago, W. Cicarini, S. Araújo, A. Sabino (Brazil)

PB 1426 Determinants of Clot Strength in Polycythemia Vera and Primary Myelofibrosis

using Rotational ThromboelastometryN. Nytofte, O. Pedersen, H. Hasselbalch (Denmark)

PB 1427 Identification & Characterization of Novel Hemostatic Biomarkers of Adverse

Clinical Events in Patients with Continuous Flow Left Ventricular Assist Device ImplantsN. Mcclane, W. Jeske, J. Walenga, V. Escalante, E. Coglianese, D. Hoppensteadt, J. Schwartz, M. Bakhos (United States)

PB 1428 Haemostasis in Children with Acute Lymphoblastic Leukemia

E. Seregina, L. Zharikova, M. Gracheva, N. Trubina, M. Korsantya, H. Sepoyan, D. Rokhoeva, A. Poletaev, T. Vuimo, F. Ataullakhanov (Russian Federation)

PB 1429 Association between FTO rs9939609 Polymorphism and Risk of Recurrent

Venous ThromboembolismA. Ahmad, K. Sundquist, B. Zöller, P.J. Svensson, J. Sundquist, A.A. Memon (Sweden)

PB 1430 The Protein Z System Dynamic in Patients Undergoing Off-pump Coronary Artery Bypass SurgeryE. Żekanowska, A. Słomka, A. Piekuś, M. Kowalewski, W. Pawliszak, L. Anisimowicz (Poland)

PB 1431 Relevance of Co Morbidities, D-Dimer, Red Cell Distribution Width and Factor

VIII Levels in ThrombosisA. Kurien, S. Badagubettu, A.S. Babu, P. Ramachandran (India)

PB 1432 Longitudinal Assessment of Coagulation and Fibrinolysis in Pregnant Women

with Risk Factors for PreeclampsiaL. Dusse, F. Lucena, P. Alpoim, A. Barbosa, A. Cabral, R. Diniz, E. Lage, P. Teixeira (Brazil)

PB 1433 Role of Oxidized High-density Lipoprotein (oxHDL) on Coagulation and Platelet Adhesion ModulationL. Pérez, F. Simón (Chile)

PB 1434 Inter-individual Variability and Normal Ranges of Whole Blood and Plasma

Thrombin Generation and Correlation with Clotting Factor Levels in a Large Healthy Control PopulationS. Bloemen, D. Huskens, J. Konings, R. Kremers, A. Miszta, B. de Laat, H. Kelchtermans (The Netherlands)

PB 1435 Venous Thromboembolism Events over Five Years Presenting with a Normal

D-DimerH. Rowswell, T. Nokes (United Kingdom)

PB 1436 Biomarkers for the Diagnosis of Venous Thromboembolism: D-dimers, Thrombin

Generation, and Phospholipid-dependent Clotting TimeN. Riva1, K. Vella1, D. Zammit1, S. Spiteri1, K. Hickey2, S. Kitchen2, M. Makris2, W. Ageno3, A. Gatt1 (1Malta, 2United Kingdom, 3Italy)

PB 1437 Risk Factors and Clinical Characteristics Favoring Pulmonary Embolism Vs

DVT in Hormonal Therapy (HT) Associated Thromboembolism. Retrospective Analysis of 73 Cases from a Single Hemostasis UnitE. Papadakis, D. Theocharidou, A. Banti, S. Efremidou, A. Kioumi (Greece)

PB 1438 The Influence of Ethnicity on Thrombin Generation

C.W. Tan, W.H. Wong, C.K. Tan, Y.H. Chan, H. Kaur, L.H. Lee, H.J. Ng (Singapore)

PB 1439 Is Platelets - Bound C4d a Marker for Active Disease and Correlates with

Hypercoagulability in Patients with Systemic Eritematosus Lupus?K. Ferreira, W. Cicarini, C. Loures, F. Campos, R. Consoli, C. Neiva, P. Pádua, L. Alves, E. Reis, T. Guimarães, V. Toledo, M.G. Carvalho (Brazil)



380 381

Tues

day

Pos

ter

Ses

sion

s

PB 1440 Profiling of Thrombotic and Inflammatory Mediators in Synovial Fluid from Patients Undergoing Primary Total Joint ArthroplastyE. Finkler, C. Wanderling, C. Thorson, K. Galicia, S. Statz, A. Otto, J. Fareed, W. Hopkinson (United States)

PB 1441 The Proteins with Prothrombine Origine in Blood Plasma of Ischemic Stroke

Patients as a Markers of HipercoagulationT. Katrii, T. Vovk, O. Savchuk (Ukraine)


PB 1442 Anti-β2-Glycoprotein I Antibodies Cause Lupus Anticoagulant and Activated Protein C Resistance via Coagulation Factor VJ.E. Molhoek, J.C.M. Meijers, S. Verhoef, P.G. de Groot, R.T. Urbanus (The Netherlands)

PB 1443 Plasma Clot Properties, Disease Phenotype, and Thrombotic Risk in Patients with a Lupus Anticoagulant: Results from the Vienna Lupus Anticoagulant and Thrombosis Study (LATS)F. Posch, J. Gebhart, S. Koder, J. Thaler, L. Hell, L.-M. Mauracher, S. Hofer, O. Köngigsbrügge, P. Quehenberger, B. Jilma, C. Ay, I. Pabinger (Austria)

PB 1444 Biophysical Characterization of Clot Retraction in Platelet Rich Plasma of

Patients with Primary Anti-phospholipid SyndromeJ. Harsfalvi, T. Feller, G. Domjan, K. Gado, K. Varnai, M.S.Z. Kellermayer (Hungary)

PB 1445 Patient-derived Anti-β2GP1 Antibodies Recognize a Peptide Motif Pattern and

Not a Specific Sequence of ResiduesP. de Moerloose, C. Fickentscher, F. Boehlen, J.-M. Tiercy, E.K.O. Kruithof, K.J. Brandt (Switzerland)

PB 1446 Longitudinal Anti-phospholipid-Antibody Trajectories for Dynamic Thrombotic

Risk Prediction in Patients with the Lupus Anticoagulant: A Joint ModelF. Posch, J. Gebhart, S. Koder, P. Quehenberger, C. Ay, I. Pabinger (Austria)

PB 1447 Impact of Adding Antiphosphatidylserine/Prothrombin Antibodies in the

Thrombotic Risk of Patients with APS Laboratory Criteria: A Prospective StudyR. Forastiero, M. Martinuzzo, A. Rossi, D. Puente, C. Colorio (Argentina)

PB 1448 Triple Positive Antiphospholipid Antibodies: Away with Titres and Ratios?

P.R.J. Ames1, V. Marottoli2, L. Iannaccone2, A. Ciampa2 (1Portugal, 2Italy)

PB 1449 oThe Effect of Treatment with Hydroxychloroquine on Soluble Tissue Factor Levels in Patients with Antiphospholipid Antibodies and Antiphospholipid SyndromeK. Breen, K. Schreiber, K. Parmar, B.J. Hunt (United Kingdom)

PB 1450 Increased Plasma Cell-free DNA (cfDNA) and Myeloperoxidase (MPO) and

Impaired Fibrinolysis in High-risk Patients with Antiphospholipid Antibodies (aPL)F. Semeraro, C.T. Ammollo, E. Bison, A. Banzato, V. Pengo, M. Colucci (Italy)

PB 1451 Alteration of Beta 2 Glycoprotein I Conformation upon Domain V Disulfide

Bond ReductionI. Buchholz1, P. Nestler1, T. McDonnell2, A. Radziszewska2, A. Rahman2, M. Delcea1 (1Germany, 2United Kingdom)

PB 1452 High Prevalence of Activated Protein C Resistance Associated with High Avidity

Anti-protein C Antibodies in Various Antiphospholipid Syndrome Clinical PhenotypesM. Efthymiou1, I. Mackie1, P. Lane1, D. Erkan2, H. Cohen1 (1United Kingdom, 2United States)

PB 1453 Clinical Impact of Triple Positivity of Antiphospholipid Antibodies in Primary Thrombotic Antiphospholipid SyndromeS. Saraiva, B. Mazetto, F. Talge, I.R. Brito, L. Quinteiro, M. Colella, E.V. de Paula, J. Annichino Bizzacchi, F. Orsi (Brazil)

PB 1454 β2GpI Binds to Fibrinogen and Alters Fibrin Generation and Degradation

L. Acquasaliente1, D. Peterle1, G. Pontarollo1, R. De Crisofaro1, V. Pengo1, N. Pozzi2, V. De Filippis1 (1Italy, 2United States)

PB 1455 Circulating Microparticles in Pregnant Patients with Primary Antiphospholipid

Antibody Syndrome: An Explorative StudyE. Campello, C. Radu, M. Tonello, C. Bulato, A. Kuzenko, E. Mattia, L. Spiezia, A. Ruffatti, P. Simioni (Italy)

PB 1456 Outcomes of Anticoagulant Therapy in Patients with Antiphospholipid

Syndrome Managed in an Anticoagulation ClinicA. Mavri, M. Stalc (Slovenia)

PB 1457 Elevated Oxidized Low Density Lipoprotein Levels in Antiphospholipid

Syndrome is Related to the Autoantibodies against High Density Lipoprotein and its Associated ProteinsK. Oku1, J. Batuca2, O. Amengual1, N. Ohnishi1, Y. Ogata1, K. Ohmura1, Y. Fujieda1, M. Kato1, T. Bohgaki1, S. Yasuda1, D. Alves2, T. Atsumi1 (1Japan, 2Portugal)



382 383

Tues

day

Pos

ter

Ses

sion

s

PB 1458 Platelet Activation by Antiphospholipid Antibodies through the IgG Receptor FcγRIIa: Possible Role in Thrombosis Associated with Antiphospholipid Syndrome?E. Coll1, M. Brodie1, L. Robles-Carrillo1, E. Lindhoff-Last2, J.L. Francis1, A. Amirkhosravi1 (1United States, 2Germany)

PB 1459 Prognostic Impact of Antiphospholipid Antibodies on the Clinical Course of

Primary Immune Thrombocytopenia or Autoimmune Hemolytic AnemiaA.C. Ladeira Cruz, M. Pereira Colella, G. Yamaguti Hayakawa, E.V. de Paula, J. Annichino-Bizzacchi, F. Andrade Orsi (Brazil)

PB 1460 Identifying “Second Hit” Risk Factors Associated with Thrombosis and

Pregnancy Morbidity in aPLs Positive PatientsY. Zuo, J. Fan, R. Sarode, D. Karp, Y.-M. Shen (United States)

PB 1462 Are Antiβ2-glycoprotein I IgG Domain I a Useful Tool to Predict Thrombosis?

A. Marco, A. Palazon-Bru, P. Marco (Spain) PB 1463 Oral Anticoagulation Cost in Primary Antiphospholipid Syndrome: Comparison

between Warfarin and Hypothetical RivaroxabanA. Ciampa1, S. Vivolo1, C. Salapete1, P. Ames2 (1Italy, 2Portugal)

PB 1464 Comprehensive Characterization of Platelet Parameters for Thrombosis Risk Prediction in Patients with the Lupus AnticoagulantJ. Gebhart, F. Posch, S. Koder, P. Quehenberger, C. Ay, I. Pabinger (Austria)

PB 1465 Severe Vitamin D Deficiency a Potentially Risk Factor for Recurrent

Miscarriages in Women with Positive Antiphospholipid AntibodiesE. Lefkou1, S. Petousis1, V. Gogou1, P. Anagnostis1, A. Mamopoulos1, T. Dagklis1, A. Nikolopoulou1, G. Gerotziafas2, A. Athanasiadis1 (1Greece, 2France)

PB 1466 Antibodies against Domain I of Beta2-glycoprotein I Have No Added

Value for Prediction of Antiphospholipid Syndrome Compared to Classical Antiphospholipid AntibodiesN. Pequeriaux, D. Hammann-Wenzlau, E. Gemen, I.-A. Haagen, M.J. Hollestelle (The Netherlands)

PB 1467 Antiphospholipid Syndrome Alliance for Clinical Trials and International

Networking (APS ACTION): Comparison of Real World and Core Laboratory Lupus Anticoagulant ResultsM. Efthymiou1, I. Mackie1, P. Lane1, V. Pengo2, D. Andrade3, R. Willis4, S. Krilis5, D. Erkan4, H. Cohen1 (1United Kingdom, 2Italy, 3Brazil, 4United States, 5Australia)

PB 1469 Thrombocytopenia is Uncommon in High-risk Patients with Antiphospholipid Syndrome (APS)E. Pontara, A. Banzato, M.G. Cattini, E. Bison, G. Baroni, A. Hoxha, A. Ruffatti, V. Pengo (Italy)

PB 1470 Circulating Neutrophil-Extracellular Traps (NETs) in Patients with the

Antiphospholipid SyndromeJ.C. Reverter, J. Bravo, G. Espinosa, R. Cervera, D. Tàssies (Spain)

PB 1471 Catastrophic Antiphospholipid Syndrome: Onset and Outcome

T. Reshetnyak, I. Shtivelband, S. Radenska-Lopovok, M. Satibaldieva, N. Seredavkina, E. Nasonov (Russian Federation)

PB 1472 Effect of Hydroxychloroquine on Circulating Levels of Inflammatory Cytokines

in Patients with Primary Antiphospholipid SyndromeB. Mazetto, S. Saraiva, S. Huber, F. Talge, L. Quinteiro, I.R. Brito, K. Zapponi, F. Bassora, J. Annichino Bizzacchi, F. Orsi (Brazil)

PB 1473 A High Molecular Weigh Protein Is Responsible of Anticoagulant Activity in

Isolated Lupus AnticoagulantA. Banzato, M.G. Cattini, T. Del Ross, S. Testa, C. Legnani, D. Petterle, E. Pontara, E. Bison, A. Ruffatti, V. De Filippis, V. Pengo (Italy)

PB 1474 DNA Methylation Pattern Analyses in Patients with Antiphospholipid Syndrome:

Screening StudyJ.Y. Kim, H.-J. Kim, H.-J. Yoon, K.S. Lee (Republic of Korea)

PB 1475 What Is the Risk of First Thrombosis in Asymptomatic Antiphospholipid

Antibodies Carriers?L. Costa, R. Matos, L. Moreira, E. Cruz, S. Morais (Portugal)

PB 1476 Clinical Relevance of Anti Phospholipid Antibodies in Deep Venous Thrombosis

D. Eissa, H. Affify, M. Ismail, A. Saad, N. Abo Shanab (Egypt) PB 1477 Results of Lupus Anticoagulant Investigation in Unselective Population of

Patients Referred for TestingS. Margetic, B. Getaldic, D. Ferenec Ruzic, I. Vuga, N. Vrkic (Croatia)

PB 1479 Detection of Thrombogenicity Positive Antiphospholipid Antibodies in

Antiphospholipid Syndrome DiagnosisJ. Ulehlova, L. Slavik, J. Prochazkova, A. Hlusi, V. Krcova (Czech Republic)

PB 1480 Tissue Factor-bearing Microvesicles and Acquired Protein S Deficiency

Contribute to DIC in a Patient with Elevated Antiphospholipid AntibodiesC. Dicke, K. Holstein, M. Voigtländer, F. Stahl, U. Schnoor, C. Bokemeyer, F. Langer (Germany)



384 385

Tues

day

Pos

ter

Ses

sion

s

PB 1481 Use of Direct Oral Anticoagulant in Antiphospholipid Syndrome: Systematic Review of LiteratureV. Dufrost, J. Risse, S. Zuily, D. Wahl (France)

PB 1482 Plasma Thrombogenic Potential in Patients with Granulomatosis with

Polyangiitis in Comparison to Antiphospholipid SyndromeM. Celińska-Lowenhoff, T. Iwaniec, J. Kosałka, J. Musiał (Poland)

PB 1483 Evaluation of Antiphospholipid Antibodies Level in Patients with Type 2

Diabetes mellitus in Enugu South East NigeriaT. Nwagha, O. Agwu, O. Ibegbulam (Nigeria)

PB 1484 Antiphospholipid Antibodies Related with Thrombosis

I. Nikoloska, R. Apostolovska, V. Neceva, S. Krstevska Balkanov, E. velkova (Macedonia, the Former Yugoslav Republic of)

PB 1485 Outcomes in Patients with Antiphospholipid Antibodies at a Tertiary Care

CenterG. Abu Zeinah, M.T. DeSancho (United States)

PB 1486 Recurrent Arteriovenous Fistula Thrombosis in Female Patient with

Antiphospholipid Syndrome (APS), Factor V Leiden Mutation and MTHFR C677 T MutationB. Ceglarek, A.J. Sikorska, K. Bykowska, J.M. Teliga Czajkowska, J. Windyga (Poland)

PB 1487 Comparison of Genetic Risk Score Models to Predict First Venous

Thromboembolism in a Population-based Case-cohort. The Tromsø StudyS.K. Braekkan1, I. Ortega2, E. Smith3, K.A. Frazer3, S. Pich2, J.-M. Soria2, E. Salas2, J.-B. Hansen1 (1Norway, 2Spain, 3United States)

PB 1488 Next-Generation DNA Sequencing Approach to Study Burden of Rare Variants

in Loci Susceptible to Cerebral Vein ThrombosisM.M. Gorski1, H.G. de Haan2, L.A. Lotta1, I. Mancini1, P. Bucciarelli1, S.M. Passamonti1, A. Cairo1, E. Pappalardo1, A. van Hylckama Vlieg2, I. Martinelli1, F.R. Rosendaal2, F. Peyvandi1 (1Italy, 2The Netherlands)

PB 1489 Impact of Age and Prothrombotic Genotypes on the Risk of Incident Venous

ThromboembolismB. Småbrekke, L. Balteskard Rinde, E.N. Smith, F.R. Rosendaal, S. Brækkan, K.A. Frazer, J.-B. Hansen (Norway)

PB 1490 Joint Effects of Ischemic Stroke and Prothrombotic Genotypes on the Risk of Venous Thromboembolism. The Tromsø StudyL.B. Rinde1, B. Småbrekke1, E. Mathiesen1, M.-L. Løchen1, I. Njølstad1, E.M. Hald1, T. Wilsgaard1, E. Smith2, T. Solomon2, K.A. Frazer2, S. Brækkan1, J.-B. Hansen1 (1Norway, 2United States)

PB 1491 Joint Effects of Myocardial Infarction and Prothrombotic Genotypes on the Risk

of Venous Thromboembolism. The Tromsø StudyL.B. Rinde1, B. Småbrekke1, E. Mathiesen1, M.-L. Løchen1, I. Njølstad1, E.M. Hald1, T. Wilsgaard1, E. Smith2, K.A. Frazer2, S. Brækkan1, J.-B. Hansen1 (1Norway, 2United States)

PB 1492 Population-based Incidence of Venous Thromboembolism in Oklahoma County,

OK April 1, 2012-March 31, 2014A. Wendelboe, J. Dvorak, M. McCumber, N. Feland, J. Campbell, K. Ding, D. Bratzler, N. Reyes, M. Beckman, G. Raskob (United States)

PB 1493 Differential Impact of Surgery as a Trigger Factor for Venous Thromboembolism

in Patients with and without Prothrombotic GenotypesE. Bjøri, H.S. Johnsen, J.-B. Hansen, S.K. Brækkan (Norway)

PB 1494 Hospitalization as a Trigger for Venous Thromboembolism - Results from a

Large Population-based Case-crossover StudyE. Bjøri, H.S. Johnsen, J.-B. Hansen, S.K. Brækkan (Norway)

PB 1495 The Rare Allele of the K858R Variant of Factor V Protects from the Risk of Venous Thrombosis but Only in Non Carriers of the FV Leiden MutationP.E. Morange, P. Suchon, A. Delluc, D. Smadja, R. Olaso, M. Germain, N. Saut, J.-F. Deleuze, D.A. Tregouët (France)

PB 1496 Joint Effects of Prothrombotic Genotypes and Body Height on Risk of Venous

Thromboembolism: The Tromsø StudyL.D. Horvei1, S. Erin N.2, K. Hindberg1, K.A. Frazer1, S.K. Brækkan1, J.-B. Hansen1 (1Norway, 2United States)

PB 1497 Factor XIII Val34Leu Polymorphism Reduces Whole Blood Clot Weight in a

Fibrinogen-dependent MannerS. Kattula1, Z. Bagoly2, N.K. Tóth2, L. Muszbek2, A.S. Wolberg1 (1United States, 2Hungary)

PB 1498 Impact of Prothrombotic Genotypes on the Association Between Red Cell

Distribution Width and Risk of Venous Thromboembolism. The Tromsø StudyJ. Lappegård1, T.S. Ellingsen1, E. Smith2, S.K. Brækkan1, K.A. Frazer2, J.-B. Hansen1 (1Norway, 2United States)



386 387

Tues

day

Pos

ter

Ses

sion

s

PB 1499 Homozygous and Heterozygous Factor V Leiden Mutation (FVL) Is Associated with an Increased Risk for Recurrent Venous Thromboembolism (VTE) after First VTER.B. Zotz, R.E. Scharf, A. Gerhardt (Germany)

PB 1500 Genotype-phenotype Correlations in a Large Cohort of Subjects with Suspicion

of Inherited Protein C or Protein S DeficiencyC. Geisen, L. Boeff, S. Koerber, F. Bergmann, A. Czwalinna, C. Heller, M. Krause, W. Miesbach, E. Seifried (Germany)

PB 1501 Identification and Characterization of a Novel Mutation at the C-terminal

Region of Antithrombin Leading to in vivo Polymerization and Venous ThrombosisT. Bhakuni, A. Sharma, M. Mahapatra, R. Saxena, M.A. Jairajpuri (India)

PB 1502 Genetic Characterization of Antithrombin, Protein C and Protein S Deficiencies

in Slavic Thromboembolic PatientsE. Wypasek1, J. Corral2, M. Alhenc-Gelas3, D.P. Potaczek4, T. Iwaniec1, W. Sydor1, M. Celińska-Lowenhoff1, J. Musiał1, A. Undas1 (1Poland, 2Spain, 3France, 4Germany)

PB 1503 The Association between Genetic Variants in Cholesteryl Ester Transfer Protein

(CETP) Gene and Hemostatic Factor Levels in Healthy Controls and the Associated Risk of a First Venous ThrombosisR. Li-Gao, S.C. Cannegieter, F.R. Rosendaal, A. van Hylckama Vlieg (The Netherlands)

PB 1504 Molecular Genetic Diagnostics of Protein S and Protein C DeficiencyO.H. Larsen, A.D. Kjærgaard, A.-M. Hvas, P.H. Nissen (Denmark)

PB 1505 GPX1 Pro198LEU Polymorphism as a Risk Factor for Venous

Thromboembolism in Young Men from North-Western RussiaZ. Sidorova, S. Svitina, L. Aleksanyan, V. Shmeleva, V. Kargin, V. Soldatenkov, S. Kapustin, A. Chechetkin (Russian Federation)

PB 1506 Genetic Association Study between Candidate SNPs and Brazilian Patients

with Venous Thromboembolism (VTE)A.V.C. Romano, J.L. Cunha, A. Barnabé, L.F.B. Sckayer, R. Secolin, Í. Lopes-Cendes, N. Wolosker, J.C.C. Guerra, T.B. Gadelha, E.V. de Paula, F.A. Orsi, J.M. Annichino-Bizzacchi (Brazil)

PB 1507 Absolute Quantification of Jak2 V617F in Patients with Splanchnic Venous

Thrombosis by Droplet Digital PCRD. Colaizzo, M.A. Guardascione, G. Favuzzi, F. Cappucci, L. Fischetti, G. Vecchione, M. Margaglione, E. Grandone (Italy)

PB 1508 Screening of Deletions in Protein S Deficient FamiliesT. Fenclova, D. Provaznikova, M. Matyskova, F. Marecek, I. Hrachovinova (Czech Republic)

PB 1509 microRNA gene (miR -146aC>G, miR -149T>C, miR -196a2T>C and miR

-499A>G) Polymorphisms in Korean Patients with Venous ThromboembolismH.W. Kim, J.O. Kim, H.J. An, K.A. Kim, E.S. Kim, J.H. Sakong, H.A. Lee, C.S. Ryu, O.J. Kim, H.-J. Yoon, N.K. Kim (Republic of Korea)

PB 1510 The Association of Arg485Lys Polymorphism with FV Levels, APC Ratio and its

Role in DVT: A Study from IndiaA. Sharma1, T. Bhakuni1, A. Biswas2, R. Ranjan1, K. Kishor1, J. Oldenburg2, R. Saxena1 (1India, 2Germany)

PB 1511 A Novel Splice Site Mutation Leading to AT Deficiency

D. Provaznikova, A. Radovska, M. Simonikova, N. Rytikova, Z. Novak, I. Hrachovinova (Czech Republic)

PB 1512 Gender Differences in the Incidence of Venous Thromboembolism among

Chronic Lung Diseases and Rheumatoid Arthritis in KoreaW.-I. Choi (Republic of Korea)

PB 1513 Application of Massive Parallel Sequencing Searching for Rare Genetic Variants

of Protein C and S Associated with Thrombophilia - Implementation to Clinical PracticeP. Vrtel, R. Vodicka, J. Ulehlova, L. Slavík, J. Prochazkova, R. Vrtel, M. Prochazka (Czech Republic)

PB 1514 Combined Protein C / Protein S Deficiency: Genotype-Phenotype Relationship in an Italian Family Carrying Two Novel MutationsG. Favuzzi, G. D'Andrea, G.L. Tiscia, F. Cappucci, L. Fischetti, E. Chinni, P. Vergura, E. Grandone, M. Margaglione (Italy)

PB 1515 Impact of Factor V-Leiden, Prothrombin G20210A and MTHFR C677T

Mutations on Egyptian Patients with Sickle Cell DiseaseA. Saad, H. Sedky, A. Osman, A. Abu-skeen, A. Abd El Maksoud, D. Gamal Eldin (Egypt)

PB 1516 Heightened Hypercoagulability in Sickle Cell Anemia Patients with Chronic Leg

UlcersE. Olayemi, D. Sackey, Y. Dei-Adomakoh (Ghana)

PB 1517 Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Trombophilia:

What Should We Know?V. Shemenkova, A. Klimenko, N. Shostak (Russian Federation)



388 389

Tues

day

Pos

ter

Ses

sion

s

PB 1518 Apolipoprotein E Gene Polymorphisms: An Indian Study Showing Lateral Association with Thrombophilic Risk Factors in Patients with Deep Vein ThrombosisP. Rastogi, N. Kumar, J. Ahluwalia, R. Das, N. Varma, V. Suri, H. Senee (India)

PB 1520 The Factor V Leiden Mutation Is Associated with Increased Sperm Count

T.E. van Mens1, U.N. Joensen2, Z. Bochdanovits1, A. Takizawa3, J. Peter1, N. Jørgensen2, P. Szecsi2, J.C.M. Meijers1, H. Weiler3, E. Rajpert-De Meyts2, S. Repping1, S. Middeldorp1 (1The Netherlands, 2Denmark, 3United States)

PB 1521 Risk Factors of Cerebral Venous Sinus Thrombosis - Single Center Experience

A. Gwozdowska, E. Odnoczko, B. Baran, K. Bykowska, J. Windyga (Poland) PB 1523 Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio as Risk

Factors for Venous ThromboembolismA. Artoni, M. Abbattista, P. Bucciarelli, F. Gianniello, I. Martinelli (Italy)

PB 1524 Quantification of the Effect of NET-derived Cell-free DNA on Thrombosis and

Haemostasis PhenotypesS. Lopez, A. Martinez-Perez, N. Vilalta, C. Muñoz, J.C. Souto, J.M. Soria (Spain)

PB 1525 Iron Deficiency Alters Red Blood Cell and Neutrophil Adhesion and Arterial

ThrombosisS. Lapping, E. Kucukal, U. Gurkan, M.K. Jain, L. Nayak (United States)

PB 1526 Complete Protein S Deficiency and Pregnancy Outcome in Murine Model

R. Prince1, N. Dewarrat1, M.D. Reina Caro1, J. Brodard1, C. Quarroz1, F. Saller2, S. Calzavarini1, A. Angelillo-Scherrer1 (1Switzerland, 2France)

PB 1527 Thrombophilic Phenotype in a Neonate and Five Young Siblings of a Family

with Homozygous Antithrombin Type 2 (Budapest III) DeficiencyH.-J. Hertfelder, M. Scheler, A. Pavlova, B. Pezeshkpoor, V. Jennissen, M. Hoemberg, T. Streichert, J. Mueller, J. Oldenburg, C. Huenseler (Germany)

PB 1528 Venous Thromboembolism in Women Using Hormonal Contraception and the

Risk of Recurrence. Findings from a Single CenterA. Latorre, A.S. Vilches, J. Cacha, M.J. Gomez (Spain)

PB 1529 Thrombophilia Screening Practices in a Tertiary Care Hospital: An Assessment

of Appropriateness and Financial ImpactN. Ganta, D. Suryanarayan, X.Y. Jiang (Canada)

PB 1530 Retrospective Analysis of the Size of Recurrent Pulmonary Embolus: Single

Centre StudyW. Thomas, O. Firth, M. Beveridge, M. Besser, T. Baglin (United Kingdom)

PB 1531 Hyperaggregability of Platelets with Low Dose of ADP and Epinephrin in Patients with Venous Thrombosis: Preliminary Results from the RETROVE Project (Risk of Enfermedad TROmboembólica VEnosa)D. Llobet, C. Vallvé, I. Tirado, J. Murillo, N. Vilalta, M. Carrasco, J. Mateo, J. Fontcuberta, J.C. Souto (Spain)

PB 1532 The Association of D-dimer Level with Common Inherited and Acquired Risk

Factors of ThrombosisA. Dobrovolsky, E. Panchenko, Z. Khasanova, E. Titaeva, E. Yarovaya, I. Trubacheva, V. Serebryakova, V. Kaveshnikov, R. Karpov (Russian Federation)

PB 1533 Antithrombin p.Thr147Ala: Not Just Another SNP?

C. Orlando, I. Pareyn, A.-S. Schelpe, K. Vanhoorelbeke, K. Jochmans (Belgium) PB 1534 EPCR 6936A/G Gene Polymorphism and Plasma Levels of Endothelial Protein

C Receptor as Risk Factors for Early-onset Venous Thromboembolism in North-Western RussiaV. Shmeleva, S. Kapustin, S. Karpich, O. Smirnova, J. Sidorova, L. Papayan (Russian Federation)

PB 1535 Risk Factor Stratification for Venous Thromboembolim in Patients with

Below Knee Injuries Treated with Immobilisation and the Future Role of ThromboprophylaxisD. Mulligan, A. Farrell, B. Lenihan, M. Watts, D. O'Keeffe (Ireland)

PB 1536 Paroxysmal Nocturnal Hemoglobinuria (PNH) in Patients Presenting with

Cerebral Vein and Sinus Thrombosis (CVST) - Results of Flow Cytometry Based Screening in Indian PatientsJ. Ahluwalia, M.U.S. Sachdeva, M. Modi, N. Kumar, P. Bose, S.K. Bose, V. Uppal, N. Varma (India)

PB 1537 High Levels of VAMP 8 and Serotonin Transporter Suggest a Tendency of

Thrombosis in Spanish Population. Preliminary Results from the RETROVE Project (Risk of Enfermedad TROmboembólica VEnosa)D. Llobet, C. Vallvé, I. Tirado, N. Vilalta, J. Murillo, J. Millón, J. Mateo, J. Fontcuberta, J.C. Souto (Spain)

PB 1538 Genetic Heterogeneity of Protein C Deficiency in Hungary; Genotype-phenotype

CorrelationsM. Speker, G. Balogh, G. Pfliegler, Z. Oláh, P. Ilonczai, K.B. Kovács, A. Kerényi, Á. Schlammadinger, K. Rázsó, Z. Boda, I. Komáromi, Z. Bereczky (Hungary)

PB 1539 Elevated Plasma Factor IXa Activity in Women Using Hormonal Contraception

P. Tanratana, P. Ellery, P. Westmark, A. Mast, J. Sheehan (United States)



390 391

Tues

day

Pos

ter

Ses

sion

s

PB 1540 Analysis of Factor V Leiden Paradox from a Large Monocentric Cohort Study: A Role for Distal Thrombosis?E. Campello, L. Spiezia, F. Dalla Valle, P. Simioni (Italy)

PB 1541 Paroxysmal Nocturnal Hemoglobinuria (PNH) and Thrombosis: Experience from

an Asian Tertiary CentreR.J. Lim, H.T. Mya, H.J. Ng, L.H. Lee (Singapore)

PB 1542 Results of Thrombophilia Testing in Infertile Women and Women Experienced a

MiscarriageS. Margetic, B. Getaldic, D. Ruzic Ferenec, I. Vuga, N. Vrkic (Croatia)

PB 1543 Importance of Thrombophilia Screening in Patients with Ocular Thrombosis

M. Alrifai, R. Fischer, K. Heidinger, B. Kemkes-Matthes (Germany) PB 1544 Screening of Thrombophilia in Latin America

C. Guillermo1, A. Blanco2, M. Echenagucia3, D.N. García2, B. Steffano1, V. Mérola1, S. Grille1, P. Turcatti1, M. Stevenazzi1, L. Diaz1, R. Martínez1 (1Uruguay, 2Argentina, 3Venezuela)

PB 1545 First Do Not Harm: Questioning Ethics Aspects of Thrombophilia Law in

ArgentinaB. Grand, A. Rossi (Argentina)

PB 1546 Extensive molecular characterization of a family with thrombophilia:

implication of multiple genetic alterations of low thrombotic risk profileM. Carrasco Exposito, I. Tirado Garcia, L. Romero Roman, N. Vilalta Seto, J. Mateo Arranz, J.A. Millon Caño, J. Fontcuberta Boj (Spain)

PB 1547 Inherited Thrombophilia and Infertility

E. Petkovikj, A. Hristova-Dimcheva, R. Grubovic, R. Apostolovska, S. Simeonova-Krstevska, M. Jakimovska, B. Todorovski (Macedonia, the Former Yugoslav Republic of)

PB 1549 Impact of the Molecular Study of the PROC, PROS1 and SERPINC1 Genes in

Patients with Venous ThrombosisP. Martinho, T. Fidalgo, A.C. Oliveira, C. Pinto, T. Sevivas, R. Salvado, M.L. Ribeiro (Portugal)

PB 1550 Cutaneous Necrosis Revealing Paroxysmal Nocturnal Haemoglobinuria

Z. Tazi Mezalek, W. Ammouri, M. Bourkia, H. Harmouche, N. Bouigua, M. Maamar, W. Mounfaloti, M. Adnaoui (Morocco)

PB 1551 Venous Thromboembolism (VTE) in Homozygous Carriers of Factor V Leiden

Mutation Patients (FVL)B. Ceglarek, A.J. Sikorska, K. Bykowska, A. Bućko, J. Windyga (Poland)

PB 1552 Characteristics and Outcomes of Patients with Cerebral Venous Sinus Thrombosis in OmanK. Al Hashmi, K. Al-Wahaibi, M. Al-Khabori, S. Al Lamki (Oman)

PB 1553 Anticoagulant Therapy in Disorders in the Fibrinolysis System among Patients

with Primary InfertilityI. Kurtov, T. Gritsenko, Y. Berman, V. Kuvaev, A. Kurtova, I. Davydkin (Russian Federation)

PB 1554 Pattern of Thrombophilia Testing in Patients with Venous Thromboembolism at

a Tertiary Care HospitalM. Gaddh, E. Cheng, Y. Lin, R. Sharma, I. Bodo (United States)

PB 1555 Meaning of Hereditary Thrombophilia in the Diagnosis of Thrombotic

Complications during Combat Gunshot InjuryK. Nikolaev, S. Kapustin, V. Zubritskij, A. Koltovich, I. Zolobov (Russian Federation)

PB 1556 Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in Patient with

Decompensated/Uncontrolled Hypertension, Hyperhomocysteinemia, Hypercholesterolemia and HyperlipidemiaB. Ceglarek, A.J. Sikorska, K. Bykowska, J.M. Teliga Czajkowska, A. Bućko, J. Windyga (Poland)


PB 1557 Twice-daily Low-dose Aspirin Improves Platelet Inhibition in Patients with Essential ThrombocytosisM.L. Larsen, O.H. Pedersen, A.M. Hvas, S.D. Kristensen, E.L. Grove (Denmark)

PB 1558 Long-term Aspirin (ASA) Use Significantly Attenuates Platelet Interactions with

von Willebrand Factor (VWF) in Acute Coronary Syndromes (ACS)D. Kenny, R. Walsh, D. Foley, A.J. Ricco, E. Dunne (Ireland)

PB 1559 Patients with Coronary Artery Disease Have a Pathological P2Y12 Platelet

Response with Heightened Procoagulant Platelet PotentialL. Pasalic, J. Lau, G. Pennings, H. Campbell, E. Wing-Lun, E. Lau, D. Connor, D. Muller, L. Kritharides, V. Chen (Australia)

PB 1560 Platelet Inhibition with Ticagrelor Versus Clopidogrel in Patients with Peripheral

Artery Disease: The EUCLID Platelet SubstudyJ. Berger, B. Katona, Y. Guo, L. Karotkin, M. Abu-Fadel, I. Arif, J. Badimon, R. Becker, A. Hirsch, H. Gornik, J. Mills, J. Olin, C. Rockman, C. Staniloe, U. Zafar, N. Zantek, D. Angiolillo, W. Hiatt, on behalf of the EUCLID Executive Committee and the EUCLID Platelet Study Investigators (United States)



392 393

Tues

day

Pos

ter

Ses

sion

s

PB 1561 Antiplatelet Agents are the Key Drugs for the Prevention of Recurrent Arterial Thrombosis in Patients with Antiphospholipid SyndromeN. Ohnishi, Y. Fujieda, Y. Ogata, S. Abe, M. Kono, S. Tanimura, R. Hisada, E. Sugawara, H. Nakamura, K. Ohmura, S. Shimamura, M. Doi, M. Kato, K. Oku, T. Bohgaki, O. Amengual, S. Yasuda, T. Atsumi (Japan)

PB 1562 Cyclic Nucleotide Modulators and P2Y12 Antagonists as Novel Anti-platelet

Combination TherapyP.C. Armstrong, P. Ferreira, M.V. Chan, C.-C. Shih, M.H. Lundberg Slingsby, T.D. Warner (United Kingdom)

PB 1563 Prasugrel vs. Ticagrelor after STEMI: Results from the Düsseldorf STEMI

RegistryM. Golabkesh, D. Dimitroulis, A. Mohring, L. Dannenberg, A. Fürnkranz, H. Makimoto, T. Zeus, M. Kelm, A. Polzin (Germany)

PB 1564 Acetazolamide and Methazolamide Suppress Platelet Procoagulant Responses

and Thrombosis in vivoE.O. Agbani, C.M. Williams, R. Aungraheeta, A.W. Poole (United Kingdom)

PB 1565 Effect of Aspirin Therapy on Abacavir-associated Platelet Hyperreactivity in

HIV-infected Patients: A Randomized, Double-blind, Placebo-controlled, Cross-over StudyD. Francisci, E. Falcinelli, E. Schiaroli, P. Minuz, S. Orsini, L. Malincarne, M. Sebastiano, A.M. Mezzasoma, M.B. Pasticci, G. Guglielmini, F. Baldelli, P. Gresele (Italy)

PB 1566 Investigation of the Physiological Mechanisms Leading to the Release of BDNF

by Platelets and their Susceptibility to Antiplatelet AgentsR. Boulahya, L. Ledoux-Hutchinson, A. Béliveau, J.-N. Vallée-Trudeau, S. Landry, Y. Merhi, J.-F. Tanguay, M. Lordkipanidzé (Canada)

PB 1567 Clopidogrel Efficiency in Cerebral Aneurysm Stenting: Are Biological Tests

Useful?N. Ajzenberg, R. Abbas, F. Tubach, D. Faille, M.-G. Huisse, L. Ikka, J. Moret, L. Spelle (France)

PB 1568 Comparison of Platelet Function Tests in a Trial of Different Aspirin Dose

Regimens in Type 2 DiabetesP. Harrison, M.A. Bethel, I. Kennedy, S. White, R.L. Coleman, R.R. Holman (United Kingdom)

PB 1569 The Offset of Ticagrelor Prior to Coronary Artery Bypass Graft (CABG) Surgery

K.W. Ow, M. Thomas, W. Parker, H. Judge, R. Storey (United Kingdom)

PB 1570 Nanoparticle Inhibition of Shear Induced Platelet AggregationD.N. Ku, C. Aidun, M. Griffin, Y. Zhu, Z. Liu (United States)

PB 1571 Plasma Fibrinogen Level is an Important Determinant of Platelet Reactivity in

the VerifyNow AssayA. Dobrovolsky, P. Laguta, E. Titaeva, E. Guskova, E. Yarovaya, E. Panchenko (Russian Federation)

PB 1572 Effects of Clopidogrel with or without Aspirin on the Generation of Extracellular

Vesicles in the Microcirculation and in Venous Blood in Healthy Young MalesL. Traby, A. Kaider, M. Kollars, S. Eichinger, M. Wolzt, P.A. Kyrle (Austria)

PB 1573 Assessment of Low Platelet Reactivity (LPR) with Multiple Electrode

Impedance Aggregometry (MEA) and Risk of Bleeding in Patients Receiving P2Y12 Receptor InhibitorsD. Dineva, Paskaleva I., Baychevа В, Gocheva N., Georgiev G., Trendafilova E. (Bulgaria)

PB 1574 Concomitant Use of Antiplatelet and Direct Oral Anticogulants Increase but Not Significantly the Bleeding Risk in Patients with Atrial FibrilationJ.J. Cerezo-Manchado, B. Navarro-Almenzar, A. Maritnez-Marin, F. Garcia-Candel, V. Cabañas, D. Iyu, N. Marin, M. Blanquer, A.B. Martinez-Garcia, S. Eduardo, J.M. Moraleda (Spain)

PB 1575 Arginine-containing Oligopeptides as Antiplatelet Agents Under Experimental

Type-2 Diabetes MellitusM. Grigorjeva, L. Luapina (Russian Federation)

PB 1576 Combined Effect of CYP2C19 G681A Polymorphism and Plateletcrit on

Clopidogrel Low-responsiveness in Thai Patients with Acute Coronary SyndromeS. Jirungda, N. Komanasin, V. Senthong, B. Pussadhamma, P. Makarawate, K. Anutarapongpan, D. Kaewkes (Thailand)

PB 1577 Inhibition of Platelet Aggregation by Fibrinogenase from the Antarctic Scallop

Adamussium colbeckiN. Raksha, D. Gladun, L. Ostapchenko (Ukraine)

PB 1578 Platelet (plt) reactivity in patients with essential thrombocythemia (ET)

receiving antiplatelets therapy with aspirin (ASA)S. Gamba, M. Marchetti, A. Vignoli, L. Russo, C.J. Tartari, C. Giaccherini, C. Verzeroli, F. Marchesi, G. Finazzi, A. Rambaldi, A. Falanga (Italy)



394 395

Tues

day

Pos

ter

Ses

sion

s

PB 1579 The Influence of Prostaglandin E1 on the Correlation between the Multiple Electrode Aggregometry ADP and the VerifyNow P2Y12 Test in Patients Using P2Y12 InhibitorsP.W.M. Verhezen, M.J.A. Vries, M.J.J. Haartmans, R.J.H. Wetzels, C.G.M. van Oerle, Y.M.C. Henskens (The Netherlands)

PB 1580 Could Aspirin Play a Role in Diminishing ADP Induced Platelet Aggregation in

Clopidogrel Naïve Patients?S. Georgantis, G. Soufla, M. Katafygioti, T. Kanellopoulou, T. Kostelidou (Greece)

PB 1581 Obesity Is Associated with Reduced Platelets SERCA3 Isoform Expression and

Subsequent Platelet Inhibition, Reversible after Weight LossR. Bobe, Z. Elaïb, M. Coupaye, J.J. Lopez, C. Repererant, A. Kondriateff, Y. Becker, M. Pépin, F. Teillet, D. de Prost, A. Stepanian (France)

PB 1582 Patterns and Levels of Platelet Glycosylation in Patients with Coronary Heart

Disease and Type 2 Diabetes MellitusL. Liping, Q. Chenxue, W. Xuelian, D. Juhua, L. Yao, G. Yan, Y. Ran, L. Yaqi (China)

PB 1583 Hemostatic Abnormalities in Patients with Ehlers-Danlos Syndrome

M. Abbattista, A. Artoni, B. Marinelli, A. Lecchi, S. Lamarca, A. Bassotti, I. Martinelli (Italy)

PB 1584 Acquired Glanzmann Thrombasthenia due to Marked Reduction of Surface

αIIbβ3 Expression with Non-function Blocking Anti-αIIbβ3 AntibodiesK. Akuta, H. Kashiwagi, T. Yujiri, N. Nishiura, Y. Morikawa, H. Kato, S. Honda, Y. Kanakura, Y. Tomiyama (Japan)

PB 1585 Platelet Function and Ibrutinib Treatment in Chronic Lymphocytic Leukaemia

and Mantle Cell Lymphoma: Effects of Drug and of Disease ItselfA. Ignatova1, E. Nikitin1, A. Tharmakulanathan2, S. Ramström2, A. Poletaev1, D. Polokhov1, A. Fedotov1, E. Seregina1, A. Pshonkin1, V. Vorobiev1, V. Ptushkin1, M. Panteleev1 (1Russian Federation, 2Sweden)

PB 1586 Chronic Immune Thrombocytopenic Purpura (ITP) in Egyptian Children: A 10

Year Single Center Retrospective StudyM. Abdelwahab, M. Aydeen, D. Ezzat (Egypt)

PB 1587 Acute Episodes of Atrial Fibrillation Cause Altered Platelet Function and

Procoagulant Microparticle ConsumptionL. Pourtau, J.M. Sellal, R. Lacroix, P. Poncelet, O. Bernus, G. Clofent-Sanchez, J.-C. Bordet, M. Hocini, M. Haïssaguerre, F. Dignat-George, F. Sacher, P. Nurden (France)

PB 1588 Impaired Platelet Responsiveness in Thrombocytopenic Cancer Patients after Chemotherapy as a Consequence of Mitochondrial DysfunctionC.C.F.M.J. Baaten1, F.C.J.I. Moenen1, Y.M.C. Henskens1, F. Swieringa1, R. Wetzels1, R. van Oerle1, H.F.G. Heijnen1, H. ten Cate1, G.P. Holloway2, E.A.M. Beckers1, J.W.M. Heemskerk1, P.E.J. van der Meijden1 (1The Netherlands, 2Canada)

PB 1589 Coated-platelet Formation is a Sensitive Indicator of Dasatinib Elicited Side-

effectsJ. Kappelmayer, I. Beke Debreceni, A. Kerényi, V. Treszkai, G. Mezei, P. Batár (Hungary)

PB 1590 Thrombocytopenia and Altered Coagulation as Independent Predictors of the

Etiology of “Tropical Jaundice” in Adults Presenting to Emergency in a Tertiary Care Hospital in North IndiaA. Bhalla, V. Suri, M. Singh, M. Biswla, R. Ratho, M.P. Singh, A. Duseja, P. Malhotra (India)

PB 1591 Plasma microRNAs Characterizingpatients with Immune Thrombocytopenia

Y. He, B. Zou, C. Ruan (China) PB 1592 Evaluation of in vitro Effects of Tyrosine-kinase Inhibitors on Primary

HaemostasisF. Eckart, M. Suttorp, R. Ursula, R. Knoefler (Germany)

PB 1593 What Do we Know about Post Transfusion Purpura? A Novel Insight into the

Correlation between HPA Antibodies and Clinical PictureI. Farkash, T. Rashal, S. Chen, M. Hareuveni, L. Bonstein, D. Stavi, Y. Bar-on, I. Avivi, I. Kirgner (Israel)

PB 1594 Further Characterization of Platelets Bearing Mutations in Calreticulin or JAK2

Genes in Essential Thrombocythemia PatientsH. Hauschner, N. Rosenberg, U. Seligsohn, M. Koren-Michowitz (Israel)

PB 1595 Clinical Evaluation of the Revised International Prognostic Score of Thrombosis

for Essential Thrombocythemia (IPSET-Thrombosis) in a Cohort of 746 Chinese Adult PatientsR. Fu, H. Li, F. Xue, X. Liu, L. Zhang, R. Yang (China)

PB 1596 Variations of Mean Platelet Volume with Time Since Blood Sampling in

Different AnticoagulantsG.M. Podda, P. Soru, G. Casazza, E.A. Femia, G. Carpani, M. Cattaneo (Italy)

PB 1597 Cytosolic Calcium Concentrations in Platelets from Patients with Pulmonary

Embolism and Implications for TherapyJ. Pike, N. Alves, J. Kline (United States)



396 397

Tues

day

Pos

ter

Ses

sion

s

PB 1598 Probable Risks and Benefits of Second Line Therapy Splenctomy versus TPO Mimetics in Chronic Idiopathic Thrombocytopenic Purpura an Experience of a Third World Country, PakistanT. Imran (Pakistan)

PB 1599 Sonoclot Signature Analysis In Thrombocytopenic Patients

K. Mishra, P. Malhotra, D. Lad, N. Varma, R.K. Dhiman, Y. Uday, A. Khadwal, G. Prakash, J. Ahluwalia, S. Varma (India)

PB 1600 High Incidence of Platelet Dysfunction is unmasked in Newly-diagnosed

Multiple MyelomaT. Ruchutrakool, B. Buasatit, P. Plurksathaporn, W. Owattanapanich (Thailand)

PB 1601 Effects of Time and Different Anticoagulants on Platelet Count in Blood Donors

and in Thrombocytopenic PatientsG.M. Podda, P. Soru, G. Casazza, E.A. Femia, G. Carpani, M. Cattaneo (Italy)

PB 1602 In vitro Ibrutinib Effect (Inhibitor of Bruton´S Tyrosine Kinase) on Platelets

Function. A Single Centre StudyS. Gkotsi, M. Dimou, A. Chanos, O. Katsarou, P. Panayiotidis, P. Kotsi (Greece)

PB 1603 The Platelet Function Analyzed by Flow Cytometry in Psoriatic Patients on Reference TherapyA. Ermakov, L. Gaikovaya, L. Karyakina, R. Pavlova, T. Vavilova (Russian Federation)

PB 1604 PANDA, a Biomarker for Diagnostic of Leaky Gut Syndrome

M. Lopez, G. Nowak (Germany)

Vascular Biology & Angiogenesis

PB 1605 Role of the Extracellular Matrix Protein Biglycan for Platelet Adhesion and Thrombus FormationN. Maurus, H. Hörmann, J.W. Fischer, M. Elvers (Germany)

PB 1606 Platelet Inhibition Augments Rupture-induced Death in a Mouse Model of

Abdominal Aortic AneurysmK. Saum1, N. Robbins1, S. Jones1, W. Bergmeier1, A. Wanhainen2, N. Mackman1, P. Owens1 (1United States, 2Sweden)

PB 1607 Protein Disulfide Isomerase Is Regulated by S-nitrosylation: Implications for

Vascular Quiescence and Thrombus FormationR.H. Bekendam1, D. Iyu2, F. Passam3, K. Deceunynck2, C. Garnier2, L. Crescence1, L. Panicot-Dubois1, R. Flaumenhaft2, C. Dubois1 (1France, 2United States, 3Australia)

PB 1608 Ultra-sensitive Molecular Magnetic Resonance Imaging of Blood Cells - Endothelium Interactions In vivoM. Gauberti, A. Fournier, S. Martinez de Lizarrondo, D. Vivien, F. Docagne (France)

PB 1609 Contribution of the P2X1 Receptor Expressed by Lung Macrophages to

Experimental TRALIM.-B. El Mdawar, B. Maître, S. Magnenat, C. Gachet, B. Hechler, H. de la Salle (France)

PB 1610 The Role of von Willebrand Factor in Experimental Malaria-associated Acute

Respiratory Distress SyndromeS. Kraisin, S. Verhenne, T. Pham, N. Vandeputte, H. Deckmyn, K. Vanhoorelbeke, P.E. Van den Steen, S.F. De Meyer (Belgium)

PB 1611 Blood Platelets Bind Aβ Peptides via Integrin αIIbβ3 and Induce Amyloid-β

Aggregation in Cerebral VesselsL. Donner, L. Gremer, G. Pagani, H. Gohlke, D. Willbold, M. Elvers (Germany)

PB 1612 Platelet Extracellular Vesicles Induce a Proinflammatory Smooth Muscle Cell

PhenotypeT. Vajen1, B.J. Benedikter1, A.C.A. Heinzmann1, E.M. Vasina1, Y. Henskens1, M. Parsons2, P.B. Maguire2, F. Stassen1, J.W.M. Heemskerk1, L.J. Schurgers1, R.R. Koenen1 (1The Netherlands, 2Ireland)

PB 1613 Conditional Knockout of Heme Oxygenase-1 in Lysozyme M Positive Cells Attenuates Angiotensin II Induced Vascular InflammationJ. Lagrange, S. Kossmann, T. Münzel, P. Wenzel (Germany)

PB 1614 Defective Fibrin Accumulation and Thrombus Stability in Endothelial Cell-

specific BAMBI Knockout-miceI.I. Salles-Crawley, A. Zalli, J.H. Monkman, D.A. Lane, J.T.B. Crawley (United Kingdom)

PB 1615 FXI Inhibition Protects from Vascular Inflammation and Endothelial

Dysfunction in Arterial HypertensionS. Kossmann1, J. Lagrange1, S. Jäckel1, K. Jurk1, M. Ehlken1, T. Schönfelder1, Y. Weihert1, M. Knorr1, M. Brandt1, A. Daiber1, M. Oelze1, C. Reinhardt1, K. Lackner1, A. Gruber2, B. Monia2, S. Karbach1, U. Walter1, Z. Ruggeri2, T. Renné3, W. Ruf1, T. Münzel1, P. Wenzel1 (1Germany, 2United States, 3Sweden)

PB 1616 Function of an Endothelial-specific GPCR in Thrombosis

L. Gottlob1, P. Dusart1, L. Fagerberg1, D.-A. Trégouët2, P. Morange2, M. Germain2, M. Civelek3, T. Renné1, J. Odeberg1, L. Butler1 (1Sweden, 2France, 3United States)



398 399

Tues

day

Pos

ter

Ses

sion

s

PB 1617 Factor VII Activating Protease (FSAP) Regulates the Expression of Inflammatory Genes through Protease Activated Receptor (PAR1) in Vascular Smooth Muscle and Endothelial CellsK. Byskov1, T. Boettger2, P.F. Ruehle2, N.V. Nielsen1, M. Etscheid2, S.M. Kanse1 (1Norway, 2Germany)

PB 1618 Regulation of Platelet String Formation on Endothelial Cells in the Presence of

Coagulation under ShearT. Shirai, J. Zilberman-Rudenko, C. Puy, K.S. Garland, D.E. Sallee, S.E. Reitsma, A. Gruber, O.J.T. McCarty (United States)

PB 1619 Recombinant Adeno-associated Virus Vector Carrying the Thrombomodulin

Lectin-like Domain Suppresses the Development of Abdominal Aortic Aneurysm in MiceH.-L. Wu, C.-H. Lai, K.-C. Wang, G.-Y. Shi (Taiwan)

PB 1620 A2 Domain of von Willebrand Factor (VWF) Mediates Human Vascular Smooth

Muscle Cells (VSMCs) Proliferation and MigrationM.E. Worou, M. Didelot, P. Legendre, V. Muczynski, P.J. Lenting, P. Lacolley, C.V. Denis, V. Regnault (France)

PB 1621 Dietary Alpha-linolenic Acid Reduces Platelet Activation and ex vivo Thrombus

Formation in Sickle Cell Disease MiceS. Stivala, S. Gobbato, N. Bonetti, G. Camici, T. Lüscher, J. Beer (Switzerland)

PB 1622 Podoplanin Overexpression on Endothelial Cells Promotes Superficial Erosive

Injury and Thrombus Formation in Rat Carotid ArteryE. Furukoji, A. Yamashita, T. Hirai, Y. Asada (Japan)

PB 1623 Evaluation a Novel Mouse Model of Abdominal Aortic Aneurysm to Study

Platelet Mechanisms of the Proinflammatory ThrombusY. Boulaftali, S. Delbosc, M.-C. Bouton, J.-B. Michel, M. Jandrot-perrus, B. Ho-Tin-Noé (France)

PB 1624 Increased Inflammatory Properties of Neutrophils and Endothelial Cells (ECs)

in Patients with Venous Thromboembolism (VTE), Long after the Acute DiseaseK.C.S. Zapponi, F. Orsi, I.R. Brito, J.L. Cunha, A.V. Romano, F. Santiago-Bassora, B.D.M. Mazetto, S.A. Montalvão, C.F. Franco Penteado, L.F.B. Sckayer, E.V. De Paula, J.M. Annicchino-Bizzacchi (Brazil)

PB 1625 Analysis of Body-wide Unfractionated Tissue Data to Identify a Core Human

Endothelial TranscriptomeL. Butler, B. Hallström, L. Fagerberg, F. Pontén, M. Uhlén, T. Renné, J. Odeberg (Sweden)

PB 1626 Effects of Aspirin and Rivaroxaban on Murine Arterial Vessel Wall Remodelling after Vascular InjuryT. Mastenbroek1, M. Kuijpers1, M. Nagy1, W. Chayouâ1, A. Brouns-Strzelecka1, P. Leenders1, H. van Essen1, S. Heitmeier2, R. van Oerle1, H. Spronk1, J. Heemskerk1, J. Cosemans1 (1The Netherlands, 2Germany)

PB 1627 Plasminogen Activator Inhibitor Type 1 in Platelets Evokes Thrombogenicity

and Increases Thrombus Size by Elevating Thrombolysis Resistance under Shear StressK. Hosokawa, T. Ohnishi-Wada, H. Sameshima-Kaneko, T. Nagasato, H. Tanaka, H. Sano, Y. Suzuki, T. Urano (Japan)

PB 1628 Tissue Engineered Small Vessel Conduits - The Anti-thrombotic Effect of Re-

endothelialisation of Decellularised Baboon ArteriesM. Meiring, M. Khemisi, L. Laker, F. Smit (South Africa)

PB 1629 APAC, a Dual Antiplatelet and Anticoagulant Heparin Proteoglycan Mimetic,

Integrates with Extravascular Matrix during Vascular InjuryK.A. Barreiro, A. Jouppila, R. Tulamo, A. Albäck, R. Lassila (Finland)

PB 1630 Protein Kinase C-Dependent Loss of Tissue Factor by Human Pericytes Results

from Altered Synthesis, Trafficking and DegradationM. Hoffman, L. Sommerville, D. Monroe (United States)

PB 1631 Design and Utility of Extracellular Matrix-embedded Microvessels to Study the Platelet-endothelium InterfaceJ. Zilberman-Rudenko, A.D. Wong, D.E. Sallee, S.E. Reitsma, C. Puy, T. Shirai, A. Mitrugno, P.C. Searson, O.J.T. McCarty (United States)

PB 1632 Micropatterning Induced Alterations of Endothelial Outgrowth Cells

M. Hagen, T. Van, M. Hinds (United States) PB 1633 Endothelial Dysfunction in Idiopathic Thromboembolism Investigated through

Gene Expression Profiling of Endothelial Colony Forming CellsC. Lodigiani, F. Calcaterra, P. Ferrazzi, L. Libre', E. Banfi, C. Carenza, D. Mavilio, S. Della Bella (Italy)

PB 1634 Role of Lysozyme M+ Cells in the Development of Angiotensin II-induced

Vascular InflammationJ. Lagrange, S. Kossmann, T. Münzel, W. Ruf, P. Wenzel (Germany)

PB 1635 The Response of HUVEC to Prolonged Shear Stress for Use in in vitro Studies

B. Apta, C. Arnold, L. Huang, M. Harper (United Kingdom)

POSTER SESSIONS


401

Wed

nesd

ayP

oste

r S

essi

ons

POSTER SESSIONS


400

PB 1636 Serum Sphingosine-1-phosphate is Not Associated with Age and Gender but with Blood Cell-related Parameters: Analysis of the Study of Health in Pomerania CohortE. Moritz, D. Wegner, S. Groß, M. Bahls, M. Dörr, S.B. Felix, T. Ittermann, S. Oswald, M. Nauck, N. Friedrich, R.H. Böger, G. Daum, E. Schwedhelm, B.H. Rauch (Germany)

PB 1637 Plasma Modification of Poly(Vinyl Alcohol) for Enhanced Endothelialization and

Anti-thrombogenicityP. Jurney1, D. Anderson1, M. Hagen1, E. Yim2, M. Hinds1 (1United States, 2Canada)

Wednesday, July 12, 2017Poster Sessions



PB 1638 Platelet α-granule Deficiency Protects Local and Distal Organs in Intestinal Ischemia Reperfusion InjuryK. Ashworth, P. Davizon-Castillo, L. Johnson, B. Branchford, D. Bark, J. DiPaola (United States)

PB 1639 Structure-function Relationships of Krait Natriuretic Peptide: Design of

Natriuretic Peptide Analogues with Vasodilatory or Renal Activities for Personalized Care of Heart Failure PatientsS. Sridharan, M. Kini (Singapore)

PB 1640 Development of a Novel Strategy to Target CD39 Antithrombotic Activity to the

Endothelial-platelet Microenvironment in Kidney Ischemia-reperfusion InjuryM. Sashindranath1, K. Dwyer1, S. Dezfouli1, C. Selan1, S. Crikis1, B. Lu1, Y. Yuan1, M. Hickey1, K. Peter1, S.C. Robson2, P. Cowan1, H. Nandurkar1 (1Australia, 2United States)

PB 1641 Trif-deficiency Impairs Leukocyte Adhesion and Netosis in Mesenteric

Ischemia-reperfusionS. Ascher, E. Wilms, K. Schwierczek, K. Jurk, C. Reinhardt (Germany)

PB 1642 Inhibition of Coagulation Factor Xa Attenuates Myocardial Ischemia

Reperfusion Injury in MiceJ.J.J. Posma1, J.J. Posthuma1, R. Van Oerle1, S. Heitmeier2, H. Ten Cate1, H.M.H. Spronk1 (1The Netherlands, 2Germany)

PB 1643 Biomarkers of Oxidative Stress in Venezuelan Sickle Cell Patients: Association

with the Clinical SeverityD. Higuera, A. Salazar, E. Hergueta, N. Estepa, E. Salazar, K. Perez, C. Ibarra, B. Guerrero (Venezuela)

PB 1644 Contribution of Neutrophil Extracellular Trap (NET) Components to the

Structure of Thrombi from Therapeutic Intervention in Ischemic Coronary, Peripheral and Cerebral Artery DiseaseÁ.Z. Farkas, V.J. Farkas, K. Bálint, I. Gubucz, I. Szikora, A. Nagy, P. Sótonyi, L. Hidi, B. Merkely, K. Kolev (Hungary)



402 403

Wed

nesd

ayP

oste

r S

essi

ons

PB 1645 A Novel Easy-to-Perform Thromboembolic Stroke Model in Mice: Application to the Study of the Thrombolytic Effect of N-acetylcysteineM. Gauberti, S. Martinez de Lizarrondo, M. Rubio, S. Goursaud, D. Vivien, C. Gakuba (France)

PB 1646 Human Platelet Alloantigens and P-Selectin Gene Polymorphisms in Pediatric

Arterial Ischemic StrokeD. Coen Herak, M. Pavic, A. Ceri, J. Lenicek Krleza, V. Djuranovic, N. Barisic, R. Zadro (Croatia)

PB 1647 MicroCT Imaging of Cerebral Thromboemboli In vivo: The Effects of Tissue

Plasminogen ActivatorD.-E. Kim (Republic of Korea)

PB 1648 Incidence Rates and Case Fatality Rates of Cerebral Vein Thrombosis: A

Population-based StudyF. Dentali, V. Gessi, F. Pomero, A. Squizzato, M. Bonzini, W. Ageno (Italy)

PB 1649 Biomarkers for the Symptomatic Carotid Atheroma

M.J. Iglesias, L. Perisic, M. Vesterlund, M. Lengquist, M.-G. Hong, L. Sanchez-Rivera, M. Berg, M. Kronqvist, P. Gillgren, F. Ponten, M. Uhlén, J.M. Schwenk, G.K. Hansson, G. Paulsson-Berne, J. Lehtiö, U. Hedin, J. Odeberg (Sweden)

PB 1650 Neutrophil Extracellular Traps (NETs) in Patients with Acute Stroke Are

Associated with Stroke Severity and ProgressionA. Moscardó, M.T. Santos, A. Lago, A.M. Latorre, J.I. Tembl, J. Salom, C. Nieves, S. Bonanad, J. Vallés (Spain)

PB 1651 Case-fatality after Venous Thromboembolism and Ischemic Stroke in Subjects

without and with Atrial Fibrillation. The Tromsø StudyE.M. Hald, L.B. Rinde, M.-L. Løchen, E.B. Mathiesen, T. Wilsgaard, I. Njølstad, S.K. Braekkan, J.-B. Hansen (Norway)

PB 1652 Role of ARHGEF10 in Platelet Function and Thrombosis

D.-H. Lu, T.-F. Huang, H.-C. Liu, S.S.-F. Gau, W.-M. Fu (Taiwan) PB 1653 The Efficacy and Safety of a Laser Thrombolytic System in Animal Thrombosis

ModelsY. Matsumoto, K. Hokamura, D. Yamashita, Y. Shimizu, Y. Takata, T. Kosugi, Y. Tamaoki, T. Kawashima, Y. Yamashita, H. Okada, T. Nakayama, K. Umemura (Japan)

PB 1654 Thrombi Retrieved from Patients Suffering Acute Ischemic Stroke Show both Active and Mechanical Interaction between Stent Retrievers and Thrombus, and is Associated with Specific Thrombus Surface CharacteristicsA.S.A. Autar, H. Hund, S.A. Ramlal, D. Hansen, M. de Maat, A. van der Lugt, D. Dippel, A.C.G.M. van Es, H.M.M. van Beusekom (The Netherlands)

PB 1655 The Effect of Recanalization on Long-term Neurologic Outcome after Cerebral

Vein ThrombosisF. Dentali, I. Martinelli, E. Rezoagli, D. Poli, S.M. Passamonti, W. Ageno (Italy)

PB 1656 Hyperglycemia Precipitates Infarct Growth and Hemorrhagic Transformation in

Ischemic Stroke Though Exacerbation of ThromboinflammationJ.-P. Desilles, V. Syvannarath, V. Ollivier, C. Journé, C. Ducroux, W. Boisseau, S. Loyau, M. Jandrot-Perrus, J.-B. Michel, M. Mazighi, B. Ho-Tin-Noé, inserm U1148 (France)

PB 1657 The Association between Ring Finger Protein213 (RNF213) Polymorphisms

and Ischemic Stroke Risk in Korean PatientsH.W. Kim, J.O. Kim, H.J. An, K.A. Kim, E.S. Kim, J.H. Sakong, H.A. Lee, C.S. Ryu, D. Oh, O.J. Kim, Y.S. Park, N.K. Kim (Republic of Korea)

PB 1658 Effects of Phosphodiesterase 3A Modulation on Murine Cerebral

MicrohemorrhagesR. Sumbria, V. Vasilevko, M.M. Grigoryan, A. Paganini-Hill, R. Kim, K. Kilday, T. Ngo, N. Chan, G. Pannu, K. Nguyen, A. Jafari, D. Cribbs, M. Fisher (United States)

PB 1659 Coding Variants in ADAMTS Genes Derived from Next Generation Sequencing

Associated with Pediatric StrokeF. Rühle, A. Witten, A. Barysenka, C. Strauss, M. Hiersche, A. Arning, U. Nowak-Göttl, M. Stoll (Germany)

PB 1660 Long-term Stroke Risk Prediction in 'Real World' Atrial Fibrillation Patients: A

Comparison of the ABC-stroke and CHA2DS2-VASc ScoresJ.M. Rivera-Caravaca1, V. Roldán1, M.A. Esteve-Pastor1, M. Valdés1, V. Vicente1, G.Y.H. Lip2, F. Marín1 (1Spain, 2United Kingdom)

PB 1661 Time-restricted Feeding Disturbs Circadian Expression of Thrombomodulin in

the Mouse through Peripheral Clock MoleculesS. Horie, K. Oishi, Kagawa Nutrition University (Japan)

PB 1662 Reduced ADAMTS13 Levels in Patients with Acute and Chronic

Cerebrovascular DiseaseF. Denorme1, P. Kraft2, I. Pareyn1, C. Drechsler2, H. Deckmyn1, K. Vanhoorelbeke1, C. Kleinschnitz2, S.F. De Meyer1 (1Belgium, 2Germany)



404 405

Wed

nesd

ayP

oste

r S

essi

ons

PB 1663 High Level of von Willebrand Factor Ristocetin Cofactor Activity is Associated with Poor 2-years' Prognosis in Cerebral InfarctionW. Shen (China)

PB 1664 Evaluation of the Thrombolytic Potential of N-acetyl Cysteine in a Mouse Model

of Thrombotic StrokeF. Denorme, H. Deckmyn, K. Vanhoorelbeke, S.F. De Meyer (Belgium)

PB 1665 Is There a Difference in Inherited Prothrombotic Polymorphisms between

Arterial Ischemic Stroke and Cerebral Sinus Venous Thrombosis in Children?A. Ceri, D. Coen Herak, A. Grzunov, J. Lenicek Krleza, V. Djuranovic, N. Barisic, R. Zadro (Croatia)

PB 1666 Alpha-2-antiplasmin Arg407Lys Polymorphism and Cryptogenic Ischemic

Cerebrovascular Events: Association with Neurological DeficitJ. Wzorek, M. Karpinski, E. Wypasek, A. Undas (Poland)

PB 1667 Association between Ring Finger Protein213 Polymorphisms (RNF213 4448

G>A, 4810G>A, 4863G>A, 4950G>A) and Moyamoya Disease (MMD) in KoreansC.S. Ryu, J.O. Kim, H.J. An, K.A. Kim, E.S. Kim, J.H. SaKong, H.A. Lee, H.W. Kim, D. Oh, O.J. Kim, Y.S. Park, N.K. Kim (Republic of Korea)

PB 1669 Early Plasma Fibrinogen Level after Thrombolytic Therapy in Acute Ischemic

Stroke Patients Cannot Predict Intracranial HemorrhageT. Ruchutrakool, Y. Nakkinkun, Y. Nilanon (Thailand)

PB 1670 Prediction of Venous Thromboembolism and Ischemic Stroke by Modified

CHA2DS2-VASc Score in Patients with Atrial Fibrillation. The Tromsø StudyE.M. Hald, L.B. Rinde, M.-L. Løchen, E.B. Mathiesen, T. Wilsgaard, I. Njølstad, S.K. Braekkan, J.-B. Hansen (Norway)

PB 1671 Safety of Aspirin for Secondary Stroke Prevention: POoled Data Reanalysis of

Aspirin for CErebraL InfArction PreventIoN : PORCELAIN StudyT. Nagao (Japan)

PB 1672 Abnormal Red Cell Indices and the Risk of Arterial Ischemic Stroke in Children

N. Sirachainan, W. Sasakakul, P. Kadegasem, P. Wongwerawattanakoon, C. Khongkhatithum, A. Chuansumrit (Thailand)

PB 1673 Remote Platelet Function Testing Using Platelet-bound P-selectin as a Marker

of Platelet Activation. Findings in Patients with Stroke or TIA Treated with ClopidogrelN. Dovlatova, S. Heptinstall, J. May, P. Bath (United Kingdom)

PB 1674 Mechanical Endovascular Therapy Plus Intravenous Tissue Plasminogen Activator versus Intravenous Tissue Plasminogen Activator Alone for the Management of Acute Ischemic Stroke: An Adjusted Indirect Treatment Comparison Meta-analysisJ. Caranfa, W. Baker, R. Ali, I. Francis, E. Bosco, A. Zichichi, C. Coleman, C. Kohn (United States)

PB 1676 Unhelpful Use of Hereditary Thrombophilia Tests in Young Patients with

Ischemic Stroke. Final Results of the AISYF's TrialJ.M. Ceresetto, C. Duboscq, P. Bonardo, L. Leon Cejas, V. Genoud, S. Palmer, G. Stemmelin, R. Reisin (Argentina)

PB 1677 Association of PAI-1 4G/5G Polymorphism with Ischemic Stroke in Young

IndiansM. Akhter1, A. Biswas2, S. Abdullah1, M. Behari3, R. Saxena3 (1Saudi Arabia, 2Germany, 3India)

PB 1678 Serotonin and von Willebrand Factor Serum Content under Ischemic Stroke

with or without Type 2 Diabetes MellitusO. Kravchenko, T. Tsarenko, O. Savchuk, L. Ostapchenko (Ukraine)

PB 1679 Incidence and Outcome of Childhood Stroke in Thailand

P. Komvilaisak, S. Tiamkao, S. Sutra, N. Sirachainan, K.T. Thepsuthammarat (Thailand)

PB 1681 Another Indication to DOACs

A.M. Pizzini, D. Galimberti, G. Malferrari, M.C. Leone, D. Arioli, A. Ghirarduzzi (Italy)


PB 1682 Chemical Footprinting Reveals Conformational Changes Following Activation of Factor XII. Stroo, A. Marquart, A. Meijer, J. Meijers (the Netherlands)

PB 1683 Acute Lowering of Factor XII Induces Accelerated Spontaneous Venous

Thrombosis in Mice: New Evidence for the Contact System that “Idles”?M. Heestermans1, K.F. Nickel2, R. van Oerle1, H.H. Versteeg1, P.H. Reitsma1, T.A. Fuchs2, T. Renné2, H.M. Spronk1, B.J.M. van Vlijmen1 (1The Netherlands, 2Germany)

PB 1684 A Two-step Mechanism for Factor XII Activation in Solution

S. de Maat1, Z.L.M. Hofman1, N. Parr1, G. Pasterkamp1, T. Renné2, C. Maas1 (1The Netherlands, 2Sweden)



406 407

Wed

nesd

ayP

oste

r S

essi

ons

PB 1685 Cell Receptor Interactions of the Contact SystemJ. Emsley1, A. Slater1, B. Kaira1, K. Mccrae2, M. Searle1 (1United Kingdom, 2United States)

PB 1686 Endothelial Cell Serpins, Including PAI-1, Form a Complex with Fxia Blocking its Activity and Inducing the Clearance, Internalization and Degradation of FXIaC. Puy, A. Ngo, E. Tucker, D. Gailani, A. Gruber, O. McCarty (United States)

PB 1687 Characterization of Polyphosphate in Endothelial Cells under Cellular Stress

R. Rigg1, L. Labberton2, K.F. Nickel3, A.T. Long3, L.M. Butler2, O.J.T. McCarty1, T. Renne2 (1United States, 2Sweden, 3Germany)

PB 1688 Identification of F11 Gene Variations Involved in the Interindividual Variability

of Factor XI in Subjects with Congenital Deficiency Caused by Recurrent MutationsS. Salloum-Asfar, J. Esteban, M.E. de la Morena-Barrio, A. Miñano, J. Padilla, V. Vicente, J. Corral (Spain)

PB 1689 Long-chain Polyphosphate Promotes FXII-dependent Platelet Consumption

under Shear FlowJ. Zilberman-Rudenko1, S.E. Reitsma1, C.P. Wiesenekker1, C. Puy1, A.T.P. Ngo1, S.A. Smith1, E.I. Tucker1, R.J. Travers1, C. Maas2, R.T. Urbanus2, D. Gailani1, J.H. Morrissey1, A. Gruber1, O.J.T. McCarty1 (1United States, 2Netherlands Antilles)

PB 1690 Fibrin is a strong activator of FXII

H. Kozarcanin, K. Nilsson Ekdahl, B. Nilsson, K. Fromell (Sweden) PB 1691 Increased Kallikrein Generation Potential in Patients Suffering from Hereditary

AngioedemaD. Biltoft, J.J. Sidelmann, A. Bygum, Y. Palarasah, J.B. Gram (Denmark)

PB 1692 Red Cell and Platelet Microvesicles Activate the Contact System of Coagulation

D. Noubouossie, M. Piegore, M. Henderson, M. Mooberry, N.S. Key (United States)

PB 1693 Contaminating Silica Particles Contribute Substantially to the Procoagulant

Activity of DNA Isolated Using Commercial KitsS. Smith, C. Baker, R. Breitenfeld, J. Morrissey (United States)

PB 1694 Genetic Determinants of Levels of Contact Activation Coagulation Factors

J.L. Rohmann1, H.G. de Haan2, A. Algra2, F.R. Rosendaal2, B. Siegerink1 (1Germany, 2The Netherlands)

PB 1695 Role of the Platelet Surface in the Activation of FXI by FXIIaS.E. Reitsma1, C. Puy1, R.T. Urbanus2, D. Gailani1, E. Tucker1, A. Gruber1, O.J.T. McCarty1 (1United States, 2The Netherlands)

PB 1696 Contribution of Intrinsic Coagulation Factors on ex vivo Thrombus Formation

and LysisJ. Konings1, J.M. Cosemans1, B. de Laat1, H. ten Cate1, Y. Dargaud2, J.W. Govers-Riemslag1 (1The Netherlands, 2France)

PB 1697 Generation of a Monoclonal Antibody against “Fast Form” Alpha-2-

macroglobulin and Development of a Method to Measure Artificial Surface Driven Protease Activation in PlasmaD. Biltoft, J.J. Sidelmann, J.B. Gram, Y. Palarasah (Denmark)

PB 1698 Haemocompatibility Properties of Polyethersulfone Based Haemodialysis

Membrane with Different Amounts of PolyurethaneF. Kamal, S.H. Sheikh Abdul Kadir, M.H.D. Othman (Malaysia)

PB 1699 Comparison of Nine Different Blood Collection Tubes for Contact Activation of

CoagulationC. Kluft1, J. Jespersen2, J.W. Govers-Riemslag1, J.J. Sidelmann2 (1The Netherlands, 2Denmark)

PB 1700 CD40L Induces Association of PRDX-2 and TRAF-2 to CD40 of Platelets from

IBD PatientsL. Youness, M. Fatimazahra, O. Mounia, N. Abdallah, S. Nezha, L. Hanane, A.C. Aziz, Z. Younes (Morocco)

PB 1701 Short-term Increase in Factor (F)XIa-dependent Procoagulant Activity in Citrate

BloodS. Prior, K. Mann, S. Butenas (United States)

PB 1703 Temporal Contribution of the Platelet Body and Balloon to Thrombin Generation

E.O. Agbani, I. Hers, A.W. Poole (United Kingdom) PB 1704 Mechanism of Growth and Inhibition of Plasma Clots Growing from a Surface

with Immobilised Tissue FactorC. Kluft1, N.A. Podoplelova2, N.M. Dashkevich2, F.I. Ataullakhanov2 (1The Netherlands, 2Russian Federation)

PB 1705 Co-operative Binding of VWF to the TSP8 and CUB Domains of ADAMTS13 is

Required for its Conformational ActivationK. South, M. Freitas, D. Lane (United Kingdom)



408 409

Wed

nesd

ayP

oste

r S

essi

ons

PB 1706 α-Synuclein Binds to Human α-Thrombin and Inhibits Thrombin-mediated Platelet Aggregation: Possible Implications in Parkinson's DiseaseG. Pontarollo, L. Acquasaliente, F. Uliana, A. Negro, V. De Filippis (Italy)

PB 1707 The Effect of Short Chained Polyphosphates on Coagulation Activation in a

Whole Blood ModelI.I. Høiland1, R.A. Liang1, N. Latysheva1, S. Beck Jensen1, B. Østerud1, S.A. Smith2, J.H. Morrissey2, T.E. Mollnes1, O.-L. Brekke1, J.-B. Hansen1, K. G. Jebsen – Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø (1Norway, 2United States)

PB 1709 Evidence for Direct and Indirect Modulation of Haemostatic Factors by miR-

494J. Tay, W. Lui, J. Tian, Q. Hughes, J. Tiao, R. Baker (Australia)

PB 1710 Situation-adjusted Anticoagulant Release System with Response to Different

Coagulation FactorsM.F. Maitz, J. Zitzmann, J. Hanke, C. Renneberg, M.V. Tsurkan, C. Sperling, U. Freudenberg, C. Werner (Germany)

PB 1711 Liver Hypoxia Regulates Protein S Levels in Obese Patients

V. Pilli, A. Dorsey, H. Chodavarapu, E. Lazartigues, R. Majumder (United States)

PB 1712 Thrombin is a Selective Inducer of Heparanase Release from Platelets and

Granulocytes via Protease-activated Receptor-1M. Tatour, M. Shapira, E. Axelman, S. Ghanem, A. Keren-Politansky, L. Bonstein, B. Brenner, Y. Nadir (Israel)

PB 1713 Effects of Exercise and Erythropoietin on Thrombotic Risk in Well-trained

CyclistsJ.A.A.C. Heuberger, J.J. Posthuma, J.I. Rotmans, P. Gal, F.E. Stuurman, J. van 't Westende, T.E. Post, J.M.A. Daniels, M. Moerland, M.L. de Kam, J. Burggraaf, H. ten Cate, A.F. Cohen (The Netherlands)

PB 1714 Fibrinogen Polymorphisms Predict Fibrinogen and Clot-related Phenotypes

Independently and through Interactions with IL-6H.T. Cronjé1, C. Nienaber-Rousseau1, L. Zandberg1, Z. de Lange1, F.R. Green2, M. Pieters1 (1South Africa, 2United Kingdom)

PB 1715 Integrative Analysis of Hemostatic Gene Regulation in the Human Liver

M. Olsson, T.M. Stanne, M. Davila, C. Jern (Sweden)

PB 1716 Effects of the fibrinogen γ' C-terminal Peptide on Thrombin-catalyzed Activation of Factor XI, Factor XIII and TAFIF. Omarova1, J. Rosing1, R.A.S. Ariens2, H.R. McPherson2, R.M. Bertina1, E. Castoldi1 (1The Netherlands, 2United Kingdom)

PB 1717 Characterization of GGCX Mutations Identified in the First Clinical Case of a

VKCFD PatientD.-Y. Jin, B. Ingram, D.W. Stafford, J.-K. Tie (United States)

PB 1718 Comprehensive Identification of miRNA-gene Interactions Reveals Extensive

Regulation of the Plasmatic Coagulation NetworkJ. Nourse, J. Braun, S. Hüttelmaier, S. Danckwardt (Germany)

PB 1719 Resolving the Roles of Platelets and (Anti)Coagulation Pathways in Whole-blood

Fibrin Formation under Flow to Phenotype Hemostatic DisordersJ.P. van Geffen1, F. Swieringa1, S.L.N. Brouns1, R.W. Farndale2, K.J. Clemetson3, E. Castoldi1, P.E.J. van der Meijden1, M.E.J. Kuijpers1, J.W.M. Heemskerk1 (1The Netherlands, 2United Kingdom, 3Switzerland)

PB 1720 Temperature Effects on Thrombin Generation

M. Moorlag, R. Kremers, B. de Laat, H.C. Hemker (The Netherlands) PB 1721 Thrombin Generation in Schizophrenia Patients Treated with Antipsychotic

MedicationsS. Allen, S. Okigbo, K. Egan, A. Al Zadjali, D. Kenny, P. Maguire, B. Kevane, F. Ni Ainle, J. Thakore (Ireland)

PB 1722 Blood Clot Contraction is Reduced in Sickle Cell Disease due to Increased

Rigidity of ErythrocytesV. Tutwiler, R. Litvinov, C. Nagaswami, E. Russell, D. Seigel, C. Villa, D. Pan, V. Muzykantov, J. Weisel (United States)

PB 1723 Tissue Factor-dependent Heme-induced Whole Blood Coagulation Activation: A

Thromboelastometry StudyB.W. Hounkpe, G.R. de Souza, M.M.L. Fiusa, M. Pereira Colella, J.M. Annichino-Bizzacchi, F. Traina, F. Ferreira Costa, E.V. De Paula (Brazil)

PB 1724 Salivary EV: A New Link between Primary and Secondary Hemostasis

Y. Yu, E. Gool, R. Berckmans, A. Sturk, A. Barendrecht, C. Maas, R. Nieuwland (The Netherlands)

PB 1725 Heme-regulated Proteins within the Blood Coagulation Cascade: Insights into

the Molecular Basis of Protein Binding to Free HemeD. Imhof, S. Mai, C.A. Bäuml, A. Wißbrock (Germany)



410 411

Wed

nesd

ayP

oste

r S

essi

ons

PB 1726 Heparan Sulfate Chains Contribute to an Anticoagulant Milieu in Malignant Pleural EffusionE. Hardak, E. Peled, Y. Crispel, S. Ghanem, J. Attias, I. Kogan, B. Brenner, Y. Nadir (Israel)

PB 1727 Myeloperoxidase (MPO) is a Negative Regulator of Phospholipid-dependent

CoagulationL. Beckmann, C. Dicke, B. Spath, B. Sievers, C. Lehr, A. Klinke, S. Baldus, V. Rudolph, F. Langer (Germany)

PB 1728 Procoagulant Properties of Microparticles Produced by Monocytes,

Granulocytes, Platelets and Endothelial CellsA. Mazurov, O. Antonova, N. Golubeva, S. Khaspekova, O. Shustova, V. Yakushkin, I. Alchinova, M. Karganov (Russian Federation)

PB 1729 Ventricular Assist Devices without Anticoagulation: An Impossible Dream?

P.A. Coghill, Z. Azartash-Namin, J.R. Stanfield, T.A. Snyder, J.W. Long (United States)

PB 1730 Beta-adrenergic Receptor Blockage Reduces Exercise-induced Alterations in

HaemostasisJ.J. Posthuma, J.J.N. Posma, R. van Oerle, H.M.H. Spronk, H. ten Cate (The Netherlands)

PB 1731 The Modification of Thrombin Generation Assay Parameters in Patients with

Recurrent Pregnancy LossD. Bahri, H. Baccouche, A. Chakroun, Z. Manai, S. Mahjoub, N. Ben Romdhane (Tunisia)

PB 1732 Desmopressin Administration in a Splenectomised Hemophilia A Patient Does

Not Affect FVIII, VWF and tPA Plasma Levels: An Evidence for an Indirect Effect of DDAVPT. Shahani1, Z. Pirdel1, H. Dinmohammadi1, L. Salarilak1, M. Karimi1, M. Jacquemin2 (1Iran, Islamic Republic of, 2Belgium)

PB 1734 Haemostatic Function after Spontaneous Intracerebral Haemorrhage

S.V. Lauridsen, A.M. Hvas, E. Sandgaard, T. Gyldenholm, C. Rahbek, N. Hjort, E.K. Tønnesen, C.L. Hvas (Denmark)

PB 1735 Anticoagulant effects of peptide Pro-Gly-Arg in aging rats

T. Obergan, M. Grigorjeva (Russian Federation) PB 1736 A Polydeoxynucleotide Derived Drug Defibrotide Inhibits Nucleosome

Generation in Whole Blood. Implications in the Management of VODJ. Fareed, U. Cornelli, D. Hoppensteadt, A. Walborn, J. Walenga, M. Iacobelli, W. Jeske (United States)

PB 1737 Influence of Polyamidoamine (PAMAM) Dendrimers on the Activity of Key Enzymes of the Coagulation System in vitroL. Mukhametova, R. Aisina, E. Ivanova, E. Zakharyan, K. Gerchkovich (Russian Federation)

PB 1738 Repetitive Strenuous Exercise Leads to Exhaustion of Haemostatic SystemA. Miszta, V. Strijbis, L.N. van der Vorm, D. Huskens, S. Zwaveling, P. G. de Groot, M. Roest, B. de Laat (The Netherlands)

PB 1739 Absence of Thrombotic Events in the Gastric Signet-ring Cell Adenocarcinoma

Patients with High Expression of HeparanaseS. Shah, C. Fourgeaud, S. Derieux, S. Mirshahi, G. Contant, C. Pimpie, I. Aldybiat, R. Lo Doco, C. Eveno, J. Soria, M. Pocard, M. Mirshahi (France)

PB 1740 Anti-TFPI Antibody Targeting the Kunitz-2 Domain of Human TFPI Efficiently

Recovers FVII Activity Comparing Kunitz 1 Domain Targeted TFPI AntagonistS. Lee, H. Kwak, S.-H. Hwang (Republic of Korea)

PB 1741 The State of Hemostasis after Nonselective Thrombolysis in Patients with

Ischemic StrokeS. Sinkov, K. Zibin (Russian Federation)


PB 1742 FXIII and EACA Increase Thrombus Stability and Decrease Pulmonary Embolism in an in vivo Mouse Model of Venous Thromboembolism, but EACA Increases Thrombus SizeS.A. Shaya, J.I. Weitz, P.L. Gross (Canada)

PB 1743 Fibrinogen May Possess a Second Factor XIII Cross-linking Site for α2-AP in

FibrinC. Duval1, H. McPherson1, K. Bridge1, M. Domingues2, R. Ajjan1, V. Ridger1, S. Connell1, H. Philippou1, R. Ariens1 (1United Kingdom, 2Portugal)

PB 1744 Fibrin-derived Bß15-42 Peptide Is a Gatekeeper of Thrombus Resolution

S. Chausheva, S. Sharma, A. Alimohammadi, P. Petzelbauer, I. Lang (Austria) PB 1745 Theoretical Model for Thrombin-FXIII-A2 Complex and the Effect of Ca2+ Ions

on the Dynamic Behavior of FXIII-A2'I. Komáromi, G. Balogh, A. Fekete, L. Muszbek (Hungary)

PB 1747 Platelet and Plasma Factor XIII Levels after Replacement Therapy in Severe Congenital Factor XIII Deficiency: Is there a Role for Factor XIII Uptake by Megakaryocytes?C. Radu, C. Bulato, E. Campello, F. Sartorello, E. Zanon, M. Milan, S. Gavasso, L. Spiezia, P. Simioni (Italy)



412 413

Wed

nesd

ayP

oste

r S

essi

ons

PB 1748 Investigating the Role that a Factor XIII Binding Site on Fibrinogen αC (233-425) Plays in Controlling Glutamine Substrate SpecificityM. Maurer1, K. Mouapi1, L. Wagner2, C. Stephens1 (1United States, 2France)

PB 1749 Genetic and Clinical Epidemiology of Congenital Fibrinogen Disorders

A. Casini, M. Blondon, P. de Moerloose, M. Neerman-Arbez (Switzerland) PB 1750 Calcium Binding Sites in Coagulation Factor XIII and Other Transglutaminases:

Their Evolution, Diversity, Conservation and Functional RelevanceS. Singh1, S.L.S. Swaminathan1, C. Reinhart1, C. Krettler1, V. Ivaskevicius1, J. Dodt1, H. Philippou2, J. Oldenburg1, A. Biswas1 (1Germany, 2United Kingdom)

PB 1751 On-demand Treatment with Fibrinogen Concentrate in Acute Bleeding and for

Surgery in Patients with Congenital Fibrinogen DeficiencyC. Ross1, B. Madan2, M. Karimi3, T. Lissitchkov4, B.A. Schwartz5, S. Knaub6, F. Peyvandi7 (1India, 2United Kingdom, 3Iran, Islamic Republic of, 4Bulgaria, 5United States, 6Switzerland, 7Italy)

PB 1752 Congenital FXIII Deficiency in Pakistan: An Update

M. Borhany1, N. Fatima1, M. Abid1, T. Shamsi1, V. Schroeder2, H.P. Kohler2 (1Pakistan, 2Switzerland)

PB 1753 Pharmacokinetics of Fibrinogen Concentrate and Efficacy in Treating Acute

Bleeding in Children and Adolescent Patients with Congenital Fibrinogen DeficiencyM. Karimi1, C. Ross2, G.R. De Angulo3, B.A. Schwartz3, C. Solomon4, F. Peyvandi5 (1Iran, Islamic Republic of, 2India, 3United States, 4Switzerland, 5Italy)

PB 1754 Factor XIII in Tears and its Possible Role in Corneal Wound Healing

Z.Z. Orosz, Á. Szöőr, Z. Veréb, Z. Hassan, É. Katona, G. Vereb, A. Facskó, L. Muszbek (Hungary)

PB 1755 A Role for Factor XIII in Clot Formation and Clot Contraction of Whole Blood

T. Plug, H.M. van Beusekom, R. van Bruggen, J.C.M. Meijers (The Netherlands) PB 1756 Structural and Phylogenetic Analysis of Coagulation Factor XIII Explains its

Uniqueness in the Transglutaminase FamilyA. Biswas1, D. Davray2, S. Singh1, V. Ivaskevicius1, H. Philippou3, J. Oldenburg1 (1Germany, 2India, 3United Kingdom)

PB 1757 In silico Analysis of Extended Promoter Regions of F13A1 and F13B Genes Indicates Putative Sites Might Underlie Regulatory Variation in Factor XIII LevelsM.A. Jamil1, S. Singh1, V. Ivaskevicius1, J. Dodt1, H. Philippou2, J. Oldenburg1, A. Biswas1 (1Germany, 2United Kingdom)

PB 1758 Fibrinogen Caracas IX a Novel Fibrinogen Mutation: FGA g. 3057 C>T (p. 104 Arg>Cys) Impair Fibrinogen SecretionR. Marchi1, M. Linares1, H. Rojas1, A. Ruiz-Sáez1, M. Meyer2, S. Brennan3 (1Venezuela, 2Germany, 3New Zealand)

PB 1759 Effect of Mutations in the Fibrinogen αR95G96D97 Sequence on Clot Structure and on the Interaction of Fibrinogen with Red Blood CellsA. Sabban1, C. Duval1, A.F. Guedes2, H. McPherson1, F. Macrae1, S. Saha1, R. Ajjan1, N.C. Santos2, R.A.S. Ariens1 (1United Kingdom, 2Portugal)

PB 1760 Evidence for the Presence of Cross-beta Structures in Fibrin Clots

S. Talens, F.W.G. Leebeek, D.C. Rijken (The Netherlands) PB 1761 Prevalence of Mild Factor XIII Deficiency Phenotype: Preliminary Results of a

WFH Sponsored CRGP StudyA. Biswas1, S. Singh1, N. Mir-Montazeri1, I.P. Claus1, V. Ivaskevicius1, E. Heathershaw2, H. Philippou2, P. Volkers1, J. Dodt1, J. Oldenburg1 (1Germany, 2United Kingdom)

PB 1762 Development of Fibrinogen Formulation with High Resistance to Thermal Stress

J. Son, M. Yoo, J. Kim, J. Seol, J. Choi (Republic of Korea) PB 1763 Cellular Factor XIII in Human Cornea

L. Muszbek, Z.Z. Orosz, H. Bárdos, A.H. Shemirani, B. Nagy, J. Kappelmayer, R. Ádány, A. Berta, A. Facskó (Hungary)

PB 1764 Fibrin-associated ROTEM Variables and Thrombin Generation in Patients with

Congenital Fibrinogen DefectsT. Szanto1, A. Jouppila1, E. Armstrong1, A. Casini2, R. Lassila1 (1Finland, 2Switzerland)

PB 1765 Studies to Determine Novel Interacting Partners and Functional Roles for

Factor XIII B SubunitS. Singh1, M.S. Akhter1, V. Ivaskevicius1, A. Reuter1, J. Dodt1, H. Philippou2, J. Oldenburg1, A. Biswas1 (1Germany, 2United Kingdom)

PB 1766 The Effect of Factor XIII Levels and Factor XIII B Subunit Polymorphisms on

the Risk of Venous ThromboembolismZ.A. Mezei, É. Katona, J. Kállai, Z. Bereczky, L. Somodi, B. Kovács, T. Miklós, É. Ajzner, L. Muszbek (Hungary)

PB 1767 Novel Immunoassay Reagent for Fibrinogen without Cross-reactivity to FgDP

and XDP in PlasmaY. Magari (Japan)



414 415

Wed

nesd

ayP

oste

r S

essi

ons

PB 1768 Galactosemia Presenting with AfibrinogenemiaF. Gümrük, İ. Yaman Bajin, S. Aytaç, T. Çelik, Ş. Yiğit, M. Çetin, A. Tokatlı (Turkey)

PB 1769 Plasma Tromboelastometry (ROTEM) Could be a Complement in Study

Fibrinogen DisordersA.B. Vilaseca, R. Barbera, G. Vidmar, G. Begue, H. Beccari (Argentina)

PB 1770 A Fibrinogen Activity Method on Photo-optical Coagulation Analyzers without

Interference from Hydroxyethyl StarchZ. Cao, A. Belanger, J. Mathew, C. Kung, R. Bottenus (United States)


PB 1771 Construct and Known Group Validity of Patient-reported Outcome (PRO) Instruments in US Adults and Caregivers of Children with Hemophilia B: Results from the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) StudyT. Buckner, R. Sidonio Jr, M. Witkop, C. Guelcher, D. Clark, W. Owens, N. Frick, N. Iyer, D. Cooper (United States)

PB 1772 High and Sustained Observed trough FIX Activity Levels with Prophylactic

Dosing of IDELVION (rFIX-FP) in Patients with Hemophilia BG. Castaman1, J.C. Gill2, J. Roberts2, J. Jochems2, Y. Li2, W. Seifert2 (1Italy, 2United States)

PB 1773 Pharmacokinetics of Recombinant Fusion Protein Linking Activated Factor VIIa

to Human Albumin (rVIIa-FP) and Eptacog Alfa in Hemophilia Patients with InhibitorsJ. Roberts1, C. Joch2, J. Yi1, S. Puli1, J. Malanghu3, E. Santagostino4 (1United States, 2Germany, 3South Africa, 4Italy)

PB 1774 Efficacy and Safety of rFVIIIFc Prophylaxis in Pediatric, Adolescent, and Adult

Subjects with Severe Hemophilia A over 3-4 Years: The ASPIRE StudyB. Nolan1, B.A. Konkle2, J. Mahlangu3, K.J. Pasi4, D. Perry4, S. Rangarajan4, G. Young2, S. Lethagen5, L.M. Cristiano2, H. Yuan2, A. Ramirez-Santiago2 (1Ireland, 2United States, 3South Africa, 4United Kingdom, 5Sweden)

PB 1775 Comparing the One-stage and Chromogenic Assay: Factor VIII Activity Assay

Discrepancy at Baseline Does Not Reflect Assay Discrepancy after DDAVP in Non-severe Hemophilia AL.M. Schütte, I. Van Moort, S.C.M. Stoof, M.P.M. De Maat, F.W.G. Leebeek, M.H. Cnossen, M.J.H.A. Kruip (The Netherlands)

PB 1776 Risk Differential in Inhibitor Development in the First Days of Treatment by Product Class: A SIPPET AnalysisF. Peyvandi1, A. Cannavò1, I. Garagiola1, R. Palla1, F.R. Rosendaal2, A. El-Beshlawy3, M. Elalfy3, V. Ramanan4, P. Eshghi5, S. Hanagavadi4, R. Varadarajan4, M. Karimi5, M.V. Manglani4, C. Ross4, G. Young6, T. Seth4, S. Apte4, D.M. Nayak4, E. Santagostino1, M.E. Mancuso1, A.C. Sandoval Gonzalez7, J.N. Mahlangu8, S. Bonanad Boix9, M. Cerqueira10, N.P. Ewing6, C. Male11, T. Owaidah12, V. Soto Arellano13, N.L. Kobrinsky6, S. Majumdar6, R. Perez Garrido9, A. Sachdeva4, M. Simpson6, M. Thomas4, E. Zanon1, B. Antmen14, K. Kavakli14, M.J. Manco-Johnson6, M. Martinez15, E. Marzouka13, M.G. Mazzucconi1, D. Neme15, A. Palomo Bravo9, R. Paredes Aguilera7, A. Prezotti10, K. Schmitt11, B.M. Wicklund6, B. Zulfikar14, P.M. Mannucci1 (1Italy, 2The Netherlands, 3Egypt, 4India, 5Iran, Islamic Republic of, 6United States, 7Mexico, 8South Africa, 9Spain, 10Brazil, 11Austria, 12Saudi Arabia, 13Chile, 14Turkey, 15Argentina)

PB 1777 Pocket Handheld Ultrasound Has High Accuracy in Identification of Effusions

and Major Landmarks in Normal and Hemophilic Joints: Expanding Point of Care for Patients with Hemophilia with Joint DiseaseJ.Y. Zhou, K.C. Rappazzo, L. Volland, M. Brackman, B. Steiner, R. Kruse-Jarres, D.V. Quon, C. Bailey, E.Y. Chang, A. von Drygalski (United States)

PB 1778 Influence of Family History on Mode of Delivery in Severe Haemophilia in the UK

E. Chalmers1, J. Alamelu1, P. Collins2, M. Mathias1, J. Payne1, M. Richards1, O. Tunstall1, M. Williams1, B. Palmer1, UKHCDO Paediatric Working Party (1United Kingdom, 2United Arab Emirates)

PB 1779 Inhibitor Development in Previously Untreated Patients Treated with Octocog

Alfa (ADVATE)A. Gringeri, K. Steinitz-Trost, H. Chehadeh (Austria)

PB 1780 Predictors of Patients with 0 Bleeds during Every-7-days Prophylaxis with BAY

94-9027 in PROTECT VIIIP.A. Holme1, M. Wang2, K. Saxena2, J. Caicedo2, L.A. Michaels2, on behalf of the PROTECT VIII investigators (1Norway, 2United States)

PB 1781 Individualizing Hemophilia Prophylaxis using Thromboelastography (TEG)

R. Carmona, H.S. Lee, E. Marquez, G. Young (United States) PB 1782 Impact of a Product-Specific Reference Standard for the Measurement of a

PEGylated rFVIII Activity: The Swiss Multicentre Field StudyO. Bulla, A. Poncet, L. Alberio, L. Asmis, A. Gähler, L. Graf, M. Nagler, J.-D. Studt, D. Tsakiris, P. Fontana (Switzerland)



416 417

Wed

nesd

ayP

oste

r S

essi

ons

PB 1783 Long-term Quality-of-Life Outcomes with rFVIIIFc Prophylaxis in Adult Subjects with Severe Hemophilia AJ. Su1, E. Tsao1, J. Feng1, K.-J. Myren2, D. Glazebrook1 (1United States, 2Sweden)

PB 1784 Bleeding Events and Safety Outcomes in Persons with Hemophilia A (PwHA)

with Inhibitors: The First Large, Prospective, Multicenter, Non-interventional Study (NIS) from a Real World SettingJ. Mahlangu1, J. Oldenburg2, M. Callaghan3, M. Shima4, E. Santagostino5, M. Moore3, M. Recht3, C. Garcia6, R. Yang7, M. Lehle8, H. Macharia8, E. Asikanius8, G. Levy3, R. Kruse-Jarres3 (1South Africa, 2Germany, 3United States, 4Japan, 5Italy, 6Costa Rica, 7China, 8Switzerland)

PB 1785 Disparities in Age at Diagnosis and Initial Treatment between People with

Moderate and Severe Haemophilia A: Evidence from the KAPPA RegisterM. Osooli1, F. Sahin2, Y. Walli3, C. Ar2, P. Holme4, S. Saulyte-Trakymiene5, L. Hvitfeldt6, M. Holmström1, E. Gouider7, A. Khelif7, O. Kassar7, S. Rauchensteiner8, K. Steen Carlsson1, J. Astermark1, E. Berntorp1, KAPPA Register Study (1Sweden, 2Turkey, 3Oman, 4Norway, 5Lithuania, 6Denmark, 7Tunisia, 8Switzerland)

PB 1786 Low Dose Prophylaxis for Children With Haemophilia - One Year Experience

from a Haemophilia Comprehensive Treatment Centre, Kerala, IndiaN. Sidharthan, R. Sudevan, V. Narayana Pillai, S. Mathew, M. Raj, D. Viswam, C. Joseph, A. Sudhakar (India)

PB 1787 Final Results from the PUP-GCP Clinical Trial: A Low Inhibitor Rate in

Previously Untreated Patients with Severe Haemophilia A Treated with OctanateA. Klukowska1, M. Jansen2, V. Komrska3, V. Vdovin4, L. Belyanskaya5, P. Laguna1 (1Poland, 2Austria, 3Czech Republic, 4Russian Federation, 5Switzerland)

PB 1788 Intracranial Hemorrhage in Hemophilia Patients: The Status of Ongoing

Retrospective-Prospective Italian Registry (2009-2016)E. Zanon, F. Demartis, A. Tagliaferri, P. Schinco, I. Cantori, M. Milan, A.C. Molinari, C. Biasoli, A. Coppola, G. Castaman, M. Luciani, G. Sottilotta, E. Santagostino (Italy)

PB 1789 Evaluation of Outcomes from Long-term Prophylaxis or Episodic Treatment of

Patients with Haemophilia A: A Systematic ReviewC. Sima1, J. Frimpter1, F. Paliargues2, P. Chu2, I. Presch2 (1United States, 2Switzerland)

PB 1790 Comparison of the Relationship between Factor IX Activity and Bleeding Risk during Prophylaxis with Nonacog Beta Pegol (N9-GP)G. Young1, W.H.O. Clausen2, C. Négrier3, B.B. Rønn2, E. Santagostino4, J. Oldenburg5 (1United States, 2Denmark, 3France, 4Italy, 5Germany)

PB 1791 Efficacy of rVIII-SingleChain in the Treatment of Adult and Adolescent Patients

with Severe Hemophilia A in EuropeR. Klamroth1, J. Oldenburg1, P. Chowdary2, M. von Depka-Prondzinski1, D. Bensen Kennedy3, I. Pabinger4 (1Germany, 2United Kingdom, 3United States, 4Austria)

PB 1792 Chronic Liver Disease in Elderly People with HemophiliaC. Qvigstad1, R.C. Tait2, S. Rauchensteiner3, C. Combescure4, E. Berntorp5, P. de Moerloose4, R. Schutgens6, P.A. Holme1 (1Norway, 2United Kingdom, 3Germany, 4Switzerland, 5Sweden, 6The Netherlands)

PB 1793 Once Weekly Rfix Prophylaxis for Severe-Phenotype Haemophilia B in Normal

Clinical Practice: Data from UKHCDO and FinlandM. Scott1, V. Nummi2, R. Lassila2, H. Xiang1, C. Hay1 (1United Kingdom, 2Finland)

PB 1794 Pharmacokinetic Guided Personalized Prophylaxis with Human-cl rhFVIII in

Adult Patients with Severe Hemophilia AC. Kessler1, M. Shima2, A.-E. Armstrong3, J. Bichler4, S. Knaub4, G. Pezeshki1, M. Wang1, J. Ducore1 (1United States, 2Japan, 3Finland, 4Switzerland)

PB 1795 Application of Pharmacokinetic-tailored Approach to Prophylaxis in Routine

Hemophilia CareS.E. Croteau, E.J. Neufeld (United States)

PB 1796 Prevalence of Cerebral Microbleeds and Macrobleeds in Neurologically

Asymptomatic Patients of Congenital HemophiliaP. Malhotra, S. Kumar, S. Mahi, J. Ahluwalia, P. Singh, V. Suri, S. Kumari, N. Varma, S. Varma (India)

PB 1797 Long-term Safety and Efficacy of Recombinant Factor VIII Fc (rFVIIIFc) for the

Treatment of Severe Haemophilia A: European Subgroup Interim Analysis of the ASPIRE StudyB. Nolan1, J. Oldenburg2, G. Castaman3, I. Woźnica-Karczmarz4, B. Winding5, J. Szamosi5, S. Lethagen5 (1Ireland, 2Germany, 3Italy, 4Poland, 5Sweden)

PB 1798 Evaluation of the Impact of Polymorphism/Mutations in Genes Associated to

Hemostasis in Clinical Diversity in Patients with Severe HemophiliaF.M.L. Fonseca, N. Temba, L.M.M. Oliveira, M.V.A. Amorim, M.G. Carvalho, D.G. Chaves (Brazil)



418 419

Wed

nesd

ayP

oste

r S

essi

ons

PB 1799 The Influence of F8 Mutation and Thrombophilic Genetic Markers on Bleeding Phenotype of Patients Affected with Severe Hemophilia A in the SIPPET CohortA. Cannavò1, S. Spena1, R. Palla1, I. Garagiola1, A. El-Beshlawy2, M. Elalfy2, V. Ramanan3, P. Eshghi4, S. Hanagavadi3, R. Varadarajan3, M. Karimi4, M.V. Manglani3, C. Ross3, G. Young5, T. Seth3, S. Apte3, D.M. Nayak3, E. Santagostino1, M.E. Mancuso1, A.C. Sandoval Gonzales6, J.N. Mahlangu7, S. Bonanad8, M. Cerqueira9, N.P. Ewing5, C. Male10, T. Owaidah11, V. Soto Arellano12, N. L. Kobrinsky5, S. Majumdar5, R. Perez Garrido8, A. Sachdeva3, M. Simpson5, M. Thomas3, E. Zanon1, B. Antmen13, K. Kavakli13, M.J. Manco-Johnson5, M. Martinez14, E. Marzouka12, M.G. Mazzucconi1, D. Neme14, A. Palomo Bravo8, R. Paredes Aguilera6, A. Prezotti9, K. Schmitt10, B.M. Wicklund5, B. Zulfikar13, F.R. Rosendaal15, P.M. Mannucci1, F. Peyvandi1 (1Italy, 2Egypt, 3India, 4Iran, Islamic Republic of, 5United States, 6Mexico, 7South Africa, 8Spain, 9Brazil, 10Austria, 11Saudi Arabia, 12Chile, 13Turkey, 14Argentina, 15The Netherlands)

PB 1800 Extensions of F9 Mutation Spectrum and Genotype-phenotype Heterogeneity in

Haemophilia BM.T.M. Khan, A. Naz, J. Ahmed, T. Sultan Shamsi, S. Ahmed, N. Ahmed, A. Imran, N. Farooq, M.T.H. Khan, A.S. Taj (Pakistan)

PB 1801 Evaluate the Situation Diagnosis and Treatment of Hemophilia in Vietnam in

2015T.M. Nguyen (Viet Nam)

PB 1802 Low Dose (20 iu/kg/week) Single Infusion Prophylaxis per Week Using Long

Acting FVIIIc (ELOCTATE, Biogen) in Severe Hemophilia A: A Cost Effective & Feasible Protocol for Resource Constraint SituationS. Apte, A. Joshi, K. Subramanian, R. Dange, R. Phatale (India)

PB 1803 Development of the Education Interventions to Enhance Adherence to

Prophylactic Treatment in Korean Hemophilia PatientsE.J. Choi, H.-J. Yoon, S.K. Park, S.K. Kim, K.Y. Yoo, J.Y. Kim (Republic of Korea)

PB 1804 Immune Tolerance Induction in Patients with Haemophilia using Fc Fusion

Recombinant Factor VIIIA. Nagao, H. Katayama, K. Amano (Japan)

PB 1805 Spectrum and Origin of Mutations in Sporadic Cases of Haemophilia A in China

Y. Lu (China)

PB 1806 The Utility of Activated Partial Thromboplastin Time Clot Wave Form Analysis in the Investigation of Hemophilia A Patients Using Destiny Max TM AnalyzerA. Abraham1, P.O. Sevenet2, M.-L. Delalande2, H.F. Margaret1, T. Geevar1, S. Singh1, R. V1, S. Deivasigamani1, S.C. Nair1 (1India, 2France)

PB 1807 Pharmacokinetics of Octocog α in Severe Hemophilia A Boys Aged Less than Six Years on Routine ProphylaxisT. Urasinski, T. Ociepa, W. Badowska, H. Bobrowska, Ł. Dakowicz, G. Dobaczewski, G. Karolczyk, A. Klukowska, A. Kołtan, M. Kostrzewska, P. Łaguna, W. Młynarski, D. Wasiński, M. Wlazłowski, I. Woźnica-Karczmarz, S. Woźniak (Poland)

PB 1808 The World Bleeding Disorders Registry: The Pilot Study

G.F. Pierce1, A. Iorio1, J. O'Hara2, S. Diop3, R. Hollingsworth2, A. Srivastava4, D. Lillicrap1, H.M. van den Berg5, C. Herr1, D. Coffin1 (1Canada, 2United Kingdom, 3Senegal, 4India, 5The Netherlands)

PB 1809 Data from the Austrian Haemophilia Registry: An Update

J. Rejtö, S. Reitter-Pfoertner, S. Kepa, S. Oberbichler, G. Schuster, W. Streif, C. Male, W. Muntean, A. Hoerbst, P. Neumeister, C. Feistritzer, I. Pabinger (Austria)

PB 1810 Application of the Pattern and Parameters of the aPTT Clot Reaction Curve in

Patients with Hemophilia A and Acquired HAR.E. Sueldo, R. Porsella, G. Guerrero, P. Do Nascimento, A. Baques, M.D.V. Arias (Argentina)

PB 1811 Secondary and Tertiary Prophylaxis in Patients Haemophiliacs, Update from

Algiers Experience about One CenterM. Bensadok, N. Ferroudj, K.W. Chennoukh, N. Zidani, T. Zidouni, M. Ramaoun, M. Belhani, S. Nekkal (Algeria)

PB 1812 Personalized Treatment in Hemophilic Patients in Argentina

A. Baques, R.E. Sueldo, G. Guerrero, P. Do Nascimento, K. Santiso, M.D.V. Arias (Argentina)

PB 1813 Global Hemostatic Assay at Different Target Procoagulant Activity of Factor VIII

and Factor IXK. Yoo, H. Yoon (Republic of Korea)

PB 1814 The Impact of Secondary and Tertiary Prophylaxis in the Reduction of Bleeding

Events in Moderate or Severe Hemophilia A or BK.B. Mendonca, B. Alvarez (Brazil)

PB 1815 New Methods of Physiotherapy in Patients with Advanced Haemophilic Arthropathy

J. Zawilski, A. Dudek, K. Zawilska (Poland)

PB 1816 High Adherence in Adult and Pediatric Patients with Hemophilia B Receiving Prophylaxis with rIX-FPE. Santagostino1, G. Kenet2, J. Oldenburg3, A. Chan4, L. Boggio5, C. Altisent6, W. Seifert3, the PROLONG-9FP Investigators (1Italy, 2Israel, 3Germany, 4Canada, 5United States, 6Spain)



420 421

Wed

nesd

ayP

oste

r S

essi

ons

PB 1818 PROTECT VIII: Can Patient Characteristics Predict Eligibility for Less-frequent Prophylaxis Dosing Regimens?J. Oldenburg1, L.A. Michaels2, M. Wang2, O. Afonja2, on behalf of PROTECT VIII investigators (1Germany, 2United States)

PB 1819 Is Intermediar Intensity Prophylaxis with Factor VIII Sufficient for Improvement of Overall Hemostasis Potential in Hemophilia A Patients?I. Djunic1, V. Dopsaj1, I. Elezovic1, P. Miljic1, M. Mitrovic1, A. Novkovic1, N.M. Hourani Soutari2, J.P. Antovic2 (1Serbia, 2Sweden)

PB 1820 Can Tertiary Prophylaxis Bring about Zero Bleed in Adult Persons with

Hemophilia? A Single Center Observation Study in JapanT. Fujii, T. Fujii, N. Yamasaki, S. Saito (Japan)

PB 1821 Personalized Treatment of Pediatric Patients with Severe Haemophilia A.

Importance of Pharmacokinetics. Assessment Benefits from Kinetics of Factor VIII (Simoctocog Alpha)E. Spallino, G. D'Antona, V. Dicembre, F. Gagliano (Italy)

PB 1822 Splenectomy for Liver Cirrhosis Improved Systemic Condition in HIV/HCV Co-

infected Patients with HemophiliacsH. Katayama (Japan)

PB 1823 Two Effective Cases of Immune Tolerance Induction Using Turoctocog Alfa

Combined with Immunosuppressive Therapy in Non-severe Hemophilia AC. Yushi, K. Amano, Y. Kamikubo, A. Ichiki, M. Bingo, T. Hagiwara, T. Suzuki, K. Fukutake (Japan)

PB 1824 Tailored Prophylaxis: A Bridge between QoL and Retrenchment. Our Experience

with Simoctocog AlfaJ. Agnelli Giacchello, A. Valpreda, E. Dosio, M. Boccadoro, A. Borchiellini (Italy)

PB 1825 Therapeutic Efficacy of Low-dose Immune Tolerance Inductionin 5 Chinese

Severe Hemophilia A Children with Inhibitor in Good RiskY. Li, G. Li, Z. Chen, X. Wu, Y. Zhen, L. Tang, R. Wu (China)

PB 1826 Efficiency of Prophylaxis in an Adult with Hemophilia after Dose Adjustment

Using a Bayesian Model FVIII Pharmacokinetics EstimationM. Canaro, B. Galmes (Spain)

PB 1827 Evaluating the Frequency of Haemophilia and Bleeding Parameters of Persons with Bleeding Disorder in South East, NigeriaT. Nwagha, S. Okparoka (Nigeria)

PB 1828 Personalized Approach to Treatment due to Pharmacokinetic Study: Description of One Case of Moderate Haemophilia A with Severe Bleeding Phenotype after Switch to Simoctocog AlfaC. Ambaglio, M. Russo, F. Zane, C. Sacco, E. Genini, P.S. Preti, G. Gamba (Italy)

PB 1829 Haemophilia and Acute Coronary Syndrome (ACS)

A.M. Pizzini, D. Galimberti, M.C. Leone, A. Casali, A. Ghirarduzzi (Italy) PB 1830 The Diagnostic Value of Rotational Thromboelastometry in Patients with Non-

severe Hemophilia AF. Vossough, M. Ahmadinejad, G. Toogeh, M.R. Managhchi (Iran, Islamic Republic of)

PB 1832 Hemophilia Care in Pakistan

M. Borhany, M. Abid, N. Fatima, T. Shamsi (Pakistan) PB 1833 Risk Management of Pelvic Pseudotumor in a Patient with Inhibitors and

Severe HemophiliaR. Silva, J. Marun, D. Perez (Colombia)

PB 1834 A Study of Home Therapy in Hemophilia Patients

K. Mikyung, Y. Gippi (Republic of Korea) PB 1835 Are we Close to International Standards for Hemophilia Care in Tunisia?

H. Elmahmoudi, M. Achour, H. Ben Neji, K. Zahra, W. Hosni, B. Meddeb, E. Gouider (Tunisia)

PB 1836 TAURUS: A Multinational Phase 4 Study Evaluating Real-world Treatment

Patterns in Previously Treated Persons with Hemophilia A Receiving BAY 81-8973 for Routine ProphylaxisK. Meijer1, U. Scholz2, B. Siegmund2, E.A.M. Beckers1, K. Batt3, S. Jain3, S. Rybowski3, E. Kellermann2, O. Afonja3, E. Musi4 (1The Netherlands, 2Germany, 3United States, 4Switzerland)


PB 1837 Natriuretic Peptides for Detection of Heart Failure in Patients with Atrial Fibrillation? An IPD Analysis of Opportunistic Screening Studies from the CommunityS. van Doorn, G.-J. Geersing, R.F. Kievit, Y. van Mourik, L.C. Bertens, E.E.S. van Riet, L.J.M. Boonman-Winter, K.G.M. Moons, A.W. Hoes, F.H. Rutten (The Netherlands)



422 423

Wed

nesd

ayP

oste

r S

essi

ons

PB 1838 Direct Oral Anticoagulants (DOAC) vs Low Molecular Weight Heparin (LMWH) as Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation (NVAF) and Concomitant Active CancerA. Varela-Magallon, P. Olivera, G. Oristrell, J. Limeres, E. Johansson, T. Canals, V. Pons, F. Bosch, A. Santamaria (Spain)

PB 1839 Thrombin Generation and International Normalized Ratio in Patients with Atrial

Fibrillation Using Rivaroxaban or WarfarinR.C.F. Duarte, D.R.A. Rios, S.M. Rezende, L.L. Jardim, J.R.S. Caiaffa, F.R. Silveira, E. Reis, C.N. Ferreira, F.F.M. Campos, M.G. Carvalho (Brazil)

PB 1840 Variation of Renal Function during Treatment with Direct Oral Anticoagulants and Risk of Major Bleeding in Patients with Non-balvular Atrial FibrillationM. Giustozzi, C. Becattini, M.G. Ranalli, G. Bogliari, F. Cianella, G. Agnelli, M.C. Vedovati (Italy)

PB 1841 Global Public Awareness about Atrial Fibrillation

A. Wendelboe1, P. Angchaisuksiri2, A. Blanco3, H. Ddungu4, J. Dvorak1, B. Hunt5, E. Hylek1, A. Kakkar5, S. Konstantinides6, M. McCumber1, C. McLintock7, T. Urano8, H. Buller9, J. Weitz10, G. Raskob1 (1United States, 2Thailand, 3Argentina, 4Uganda, 5United Kingdom, 6Germany, 7New Zealand, 8Japan, 9The Netherlands, 10Canada)

PB 1842 VKA Treatment and Bleeding Rate of Patients Aged Older than 90 Years:

Results from a Prospective Multicentre START Register StudyD. Poli, E. Antonucci, S. Fumagalli, L. Migliaccio, F. Marongiu, A. Tripodi, V. Pengo, S. Testa, G. Palareti, START-Register participants (Italy)

PB 1843 Low Performance of the CHA2DS2-VASc Rule for Predicting Stroke Risk in

Atrial Fibrillation Patients: A Systematic Review and Meta-analysisS. van Doorn, T.P.A. Debray, F. Kaasenbrood, A.W. Hoes, F.H. Rutten, K.G.M. Moons, G.-J. Geersing (The Netherlands)

PB 1844 Improving Appropriate Use of NOACs in AF: Success of Online CME

J. Spyropoulos (United States)

PB 1845 Optimisation of Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation Using a Virtual Clinic ModelA. Brown, R. Byrne, H. William, N. Hamedi, A. Hodgkinson (United Kingdom)

PB 1846 Evaluation of Antithrombotic Management in Patients with Atrial Fibrillation at

a Tertiary Care Academic Medical CenterS. Bhatt, M. Adra, J. Lacoste, E. Seoane-Vazquez (United States)

PB 1847 Recent Years Trends in Real-life Antithrombotic Therapy for In- and Out-patients with Atrial Fibrillation in MoscowA. Melekhov, G. Gendlin, E. Dadashova, E. Alekseeva, I. Zaigraev, I. Nikitin (Russian Federation)

PB 1848 Should we Abandon the APTT for Monitoring the Anticoagulant Effect of

Unfractionated Heparin?D. Jayakody Arachchillage, F. Kamani, S. Deplano, S. Fox, M. Mcevoy, L. Tillyer, M. Laffan (United Kingdom)

PB 1849 Evaluation of the 4T Score and Rapid Anti PF4/Heparin Antibodies Detection

for Heparin Induced Trombocytopenia (HIT) Diagnosis in Clinical Practice. A Multicenter StudyM.J. Villagra Iturre, N. Schütz, V. Otero, M.E. Ariscancella, A. Rossi, C. Fondevila, L.H. Barrera, M.S. Lopez, J. Oyhamburu, S. Viñuales, D. Penchasky, J. Arbelbide, M.E. Martinuzzo (Argentina)

PB 1850 Risk of Thromboembolic Disease in Renal Transplant Patients

V. Privitera, N. Schutz, S. Viñuales, V. Otero, D. Penchasky, N. Imperiali (Argentina) PB 1851 Validation of Risk Assessment Models for Venous Thrombosis in Hospitalized

Medical PatientsB. Nemeth, M. Cobben, W. Lijfering, S. Cannegieter (The Netherlands)

PB 1852 In ECMO Patients Anticoagulated with Heparin the Dose-response Relationship

Disappears when the Dose is Adjusted by ACT but it is Preserved with Anti-Xa ActivityF. Guerrero, J.M. Conil, A. Jacquemin, C. Delmas, T. Seguin, B. Marcheix, V. Memier, N. Savy, B. Georges (France)

PB 1853 AVAIL-MoNa-Study: Audit of Venous Thromboembolism Evaluation and

Management Thromboprophylaxis in Moroccan Hospitals - National LevelZ. Tazi Mezalek, Y. Elachhab, L. Essadouni, M. Samkaoui, K. Serraj, N. Kanjaa, Z. Belkhadir, B. Housni, M. Awab, M. Faroudy, W. Bono, S. Kabbaj, M. Akkaoui, M. Barakat, A. Samir, R. Rifai, C. Nejjari, A. Azzouzi (Morocco)

PB 1854 A Post Hoc Analysis of Dalteparin versus Vitamin K Antagonist (VKA) for the

Treatment of Cancer-associated Venous Thromboembolism (VTE) in High-risk Patients with Metastatic Disease and Recent Antineoplastic TreatmentS. Woodruff1, A. Lee2, M. Carrier2, G. Feugère2, P. Abreu1, J. Heissler1 (1United States, 2Canada)

PB 1855 Tinzaparin for the Treatment of Superficial Vein Thrombosis of the Lower Limbs

K. Nikolakopoulos, C. Papageorgopoulou, S. Kakkos, A. Kouri, S. Papadoulas, I. Ntouvas, G. Lampropoulos, I. Tsolakis (Greece)



424 425

Wed

nesd

ayP

oste

r S

essi

ons

PB 1856 Structural and Haemostatic Features of Pharmaceutical Heparins from Different Animal Sources: Challenges to Define Thresholds Separating Distinct DrugsM.S. Pereira, A.M.F. Tovar, G.R.C. Santos, N. Capille, B.F. Glauser, E. Vilanova, P.A.S. Mourão (Brazil)

PB 1857 The Effect of Prolongation of Initial Enoxaparin Therapy to One Month on the

Risk of VTE Recurrences and the Recanalization of Deep VeinsN. Vorobyeva, O. Ermolina, T. Balakhonova, A. Kirienko, E. Panchenko (Russian Federation)

PB 1858 Validation of the Pulmonary Embolism Severity Index (PESI) and Simplified PESI in Asian Patients with Acute Pulmonary EmbolismW.Y. Jen, P. Kojodjojo, H.E.E. Lee, Y.H. Lee, Y.P. Ren, T.J.S. Tan, Y. Song, T. Zhang, L. Teo, Y.L. Chee (Singapore)

PB 1859 Help the Aged? Are we Failing to Protect Patients with Dementia from the

Risks of Developing Hospital Associated Venous Thrombo-Embolism?A. McSorley, M.D. Creagh, A. Mabin, S. Gupta (United Kingdom)

PB 1860 The Efficacy and Safety of Anticoagulations in Cerebral Vein Thrombosis: A

Systematic Review and Meta-analysisB. Al Rawahi1, M. Almegren2, M. Carrier3 (1Oman, 2Saudi Arabia, 3Canada)

PB 1861 Study of Bioaccumulation of Tinzaparin in Renally Impaired Patients when

Given at Prophylactic Dose: The STRIP StudyD. Projean, S. Lalonde, J. Morin, E. Nogues, A. Séguin, A. Vincent, V. Masson, J.-P. Lafrance, J. Fafard, J. Kassis, M. Lordkipanidzé (Canada)

PB 1862 Thromboembolic Events Following Splenectomy: Risk Factors, Prevention,

Management and OutcomesA. Rottenstreich, G. Kleinstern, G. Spectre, N. Da'as, E. Ziv, Y. Kalish (Israel)

PB 1863 Low and High Responders to Unfractionated Heparin Can Be Distinguished in Vitro by Inhibition of Thrombin GenerationL.N. van der Vorm, H. de Haan, D. Huskens, J.A. Remijn, B. de Laat (the Netherlands)

PB 1864 Should Anticoagulation Therapy for Cancer Associated Pulmonary Embolism

(PE) Be Modified in Individuals with Brain Metastasis or Thrombocytopenia?K. Musgrave, L. Stuart, J. Hanley, P. Kesteven, J. Simpson (United Kingdom)

PB 1865 Comparison of the Injection Site Reactions Elicited by Two Subcutaneously

Injected Heparins, Nadroparin Calcium and Enoxaparin SodiumJ.J. van Tonder, S. Mathijs, J.M. Dippenaar, O. Greeff (South Africa)

PB 1866 The Incidence of Adverse Events in Patients Treated with Therapeutic Dose Enoxaparin in Relation to Body Mass IndexR.M.M. Al-Shehristani (Iraq)

PB 1867 Management of Venous Thromboembolism in Patients with Glioma

M. Almegren1, C. De Wit2, M. Carrier2 (1Saudi Arabia, 2Canada) PB 1868 Resistance of Liquid Anti-Xa Assay (IL) to Platelet Factor 4 Interference

J. Gabbeta, V. Krougliak, C. Kung, R. Bottenus, M. Triscott (United States) PB 1869 A Matched Case-control Study to Determine Early Post-operative

Haematological Complications after Renal Transplantation in Chronic Renal Failure Patients Receiving Therapeutic AnticoagulationE. Meeks, E. Thompson, P. Goldsmith, J. Sexton, S. Mehra (United Kingdom)

PB 1870 Factors Associated with Thromboembolic Events Following Cytoreductive

Surgery and Hyperthermic Intraperitoneal ChemotherapyA. Rottenstreich, Y. Kalish, G. Kleinstern, A. Ben Yaacov, J. Dux, A. Nissan (Israel)

PB 1871 Clinical Course of Patients Presenting with Acute Superficial Vein Thrombosis:

A Post-hoc Analysis of the ICARO Study on 488 PatientsF. Dentali1, S. Barco2, F. Pomero1, M.N.D. Di Minno1, G. Barillari1, M.S. Napolitano1, W. Ageno1 (1Italy, 2Germany)

PB 1872 The Assessment of Safe Prescribing and Cost-effectiveness of Low Molecular

Weight Heparin (LMWH) TreatmentJ.K. Chahal, C.Y. Zhang, V. Vakulenko, P.K. MacCallum, S. Antoniou (United Kingdom)

PB 1873 Sustained Anticoagulant Effect and High Inter-individual Variability of Treatment with Rivaroxaban. An ex vivo Analysis of Thrombin Generation and ThromboelastometryS. Salta, P. Van Dreden, E. Lefkou, H. Ketatni, A. Khaterchi, L. Papageorgiou, I. Elalamy, G. Gerotziafas (France)

PB 1874 Comparison of UFH and Enoxaparin Originated from Bovine, Ovine and Porcine

Mucosa with Functional Coagulation AssaysG. Gerotziafas1, P. Van Dreden1, W. Jeske2, J. Walenga2, D. Hoppensteadt2, M. Grusse1, A. Larsen1, I. Elalamy1, Y. Yao2, J. Fareed2 (1France, 2United States)

PB 1875 Efficacy and Safety of Pharmacological Thromboprophylactic Agents for the

Prevention of Venous Thromboembolism after Major Abdominal Surgery: A Systematic Review and Meta-AnalysisB. Al Rawahi1, G. Le Gal2, R. Auer2, M. Carrier2 (1Oman, 2Canada)



426 427

Wed

nesd

ayP

oste

r S

essi

ons

PB 1876 Comparative Anticoagulant Effects of Recombinant Thrombomodulin, Antithrombin, and Unfractionated Heparin, Hematological ImplicationsZ. Siddiqui, P. Aggarwal, O. Iqbal, D. Hoppensteadt, M. Lewis, S. Abro, K. Tsuruta, J. Fareed (United States)

PB 1877 Nuts and Bolts of Running a Pulmonary Embolism Response Team: Results

from an Organizational Survey of the National PERT™ Consortium MembersG. Barnes, J. Giri, D.M. Courtney, S. Naydenov, T. Wood, R. Rosovsky, K. Rosenfield, C. Kabrhel, National PERT Consortium Research Committee (United States)

PB 1878 Long Term Anticoagulant Treatment Management in Patients with Portal Vein Thrombosis at High Bleeding RiskM. Napolitano, S. Mancuso, S. Raso, M.R. Lanza Cariccio, M.F. Mansueto, S. Siragusa (Italy)

PB 1879 Antikoagulant Effects of New Vegetable Heparinoid

M. Lyapina, M. Grigorjeva (Russian Federation) PB 1880 Establishing the Heparin Therapeutic Range Using aPTT and Anti-Xa

Measurements for Monitoring Unfractionated Heparin TherapyA. Rashid, B. Moiz, N. Kazmi, B. Rizvi (Pakistan)

PB 1881 Patients Are More Adherent to Treatment with LMWH Nadroparin than

Enoxaparin for Cancer Related Venous ThromboembolismS. van der Wall1, F. Klok1, P. den Exter1, D. Barrios2, R. Morillo2, S. Cannegieter1, D. Jimenez2, M. Huisman1 (1The Netherlands, 2Spain)

PB 1882 Prevalence of FOXD1 Mutations in Primigravidae with Pregnancy LossJ.-C. Gris, E. Mercier, S. Bouvier, E. Cochery-Nouvellon, G. Lissalde-Lavigne (France)

PB 1883 Prothrombin Fragment F1+2 (F1F2) in Pregnancy Is Associated with a History

of Venous Thromboembolism (VTE) and ThrombophiliaR.B. Zotz, R.E. Scharf, A. Gerhardt (Germany)

PB 1884 Recurrent Venous Thromboembolism (VTE) in Pregnancy in Women with a

History of First Venous ThromboembolismA. Gerhardt, R.E. Scharf, R.B. Zotz (Germany)

PB 1885 Incidence and Risk Factors of Pregnancy-associated Venous Thromboembolism

in Singhealth, a Major Healthcare Cluster in SingaporeS.L. Jaya-Bodestyne, S.Y. Tan, C.K. Ng, T.C. Tan, L.K. Tan, J.C. Allen, Y. Yang, S.X.S. Tan, L.H. Lee (Singapore)

PB 1886 The Features of Pregnancy Management in Paroxysmal Nocturnal HemoglobinuriaM. Vinogradova, A. Kulagin, T. Kirsanova, R. Shmakov (Russian Federation)

PB 1887 High Levels of Complement C3 Increases the Risk for Postnatal Venous

ThrombosisA.E.A. Dahm, E.M. Jacobsen, A.F. Jacobsen, H. Skuterud Wik, P.M. Sandset (Norway)

PB 1888 Risk of Venous Thromboembolism in Unsuccessful ART Cycles: An Italian Cohort StudyM. Villani, D. Colaizzo, F. Cappucci, P. Totaro, G. Favuzzi, M. Margaglione, E. Grandone (Italy)

PB 1889 M2 Haplotype in Annexin A5 Gene and Antiphospholipid Antibodies: Possible Relationship and Clinical Impact in a General Obstetric PopulationM. Villani, E. Chinni, G.L. Tiscia, F. Cappucci, L. Fischetti, M. Margaglione, E. Grandone (Italy)

PB 1890 Recurrent Miscarriage Predictive Capacity Using Thrombo inCode - Recurrent

MiscarriageJ.A. Páramo, J. Bellver, P. Llamas, S. Cabanillas, R. Lecumberri, P. Alamá, A. García-Raso, A. Alfonso, V.H. Gómez, C. Miranda, C. Díaz, K. Guillén, S. Pich, I. Ortega, E. Salas (Spain)

PB 1891 Effect of Blood Loss during Caesarean Section on Coagulation

C. Thomassen1, T. Hackeng1, S. Costa1, E. Stickeler2, S. Tchaikovski2 (1The Netherlands, 2Germany)

PB 1892 Assessment of Peripartum Management in a Population at High Risk for Venous ThromboembolismC. Berens, A. Esser, J. Nadal, J. Oldenburg, B. Pötzsch, H. Rühl (Germany)

PB 1893 Role of ADAMTS-13 Activity and Inhibitor Monitoring during Pregnancy in

Women with History of Severe PreeclampsiaV. Bitsadze, S. Akinshina, A. Makatsariya (Russian Federation)

PB 1894 Assessment of Annexin A5 and Annexin A2 Levels as Biomarkers for Pre-

eclampsia: A Pilot StudyM. Abd El-Latif1, H. Azzam1, M. Othman2, O. Warda1, S. El-Sharawy1, H. Ghoneim1 (1Egypt, 2Canada)

PB 1895 Attenuated Thrombin Generation and Enhanced Fibrinolytic Activity in Early

Onset PreeclampsiaK. Egan1, H. O'Connor1, C. Monteith1, K. Parmar2, B. Kevane1, E. Tully1, F. Malone1, E. Dunne1, D. Kenny1, P. Maguire1, P. Szklanna1, S. Allen1, N. Mc Callion1, B.J. Hunt2, F. Ni Ainle1 (1Ireland, 2United Kingdom)



428 429

Wed

nesd

ayP

oste

r S

essi

ons

PB 1896 Management of Venous Thromboembolism in Women during Pregnancy and Puerperium (SAVE): A cross-sectional registry in Africa, Eurasia, Middle East and South AsiaJ.-C. Gris, J. Aoun, SAVE Study Group (France)

PB 1897 Genetic Variants Associated with Thrombophilia and Gestational Complications

in an Argentinian CohortG. de Larrañaga, F. Aranda, S. Udry, M. Moiana, A. Lucero, V. Lara, O. Latino, S. Perés (Argentina)

PB 1898 Risk Factors for Venous Thromboembolism and Pregnancy Outcomes in Women

with Pelvic Vein Thrombosis during Pregnancy - A Retrospective Study from a Stockholm Cohort, Ranging from 2000 to 2014R. Chaireti, S. Lundgren Hinnerdal, K. Bremme (Sweden)

PB 1899 Maternal Carriage of the Annexin A5 M2 Haplotype is Associated with a Higher

Risk of Suffering from Gestational Vascular ComplicationsF. Aranda1, S. Udry1, S. Perés1, L.C. Amshoff2, N. Bogdanova2, P. Wieacker2, M. Moiana1, J.O. Latino1, G. de Larrañaga1, A. Markoff2 (1Argentina, 2Germany)

PB 1900 Pregnancy-associated Hemolytic Uremic Syndrome as a Cause of Maternal

MortalityT. Kirsanova, M. Vinogradova (Russian Federation)

PB 1901 The Role of Acquired von Willebrand Syndrome in Bleeding during Pregnancy

and Cesarean Section in Patients with Hereditary Connective Tissue Diseases (Marfan Syndrome, Ehlers-Danlos Syndrome, Hereditary Hemorrhagic Telangictasia)L. Radetskaya, A. Makatsariya, O. Kaplina (Russian Federation)

PB 1902 Impact of Blood Hypercoagulability on in vitro Fertilization Outcomes: A

Prospective Longitudinal Observational StudyP. Van Dreden, E. Lefkou, E. Mathieu d'Argent, M. Grusse, M. Comtet, R. Sangare, H. Ketatni, A. Larsen, I. Elalamy, G. Gerotziafas (France)

PB 1903 Women with Homozygous AT Deficiency Type II Heparin Binding Site (HBS)

Are at High Risk of Pregnancy Loss and Pregnancy ComplicationsJ. Kraft, R. Sunder-Plassmann, P. Quehenberger, G. Tews, M. Langer, I. Pabinger (Austria)

PB 1904 Use of Intravenous Immunoglobulin in the Antenatal Management of

Haemolytic Disease of the Fetus and Newborn (HDFN): A Case Series from the East Midlands, United KingdomG. Swallow, B. Myers, J. Davis, A. Dillon, E. Millen, A. Mahendru (United Kingdom)

PB 1905 Genetic Hypofibrinolysis, Fetal Loss Syndrome and Pro-inflammatory Status in Women with Metabolic SyndromeT. Pshenichnikova, E. Perederyaeva (Russian Federation)

PB 1906 Venous Thromboembolism in Women Undergoing Assisted Reproduction: Data

from RIETEE. Grandone1, M. Villani1, D. Colaizzo1, C. Fernández-Capitán2, J. Del Toro2, V. Rosa2, A. Bura-Riviere3, I. Quere3, P. Di Micco1, A. Blanco-Molina2, M. Monreal2, RIETE Investigators (1Italy, 2Spain, 3France)

PB 1907 Outcomes of Threatened Abortions Following Anticoagulation Treatment to

Prevent Recurrent Pregnancy LossA. Rottenstreich, G. Kleinstern, H. Amsalem, Y. Kalish (Israel)

PB 1908 OTTILIA and FIRST: Preliminary Data from Two Ongoing International

Registries on Foeto-maternal Prognosis in Women with Recurrent Reproductive Failures after Spontaneous or Assisted ConceptionM. Villani1, G. Larciprete1, M. Kovac2, I. Martinelli1, E. Tamborini Permunian1, R. Cacciola1, G. Lo Pinto1, E. Bucherini1, V. De Stefano1, C. Lodigiani1, T. Bartolotti1, P. Totaro1, D. Carone1, D. Baldini1, J.-C. Gris3, B. Brenner4, M. Monreal5, E. Grandone1 (1Italy, 2Serbia, 3France, 4Israel, 5Spain)

PB 1909 Efficacy and Safety of Treatment with High Dose Thromboprophylaxis in Pregnant Women - A Retrospective Study from a Stockholm Cohort, Ranging from 2004 to 2014R. Chaireti, A. Lannemyr, L. Thyni, K. Bremme (Sweden)

PB 1910 Thromboelastography Analysis of Haemostasis in Pre-eclamptic, Hypertensive

and Normotensive Pregnant and Non-Pregnant WomenE. Murray, M. Murphy, G.N. Smith, C.H. Graham, M. Othman (Canada)

PB 1911 Pregnancy Loss in APA-positive Women

D. Khizroeva, N. Makatsariya, N. Stuleva, N. Khamani (Russian Federation) PB 1912 Obesity and Thromboembolic Risk during Hospitalization in Pregnancy:

Preliminary ResultsV. Barros, A.M. Igai, M.R. Bortolotto, R. Francisco, M. Zugaib, Thrombosis and thrombophilia in pregnancy (Brazil)

PB 1913 Management of a Pregnant Patient with Antithrombin Deficiency and Acute

Venous ThromboembolismJ. Hews-Girard, L. Skeith, N. Rydz (Canada)

PB 1914 Prevalence of FOXD1 Mutations in the Obstetric Antiphospholipid Syndrome

J.-C. Gris, E. Mercier, S. Bouvier, E. Cochery-Nouvellon, G. Lissalde-Lavigne (France)



430 431

Wed

nesd

ayP

oste

r S

essi

ons

PB 1915 Management of Pregnancy in Cobalamin C Defect Causing Homocystinuria and Methylmalonic AciduriaE. Grandone, M. Villani, G. Vecchione, A. Leccese, R. Santacroce, P. Martinelli, G.M. Maruotti, L. Fischetti, G. Corso, M. Margaglione (Italy)

PB 1916 Clinical Value of Antiphospholipid Antibodies Assesment in Women Undergoing

IVF with History with IVF FailureD. Khizroeva, N. Stuleva, N. Makatsariya, N. Khamani (Russian Federation)

PB 1917 Antiphospholipid Antibodies in Women with of Severe Preeclampsia

D. Khizroeva, V. Bitsadze, N. Makatsariya (Russian Federation) PB 1918 The Clinical Significance of Determining the Activity and Inhibitor of

Adamts-13 in the Management of Pregnant Women with Severe Preeclampsia and Thrombotic Microangiopathy HistoryA. Makatsariya, V. Bitsadze, D. Khizroeva (Russian Federation)

PB 1919 Different Approaches of Thromboprophylaxis during Pregnancy in the Routine

Clinical Practice. Results from the TEAM ProjectA. Santamaria, E. Marti, TEAM Project of the SETH (Spain)

PB 1920 In the TEAM PROJECT, the Management of Placental-mediated Pregnancy

Complication (PMC) Reflects a Real Gap between Evidence-based Guidelines and Routine Clinical PracticeA. Santamaria, E. Marti, on behalf of the TEAM Porject form the SETH (Spain)

PB 1921 Risk Assessment of Venous Thromboembolism in Women Furing Pregnancy and

Puerperium (SAVE): A Cross-Sectional Registry in Africa, Eurasia, Middle East and South AsiaJ.-C. Gris, J. Aoun, SAVE study group (France)

PB 1922 Evaluation of Venous Thrombo-embolism Risk and Adequacy of Prophylaxis in

High Risk Pregnancy in Saudi Arabia (The Saudi Arabian Pregnancy Venous Thromboembolism Registry)S. Abu-Harbesh, H. Yousef, F. Al-Qahtani, M. Kolkailah, The Saudi Arabian Pregnancy Venous ThromboEmbolism Registry (Saudi Arabia)

PB 1923 Ischemic-stroke due to an Embolic Thrombus in Carotid Artery in Recent

Postpartum: Case Report and Review of the LiteratureC. Borim, V. Barros, R. Francisco, M. Zugaib (Brazil)

PB 1924 Hypodysfibrinogenemia: AChallenge in Maternity Ward - Course of Pregnancy

and a Literature ReviewJ.M. Teliga-Czajkowska, A. Sikorska, B. Ceglarek, K. Bykowska, B. Baran, E. Dmoch-Gajzlerska, K. Czajkowski (Poland)

PB 1926 Perinatal Outcomes in Women whith History of Ischemic StrokeA. Makatsariya, S. Akinshina, V. Bitsadze, D. Khizroeva, V. Nemirovski (Russian Federation)

PB 1927 Pregnancy Complications in Women with Thrombophilia and their Future

Pregnancy Outcome after Anti-coagulant TreatmentN. Dally, G. Jiries, Y. Zivony, B. Eshel, M. Kashlikov (Israel)

PB 1928 What is the Actual Role of Antiphospholipid Antibodies in Obstetric Morbidity?

L. Costa, R. Oliveita, N. Pinho, N. Seidi, F. Leite, E. Cruz, J. Braga, S. Morais (Portugal)

PB 1929 Low Molecular Weight Heparin for Women with Pathologic Evidence of

Placental MalperfusionA. Gomez-Arteaga, M.T. DeSancho (United States)

PB 1930 Pregnancy and Perinatal Outcomes in Women with History of Venous

ThromboembolismA. Makatsariya, S. Akinshina, V. Bitsadze, D. Khizroeva (Russian Federation)



PB 1931 Intracranial Haemorrhage Associated with during the Course of Extracorporeal Membrane Oxygenation for Severe Respiratory FailureD. Jayakody Arachchillage, M. Passariello, T.C. Aw, L. Owen, W. Banya, R. Trimlett, A. Kelleher, C. C Morgan, B. Patel, J. Pepper, S. Ledot (United Kingdom)

PB 1932 Classic Pathways of Fibrinolytic Activation Are Secondary in Non-traumatic

HyperfibrinolysisJ. Zipperle, S. Bahrami, H. Redl, H. Schöchl (Austria)

PB 1933 Soluble Fibrin Causes an Acquired Platelet GPVI-deficiency in Response to

Convulxin, Collagen-related Peptide and Collagen: Implications for Trauma Induced CoagulopathyS. Diamond, M. Lee, B. Herbig (United States)

PB 1934 Acquired Hemophilia A and Concomitant Factor XIII Consumption: A Case

SeriesJ. Abdulrehman, B.L. Houston, J.M. Teitel, M. Sholzberg (Canada)



432 433

Wed

nesd

ayP

oste

r S

essi

ons

PB 1935 Von Willebrand Factor and ADAMTS13 in Bothrops jararaca Envenomation: Involvement of Snake Venom Metalloproteinases and BotrocetinC. Martos Thomazini, M. Larami Santoro (Brazil)

PB 1936 Efficacy and Safety of Combined Use of aPCC and Antifibrinolytics in Acquired

Hemophilia A: Results from the FAIR RegistryE. Zanon, S. Pasca, G. Gamba, G. Giuffrida, A. Falanga, A.B. Federici, I. Cantori, S. Siragusa, M.G. Mazzucconi, G. Piseddu, A. Rocino, R.C. Santoro, C. Lodigiani (Italy)

PB 1937 Prediction of Outcome in Acquired Hemophilia A

M. Escobar, E. Donnachie (United States) PB 1938 Severe Bleeding Diatheses in an Elderly Patient due to Autoantibody against

Factor XIII A Subunit; Novel Approach to the Diagnosis and Classification of Anti-FXIII AntibodiesM. Kun1, N. Szuber2, É. Katona1, K. Pénzes1, A. Bonnefoy2, B. Bécsi1, F. Erdődi1, G.-E. Rivard2, L. Muszbek1 (1Hungary, 2Canada)

PB 1939 Usefulness of Anti-factor VIII IgG Antibodies Detection by ELISA in the

Management of Patient with Acquired Hemophilia AL. Mauge, I. Bozinovic, D. Helley, D.M. Smadja, M. Alhenc-Gelas, L. Darnige (France)

PB 1940 Pulsatility as a Modulator of Circulatory Support-related Acquired VWF Defect

A. Rauch, F. Vincent, V. Loobuyck, M. Moussa, H. Spillemaeker, N. Rousse, A. Ung, D. Corseaux, E. Jeanpierre, C. Caron, A. Dupont, A. Vincentelli, E. Van Belle, S. Susen (France)

PB 1941 Acquired von Willebrand Syndrome in Infants with Aortopulmonary Shunt

G. Wiegand, V. Icheva, U. Budde, M. Hofbeck (Germany) PB 1943 Successful Inhibitor Eradication with Ofatumumab in a Patient with Acquired

Hemophilia AR. Fischer, M. Alrifai, K. Heidinger, B. Kemkes-Matthes (Germany)

PB 1944 Individualization of Treatment with Recombinant Porcine FVIII (rpFVIII)

Depending on Inhibitor Titres in a Patient with Acquired Hemophilia A (AHA)M. Stemberger, M. Spannagl, M. Angstwurm (Germany)

PB 1946 Thrombin Generation in Healthy Controls and Patients with Cirrhosis of the

Liver: Comparison between Platelet-rich and Platelet-poor PlasmaT. Siegemund, S. Rabe, R. Siegemund, S. Petros (Germany)

PB 1947 Acquired von Willebrand Syndrome (AVWS): Diagnostic and Treatment, a Single Centre ExperienceJ. Costa Pinto Prego de Faria, M.D.C. Gómez del Castillo Solano, M. Fernández Docampo, A. Pérez Rodríguez, M.F. López Fernández (Spain)

PB 1948 Heparin-Like Substance in Patients with Dengue Infection and Prolonged

Activated Partial Thromboplastin TimeY. Chinthammitr, N. Tirachaimongkol, T. Ruchutrakool, B. Suwannawiboon, T. Akarawikrai, C. Washirasaksiri, Y. Nakkinkun, T. Binhama, S. Sonprasert (Thailand)

PB 1949 Acquired Hemophilia: Initial Presentation, Management and Outcome.

Experience of a Single Hemophilia CentreF. Vasconcelos, B. Delgado, C. Vaz, M. Carvalho, L. Gonçalves, M. Lopes, C. Koch (Portugal)

PB 1950 Two Patient Cases of Acquired Hemophilia Treated with Recombinant Porcine

Sequence FVIII (rpFVIII, OBIZUR®)E. Armstrong, E. Poikonen (Finland)

PB 1951 Acquired von Willebrand Syndrome Associated with Monoclonal Gammopathy:

Importance of Hemostasis Screening in the Preoperative Management of Three Case StudiesM. Kurdi, K. Maloum, C. Settegrana, H. Rouatbi, A. Ankri, I. Martin-Toutain (France)

PB 1952 Study of Clinical Characteristics, Laboratory Findings and Response to the

Treatment of Patient with Acquired Hemophilia in National Institute of Hematology and Blood Transfusion of VietnamT.M. Nguyen (Viet Nam)

PB 1953 Acquired Hemophilia A in China: A Result of a Multicenter, Prosepective Study

in ChinaB. Sun (China)

PB 1954 Clinical Importance of Vascular Wall Antithrombotic Activity Disorder

Detection in the Course of Hormonal Replacement Therapy (HRT) and its Pharmacological CorrectionS. Ermoshina, N. Khamani, V. Bitsadze (Russian Federation)

PB 1955 Some Haemostatic Parameters and International Normalize Ratio (INR) Values

of Patients with Snakebite Envenomation Before, During and After Treatment with Antivenom Snakebite Research, Training and Treatment Centre, General Hospital, Kaltungo, Gombe State, North-Eastern NigeriaR.A. Anyanwu, N. Mohammed (Nigeria)



434 435

Wed

nesd

ayP

oste

r S

essi

ons

PB 1957 Utility of Measurement of Plasma Thrombin Generation Using Calibrated Automated Thrombography (CAT) in the Management of Acquired HaemophiliaS.Y.M. Tan, W.H. Wong, C.W. Tan, H. Kaur, D. Tan, L.H. Lee, D. Mya, H.J. Ng (Singapore)

PB 1958 Acquired Haemophilia Patients' Journey from the Exhaustive French

Nationwide Database Collecting the Activity in Hospital (Programme of Medicalisation of the Systems of Information - PMSI)J.-F. Schved, A. Aouba, A. Borel-Derlon, J.-Y. Borg, A. Gaude, B. Guillet, H. Lévesque, B. Villette (France)

PB 1959 A Report of Clinicians' Attitude Survey of Acquired Hemophilia A for Improving

its Prognosis in JapanY. Seki, O. Nagano, H. Nemoto, T. Kasami, S. Miyakoshi (Japan)

PB 1960 An Unusually High Incidence of Acquired Haemophilia A in Two Provinces in

North-Eastern Italy in the Winters 2014 through 2016P. Pradella, M. Giavitto, G. Festini, M. Miccio, G. Boscutti, V. Di Maso, M. Vidus Rosin, L. Mascaretti (Italy)

PB 1961 Acquired Haemophilia: Overcoming Practical Challenges to Deliver Optimal

Nursing CareD. Pollard, J. Stanley, C. Harrison, K. Coutts, A. Jones, C. Forrester, S. Johns, E. Warner (United Kingdom)

PB 1962 Pulmonary Thromboembolism due to Lead Poisoning in Opium Addict Patients

B. Shakerian, N. Razavi (Iran, Islamic Republic of) PB 1963 Hemostatic Alterations in Hematological Disorders Rather than Inherited

CoagulopathiesA. Naz, F. Ahmed, N. Ahmed, S. Ansari, T. Farzana, T. Shamsi (Pakistan)

PB 1964 Acquired Factor XIII Deficiency in the Inpatient Setting: Retrospective Case

SeriesF. Chuiber, N.P. Schutz, V. Otero, L.H. Barrera, D. Altuna, M.S. López, J. Oyhamburu, S. Viñuales, D. Penchasky, J. Arbelbide, D. Fantl, M. Martinuzzo (Argentina)

PB 1965 Bleeding Manifestations as First Clinical Presentation of Systemic Lupus

Erithematosus: A Case of Acquired von Willebrand Syndrome (AVWS)O. Paoletti, R. Morandini, E. Cancellieri, A. Zimmermann, M. Tala, S. Zambelli, C. Dellanoce, S. Caroli, N. Delpero, E. Spotti, S. Testa (Italy)

PB 1966 IPS Derived Vascular Endothelial Cells (vECs) from HA-patients with Nonsense Mutations Are a Potential Cell-model to Study the MHC-driven Risk for Inhibitor DevelopmentH. Singer, N. Nüsgen, J. Müller, J. Oldenburg, O. El-Maarri (Germany)

PB 1967 Investigation of an F8 Exon 25 Deletion Suggests an Unusual Mutation Mechanism

B. Theophilus, A. Guilliatt, J. Motwani, M. Williams (United Kingdom) PB 1968 Stoichiometry of Immunodominant Factor VIII Immune Complexes

P. Lollar, E.T. Parker, C.B. Doering (United States) PB 1969 Analysis of VWF-FVIII Interaction in Natural pdFVIII/VWF Complex Compared

with rFVIII+VWF Complex through a Novel Flow Cytometry TechniqueM.I. Bravo, A.M. Ortiz, M. Costa, S. Grancha, J.I. Jorquera (Spain)

PB 1970 FVIII-vWF Complex Displays Greater Efficiency than Vwf-Free Preparations in

Restoring Thrombin Generation in Hemophilic Plasma with Inhibitor under Conditions of Physiological RelevanceC.T. Ammollo, F. Semeraro, A.M. Mezzasoma, N. Semeraro, P. Gresele, M. Colucci (Italy)

PB 1971 40 kDa PEG of N9-GP is Eliminated from Tissues and Will Reach Steady State

after Chronic DosingI. Bjoernsdottir1, O. Sternebring1, H. Jacobsen1, J. Sims2 (1Denmark, 2Switzerland)

PB 1972 Spectrum of F8 Gene Mutations with FVIII Assay Discrepancies in an Irish

Patient Cohort with Mild/Moderate Haemophilia AC. Keenan, R. Campbell, M. Doyle, M. Byrne, K. Ryan, J. O'Donnell, B. White, N. O'Connell (Ireland)

PB 1973 Identification of High-molecular Weight Species in Commercial Recombinant

Factor VIII ProductsJ.F. Healey, E.T. Parker, P. Lollar (United States)

PB 1974 Pharmacokinetics (PK) of N8-GP (Turoctocog Alfa Pegol) Dosed

Subcutaneously (SC) to Non-human Primates (NHPs) and Prediction of Human PK ProfileF. Rode, M. Loftager, D.M. Karpf, J.H. Faber, A.V. Groth, J. Haaning (Denmark)

PB 1975 Molecular Characterisation of Variants on Non-coding RNA Genes in

the X-inactivation Centre from Three Symptomatic Carriers with Severe Haemophilia A (HA) and Extremely Skewed X-chromosome InactivationC.P. Radic, M.M. Abelleyro, V.D. Marchione, L. Primiani, M. Candela, D. Neme, M. Bonduel, M. de Tezanos Pinto, L.C. Rossetti, C.D. De Brasi (Argentina)



436 437

Wed

nesd

ayP

oste

r S

essi

ons

PB 1976 Clinical Trials and Registries in Rare Diseases: Opponents or Collaborators?C. Keipert1, C.J. Jonker2, H.M. van den Berg2, A. Hilger1 (1Germany, 2The Netherlands)

PB 1977 In Haemophilic Patients, Individual Factor VIII or IX Level for the Correction of

Thrombin Generation Is PredictableB. Tardy-Poncet, P. Chelle, A. Montmartin, M. Piot, M. Cournil, C. Morin (France)

PB 1978 Factor 8 Assay Discrepancy in a United States Non-severe Hemophilia A Cohort

H.C. Okoye1, B.I. Nielsen2, K. Lee2, N.S. Key2, M.A. Rollins-Raval2 (1Nigeria, 2United States)

PB 1979 Aberrant Inflammatory Cytokines, Skew T Helper Cells and Decreased

Regulatory T Cell Numbers in Hemophilia A Patients with FVIII InhibitorD. Zhang, F. Xue, R. Yang (China)

PB 1980 Hemophilia A and the Role of Factor VIII in Balancing Pro- and Anticoagulant

ProcessesV.J.F. Strijbis, R.M.W. Kremers, I. van Moort, D. Huskens, S. Bloemen, H. Kelchtermans, M. de Maat, B. de Laat (the Netherlands)

PB 1981 Towards a Methylation Based Detection of F8 RearrangementsO. El-Maarri, A. Sharma, A. Jamil, N. Nüsgen, B. Pezeshkpoor, A. Pavlova, J. Oldenburg (Germany)

PB 1982 The Combined Use of Bypassing Agents with Antithrombin Reduction in

Plasma of Hemophilia A and B Patients with InhibitorsT. Livnat1, A. Sehgal2, K. Qian2, H.V. Nguyen2, B. Sorensen2, G. Kenet1 (1Israel, 2United States)

PB 1983 Plasma Steady State PEG Concentrations Are Reached in Patients after Once

Weekly Prophylactic Treatment with N9-GPO. Sternebring1, I. Bjoernsdottir1, A.J. Benie1, B.O. Petersen1, M. Panduro1, H. Jacobsen1, J. Sims2 (1Denmark, 2Switzerland)

PB 1984 Thrombin Generation Assay as Additional Tool in Diagnosis of Mild/Moderate

Haemophilia A Patients with Discrepancies in FVIII Activity AssaysB. Baran, E. Stefanska-Windyga, A. Buczma, E. Odnoczko, J. Windyga (Poland)

PB 1985 Burden of Comorbidities in Persons Living with Haemophilia: Insight from the

PROBE Phase 2b Study DatabaseM. Skinner1, C. Chai-Adisaksopha2, R. Curtis1, N. Frick1, M. Nichol1, D. Noone3, B. O'Mahony3, D. Page2, J. Stonebraker1, A. Iorio2 (1United States, 2Canada, 3Ireland)

PB 1986 Cost-Effective Algorithm for Molecular Diagnosis of Families with Severe Haemophilia A in ArgentinaV.D. Marchione, M.M. Abelleyro, L. Primiani, C.P. Radic, D. Neme, M. de Tezanos Pinto, C.D. De Brasi, L.C. Rossetti (Argentina)

PB 1987 Tissue Factor and Phospholipid-activated Thrombin Generation Assays for

Detection of Factor VIIa Activity, Dose and Duration of Effect in MiceS.S. Surov, A.R. Rezaie, M.V. Ovanesov (United States)

PB 1988 Assessment of F9 Mutation Associated with Inhibitor Development in Japanese

Hemophilia B PatientsH. Sakane, S. Tamura, E. Hashimoto, A. Fujioka, A. Makiyama, N. Kawamura, S. Suzuki, Y. Takagi, T. Kanematsu, M. Kishimoto, M. Ogawa, N. Suzuki, T. Matsushita, H. Yada, M. Shima, T. Kojima, Japan Hemophilia Inhibitor Study (Japan)

PB 1989 Homogenous Reactivity of Recombinant FVIII against Inhibitors in the

Presence of VWF Regardless Origin of Cell Line or Sequence IntegrityM.I. Bravo, A.M. Ortiz, M. Costa, S. Grancha, J.I. Jorquera (Spain)

PB 1990 Validation of the Factor IX One-stage aPTT Clot Assay Calibrated with Pooled

Normal Plasma for the Measurement of N9-GP in Patient PlasmaS. Tiefenbacher1, M. Robinson1, M. Høgh Sørensen2, M. Ezban2 (1United States, 2Denmark)

PB 1991 Haemophilia A and B in Costa Rica - An Update of the National Register

L. Salazar-Sanchez1, A. Pavlova2, B. Hernandez-Salazar1, J. Oldenburg2, P. Chaverri-Saenz1, M. Sandoval-Leal1, G. Jimenez-Cruz1 (1Costa Rica, 2Germany)

PB 1992 Understanding Hemophilia A and B Factor Replacement Administration

Patterns: A Feasibility StudyP. Fogarty1, D. Spurden2, J. Alvir1, B. Tortella1, M. McDonald1, A. Chhabra1, M. Cicchetti1, L. Lee1, A. Berk1, S. Huang1, A. Plail1 (1United States, 2United Kingdom)

PB 1993 Prevalence and Possible Risk Factors of Hyperhomocysteinemia in Patients

with Severe Hemophilia from North-Western RussiaS. Kapustin, V. Soldatenkov, V. Kargin, V. Shmeleva, L. Aleksanyan, V. Burakov, O. Smirnova, A. Titov, L. Papayan (Russian Federation)

PB 1994 A Thrombomodulin Gene Variant Leading to Hyperthrombomodulinaemia and

an Inherited Bleeding DisorderR.C. Tait, K. Downes, N.J. Mutch, E. Leishman, A.-L. Latif, S.V.V. Deevi, C.S. Whyte, K. Megy, K. Gomez, C. Bagot, N.I.H.R. Bio Resource (United Kingdom)



438 439

Wed

nesd

ayP

oste

r S

essi

ons

PB 1995 Importance of the ADP-dependent Amplification Pathway in Platelet Activation is Influenced by CalDAG-GEFI Expression LevelG. Florence1, M. Poggi1, A. Henneuse1, D. Ghalloussi1, R. Piatt2, J.-C. Gris1, S. Claeyssens1, P.E. Morange1, P. Nurden1, A.T. Nurden1, W. Bergmeier2, M.-C. Alessi1, M. Canault1 (1France, 2United States)

PB 1996 Association of Homozygous PAI-1 Deficiency with Cardiac Fibrosis in Humans

S. Gupta, S. Khan, S. Shah, M. Heiman, E. Klaychko, A.S. Baldridge, P. Flevaris, D. Lee, J. Carr, B. Benefield, L. Nelson, A. Shapiro, D. Vaughan (United States)

PB 1997 Molecular, Diagnostic and Clinical Features of 216 Patients from 46 Unrelated Families with FXI Deficiency Caused by Different Recurrent and Sporadic Mutations. Data from A 60000 Inhabitants Spanish TownM.E. de la Morena-Barrio, J. Esteban, S. Salloum-Asfar, J. Padilla, A. Miñano, I. Campillo, J.M. Soria, F. Vidal, J. Corral, V. Vicente (Spain)

PB 1998 The International Society on Thrombosis and Haemostasis - Bleeding

Assessment Tool (ISTH-BAT) and the Risk of Future BleedingM.R. Fasulo1, E. Biguzzi1, M. Abbattista1, F. Stufano1, M.T. Pagliari1, I. Mancini1, M. Gorski1, A. Cannavò1, M. Corgiolu1, F. Peyvandi1, F.R. Rosendaal2 (1Italy, 2Netherlands Antilles)

PB 1999 Efficacy and Safety of a New Fibrinogen Concentrate for the Treatment of

Bleeding Episodes and Prevention of Excessive Bleeding during Surgery in Children with Congenital Fibrinogen DeficiencyC. Djambas Khayat1, M. El Khorassani2, S. Aytac3, A. Dahmane4, S. Pujol4, C. Henriet4, F. Bridey4, C. Rothschild4 (1Lebanon, 2Morocco, 3Turkey, 4France)

PB 2000 In Vitro Study of a New Plasma-derived Factor V (FV) Concentrate: Dose-

response Evaluation in Plasma from Patients with Congenital FV DeficiencyP. Simioni, C. Novembrino, C. Bulato, M. Boscolo Anzoletti, G. Tagariello, S. Gavasso, C. Berbenni, L. Spiezia, E. Campello, F. Peyvandi (Italy)

PB 2001 Multi-platform Characterization and Application of a Bleeding Assessment Tool

in a Cohort of Patients with Factor XIII DeficiencyA. Abraham, H.F. Margaret, T. Geevar, S. Singh, R. V, J. Mammen, S.C. Nair (India)

PB 2002 New Bleeding Disorder with Enhanced Fibrinolysis due to Lysinuric Protein

Intolerance and Renal FailureH. Pitkänen, M. Kärki, L. Tanner, K. Näntö-Salonen, H. Niinikoski, R. Lassila (Finland)

PB 2003 Mutation Profile of Factor X Deficiency

A. Pavlova, B. Pezeshkpoor, U. Scholz, B. Zieger, J. Oldenburg (Germany)

PB 2004 Retrospective Evaluation of Phenotype and Management of Dysfibrinogenemia and Hypodysfibrinogenemia in a Cohort of Italian PatientsC. Santoro, F. Massaro, E. Baldacci, G. Ferrara, F. Malaspina, R. Santoro, S. Pasca, G. Castaman, F. Peyvandi, M.G. Mazzucconi (Italy)

PB 2005 Use of a Population Pharmacokinetic Model to Determine Pharmacokinetic

Parameters of a New Fibrinogen Concentrate in Pediatric Afibrinogenemic Subjects ≤12-year OldA. Bellon1, C. Djambas Khayat2, M. El Khorassani3, C. Rothschild1, W. Stevens1, C. Henriet1, E. Fuseau1, F. Bridey1 (1France, 2Lebanon, 3Morocco)

PB 2006 Safety and Efficacy of Recombinant Factor XIII (rFXIII-A2) in Patients with Congenital FXIII-A Subunit Deficiency Undergoing Minor Surgical Procedures: Results from the Mentor™2 TrialA. Inbal1, B. Kerlin2, D. Nugent2, J. Oldenburg3, K. Cepo4, M.-L. Garly4, M. Carcao5 (1Israel, 2United States, 3Germany, 4Denmark, 5Canada)

PB 2007 Investigation of Medical Indications for PNH Screening Experiment by Flow CytometryM. Zhu, W. Shen, L. Dai, J. Yuan, L. Jin (China)

PB 2008 Clinical and Molecular Data in 15 Italian Subjects with Congenital FXI

DeficiencyG. Favuzzi, G.L. Tiscia, M.R. Lupone, F. Cappucci, M. Schiavulli, V. Mirabelli, E. Chinni, N. Giuliani, R. Caliandro, M. Margaglione, E. Grandone (Italy)

PB 2009 Are Heterozygotes of Factor XIII Deficiency Prone to Bleeding? A New Finding

in Area of Rare Bleeding DisordersM. Naderi, A. Dorgalaleh, P. Eshghi (Iran, Islamic Republic of)

PB 2010 FVII Deficiency: Characterization of Three Different Mutations in the FVII

Catalytic DomainM.E. Chollet Dugarte1, E. Andersen1, E. Skarpen1, C.F. Myklebust1, C. Koehler1, M. Pinotti2, F. Bernardi2, B. Thiede1, P.M. Sandset1, G. Skretting1 (1Norway, 2Italy)

PB 2011 Correction of Coagulopathy Related to Severe Factor V Defects with a New

Plasma-derived FV Concentrate: An In vitro Study with ROTEMC. Bulato, L. Spiezia, C.M. Radu, E. Campello, S. Gavasso, G. Barillari, P. Pradella, P. Simioni (Italy)

PB 2012 Molecular Analysis and Clinical Description of an Italian Cohort of Patients

with FXI DeficiencyG. Quintavalle, F. Riccardi, G.F. Rivolta, A. Tagliaferri (Italy)



440 441

Wed

nesd

ayP

oste

r S

essi

ons

PB 2013 Bernard-soulier Syndrome in Pakistan: Biochemical and Molecular Analysis Leading to Identification of a Novel MutationD. Böckelmann1, M.Y. Jamal2, E. Lerner1, A. Naz2, B. Zieger1 (1Germany, 2Pakistan)

PB 2014 Genotypic Abnormalities in Phenotypic Confirmed Patients with Rare Bleeding

DisordersW. van Heerde, A. Simons, S. Krouwel, S. Schoormans, M.R. Nijziel (The Netherlands)

PB 2015 Evaluation of the Use of Bleeding Assessment Tools in FXI Deficiency

G. Gidley, A. Cumming, J. Thachil, C. Hay, M. Sutherland, S. Keeney, B. Sempasa, P. Bolton-Maggs, J. Burthem (United Kingdom)

PB 2016 Clinical Presentation and Management of Glanzmann′s Thrombasthenia: A Case

StudyI. Sasmaz, B. Antmen, B. Karagun, G. Leblebisatan, Y. Kilinc (Turkey)

PB 2017 Prevalence of Menorrhagia in Women Diagnosed with Congenital Bleeding DisordersM. Borhany, N. Fatima, M. Abid, T. Shamsi (Pakistan)

PB 2018 Thrombotic Complications in a Patient with Congenital Afibrinogenemia

S. Vakalopoulou, A. Papagianni, M. Stagou, P. Kotsi, G. Vasileia (Greece) PB 2020 Identification of Novel and Recurrent Mutations in F13B Gene Causing Mild

FXIII DeficiencyV. Ivaskevicius, A. Biswas, S. Singh, A. Pavlova, J. Oldenburg (Germany)

PB 2021 Bleeding Score as a Diagnostic Tool in Patients of Autosomal Recessive

Inherited Bleeding DisordersA. Naz, N. Ahmed, S. Tariq, S. Amanat, F. Raziq, T.S. Shamsi (Pakistan)

PB 2023 Acute Coronary Syndrome in a Patient with Factor V Deficiency: A Case Report

S. Anzej Doma, D. Andoljsek, I. Preloznik Zupan (Slovenia) PB 2024 Congenital Hypoprothrombinemia Presenting in the Neonatal Period: Report of

2 Cases in South of IranM. Bordbar, M. Aali, K. Kamali (Iran, Islamic Republic of)

PB 2025 Rare Bleeding Disorders in the Netherlands (RBiN)

J.L. Saes, S. Schols, Y. Smit, M. Peters, K. Meijer, F.J.M. van der Meer, M. Cnossen, R. Schutgens, L. Nieuwenhuizen, W. van Heerde, M. Nijziel (The Netherlands)

PB 2026 Identification of Two Novel F5 Compound Heterozygous Mutations in Two Norwegian Patients with Severe Factor V Deficiency NN. Iversen, H. Glosli, M. Sletten, M. Skogstad Le, M. Hellum, M. Tinholt, P.A. Holme, C. Henriksson (Norway)

PB 2027 Retrospective Evaluation of Phenotype and Management of A-hypo-

Fibrinogenemia in a Cohort of Italian PatientsC. Santoro, F. Massaro, E. Baldacci, G. Ferrara, A. Ferretti, R. Santoro, S. Pasca, G. Castaman, F. Peyvandi, M.G. Mazzucconi (Italy)

PB 2028 Factor X Deficiency Followed by a Tertiary Pediatric Hematology Center

G. Aydogan, Z. Salcioglu, F. Akici, N. Ozdemir, H. Sen, C. Bayram, A. Aycicek, E. Uysalol, G. Ersoy, I. Al, T. Tahtakesen, E. Arslantas (Turkey)

PB 2029 Correlation of Hemorrhagic Complications with Novel Mutations in FGA And

FGG: In Punjabi Congenital Afibrinogenemia PatientsT. Khan, A. Naz, A. Imran, T. Shamsi (Pakistan)

PB 2030 Treatment of a Rare Case of Congenital A/Hypo Dysfibrinogenemia with

Fibrinogen Concentrates: Comparison between Fibrinogen Levels and ROTEM® ParametersH.A. Guglielmone, F. Gonzalez, B. Rossi, S. Marun (Argentina)

PB 2031 A New Autosomal Dominant Inherited FVIII Defect: Evidence of a Novel

Genetic Determinant of Circulating FVIII LevelsV. Daidone, E. Galletta, A. Casonato (Italy)

PB 2032 Rare Bleeding Disorders: Snapshot from a Tertiary Care Hospital of Pakistan

A. Rashid, A.M. Memon (Pakistan) PB 2033 Severe Congenital Factor VII Deficiency in Northern Region of Turkey

D. Albayrak, C. Albayrak (Turkey) PB 2034 Evaluation of Rare Factor Deficiencies in Presurgical Plasma Samples

Z. Kaya, Ç. Özütok (Turkey) PB 2035 Spotting of Two Novel Mutations in FGG Gene: In Unrelated Patients of

Congenital Afibrinogenemia in PakistanT. Khan1, A. Naz1, A. Biswas2, A. Goodeve3, N. Ahmed1, S. Ahmed1, T. Shamsi1, J. Oldenburg2 (1Pakistan, 2Germany, 3United Kingdom)

PB 2036 Factor VII Deficiency: One Novel Mutation and Genotype-phenotype Correlation

in Patients from Southern ItalyG. Tiscia, G. Favuzzi, E. Chinni, D. Colaizzo, L. Fischetti, M. Intrieri, M. Margaglione, E. Grandone (Italy)



442 443

Wed

nesd

ayP

oste

r S

essi

ons

PB 2037 Successful Delivery in an Afibrinogenemia Patient after Three Abortions: A Case Report and Review of LiteratureM. Karimi, M. Bordbar, M. Aali, A. Bazrafshan, H. Tavoosi, J. Gerdabi (Iran, Islamic Republic of)

PB 2038 Are Screening Coagulation Tests Useful to Predict the Clinical Phenotype in

Patients with A/Hypo/Dysfibrinogenemia? A Single Institution ExperienceH.A. Guglielmone, S. Minoldo, M.A. Alvarez Bollea, G.D. Jarchum (Argentina)

PB 2039 Congenital Afibrinogenemia Case Presenting with Surrenal Bleeding and

Cervical HematomaH. Kızılocak, N. Özdemir, Z. Şalcıoğlu, B. Koç, E.P. Uysalol, C. Bayram, G. Dikme, T. Celkan (Turkey)

PB 2040 Severe Congenital Factor X Deficiency in the Northern Region of Turkey:

Successful Prophylaxis with Activated Prothrombin Complex ConcentratesC. Albayrak, D. Albayrak (Turkey)

PB 2041 Pseudoxanthoma Elasticum-like Disease with Deficiency of Vitamin

K-dependent Clotting Factors, Hypofibrinogenemia and Cutis Laxa Features: A Case ReportK. Taouli Allal, M. Hanini, O. Boudghene Stambouli, S. Bouali, I. Gaouar (Algeria)

PB 2042 Rare Inherited Coagulation Disorder (RICD) in Females - Data from a

Developing CountryS. Hussain, S. Baloch, A. Gaffar, A. Najmuddin, S. Aqeel, F. Musheer, S. Nawaz (Pakistan)

PB 2043 Congenital Factor V Deficiency

E. Yakovleva, N. Konyashina, L. Gorgidze, O. Polevodova, E. Likhacheva, M. Kumskova, N. Zozulya (Russian Federation)

PB 2044 Von Willebrand Factor Deficiency Reduces Experimental Liver Fibrosis in Mice

J. Luyendyk1, N. Joshi1, A. Kopec1, J. Ray1, H. Cline-Fedewa1, D. Groeneveld2, T. Lisman2 (1United States, 2The Netherlands)

PB 2045 Genotypical Classification of Patients with von Willebrand Disease

W. van Heerde, A. Simons, S. Krouwel, S. Schoormans, B. Laros, P. Brons, M.R. Nijziel (The Netherlands)

PB 2046 Common VWF Sequence Variants Associated with Higher VWF and FVIII Are

Less Frequent in Subjects Diagnosed with Type 1 VWDV. Flood, J. Johnsen, P. Christopherson, S. Haberichter, R. Udani, D. Bellissimo, K. Friedman, R. Montgomery (United States)

PB 2047 Interactomics of the Weibel-palade Body Exocytotic MachineryM. Schillemans, M. Wahedi, D. van Breevoort, M. van den Biggelaar, J. Voorberg, R. Bierings (The Netherlands)

PB 2048 Structural Thermodynamics of a Clinically Elusive High-affinity von Willebrand

Factor Binding to Platelet GPIbαA. Tischer1, V. Machha1, J. Frontroth2, M. Brehm3, T. Obser3, R. Scheppenheim3, L. Mayne1, S.W. Englander1, M. Auton1 (1United States, 2Argentina, 3Germany)

PB 2049 Pro-angiogenic Signal in Plasma of Left Ventricular Assist Device PatientsA. Sharma, Y. Wang, D. Mukhopadhyay, R. Safford, J. Blackshear (United States)

PB 2050 Characterisation of Q1541R, a Novel von Willebrand Factor Variant Causing

Type 2A von Willebrand Disease - ADAMTS13 Cleavage of Type 2A Variants under Shear StressT. McKinnon1, V. Jenkins1, F. Zhang2, M. Laffan1, J. O'Donnell3 (1United Kingdom, 2United States, 3Ireland)

PB 2052 FVIIIa Mimicking Bispecific Antibody (Emicizumab) Improved Thrombus

Formation of Type 2N von Willebrand Disease (VWD) under Both High and Low Shear ConditionsH. Yaoi, Y. Shida, T. Kitazawa, K. Hattori, M. Shima, K. Nogami (Japan)

PB 2053 Perioperative Management of von Willebrand Patients with Desmopressin;

Towards a Predictive Population PK ModelJ.M. Heijdra, M.J.H.A. Kruip, F.W.G. Leebeek, M.H. Cnossen, 'OPTI-CLOT' study group (The Netherlands)

PB 2054 In-Frame Heterozygous Large Deletion in von Willebrand Factor (VWF) Gene in

a Patient with Severe Bleeding Manifestations Might Accelerate VWF ClearanceH. Yadegari1, N.M. Marquardt1, V. Ivaskevicius1, O. Rawley2, L. Swystun2, D. Lillicrap2, J. Oldenburg1 (1Germany, 2Canada)

PB 2055 Acquired von Willebrand Disease in Patients with Extracorporal Membrane

Oxygenation: The VWF:GPIbM/VWF:Ag Ratio is a Sensitive Diagnostic ToolS. Flommersfeld, K. Dielmann, T. Vassiliou, U.J. Sachs (Germany)

PB 2056 Different Modes of Association between Protein Disulfide Isomerase PDIA1 and

VWF in von Willebrand DiseaseM.A. Brehm, S. Vollmers, G. König, T. Obser, R. Schneppenheim (Germany)



444 445

Wed

nesd

ayP

oste

r S

essi

ons

PB 2057 Mutational Screening of a Type III VWD Cohort from Cohort Reveals 19 Novel Mutations in the VWF GeneS. Ahmed1, A. Biswas2, A. Naz1, H. Yadegari2, N. Ahmed1, N. Saqlain1, A. Imran1, F. Raziq1, T.S. Shamsi1, J. Oldenburg2 (1Pakistan, 2Germany)

PB 2058 Effect of Elongational Flow on von Willebrand Factor Cleavage by ADAMTS13

M. Bortot1, D. Bark1, K. Neeves1, K. Leiderman1, A. Fogelson1, S. Aguila Martinez2, C. Ng1, J. Di Paola1 (1United States, 2Ireland)

PB 2059 Wound Healing is Not Delayed in Mice with Reduced von Willebrand Factor in

Spite of the Presence of a Severe Bleeding TendencyM. Hoffman, K. Gorman, G. Pitoc, B. Sullenger, D. Monroe (United States)

PB 2060 Variability in von Willebrand Factor Parameters in Blood Outgrowth Endothelial

Cells from Healthy ControlsA. de Jong, E.M. Weijers, R.J. Dirven, M.J. Streur, J. Eikenboom (The Netherlands)

PB 2061 A Cell-based Assay to Quantify αIIbβ3 Integrin Binding of von Willebrand Factor MutantsG. König, T. Obser, R. Schneppenheim, M. Brehm (Germany)

PB 2062 Heterozygous Splicing Mutations Associated with Severe Type 1 von Willebrand

DiseaseG. Castaman, A. Coppola, A. Volta, A. Kura, S. Linari, L. Pieri, F. Demartis, B. Giusti (Italy)

PB 2063 Single Centre Audit of Laboratory Testing in Sub-classification of Type 2 von

Willebrand DiseaseR. Kohli, P. Batty, S. Platton, K.J. Pasi, L. Bowles (United Kingdom)

PB 2064 Von Willebrand Factor Testing through the Ages: A Review of Recent Results

from the 'Royal College of Pathologists of Australasia Quality Assurance Program'R. Bonar, E. Favaloro (Australia)

PB 2065 Comparing Platelet-dependent von Willebrand Factor Activity Assays in 661

Patients with von Willebrand Disease - from the WiN StudyJ. Boender, J. Eikenboom, J. van der Bom, K. Meijer, J. de Meris, K. Fijnvandraat, M.H. Cnossen, B. Laros-van Gorkom, E. Mauser-Bunschoten, M.P.M. de Maat, F.W.G. Leebeek, WiN Study Group (The Netherlands)

PB 2066 Occurrence of Subclinical and Late Arthropathy in Patients with von Willebrand

DiseaseG. Castaman, S. Linari, F. Demartis, L. Pieri, C. Martinoli (Italy)

PB 2067 The Effect of Thioredoxin-1 on von Willebrand Factor FunctionV. Ruiz De Miguel, M. Laffan, T. McKinnon (United Kingdom)

PB 2068 The Prevalence of Bleeding Disorders in Women with Histologically Proven

EndometriosisS. Heynemann, R. Dauer, C. Barnes, S. Grover (Australia)

PB 2069 Report of the ISO15189 Accreditaion of the Hydragel 5 von Willebrand

Multimers Assay. A within-day MethodA. Lemaitre1, G. Nouadje2, G. Beaulieu2, H. Bautista2, S. Eeckhoudt1 (1Belgium, 2France)

PB 2070 Comparison of Three Different Factor VIII Assays in 154 Patients with Type 3

von Willebrand Disease: Results from the 3WINTERS-IPS CohortJ. Goudemand1, C. Caron1, E. Jeanpierre1, Z. Badiee2, M.-R. Baghaipour2, L. Baronciani3, J. Batlle4, E. Berntorp5, I. Bodo6, U. Budde7, G. Castaman3, J. Eikenboom8, P. Eshghi2, C. Ettorre3, A. Goodeve9, C. Hay9, H. Hoorfar2, M. Karimi2, B. Keikhaei2, R. Lassila10, F. Leebeek8, M.F. Lopez Fernandez4, P.M. Mannucci3, M.G. Mazzucconi3, M. Morfini3, J. Oldenburg7, R. Parra Lòpez4, I. Peake9, F. Peyvandi3, R. Schneppenheim7, A. Tiede7, G. Toogeh2, A. Tosetto3, M. Trossaert1, S.O.R. Zekavat2, E. Zetterberg5, A. Federici3 (1France, 2Iran, Islamic Republic of, 3Italy, 4Spain, 5Sweden, 6Hungary, 7Germany, 8The Netherlands, 9United Kingdom, 10Finland)

PB 2071 Treatment of Gastrointestinal Bleeding Episodes with Recombinant von

Willebrand Factor (rVWF) in Patients with Severe von Willebrand Disease (VWD): Sub-analysis from Pivotal Phase III On-demand StudyF. Leebeek1, M. Chapman2, B. Ploder3, A. Sytkowski2, A. Novack2, B. Ewenstein2 (1Netherlands Antilles, 2United States, 3Austria)

PB 2072 Type of Renal Replacement Therapy, Access and von Willebrand Factor (VWF) Function

J. Blackshear, D. Chen, R. Safford, N. Aslam (United States) PB 2073 Retrospective Single Centre Study of On-demand and Treatment Prophylaxis in

24 Patients with Type 3 von Willebrand DiseaseM. Hendelmeier, V. Hornick, D. Wirtz, N. Marquardt, H.-H. Brackmann, G. Goldmann, J. Oldenburg (Germany)

PB 2074 Trends in Severity of Acquired von Willebrand Syndrome with Lower Rotational

Speed Left Ventricular Assist DeviceJ. Blackshear, S. Schettle, D. Joyce, D. Chen (United States)

PB 2075 Prevalence of von Willebrand Disease among Saudi Students: from Saudi Screening Program for Bleeding Disorders (SSBD)T. Owaidah, E. Abu- Douleh, A. Abdul Albanyan, H. Al Zahrani, M. Saleh, A. Almomen, K. Alsaleh (Saudi Arabia)



446 447

Wed

nesd

ayP

oste

r S

essi

ons

PB 2076 Molecular Caracterization of Type 2 von Willebrand DiseaseS. Freitas, D.C. Gonçalves, C. Velloso-Rodrigues, A.N.L. Prezotti, M.S. Renni, S.M. Rezende (Brazil)

PB 2077 Validation of a Rapid Diagnostic Approach with Automatic Tests in a Cohort of

Chinese Patients with von Willebrand Disease: Results from the Chinese-Italian CReWilAct StudyZ. Yu1, J. Yin1, W. Zhang1, Z. Wang1, Z. Ma1, X. Bai1, C. Ruan1, C. Bianchi2, D. Intini2, A. Lattuada2, E. Sacchi2, A.B. Federici2 (1China, 2Italy)

PB 2078 The Self-association of Ristocetin

P. Lollar, W. Deng (United States) PB 2079 VWD2M Genotype Carrying Double Heterozygous Mutations with More Severe

Phenotype than Classic VWD2MA.I. Woods, J. Paiva, A.C. Kempfer, A. Blanco, A. Sanchez Luceros, M.A. Lazzari (Argentina)

PB 2080 The Occurrence of Prothrombotic Mutations in a Patient with von Willebrand

Disease and Symptomatic Bleeding DisorderA. Sikorska, J.M. Teliga-Czajkowska, B. Ceglarek, K. Bykowska, B. Baran, J. Windyga (Poland)

PB 2081 Von Willebrand Factor (VWF) Propeptide (VWFpp) and VWFpp to VWF Antigen

(VWF:Ag) Ratio in Assessment of Inherited (VWD) and Acquired (AVWS) von Willebrand DiseaseK. Bykowska, E. Czajkowska, A. Misiak, A.J. Sikorska, D. Zakrzewski, B. Ceglarek, B. Baran, J. Windyga (Poland)

PB 2082 Extensive Bilateral Mandibular Pseudotumor in a Boy with Type 3 von

Willebrand Disease (VWD) Treated with Plasma Derived VW/Factor VIII Concentrate (FC): Diagnosis, Treatment and OutcomeJ.P. Frontroth, G. Sciuccati, M. Hepner, L. Galluzzo, C. Pepe, S.E. Annetta, G. Pieroni, M. Bonduel (Argentina)

PB 2083 Laboratory Identification of von Willebrand Disease: A Contemporary Approach

E.J. Favaloro, S. Mohammed, S. Oliver, K.K.E. Lau, L. Pasalic (Australia)

PB 2084 Importance of Classification and Genetic Tests in the Diagnosis of von Willebrand Disease Type 2B and 2NA. Kerényi, J. Kállai, R. Gindele, I. Szegedi, J. Hársfalvi, A. Szederjesi, Z. Szabó, C. Kiss, I. Bodó, Z. Bereczky, L. Muszbek, J. Kappelmayer (Hungary)


PB 2085 Molecular Genetic Investigations in Hereditary Hemorrhagic Telangiectasia in Hungary; Identification of a Founder MutationR. Gindele, T. Major, Z. Szabó, K.B. Kovács, G. Pfliegler, Z. Bereczky (Hungary)

PB 2086 How Well can Laboratories Make a Diagnosis of Type 3 VWD? Results from a

UK NEQAS (Blood Coagulation) Diagnostic Challenge ExerciseI. Jennings, L. Brown, D. Kitchen, S. Kitchen, T. Woods, I. Walker (United Kingdom)

PB 2087 Rivaroxaban but Not Apixaban Causes False-positive Results in Lupus Anticoagulant Testing that Can Be Overcome with Andexanet AlfaR.I. Baker, G. Gilmore, J. Tiao, S.R. McGregor (Australia)

PB 2088 The Feasibility of Heparin Neutralization Assay to Replace Serotonin Release

Assay in the Diagnosis of Heparin-induced ThrombocytopeniaG. Zheng, M. Streiff, C. Takemoto, J. Bynum, E. Gelwan, J. Jani, D. Judge, T. Kickler (United States)

PB 2089 One Stage and Chromogenic FVIII Assays in Spiked and Post Infusion Samples

Containing rFVIIIFc or Recombinant FVIII: Data from a UK NEQAS for Blood Coagulation SurveyS. Kitchen, I. Jennings, M. Makris, D. Kitchen, T. Woods, I. Walker (United Kingdom)

PB 2090 Epitope Mapping of Anti-FVIII Antibodies in Hemophilia A Patients Using

LumiTope, a FVIII Domain-specific Multiplex Microsphere Based ImmunoassayB. Pezeshkpoor, A.-C. Berkemeier, J. Müller, T. Albert, J. Oldenburg (Germany)

PB 2091 Investigation of an Incidental Finding of Factor 8 Gene Duplication Detected

by Chromosomal Microarray AnalysisR. Dardik, E. Avishai, N. Rosenberg, D. Eli, G. Kenet (Israel)

PB 2092 Thromboxane Formation Assay to Identify High on-treatment Platelet Reactivity

to AspirinL. Dannenberg, A. Mohring, C. Helten, K. Bartkowski, T. Zeus, M. Kelm, T. Hohlfeld, A. Polzin (Germany)

PB 2093 Prospective Multicenter Validation of Standard and Age-adjusted D-Dimer Testing in Patients with Suspected Pulmonary Embolism (PE) and Deep Venous Thrombosis (DVT)B.A. Parry1, J.E. Hollander1, A.M. Chang1, S.M. Schellong2, D. Theodoro1, S. House1, G.J. Fermann1, N. Giordano1, E.K. Deadmon1, Y. Chang1, J. Cohen1, N. Robak1, A.J. Singer1, F. LoVecchio1, M. Mulrow1, E.L. Walters1, E.T. Reibling1, S. Francis1, S.M. Griffin1, A.T. Limkakeng Jr.1, P.S. Wild2, J.H. Prochaska2, E. Zeserson1, B. Davis1, N.T. Gentile1, P. McNelis1, J. Delgado1, P. Kuempers2, N. Werner2, C. Kabrhel1 (1United States, 2Germany)



448 449

Wed

nesd

ayP

oste

r S

essi

ons

PB 2095 The Detection of Cross-reactive Antibodies to Recombinant Porcine FVIIIA.E. Bowyer, M.F. Shepherd, S. Kitchen, M. Makris (United Kingdom)

PB 2096 Mixing Test to Discriminate between Lupus Anticoagulant and Direct Oral

Anticoagulant in Diluted Russell's Viper Venom Time TestO. Kumano, Y. Komiyama (Japan)

PB 2097 Assessment of Three Contact Activation Reagents for the Diagnosis of Factor XI

DeficiencyS. Salloum-Asfar, M.E. de la Morena-Barrio, J. Esteban, A. Miñano, C. Aroca, J. Padilla, V. Vicente, V. Roldán, J. Corral (Spain)

PB 2098 Platelet Reactivity in a Large Population with the Bruneck Cohort

M.V. Chan1, T. Barwari1, J.E. Huffman2, P.C. Armstrong1, P. Santer3, S. Kiechl4, J. Willeit4, M. Mayr1, A.D. Johnson2, T.D. Warner1 (1United Kingdom, 2United States, 3Italy, 4Austria)

PB 2099 Evaluation of IgG4 Anti-FVIII as Strategy to Improve the Diagnosis of Factor

VIII Inhibitor in Association with Modified-Bethesda AssayS.A.L. Montalvao, L.B. Rosa, A.A. Oliveira, P.S. Elídio, H.J. Aguiari, A.A.L. Sambo, M.M.T. Hosokawa, M.C. Della-Piazza, C.S. Costa-Lima, S.S. Medina, M.C. Ozelo (Brazil)

PB 2100 Comparison of Age-adjusted D-dimer and Clinical Probability-adjusted D-dimer

for Diagnosing Pulmonary EmbolismS. Sharif, C. Kearon, M. Li, M. Eventov, R. Jiang, P. Sneath, R. Leung, K. de Wit (Canada)

PB 2101 The Screening aPTT Mixing Test Is Not Sufficient to Rule Out the Presence of

InhibitorS.A.L. Montalvao, A.A. Oliveira, L.B. Rosa, H.J. Aguiari, P.S. Elídio, A.L.A. Sambo, M.M.T. Hosokawa, M.C. Della-Piazza, C.S. Costa-Lima, S.S. Medina, M.C. Ozelo (Brazil)

PB 2102 Quantitation of Dabigatran by Global and Specific Coagulation AssaysJ. Lozier, K. Nghiem, A. Cullinane, R. Alfaro, L. Gordon, C. Hadigan, P. Kumar (United States)

PB 2104 Influence of the Statistical Approach on Cut-off Values of IgG/IgM

Anticardiolipin and Anti-β2 Glycoprotein I Antibodies in Classification of Antiphospholipid SyndromeL. Vanoverschelde1, H. Kelchtermans2, J. Musial3, B. de Laat2, K. Devreese1 (1Belgium, 2The Netherlands, 3Poland)

PB 2105 Reference Interval Mean Clotting Times Should Not Be Used to Calculate Lupus Anticoagulant Mixing Test Ratios Unless They Match the Normal Pooled Plasma Clotting TimeG.W. Moore, J.C. Maloney, N. de Jager, C. Dunsmore, D.K. Gorman, R.F. Polgrean (United Kingdom)

PB 2106 Lupus Anticoagulant-hypoprothrombinemia Syndrome (LAHPS): Report of 4 Cases

L. Remotti, M.L. Romero, S.H. Grosso, M.F. Ingratti, M.P. Vera Morandini, A. Sánchez-Luceros, A.N. Blanco (Argentina)

PB 2107 Fibrinogen Prothrombin Time Derived Method Is Not Useful in Anticoagulated Patients by LMWH or RivaroxabanC. Duboscq, M. Martinuzzo, J. Ceresetto, M. Lopez, L. Barrera, J. Oyhamburu, G. Stemmelin (Argentina)

PB 2108 Development of Novel Assays for Factor VIII Potency DeterminationM. Kusch, S. Rosenkranz, A. Schroda, C. Grundmann, S. Keitel, A. Hunfeld, R. Seitz, G.J.K. Praefcke (Germany)

PB 2109 Evaluations of Automated Chromogenic Assays for the Diagnosis and

Monitoring of Haemophilic PatientsC. Novembrino, M. Boscolo Anzoletti, E. Biguzzi, M.R. Fasulo, F. Peyvandi (Italy)

PB 2110 Evaluation of Utility of ISTH Scoring System and its Modifications in Diagnosis

of Disseminated Intravascular Coagulation in a Tertiary Care Centre in Southern IndiaP.S. Muddana, R. Kar, S.S. Kar (India)

PB 2111 Method Comparison of the Atellica COAG 360 System* with Sysmex CS-2000i

System and BCS XP SystemE. Knoch1, O. Bätz1, C. Haas1, M. Haddad1, Y. Henskens2, T. Renné1 (1Germany, 2The Netherlands)

PB 2112 Evaluation of an Automated Chemiluminescent Assay and two ELISA's for Detection of Heparin Induced IgG Antibodies in the Diagnosis of Heparin Induced Thrombocytopenia (HIT)L. De Cooman, K. Devreese (Belgium)

PB 2113 The Influence of a High Fat Meal, Smoking, Coffee, Exercise and Sample

Storage on Light Transmission and Impedance Aggregometry in Healthy VolunteersY. Henskens, J. Krekels, D. van den Kerkhof, R. Wetzels, P. Verhezen (The Netherlands)



450 451

Wed

nesd

ayP

oste

r S

essi

ons

PB 2114 Automated Data Management for Thrombin GenerationK.G. Guria, H. Elsinga, P.W. Hemker, H.C. Hemker (The Netherlands)

PB 2115 The Laboratory Control of Anticoagulant Thromboprophylaxis during Early

Postpartum Period after the Caesarean DeliveryE. Koltsova, A. Balandina, K. Grischuk, M. Shpilyuk, E. Seregina, N. Dashkevich, A. Poletaev, A. Pyregov, G. Sukhih, I. Serebriyskiy, F. Ataullakhanov (Russian Federation)

PB 2116 Forty Years of Riddle Solving to Decipher Puzzling Test Results in the Coagulation LaboratoryA. Zivelin (Israel)

PB 2117 “Function over Form”? Low Dose V/Q SPECT is Superior to Planar V/Q and

Has a Diagnostic Yield Approaching that of CTPA in the Diagnosis of Acute Pulmonary Thromboembolic DiseaseL. Stephens, I. Niematallah, M. Memmott, R. Sajjan, J. Thachil, S. Muthu (United Kingdom)

PB 2118 Point-of-care INR with CoaguChek XS Pro is comparable to laboratory INR in a

hospital settingA.K. Stroobants, B.S. van der Veen, A. Sturk (The Netherlands)

PB 2119 Evaluation of Assay Performance Monitoring Edoxaban Plasma Concentration

with Technoview® Edoxaban and Technochrom® Anti-XaS. Geiter1, M. Unterberger1, M. Llusa1, M. Griffiths1, L. Wagner1, L. He2, N. Binder1 (1Austria, 2United States)

PB 2120 Evaluation of Platelet Response by Whole Blood Multiple Electrode

Aggregometry Method in Patients Using Antiplatelet TherapyM. Matos, E. Taniguchi, C. Finazzo, E. Sanches, A. Maia (Brazil)

PB 2121 Evaluation and Comparison of the Productivity of the Atellica COAG 360

System* and the BCS XP System in Daily Routine SettingS. Echternacht, K.-P. Kienle, I. Hoberg, M. Haddad (Germany)

PB 2122 Rotational Thromboelastometry Parameters Have Variable Correlation with Plasma-based Assays of Coagulation across Trimesters of Pregnancy: A Cross-sectional StudyK. Fox, A. Shamshirsaz, H. Erfani, V. Kostousov, K. Bruzdoski, S.-K. Hui, J. Teruya (United States)

PB 2123 Thrombin Generation Assay CANNOT Identify Antithrombin Resistance During Anticoagulant TherapyY. Takagi1, S. Suzuki1, N. Kawamura1, A. Makiyama1, H. Sakane1, E. Hashimoto1, A. Fujioka1, S. Tamura1, A. Takagi1, V. Djordjevic2, T. Kojima1 (1Japan, 2Serbia)

PB 2124 Clot Wave Form Parameters of Prolonged APTT in Different Situations: Is There

Any Difference between Them?M.E. Martinuzzo, E. Sueldo, R. Porsella, M.A. D´Adamo, M.S. Lopez, L.H. Barrera, M.G. Gurfinkiel, M. Arias, J. Oyhamburu (Argentina)

PB 2125 Hereditary Angioedema: Role of Genetic Test in Diagnosis

P. Martinez, P. Rozenfeld (Argentina)

PB 2126 Alterations in the Parameters of Classic, Global and Innovative Assays of Hemostasis Caused by Sample Transport via a Pneumatic Tube SystemA. Poletaev, A. Ignatova, E. Koltsova, A. Kuprash, P. Gitelson, H. Sepoyan, A. Balandina, G. Novichkova, M. Panteleev (Russian Federation)

PB 2127 Productivity Evaluation of a Novel Blood Coagulation Analyzer in the 24/7

Clinical Coagulation Laboratory EnvironmentS. Echternacht, A. Patapovas, S. Kuehn, E. Langer, K. Hegel (Germany)

PB 2128 Mutation Screening for the C677T Variant in the MTHFR Gene by Melting

Point Analysis with the Real Time PCR: Detection of a Rare Variant Val225IleI. Tirado Garcia, L. Romero Roman, A. Oliver Samper, N. Vilalta Seto, I. Coll Torrents, E. Martínez-Sánchez, J. Mateo Arranz, J.C. Souto Andrés, J. Fontcuberta Boj (Spain)

PB 2129 Evaluation of Potential Sources of Variation in 1-stage Factor IX Assays

J. Needham, H. Lewis, M. Stringer, S. Mangles, S. Rangarajan (United Kingdom)

PB 2130 The Calibrated Automated Thrombography in Normal Pregnancy

N. Silina, O. Smirnova, A. Nikolaeva, O. Golovina, L. Papayan (Russian Federation)

PB 2131 The Impact of Pre-analytical Variables and Reagents on the Results of Thrombin Generation - Lessons Learned from the Generation of Normal Reference RangesE. Fosbury (United Kingdom)

PB 2132 High Level of Concordance for Routine Assays between Results Obtained with

Two Automated Coagulation AnalyzersS. Just1, D. Zebeljan1, L. Smith2, J. Loats1, K. Hill1, G. Lakos2 (1Australia, 2United States)



452 453

Wed

nesd

ayP

oste

r S

essi

ons

PB 2133 Current Practice Related to D-dimer Testing in CroatiaS. Margetić, A. Bronić, D. Coen Herak, M. Milic Gall (Croatia)

PB 2134 Usefulness of APTT Reagents for LA Detection and Frequency of LA Positive

Patients in APTT Prolonged PatientsS. Anun, A. Pirunsarn, K. Boonyoung, P. Mitreejit (Thailand)

PB 2135 An Evaluation of the Activated Partial Thromboplastin Time Waveform in

Various DiseasesT. Matsumoto, H. Wada, K. Ohishi, N. Katayama (Japan)

PB 2136 Identification of Rare Inherited Diseases by Next Generation Sequencing

S. Shahid, S. Ahmed, S. Munzir, T. Shamsi (Pakistan)

PB 2137 Type and Frequency of Hemoglobinopathies, Diagnosed in the Area of Karachi, in PakistanS. Shabbir (Pakistan)


PB 2138 Evaluation of a Novel Short-acting Direct Dual FXa/FIIa Inhibitor for its Use in Acute AnticoagulationS. Heitmeier, S. Allerheiligen, J. Strassburger, A. Buchmueller, C. Gerdes, M.J. Gnoth, B. Riedl, V. Laux (Germany)

PB 2139 Discovery of ONO-5450598, a Highly Orally Bioavailable Small Molecule

Factor XIa Inhibitor: The Pharmacokinetic and Pharmacological ProfilesS. Kouyama, T. Ono, T. Hagio, S. Sakimoto, H. Miyata, M. Tanaka, T. Kouda, N. Nakanishi, K. Tanaka, D. Yanagida, M. Sakai, H. Matsuya, A. Imagawa, Y. Hirota, K. Kawabata, H. Habashita (Japan)

PB 2140 Discovery and Profiling of BAY-224 - A Novel Active Site Inhibitor of Thrombin

for Oral Treatment of ThrombosisS. Heitmeier, S. Allerheiligen, K.M. Gericke, A. Tersteegen, M.V. Schmidt, J. Strassburger, A. Buchmueller, C. Gerdes, P. Ellinghaus, B. Riedl, V. Laux (Germany)

PB 2141 Incidence of Venous Thromboembolism in Asian Populations: A Systematic ReviewL.H. Lee1, W. Chen2, J. Rauvl3, C.-C. Wu4, A. Gallus5 (1Singapore, 2China, 3India, 4Taiwan, 5Australia)

PB 2142 Thrombin Exosite 1 Inhibition with JNJ-375 Causes Anti-coagulation and

Inhibits Thrombus Formation in a Human Translational Model of ThrombosisS. Wilson1, T. Connolly2, G. Peters2, A. Gosh2, M. Johnson2, D. Newby1 (1United Kingdom, 2United States)

PB 2143 Vena Cava Filter Retrieval Rates and Factors Associated with Retrieval in the United StatesJ. Brown, V. Adams, J. Talbert (United States)

PB 2144 Dabigatran Neutralizing Antibody, Idarucizumab, Exhibits Procoagulant and

Platelet Activation Responses in Whole BloodZ. Siddiqui1, O. Iqbal1, D. Hoppensteadt1, M. Lewis1, R. Rege1, S. Abro1, E. Ramacciotti1, I. Elalamy2, J. Fareed1 (1United States, 2France)

PB 2145 ONO-5450598, an Orally Available Small-molecule Inhibitor of Activated

Blood Coagulation Factor XI, Inhibits Arterial Thrombus Formation without Increasing Bleeding when Used in Combination with Clopidogrel in RabbitsT. Ono, S. Kouyama, T. Hagio, H. Miyata, S. Sakimoto, M. Tanaka, T. Koda, N. Nakanishi, K. Tanaka, D. Yanagida, M. Sakai, H. Matsuya, A. Imagawa, Y. Hirota, K. Kawabata, H. Habashita (Japan)

PB 2147 Inter-individual Variation in Plasma Levels of Direct Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation I. Paskaleva, E. Doncheva, D. Dineva (Bulgaria)

PB 2148 Idarucizumab, a Specific Antidote for Dabigatran, Cross-reacts with Melagatran and May also Interact with other Benzamidine-containing CompoundsJ. Fareed1, L. Reikensmeyer1, A. Walborn1, D. Hoppensteadt1, J. Walenga1, E. Ramacciotti1, S. Abro1, W. Jeske1, B. Lewis1, O. Bouchard1, I. Elalamy2 (1United States, 2France)

PB 2149 Influence of Dabigatran on Rotational Thromboelastometry

M. Bozic Mijovski, N. Vene, N. Snoj, P. Gradisek, A. Mavri (Slovenia) PB 2150 Direct Oral Anticoagulants for Thromboprophylaxis in Orthopedic Surgery in the

Real World: A Systematic Review of Population Based StudiesF. Al-Ani, A. Garcia-Horton, A. Lazo-Langner (Canada)

PB 2151 Heparin Calibrated Anti-Xa Assays for the Measurement of Low Levels of Direct

Factor Xa InhibitorsL. Sabor, M. Raphaël, J.-M. Dogné, F. Mullier, J. Douxfils (Belgium)

PB 2152 Efficacy of a Novel Contact Pathway Inhibitor, Ir-CPI, on in vitro Clotting Induced by PCI Catheter SegmentJ. Douxfils, D. Gheldof, S. Derochette, J. Tassignon, C. Meinguet, M. Guyaux, J.-M. Dogné, E. Godfroid (Belgium)

PB 2153 New Parenteral Poly (2-(acrylamide)-2-methylpropanesulfonic Acid) - Based

Anticoagulants (NPACs): Efficacy and Safety Studies in RatsB. Kalaska1, K. Kaminski1, J. Miklosz1, S.-I. Yusa2, K. Nakai2, K. Szczubialka1, D. Pawlak1, M. Nowakowska1, A. Mogielnicki1 (1Poland, 2Japan)



454 455

Wed

nesd

ayP

oste

r S

essi

ons

PB 2154 INR Might Be a Useful Predictor for Upcoming Minor to Major Bleedings in Patients Treated with NOACP. Bhardwaj, L.B. Petersen, T.S. Binko, T.B.S. Jørgensen, M.L. Nepper, A.M.K. Andersen, J.R. Petersen, G. Gleerup Fornitz (Denmark)

PB 2155 Correlation between Thromboelastometry and HPLC-MS/MS for Rivaroxaban

MonitoringV. Aranda, D. Priscilla, M. Colombini, M. Claudio, M. Cristovão, F. Carlos, J. Guerra (Brazil)

PB 2156 Comparative Studies on the Anticoagulant Actions of Recombinant

Thrombomodulin and Heparin and their Neutralization by FEIBA as Measured by ThromboelastographyP. Aggarwal, Z. Siddiqui, O. Iqbal, W. Jeske, D. Hoppensteadt, K. Tsuruta, J. Fareed (United States)

PB 2157 Diclofenac for the Treatment of Acute Symptomatic Intermediate-risk

Pulmonary EmbolismD. Jimenez1, R. Nieto1, J. Corres1, C. Fernandez-Golfin1, J.L. Zamorano1, D. Barrios1, R. Morillo1, E. Barbero1, M. Huisman2, J. Kline3, R. Yusen3 (1Spain, 2The Netherlands, 3United States)

PB 2158 Anticoagulant and Antiaggregation Effect of New Aminoestrogen

M. Flores-Garcia, A. De la Peña-Díaz, E.C. Uribe-Lezama, J.M. Fernández-González, R. Botello-Maraver, M.A. Candia-Ramírez, O. Zepeda-García, E. Flores-C, E. Pinzón-Estrada (Mexico)

PB 2159 Anticoagulant Actions of Recombinant Thrombomodulin and Heparin and their

Neutralization by FEIBAM. Lewis, P. Aggarwal, Z. Siddiqui, O. Iqbal, W. Jeske, D. Hoppensteadt, K. Tsuruta, J. Fareed (United States)

PB 2160 Sulodexide Efficiently Inhibits Thrombin Generation and Clot Formation via

the Anti-Xa and Anti-IIa Activity. An in vitro Comparison with the LMWH Enoxaparin and UFHG. Gerotziafas1, P. Van Dreden1, S. Salta1, L. Papageorgiou1, W. Jeske2, J. Walenga2, D. Hoppensteadt2, M. Grusse1, A. Larsen1, I. Elalamy1, A. Nicolaides3, J. Fareed2 (1France, 2United States, 3Cyprus)

PB 2161 Porcine and Ovine Mucosal Heparins and Their Depolymerized Derivatives are Comparable in Contrast to Their Bovine EquivalentsW. Jeske, O. Bouchard, M. Lewis, D. Hoppensteadt, P. Maia, A. Silva de Castro, E. Kumar, N. Guler, D. Kahn, J. Walenga, J. Fareed (United States)

Pediatrics

PB 2162 ISTH DIC Score is Associated with Mortality in Children with Disseminated Intravascular CoagulationB. Pongtanakul, C. Wangkittikal, N. Narkbunnam (Thailand)

PB 2163 Out of Sight, Out of Mind - The Acquired von Willebrand Syndrome is a Bleeding Cause in Disguise during Congenital Heart Disease SurgeryV. Icheva, M. Nowak-Machen, C. Schlensak, K. Jaschonek, U. Budde, M. Hofbeck, G. Wiegand (Germany)

PB 2164 International Survey of the Management of Disseminated Intravascular

Coagulation among Pediatric and Neonatal Health Care PractitionersZ. Solh1, R. Rajagopal2, J. Thachil3, A. Chan1, N. Heddle1, P. Monagle2 (1Canada, 2Australia, 3United Kingdom)

PB 2165 Efficiency and Safety of Off-label Use of Recombinant Activated Coagulation

Factor VII (rFVIIa) in Pediatric Oncological and Hematological PatientsD. Fedorova, P. Zharkov, A. Pshonkin (Russian Federation)

PB 2166 Intracranial Hemorrhage in Children with Immune Thrombocytopenic Purpura:

A Systematic ReviewS. Khaliq, M. Rehan, S. Saeed, Lubna Zafar (Pakistan)

PB 2167 Comparison of 3 Current Disseminated Intravascular Coagulation (DIC) Scores

in Pediatric Intensive Care Unit (PICU)R. Natesirinilkul, W. Padungmaneesub, S. Reungrongrat, S. Manowong, S. Inthapaen (Thailand)

PB 2168 Predictors of Postoperative Bleeding in Children Undergoing Cardiopulmonary

Bypass: A Preliminary Italian StudyL. Spiezia, G. Di Gregorio, E. Campello, S. Maggiolo, G. Bortolussi, G. Stellin, P. Simioni, V. Vida (Italy)

PB 2169 Clinical Utility and Mechanism of Thrombin Generation in Children with Liver

DiseaseW. Beatie1, R. Kremers2, T. Peters2, B. de Laat2, M. Magnusson3, W. Hardikar1, P. Monagle1, V. Ignjatovic1 (1Australia, 2The Netherlands, 3Sweden)

PB 2170 Carotid Intima Media Thickness and Obesity Phenotypes among Children and AdolescentsG. Asghari, P. Mirmiran, F. Hosseinpanah, P. Dehghan, M. Tohidi, F. Azizi (Islamic Republic of Iran)



456 457

Wed

nesd

ayP

oste

r S

essi

ons

PB 2171 Acquired von Willebrand Syndrome (aVWS) in Severely Ill Pediatric Patients with Bleeding ComplicationsI. Wieland, K.-W. Sykora (Germany)

PB 2172 Thrombopoietin Receptor Agonists for Children with Refractory Immune ThrombocytopeniaJ. Zanabili Al-Sibai, T. Arias Fernández, M.Á. Fernandez Rodríguez, L.F. Ávila Idrovo, L. Morais Bras, C. Castañón Fernández, A. Solé Magdalena, S. Shehadeh, S. González Muñiz, M.P. Palomo Moraleda (Spain)

PB 2173 An Unusual Cause of Bleeding in a Young Girl with Systemic Lupus

Erythematosus: Lupus Anticoagulant Hypoprothrombinemia SyndromeS. Singh, A. Jindal, N. Kumar, J. Ahluwalia (India)

PB 2174 Cost-benefit Relationship of the Collagen-binding Assay on von Willebrand

Disease Study in ChildrenP. Zúñiga C, J.G. Martínez Órdenes, P. Sepulveda M, G. Muñoz S (Chile)

PB 2175 Severe Factor VII Deficiency in Lebanon: The Impact of Molecular Studies,

Prenatal Diagnosis and Primary ProphylaxisR. Farah1, J. Al Danaf1, H. Farhat1, M. Giansily-Blaizot2 (1Lebanon, 2France)

PB 2177 Genetic Confirmation and Identification of Novel Mutations in Glanzmann

Thrombasthenia and von Willebrand Disease Families by Diagnostic Exome SequencingY.J. Shim, E.M. Choi, H.S. Kim, J.M. Lee (Republic of Korea)

PB 2178 Application of Different Technologies during Prenatal Diagnosis in Glanzmann´s

ThrombastheniaM. Jiang (China)

PB 2179 Continuous Infusion of Recombinant Factor IX in a Neonate with Severe

Hemophilia B and A Vascular Ring Requiring Surgical CorrectionC. Hugge, C. Huddleston, L. Cerny, N. Hillman (United States)

PB 2180 Tailored Prophylaxis in Children with Hemophilia A: A New Approach for the

FutureS. Pasca, P. Cogo, M. Milan, L. Sarolo, E. Zanon (Italy)

PB 2181 Normal aPTT in Children with Mild Factor XI Deficiency

J. Puetz, C. Hugge, K. Moser (United States)

PB 2182 Impact of SIPPET [Survey of Inhibitors in Plasma-product Exposed Toddlers] Study on Clinical Practice in United States: A Survey of Hemophilia and Thrombosis Research Society [HTRS] MembersA. Al-Huniti, A. Sharathkumar (United States)

PB 2183 Intraosseous Infusion of Recombinant Factor IXC. Hugge, J. Puetz, R. Fleming (United States)

PB 2184 The Differential Diagnosis of Acute Rheumatic Fever in a Hemophilic Child

M. Sezgin Evim, A. Meral Güneş, B. Baytan (Turkey) PB 2185 Proteomic Analysis of Changes Induced by Infant Cardiopulmonary Bypass

U. Nag, J. Otto, C. Mccoy, H. Leraas, J. Kim, C. Brady, J. Turek, J. Lawson, E. Tracy (United States)

PB 2186 Spatial Clot Propagation in Neonates and Adults

A. Schlagenhauf, S. Pohl, E. Zoehrer, B. Leschnik, H. Haidl, W. Muntean, S. Gallistl (Austria)

PB 2187 Platelet-leukocyte Aggregates as Possible Biomarkers of Thrombotic Risk in

Children with Hereditary Spherocytosis and SplenectomyC. García, A. Moscardó, S. Izquierdo, A.M. Latorre, B. Argiles, M.T. Santos, J. Vallés, M.Á. Dasí (Spain)

PB 2188 Pediatric Chronic Kidney Disease: Assessment of Endothelial Function and

HemostasisL. Dusse, R. Silva, L. Sousa, C. Loures, M. Carvalho, E. Reis, A. Simões-Silva (Brazil)

PB 2189 Derivation of a Clinical Prediction Rule to Use with D-dimer to Exclude

Pulmonary Embolism in ChildrenJ. Kanis, J. Pike, C. Hall, J. Kline (United States)

PB 2190 Thrombin Generation in Pediatric Patients with Generalized Infectious Diseases

and Multiple Organ Dysfunction SyndromeL. Papayan, O. Smirnova, O. Golovina, L. Alekseeva, A. Vilnits, S. Bessmeltsev (Russian Federation)

PB 2191 A New ADAMTS13 Mutation and Pharmacokinetic Properties in Congenital

Thrombotic Thrombocytopenic Purpura (TTP)J.D.A. Carneiro, D.M. Celeste, M.N.P.F. Oliveira, G.A.C. Zanatta, T.R.F. Rocha, M.P. Garanito (Brazil)

PB 2192 Thromboelastographic (TEG) Parameters in Newly Diagnosed Pediatric Patients

with Acute Lymphoblastic Leukemia (ALL) and Central Venous Catheters (Cvcs)R. Ko, L. Ji, R. Carmona, R. Sposto, G. Young (United States)

PB 2193 Look, Feel, Move: A Case of Idiopathic Femoral Artery Thrombosis in a NeonateC. Williams, C. Mayes, C. Macartney (United Kingdom)



458 459

Wed

nesd

ayP

oste

r S

essi

ons

Platelets - Basic

PB 2194 Inhibitors of Apoptosis Signal-regulating Kinase 1 (MAP3K5), as Anti-thrombotic AgentsM. Naik, X. Chen, J. Wu, T. Stalker, D. Maloney, A. Jadhav, U. Naik (United States)

PB 2195 The Oral Bruton's Tyrosine Kinase Inhibitor Ibrutinib Selectively Blocks

Atherosclerotic Plaque-induced Platelet Thrombus FormationB. Kristina, J. Janina, Prof. Dr. med. Wolfgang Siess (Germany)

PB 2196 The anti-asthma therapeutic zafirlukast is a broad spectrum thiol isomerase

inhibitor that inhibits platelet functionL.-M. Holbrook1, S. Nock1, S. Ryan1, J. Romanowski2, D. Kennedy2, J. Gibbins1 (1United Kingdom, 2United States)

PB 2197 Potentiation of TRAP-6-induced Platelet Dense Granule Release by Blockade of

P2Y12 Signaling with MRS2395A. Mitrugno, R.A. Rigg, N.B. Laschober, A.T.P. Ngo, J. Pang, C.D. Williams, J.E. Aslan, O.J.T. McCarty (United States)

PB 2198 Discovery and in vitro Pharmacology of BAY-386 - A Novel, Reversible PAR-1

AntagonistC. Gerdes1, M. Jeske1, M.J. Gnoth1, E. Bender1, K. Zimmermann1, A. Buchmueller1, P. Ellinghaus1, A. Itakura2, V. Laux1, O.J. McCarty2 (1Germany, 2United States)

PB 2199 Selective Serotonin Reuptake Inhibitors Inhibit Convulxin- and Fibrinogen-

induced Phosphorylation of Syk in Human PlateletsY.-L. Tseng, J.P.-C. Chang, H.-Y. Lane (Taiwan)

PB 2200 Citalopram Inhibits Platelet Function through a SERT-Independent Mechanism

H.G. Roweth, R. Yan, A.H. Watson, R.W. Farndale, G.E. Jarvis (United Kingdom) PB 2202 What is the Optimal Treatment Option for A Patient with X-linked

Thrombocytopenia?M. Gresikova1, T. Freiberger2, B. Ravčuková2 (1Slovakia, 2Czech Republic)

PB 2203 The Effect of Vorapaxar on Platelet-mediated Inflammatory Response

A. Tsouka, I. Moschonas, S. Papadaki, A. Tselepis (Greece) PB 2204 APAC, a Dual Antiplatelet and Anticoagulant Attenuates Collagen-induced

Platelet Aggregation and Fibrin Elasticity in BloodA. Jouppila, M. Lemponen, R. Lassila (Finland)

PB 2205 Citrated Iron Oxide Nanoparticles Inhibit Thrombin-evoked Ca2+ Signalling in Human PlateletsS. Moise, N. Telling, A. Harper (United Kingdom)

PB 2206 Induction of Diabetes Attenuates the Antithrombotic Effect of Clopidogrel in

Apolipoprotein E-deficient MiceA. Sugidachi1, K. Ohno1, J.A. Jakubowski2, Y. Ito1, A. Tomizawa1, M. Mizuno1 (1Japan, 2United States)

PB 2208 With an ASA Dose that Inhibits Prostacyclin Formation, Clopidogrel Has a Lesser Antithrombotic EffectR. Ni1, N. Vaezzadeh1, J. Zhou1, J.I. Weitz1, M. Cattaneo2, P.L. Gross1 (1Canada, 2Italy)

PB 2209 Inhibition of Human Platelet Aggregation by Some Newly Synthesized S-Esters

of Thiosulfonic AcidT. Halenova, I. Nikolaeva, A. Nakonechna, V. Lubenets, O. Savchuk (Ukraine)

PB 2210 Looking for the Best Experimental Conditions for Studying the Effect of Aspirin

on Murine HemostasisB. Decouture, B. Dizier, P. Gaussem, C. Bachelot-Loza (France)

PB 2211 Platelet Microvesicle Formation during the Hemostatic Response is Regulated

by P2Y12 SignalingM. Tomaiuolo, C. Matzko, I. Poventud-Fuentes, J. Weisel, L. Brass, T. Stalker (United States)

PB 2212 Convection through Platelet Thrombi

S. Kobayashi1, M. Komatsu1, D. Ku2 (1Japan, 2United States) PB 2213 Different Prothrombotic Phenotypes of Atherosclerosis-prone Apoe-/- and Ldlr-/-

MiceJ.P. van Geffen, F. Swieringa, J.C. Sluimer, E.A.L. Biessen, J.W.M. Heemskerk, M.E.J. Kuijpers (The Netherlands)

PB 2214 PCSK9, Not only A Modulator of Cholesterol Levels but Also of Platelet

FunctionL. Rossetti, N. Ferri, S. Marchianò, B. Canciani, D. Trabattoni, F. Santilli, G. Davì, E. Tremoli, M. Camera (Italy)

PB 2215 Increased Platelet P2Y12 Expression in Diabetes and the Therapeutic

Implication of Inverse Agonist for Antiplatelet TherapyL. Hu, L. Chang, Z. Ding (China)



460 461

Wed

nesd

ayP

oste

r S

essi

ons

PB 2216 Elevated Activity of Fibrinogen-like Protein 2, (FGL2/fibroleukin) in Platelets of Cancer PatientsE. Rabizadeh, Y. Zimra, I. Cherny (Israel)

PB 2217 Dynamics of Single Platelet Dense Granule Release Induced by Various

Concentrations of Thrombin and ADPT. Shepelyuk, D. Nechipurenko, F. Ataullakhanov, M. Panteleev (Russian Federation)

PB 2218 Comparison of Reticulated and Non-reticulated Platelet Function and

ReleasatesM.A. Hayman, P.C. Armstrong, T.D. Warner (United Kingdom)

PB 2219 Platelet S1P: Evidence for the Involvement of the Membrane Transporter MRP4

during its Secretion, and Identification of Surface ReceptorsB. Decouture, P. Thérond, E. Dréano, D. Pidard, J.-S. Hulot, P. Gaussem, C. Bachelot-Loza (France)

PB 2220 The Framingham Heart Study (FHS): Results from >900 Individuals with

Detailed Platelet Function TestingJ. Huffman1, M.-H. Chen1, C. Wallace de Melendez1, A. Lachapelle1, C. Song1, P. Sutherland1, M. Hayman2, P. Armstrong2, M. Chan2, T. Warner2, A. Johnson1 (1United States, 2United Kingdom)

PB 2221 Polyphosphate Nanoparticles on the Platelet Surface Trigger Contact System

ActivationJ.J.F. Verhoef1, A.D. Barendrecht1, K.F. Nickel2, K. Dijkxhoorn1, E. Kenne3, L. Labberton3, O.J. McCarty4, R. Schiffelers1, A.P. Hendrickx1, H. Schellekens1, M.H. Fens1, S. de Maat1, T. Renne3, C. Maas1 (1The Netherlands, 2Germany, 3Sweden, 4United States)

PB 2222 Analysis of Integrin β3 Clustering and Kindlin Association Using a Novel

STORM Microscopy MethodM. Abo Hassan, C. Jones (United Kingdom)

PB 2223 Shear-mediated Platelet Activation (SMPA) Yields a Differing “Activation

Signature” than that of Biochemical AgonistsY. Roka-Moiia1, N. Bajaj1, D.E. Palomares1, A. Dimasi2, A. Redaelli2, D. Bluestein1, M.J. Slepian1 (1United States, 2Italy)

PB 2225 Investigating Platelet Functional Heterogeneity Using Droplet Microfluidics

M.S.A. Jongen, N.A. Englyst, J.J. West (United Kingdom)

PB 2226 Sickle Cell Disease Patients under Regular Transfusion Program Have Decreased in vitro Platelet AggregationR.C. Saez, G.G. Yamaguti-Hayakawa, B.K.L. Duarte, S. Ospina, S.S. Medina, F.F. Costa, M.C. Ozelo (Brazil)

PB 2227 Microthrombocytopenia and Defective GPVI/ITAM Signaling in Mice Lacking

the Small GTPase RhoBK. Aurbach1, S. Dütting1, C. Brakebusch2, U.G. Knaus3, I. Pleines1, B. Nieswandt1 (1Germany, 2Denmark, 3Ireland)

PB 2228 Characterization of in Vitro Cell-free Induced Fibrillar Fibronectin: Morphology

Dependent Effects on Platelet FunctionK. Huynh1, P. Le1, N. Mai1, V. Stoldt2, H. Nguyen1, T. Vo1 (1Viet Nam, 2Germany)

PB 2229 Extracellular Histones Stimulate Clot Retraction and Induce Resistance to

FibrinolysisC.T. Ammollo, N. Semeraro, M. Colucci, F. Semeraro (Italy)

PB 2230 Evaluation of the Total Thrombus-formation System (T-TAS): Application to

Human and Mouse Blood AnalysisR. Al Ghaithi, J. Mori, L. Hardy, H. Philippou, E. Hethershaw, N.V. Morgan, Y.A. Senis, P. Harrison (United Kingdom)

PB 2231 The Mechanisms Underlying Core-and-Shell Architecture of Arterial Thrombus

and it´s Dynamics Described with Computational ModelingV.N. Kaneva, D.Y. Nechipurenko, F.I. Ataullakhanov, M.A. Panteleev (Russian Federation)

PB 2232 Effects of pH and Concentration of Sodium Citrate Anticoagulant on Platelet

Aggregation Measured by Light Transmission Aggregometry Induced by Adenosine DiphosphateK. Germanovich1, E.A. Femia1, C. Cheng1, N. Dovlatova2, M. Cattaneo1 (1Italy, 2United Kingdom)

PB 2233 Idelalisib and Platelet Aggregation in Patients with Chronic Lymphocytic

Leukemia (CLL)A. Artoni, P. Bucciarelli, R. Cassin, S. Lamarca, A. Lecchi, G. Reda, A. Cortelezzi, F. Peyvandi (Italy)

PB 2234 Platelet Investigations in Patients with Essential Thrombocytosis

O.H. Pedersen, M.L. Larsen, E.L. Grove, P.H. Nissen, S.D. Kristensen, A.M. Hvas (Denmark)



462 463

Wed

nesd

ayP

oste

r S

essi

ons

PB 2235 Computational Analysis of Shear Stress Distribution during Thrombus Formation in a Blood Vessel and Parallel Plate Flow ChamberA. Megalinskiy, D.Y. Nechipurenko, F.I. Ataullakhanov, M.A. Panteleev (Russian Federation)

PB 2236 Platelet Function during Prolonged Targeted Temperature Management after

Cardiac Arrest: A Randomised Clinical TrialA. Jeppesen, H. Kirkegaard, S. Ilkjær, A.-M. Hvas (Denmark)

PB 2237 An Absence of Platelet Activation Following Thalidomide Treatment in vitro or in vivo

J. Qiao1, Y. Wu1, X. Wu1, Y. Liu1, X. Li1, W. Ju1, L. Zeng1, E. Gardiner2, R. Andrews2, K. Xu1 (1China, 2Australia)

PB 2238 Reduced Left Ventricular Function Compared to Preserved Function after Myocardial Infarction is Associated with a Different Platelet PatternC. Christersson, Å. Thulin, A. Siegbahn (Sweden)

PB 2240 Lymphocyte-platelet Adhesion and Clusters Formation in Patients Infected with

Influenza A/H3N2A. Emelianov, A. Emelianova, N. Belozerceva, O. Solpova, A. Solpov, Y. Vitkovsky (Russian Federation)

PB 2241 Detection and Characterization of Extracellular Vesicles at Different Stages of

Platelet Concentrate Storage Using High-resolution Flow CytometryO. Sirotkina, V. Kishenko, A. Golovkin, M. Belyakova, K. Kondratov, A. Fedorov, T. Vavilova (Russian Federation)

PB 2242 New Opportunities in Express-evaluation of Living Platelets

I. Vasilenko, E. Vlasova, V. Metelin, A. Balkanov, R. Lifenko, V. Khvatov, M. Makarov (Russian Federation)

PB 2243 Comparing Platelet Reactivity in Patients with Chronic Kidney Disease to that

in Healthy VolunteersH.E. Allan, M.V. Chan, P.C. Armstrong, M.M. Yaqoob, T.D. Warner (United Kingdom)

PB 2244 Disaggregation Following Agonist-induced Platelet Activation in Patients on

Dual Antiplatelet TherapyP.P. Wadowski, B. Eichelberger, C. Kopp, J. Pultar, D. Seidinger, R. Koppensteiner, I.M. Lang, S. Panzer, T. Gremmel (Austria)

PB 2245 In vitro Study on the Effects of Ibrutinib (Ibr) on Platelet (Plt) Function via Light Transmission Aggregometry (LTA): Platelet Aggregation (PA) ResultsJ. Ninomoto1, A. Mokatrin1, T. Kinoshita1, C. Marimpietri1, B.Y. Chang1, J. Sukbuntherng1, D.F. James1, M. Crowther2 (1United States, 2Canada)

PB 2246 The Use of Laser Therapy for Muscle Bleeding in Glanzmann Thrombasthenia - A Case ReportB. Choinska, P. Laguna, K. Scipio del Campo, M. Matysiak (Poland)

PB 2247 Amniotic Fluid-derived Mesenchymal Stem Cells (AF-MSCs) Decrease Agonists

Platelet ResponseM. Fernández-Arrausi, D. Iyu, E.G. Navarro, J.J. Cerezo-Manchado, M. Rodríguez-Valiente, A.I. García-Guillén, J.M. Moraleda, F. García-Candel, N.M. Atucha (Spain)

Poster Session 12:00 – 13:15 Exhibition Hall 6.2


PB 2248 Clopidogrel Does Not Protect Mice from Sepsis or Septic ShockY. Rabouel, S. Magnenat, F. Lefebvre, J. Boisramé-Helms, F. Meziani, B. Hechler, C. Gachet (France)

PB 2249 Dysregulation of NET Formation Following Thermal Injury and its Association

with Multiple Organ FailureR. Dinsdale, J. Hazeldine, K. Altarrah, P. Hampson, A. Devi, C. Wearn, A. Bamford, J. Bishop, J. Lord, N. Moiemen, P. Harrison (United Kingdom)

PB 2250 Hageman Factor Regulates Inflammatory Responses in Human Lungs

L. Wujak1, R. Hess1, C. Hesse1, K. Sewald1, S. de Maat2, C. Maas2, F. Bonella1, K. Preissner1, P. Markart1, M. Wygrecka1 (1Germany, 2The Netherlands)

PB 2251 Differential Impact of Triggers on the Risk of Incident Venous

Thromboembolism in Hospitalized Subjects with and without Acute Infection - Results from a Population-based Case-crossover StudyG. Grimnes, T. Isaksen, V. Tichelaar, S.K. Braekkan, J.B. Hansen (Norway)

PB 2252 Inhibition of the Major Endothelial Cell Integrin αVβ3, Both Pre- and Post-

infection, Prevents Bacterial Binding in 2D Dynamic and 3D ex vivo Models of SepsisC. Garciarena1, A. Wong2, S. Peter2, S. Kerrigan1 (1Ireland, 2United States)

PB 2253 RNA and Histones in Dead Cells Synergistically Provoke FSAP Activation in

SerumG. Marsman, I. Bulder, F. Stephan, B. Luken, S. Zeerleder (The Netherlands)



464 465

Wed

nesd

ayP

oste

r S

essi

ons

PB 2254 Impact of Acute Infection during Hospitalization on the Risk of Incident Venous Thromboembolism - Results from a Population-based Case-crossover StudyG. Grimnes, T. Isaksen, V. Tichelaar, S.K. Braekkan, J.B. Hansen (Norway)

PB 2255 C-reactive Protein and Risk of Venous Thromboembolism - Results from a

Population-based Case-crossover StudyG. Grimnes, T. Isaksen, V. Tichelaar, S.K. Braekkan, J.B. Hansen (Norway)

PB 2256 DNA and Factor VII-activating Protease Protect against the Cytotoxicity of

HistonesG. Marsman1, H. von Richthofen1, I. Bulder1, F. Lupu2, J.A. Hazelzet1, B.M. Luken1, S. Zeerleder1 (1The Netherlands, 2United States)

PB 2257 Nucleated Platelet Response to a Single Stranded RNA Viral Product through

Pattern Recognition Receptors Revealed by RNA SequencingF. Ferdous, C. Saski, W. Bridges, M. Burns, K. Elliott, H. Dunn, T. Scott (United States)

PB 2258 MiR146a-5p Deficiency Exacerbates Neutrophil Extracellular Trap Formation

A.B. Arroyo Rodríguez, A.M. De los Reyes García, N. García Barberá, V. Roldán, R. Teruel Montoya, V. Vicente, R. González Conejero, C. Martínez (Spain)

PB 2259 Inflammation Augments NFκB Dependent Production of TF in Preadipocytes

T. Sovershaev1, C. Ramberg1, M. Wabitsch2, L. Wilsgard1, N. Latysheva1, J.-B. Hansen1 (1Norway, 2Germany)

PB 2260 Evaluation of the Impact of Hypofibrinolysis Induced by Tranexemic Acid in

Murine Experimental SepsisY. Alves Campos Nogueira, B. Wilfried Hounkpe, F. Loureiro Andrade Orsi, C. Emilio Levy, J.M. Annichinno Bizzacchi, E. Vinicius De Paula (Brazil)

PB 2261 Elevated Levels of Endogenous Activated Protein C Predict Mortality in Septic Shock

J. Müller, B. Pötzsch, J. Oldenburg, D. Loßnitzer, T. Becher (Germany) PB 2263 In vitro Disruption of Endothelial Barrier Integrity by Serum from Patients with

Septic ShockM.M.L. Fiusa1, L.N.G. Costa1, G.R. de Souza1, R.N. Angerami1, M.A. Carvalho-Filho1, D. Garcia-Weber2, J. Millán2, E.V. de Paula1 (1Brazil, 2Spain)

PB 2264 The Potential Roles of IL-33 and TGF-β1 in the Pathogenesis of Stevens-

Johnson Syndrome/ Toxic Epidermal NecrolysisO. Iqbal, C. Bouchard, M. Mosier, S.D. Till, J. Fareed (United States)

PB 2265 Assessment of the Concentration and the Functional Activity of Plasma Inter-

alpha Trypsin Inhibitor in Patients with Inflammatory DiseasesJ.-L. Plantier, V. Devos, S. Jorieux (France)

PB 2266 2',3-dihydroxy-5-methoxybiphenyl Suppresses fMLP-induced Superoxide Anion Production and Cathepsin G Release by Targeting the β-subunit of G-protein in Human NeutrophilsH.R. Liao, I.-S. Chen, Y.-J. Day, S.-Z. Lin, C.-P. Tseng (Taiwan)

PB 2267 A Comparison of Scoring Systems and Surrogate Markers of Death in a Cecal

Ligation and Puncture Sepsis ModelD.J. Dwivedi, S.H.C. Mai, M. Khan, A.E. Fox-Robichaud, P.C. Liaw (Canada)

PB 2269 High Altitude Venous Thromboembolism

N. Pandit, L. Seetoh (Singapore) PB 2270 Venous Involvement in Behcet's Disease: A Retrospective Analysis of 75 Cases


PB 2271 Arterial Involvment in Behcet's Disease: A Retrospective Study of 75 Cases


PB 2272 Self Extracellular RNA and Exogenous Danger Signals Act Synergistically to

Induce Cytokine Production in MacrophagesH.F. Noll, J. Behnke, K.T. Preissner, S. Fischer (Germany)

PB 2273 Neutrophil Extracellular Trap (NET) Formation in Patients with Behcet's

DiseaseY. Boulaftali, A. Lejoncour, S. Loyau, N. Le Lay, L. Venisse, M.-C. Bouton, A. Dossier, F. Domont, T. Papo, M. Jandrot-Perrus, P. Cacoub, N. Ajzenberg, D. Saadoun (France)

PB 2274 A Basal-state Monocyte Gene Transcription Profile Is Associated with

Circulating Levels of Th1 Cells: The Multi-Ethnic Study of Atherosclerosis (MESA)N.C. Olson, A. Ellis, L.M. Reynolds, M.F. Doyle, C.L. Wassel, B.M. Psaty, Y. Liu, R.P. Tracy (United States)

PB 2275 Proinflammatory Polarized Macrophages Have Reduced Microvesicles and

Coagulatory FunctionP. Hohensinner, J. Kirchbacher, J. Baumgartner, L. Hell, I. Pabinger, W. Speidl, J. Wojta (Austria)

PB 2276 Modulation of Macrophage Functions by Thrombin

M. Lopez, J. Rodriguez, H. Cabrera-Fuentes, K. Preissner (Germany)



466 467

Wed

nesd

ayP

oste

r S

essi

ons

PB 2277 Interleukin-6 in the Development of Venous ThrombosisS.H. Karbach1, R. Schüler1, A. Gabele1, F. Ridder1, K. Schäfer1, H. Rossmann1, T. Korn1, H.M.H. Spronk2, B. Lämmle1, T. Münzel1, A. Waisman1, P. Wenzel1 (1Germany, 2The Netherlands)

PB 2278 The First Year after Diagnosis of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-

Associated Vasculitis is Critical for Development of Venous Thromboembolism (VTE) in These PatientsA. Antovic, E. Svensson, O. Börjesson, A. Bruchfeld, I. Gunnarsson (Sweden)

PB 2279 Protein Arginine Deiminase-4 Does Not Influence Antibacterial, Inflammatory

or Procoagulant Responses during Gram-negative Pneumonia Derived SepsisT.A.M. Claushuis1, A.L. Luitse1, L.A. van Vught1, J. Horn1, O.J. de Boer1, J.M. Lankelma1, L. Boon1, A. Zychlinsky2, A.F. de Vos1, C. van 't Veer1, T. van der Poll1 (1The Netherlands, 2Germany)

PB 2280 NETs, FSAP and their Complicity in the Context of Immunity and Thrombosis

S. Grasso1, A. Neumann2, M. von Köckritz-Blickwede2, S. Kanse1 (1Norway, 2Germany)

PB 2281 Immunology Studies on Recombinant Factor VIII Fc Fusion Protein

K. Kis-Toth, A. Simpson, K. Henry, C. Loh (United States) PB 2282 Luminex© Bead-based Assay for Early Detection of GPIIbIIIa Allo-

immunization in Glanzman ThrombastheniaA. Dupuis, E. Le Toriellec, M. Schwebel, A. Parrisiadis, H. Ansart-Pirenne, R. d’Oiron, C. Lavenu Bombled, C. Gachet, P. Bierling, L. Croisille (France)

PB 2283 Tranexamic Acid Blocks Fibrinolysis but Not Overall Plasmin Generation and

Modulates the Immune Response in Patients Undergoing Coronary Artery Surgery. A Sub-study of the “Aspirin and Tranexamic Acid for Coronary Artery Surgery” (ATACAS) TrialD.F. Draxler, G. Hanafi, S. Zahra, S. Vorontsov, B. Niego, H. Ho, M. DagIas, I. Goncalves, H. Tran, S. Wallace, M. Plebanski, P. Myles, R.L. Medcalf (Australia)

PB 2284 Impact of Systemic Inflammation in Lung Transplant Outcome

J. Walenga, W. Jeske, E. Lowery, A. Walborn, M. Yong, A. Rodrigues, W. Vigneswaran (United States)

PB 2285 Protease Activated Receptor-2 (PAR-2) Serves as a Dominant Receptor for Factor VII Activating Protease (FSAP)K. Byskov, S.M. Kanse (Norway)

PB 2286 Protective and Detrimental Effects of Anticoagulation in a Mouse Model of

Multiple SclerosisS. Wang, M. Henderson, B. Reeves, N. Mackman, R. Pawlinski (United States)

PB 2287 Crosstalk between Epidermal Growth Factor Receptor (EGFR) and TF/FVIIa/PAR2 Pathway Mediates Chemotherapy Resistance in Cervical CancerR.Q. Monteiro, L.R. Almendra, I. Guimarães, A.C. Pires, A. Melo, S. Ortiz-Costa, C. Sternberg, V.H. de Almeida (Brazil)

PB 2288 Monocyte Activation by Thrombin Leads to an Upregulation of Molecules Involved in FibrinolysisB. Thaler, P. Hohensinner, J. Baumgartner, C. Schörgenhofer, B. Jilma, M. Fischer, W. Speidl, J. Wojta (Austria)

PB 2289 Activated Protein C (APC) via PAR1 Protects Neurons from Death in the Model

of Neuroinflammation in vitroI. Babkina1, L. Gorbacheva1, S. Strukova1, V. Pinelis1, G. Reiser2 (1Russian Federation, 2Germany)

PB 2290 Role of Protease-activated Receptor 4 in Regulating Platelet-leukocyte

Interactions in Whole BloodR.A. Rigg, A. Mitrugno, L.D. Healy, A.T.P. Ngo, M.T. Duvernay, C.W. Lindsley, H.E. Hamm, A. Gruber, O.J.T. McCarty (United States)

PB 2291 Activation of PAR2 by Factor Xa Increases the Permeability across Cultured

Endothelial Cell MonolayersN. Benelhaj, A. Maraveyas, M. Johnson, C. Ettelaie (United Kingdom)

PB 2292 The Influences of Diabetes and Inflammation on the Effects of Thrombin and

Activated Protein C on Mast Cell SecretionI. Goliako, L. Gorbacheva (Russian Federation)


PB 2293 External Validation of Generic and Cancer-Specific Risk Stratification Tools for Predicting 30-day Mortality in Patients Presenting with Pulmonary Embolism and Active CancerJ. Caranfa, E. Weeda, E. Nguyen, S. Zeichner, C. Coleman, C. Kohn (United States)

PB 2294 Predictors of 30-day Mortality among Patients with Cancer-associated

Thrombosis in the RIETE DatabaseA. Tafur1, H. Fuentes1, J. Caprini1, A. Rivas2, F. Uresandi2, R. Duce3, R. Lopez-Reyes2, A. Visona3, M. Monreal2, RIETE Group (1United States, 2Spain, 3Italy)

PB 2295 Thrombosis after Orthotopic Liver Transplantation for Hepatocellular

Carcinoma: Incidence, Implications and Risk FactorsA. Maino, M. Abbatista, P. Bucciarelli, A. Artoni, S. Bhoori, F. Ponziani, U. Maggi, G. Rossi, T. De Feo, F. Peyvandi, V. Mazzaferro, I. Martinelli (Italy)



468 469

Wed

nesd

ayP

oste

r S

essi

ons

PB 2296 Predicting the Risk of Recurrent Venous Thromboembolism in Patients with Cancer: The REMARK StudyN. van Es1, M. Louzada2, M. Carrier2, V. Tagalakis2, P. Gross2, S. Shivakumar2, M. Rodger2, P.S. Wells2 (1The Netherlands, 2Canada)

PB 2297 Comparative Analysis of Predictive Models for Thromboembolic Events in

Lymphoma PatientsD. Antic, N. Milic, S. Nikolovski, M. Todorovic, J. Bila, P. Djurdjevic, B. Andjelic, V. Djurasinovic, A. Sretenovic, V. Vukovic, J. Jelicic, B. Mihaljevic, Serbian Lymphoma Group (Serbia)

PB 2298 Outcomes of Subsegmental Pulmonary Embolism (SSPE) in Cancer Population

M. Yan, C.C. Wu, W. Qiao, C.M. Rojas-Hernandez (United States) PB 2299 Screening for Cancer in Patients with Unprovoked Venous Thromboembolism: A

Systematic Review and Individual Patient Data Meta-AnalysisN. van Es1, G. Le Gal2, H.-M. Otten1, P. Robin3, A. Piccioli4, R. Lecumberri5, L. Jara-Palomares5, P. Religa6, V. Rieu3, M. Rondina7, M. Beckers8, P. Prandoni4, P.-Y. Salaun3, M. Di Nisio4, P.M. Bossuyt1, H.R. Büller1, M. Carrier2 (1The Netherlands, 2Canada, 3France, 4Italy, 5Spain, 6Sweden, 7United States, 8Belgium)

PB 2300 Cancer Cell Derived Extracellular Vesicles Increase Extracellular Vesicle

Dependent Tissue Factor Activity of Peripheral Blood Mononuclear Cells in the Presence of PlateletsT. Däullary, L. Hell, E. Grilz, L.-M. Mauracher, J. Schmid, C. Ay, I. Pabinger, J. Thaler (Austria)

PB 2301 Impact of Regular Physical Activity on the Risk of Cancer-related Venous

Thromboembolism - The Scandinavian Thrombosis and Cancer (STAC) CohortL.H. Evensen1, M.T. Severinsen2, J. Hammerstrøm1, S.K. Braekkan1, S.R. Kristensen2, S.C. Cannegieter3, O.V. Gran1, A. Tjønneland2, F.R. Rosendaal1, H. Skille1, K. Overvad2, I.A. Næss1, J.B. Hansen1 (1Norway, 2Denmark, 3The Netherlands)

PB 2302 Immunomodulatory Changes at the Tumor Microenvironment Induced by a

Kunitz-type Inhibitor Improve Antitumoral Activity CD8+T-dependent Manner on Orthotopic Kidney Tumor ModelJ.G. de Souza, F.V. Pereira, P. Boufleur, J.M. Sciani, C.S. Origassa, M. Amano, N.O.S. Câmara, A.M. Chudzinski-Tavassi (Brazil)

PB 2303 Elevated Risk of Venous Thrombosis Post Allogeneic Transplantation for

Leukemia: Patient Characteristics of a Single Centre CohortR. Ikesaka, N. Cantor, M. Carrier, M. Sabloff (Canada)

PB 2304 Combination of Podoplanin Expression and IDH-1 Mutation Status in Primary Malignant Brain Tumors Identifies Patients at Risk of Venous ThromboembolismJ. Riedl, P.M.S. Nazari, M. Preusser, F. Posch, C. Marosi, P. Birner, J. Thaler, G. Ricken, J.A. Hainfellner, I. Pabinger, C. Ay (Austria)

PB 2305 Podoplanin Promotes Oral Cancer Malignancy by Inducing Intravascular

Coagulation in Orthotopic Xenograft Mice ModelH.-Y. Lee, J.-C. Cheng, C.-P. Tseng (Taiwan)

PB 2306 Thrombin Generation in Patients with Active Multiple Myeloma and Impact of

Immunomodulators. The ROADMAP StudyL. Papageorgiou1, P. Van Dreden1, D. Fotiou2, M.S. Guye1, L. Garderet1, E. Terpos2, S. Salta1, T. Sergentanis2, M. Dimopoulos2, A. Larsen1, I. Elalamy1, G. Gerotziafas1 (1France, 2Greece)

PB 2307 Impact of the Extensive Cancer Screening in Patients with a First Episode,

Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysisC. Chai-Adisaksopha, E. Tseng, M. Crowther, A. Iorio, M. Carrier (Canada)

PB 2308 Paradoxal Roles of Platelets in Colorectal Cancer Behavior

L. Plantureux, L. Crescence, F. Dignat George, L. Panicot-Dubois, C. Dubois (France) PB 2309 The Modified Ottawa Score and Clinical Events in Hospitalized Patients with

Cancer-associated Thrombosis from the Swiss VTE Registry (SWIVTER)A. Alatri, L. Mazzolai, N. Kucher, D. Aujesky, J.H. Beer, T. Baldi, M. Banyai, D. Hayoz, T. Kaeslin, W. Korte, R. Escher, M. Husmann, B. Frauchiger, R.P. Engelberger, I. Baumgartner, D. Spirk (Switzerland)

PB 2310 Predictive Value of D-dimers and Microparticle-associated Tissue Factor

Activity for the Risk of Thrombosis in Pancreatic CancerD. Faille, N. Ajzenberg, E. de Raucourt, P. Hammel, P. Lévy, P. Ruszniewski, V. Rebours (France)

PB 2311 Venous Thromboembolism Leads to Poor Survival in Patients with High Grade

B Cell Lymphoma - A 7-year Single Centre AnalysisM. Grech, M. Debono, D. Farrugia, D.J. Camilleri, A. Gatt (Malta)

PB 2312 Performance of Khorana Score Models in Predicting Occurrence of Incidental

Venous Thromboembolism (VTE) in CancerV.K. Tang, C.P. Escalante, T.P. Lam, M.N. Richardson, C.M. Rojas Hernandez (United States)

PB 2315 Audit: Use of Khorana Score in Newly Diagnosed Patients with Pancreatic CancerC. Carson, G. Benson (United Kingdom)



470 471

Wed

nesd

ayP

oste

r S

essi

ons

PB 2316 Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: A Meta-analysis of Randomized Controlled TrialsF. Dentali1, M.N.D. Di Minno1, R. Lupoli1, G. Conte1, N. Van Es2, H. Buller2, W. Ageno1 (1Italy, 2The Netherlands)

PB 2317 Podoplanin-dependent Platelet Aggregation Mediated by Human Glioblastoma Cell LinesP. Mir Seyed Nazari, J. Riedl, L. Hell, C. Brostjan, W. Berger, D. Lötsch, C. Marosi, M. Preusser, S. Panzer, I. Pabinger, C. Ay (Austria)

PB 2318 Tumor cell-induced Platelet Secretion: Role of Protease-activated Receptors

A. Mitrugno, R.A. Rigg, C. Pui, O.J.T. McCarty (United States) PB 2319 Can NETs or miRNAs Predict Early Surgery-related Pulmonary Embolism in

Patients with Intracranial Tumors?J. Oto1, E. Plana1, D. Hervás1, L. Martos1, L.A. Ramón1, M.J. Solmoirago1, Á. Fernández-Pardo1, F. España1, S. Navarro1, A. Artoni2, P. Bucciarelli2, G. Carrabba2, G. Merati2, P. Medina1 (1Spain, 2Italy)

PB 2320 Thromboprophylaxis Strategy in Cancer Outpatients: CAT AXIS, a Case-vignette

Study on Clinical Practice In FranceI. Elalamy, F. Scotte, D. Mayeur, G. Meyer (France)

PB 2321 Peripherally Inserted Central Catheter (PICC) Related Thrombosis in 230

Patients with Hematological Malignancies. A 6 Years Single Experience CenterM. Baile, A. Veiga, M. López-Parra, M. Sánchez-Barba, N. Arratibel, B. Rodríguez, M. Sastre, O. Del Rey, A.Á. Martín, M. Cabrero, J.R. González-Porras, J.M. Bastida (Spain)

PB 2322 The Management of Non DVT-PE Cancer-associated Thrombosis: A Single

Centre ExperienceA. Doyle, D. McClinton, V. McDonald (United Kingdom)

PB 2323 Bioinformatic Analysis of Collaborative Interaction between Platelet and Cancer

Cell Derived Microparticles in Evolving a Post Code Mechanism for Breast Cancer Metastasis and Identification of CD9 as Potential Drug Resistance MarkerR.K. Vangala, A. Sharma, M. Ghatge (India)

PB 2324 Tumour Microvesicles Interact with Endothelial Cells under Venous Flow in vitro

A. Algarni, J. Greenman, L. Madden (United Kingdom)

PB 2325 The STEP-CAT Cohort Management Study: Step-Down to Prophylactic Doses of Enoxaparin after a Minimum of 3-6 Months of Anticoagulation for the Treatment of Cancer-associated ThrombosisV. Tagalakis, T. Djouonang, M. Carrier, N. Routhier, S. Shivakumar, S. Solymoss, M. Louzanda, C. Sperlich, S.R. Kahn (Canada)

PB 2326 Myeloma Plasma Cells Express Tissue Factor and Trigger Thrombin Generation

L. Papageorgiou, H. Mokrani, L. Garderet, C. Mazurier, A. K.Larsen, P. Van Dreden, I. El Alamy, G. Gerotziafas (France)

PB 2327 Radiotherapy Does Not Affect CoagulationK.M. Begtrup, J.A. Højbjerg, B. Offersen, A.-M. Hvas (Denmark)

PB 2328 Usefulness of D-dimer in the Diagnosis of Deep Vein Thrombosis after

Neurosurgery for Glioblastoma and MeningiomaM.T. Sartori, F. Boscaro, A. Della Puppa, E. De Bon, F. Dalla Valle, C. Piovella, A. Padoan, R. Scienza, P. Prandoni (Italy)

PB 2329 Predictors of Mortality in Lung Cancer with Pulmonary Embolism: Concurrence

of Pulmonary Embolism with Lung Cancer and Central EmboliS.-I. Cha, Y.H. Lee, H. Seo (Republic of Korea)

PB 2330 Patients with Venous Thromboembolism Events Admitted in a Tertiary Care

Hospital: Follow-up for One Year and Correlation with CancerF. Sabio, L. Gonçalves, C. Monteiro, C. Marujo, C. Koch (Portugal)

PB 2331 Cement Pulmonary Embolism as a Complication of Percutaneous Vertebroplasty

in Cancer PatientsA. Mansour1, H. Abuali1, S. Salah2, M. Ma'koseh1, N. Shaikh-Salem1, K. Abushalha1, H. Abdel-Razeq1 (1Jordan, 2Canada)

PB 2332 Renal Cell Carcinoma with Neoplastic Thrombosis: A Treatment Challenge for a

Rare EntityV. Pons, P. Raheja, P. Olivera, A. Varela, T. Canals, E. Johansson, V. Cortina, M. Constans, F. Bosch, A. Santamaria (Spain)

PB 2333 Silent Venous Thromboembolism in Patients Undergoing Thoracic Surgery in

the Course of Lung CancerB. Kazanecka, P. Kuca, M. Dybowska, J. Burakowski, C. Czajka, F. Grzegorczyk, W. Tomkowski (Poland)

PB 2334 Demographic Data and Outcomes of Pediatric Patients with Tumor and Thrombosis

P. Wongmas, P. Komvilaisak, S. Wiangnon, A. Jetsrisuparb (Thailand)



472 473

Wed

nesd

ayP

oste

r S

essi

ons

PB 2335 Retrospective Cohort Study of Venous Thromboembolism (VTE) Rates in Ambulatory Cancer Patients, and Association with Khorana ScoreK. Austin, J. Borrowman, L. Blake, M. Scully, M. Thomas (United Kingdom)

PB 2337 Subclinical Portal Vein Thrombosis in Liver Cirrhosis Patients Increase Risk of 30 Days Mortality: Preliminary StudyA. Kurniawan, N.P.H. Lugito (Indonesia)

PB 2338 Relationship of Platelets Parameters with JAK2 V617F Mutation Status and

Thrombotic Risk in Myeloproliferative DisordersH. Baccouche, D. Bahri, A. Chakroun, S. Mahjoub, Z. Manai, N. Ben Romdhane (Tunisia)

PB 2339 Genetic Forms of a Thrombophilia in Cancer Patients with Recurrent VTEA. Vorobev, A. Makatsariya, A. Solopova (Russian Federation)

PB 2340 Acute Pulmonary Embolism in Cancer Patients: Clinical Findings and Outcome

B. Vitola, D. Kigitovica, V. Gibietis, S. Strautmane, A. Skride (Latvia) PB 2341 Subarachnoid Hemorrhage and General Anesthesia Inhibit the Brain (G)

Lymphatic System in Mice and Non-human PrimatesM. Gauberti, T. Gaberel, S. Goursaud, S. Martinez de Lizarrondo, D. Vivien, C. Gakuba (France)

PB 2342 Association between Hepatic Triglyceride Content and Coagulation Factor

Levels: The Netherlands Epidemiology of Obesity (NEO) StudyV.M. Morelli, R. de Mutsert, A. de Roos, H.J. Lamb, A. van Hylckama Vlieg, M.H.A. Bos, F.R. Rosendaal, W.M. Lijfering, S.C. Cannegieter (The Netherlands)

PB 2343 Portal Vein Thrombosis Associated with Abdominal Inflammatory Conditions

V. Tran, A. Acuna-Villaorduna, H. Billett (United States) PB 2344 Role of ADAMTS13 Deficiency in the Pathogenesis of Portal Vein Thrombosis

Complicating Liver CirrhosisS. Lancellotti, M. Basso, M. Sacco, L. Riccardi, M. Pompili, R. De Cristofaro (Italy)

PB 2345 Haemostatic Changes in Cirrhotic Patients Treated with Direct-acting Antiviral

TherapyE. Campello, A. Zanetto, L. Spiezia, C. Radu, S. Gavasso, A. Ferrarese, A.C. Frigo, G. Germani, M. Senzolo, P. Burra, F.P. Russo, P. Simioni (Italy)

PB 2346 The Risk of Venous Thromboembolism in Women with Polycistic Ovarian

Syndrome: An Italian StudyL. Filippi, R. Mioni, R. Pesavento, D. Ceccato, A. Dalla Ca', A. Gambineri, F. Fruzzetti, L. Cervino, M.E. Fulghesu, R. Vettor (Italy)

PB 2347 Fibrinogen Estimation in Patients with Liver DiseaseK. Rizzo, K. Vella, D. Zammit, P. Gatt, C. Grima, M. Vassallo, P. Ellul, J. Gerada, N. Azzopardi, J. Pocock, M. Borg Inguanez, A. Gatt (Malta)

PB 2348 A Rat Model to Evaluate Formation of Venous Thromboembolism after Prolonged Tourniquet ApplicationO. Mian, J. Gantioqui, P. Liao, J. Zhou, J. Weitz, A.K.C. Chan (Canada)

PB 2349 Increased Baseline TF Activity in Women with Unexplained Pregnancy Loss: An

Additional Argument for a Basal Endothelial Dysfunction?E. Pasquier, P. Van Dreden, A. Rousseau, L. de Saint Martin, D. Mottier, F. Couturaud (France)

PB 2350 HABP2 (PHBP/FSAP) is the Major Plasma Protease that Promote Extracellular Histone DegradationY. Amemiya, J. Mutoh, E. Suzuki, K. Hasumi (Japan)

PB 2351 Adjunctive Hemostatic Application of Highly Adhesive Drug Loadable Powder

for Partial Hepatectomy Bleeding in a Swine ModelL. Eunhye, M. Jin Hee, A. Sukyung, K. Keunsu, L. Don Haeng (Republic of Korea)

PB 2352 The ratio "Tissue Factor / Tissue Factor Pathway Inhibitor" as a Major

Determinant of Hypercoagulabilty in Cirrhotic PatientsP. Van Dreden, M. Grusse, D. François, R. Bironien, M. Vasse (France)

PB 2353 Upper Regulation of Plasma Endocan and D-Dimers in Individuals with

Compensated Liver DiseaseD. Van Thiel, M. George, D. Hoppensteadt, D. Syed, R. Wahi, D. Fareed, J. Fareed (United States)

PB 2355 Effect of Extract Ethanol of Poguntano Leaves in Hemostasis Disturbances in

Alloxan Induced Diabetic RatsS.S. Widjaja, D. Munir (Indonesia)

PB 2356 Recurrent Budd-Chiari Syndrome (BCS) in a Patient with Polycythemia Vera

(PV), Protein S Deficiency and Hyperhomocysteinemia (HH) and Abnormal Resistance to Activated Protein (APCR) in the Absence of Factor V Leiden Mutation (FVL) Following Liver TransplantA. Sikorska, B. Ceglarek, B. Baran, E. Pleban, K. Bykowska, P. Szopiński (Poland)



474 475

Wed

nesd

ayP

oste

r S

essi

ons


PB 2357 Knock down the CD70 Expression in DCs Could Inhibit the CD4+ T Cells Differentiating to Tregs in ITPZ. Zhou, Y. Wang, H. Li, R. Yang (China)

PB 2358 IL-10 Producing B Cells Induced by CD72 Ligation Suppress Th1 and Th17 Polarization in Primary Immune ThrombocytopeniaM. Lyu, Y. Hao, Y. Li, C. Lyu, H. Li, F. Xue, X. Liu, L. Zhang, R. Yang (China)

PB 2359 Impact of Platelet Transfusion on Thromboembolic Events in Patients with Acute Heparin-induced ThrombocytopeniaS. Miyata, T. Maeda, H. Yamamoto, H. Okazaki (Japan)

PB 2360 Isolation of a Monoclonal IgG Kappa with Functional Autoantibody Activity

against Platelet Factor 4/Heparin from a Patient with a Monoclonal Gammopathy of Undetermined Significance and Clinically Overt Heparin ThrombocytopeniaD. Faille, M. Hurtado-Nedelec, A. Ouedrani, J. Amiral, M.-G. Huisse, M.-P. Chauveheid, M. Mazighi, N. Ajzenberg (France)

PB 2361 Anticoagulation Stewardship Program for Heparin Induced Thrombocytopenia: A Cooperative Effort between a Community Hospital System Pharmacy Anticoagulation Service and an Associated Reference LaboratoryC. Mahan, L. Kelly, A. Pierce, A. Burnett, A. Haghamad (United States)

PB 2362 IP-10 and MCP-1 Gene Polymorphisms in Chinese Patients with Chronic

Immune ThrombocytopeniaX. Zhang, D. Zhang, R. Yang (China)

PB 2363 Decreased TLR4 Expression on Monocytes May Cause Regulatory T Cells

Abnormality in Patients with Primary Immune ThrombocytopeniaY. Hao, H. Li, Y. Li, M. Lyu, R. Fu, L. Zhang, R. Yang (China)

PB 2364 The Abnormal Expression of Rap1 in Various Cells of Patients with Immune

ThrombocytopeniaW. Liu, H. Li, R. Yang (China)

PB 2365 Resequencing of GWAS Loci Identifies New Candidate Genes on Chromosome

5 for Heparin-induced ThrombocytopeniaA. Witten, J. Bolbrinker, A. Barysenka, F. Rühle, E. Garbe, R. Kreutz, M. Stoll (Germany)

PB 2366 Elevated Plasma sCXCL16 Correlated with Th1 Polarization in Patients with

Primary Immune ThrombocytopeniaY. Hao, Y. Li, H. Li, M. Lyu, R. Fu, L. Zhang, R. Yang (China)

PB 2367 Time to Disappearance of Platelet-activating Antibodies Depends on the Strength of Their Platelet Activating Properties in Patients with Heparin-induced ThrombocytopeniaT. Maeda, H. Okazaki, S. Miyata (Japan)

PB 2368 Predictive Factors for Successful Splenectomy in Immune Thrombocytopenic Purpura

M. Mitrovic, S. Matic, J. Bodrozic, M. Smiljanic, D. Antic, I. Djunic, M. Virijevic, P. Miljic, D. Tomin, N. Suvajdzic (Serbia)

PB 2369 The Th17/Treg Imbalance and Fatigue in Primary Chronic Immune ThrombocytopeniaY. Li, Y. Hao, M. Lyu, H. Li, R. Yang (China)

PB 2370 Predictors of Fatigue among Individuals with Primary Immune

Thrombocytopenia in ChinaY. Li, Y. Hao, M. Lyu, R. Yang (China)

PB 2371 Elevated Plasmacytoid DCs Proportion and Plasma IFNα Concentration in

Active ITP PatientsH. Li, Y. Hao, R. Yang (China)

PB 2372 A Prospective, Double-blind, Multicenter Study on FCM-based Measurement of Circulating Reticulated Platelets as a Diagnostic Assay for Immune ThrombocytopeniaY. Hou, R. Xu, D. Li, K. Bi, X. Wang, C. Zheng, M. Hou, J. Peng (China)

PB 2373 Comparison Head-to Head of Two Functional Assays in the Assessment of

Heparin-induced ThrombocytopeniaM.-C. Gonthier, D. Faille, M. Alhenc-Gelas, C. Pouplard, N. Hezard, M.-G. Huisse, M.-C. Bourrienne, N. Ajzenberg (France)

PB 2374 Regulation of FcγRIIA-mediated Platelet Activation by a Cytochalasin-sensitive

Cytoskeletal Rearrangement: its Clinical Application to the Detection of Functional HIT AntibodyA. Yasumoto, Y. Yatomi (Japan)

PB 2375 Vitamin D Receptor Gene Polymorphisms in Adult Primary Immune

ThrombocytopeniaM. Sakr (Egypt)

PB 2376 Anti-PF4/Heparin Antibodies and Platelet Derived PF4 Bearing Microparticles

in Acute SepsisM.T. Sartori, C. Zurlo, E. Campello, M. Bon, E. Duner, C.M. Radu, R. Bendo, P. Simioni, F. Fabris (Italy)



476 477

Wed

nesd

ayP

oste

r S

essi

ons

PB 2377 Monocyte Subsets and Platelet Apoptosis in Patients with Primary Immune ThrombocytopaeniaR. Justo Sanz, I. Fernandez Bello, D. Hernandez-Florez, E. Monzón Manzano, M. Álvarez Román, M. Martín Salces, L. Valor, M. Rivas Pollmar, V. Jiménez Yuste, J. Lopez-Longo, N. Butta (Spain)

PB 2378 BAFF-TACI Signaling Promotes the Differentiation of Terminal Effector T Cells in Primary Immune Thrombocytopenia (ITP)Y. Min1, X. Li1, M. Nie1, C. Wang1, P. Jun1, M. Hou1, N. Li2, Y. Shi1 (1China, 2Sweden)

PB 2379 Delayed Clearance of Argatroban in Patients with Heparin Induced ThrombocytopeniaE. Groarke, A.M. Sweeney, N. O'Connell (Ireland)

PB 2380 Sleep Quality in Chinese Patients with Primary Immune Thrombocytopenia:

Contributing Factors and Effects on Health-related Quality of LifeY. Li, B. Sun, Y. Hao, M. Lyu, H. Li, R. Yang (China)

PB 2381 Immune Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection and Non-alcoholic Fatty Liver DiseaseT. Saralidze, F. Gabunia, N. Gogokhia, T. Svanidze, T. Saralidze (Georgia)

PB 2382 Epidemiology and Management of Immune Thrombocytopenia: A Nationwide Population-based Study in KoreaS.-M. Bang, J.Y. Lee, J.-H. Lee, H. Lee, B. Kang, J.-W. Kim, S.H. Kim, J.-O. Lee, J.W. Kim, Y.J. Kim, K.-W. Lee, J.H. Kim, H.S. Choi, J.S. Lee (Republic of Korea)

PB 2383 Laboratory Identification of Heparin Induced Thrombocytopenia: A Re-evaluation

E.J. Favaloro, G. McCaughan, K.K.E. Lau, S. Mohammed, L. Pasalic (Australia) PB 2384 Experience in Diagnostic Assays for Heparin-induced Thrombocytopenia

A. Keren Politansky, R. Hoffman, Y. Nadir, B. Brenner, G. Sarig (Israel) PB 2385 Prevalence of Heparin Induced Thrombocytopenia among Iranian Patients with

Cardiac SurgeryM. Shahbazi, M. Ahmadinejad, A. Chegini, R. Shamriz, Z. Ahmadinejad (Iran, Islamic Republic of)

PB 2386 HIT or Miss: Improving the Quality of Diagnosing Heparin-induced

Thrombocytopenia at an Academic Medical CenterM. Schaffner, I. Bogdanich, M. Zimmerman, J. Smelser, R. Hobbs, U. Perepu (United States)

PB 2387 Practical Limitations of Diagnostic Algorithms in the Management of Heparin Induced Thrombocytopenia: Clinical Case ReportS. Nowak-Harnau, S. Enkel, M. Jurisic, C. Reiß, B. Zimmermann, R. Jouni, T. Bakchoul (Germany)

PB 2388 Low Serum Vitamin D Levels in Egyptian Adults with Chronic Primary Immune

Thrombocytopenia: A Single Center StudyA.R. Soliman1, W. Elsalakawy1, A. Saeed1, S. Mohammed2 (1Egypt, 2Libyan Arab Jamahiriya)

PB 2389 Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in

Patients with Primary Immune Thrombocytopenic PurpuraJ. Hong, S.-M. Bang, Y.-C. Mun, H.-Y. Yhim, J.H. Lee, D. Oh (Republic of Korea)

PB 2390 Quantification of Specific T and B Cells Immunological Markers in Children with Chronic and Transient ITPS. Levy mendelovich, A. Lev, S. aviner, N. Rosenberg, H. Kaplinsky, S. Nechama, H. Miskin, A. Dvir, G. Kenet, I. Shoshan Eizen, R. Somech (Israel)

PB 2391 Risk of Cancer Occurrence and Survival in Patients with Primary Immune ThrombocytopeniaJ.-D. Wang, Y.-T. Tsan, W.-C. Chan, K.-M. Tong, C.-H. Lin (Taiwan)

PB 2392 Bleeding Outcome during Pregnancy in Patients Diagnosed with Immune ThrombocytopeniaB. Suwanawiboon, O. Amornariyakool (Thailand)

PB 2393 Development of PF4/Heparin Dependent Antibodies in Patients Undergoing

Extracorporeal Membrane Oxygenation and Clinical ImpactC. Vayne, M.A. May, E. Lemoine, E.A. Guery, J. Rollin, Y. Gruel, C. Pouplard (France)

PB 2394 Platelet Survival in Treatment of ITP

M. Kostal, P. Dulicek, E. Ivanova, P. Sadilek (Czech Republic) PB 2395 When Cancer Patients are HIT: A Literature Review of Heparin-induced

Thrombocytopenia (HIT) and Clinical Outcomes in Cancer PatientsT.H. Oo, C.M. Rojas-Hernandez (United States)

PB 2396 Evaluation of Increased Incidence of Heparin Induced Thrombocytopenia at a

Large Academic Teaching HospitalJ. Rimsans, M. Barra, H. Badreldin, J. Lauffenburger, J.M. Connors (United States)

PB 2398 rhTPO is Conductive to Remission from Acute Hemorrhage Phase of Children

Severe ITPM. Jingyao, C. Zhenping, W. Runhui (China)



478 479

Wed

nesd

ayP

oste

r S

essi

ons

PB 2399 Neuropilin-1 Expression on Regulatory T Cell Can Affect its Immunosuppressive Function in ITPH. Zhou, L. Su, L. Liu, Y. Song (China)

PB 2400 Thrombotic Events in Patients Treated with EltrombagT. Arias Fernández, J. Zanabili Al-Sibai, S. Gonzalez Muñiz, P. Palomo Moraleda, L.R. Morais Bras, L.F. Avila Idrovo, C. Castañon Fernandez, A. Sole Magdalena, A. Fernandez Rodriguez (Spain)

PB 2401 Familial Thrombocytopenia - Course of 3 Subsequent Pregnancies in an Idiopathic Thrombocytopenic Purpura (ITP) Patient; Case ReportJ.M. Teliga-Czajkowska, A. Sikorska, B. Ceglarek, K. Bykowska, E. Dmoch-Gajzlerska, K. Czajkowski (Poland)

PB 2402 Treatment Options and their Outcomes in Pediatric Immune Thrombocytopenic Purpura PatientsK. Perveen, S. Ansari, S. Parveen, S. Munzir, T. Shamsi (Pakistan)

PB 2404 Childhood Immune Thrombocytopenic Purpura (ITP) in Gorgan Taleghani HospitalN. Mirbehbahani, Z. Payab (Iran, Islamic Republic of)

PB 2405 Pharmacokinetic Variations, Fc Receptor Polymorphisms and their Impact on

Response to IVIG in Pediatric Immune ThrombocytopeniaD.E. Schmidt, K.M.J. Heitink-Polle, A.G. Laarhoven, B. Veldhuisen, M.C.A. Bruin, L. Porcelijn, E. van der Schoot, G. Vidarsson, M. de Haas (The Netherlands)

PB 2406 Fetal/Neonatal Alloimmune Thrombocytopenia - An Underestimated Life-

threatening Clinical ConditionL. Bonstein, R. Lauterbach, N. Atweh, A. Abu-rumi, N. Haddad (Israel)

PB 2407 Variable Impairment of Platelet Function in Patients with Severe, Genetically

Linked Immune DeficienciesM. Nagy1, T.G. Mastenbroek1, N.J.A. Mattheij1, S. de Witt1, K.J. Clemetson2, J. Kirschner3, A.S. Schulz3, J.M.E.M. Cosemans1, B. Zieger3, J.W.M. Heemskerk1 (1The Netherlands, 2Switzerland, 3Germany)

PB 2408 Whole Blood Aggregometry to Assess Platelet Function in Children on

Cardiopulmonary BypassR. Bercovitz, C. Drew, S. Jobe, D. Newman (United States)

PB 2409 Platelet PAC1 expression and dense granules function reflects bleeding severity

in childrenP. Zharkov, I. Demina, D. Fedorova, M. Panteleev (Russian Federation)

PB 2411 Utility of Small Volume Whole Blood Platelet Function Assays in Adolescent Women with Heavy Menstrual BleedingA. Rocheleau, A. Khader, A. Ngo, M. Recht, O. McCarty, K. Haley (United States)

PB 2412 Novel Mutations in Thai Patients with Glanzmann Thrombasthenia

D. Sosothikul, P. Suchartlikitwong, Y. Kittikalayawong, R. Hirunsatit, C. Ittiwut, V. Shotelersuk, K. Suphapeetiporn (Thailand)

PB 2413 Chemotherapy Induced Thrombocytopenia and Bleeding in Children and Young

Adults with CancerS. Mkhitaryan, S. Danielyan, A. Avagyan, D. Zohrabyan, L. Sargsyan, L. Safaryan, L. Harutyunyan, L. Hakobyan, S. Iskanyan, S. Bardakchyan, R. Papyan, M. Asatryan, G. Tamamyan (Armenia)

PB 2414 Pregnancy Management of Fetal Alloimmune Thrombocytopenia (NAIT): A Case ReportO. Paoletti, L. Pecoroni, P. Cavalli, M. Crotti, M. Franchini, G. Marchitelli, R. Morandini, C. Paccapelo, C. Poggiani, A. Riccardi, A. Zimmermann, S. Testa (Italy)

Vascular Biology & Angiogenesis

PB 2415 Thioredoxin Interacting Protein Endothelial Deletion Protects from Alterations of Angiogenic Process in Adult Mice Submitted to Vascular Accelerated AgingA. Domingues, B. Dizier, P. Gaussem, C. Boisson-Vidal, V. Nivet-Antoine (France)

PB 2416 FHL2 is Important for Angiogenesis and Regulates TF Expression in Normal VasculatureC. Kroone, H.H. Versteeg (The Netherlands)

PB 2417 MiRNA-21 Mediates the Antiangiogenic Activity of Metformin through Targeting

PTEN and SMAD7 Expression and PI3K/AKT PathwayM. Luo, X. Tan, J. Wu (China)

PB 2418 Role of SerpinE2 (PN-1) in Diabetic Microangiopathy

L. Idir, K. Aymonnier, Y. Boulaftali, M. Jandrot-Perrus, M.-C. Bouton, V. Arocas (France) PB 2419 Human Aortic Valvular Interstitial Cells: Evidence of Vasculogenic Potential

during Aortic Valve StenosisN. Gendron1, M. Rosa1, Y. Sottejeau1, A. Blandinieres1, E. Rossi1, A. Cras1, E. Van Belle1, N. Bacha1, A. Vincentelli1, N. Nevo1, B. Staels1, R. Jashari2, A. Dupont1, P. Gaussem1, S. Susen1, D. Smadja1 (1France, 2Belgium)



480 481

Wed

nesd

ayP

oste

r S

essi

ons

PB 2420 Nestin Is an Endothelial Enriched Protein in the Nonproliferative Vasculature with Potential Role in Endothelial ApoptosisP. Dusart1, L. Fagerberg1, B. Hallström1, M. Uhlén1, M. Civelek2, M. Germain3, P. Morange3, D.-A. Tregouet3, T. Renné1, J. Odeberg1, L. Butler1 (1Sweden, 2United States, 3France)

PB 2421 Shiga Toxin Type 2, a Causal Agent of Hemolytic Uremic Syndrome, Improved

Angiogenic and Repair Abilities of Late Outgrowth Endothelial Progenitor CellsH.A. Mena, V.I. Landoni, P. Schierloh, N. Rodriguez Rodrigues, M. Schattner, G.C. Fernández, S. Negrotto (Argentina)

PB 2422 Osteoprotegerin Promotes Tumour Development by Increasing NeovascularizationC. Boisson-Vidal1, Z. Benslimane-Ahmim1, A. Lokajczyk1, B. Dizier1, D. Heymann2 (1France, 2United Kingdom)

PB 2423 Platelet Endothelial Aggregation Receptor-1 (PEAR1) Modulates

Neoangiogenesis Via the Notch PathwayM. Criel, K. Cludts, L. Marleen, C. Vandenbriele, L. Liesenborghs, P. Verhamme, M. Hoylaerts (Belgium)

PB 2424 Angiostatin Demonstrates Differential Hypoxic-dependent Anti-angiogenic Effects on Cardiac Endothelial Cells Derived from Non-vs Type 2 DiabeticsN. Govindasamy, N. Lifeso, P. Jurasz (Canada)

PB 2425 Structural and Functional Study of Hypochlorous Acid Modified Human Antithrombin: Possible Role in CancerP. Ahmad, M.A. Jairajpuri (India)

PB 2426 Frequency of Post Thrombotic Syndrome (PTS) in Patients with Proximal Deep

Venous Thrombosis (DVT) - A Prospective Observational Study from a Tertiary Care Hospital in North IndiaV. Suri, S. Kumar, P. Malhotra, N. Kalra, U. Gorsi, J. Ahluwalia, G. Prakash, A. Rani Khadwal, S. Kumari, S. Jain, N. Varma, S. Varma (India)

PB 2428 Intracellular von Willebrand Factor Predominately Influences Angiogenesis

S. Selvam, M. Bowman, C. Pruss, P. James (Canada) PB 2429 Low Grade Inflammation Inhibits VEGF Induced HUVECs Migration in p53

Dependent MannerM. Yamakuchi, S. Panta, T. Hashiguchi (Japan)

PB 2430 Oroxin A Effectively Inhibits Breast Cancer Cell-mediated Tumor Vasculogenic

MimicryJ. He, J. Wang, X. Yang, H. Qian, L. Qin (China)

PB 2431 Acidic preconditioning improves endothelial progenitor cell survival and angiogenesis under proinflammatory conditions and post-ischemic tissue regeneration in a murine model of type II diabetesS. Negrotto1, H.A. Mena1, C. Boisson-Vidal2, M. Schattner1 (1Argentina, 2France)

PB 2432 Angiopoietin-2 Reduces Arteriogenesis Associated with the Suppression of the Infiltration of Macrophages in Mouse Ischemia Hindlimb ModelJ. Wu, X. Tan, K. Yan (China)

PB 2433 Role of Circulating Endothelial Progenitor Cells at the Early-stage of Neovascularization in Post-menopausal Luminal-A-Type Breast-cancer PatientsB. Ruszkowska-Ciastek, P. Rhone, R. Wieczór, D. Rość (Poland)

PB 2434 Pro-Angiogenic Biomarkers are Upregulated in Patients with Advanced Osteoarthritis Undergoing Orthopedic SurgeryL. Shih, M. Rondina, N. Guler, D. Syed, A. Walborn, D. Hoppensteadt, J. Fareed (United States)

PB 2435 VEGF-induced Angiogenesis Requires AutophagyK. Spengler, N. Kryeziu, S. Lindenmüller, L.-O. Klotz, A.S. Mosig, R. Heller (Germany)

PB 2436 G-protein Coupled Receptor 15 Mediates Angiogenesis and Cytoprotective Function of ThrombomodulinB. Pan1, X. Wang1, C. Nishioka1, G. Honda1, L. Zeng2, K. Xu2, T. Ikezoe1 (1Japan, 2China)

PB 2437 CCL5 and CXCL4 Are Rapidly Internalized in Endothelial CellsA. Dickhout, T.M. Hackeng, R.R. Koenen (The Netherlands)

PB 2438 Biased Activation of PAR1: Dissecting Signal Transduction Networks that Regulate the Endothelial Barrier FunctionB.L. van den Eshof, A.J. Hoogendijk, P.J. Simpson, F.P.J. van Alphen, K. Mertens, A.B. Meijer, M. van den Biggelaar (The Netherlands)

PB 2440 Major Endothelial Cell Integrin, Alphavbeta3 as a Target in Gram-negative Sepsis Caused by Urinary Tract InfectionT. McHale, C. Garcierena, S. Smith, F. Fitzpatrick, S. Kerrigan (Ireland)

PB 2441 Free Heme Triggers the Disruption of the Endothelial Barrier

M.M.L. Fiusa1, D. Garcia-Weber2, M. Lazarini1, J.M. Annichino-Bizzacchi1, F. Ferreira Costa1, J. Millán2, E.V. de Paula1 (1Brazil, 2Spain)

POSTER SESSIONS


483

POSTER SESSIONS


482

PB 2442 The Relevance Study of between miRNA Machinery Gene Polymorphisms (DICER rs3742330A>G, DROSHA rs10719T>C, RAN rs14035C>T, XPO5 rs11077A>C, DGCR8 rs417309G>A) and the Risk of Recurrent Implantation Failure (RIF) in Korean WomenC.S. Ryu, S.H. Cho, J.O. Kim, H.J. An, E.S. Kim, J.H. SaKong, H.A. Lee, H.W. Kim, D. Oh, J.H. Kim, W.S. Lee, N.K. Kim (Republic of Korea)

PB 2443 Plasma microRNA (miRNA) Profiling in Immune Thrombocytopenia (ITP)

before and during Treatment with Thrombopoietin Receptor Agonists (TPO-RA)L. Garabet1, W. Ghanima1, A. Rangberg1, R. Teruel-Montoya2, C. Martinez2, J.B. Bussel3, P.M. Sandset1, C. Monceyron Jonassen1 (1Norway, 2Spain, 3United States)

PB 2444 The Role of miR-143 in Collateral Vessel Growth

T. Hammerschick, K. Troidl, K.T. Preissner, S. Fischer (Germany) PB 2445 Circulating miRNA-24 as a Potential Biomarker for Coronary Heart Disease in

Type 2 Diabetes Mellitus PatientsX. Deng, M. Luo, J. Wu (China)

PB 2446 Circulating Extracellular Vesicles microRNA Profile in Transfusion Dependent

β-ThalassemiaC. Levin, A. Rebibo-Sabbah, A. Koren, B. Brenner, A. Aharon (Israel)

PB 2447 Plasma miR-103b as a Novel Biomarker for Screening Pre-diabetes and Newly

Diagnosis of Type 2 DiabetesM. Luo, Y. Luo, J. Wu (China)

PB 2448 Overexpression of p21Cip1 and p27Kip1 Regulates the Proliferation of

Endothelial Colony Forming Cells from Patients with Deep Venous ThrombosisJ.A. Alvarado Moreno, D. Moreno Lorenzana, J.R. Hernández López, J. Ramirez-Chan, I. Isordia Salas, M.A. Chávez Gonzalez, A. Majluf Cruz (Mexico)

Publication Only

PO 01 New Potential Marker for Analysis of the Organism State Under the Cardiovascular DisordersY. Tyravska, V. Lizogub, T. Katrii, O. Savchuk (Ukraine)

PO 02 Apolipoproteins and Serum Inflammatory Markers in Young Patients with Myocardial InfarctionK. Dahal, P. Karki, R. Maskey, K. Sherpa, M. Lamsal (Nepal)

PO 03 Particularities of Superficial Venous ThrombosisF. Saïd, A. Hamzaoui, I. Ben Ghorbel, M. Lamloum, T. Ben Salem, M. Khanfir, M.H. Houman (Tunisia)

PO 04 Venous Thrombosis in Systemic Lupus ErythematosusF. Saïd, A. Hamzaoui, I. Ben Ghorbel, M. Lamloum, T. Ben Salem, M. Khanfir, M.H. Houman (Tunisia)

PO 05 Clinical Profil of Digestive Thrombosis Patients

F. Saïd, Z. Meddeb, M. Lamloum, S. Hamrouni, I. Ben Ghorbel, T. Ben Salem, M. Smiti, M.H. Houman (Tunisia)

PO 06 Prevalence of Resistance to Anti-platelet Therapy among Patients with

Ischemic Stroke - Preliminary ResultsA. Pathare, O. Al Awidi, A. Alsiyabi, A. Gujjar (Oman)

PO 07 Intracerebral Hemorrhage under Antithrombotic Medication in a Recent YearT. Nakase, J. Moroi, T. Ishikawa (Japan)

PO 08 Methylenetetrahydrofolate Reductasa (MTHFR) C 677 Mutation-risk Factor for Ischemic Stroke or Not - Case ReportD. Stambolieva, M. Sorova (Macedonia, the Former Yugoslav Republic of)

PO 09 Role Glycin-containing Olygopeptides in Platelet AggregationM. Golubeva (Russian Federation)

PO 10 Bleeding Disorders in Ashkenazi JewsH.D. Solomons (South Africa)

PO 11 Management of a Severe Congenital Protein C Deficiency Case

N. Özdemir, H. Kızılocak, G. Dikme, T. Celkan (Turkey)

PO 12 Laboratory Detection of Thrombophilic Markers FrequencyV. Neceva (Macedonia, the Former Yugoslav Republic of)

Pos

ter

Ses

sion

s



484 485

PO 13 Red Blood Cells Distribution Width to Estimate Lupus ActivityS. Shoeib, M. Abdelhafez, A. Hassan, H. Sherif (Egypt)

PO 14 Levels of von Willebrand Factor Antigen in Apheresis Donors and in Mild Bleeders with Near Normal Screening Coagulogram: A Study from a Tertiary Care Teaching Hospital, South IndiaR. Kar, P.L. Ambika, R. Kulkarni, D. Basu, S.S. Kar (India)

PO 15 Screening Test for Leiden Mutation RelevanceN. Lazic, Z. Pastar, D. Mandic (Bosnia and Herzegovina)

PO 16 Simultaneously Label-free Measurement of Hemoglobin Concentration and Erythrocyte Shape by Scanning Flow CytometryE. Iastrebova, K. Gilev, A. Chernyshev (Russian Federation)

PO 17 Interaction of Antithrombotic Preparation Pijavit with Proteinase Complex

Longolytin and its Producer Imperfect Fungi Arthrobortys LongaL. Podorolskaya, T. Sharkova, I. Pavlova (Russian Federation)

PO 18 Immune Tolerance Induction in an Adult Haemophilia A Patient with a Long-standing InhibitorC. Feistritzer, D. Nachbaur, M. Steurer (Austria)

PO 19 Evaluation of the Quality and Safety of Care in Hemophilia Self-treatmentM. Djaafri, M. Sehab, L. Zatla, R. Messaoudi, D. Saidi, H. Touhami (Algeria)

PO 20 Participation of a Group of Healthcare Professionals in the Improvement of Hemophilia Treatment in Latin AmericaC.A. Montano Mejia1, M.S. Cruz2, F.A. Espinosa Chacur3, J.F. Lemos Garcia4, G.F. Rojas Alba5, A. Quiroz Astigarraga6, C.G. Carrera Calero7, A. Peña Hernandez8, O.A. Avendaño9, J.M. Cortes Bernal1, A.M. Gaona Tottil6 (1Colombia, 2Argentina, 3Chile, 4Uruguay, 5Bolivia, 6Paraguay, 7Ecuador, 8Honduras, 9Guatemala)

PO 21 Successful Non-operative Management of Intra-abdominal Hemorrhage in Patient with HemophiliaH.S. Yoon, M.J. Kim (Republic of Korea)

PO 22 Inhibitor Screening of Children with Hemophilia in the Diyarbakır - A Single

Centre StudyM. Söker, H. Uzel, K. Öncel, S. Söker (Turkey)

PO 23 Liver Transplantation in Hemophilia PatientsA. Aires, M.J. Diniz, M. Antunes, A. Santos, T. Araújo, A. Mascarenhas, M. Rameiras, M. Campos, A. Ribeiro, S. Gouveia, E. Barroso, R. Perdigoto, A. Ferreira (Portugal)

PO 24 Chronic Osteolytic Lesions Secondary to Gigantic Pseudotumor of the Thigh in a Young Adult with Hemophilia B: Poor Prognosis and OutcomeR. Silva, J. Marun, D. Perez (Colombia)

PO 25 Pseudotumor ans Succeful Conservative Management in Hemophilia Patient

with InhibitorsR. Silva, J. Marun, D. C (Colombia)

PO 27 Unexpected Incidence of Inhibitor Development in a Hemophilic Population from the North of SpainL.F. Avila Idrovo, A. Bernardo Gutérrez, D. Martinez Carballeira, I. Soto Ortega (Spain)

PO 28 Hereditary Hypofibrinogenemia - Rare Familial Disease with Tendency to Increased BleedingJ. Prochazkova, L. Slavík, J. Ulehlova, V. Krcova, A. Hlusi (Czech Republic)

PO 29 A Case with Factor X Deficiency and Malignant MelanomaB. Koc, S. Buyukkapu Bay, B. Zulfikar, F. Taş, R. Kebudi (Turkey)

PO 30 Inherited Thrombocytopathy - Impact on Patient's QOL

J.M. Teliga-Czajkowska, A. Sikorska, B. Ceglarek, K. Bykowska, A. Bućko, E. Dmoch-Gajzlerska, K. Czajkowski (Poland)

PO 31 Duodenal Dieulafoy´s Lesion in a Patient with Type 2 von Willebrand Disease:

Case Report from ColombiaJ. Restrepo-Avenia, J. Duque-Gil, J. Ramirez-Varela (Colombia)

PO 32 Von Willebrand Disease Diagnosis in Algeria: A Monocentric StudyH. Boukerb (Algeria)

PO 33 The Relevance of Personalized Therapy by New Oral Anticoagulants. Current Possibilities of Laboratory Monitoring and Control in Difficult PatientsS. Safiullina, T. Vuimo, I. Tyutlina, L. Feiskhanova (Russian Federation)

PO 34 Long-term Anticoagulation with Direct Oral Anticoagulants (DOACs) for the Prevention of Recurrent Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE)R. Santoro, P. Iannaccaro, S. Morgione, M.T. Paparo (Italy)

PO 35 Laboratory Tests for Management in Patient with Direct Oral AnticoagulantsL.F. Avila Idrovo, A. Bernardo Gutérrez, A. Caro Gómez, A. Fonseca Mourelle, L. Rodriguez Lorenzo, A.P. Rodriguez Gonzalez, I. Soto Ortega (Spain)

Pos

ter

Ses

sion

s



486 487

Pos

ter

Ses

sion

s

PO 36 Effective reversal of High Dose Dabigatran Intoxication by Idarucizumab in a Bleeding Polytrauma PatientS. Ohlenforst, V. Ivaskevicius, C. Deborre, N. Theuerkauf, C. Putensen, J. Oldenburg, H.-J. Hertfelder (Germany)

PO 37 Does Intra-venous Unfractionated Heparin (UFH) Have a role In the

Management of Acute Peripheral Vascular Ischaemia and Surgery In 2017?M. Creagh, S. Matthews, V. Sathish, X. Taylor (United Kingdom)

PO 38 Oral Anticoagulants in Patients with Hereditary Protein Z Deficiency - A Case

ReportJ.C. Groß, B. Hummel, H. Lauer, B. Stephan, J. Schenk, H. Eichler (Germany)

PO 39 Prevalence of Laboratory Markers of Thrombophilia in Pregnant Women with

Normal Obstetric OutcomesE. Ferreira Filho, V. Barros, F. Baptista, R. Francisco, M. Zugaib, THROMBOSIS AND THROMBOPHILIA IN PREGNANCY (Brazil)

PO 40 Variation of Clotting Factor Levels of Pregnant Women Attending Antenatal Clinics in Irrua Specialist Teaching Hospital (ISTH), Irrua, Edo State, NigeriaR.A. Anyanwu, K.C. Lele (Nigeria)

PO 41 Catastrophic Antiphospholipid Syndrome in Obstetrics Practice (Clinical case)

A. Makatsariya, V. Bitsadze, D. Khizroeva (Russian Federation)

PO 42 Personalized Antithrombotic Prophylaxis in Patients with Multigenie and Combined Forms of Thrombophilia and APSV. Bitsadze, D. Khizroeva, A. Makatsariya, D. Kapanadze (Russian Federation)

PO 43 Thrombophilia and IVF

A. Rumjana, I. Nikoloska, V. Neceva, R. Dukovski, E. Petkovikj, S. Krstevska Balkanov, D. Trajkov (Macedonia, the Former Yugoslav Republic of)

PO 44 Risk Factors and Outcome of Thromboembolism in Pregnancy and Postpartum

Period: A Two Years Retrospective Analysis in a Tertiary Care Hospital of PakistanA. Rashid, B. Moiz (Pakistan)

PO 45 The Clinical Significance of Determining Homocysteine Levels and Functions

of the Natural Anticoagulants in Women Taking Combined Oral Contraceptives and Planning PregnancyV. Bitsadze, N. Khamani, O. Kaplina (Russian Federation)

PO 46 Case Reports of Successful Management of Pregnancy Complications and VTE in Women with Inherited ThrombophiliaL. Makhaldiani, N. Pirtskhelani, N. Kochiashvili, K. Kartvelishvili (Georgia)

PO 47 Control of the Anticoagulants and Antiplatelets during the Pregnancy in Women with Complicated Obstetric Medical History with Routines and Global Tests for Assessment of HemostasisS. Safiullina, T. Vuimo, L. Feiskhanova, N. Ilizarova (Russian Federation)

PO 49 β2GPI Titer and its Clinical Correlation with Laboratory Antiphospholipid Antibodies Syndrome Presented by Fetal LossN. Kassim, M. Ismail, D. Khattab, A. Attia, A. Salama, R. Mohie Eldine (Egypt)

PO 50 Antiphospholipid Syndrome in Pregnancy: A Case Report

F. Raka (Macedonia, the Former Yugoslav Republic of)

PO 51 One Hundred Days of Repetitive Thrombosis - Diagnostic and Therapeutic ChallengeN. Diaconu, Doina Bejenari (Moldova, Republic of)

PO 52 Pulmoner Thromboembolism: A Rare Cause of Respiratory Distress in Infants with NeuroblastomaT. Patiroglu, S. Kose, A. Ozcan, E. Unal, M. Karakukcu, A. Coskun (Turkey)

PO 53 A Challenging Deep Venous Thrombosis in a ChildA. Unuvar, S. Karaman, Z. Karakas, B. Bilgic, M. Aksoy (Turkey)

PO 54 Use of Direct Oral Anticoagulants in Multiple Myeloma Patient with Atrial

FibrilationA. Maritnez-Marin, J.J. Cerezo-Manchado, V. Cabañas, F. Garcia-Candel, E. Fernandez, M. Moya-Arnau, B. Navarro-Almenzar, J.M. Moraleda (Spain)

PO 55 Clinical Analysis of 399 Cases of Malignant Tumor Complicated with Venous Thrombosis in the Uygur and Han nationality in XinjiangQ. Luo (China)

PO 56 Circulating Neutrophil-extracellular Traps (NETs) Are Elevated in Patients with

EndometriosisD. Tàssies, J. Munrós, A. Perez, F. Carmona, J.C. Reverter, M.A. Martinez-Zamora (Spain)

PO 57 Thrombophila Associated with an Unusual Presentation of Liver Fibrosis/Cirrhosis and Splanchnic Vein ThrombosisM.C. Shen, C.Y. Lin, C.W. Lee, C.T. Chou, J.S. Lin, S.F. Kuo, B.D. Lin, H.N. Hsieh (Taiwan)

PO 58 Antithrombin Activity in Newly Diagnosed Diabetis Mellitus Patient seen at the University of Benin Teaching Hospital, Benin City, NigeriaB. Nwogoh, K. Akaba (Nigeria)


489

POSTER SESSIONS


488

NOTES

PO 59 Portal, Mesenteric and Splenic Vein Thrombosis in a Patient with Homozygous Factor V Leiden Mutation (A1691G) Receiving Oral ContraceptionA. Sikorska, B. Ceglarek, K. Bykowska, A. Bućko, A. Gwozdowska, J.M. Teliga-Czajkowska, J. Windyga (Poland)

PO 60 Deep Vein Thrombosis in a Family with Leiden Mutation (FVL, G1691A), Antithrombin Deficiency (AT) and ARhD (+) Blood TypeA. Sikorska, B. Ceglarek, K. Bykowska, E. Odnoczko, B. Baran, J.M. Teliga-Czajkowska, J. Windyga (Poland)

PO 61 Prothrombotic Mutations, Protein C Deficiency and Hyperhomocysteinemia in a

Patient Presenting Recurrent Venous ThrombosisA. Sikorska, B. Ceglarek, K. Bykowska, B. Baran, E. Odnoczko, E. Pleban, P. Szopiński (Poland)

PO 62 Rise and Fall of Thrombophilia Law in ArgentinaB. Grand, A. Rossi (Argentina)

PO 63 Hypofibrinogenemia and ThrombosisY. Ouarhlent, H. Laiaidhi., F. Mezhoud, R. Chafai (Algeria)

PO 64 Role of Thrombophilia Testing in Retinal Vein Occlusion: Single Center Experience from OmanK. Al Hashmi, F. Al-Ghafri, A. Pathare (Oman)

PO 65 Acute Severe Thrombocytopenia Induced by Abciximab: A Case ReportL. Gonçalves, S. Afonso, H. Nascimento, A. Leite, C. Koch (Portugal)

PO 66 Prolactin Level in Patients' Sera with Hepatitis C Virus Related ThrombocytopeniaA. Hassan, S. Shoeib, M. Abdelhafez, W. Algheriany (Egypt)

PO 67 Study of Serum Prolactin in Primary Immune Thrombocytopenic PatientsM. Abdelhafez, S. Shoeib, S. Gazareen, H. Elkholy (Egypt)

PO 68 Immun Trombocytopenic Purpura in a Patient with History of Non-Hodgkin Lymphoma and Common Variable Immune DeficiencyF.N. Kalkan, Ş. Ünal, F. Gümrük, M. Çetin (Turkey)



491

POSTER SESSIONS


490

• 2017 Webinar Series, Plus Archived 2014-2016 Webinars Covering Laboratory and Clinical Science

• New! Integration with JTH Articles and Research

• Webcasts, Posters and Abstracts from Congresses and SSC Meetings

• Education Courses – Access the ISTH Course on Venous Thrombosis

• CME Opportunities

Participate in the ISTH Academy!Your Personal Resource for Education

academy.isth.org

New Educational Opportunity: ISTH Training Fellowship ProgramAttention early career professionals! The ISTH Training Fellowships are an excellent opportunity to study at

prestigious host institutes with expert clinicians and researchers. Training Fellowship grants provide financial support for a period of up to two months for clinicians and scientists within 10 years of completion of a Ph.D.

or clinical subspecialty training.

Learn more at isth.org/fellowships

The ISTH Academy includes a comprehensive webinar series, educational webcasts and online webinar series, educational webcasts and online course modules for scientists, physicians and allied health professionals with notable speakers and health professionals with notable speakers and presenters on a variety of topics related to bleeding and clotting. All accessible from a computer and location of your choice, let the ISTH Academy provide you with the knowledge needed to advance science and patient care to improve the health outcomes for patients around the world.

Join Us! For more information on upcoming programming, visit academy.isth.org.

Congress Information

Venue and ContactsVenue Floor Plans

ISTH 2017 Attendee Services and InnovationsCongress Information

ISTH 2017 Networking EventsISTH 2017 5K Charity Run/Walk

Local InformationTransportation



492 493

VENUE AND CONTACTS

VenueMesse Berlin Messedamm 2614055 Berlin, GermanyT: +49 30-3038-3000E: [email protected]: www.messe-berlin.de

ContactsISTH Headquarters:International Society on Thrombosis and Haemostasis (ISTH) 610 Jones Ferry RoadSuite 205Carrboro, NC 27510 USAT: +1 919-929-3807F: +1 919-929-3935E: [email protected]: www.isth.org

Executive Meeting Matters: Lisa Astorga ISTH Director of MeetingsE: [email protected]

Sponsorship and Exhibition:Thomas ReiserExecutive DirectorT: +1 919-929-3807E: [email protected]

Marketing and Media:Louise M. St. GermainDirector of Marketing and MembershipT: +1 919-929-3807E: [email protected]

Membership Questions or General ISTH Inquiries:ISTH Membership StaffT: +1 919-929-3807E: [email protected]

ISTH 2017 Organizing Secretariat:(Registration, Logistics, Exhibition, Hotel Accommodations)c/o K.I.T. Group GmbHKurfuerstendamm 7110709 BerlinGermanyT: +49 30-24603-0E: [email protected] [email protected] [email protected]

Abstract Questions:E: [email protected]

ShiCo4056_VersionC_Resize_FINAL.indd

ClientJob

LiveTrim

Bleed

UsersCurrent Date

Creation Date

Printed atPage #

ShireShiCo 4056

142 mm x 204 mm148 mm x 210 mm154 mm x 216 mm

Derek Rush / Jovan Sekulovski 5-24-2017 11:52 AM5-24-2017 11:08 AM

None1

Job Info Approvals

FontsHelvetica Neue (35 Thin, 45 Light)

Inks Cyan, Magenta, Yellow, Black Images

Shire_Logo_PMS3005_4C.eps (33.1%), SHICO_g_563875809_SWOP_ext.tif (CMYK; 797 ppi; 37.6%)

Art DirectorCopywriterAccountStudio ArtistProofreaderProject Mgr

Jess S x291derek x230 Meredith x239

MATERIALS PREPARED BY SEIDEN

212.223.8700

FINALRound:

Notes

For more information, please visit shire.com

INTSP/C-ANPROM/CORP/16/0022 S13862 05/16

Our purpose is clear: to make a difference in the lives of those living with and affected by rare diseases and highly specialized conditions.

Unmet needs require unmatched commitment.

T:148 mmT:210 m

m


494 495

Hall 7Level 1

Hall 7 Mezzanine 1

Hall 7 Level 2

Hall 7 Level 3

Hall 7 Mezzanine 2

1

12

34

5

2

3

4

5

6

1

2

3

4

5

6

Hall22

Meeting Bridge ACompany Meeting Suites

Hall62

Entrance Hall 7

with Badge only

New York

London

Paris

Helsinki1

Helsinki2

Berlin

Gera

Ulm

To Rooms

Passau 2-4, 7, 9

Trier 1-3, 5, 6

Posters

Posters

PostersCollaborative

Meeting Rooms

Exhibition

Exhibition

Exhibition

Hall42

To Rooms

Frankfurt, Jena

Budapest

City Cube

Level 1

A2A3

A4A5

A7

A8

A6

A1

City CubeLevel 2

Hall B

City CubeLevel 3

CityCube

Entrance

Messedamm

S1 Press Room

Speaker Ready Room

Registration Counter Congress Material

Walkway to Exhibition

Halls / Hall 7

S2 Press Briefing Room

ISTH Secretariat

City CubeLevel ZE1

R2-R12 Master Classes/

Career Development

First Aid in 2.1

Connector to Hall 7 / Exhibition HallsMeeting Bridge BCompany Meeting Suites

Meeting Bridge CCompany Meeting Suites

Connector to Hall 7 / Exhibition Halls

To Room Regensburg

VENUE FLOOR PLANS

Overview of all areas

Cloakroom Hall 22, 42, 62

Exhibition & Catering

Poster areas

Catering / Lounge Area

Session Rooms

Meeting Rooms

Corporate Meeting Suites

Press Rooms

Bistro

Toilets

Elevator

Escalator

Stairs

VENUE FLOOR PLANS


496 497

A1

A2

A3

A4

A5

A6

A7

A8

Speaker Ready Room

PartnerResourceCenter

On this Level:Session Rooms: A1-A8Speaker Ready Room

Partner Resource Center

* Only Saturday, Sunday, Thursday

VENUE FLOOR PLANS

CityCube Level 1 – Lower Level

Cloa

kroo

m Busi

ness

Ce

nter

Cong

ress

Mat

eria

lsRe

gist

ratio

n Ar

ea

Mai

n En

tran

ce

Pray

er R

oom

Indu

stry

Wel

com

e De

sks

Self

Prin

ting

Term

inal

s

Self

Prin

ting

Term

inal

s

On

this

Lev

el:

Reg

istr

atio

n A

rea

Con

gres

s M

ater

ials

Pic

k U

pIn

dust

ry W

elco

me

Des

ksB

usin

ess

Cen

ter

Clo

akro

omP

raye

r R

oom

O

nly

Sat

urda

y, S

unda

y, T

hurs

day

VENUE FLOOR PLANS

CityCube Level ZE1 – Main Entrance/Registration Level


498 499

Hall B

BerlinInfo

SeatingArea

SeatingArea

On this Level:Session Room: Hall B

Internet StationsCube CafeBerlin Info

Walkway to Hall 7 & Exhibition Halls 2.2, 4.2, 6.2

VENUE FLOOR PLANS

CityCube Level 2 – Plenary Hall Level

ISTH Secretariat

S4 S3Grifols

S2 Press Briefing

Room

S1PressRoom

R12 R11 R10 R8 R7 R6 R5 R4 R3 R2 R1R9

R13

M8 M7 M6 M5 M3 M2 M1

SeatingArea

SeatingArea

SeatingArea

Way toR+S Rooms

On this Level:Meeting Rooms: M1-M8, R1-R13

ISTH Secretariat / Press Room: S1 / Press Briefing Room: S2 / Meeting Room: S3

VENUE FLOOR PLANS

CityCube Level 3 – Permanent Meeting Rooms and Press Rooms


500 501

New

Yor

kLo

ndon

Pari

s

On

this

Lev

el:

Ses

sion

Roo

ms:

New

Yor

k, L

ondo

n, P

aris

VENUE FLOOR PLANS

Hall 7 Level 1 – Lower Level

Meeting Bridge A Meeting Bridge B Meeting Bridge C

Lindau3

Lindau2

Lindau1

Lindau6

Lindau5

Lindau4

Dessau3

Dessau2

Dessau1

Dessau 6

Dessau 5

Dessau4

Weimar 3

Weimar 2

Weimar 1

Weimar 5

Weimar 4

To Hall 2.2 To Hall 4.2 To Hall 6.2

Gera

On this LevelCorporate Meeting Suites:

Lindau 1-6, Meeting Bridge A Weimar 1-5, Meeting Bridge B Dessau 1-6, Meeting Bridge C

Gera, Foyer Mezzanine 1

VENUE FLOOR PLANS

Hall 7 Mezzanine 1 – Corporate Meeting Suites




502 503

Buda

pest

Pass

age

toEx

hibi

tion

Hal

l 6.2

& P

oste

rs

Hel

sink

i 2H

elsi

nki 1

Pass

age

toEx

hibi

tion

Hal

l 2.2

& P

oste

rs

Pass

age

toEx

hibi

tion

Hal

l 4.2

& P

oste

rs

Part

ner

Reso

urce

Ce

nter

Job

Boar

d

Entr

ance

with

Badg

eon

lyO

n th

is L

evel

:S

essi

on R

oom

s: H

elsi

nki 1

-2, B

udap

est

Par

tner

Res

ourc

e C

ente

rJo

b B

oard

Pass

age

to C

ityCu

be

VENUE FLOOR PLANS

Hall 7 Level 2 - Ground Level

Berlin

On this Level:Session Room: Berlin

VENUE FLOOR PLANS

Hall 7 Level 3 - Upper Level


504 505

ISTH 2017 ATTENDEE SERVICES AND INNOVATIONS

Ancillary Meeting RoomsAncillary Meeting Rooms are pre-arranged by related organizations or partners for internal meetings on the occasion of the ISTH 2017 Congress. The locations of these meeting rooms are primarily in the CityCube Building of the congress center. Please check with the organi-zers of your meetings for the exact location.

Business CenterThe convention center has its own Business Center that provides the following services:

Printing (including business cards)CopyingFaxingScanningUse of laptopInternetPhone

The Business Center is located on the main entrance level of the CityCube Berlin.

Business Center Hours:Date HoursFriday, July 7 12:00–18:00

Saturday, July 8 – Wednesday, July 12 08:00-18:00

Thursday, July 13 08:00–13:00

Certificates of Attendance Certificates of Attendance will be available for printing on Wednesday, July 12, and Thursday, July 13, at the REACT Fast terminals located in the Registration Area on the main entrance le-vel of the CityCube Berlin. Attendees will need to scan their name badge to print a certificate.

Cloakroom and LuggageThe cloakroom (free of charge) is located on the main entrance level of the CityCube Berlin near the Registration Area. It is open at the following times:

Date HoursSaturday, July 8 08:00–18:00Sunday, July 9 – Wednesday, July 12 06:30–19:00Thursday, July 13 07:30–15:00

Collaborative Meeting RoomsLocated in Hall 6.2.b, the congress will feature Attendee Collaborative Meeting Rooms accom-modating up to 10 persons and can be booked by congress attendees to meet and collaborate in private, formal meeting spaces. Collaborative Meeting Rooms are free to reserve for up to 45 minutes beginning at the top of each hour and are each equipped with a meeting table, sea-ting, flat screen monitor, and cable to connect a personal laptop. Each congress attendee may reserve one 45-minute time slot per day. No ca-tering will be provided.

To reserve a Collaborative Meeting Room, visit www2.kit.de/profileportal/login/ISTH/en or see the service desk in Hall 6.2b onsite.

Conference CapturesPlenary and State-of-the-Art lectures of ISTH 2017 will be recorded and available online 24 hours after the presentation to both meeting attendees and ISTH members. These lectures can be accessed on the ISTH Academy at aca-demy.isth.org or by downloading the ISTH Aca-demy Mobile App (search Apple Store or Google Play for ISTH Congress). ISTH full members must use their ISTH login credentials for full access to the Academy. Non-member congress attendees must use their email address and password “isth2017” to access the meeting content. Contact [email protected] for any login issues. Conference captures, e-posters and Academy content may also be viewed in the ISTH 2017 Academy e-Education Zone located in Hall 6.2.a.


Congress Mobile AppUse your mobile device to navigate the ISTH 2017 Congress by downloading the free Con-gress Mobile App (Apple Store or Google Play)! It conveniently provides iPhone/iPad, Windows and Android smartphone and tablet users with on-the-go access to the ISTH 2017’s most im-portant informational and interactive features, such as program overviews, speaker and abs-tract information, general meeting and exhibitor information, venue and city maps and tips.

Internet StationsThe ISTH 2017 Internet Stations are located in three locations (one in each of the Exhibit Halls 2.2, 4.2 and 6.2.a), as well as in front of Hall B on Level 2 of the CityCube Berlin and allow participants to stay connected while attending the congress. Attendees can use the Internet Stations to check email, print airline boarding passes and search the internet. Each station features eight (8) computer terminals as well as one (1) printer for the exclusive use of meeting attendees.

ISTH Academy e-Education ZoneExplore the world of the ISTH Academy in the e-Education Zone. Participants and Academy users may browse the extensive Academy ar-chive including content from past ISTH mee-tings and the webinar series plus watch select presentations you missed from the ISTH 2017 Congress and browse ISTH 2017 e-posters! Go to the ISTH Academy e-Education Zone to ex-perience everything the ISTH Academy has to offer!

ISTH Congress DailyThe ISTH 2017 Congress publishes its official daily news online and via email during the mee-ting, as well as a post-congress issue two weeks following the meeting. The ISTH Congress Daily can be accessed via the Congress Mobile App and is also sent via email to all congress regist-rants and ISTH members. It can also be acces-sed directly at: www.isthcongressdaily.org.

ISTH Congress TVThe ISTH is proud to present ISTH Congress TV, featuring 30 minutes of video program-ming Monday, Tuesday and Wednesday during the meeting. ISTH Congress TV focuses on the scientific content of the congress, such as re-viewing top abstracts, interviews with authors, expert interviews and discussions on the impact of presented data on patient care and much more. Programming will be featured on the ISTH Congress Daily website and archived on the ISTH Academy.

ISTH Congress Virtual EventAlthough the conference in Berlin will bring to-gether the leaders in our field, we know there are many medical professionals that can’t be there face-to-face and would still benefit from the ISTH educational content. As the Society looks to the future and in an effort to engage a wider audience, an online component of the meeting is being offered at no charge. Select Plenary and State-of-the-Art sessions will be streamed around the world for those that are unable to attend. Sessions will be available each day to better accommodate international time zones. Live scientific moderators will be available online to answer virtual attendee questions. The content will be accessible July 10-12 from 15:30 to 18:30 UTC for those who register for the online meeting. Archives of the sessions will be available the following day on the ISTH Academy for ISTH members and con-gress participants. Please visit academy.isth.org for a schedule of the sessions and when they will be available for viewing.


506 507


Congress attendees and ISTH members, will receive wider access to recorded content and will be able to access all recorded sessions on the ISTH Academy website and Academy Mobi-le App 24 hours after the session.

Job BoardISTH 2017 Congress participants may share open position announcements via a job board located in the Foyer to Building 7. Simply bring your printed job announcement(s) and use the provided board to display your announcements. ISTH members and congress participants are also encouraged to announce open positions via the ISTH Online Career Center at jobs.isth.org.

Partner Resource CentersPartner organizations and congress organizers who would like to announce upcoming mee-tings may do so by displaying materials at the official Partner Resource Centers. Likewise, participants are encouraged to visit these Re-source Centers to learn about upcoming scienti-fic events in the field. Partner Resource Centers are located in the Foyer to Hall 7, in the Foyer to Hall A on Level 1 of the CityCube Berlin and in Hall 6.2.b.

Passport ProgramParticipate in the ISTH 2017 Passport Program by visiting exhibitors or other participating des-tinations, asking questions and learning about products and services of industry partners and/or Society and the congress. Gain new insights, earn points, compete with your fellow attendees and be eligible to win exciting prizes that the ISTH will raffle off among the highest ranked Passport Program participants. Conveniently access the Passport Program through the Con-gress Mobile App.

Download the ISTH app and scan this code to get started

Product TheatersNew this year, ISTH 2017 features Product The-aters that allow companies and organizations to present new research findings on products, provide product details, and/or give demonstra-tions to a small group of interested participants. Product Theaters are located in each of the Exhibition Halls (2.2, 4.2 and 6.2.a) and their programs can be found in the dedicated section in this program, as well as in the official ISTH 2017 Show Guide publication. Product Theater presentations take place daily (Monday-Wed-nesday) between 12:15 and 13:00.

Relax and Recharge AreasRelax and unwind in five (5) dedicated “Relax and Recharge” areas at the congress. Busy par-ticipants can sit, continue their conversations with colleagues or get some work done. These areas offer outlets to recharge computers/mobi-le devices either on site or to leave them in the provided charging stations. Relax and Recharge areas are located in the Exhibition Halls (three areas in Hall 2.2; two areas in Hall 4.2). Additi-onal seating can be found in Hall 6.2.b.


Show Guide to the Exhibition, Supported Symposia and Product TheatersFor a detailed program of the Industry Symposia and Product Theater Sessions, as well as a full profile of the ISTH 2017 exhibitors (including floor plans), please consult the ISTH Show Gui-de. The Show Guide can be collected from distri-bution boxes around the congress center. Please return your Show Guide publication after use.

Transit (Local)Participants have a logo on their name badge indicating that they have free access to all pub-lic transportation in Zone AB in Berlin. The closest station to the venue is The Messe Süd Station and is located across the street.Please note: Exhibitors do not have the logo on their badge.

Please visit the Berlin Public Transportation website at www.bvg.de for more information.

Virtual Delegate BagConsult the ISTH 2017 Virtual Delegate Bag to take advantage of a new and innovative service. Receive exclusive and valuable information from the ISTH and its partner organizations, as well as supporters and exhibitors. Conveniently accessible via the Congress Mobile App or via: goveb.co/ml/13ad97. The Virtual Delegate Bag is always with you without having to carry it around.


508 509

CONGRESS INFORMATION

AbstractsISTH 2017 abstracts are available online for easy viewing and download from the journal website of ISTH’s new open-access journal, Research and Practice in Thrombosis and Ha-emostasis (RPTH). Access them via the Con-gress Mobile App, the ISTH 2017 website at isth2017.org and/or the RPTH website at www.isth.org/rpth.

AccommodationsParticipants who have booked their accommo-dations in advance can visit the Registration Help Desk counter located in the Registration Area on the main entrance level of the CityCube Berlin for any questions related to their hotel booking. The staff at this counter can also help you to find and book rooms if required and sha-re pending availabilities.

ATM/Cash MachinesATMs are widespread and found in most banks, hotels and shopping centers in Berlin. In the convention center, an ATM machine is located in the main entrance of the CityCube Berlin.

BadgesParticipants receive their name badges when collecting their meeting documents onsite. Par-ticipants are required to wear a name badge du-ring all meeting events, including the Networking Evening (if applicable). Please note that admis-sion to scientific sessions and the exhibition is restricted to participants wearing their badges.

Please note:• Exhibitors are not admitted to the scientific

sessions.• The charge for the replacement of a lost

badge is EUR 10.

Berlin Information Desk For city information, please visit the Berlin In-formation Desk located near the Registration Area on Level 2 next to the escalators in the CityCube Berlin.

Date HoursSaturday, July 8 10:00–17:00Sunday, July 9 09:30–18:00Monday, July 10 09:00–16:00Tuesday, July 11 09:00–16:00Wednesday, July 12 09:00–16:00Thursday, July 13 09:00–15:00

CME/AccreditationThe XXVI Congress of the ISTH and 63rd Annual Scientific and Standardization Committee (SSC) Meeting, Berlin, Germany, 08/07/2017-13/07/2017 has been accredited by the Euro-pean Accreditation Council for Continuing Medical Education (EACCME®) with 28 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent num-ber of AMA PRA Category 1 CreditsTM. Informa-tion on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Congress BagThe congress bag, including all delegate materi-als, is distributed to registered participants at the congress bag desk in the Registration Area. Please note that there are no replacements for lost bags.


Duplicating/RecordingAny form of duplication (recording, audio ta-ping, photography and/or video) of sessions is prohibited without expressed written consent of the author and congress organizer. Please do not use your mobile device to duplicate or re-cord any sessions.

We kindly ask that attendees DO NOT photo-graph, record, film, or use a cellphone to cap-ture images of presentations at any time during the meeting, as well as on the poster and exhi-bit floors.

Please note that you may be photographed, vi-deotaped and/or recorded during your visit by the official ISTH 2017 photography/video team. By entering the ISTH 2017 Congress, you agree to each of the following: 1) You consent to be photographed, filmed and/or otherwise recorded in connection with, or as part of ISTH 2017 journalistic, advertising, marketing, promotio-nal, archival and/or security activities; 2) You consent to such photography, filming and/or re-cording and to any use, in any and all media th-roughout the world in perpetuity, without com-pensation to you, of your appearance, voice and/or name for the above noted purposes; 3) You understand that all photography, filming and/or recording will be done in reliance on these consents given by you by entering the congress; 4) To protect, among other things, the personal information of our attendees, you agree not to reproduce, perform, display or upload any pho-tographs of sessions/presentations.

If you do not wish to be photographed or filmed via the official congress photography and video team, kindly inform representatives of your pre-ference.

Emergency Phone NumbersDial 110 or 112 for all emergencies (police, fire, medical). Callers will then be placed th-rough to the appropriate emergency service.

Exhibition HoursThe ISTH 2017 Industry Exhibition is located in Halls 2.2, 4.2 and 6.2.

Date HoursSunday, July 9 18:30–21:00(Welcome Reception in the Exhibition Halls)Monday, July 10 10:30–17:00 Tuesday, July 11 10:30–17:00Wednesday, July 12 10:30–17:00

Insurance and LiabilityIt is recommended that participants obtain adequate insurance coverage for travel, health and accidents before they depart from their countries of residence. ISTH and K.I.T. Group as organizers cannot accept responsibility for personal injuries, or loss of, or damage to priva-te property belonging to the conference partici-pants and accompanying persons.

ISTH SecretariatThe ISTH secretariat is located in Room M4 on Level 3 of the CityCube Berlin.

LanguageThe official language of the meeting is English. There is no simultaneous translation service provided.

Lost and FoundFound articles may be brought to the Regist-ration Area on the main entrance level of the CityCube Berlin.

Lunches and Coffee BreaksLunch is provided as part of the registration fee on each of the congress days. Lunch vouchers are provided as part of the registration package. The vouchers are valid from Saturday, July 8, to Wednesday, July 12.

From Monday, July 10, to Wednesday, July 12, lunch and coffee breaks will be available in the catering areas of Exhibition Halls 2.2, 4.2 and 6.2. On Thursday, July 13, coffee and a lunch


510 511


snack will be available in the Foyers of the Ci-tyCube Berlin.

On Saturday and Sunday, July 8-9, lunch and coffee will be available in the Foyers of the Ci-tyCube Berlin.

Mobile TelephonesAs a courtesy to speakers and other partici-pants, all mobile phones and pagers must be turned off when attending sessions or symposia.

Notepads and PensA notepad and pen are included in the congress bag.

Hours

Friday Saturday Sunday Monday Tuesday Wednesday Thursday

Registration Area 12:00– 08:00– 06:30 – 06:30 – 06:30– 06:30 – 07:30–18:00 18:00 20:00 19:00 19:00 19:00 15:00

Speaker Ready Room12:30– 07:30– 07:30– 07:30– 07:30– 07:30– 07:30– 20:00 18:00 18:00 18:00 18:00 18:00 13:00

Exhibition Area 18:30– 10:30– 10:30– 10:30– 20:30 17:00 17:00 17:00

Poster Pick–Up Booth 18:30– 7:30– 7:30– 7:30– 21:00 18:00 18:00 12:00 Press Room 10:00– 8:30– 8:30– 8:30– 17:00 17:00 17:00 17:00


Pocket ProgramA pocket program is provided to participants upon registration. It is a handy reference and contains a program-at-a-glance, venue and con-gress information and map, information about Berlin and other useful tips.

Poster SessionsPosters will be presented on different days during the congress and are accessible at the same times as the exhibition opening hours. The official poster sessions will take place as follows:

Date HoursMonday, July 10 12:00–13:15Tuesday, July 11 12:00–13:15Wednesday, July 12 12:00–13:15

Poster Areas are located in Halls 2.2, 4.2 and 6.2.

Posters can be hung beginning at 07:30 and should be dismantled by 17:00 each day. Pos-ters not taken down after the dismantling time will be discarded.

Poster strips are available for hanging posters and can be found at the Poster Help Desk loca-ted next to the Poster Area.

Prayer RoomAn all-denomination prayer room is located in Room O13 on the main entrance level of the CityCube Berlin.

Press Room ISTH 2017 features a press room (Room S1) available for journalists attending the congress, as well a press briefing room (Room S2). Both rooms will be open Sunday, July 9, from 10:00-17:00, and Monday to Wednesday from 8:30-17:00 and are located on Level 3 of the City-Cube Berlin.

All journalists are asked to register first. To use the press room, media credentials must be pre-sented. Public relations and company represen-tatives may enter the room to drop off materials to share with the media; however, we kindly ask that they do not stay. All media are asked to follow the media policy in its entirety.

For a full schedule of media briefings, see the board in front of the press briefing room or stop by the press lounge for the schedule.

Poster Pick-Up BoothAccepted poster presenters were offered the opportunity to have their posters professionally printed and delivered to the congress at no cost.If you have opted to take advantage of this ser-vice, kindly note that you can pick up your pos-ter(s) at the Poster Pick-Up Booth located in

Friday Saturday Sunday Monday Tuesday Wednesday Thursday

Business Center 12:00– 08:00– 08:00– 08:00– 08:00– 08:00 – 08:00– 18:00 18:00 18:00 18:00 18:00 18:00 13:00

Cloakroom12:00– 08:00– 06:30– 06:30– 06:30– 06:30– 07:30 –18:00 18:00 20:00 19:00 19:00 19:00 15:00

Online DisclosuresAs part of the CME accreditation procedures, all speakers are obliged to provide disclosure of potential conflicts of interest. On the first slide of every presentation, these disclosures must be presented. The Speaker Ready Room can assist you with drafting this slide.

OverflowPlease be advised that overflow rooms are avai-lable in Room A4 on Level 1 of the CityCube Berlin and in Room Paris on Level 1 of in Hall 7.1c. Should any session be full, the Overflow will be activated and a hostess will direct you to the Overflow room.


512 513


Hall 6.2.b during the following times:

Date HoursSunday, July 9 18:30–21:00Monday, July 10 07:30–18:00Tuesday, July 11 07:30–18:00 Wednesday, July 12 07:30–12:00

Program ChangesProgram changes will be made public via the official ISTH 2017 Congress Mobile App and the website.

Registration Location and HoursRegistration starts on Friday, July 7, in the af-ternoon. The Registration Area is located on the main entrance level of the CityCube Berlin and is open during the following hours:

Date HoursFriday, July 7 12:00–18:00Saturday, July 8 08:00–18:00Sunday, July 9 06:30–20:00Monday, July 10 06:30–19:00Tuesday, July 11 06:30–19:00Wednesday, July 12 06:30–19:00Thursday, July 13 07:30–15:00

SmokingPlease note that this is a non-smoking meeting. Smoking is neither permitted in or outside the meeting halls nor in the exhibition area.

Social MediaISTH 2017 encourages the use of social media, such as Twitter, Facebook, LinkedIn, Instagram and other social media platforms at the confe-rence as a way to summarize, highlight, excerpt, review or promote the presented materials of the congress in general, provided that:

Copyright law is observed;Verbatim information is limited to a few quotes.The author or speaker is referenced and cited appropriately.

Congress hashtag: #ISTH2017

To get the latest updates throughout the con-gress, follow ISTH online via the following links:

www.facebook.com/internationalsocietythrom-bosisandhaemostasis

www.twitter.com/isth

www.linkedin.com/company/2253026/

www.instagram.com/isthofficeteam


Speaker Ready Room Speakers were contacted in advance to upload their presentations but should still report to the Speaker Ready Room at least two hours in advance of their presentation to ensure proper viewing. All conference rooms feature state-of-the-art technical equipment. Audiovisual mate-rial will be available for your presentation. The use of your own laptop during your presentation is prohibited.

The Speaker Ready Room is located in the Foyer on Level 1 of the CityCube Berlin. The opening times of the Speaker Preview Room are as follows:

Date HoursFriday, July 7 12:30–20:00Saturday, July 8 07:30–18:00Sunday, July 9 07:30–18:00Monday, July 10 07:30–18:00Tuesday, July 11 07:30–18:00Wednesday, July 12 07:30–18:00Thursday, July 13 07:30–13:00

Travel AwardsTravel Award recipients can go to the specific “Travel Award” desk in the Registration Area on the main entrance level of the CityCube Berlin to receive their grant. Grants can be collected between 08:00 on Saturday, July 8, through 12:00 on Tuesday, July 11. See page 24 for more information about travel grants.

Useful Telephone NumbersRegistration Help Desk: +49 30 30 38 81600

Hotel Information Desk: +49 30 30 38 81605

ISTH Executive Office: +49 30 30 38 81601

Water StationsStaying hydrated is always important, particu-larly during a busy day at ISTH 2017. Water stations are located throughout the convention center for the convenience of our attendees.

WebsiteUp-to-date information regarding the congress program, including all abstracts, is available at www.isth2017.org.

WIFIWIFI is available throughout the entire conven-tion center.

WiFi Name: ISTH2017

Password: sobibivv



514 515

ISTH 2017 NETWORKING EVENTS

Opening Ceremony and Welcome ReceptionSunday, July 9, 2017Time: 18:00–21:00Venue: Messe Berlin Price: Included in registration fee

The Opening Ceremony takes place in the Plenary Hall (Hall B) on Level 2 of the CityCube Berlin from 18:15–19:15. Under the theme “River of Knowledge,” participants are invited to enjoy a journey through the host countries Germany, Austria and Switzerland.

The Welcome Reception will take place in the adjacent Exhibition Halls 2.2, 4.2 and 6.2 from 19:15–21:00.

ISTH 2017 Congress Networking EveningWednesday, July 12, 2017Time: 18:30–1:00Venue: Tempodrom, Möckernstraße 10, 10963 BerlinPrice: 120,00 € (inclusive of VAT)

Join us for this exciting event at the visionary and unique Tempodrom where participants will have the opportunity to network with friends and colleagues. The evening will feature musical performances from local artists, local cuisine combined with inspirations from other countries, and a great selection of drinks.

Tickets can be purchased in the Registration Area on the main entrance level of the CityCube Berlin at the Congress Networking Event Counter or via your online ISTH Congress Profile at www2.kit.de/profileportal/login-7479.

Thrombosis and Haemostasis (1957 – 2017)

Celebrate with us the 60th Anniversary of our journal Thrombosis and Haemostasis !

Visit us at our booth 638 in Hall 6.2a and get your free sample copy!

Sign up for our free eTOC service: www.schattauer.de/eTOC-EN.html

1703074_corr.indd 1 03.04.2017 11:26:35



516 517

ISTH 2017 5K CHARITY RUN/WALK

Keep Life Flowing – Benefiting World Thrombosis DayTuesday, July 11, 2017 Time: 20:00 - 21:30 Venue: Grunewald, BerlinBuses will leave in front of the CityCube Berlin between 19:15-19:30 at the latest.Registration: Fee €10

Join us for the ISTH 2017 5K Charity Run to stay fit, help raise awareness and support ISTH’s World Thrombosis Day awareness campaign.

All congress attendees are invited to participate in a beautiful evening run (or walk) nearby in Berlin’s famous Grunewald forest while positively impacting their health and contributing to a good cause.For more information and to register, please visit my2.raceresult.com/67475/ or visit the Charity Run Information Desk in the Registration Area on the main entrance level of the CityCube Berlin.

You’re Invited!

“THE BEST LABORATORY HEMATOLOGY MEETING IN THE WORLD TODAY”

WWW.ISLH.ORG

Conference Dates: May 10-12Educational Workshop: May 9

Abstract Submission Deadline: February 1Early Registration Deadline: April 10

ISLH 2018Brussels, Belgium

C

M

Y

CM

MY

CY

CMY

K

ISLH 2018 - ISTH Ad V2.pdf 1 5/17/17 5:11 PM


518 519

LOCAL INFORMATION

Currency, Banks and Foreign Exchange OfficesThe Euro (EUR) is the unit of currency in Ger-many, which comes in bills and coins.Only major banks exchange foreign currency. Banking hours are Monday to Friday, 09:00 to 17:00. Currency exchange is also available at the airport.

ClimateBerlin has a humid continental climate. Sum-mers are usually warm and humid with mode-rate rainfall. The average temperature in July is 18 degrees C (64 degrees F), with a high around 23 degrees C (73 degrees F) and 13 degrees C (55 degrees F) for a low.

Credit CardsCredit cards are accepted at most (but not all) major retailers, in hotels and shop but it is ad-visable to still carry cash for some transactions.

ElectricityElectrical sockets in Germany usually supply electricity between 220 – 240 volts. Germany uses two of the European standard electrical socket types: The “Type C” Europlug and the “Type E” and “Type F” Schuko. An adapter is necessary if your appliances do not already have these types of shapes to match the socket.

RestaurantsBerlin is an international metropolis and has a va-riety of cuisines to choose from when dining out.

Restaurants usually open at 18:00, with the busiest time between 20:00 and 22:00. Re-servations are recommended, particularly on Thursday, Friday and Saturday evenings.

Tip and VAT are included in the bill, but if ser-vice is exceptional a 10-15% tip on the pre-tax bill is a standard expression of appreciation when dining out in the city. For more informa-tion and to find the right restaurant please visit www.visitberlin.de/en/experience/food-drinks.

Shopping in BerlinBerlin has a wide variety of shopping options. From traditional and new department stores, modern shopping malls, luxury designer shops to small handcraft manufactures, flea and an-tique markets and bargain stores - you'll find it all. Please note that shops are usually closed on Sunday. Visit www.berlin.de/en/shopping/ for more information.

TaxesIn Germany, the standard Value Added Tax (VAT) rate is 19% of the net price. All beverages, except milk and bottled water, are also taxed at the standard VAT rate. Products used on a daily basis such as books, newspapers, and food, as well as art, are taxed at the reduced rate of 7%.

Non-EU residents may qualify for a refund of some of the VAT they have paid during their visit in Germany. Please visit the Berlin.de website for more information:www.berlin.de/en/tourism/travel-information/ 1741381-2862820-value-added-tax-vat-refund.en.html.

Time ZoneStandard time zone: UTC/GMT +1 hourDaylight Savings Time: +1 hourBerlin is on CET (Central European Time)

TippingTips and value added tax (VAT) are officially in-cluded in all prices. For exceptional service, an extra tip is recommended. When tipping at a restaurant, tips should be handed to the waiter/waitress and not left on the table.

Taxis: 10%Restaurants: 10% – 15%Porters: € 2 - 3 per itemRoom maids: € 2 - 3 per dayHairdressers: 10%

TRANSPORTATION IN BERLIN

Berlin is the capital of Germany and its largest city. An international business hub, Berlin is a popular destination for professionals as well as tourists. The city is known for its distinctive history, modern economy, diverse architecture and high quality of living. As the ISTH 2017 Congress takes place during peak summer tou-rism season, the city is alive right now with a cosmopolitan mix of people and events.

Berlin's City TransitBerlin’s public transit system will take you al-most anywhere you want to go. Participants will have a logo on their name badge indicating that they have free access to all public transporta-tion in Zone AB (exhibitors do not receive this benefit).

How to get to the Messe Berlin convention center: From the airport: Two airports can be found in Berlin – Tegel Air-port and Schönefeld Airport. However, Tegel Airport (TXL) is located 8 km north-west out-side the city center and Schönefeld Airport is situated 18 km south-east from the city center. From both airports, you can reach the city cen-ter either by taxi, car or public transportation.

By car: From Tegel Airport: take the A100 and exit at Messedamm/Messe Gelände/ICC then follow the signs on Messedamm to the CityCube Ber-lin.From Schönefeld Airport: take the A113 to the A100. Exit at Messedamm/Messe Gelände/ICC then follow the signs on Messedamm to the Ci-tyCube Berlin.

By taxi: The transfer by taxi takes approximately 20 (Te-gel) to 30-40 minutes (Schönefeld) according to the traffic and costs around €18 (Tegel) or €35 (Schönefeld). Taxis are always available in front of the airport building.

By public transportation:From Tegel Airport: take the bus lines X9 or 109 direction Zoologischer Garten. At Zoologi-scher Garten take the S-Bahn line 5 direction Spandau and get off at Messe Süd. Price for one journey: Single Ticket Berlin Zone AB: 2,70€

From Schönefeld Airport: take the regional express train RB19 direction Gesundbrunnen and stop at Hauptbahnhof. From there take the S-Bahn line 5 direction Spandau and get off at Messe Süd.Price for one journey: Single Ticket Berlin Zone ABC: 3,30€

Public transport in the cityThe public transportation system in Berlin is very well organized. Detailed information regar-ding public transportation is available at www.bvg.de.

Messe Berlin public transport connection S-Bahn 5: From the city center take the direc-tion Spandau and stop at Messe Süd Station. Entrance to the CityCube Berlin is across the street.

Taxis The standard color for taxis is beige. Taxis can be identified by the signage on the roof. If the light on the roof is switched on, the taxi is avai-lable and can be hailed by raising your hand. For easy access, download MyTaxi via its app to order a taxi with ease.

Phone: +49 030-202-020 (24h service) or book online: www.taxi-berlin.deYou will find a taxi point with taxis available at any time in front of the CityCube Berlin.



520 521

Management of bleedingin anticoagulated patients

Sunday 9 July 2017, 16:15–17:45Room A3, CityCube Berlin, Berlin, Germany

A CSL Behring-sponsored satellite symposium at the XXVI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

The licensing status of the products mentioned herewith differs between countries. Please contact your local medical representative for information. PCCs are not approved for the treatment of major bleeding associated with factor IIa or Xa inhibitor therapy.

Co-chairs: Jerrold Levy (USA), Walter Ageno (Italy)

16:15 – Chairs’ welcome

The safety profile of PCC in warfarin reversal trialsTruman J Milling Jr (USA)

Warfarin reversal treatment: PCC versus FFPMark Crowther (Canada)

Treatment of rivaroxaban-associated bleeding emergencies: a single-centre pilot studyBettina Schenk (Austria)

The clinical reality of bleeding complications during anticoagulant therapy: the RADOA registryEdelgard Lindhoff-Last (Germany)

17:45 – Close of symposium

PLEASE VISIT US AT BOOTH 420

CSL0560g ISTH Advert A5.indd 1 5/24/17 10:48 AM

Supported Symposia and Product Theater Overview and Listing

Exhibition and Congress SupportSupported Symposia and Product Theater Presentations

Exhibitor Floor PlanExhibitor and Supporter List

Corporate Meeting Suites


522 523

EXHIBITOR AND SUPPORTER LIST

Bioverativ.com

Science matters.Because patients matter.It’s because of this belief that we:

Brought the leading extended half-life therapies to people with hemophilia —innovation that has changed the way hemophilia can be managed.

Opened the world’s largest genetic hemophilia repository to scientists through My Life, Our Future, together with program co-founders the American Thrombosis and Hemostasis Network, Bloodworks Northwest, and the National Hemophilia Foundation.

Transformed humanitarian aid in hemophilia, with Sobi, by committing to donate up to one billion IUs of factor therapy over 10 years to help close the treatment gap in the developing world. More than 12,300 people have been treated through the WFH Humanitarian Aid Program, which is receiving 500 million IUs over five years.

We not only believe great science can conquer the toughest medical challenges, we live it every single day.

EXHIBITION AND CONGRESS SUPPORT

ISTH wishes to recognize the following companies and organizations for their support of ISTH 2017.

Platinum

Gold

Silver

Bronze

Other Supporters

SUPPORTED SYMPOSIA


525


524

wilate® for a Lifetime of CareBleeding Management

Across High-Risk Patient Populations

symposium

Monday 10 July, 2017. 13:15 –14:30, Room Paris

symposium

Towards Life Without Limitation Growing Experience with Nuwiq® in Patients with Haemophilia A

Sunday 9 July, 2017. 16:15–17:45, Room A8Pier M. Mannucci (Chair), Ellis J. Neufeld,

Natascha Marquardt, John Pasi, Massimo Morfini

Ute Scholz (Chair), Stacy Croteau, Jill Johnsen, John Pasi, Robert Klaassen

Supported Symposia and Product Theater Presentations

SUPPORTED SYMPOSIASUPPORTED SYMPOSIA


526 527

Sunday, July 9, 2017Supported Symposia

For more details and the program of each of these symposia and sessions, please refer to the ISTH Show Guide. It is distributed at the entrances of the Exhibition Halls.

14:15 – 15:45 A1

Engaging in New Options for Anticoagulation TherapyITREAS (supported by an unrestricted grant from Daiichi-Sankyo Europe GmbH).

14:15 – 15:45 A2

Thrombotic Microangiopathies: Challenging Diseases, Challenging StoriesAlexion Pharmaceuticals, Inc.

14:15 – 15:45 A3

DOACs and Reversal Agents: Take the Next Step in Anticoagulation CareBoehringer Ingelheim

14:15 – 15:45 A5

Venous Thromboembolism (VTE): Pervasive, Persistent, Preventable The Unmet Need in Acutely Ill Medical Patients After Hospital Discharge Portola Pharmaceuticals

14:15 – 15:45 A7

Innovating for Improved Outcomes: Driving the Evolution of Hemophilia A Management Bayer

14:15 – 15:30 A8

SIPPET Study: One Year Later. New Insights to Help Manage “my Next Patient” Grifols

16:15 – 17:45 A1

Haemostatic Control of aPCC: Update on the MOA, Efficacy, and SafetyShire Pharmaceuticals Inc.

16:15 – 17:45 A2

Controversies in Cancer and Thrombosis: Management of High-Risk PatientsPfizer

16:15 – 17:45 A3

Management of Bleeding in Anticoagulated Patients CSL Behring

Sun

day

Sup

port

ed S

ympo

sia



528 529

16:15 – 17:45 A5

Stopping the VTE Epidemic in Hospitalized Medically ill Patients: An Innovative, Cutting Edge and State-Of-The-Art Action PlanMEDSCAPE EDUCATION & NATF

16:15 – 17:45 A6

Breaking Scientific Walls in the Treatment of Haemophilia and Rare Bleeding Disorders: From Laboratory Assays to Patient OutcomesNovo Nordisk Health Care AG

16:15 – 17:45 A7

The Challenge of Cancer Associated Thrombosis (CAT): Are NOACs an Option?Bayer

16:15 – 17:45 A8

Towards Life Without Limitation: Growing Experience with Nuwiq® in Patients with Hemophilia AOctapharma

Monday, July 10, 2017Supported Symposia

13:15 – 14:30 New York

Managing Extended Anticoagulation Therapy in Venous Thromboembolism. What Have We Learned From EINSTEIN CHOICE?Bayer

13:15 – 14:30 London

Fc Extended Half-Life Recombinant Factor Concentrates: Recent Updates on Haemophilia Management and Treatment GoalsSobi Bioverativ

13:15 – 14:30 Paris

wilate® for a Lifetime of Care: Bleeding Management Across High-Risk Patient PopulationsOctapharma

13:15 – 14:30 Helsinki 1

Haemostasis in Critical Care MedicineStago

Mon

day

Sup

port

ed S

ympo

sia



530 531

13:15 – 14:30 Helsinki 2

rpFVIII in Acquired Haemophilia A: Real-World ExperienceShire Pharmaceuticals Inc.

13:15 – 14:30 Budapest

Individualising Treatment and Redefining Physical Activity to Optimise Joint HealthPfizer

13:15 – 14:30 Berlin

Beyond Factor: Potential New Approaches to HemophiliaAlnylam Pharmaceuticals

Tuesday, July 11, 2017Supported Symposia

13:15 – 14:30 New York

Gene Therapy: A New Treatment ParadigmBioMarin Pharmaceutical Inc.

13:15 – 14:30 London

Venous Thromboembolism - Improving Patient Care With non VKA Oral AnticoagulantsBristol-Myers Squibb and Pfizer

13:15 – 14:30 Paris

Treating Thrombosis Today: From Latest Data to Clinical ApplicationMedscape Education

13:15 – 14:30 Helsinki 1

Anticoagulation and Reversal: Clinical Cases to Test your KnowledgeBoehringer Ingelheim

13:15 – 14:30 Helsinki 2

Immune Tolerance Induction (ITI): What Have We Learned in the Past 40 Years?Grifols

Tues

day

Sup

port

ed S

ympo

sia



532 533

13:15 – 14:30 Budapest

Reach High in Haemophilia A: Treatment With AFSTYLACSL Behring

13:15 – 14:30 Berlin

Extended Half-Life rFVIII: Advanced Therapeutic Options Providing Benefits in Clinical PracticeShire Pharmaceuticals Inc.

Wednesday, July 12, 2017Supported Symposia

13:15 – 14:30 New York

Living With Haemophilia A: Raising the Bar for New TreatmentsRoche/Chugai

13:15 – 14:30 Paris

IDELVION: A Gold Standard in the Treatment of Haemophilia B?CSL Behring

13:15 – 14:30 Helsinki 1

Management of Direct Oral Anticoagulants— Challenges and PerspectivesDOASENSE GmbH

13:15 – 14:30 Helsinki 2

The Continuing Challenge of Venous Thromboembolism: Insights From the GARFIELD-VTE Registry The GARFIELD-VTE registry is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer AG (Berlin, Germany).

13:15 – 14:30 Budapest

Towards a New Era in Haemophilia CarePfizer

Wed

nesd

ay

Sup

port

ed S

ympo

sia

SUPPORTED SYMPOSIA


534 535

PRODUCT THEATER PRESENTATIONS

Monday, July 10, 2017Product Theaters

12:15 – 13:00 Exhibition Hall 2.2

Kovaltry in Practice: Insights From Real-World ExperienceBayer


The Patient Experience in Haemophilia A: Half-Life Is Not Even Half the StoryCSL Behring


4 Patients - 4 Solutions SVT - HIT - GFR - CATAspen Parenteral AnticoagulantsAspen

Mon

day

AGENDATIME TOPIC 13:15 Welcome and introduction Robert Klamroth (Germany)

13:25 Individualised approaches to treatment: the role of pharmacokinetics in supporting patient lifestyles Gerry Dolan (UK)

13:45 Optimising outcomes in haemophilia care: the role of physical activity Sébastien Lobet (Belgium)

14:05 Joint health maintenance over the long-term: the use of ultrasound as a real-time decision making tool Carlo Martinoli (Italy)

14:25 Panel discussion Robert Klamroth (Germany)

14:30 Meeting close

AGENDATIME TOPIC 13:15 Welcome and introduction John Pasi (UK)

13:25 The secret life of FIX: where are we now? Gerry Dolan (UK)

13:45 Thinking outside the factor: the future of non-factor based haemophilia therapy Andreas Tiede (Germany)

14:00 Towards endogenous prophylaxis: gene therapy Thierry VandenDriessche (Belgium)

14:20 Panel discussion John Pasi (UK)

14:30 Meeting close

Berlin Olympic Stadium

Individualising treatment and redefining physical activity to optimise joint health

Towards a new era inhaemophilia care

These symposia are sponsored by funding from Pfizer

PP-BEN-GLB-0014 / PP-HEM-DEU-0207 Date of preparation: April 2017

Pfizer Satellite Symposium at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress

Building on our Heritage to of CarePioneer a New Era

Wednesday July 12th 201713:15–14:30Budapest Room, Messe Berlin GmbHChair: John Pasi (UK)

Monday July 10th 201713:15–14:30Budapest Room, Messe Berlin GmbH Chair: Robert Klamroth (Germany)

House of World Cultures

Pro

duct

The

ater

s


536 537


Tuesday, July 11, 2017Product Theaters


NOACs in Venous Thromboembolism: Learnings From the Real WorldBayer


ST Genesia®: Thrombin Generation Entering the Clinical LabStago


Wednesday, July 12, 2017Product Theater


Integrating the Only Specific Replacement Therapy for Factor X Deficiency Into Clinical PracticeBio Products Laboratory Ltd.


Tough Decisions in the Treatment of VTE A Multidisciplinary Case-Based DiscussionBristol-Myers Squibb and Pfizer


Haemophilia Academy at 10 Years: A Platform for Career Development and Global NetworkingHaemophilia Academy

Wed

nesd

ayP

rodu

ct T

heat

ers



538 539

This meeting is sponsored by Shire and is not affiliated with the ISTH Annual Meeting & Exhibition

©2017 Shire U.S. Inc. Lexington MA 02421. All rights reserved. 1-800-829-2068. SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceuticals Holdings Limited or its affiliates

Product Code VV- MEDICOM -1758 04.2017

Please join us at the Shire satellite symposium to learn more about:

Extended half-life rFVIII: Advanced therapeutic options providing benefits in clinical practice

Tuesday July 11th | 13:15 – 14:30Hall 7.3 | 3rd Floor | Room: BerlinCity Cube & Messe Berlin Exhibition Grounds, Berlin, Germany

Chair: Dr. Robert Klamroth, Germany

ISTH A5 Advert_13NH.indd 1 02/06/2017 09:21

EXHIBITION FLOOR PLAN

Exhibition and Exhibitors


540 541


Poster AreaPoster Area

Poster Area

ExhibitionArea

ExhibitionArea

ExhibitionArea

ExhibitionArea

ExhibitionArea

Catering &

Seating Area to H

all 4.2

to Hall 2

.2

Passage

to Hall 7

.2P

assage to H

all 7.2

Passage

to Hall 7

.2

to Hall 6

.2to H

all 4.2

Collaborative M

etting Rooms

Overview


215214

234233

235

221

411

410

403

430

431

432

412

421

420

443

405

404

413

415

414

416

400 440401

434

433

444

417

441

442

618

617

619

607

606

608628

627

629

615

614

616

625

624

626

634

633

635

643

645

638

639 648

636

637

646

647604

603

605

655

656

651

653

652

654

601

600

602

222

402

211

210

200

231

230

232

212

221

220

221

240

213

216

Poster Area Poster AreaCateringArea

CateringArea

Catering Area

Internet Station

Internet Station

Internet Station

Seating AreaSeating Area

Seating Area

Catering & Seating Area

Poster Pick-UpBooth

Product Theater

Helpdesk

PosterDesk

PosterDesk

PosterDesk

CateringArea

Catering Area

Seating AreaSeating AreaProduct Theater

Internet Station

Relax and Recharge Area





ISTH 2017Congress TV Studio

Room Ulm

HALL 2.2

to Hall 4.2 to Hall 2.2

Passage to Hall 7.2

HALL 4.2

to Hall 6.2

Passage to Hall 7.2

to Hall 4.2

HALL 6.2

Passage to Hall 7.2

Poster AreaProduct Theater

Collaborative Metting Rooms

Seating Area

Hall 2.2 Hall 4.2 Hall 6.2

ISTH Academy e-Education Zone Massage Station

Hall 22

Exh

ibit

ion


542 543


215214

234233

235

221

411

410

403

430

431

432

412

421

420

443

405

404

413

415

414

416

400 440401

434

433

444

417

441

442

618

617

619

607

606

608628

627

629

615

614

616

625

624

626

634

633

635

643

645

638

639 648

636

637

646

647604

603

605

655

656

651

653

652

654

601

600

602

222

402

211

210

200

231

230

232

212

221

220

221

240

213

216


CateringArea

Catering Area

Internet Station

Internet Station

Internet Station


Seating Area


Poster Pick-UpBooth

Product Theater

Helpdesk

PosterDesk

PosterDesk

PosterDesk

CateringArea

Catering Area


Internet Station







Room Ulm

HALL 2.2


Passage to Hall 7.2

HALL 4.2

to Hall 6.2

Passage to Hall 7.2

to Hall 4.2

HALL 6.2

Passage to Hall 7.2



Seating Area



Hall 42


215214

234233

235

221

411

410

403

430

431

432

412

421

420

443

405

404

413

415

414

416

400 440401

434

433

444

417

441

442

618

617

619

607

606

608628

627

629

615

614

616

625

624

626

634

633

635

643

645

638

639 648

636

637

646

647604

603

605

655

656

651

653

652

654

601

600

602

222

402

211

210

200

231

230

232

212

221

220

221

240

213

216


CateringArea

Catering Area

Internet Station

Internet Station

Internet Station


Seating Area


Poster Pick-UpBooth

Product Theater

Helpdesk

PosterDesk

PosterDesk

PosterDesk

CateringArea

Catering Area


Internet Station







Room Ulm

HALL 2.2


Passage to Hall 7.2

HALL 4.2

to Hall 6.2

Passage to Hall 7.2

to Hall 4.2

HALL 6.2

Passage to Hall 7.2



Seating Area



Hall 62

Exh

ibit

ion


544 545

EXHIBITOR & SUPPORTER LIST / BOOTH NUMBER

Booth Number Hall Number Company

200 Hall 2.2 International Society on Thrombosis and Haemostasis (ISTH)

200 Hall 2.2 ISTH 2019 – Melbourne

200 Hall 2.2 ISTH SSC 2018

200 Hall 2.2 Journal of Thrombosis and Haemostasis

200 Hall 2.2 Research and Practice in Thrombosis and Haemostasis

211 Hall 2.2 GRIFOLS

212 Hall 2.2 Alexion Pharmad

213 Hall 2.2 Kedrion Biopharma

214 Hall 2.2 Bio Products Laboratory

215 Hall 2.2 SEBIA

216 Hall 2.2 Alnylam Pharmaceuticals

220 Hall 2.2 Bayer

221 Hall 2.2 Shire

222 Hall 2.2 Novo Nordisk Healthcare

231 Hall 2.2 Boehringer Ingelheim

232 Hall 2.2 HYPHEN BioMed

233 Hall 2.2 5-Diagnostics

234 Hall 2.2 Affinity Biologicals

235 Hall 2.2 Novo Nordisk Haemophilia Foundation

241 Hall 2.2 Stago

242 Hall 2.2 Thrombosis Research Institute

400 Hall 4.2 Haemochrom Diagnostica

401 Hall 4.2 HemoSonics

402 Hall 4.2 Aspen Europe

403 Hall 4.2 LFB BIOMEDICAMENTS

404 Hall 4.2 Roche

405 Hall 4.2 Instrumentation Laboratory

410 Hall 4.2 Bioverativ

410 Hall 4.2 Sobi



411, 421 Hall 4.2 Octapharma

412 Hall 4.2 Roche Diagnostics International

413 Hall 4.2 Technoclone

414 Hall 4.2 3i - Intelligent Imaging Innovations

415 Hall 4.2 LABITEC LABOR BIOMEDICAL TECHNOLOGIES

416 Hall 4.2 Chrono-log Corp.

417 Hall 4.2 DOASENSE

420 Hall 4.2 CSL Behring

430 Hall 4.2 BMS Pfizer Alliance

431 Hall 4.2 Pfizer

432 Hall 4.2 BioMarin Pharmaceutical

433 Hall 4.2 Haemoscan

434 Hall 4.2 uniQure

440 Hall 4.2 Portola Pharmaceuticals

441 Hall 4.2 Daiichi Sankyo

442 Hall 4.2 Biotest

443 Hall 4.2 Siemens Healthineers

443 Hall 4.2 Sysmex

444 Hall 4.2 Abbott

600 Hall 6.2 Diagon

601 Hall 6.2 Emosis Diagnostics

602 Hall 6.2 HRA Healthcare Research & Analytics

603 Hall 6.2 American Heart Association

604 Hall 6.2 European Haemophilia Consortium

605 Hall 6.2 EU Horizon 2020 MSCA ITN "PROFILE"

606 Hall 6.2 European and Mediterranean League Against Thrombotic Diseases

607 Hall 6.2 Deutsche Gesellschaft für Angiologie

608 Hall 6.2 APSTH

614 Hall 6.2 Precision Biologic

Exh

ibit

ion


546 547



615 Hall 6.2 ACON Laboratories

616 Hall 6.2 Haematologic Technologies

617 Hall 6.2 World Federation of Hemophilia

618 Hall 6.2 Comite de Trombosis y Hemostasia AMEH-CLAHT AC

619 Hall 6.2 International Network of Venous Thromboembolism Clinical Research Networks

624 Hall 6.2 Mitsubishi Tanabe Pharma

626 Hall 6.2 Medtronic

627 Hall 6.2 Wiley

628 Hall 6.2 Wisepress

629 Hall 6.2 GTH

633 Hall 6.2 Haemonetics

634 Hall 6.2. British Society of Hematology/National Institute of Health Research

635 Hall 6.2 DSM Pentapharm

636 Hall 6.2 International Initiative on Thrombosis and Cancer (ITAC-CME)

637 Hall 6.2 Hematological Journal

638 Hall 6.2 Thrombosis and Haemostasis

639 Hall 6.2 European Hematology Association

643 Hall 6.2 Enzyme Research Laboratories / R2 Diagnostics

645 Hall 6.2 Sekisui Diagnostics

646 Hall 6.2 Karger Publishers

647 Hall 6.2 The Lancet

648 Hall 6.2 Thrombosis.TV

651 Hall 6.2 International Self-Monitoring Association of Oral Anticoagulated Patients (ISMAAP)

652 Hall 6.2 phamax

653 Hall 6.2 ORGENTEC - Corgenix

654 Hall 6.2 Phenom-World

655 Hall 6.2 BioMedica Diagnostics

656 Hall 6.2 Helena Biosciences

EXHIBITOR & SUPPORTER LIST / ALPHABETICAL

Company Booth Number Hall Number

3i - Intelligent Imaging Innovations 414 Hall 4.2

5-Diagnostics 233 Hall 2.2

Abbott 444 Hall 4.2

ACON Laboratories 615 Hall 6.2

Affinity Biologicals - Hemostasis Reference Lab 234 Hall 2.2

Alexion Pharma 212 Hall 2.2

Alnylam Pharmaceuticals 216 Hall 2.2

American Heart Association 603 Hall 6.2

APSTH 608 Hall 6.2

Aspen Europe 402 Hall 4.2

Bayer 210, 220, 230, 240 Hall 2.2

Bio Products Laboratory 214 Hall 2.2

BioMarin Pharmaceutical 432 Hall 4.2

BioMedica Diagnostics 655 Hall 6.2

Biotest 442 Hall 4.2

Bioverativ 410 Hall 4.2

BMS Pfizer Alliance 430 Hall 4.2

Boehringer Ingelheim 231 Hall 2.2

British Society of Hematology/National Institute of Health Research 634 Hall 6.2.

Chrono-log Corp. 416 Hall 4.2

Comite de Trombosis y Hemostasia AMEH-CLAHT 618 Hall 6.2

CSL Behring 420 Hall 4.2

Daiichi Sankyo 441 Hall 4.2

Deutsche Gesellschaft für Angiologie 607 Hall 6.2

Diagon 600 Hall 6.2

DOASENSE 417 Hall 4.2

DSM Pentapharm 635 Hall 6.2

Emosis Diagnostics 601 Hall 6.2

Enzyme Research Laboratories / R2 Diagnostics 643 Hall 6.2

Exh

ibit

ion


548 549



EU Horizon 2020 MSCA ITN "PROFILE" 605 Hall 6.2

European and Mediterranean League Against Thrombotic Diseases 606 Hall 6.2

European Haemophilia Consortium 604 Hall 6.2

European Hematology Association 639 Hall 6.2

GRIFOLS 211 Hall 2.2

GTH 629 Hall 6.2

Haematologic Technologies 616 Hall 6.2

Haemochrom Diagnostica 400 Hall 4.2

Haemonetics 633 Hall 6.2

HaemoScan 433 Hall 4.2

Helena Biosciences 656 Hall 6.2

Hematologica Journal 637 Hall 6.2

HemoSonics 401 Hall 4.2

HRA Healthcare Research & Analytics 602 Hall 6.2

HYPHEN BioMed 232 Hall 2.2

I&L Biosystems 625 Hall 6.2.

Instrumentation Laboratory 405 Hall 4.2

International Initiative on Thrombosis and Cancer (ITAC-CME) 636 Hall 6.2

International Network of Venous Thromboembolism Clinical Research Networks 619 Hall 6.2

International Society on Thrombosis and Haemostasis (ISTH) 200 Hall 2.2

ISTH 2019 – Melbourne 200 Hall 2.2

ISTH SSC 2018 200 Hall 2.2

Journal of Thrombosis and Haemostasis 200 Hall 2.2

International Self-Monitoring Association of Oral Anticoagulated Patients (ISMAAP) 651 Hall 6.2.

Karger Publishers 646 Hall 6.2

Kedrion Biopharma 213 Hall 2.2

LABITEC LABOR BIOMEDICAL TECHNOLOGIES 415 Hall 4.2

LFB BIOMEDICAMENTS 403 Hall 4.2

Medtronic 626 Hall 6.2



Mitsubishi Tanabe Pharma 624 Hall 6.2

Novo Nordisk Healthcare 222 Hall 2.2

Novo Nordisk Haemophilia Foundation 235 Hall 2.2

Octapharma 411, 421 Hall 4.2

ORGENTEC - Corgenix 653 Hall 6.2

Pfizer 431 Hall 4.2

phamax 652 Hall 6.2

Phenom-World 654 Hall 6.2

Portola Pharmaceuticals 440 Hall 4.2

Precision Biologic 614 Hall 6.2

Research and Practice in Thrombosis and Haemostasis 200 Hall 2.2

Roche 404 Hall 4.2

Roche Diagnostics International 412 Hall 4.2

SEBIA 215 Hall 2.2

Sekisui Diagnostics 645 Hall 6.2

Shire 221 Hall 2.2

Siemens Healthineers 443 Hall 4.2

Sobi 410 Hall 4.2

Stago 241 Hall 2.2

Sysmex Corporation 443 Hall 4.2.

Technoclone 413 Hall 4.2

The Lancet 647 Hall 6.2

Thrombosis and Haemostasis 638 Hall 6.2

Thrombosis Research Institute 242 Hall 2.2

Thrombosis.TV 648 Hall 6.2

uniQure 434 Hall 4.2

Wiley 627 Hall 6.2

Wisepress 628 Hall 6.2

World Federation of Hemophilia 617 Hall 6.2

Exh

ibit

ion

COMPANY PROFILESCOMPANY PROFILES


550 551

Booth 414 Hall 4.23i - Intelligent Imaging Innovations

Königsallee 9-21 D-37081 Göttingen Germany+49 0 551 508 39 266 +49 0 551 508 39 268 www.intelligent-imaging.com

3i designs and manufactures technologies for live-cell and intravital fluorescence microscopy including digital holography, spinning disk con-focal, multi-photon and lightsheet. SlideBook software manages everything from instrument control to image capture, processing and data analysis.

Booth 233 Hall 2.25-Diagnostics

Heuberg 7 4051 Basel Switzerland+41 61 588 07 84 +41 61 588 07 86 www.5-diagnostics.com

5-Diagnostics offers innovative IVD systems, ready to use assays and biochemicals to the research and diagnostic market. Recently launched assays are heparin QC bioreagents and buffers in compliance with EP and USP and the NAPTT reagent for the detection of activated coagulation factors in therapeutic products or for detecting contact activation and hyper coagulability.

Booth 444 Hall 4.2Abbott

100 Abbott Park Road 60064 Abbott Park, IL United States+1 224 6676100 www.abbottdiagnostics.com

Abbott is a global leader in in vitro diagnostics offering a broad portfolio spanning immuno-assay, clinical chemistry, hematology, blood screening, molecular, bio-identification, point of care, and informatics. Our diagnostics solu-tions are more than just a test or data point, they are designed to anticipate, leverage and improve decision-making and patient care across the entire health care system.

Booth 615 Hall 6.2ACON Laboratories

10125 Mesa Rim Road 92121 San Diego, CAUnited States+1 858 875 8000 +1 858 875 8098www.aconlabs.com

ACON Laboratories is leading the way to make high quality point-of-care diagnostics and med-ical devices more affordable to people around the world for over 21 years.

ACON offers Mission® brand and OEM/private label products for both PT/INR and Cholesterol Monitoring Systems, in addition to several other point-of-care meters and test strips.ACON is committed to continuously monitoring our quality systems to ensure their effectiveness and compliance to all applicable regulatory and quality requirements. Exceeding customer ex-pectations and maintaining customer loyalty are our top priorities.

Booth 234 Hall 2.2Affinity Biologicals - Hemostasis Reference Lab

1348 Sandhill Dr. L9G4V5Ancaster, ONCanada +1 905 304 9896 +1 905 304 9897 www.affinitybiologicals.com

Affinity Biologicals, Inc. is a primary manu-facturer of products used worldwide in throm-bosis and haemostasis research and medical diagnostics. Products include an extensive line of antibodies, ELISA kits, and human plasma products.

Hemostasis Reference Laboratory offers a com-plete range of testing for clinical trials, sample analysis, research projects, product evaluation, value assignments, instrument validation, and more servicing pharmaceutical companies, di-agnostic manufacturers, veterinarians, and re-searchers

Booth 212 Hall 2.2Alexion Pharma GmbH

Giesshubelstrasse 28 8045 Zurich Switzerland+41 21 318 4000+41 44 457 4001www.alexionpharma.eu

Alexion is a global biopharmaceutical company focused on developing and delivering life-trans-forming therapies for patients with devastating and rare disorders. Alexion developed and com-mercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat pa-tients with paroxysmal nocturnal hemoglobin-uria (PNH) and atypical hemolytic uremic syn-drome (aHUS), two life-threatening ultra-rare disorders. As the global leader in complement inhibition, Alexion is strengthening and broad-ening its portfolio of complement inhibitors.

Booth 216 Hall 2.2Alnylam Pharmaceuticals

300 Third Street 02142 Cambridge, MA United States+1 617 551 8200 +1 617 551 8101 www.Alnylam.com



552 553

Alnylam is leading the translation of RNA in-terference (RNAi) into a whole new class of in-novative medicines with the potential to trans-form the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics rep-resent a powerful, clinically-validated approach for the treatment of a wide range of debilitating diseases.

Booth 603 Hall 6.2American Heart Association

7272 Greenville Avenue 75231 Dallas, TX United States+1 214 570 5978 www.heart.org

American Heart Association is the nation’s old-est and largest voluntary organization dedicated to fighting heart disease and stroke. Founded by six cardiologists in 1924, our organization now includes more than 30 million volunteers and supporters. We have invested more than $4 bil-lion in research. American Stroke Association is a division that brings together the organization’s stroke-related activities.

Booth 608 Hall 6.2APSTH

Asahikawa Medical UniversityMidorigaoka Higashi 2-1-1-1078-8510 Asahikawa Japan www.apsth.org

The Asian-Pacific Society of Thrombosis and Hemostasis, hereafter referred to as “APSTH”, is a non-profit-making organization, which shall be open to any interested workers in the field of thrombosis and hemostasis in the Asian and Pa-cific regions. The objectives of APSTH are to fos-ter and advance clinical and scientific knowledge in the field of thrombosis, hemostasis and vascu-lar biology in the Asian and Pacific regions, and to promote scientific exchange and cooperation through scientific meetings and publications.

Booth 402 Hall 4.2Aspen Europe

Montgelaspark, Montgelasstr. 14 81679 München Germany+49 89 93083800 +49 89 95993517 www.aspenpharma.com

Aspen is a global pharmaceutical company with an extensive portfolio in speciality, branded and generic and healthcare products with par-ticular focus on therapeutic areas that include thrombosis, anesthesia, high potency & cyto-toxics and infant nutritionals. Aspen product range provides treatment for a broad spectrum of acute and chronic conditions experienced throughout all stages of life. Aspen has been offering the market a portfolio of quality inject-able antithrombotics since 2014, with these product manufactured at Aspen sites in Europe.

Booth 210, 220, 230, 240 Hall 2.2Bayer

Müllerstraße 178 13353 Berlin Germany+49 30 4681111 www.bayer.com

Bayer: Science For A Better Life

Bayer is a global enterprise with core compe-tencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. For more information, go to www.bayer.com.

Booth 214 Hall 2.2Bio Products Laboratory

Dagger Lane WD6 3BX Elstree United Kingdom+44 0 2089572200 +44 0 2089572601 www.bpl.co.uk

BPL is a leading manufacturer of plasma-de-rived protein therapies with global headquarters in England. The company exports to more than 45 countries and has 60+ years of experience developing and manufacturing plasma-derived therapies since being established as part of the Lister Institute in 1950. It currently markets a wide range of products including coagulation factors, human immunoglobulins, and albumin. BPL is committed to investment in research and development to maintain its position as a supplier of high-quality products worldwide.

Booth 432 Hall 4.2BioMarin Pharmaceutical

105 Digital Drive 94949 Novato, CA United States+1 415 506 6700 www.biomarin.com

BioMarin develops and commercializes inno-vative biopharmaceuticals for serious diseases and medical conditions.



554 555

Approved products include the first and only medications for PKU and LEMS, and the first and only enzyme replacement therapies for MPS I, MPS VI and Morquio A syndrome. Visit www.biomarin.com to learn more.

Booth 655 Hall 6.2BioMedica Diagnostics

PO Box 1030 B0N 2T0 Windsor, ON Canada+1 902 798 5105 +1 902 7981025 www.biomedicadiagnostics.com

BioMedica focuses on thrombosis & haemost-asis diagnostic solutions for human and animal health. BioMedica offers a complete line of dia-gnostic and research products, recently strengt-hened by an acquisition of specialty coagulation products and technologies.

The BioMedica line-up includes high quality kits, controls, reagents and calibrators that are designed for use in routine and specialty coa-gulation and are also widely used in research and industry spaces. Many products are Health Canada Registered, FDA 510(k) cleared and/or CE marked.

Booth 442 Hall 4.2Biotest

Landsteinerstr. 5 63303 Dreieich Germany+49 6103 8010+49 6103 801150 www.biotest.com

Biotest AG is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical develop-ment to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coag-ulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibod-ies in the indication cancer of plasma cells and systemic lupus erythematosus (SLE), which are produced by recombinant technologies. Biotest has more than 2,200 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Booth 410 Booth 410 Hall 4.2Bioverativ

225 Second Avenue02451Waltham, MAUnited States+1 781-663-4400www.bioverativ.com

Bioverativ is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ’s mission is to create progress for patients where they need it most, and its hemophilia therapies when launched represented the first major advancements in he-mophilia treatment in more than two decades. For more information, visit www.bioverativ.com.

Booth 430 Hall 4.2BMS Pfizer Alliance

Walton Oaks, Dorking Road, Walton on the Hill KT20 7NS Tadworth United Kingdom+44 1304 616161 In 2007, Pfizer and Bristol-Myers Squibb en-tered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoag-ulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb’s long-standing strengths in cardiovascular drug development and commercialization with Pfiz-er’s global scale and expertise in this field.

Booth 231 Hall 2.2Boehringer Ingelheim

Bingerstrasse 173 55216 Ingelheim Germany+49 6132 77 181805 www.boehringer-ingelheim.com

Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquar-tered in Ingelheim, Germany, Boehringer Ingel-heim operates globally through 145 affiliates and a total of some 50 000 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, man-ufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Booth 634 Hall 6.2British Society of Hematology / National Institute of Health Research

100 White Lion Street N1 9PF LondonUnited Kingdom+44 20 7713 0990

The British Society for Haematology is the hae-matology hub for all health care professionals and the voice for the specialty in the UK.The NIHR Clinical Research Network (CRN) provides the infrastructure that allows high-quality clinical research to take place in the NHS in England.



556 557

This includes assisting researchers, the life sciences industry and funders to deliver their studies in the NHS, and supporting the research community to maximize the value of leading-edge approaches and techniques, so that patients can benefit from new and better treatments.

Booth 416 Hall 4.2Chrono-log Corp.

2 West Park Road 19083 Havertown, PA United States+1 610 853 1130 +1 610 853 3972 www.chronolog.com

Hemostasis defects may be due to Platelet ab-normalities such as VWD, Glanzmann’s, Secre-tion Defects, and anti-platelet drugs such as As-pirin and Plavix. In addition to LTA with PRP, Chrono-log also offers Whole Blood Impedance Aggregation/WBA and ATP Release with Lumi-nescence. The Model 700’s provide all of three of these testing capabilities while the NEW Model 490-4+4 provide LTA testing in 4 or 8 test channels. To discuss your platelet testing needs, please visit with us at Booth No. 416.

Booth 618 Hall 6.2Comite de Trombosis y HemostasiaAMEH-CLAHT AC

2do Retorno de Pablo de la Llave 35-4 4730 Mexico City Mexico+52 55 54367350 www.cth.org.mx

To promote the increase of clinical knowledge, research, and rise awareness within the general population.Organize and sponsor congresses, seminars, conferences, courses and meetings between health professionals interested in our fields of study.To fosters the bond of union and collaboration with affiliated and international grupos while generating an inclusive environment among all actors to achieve excellence in our purposes.

Booth 420 Hall 4.2CSL Behring

Emil-von-Behring-Straße 76 35041 Marburg Germany+49 6421 39 12 www.CSLBehring.com

CSL Behring is a global biotherapeutics lead-er driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative

therapies that are used to treat coagulation dis-orders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The parent company, CSL Limited (ASX:CSL), headquartered in Mel-bourne, Australia, employs nearly 20,000 peo-ple, delivering its life-saving therapies to people in more than 60 countries.

Booth 441 Hall 4.2Daiichi Sankyo

Zielstattstrasse 48 81379 Munich Germany+49 89 78080 www.dsi.com

At Daiichi Sankyo, we are dedicated to the creation and supply of innovative pharmaceu-tical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of sci-entific expertise, we draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, our research and de-velopment is focused on bringing forth novel therapies in oncology, including immuno-oncol-ogy. For more information, please visit: www.daiichi-sankyo.eu.

Booth 607 Hall 6.2Deutsche Gesellschaft für Angiologie

Schiffbauerdamm 40 10117 Berlin Germany+49 30 20888831 +49 30 20888833 www.risiko-thrombose.de

The Aktionsbündnis Thrombose is an alliance of the leading scientific organizations in the field of thrombosis research in Germany: DGA (ini-tiator) GTH, DGP and the patient organization Gefäßliga. With the campaign Risiko Throm-bose and the celebration of the World Throm-bosis Day in Germany the organizations have joined their efforts to increase the awareness of thrombosis, its causes, the risk factors, symp-toms and prevention and treatment in order to reduce the mortality and disability caused by the condition.

Booth 600 Hall 6.2Diagon

Baross street 48-52 1047 Budapest Hungary+36 1 3696500 +36 1 3696301 www.diagon.com



558 559

At Diagon Ltd. we strive to bring laboratory professionals unique solutions for their testing needs. As market leader in diagnostic systems for hematology and hemostasis our success comes from proven record of high performance and reliable solutions, resulting from our com-mitment to and understaning of our customers and our dedication to innovation and quality.Founded in 1989 Diagon’s success builds on more than 25 years experience in R&D and world class manufacturing in vitro diagnostic products and analysers.

Booth 417 Hall 4.2DOASENSE

Waldhofer Str. 102 69123 Heidelberg Germany+49 6221 8259785 +49 6221 8259786 www.doasense.de

DOASENSE presents a new generation of devic-es for point-of-care testing for Direct Oral Anti-coagulants (DOACs):- DOAC testing – now fast and easy as with cre-atinine.Our proprietary technologies for assessing DOACs in urine provide crucial data to health-care professionals, all in a swift and easy as-sessment process.- When every minute counts ... fast DOAC tes-ting really matters.

Booth 635 Hall 6.2DSM Pentapharm

Dornacherstrasse 112 4147 Aesch BL Switzerland+41 61 706 48 48 +41 61 706 48 00 www.pentapharm.com

DSM Pentapharm is focused on development and production of diagnostic reagents for co-agulation disorders and has been in operation since 1948. We are a high-quality manufac-turer of diagnostic kits. We also offer various reagents (from research to bulk quantities) in-cluding custom/OEM manufacturing as well as synthesis of peptides and small organic mole-cules. Besides Diagnostic, we produce active pharmaceutical ingredients.

Booth 601 Hall 6.2Emosis Diagnostics

11 rue de l’Industrie 67400 Illkirch France +33 0 366326326 www.emosis-diagnostics.com/en

Since its inception in 2015, EMOSIS is com-mitted to innovative platelet- or microparti-cle-based diagnostics kits used on off-the-shelf benchtop flow cytometers. Routinely diagnosing and differentiating among various bleeding and

thrombotic disorders will enable faster monitor-ing and cost-effective therapeutic decisions. We will support several clinical applications such as confirming the diagnosis of HIT (first test in 2017), assessing various platelet functions or testing hypercoagulable states. See more on www.emosis-diagnostics.com

Booth 643 Hall 6.2Enzyme Research Laboratories / R2 Diagnostics

1801 Commerce Drive 46628 South Bend, IN United States+1 574 288 2268 +1 574 288 2272 www.r2diagnostics.comwww.enzymeresearch.com

Enzyme Research Laboratories provides puri-fied coagulation and fibrinolytic proteins from human plasma, other source plasmas and plate-lets. Additionally, we offer monoclonal and poly-clonal antibodies, immunodepleted plasmas and ELISA reagents. Custom purifications and contract services are also available.R2 Diagnostics focuses on the production of high quality, innovative products for the hemo-stasis diagnostic market. Our products are de-signed to detect thrombophilia, including kits for PC, PS and lupus anticoagulants.

Booth 605 Hall 6.2EU Horizon 2020 MSCA ITN „PROFILE“

PROFILEEtienne Sabbelaan 538500KortrijkBelgium+32 56 246061www.itn-profile.eu

The “PROFILE” Innovative Training Network within the EU Horizon 2020 MSCA program aims at stratifying patients with acquired thrombotic purpura (TTP) by extending disease pathology using new types of biomarkers and predicting risk for relapse. The outcomes of this project will guide development of person-alised medicine for TTP patients. We group top academic experts and frontline innovators from industry in the EU. The project is coordinated by prof. Karen Vanhoorelbeke from KU Leuven, Belgium.

Booth 606 Hall 6.2European and Mediterranean League Against Thrombotic Diseases

Institut Català de Ciències Cardiovasculars (ICCC) 08025 Barcelona Spain+34 93 556 58 86+34 93 556 55 59 www.medleague-thrombosis.org



560 561

EMLTD is a non-profit Society created with the aim to promote the scientific advance and dissemination of knowledge in the diagnosis, prophylaxis and treatment of Thrombosis and Haemostasis.

It aims to create bridges between the clinical practice and the basic science, bringing togeth-er research scientists on vascular and molecular biology and clinicians of many different spe-cialties related to thrombosis. We contributes to the translation of scientific advances to the clinical practice with a multidisciplinary and international approach organizing international Congresses oriented to the advance in the fight against thrombosis.

Booth 604 Hall 6.2European Haemophilia Consortium

rue de l’industrie 10 1000 Brussels Belgium +32 0 28932470 www.ehc.eu

The European Haemophilia Consortium (EHC) is an umbrella organisation that represents 45 national patients’ groups, active in the area of rare bleeding disorders such as haemophilia and von Willebrand Disease. Through advoca-cy, project developments and work with stake-holders, the EHC aims to improve the quality of life of the 90 000 people in Europe affected by these disorders. It is a member of the European Organisation for Rare Diseases and the Europe-an Patients’ Forum, and has a close collabora-tion with the World Federation of Hemophilia.

Booth 639 Hall 6.2European Hematology Association

Koninginnegracht 12b 2514 AA Den Haag Netherlands+31 70 3020099 www.ehaweb.org

The European Hematology Association (EHA) promotes excellence in patient care, research and education in hematology.EHA fulfills its mission through live events where hematology professionals meet to learn and network, an educational program based on the European Hematology Curriculum, publish-ing the latest innovation in the field, investing in career development of hematologists and lob-bying for hematology.

Booth 211 Hall 2.2GRIFOLS

Avda. de la Generalitat 152-158 08174 Barcelona Spain+34 670 920 481 +34 93 8008619 www.grifols.com

Grifols is a global healthcare company with more than 75-year legacy focused on improv-ing people’s health and well-being by offering high-quality plasma-derived protein therapies,

innovative diagnostic tools and essential hospi-tal services.In the field of hemostasis we are committed to offering complete disease management com-prising a clear and precise diagnosis and plas-ma-derived therapies with outstanding records of efficacy and safety, to treat patients with coagu-lation disorders and improve life expectancy.

Booth 629 Hall 6.2GTH

Feodor-Lynen Str. 5 30625 Hannover Germany +49 511 5328488 +49 511 5324146 www.gth-online.org

GTH is the scientific society on Thrombosis & Hemostasis in Germany, Austria, and Switzer-land. It is ISTH’s partner society in this geo-graphic region. GTH offers an annual meeting that takes place at the end of February each year. Forthcoming GTH meetings will be in Vi-enna (2018) and Berlin (2019). GTH is the partnering society of two scientific journals, Hä-mostaseologie (Editor-in-Chief Rüdiger Scharf) and Thrombosis & Hemostasis (Editors-in-Chief Christian Weber and Gregory Lip).

Booth 616 Hall 6.2Haematologic Technologies

57 River Road 05452 Essex Junction, VT United States+1 802 878 1777 +1 802 878 1776 www.haemtech.com

Haematologic Technologies, Inc. (HTI) is a pri-mary manufacturer of research reagents, spe-cializing in the isolation and characterization of plasma proteins involved in the regulation of blood coagulation and fibrinolysis. Our prod-uct line of highly purified proteins includes zymogens, enzymes, cofactors, and inhibitors as well as monoclonal and polyclonal antibod-ies. Services available by contract include: cGMP stability, release and other QC testing, ADA and TGA assay development and custom blood collection tube manufacturing.

Booth 637 Hall 6.2Haematologica Journal

via G. Belli, 4 27100 Pavia Italy +39 0 38227129 www.haematologica.org



562 563

Haematologica The official journal of the Euro-pean Hematology AssociationFounded in 1920 and published by the Ferrata Storti Foundation (Pavia, Italy). Haematologica publishes articles in the broad field of hemato-logy, reporting on novel findings in basic, clini-cal and translational research. Haematologica ranks 4th out of all hematology related journals.Print Circulation: 40002015 ISI Impact Factor: 6.6712014 Citations: 14.110

Booth 400 Hall 4.2Haemochrom Diagnostica

Renteilichtung 1 45134 Essen Germany+49 201 843770 +49 201 536456 www.haemochrom.de

For more than 25 years, Haemochrom Diagnos-tica has been playing an important role in sup-plying the pharmaceutical industries, university research and routine diagnostic laboratories with reagents within haemostasis diagnostics and en-dotoxin analytics in central and northern Europe.In cooperation with well-known manufacturers, Haemochrom Diagnostica offers a wide range of products for all current instrumentation sys-tems based on certified and validated methods as well as an innovative reagent within endotox-in analytics.

Booth 633 Hall 6.2Haemonetics

400 Wood Road 02184 Braintree, MA United States +1 781 848 7100 +1 781 394 0538 www.haemonetics.com

Haemonetics is a global healthcare company dedicated to providing innovative blood man-agement solutions for our customers. We offer the TEG® 5000 Hemostasis Analyzer System which has been shown to reduce unnecessary blood component administration to help reduce the risks, complications, and costs of allogeneic transfusions. TEG provides a unique and more complete picture of hemostasis to facilitate a better understanding of each patient’s risk of hemorrhage or thrombosis. http://www.haemon-etics.com.

SupporterHaemophilia Academy

160 Blackfriars Road7th FloorSE1 8EZLondonUnited Kingdomwww.haemophiliaacademy.com

The Haemophilia Academy is an annual, hae-mophilia-focused educational training course

run by international experts in haematology. Its aim is to provide specific education and sup-port for haemophilia treaters at an early stage in their career. The interactive programme is desi-gned to equip participants with the knowledge and skills that they need to develop their career in haemophilia and to work together to discuss how to apply this information in a way that will help to improve patient care.

The Haemophilia Academy is supported by an unrestricted educational grant from Novo Nordisk Health Care AG.

Booth 433 Hall 4.2Haemoscan

Stavangerweg 23-23 9723JC Groningen Netherlands +31 50 7370187 www.haemoscan.com

HaemoScan is a leading company in haemo-compatibity research and development of circu-lating-blood test models. We have experience in testing medical devices with blood according to ISO 10993-4 in order to obtain CE and FDA certification. HaemoScan is innovative in the field of biomarker analysis and has developed many assays to measure or-gan damage. HaemoScan tests human or an-imal coagulation, inflammation, organ, tissue, and other blood responses and has developed several haemocompatibility test kits.

Booth 656 Hall 6.2Helena Biosciences

Queensway South NE11 0SD Gateshead United Kingdom +44 0191 4828440 www.helena-biosciences.com

Helena Biosciences is a world-leading Coagu-lation manufacturer specialising in the design and development of advanced laboratory analy-sers, interpretation software and reagents, sell-ing to end-users, distributors and OEM clients.We offer an extensive portfolio of reagents for the testing of various disorders, with validated support for a wide range of industry-standard and Helena-branded analysers:-Routine (PT, APTT, Fibrinogen, TT)-Factor Deficient Plasmas-D-Dimer-Antithrombin, Protein C, Protein S, Lupus Anticoagulant-Controls/Calibrators

Booth 401 Hall 4.2HemoSonics

400 Preston Ave, Suite 250 22903 Charlottesville, VA United States +1 434 2021032 www.hemosonics.com



564 565

HemoSonics, an innovative diagnostic compa-ny, is bringing to market the Quantra™ Hemost-asis Analyzer, a next-generation platform that provides rapid, near-patient measurement of key hemostasis parameters to guide treatment in critical bleeding situations. The Quantra uses SEER, a proprietary ultrasound-based technolo-gy, to rapidly measure the clot time and stiff-ness of whole blood during coagulation. Fast, easy-to-interpret results enable clinicians to make rapid transfusion decisions. Visit the our booth to see the Quantra live.

Booth 602 Hall 6.2HRA Healthcare Research & Analytics

2 Clarke Drive 08512 Cranbury, NJ United States +1 609 7167777 +1 609 7167777 www.hraresearch.com

HRA–Healthcare Research & Analytics is the market leader in conference-based healthcare research, with nearly 40 years of experience. We gather insights with actively engaged he-althcare professionals using self-administered surveys on iPads in the confines of our booth. We will be gathering the answers to vital mar-keting and clinical questions – answers that can affect the introduction of new products or the continuation of existing healthcare products and services. HRA provides solutions suppor-ting decision-making/strategy development across healthcare channels.

Booth 232 Hall 2.2HYPHEN BioMed

155 rue d‘Eragny 95000 Neuville sur Oise France +33 1 34406510 +33 1 34487184 www.hyphen-biomed.com

HYPHEN BioMed is highly specialized for de-veloping, manufacturing and distributing in-vi-tro diagnostic and research reagents in throm-bosis and hemostasis. Being expert in the field, the company provides innovative and value-ad-ding solutions to hospital laboratories (e.g., DOACs, HIT, Hemophilia), research institutions and pharmaceutical industry (customized solu-tion). Our unique offer of high quality reagents is available worldwide through an extensive dis-tributor network in all major markets: Find your local distributor on our web site.

Booth 625 Hall 6.2I&L Biosystems

Königswinter Str. 409a 53639 Königswinter Germany +49 2223 91920 www.il-group.eu

The company was founded in 1991. Focus of I&L is on sales and distribution of high quality laboratory equipment to customers and rese-archers in microbiology, cell biology and bio-technology markets in Western Europe, UK and Scandinavia. Excellent products, competent advice and fast service are basis for long-lasting relationships with our customers in industry, research and development. We present you at booth 625 - Multi-Well Microfluidics as well as Live Cell-Imaging Systems for your incubator.

Booth 405 Hall 4.2Instrumentation Laboratory

180 Hartwell Road 01730 Bedford, MA United States +1 800 955-9525 www.werfen.com

Instrumentation Laboratory (IL) is passionate about delivering innovative IVD solutions for a range of Hemostasis testing needs. The IL booth features: ACL TOP® Family 50 Series Systems, new HemoCell® Specialized Lab Automation and new HemoHub® Intelligent Data Manage-ment, ACL AcuStar® System, and HemosIL® assays. With the recent acquisition of Tem and Accriva, IL has expanded its leadership into He-mostasis point-of-care testing, with ROTEM® Patient Blood Management, Hemochron® and VerifyNow® systems. IL is a Werfen Company.

Booth 636 Hall 6.2International Initiative on Thrombosis andCancer (ITAC-CME)

72-A Brunswick Blvd. H9B 2C5 Dollard-des-Ormeaux Canada +1 514 685-1888 +1 514 685-7668 www.itaccme.com

ITAC-CME is the education section of the non- profit physician organization Groupe Franco-phone Thrombose et Cancer, a multidisciplinary group of healthcare providers globally. ITAC-CME published the 2016 International Clinical Practice Guidelines including Guidance for Di-rect Oral Anticoagulants in the Treatment and Prophylaxis of Venous Thromboembolism in Patients with Cancer (The Lancet Oncology, Vo-lume 17, No. 10, October 2016), endorsed by ISTH. ITAC-CME is implementing and measu-ring the clinical adoption of the guidelines in clinical practice to prevent and manage VTE in cancer patients.



566 567

Booth 619 Hall 6.2International Network of Venous Thromboembolism Clinical Research Networks

INVENT

501 Smyth Road, Box 180 K1H 8L6 Ottawa, ON Canada +1 613 7378899 www.invent-vte.com

INVENT is an independent, not-for-profit net-work of academic research groups. INVENT exists to promote international collaboration between academic research networks that con-duct venous thromboembolism (VTE) related clinical research, and to enhance the profile, science and impact of investigator-led VTE cli-nical research. INVENT seeks to improve the care of patients affected by VTE around the wor-ld through the promotion of high quality clinical research into the causes, prevention, diagnosis and optimal management of VTE.

Booth 651 Hall 6.2ISMAAP (International Self-MonitoringAssociation of anticoagulated Patients - nonProfit-Geneva/Switzerland)

30, route de ChêneCH-1211GenevaSwitzerland

ISMAAP (International Self-Monitoring Asso-ciation of oral anticoagulated Patients). More than 4.000.000 patients in Europe are living on long-term oral VKA anticoagulants. But only 3000.000 of these patients manage the INR self-monitoring on their own and take control of their anticoagulation therapy. International scientific studies and experience of these anti-coagulated patients have shown a better quality of compliance. ISMAAP activities are focussed on these patients to offer them information around the life with VKA anticoagulants.

Booth 200 Hall 2.2ISTH - International Society on Thrombosisand Haemostasis

610 Jones Ferry Rd. Ste. 20527510Carrboro, NCUnited States+1 919 929 3807 +1 919 929 3935http://www.isth.org

The International Society on Thrombosis and Haemostasis (ISTH) is a global not-for-profit membership organization advancing the un-derstanding, prevention, diagnosis and treat-ment of thrombotic and bleeding disorders.The Society is dedicated to transformative scientific discoveries and clinical practices, the development of young professionals and the education of physicians, scientists and allied health professionals wherever they may live.

Booth 200 Hall 2.2ISTH 2019 - Melbourne


The ISTH invites you to attend the next ISTH Congress in Melbourne, Australia! Save the da-tes of July 6-10, 2019 and plan to join thous-ands of the world’s experts in thrombosis, he-mostasis and vascular biology. This meeting has the greatest impact on the future of basic scien-ce and clinical practice, and your attendance and contribution is essential to the advance-ment of the field of thrombosis and hemostasis. Learn more at ISTH2019.org.

Booth 200 Hall 2.2ISTH SSC 2018


The ISTH is proud to present the next Scienti-fic and Standardization Committee (SSC) mee-ting in Dublin, Ireland on 18-21 July 2018. Both engaging and insightful, ISTH SSC 2018

is unlike any other meeting. It is an excellent and affordable scientific event in the field of thrombosis and hemostasis that brings together the world’s leading experts. Through the ef-forts of thousands of specialists, SSC meetings are a vivid platform for scientific and clinical working groups that lay the foundation for fu-ture breakthroughs. SSC 2018 will facilitate an exciting discourse about current diagnostic and therapeutic challenges, discussing novel approaches and standards that allow the field to work together toward real-time and patient-cen-tric solutions. Learn more at SSC2018.org.

Booth 200 Hall 2.2Journal of Thrombosis and Haemostasis


The Journal of Thrombosis and Haemostasis (JTH) is the flagship journal of the ISTH and is the leading medical journal in the fields of thrombosis and haemostasis. Through the diffu-sion and exchange of information and ideas wi-thin the international research community, JTH strives to advance science related to the import-ant medical problems of thrombosis, bleeding disorders, and vascular biology. It publishes high quality, original research reports; state-of-the-art reviews; letters and announcements; and invited commentary and debate on timely topics. Submit your research at jth.isth.org.



568 569

Booth 646 Hall 6.2Karger Publishers

Allschwilerstrasse 10 4009 Basel Switzerland +41 61 3061200 +41 61 3061234 www.karger.com

S. Karger Medical Publishers present their journals ‘Acta Haematologica’ and ‘Transfusion Medicine and Hemotherapy’, as well as the new book ‘SickKids Handbook of Pediatric Thrombo-sis and Hemotasis’. Publications are accessible online, with full-text search of articles, pay-per-view options and many other services. Founded 127 years ago, this Swiss-based family-owned publishing house combines highly sophisticat-ed production technology with customized ser-vices for its authors, editors and readers.

Booth 213 Hall 2.2Kedrion Biopharma

Località ai Conti Castelvecchio Pascoli - Barga 55051 Lucca Italy +39 0583 767100 +39 02 57763770 www.kedrion.com

Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-de-

rived therapies for use in treating patients suf-fering from hemophilia, immune deficiencies and other serious illnesses. Headquartered in Italy, the company has a market presence in approximately 100 countries. Kedrion acts as a bridge between donors and the people who need treatments, and works on a global scale to expand the patients’ access to available treat-ments.

Booth 415 Hall 4.2LABITEC LABOR BIOMEDICAL TECHNOLOGIES

An der Strusbek 6 22926 Ahrensburg Germany +49 0 410247950 +49 0 4102479535 www.labitec.de

LABiTec GmbH offers a full range of high quality coagulation and platelet aggregation semi and fully automated analysers, consumables and re-agents. As a competent partner in customized developments of system concepts, components and disposable solutions we guarantee unique and market oriented products and instrumenta-tion to clients all over the world.

Booth 403 Hall 4.2LFB BIOMEDICAMENTS

3, avenue des Tropiques 91958 COURTABOEUF France +33 1 69 82 70 10 +33 1 69827456 www.groupe-lfb.com/en

LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products indicated for the treatment of serious and often rare diseases in major therapeutic areas: hemo-stasis, immunology, intensive care and perina-tal care. LFB Group is one of the leading Euro-pean players specialized in biological medicinal products, and for the development and produc-tion of proteins and innovative treatments de-rived from biotechnologies. With 2,111 employ-ees, the LFB group currently markets medicinal products in 40 countries throughout the world. http://www.groupe-lfb.com

SupporterMedscape

825 8th Avenue 10019 New York, NY United States +1 212 301 6700 www.medscape.com

Medscape is the leading online global destina-tion for physicians and healthcare profession-als worldwide, offering the latest medical news and expert perspectives; essential point-of-care drug and disease information; and relevant pro-fessional education and CME. Medscape offers specialists, primary care physicians and other health care professionals the most robust and integrated medical information and educational tools across more than 33 medical specialties. Given its strong editorial credibility, Medscape is the preferred source of information for physi-cians worldwide.

Booth 626 Hall 6.2Medtronic

Victor von Bruns strasse 19 8212 Neuhausen Am Rheinfall Switzerland +41 52 556 06 00 www.medtronic.com

As a global leader in medical technology, ser-vices and solutions, Medtronic improves the lives and health of millions of people each year. We use our deep clinical, therapeutic and eco-nomic expertise to address the complex chal-lenges faced by healthcare systems today. Let’s take healthcare Further, Together. Learn more at Medtronic.eu.



570 571

Booth 624 Hall 6.2Mitsubishi Tanabe Pharma

Willstätterstr. 30 40549 Düsseldorf Germany+49 0211 52054 40 +49 0211 52054499 www.mt-pharma-de.com

Mitsubishi Tanabe Pharma GmbH, headquar-tered in Düsseldorf, Germany, was founded in 2003 under the name Mitsubishi Pharma Deutschland GmbH as a subsidiary of Mitsub-ishi Pharma Europe Ltd. (London / UK). It was the first country’s representative agency to bring products from its own research to the market outside Asia.The main focus of business activity in Germany, Austria and Switzerland is the marketing of the thrombin inhibitor Argatra® (Argatroban mono-hydrate).

Booth 222 Hall 2.2Novo Nordisk Healthcare

Thurgauerstrasse 36 8050 Zurich Switzerland +41 044 914 11 77 +41 79 9096923 www.novonordisk.com

Novo Nordisk is a global healthcare company with more than 90 years of innovation and lead-ership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nor-disk employs approximately 41,600 people in 75 countries and markets its products in more than 180 countries.For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Booth 235 Hall 2.2Novo Nordisk Haemophilia Foundation

Thurgauerstrasse 36/38 8050 Zurich Switzerland www.nnhf.org

Founded in 2005 and situated in Zurich, Swit-zerland, Novo Nordisk Haemophilia Foundation (NNHF) is a non-profit organisation dedicat-ed to defining and funding sustainable pro-grammes which improve access to quality care benefitting people with haemophilia and allied bleeding disorders in developing and emerging countries. With local partners and renowned ex-perts, we address three focus areas: capacity building; diagnosis and registry; education and empowerment.

Booth 411, 421 Hall 4.2Octapharma

Seidenstrasse 2 8853 Lachen Switzerland +41 55 4512121+41 55 4512110 www.octapharma.com

Octapharma develops and produces human pro-teins from human plasma and human cell lines for the treatment of patients in the areas:- Haematology- Critical Care- ImmunotherapyThe Swiss-based family-owned company is one of the world’s largest manufacturers of human proteins. Employing over 7000 people in 113 countries Octapharma has been advancing hu-man life since 1983. www.octapharma.com

Booth 653 Hall 6.2ORGENTEC - Corgenix

11575 Main Street 80020 Broomfield, CO United States +1 303 457 4345 +1 303 453-8868 www.corgenix.com

ORGENTEC-Corgenix will highlight the Aspirin-Works® Test. An ELISA test to determine levels of 11-dehydro thromboxane B2 (11 dhTxB2) in human urine, which aids in the qualitative de-

tection of aspirin effect in apparently healthy individuals post ingestion. The AspirinWorks Test assesses systemic thromboxane produc-tion, a metabolite of Thromboxane A2. The test allows for individualized aspirin therapy. Visit to learn about new study: McCullough et al. “Urinary 11-dehydro-Thromboxane B2 and Mortality in Patients with Stable Coronary Artery Disease” AJC 2017

Booth 431 Hall 4.2Pfizer

235 E. 42nd Street 10017 New York, NY United States +1 212 733 2323 www.pfizer.com

At Pfizer, we apply science and our global re-sources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer prod-ucts. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.



572 573

Booth 652 Hall 6.2phamax

Baarerstrasse 82 6300 Zug Switzerland +41 61 8215687 +41 61 8215836 www.phamax.ch

phamax is a specialized scientific and analytical healthcare market access firm headquartered in Zug, Switzerland with offices in Bangalore, In-dia and Singapore.We bring forth credible scientific evidence and unbiased recommendations globally, and for-mulate robust health plans and colloborate with health ministries, physician associations, pati-ent groups and the healthcare industry to aid access to care for patients. Our scientific initia-tives range from real world studies, stakeholder engagements, policy shaping, health economics outcomes research and scientific publications to patient access programs.

Booth 654 Hall 6.2Phenom-World

Dillenburgstraat 9T 5652 AM Eindhoven Netherlands +31 40 259 73 60 www.phenom-world.com

Phenom-world is globally the yearly number 1 manufacturer of desktop scanning electron mi-croscopes and imaging & analysis packages for sub-micron-scale applications.Delphi is the world’s first fully integrated solu-tion that enables fast correlative microscopy with unique overlay precision.The Delphi is easy to use for both light- and electron microscopy users. It opens the door to these techniques for all laboratories through a cost-efficient package.

Booth 440 Hall 4.2Portola Pharmaceuticals,

270 East Grand Ave 94080 South San Francisco, CA United States +1 650 246 7000 +1 650 246 7376www.portola.com

Portola Pharmaceuticals is a biopharmaceu-tical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Fac-tor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cer-dulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers.

Booth 614 Hall 6.2Precision Biologic

140 Eileen Stubbs. Ave. B3B 0A9 Dartmouth Canada +1 902 468 6422 www.precisionbiologic.com

Twenty-five years ago we launched our first cryo-check™ product—a normal control for PTs and APTTs that could also be used as an alternative to in-house collected pools of normal plasma.The benefits of frozen quickly caught on and cryocheck grew from a single product to an in-tegrated line of frozen diagnostic products that are synonymous with quality in labs around the globe.With our lab, biotech and pharma partners, we’re now developing new products to address current and future challenges in the diagnosis and therapeutic monitoring of disease.

Booth 200 Hall 2.2Research and Practice in Thrombosis andHeamostasis

610 Jones Ferry Rd. Ste. 20527510Carrboro, NCUnited States+1 919 929 3807 + 1 919 929 3935http://www.isth.org

The ISTH is excited to announce the launch of its new open access journal, Research and Prac-

tice in Thrombosis and Haemostasis (RPTH). As an open access and online-only publication, RPTH will serve as a catalyst for global discus-sion and connect scientists and clinicians with the non-scientist public to discuss the latest findings and research in the field. Visit rpth.isth.org to get started.

Booth 404 Hall 4.2Roche

Konzern-Hauptsitz Grenzacherstrasse 124 CH-4070 Basel Switzerland +41 61 688 1111 www.roche.com

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and di-agnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a front-runner in diabetes management. Roche’s per-sonalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.



574 575

Booth 412 Hall 4.2Roche Diagnostics International

Forrenstrasse 2 6343 Rotkreuz Switzerland +41 41 799 2244 +41 79 5398222www.roche-rotkreuz.com

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmolo-gy and diseases of the central nervous system. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Booth 215 Hall 2.2SEBIA

27 rue Léonard de Vinci, Parc Technologique Léonard de Vinci 91008 Evry Cedex France +33 0 169898080 www.sebia.com

Sebia, world leader in protein electrophoresis, develops, manufactures and commercializes

IVD tests and analyzers dedicated to the in vi-tro diagnosis of cancer, inflammatory diseases, diabetes and hemoglobin disorders. Sebia’s fo-cus on both, gel and capillary electrophoresis techniques, enables it to maintain a sustained R&D program, providing access to genuine in-novations in any lab. Sebia recently introduced the von Willebrand Multimers assay, to address the diagnostics unmet needs of this coagulation disorders.

Booth 645 Hall 6.2Sekisui Diagnostics

4 Hartwell Place 02421 Lexington, MA United States +1 781 652 7800 www.sekisuidiagnostics.com

Sekisui Diagnostics is committed to improving patient’s lives by providing innovative medical diagnostics to physicians and laboratories. We develop, manufacture, and supply over one bil-lion tests each year through our global commer-cial network. Our range of coagulation products include the high throughput CP3000 instru-ment system with dedicated barcoded reagents, as well as specialty and research use coagula-tion reagents. Our other product lines include clinical chemistry, diabetes, infectious disease rapid tests and novel markers. In addition, we offer enzymes and specialist biochemicals to the global healthcare market.

Booth 221 Hall 2.2Shire

Zählerweg 10 6300 Zug Switzerland+41 41 288 40 00 www.shire.com

Shire is the leading global biotechnology com-pany focused on serving people with rare diseas-es and other highly specialized conditions. We strive to develop best-in-class products across our core therapeutic areas including Hematol-ogy, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal/Internal Medicine/Endocrine, Hereditary An-gioedema, and Oncology

Booth 443 Hall 4.2Siemens Healthineers

Emil-von-Behring Str.76 35041 Marburg Germany+49 6421 390www.siemens.com/healthcare

Siemens Healthineers is committed to becom-ing the trusted partner of healthcare providers worldwide, enabling them to improve patient outcomes while reducing costs. Driven by our long legacy of engineering excellence and our pioneering approach to developing the latest advancements, we are a global leader in medi-cal imaging, laboratory diagnostics, clinical IT,

and services. We are dedicated to helping our partners be successful–clinically,operationally and financially–from prevention through diag-nosis and treatment.

Booth 410 Hall 4.2Sobi

Tomtebodavägen 23A 112 76 Stockholm Sweden +46 8 697 20 00 www.sobi.com

Sobi is a pioneer in rare diseases. Our history of innovation in haemophilia treatments stretches over 50 years. We have the simple goal to pro-vide people with haemophilia treatment choic-es that will help them live the lives they want. Please visit: www.sobihaemophilia.com.

SupporterSpark Therapeutics

3737 Market Street, Suite 1300 19104 Philadelphia, PA United States +1 215 220 9300 www.sparktx.com

Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and deliver-ing gene therapies that address inherited retinal



576 577

diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by tar-geting the liver. Our validated platform success-fully has delivered proof-of-concept data with investigational gene therapies in the retina and liver.

Booth 241 Hall 2.2Stago

3 allée Thérésa 92600 Asnières-sur-Seine France +33 1 46882020 +33 1 47910891 www.stago.com

Stago, created in 1945, is an IVD Company which develops and markets reagents and au-tomated systems for the investigation of blood coagulation disorders. Stago is a leading player in Haemostasis. Headquarters, as well as R&D, manufacturing and logistics activities are locat-ed mainly in the Paris area (France). Its prod-ucts are also available in more than 110 coun-tries throughout the world through a network of 15 affiliates and 95 distributors. In 2016, Sta-go has more than 2,200 employees worldwide.

Booth 443 Hall 4.2Sysmex Corporation

4-4-4 Takatsukadai, Nishi-ku651-2271 KobeJapan+81 78 265 0500+81 78 265 0524www.sysmex.co.jp/en

Sysmex Corporation is an integrated supplier of the instruments, reagents and software that are essential to testing processes performed during health checkups, treatment and ongoing dis-ease management. Sysmex products are used by medical institu-tions in more than 170 of the world’s countries and Sysmex holds the top share of the global market in the field of hematology. We are ex-panding our operations, augmenting our tradi-tional strength in hematology with non-hema-tology fields such as immunochemistry and hemostasis, as well as the life science field. Sysmex is leveraging its proprietary technolo-gies to create new testing and diagnostic tech-nologies that aim to ensure optimal healthcare for all.

Booth 413 Hall 4.2Technoclone

Brunner Str. 67 1230 Vienna Austria +43 1 863730 +43 1 8637344 www.technoclone.com

Technoclone offers both global as well as spe-ciality coagulation tests, a fully automated co-agulation analyzer the Ceveron® alpha and the new semi-automated analyzers the Ceveron® one, four and ten. Ceveron® alpha TGA offers the unique feature of a fully automated throm-bin generation measurement in the routine: CV <5% and assay times <20min Peak Thrombin. Furthermore it provides a complete range of ADAMTS-13 ELISAs, as well a complete port-folio for the new anticoagulants such as for Xa inhibitors and direct thrombin inhibitors

Booth 647 Hall 6.2The Lancet

125 London Wall EC2Y 5AS London United Kingdom +44 207 424 4950 www.thelancet.com

The Lancet is a family of world-class journals committed to improving lives through medical research. With offices in London, New York, and Beijing, the Lancet publishes a weekly journal and monthly specialty journals, including The Lancet Haematology.

Booth 638 Hall 6.2Thrombosis and Haemostasis

Hölderlinstraße 3 70174 Stuttgart Germany +49 711 2298763www.thrombosis-online.com

Thrombosis and Haemostasis publishes reports on basic, translational and clinical research dedicated to novel results and highest quality in any area of thrombosis and haemostasis, vas-cular biology and medicine, inflammation and infection, platelet and leukocyte biology.Thrombosis and Haemostasis provides position and guideline papers, state-of-the-art papers, expert analysis and commentaries, and dedicat-ed Theme issues covering recent developments and key topics in the field.

Booth 242 Hall 2.2Thrombosis Research Institute

Emmanuel Kaye Building SW3 6LR London United Kingdom +44 207 351 8300 www.tri-london.ac.uk

Internationally renowned for pioneering, multi-disciplinary research, the Thrombosis Re-search Institutes are dedicated to the study of thrombosis and related disorders. Two research establishments in London and Bangalore are



578 579

united by their shared mission: To provide excellence in thrombosis research, education and patient care and to develop new strategies to prevent and treat thrombosis, thereby reducing healthcare costs and saving millions of lives.

Booth 648 Hall 6.2Thrombosis.TV

6707 113th Place SE 98006 Bellevue, WA United States +1 267 3950001 www.totalcme.com

Thrombosis.tv is a leading online destination for high quality venous and arterial thrombosis education, news and expert opinion. We offer health care professionals the timeliest compre-hensive and relevant clinical information to im-prove patient care.

Booth 434 Hall 4.2uniQure

Paasheuvelweg 25a 1105 BA Amsterdam Netherlands +31 20 240 6000 www.uniqure.com

uniQure is delivering on the promise of gene therapy, single treatments with potentially cu-rative results. We are advancing a focused pipe-line of innovative adeno-associated virus (AAV)-

based gene therapies, and have established clinical proof-of-concept in our lead indication, hemophilia B.

Our vision is to build an industry-leading, fully integrated global company that leverages its val-idated technology and manufacturing platform to deliver transformative gene therapy products to patients with serious unmet medical needs.

Booth 627 Hall 6.2Wiley

The Atrium PO19 8SQ Chichester, West Sussex United Kingdom +44 1243 779777 +44 1243 775878 www.wiley.com

Wiley, a global company, helps people and orga-nizations develop the skills and knowledge they need to succeed. Our online scientific, techni-cal, medical, and scholarly journals, combined with our digital learning, assessment and cer-tification solutions help universities, societies, businesses, governments, and individuals in-crease the academic and professional impact of their work.

Booth 628 Hall 6.2Wisepress Ltd

15 Lyon Road SW19 2RL London United Kingdom +44 20 87151812 www.wisepress.com

Wisepress.com, Europe’s leading conference bookseller, attend around 200 conferences ev-ery year. We have an extensive range of books and journals relevant to the themes of this con-ference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.

Booth 617 Hall 6.2World Federation of Hemophilia

1425, boul. René-Lévesque Ouest, bureau 1010 H3G 1T7 Montréal, QC Canada +1 514 875 7944+1 514 875 8916 www.wfh.org

For 50 years, the World Federation of Hemo-philia (WFH) has provided global leadership to improve and sustain care for people with inher-ited bleeding disorders, including hemophilia, von Willebrand disease, rare factor deficiencies,

and inherited platelet disorders. Come visit our booth and enter a draw for a trip to the WFH 2018 World Congress in Glasgow, Scotland, May 20-24, 2018. The WFH World Congress is the largest international meeting for the global bleeding disorders community.


580 581

CORPORATE MEETING SUITES

Company Room Location

Alnylam Pharmaceuticals Lindau 5 Hall 7, Meeting Bridge A, Mezzanine Level 1

Alnylam Pharmaceuticals Lindau 6 Hall 7, Meeting Bridge A, Mezzanine Level 1

Bayer Ulm Entrance Foyer to Hall 2.2, Level 2

Boehringer Ingelheim Dessau 1 Hall 7, Meeting Bridge C, Mezzanine Level 1

BioMarin Pharmaceuticals Lindau 4 Hall 7, Meeting Bridge A, Mezzanine Level 1

CSL Behring Dessau 6 Hall 7, Meeting Bridge C, Mezzanine Level 1

Daiichi Sankyo Dessau 3 Hall 7, Meeting Bridge C, Mezzanine Level 1

F. Hoffmann-La Roche Lindau 2 Hall 7, Meeting Bridge A, Mezzanine Level 1

F. Hoffmann-La Roche Dessau 4 Hall 7, Meeting Bridge C, Mezzanine Level 1

Grifols S3 CityCube Berlin, West Lobby 3, Level 3

Novo Nordisk Healthcare Lindau 1 Hall 7, Meeting Bridge A, Mezzanine Level 1

Octapharma Weimar 1 Hall 7, Meeting Bridge B, Mezzanine Level 1* Regensburg Entrance Foyer of Hall 4.1, Level 1*

Pfizer Weimar 2 Hall 7, Meeting Bridge B, Mezzanine Level 1

Pfizer Weimar 4 Hall 7, Meeting Bridge B, Mezzanine Level 1

Portola Pharmaceuticals Dessau 2 Hall 7, Meeting Bridge C, Mezzanine Level 1

Sanofi Genzyme Frankfurt 2 Back Foyer of Hall 4.2, Level 2

Shire Lindau 3 Hall 7, Meeting Bridge A, Mezzanine Level 1

Shire Dessau 5 Hall 7, Meeting Bridge C, Mezzanine Level 1

Sobi/Bioverativ Weimar 3 Hall 7, Meeting Bridge B, Mezzanine Level 1

Sobi/Bioverativ Weimar 5 Hall 7, Meeting Bridge B, Mezzanine Level 1

Sobi/Bioverativ Gera Hall 7, Foyer of Meeting Bridge C (7b), Mezzanine Level 1

CORPORATE MEETING SUITES

World Federation Weimar 1 Hall 7, Meeting Bridge B, Mezzanine Level 1*of Hemophilia

Corporate Meeting Suites starting from Monday, July 10 at 07:00.

Company Room Location

Bayer Passau 7 Back Foyer of Hall 2.2, Mezzanine Level 1 (Z1)

Bioverativ Jena 1 Back Foyer of Hall 6.2, Mezzanine Level 1 (Z1)

Pfizer Trier 5 Back Foyer of Hall 2.2, Mezzanine Level 1 (Z1)

Phamax Trier 4 Back Foyer of Hall 2.2, Mezzanine Level 1 (Z1)

Roche Products Ltd Trier 1 Back Foyer of Hall 2.2, Mezzanine Level 1 (Z1)

Shire Jena 2 Back Foyer of Hall 6.2, Mezzanine Level 1 (Z1) Passau 4 Back Foyer of Hall 2.2, Mezzanine Level 1 (Z1)

Sobi Passau 9 Back Foyer of Hall 2.2, Mezzanine Level 1 (Z1)

uniQure Trier 2 Back Foyer of Hall 2.2, Mezzanine Level 1 (Z1)

* Weimar 1 is assigned to Octapharma from July 8 until July 10 at 13:00. Weimar 1 is assigned to World Federation of Hemophilia from July 10 at 14:00. Regensburg is assigned to Octapharma from Monday 10 at 14:00.


582 583

CONFLICT OF INTEREST DISCLOSURE INFORMATION

Local Organizing Committee

Anne Angelillo-ScherrerReceipt of honoraria or consultation fees: Amgen (2013), Bayer (2013), Debiopharm (2016-2017), GSK (2013), Mitsubishi (2013), Pfizer (2016), Vifor (2016-2017)

Andreas GreinacherReceipt of grants/research supports: Deutsches Rotes Kreuz Blutspendedienst NSTOB; Rovi, Sagent, Biomarin/Prosensa Aspen, Boehringer Ingelheim, Merck Sharp and Dome, Bayer Healthcare, Gore Inc.Receipt of honoraria or consultation fees: Aspen, Boehringer Ingelheim, MSD, Macopharma, Bristol Myers Squibb, Chromatec, Instrumentation Laboratory

Bettina Kemkes-MatthesReceipt of honoraria or consultation fees: (travel grants) Bayer Healthcare, Stemens, Boehringer Ingelheim, Biotest, CSL, Daiichi Sankyo, Novo Nordisk, Pfizer, Sobi, Shire, Baxalta

Christoph MaleReceipt of grants/research supports: Bayer, Baxter/Shire, Biotest, Bristol-Myers Squibb, Boehringer Ingelheim, CSL Behring, Novo NordiskReceipt of honoraria or consultation fees: Bayer, Bristol-Myers Squibb, CSL BehringParticipation in a company sponsored speaker’s bureau: Baxter/Shire, Biotest, Boehringer Ingelheim, Novo Nordisk

Christine MannhalterReceipt of honoraria or consultation fees: Bayer Austria, QiagenSpouse/partner: Stocks – Baxter, Novartis, Bayer, Pfizer, Novo Nordisk

Johannes OldenburgReceipt of grants/research supports: Baxter, Bayer, Biotest, CSL Behring, Grifols, Novo Nordisk, Octapharma, and PfizerReceipt of honoraria or consultation fees: Baxter, Bayer, Biogen Idec, Biotest, Chaugai, CSL Behring, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche, and Swedish Orphan BiovitrumParticipation in a company sponsored speaker’s bureau: Baxter, Bayer, Biogen Idec, Biotest, Chugai, CSL Behring, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche and Swedish Orphan Biovitrum

Ingrid Pabinger-FaschingReceipt of grants/research supports: CSL BehringReceipt of honoraria or consultation fees: Bayer, CSL Behring, Boehringer Ingelheim, Pfizer, Daiichi Sankyo, Baxter/Shire, Biotest, Amgen, Novartis

Klaus T. PreissnerNo potential conflict of interest to report

Wolfram RufReceipt of grants/research supports: Novo NordiskReceipt of honoraria or consultation fees: ICONIC Therapeutics

Christian WeberNo potential conflict of interest to report

CONFLICT OF INTEREST DISCLOSURE INFORMATION

Scientific Program Committee Topic Chairs

Hellmut G. AugustinNo potential conflict of interest to report

Christoph J. BinderReceipt of honoraria or consultation fees: SanofiOther Support: Board Member, Technoclone GmbH

Sabine EichingerReceipt of honoraria or consultation fees: Bayer, Boehringer-Ingelheim, Pfizer, Daiichi-Sankyo

Bernd EngelmannNo potential conflict of interest to report

Meinrad GawazNo potential conflict of interest to report

Berend IsermannNo potential conflict of interest to report

Stavros KonstantinidesReceipt of grants/research supports to my institution: Bayer HealthCare, Boehringer Ingelheim, Actelion, Daiichi SankyoReceipt of honoraria or consultation fees: Bayer HealthCare, Pfizer – Bristol-Myers Squibb, Servier, Actelion

Karl LacknerReceipt of grants/research supports: Abbott Diagnostics, Roche Diagnostics, Thermo Fisher, Siemens Healthcare

Bernhard NieswandtNo potential conflict of interest to report

Erhard SeifriedNo potential conflict of interest to report

Andreas TiedeReceipt of grants/research supports: Bayer, Biotest, CSL Behring, Novo Nordisk, Octapharma, Pfizer, ShireReceipt of honoraria or consultation fees: Bayer, Biogen Idec, Biotest, Boehringer Ingelheim, CSL Behring, Leo Pharma, Novo Nordisk, Octapharma, Pfizer, Shire, and SOBI

Johann WojtaNo potential conflict of interest to report




584 585

Discover the new episode about primary haemostasis

and coagulation cascade update

Developped in collaboration with Pr C. NEGRIER and Dr L. RUGERI, Lyon HTC, France

COME TO HALL 4.2 NR. 403

TAKE CONTROL OF HAEMOSTASIS

Enjoy a UNIQUE experience!

TAKE CONTROL OF HAEMOSTASIS

Stud

io 2

01 -

MRA

6948

2 -

JULY

201

7

8536 (MK3)Invitation Stand CIB_LFB.indd 1 02/05/2017 15:33

Authors Index

AUTHORS INDEXAUTHORS INDEX


586 587

Aut

hors

Ind

ex

A

Abad A., PB 972Abajas Y., PB 097Abbattista M., PB 1583Abdelhafez M., PO 67Abdel-Razeq H., PB 619, PB 2331Abdelwahab M., PB 1586Abdul Karim F., PB 965Abdulrehman J., PB 1934Abegunde S., PB 1018Abelleyro M.M., PB 1070Åberg M., ASY 34.4, OC 41.4Abo Hassan M., PB 2222Abraham A., PB 762, PB 1806, PB 2001Abraham M.-K., PB 020Abraham S., OC 30.5Abu Zeinah G., PB 1485Abu-Harbesh S., PB 1922Adam F., OC 53.4Adamkewicz J.I., OC 47.1, PB 954Adams G., OC 05.4Adams M., PB 1295Adili R., PB 073Agazzoni M., PB 514Agbani E.O., OC 55.5, PB 1564, PB 1703Ageno W., ASY 35.4, OC 73.3, PB 484Agius C., PB 050Agnelli Giacchello J., PB 1824Aguila S., OC 08.3Aharon A., PB 664, PB 2446Ahluwalia J., PB 1536Ahmad A., PB 1429Ahmad P., PB 2425Ahmadinejad M., PB 1830, PB 2385Ahmed S., PB 2057, PB 2136Ahn H., OC 75.4Ahsan A., PB 1014Ahsan S., PB 1025Aires A., PO 23Aisina R., PB 183

Ajzenberg N., PB 657, PB 1567, PB 2373Akbar H., OC 30.1Akbar R., PB 315, PB 1034, PB 1598Akhter M., PB 1677Akuta K., PB 1584Al Ghaithi R., PB 2230Al Hashmi K., PB 1552, PO 64Al Massarani G., PB 680Al Rawahi B., PB 1860, PB 1875Alatri A., PB 620, PB 2309Albayrak C., PB 721, PB 2040Albayrak D., PB 2033Alberelli M.A., PB 753, PB 1346Albisetti M., PB 1108Al-Dabet M.M.A., PB 866Aldossary M., OC 59.4Aleman M., OC 47.3, PB 139, PB 1127Alemanno L., PB 1282Alessi M.-C., PB 728Algarni A., PB 2324Alhamdi Y., OC 74.2Ali S.A., PB 296Alikhan R., PB 492Aliotta A., PB 1335Allan H.E., PB 2243Allende M., OC 71.1Allerkamp H., PB 093Almegren M., PB 1867Almutairi M., PB 186Alouda S., PB 1288Alrifai M., PB 1543Alshammari H., PB 811Al-Shehristani R.M.M., PB 1866Althaus K., OC 69.5Altuner Torun Y., PB 687Alvarado Moreno J.A., PB 2448Alvarez-Flores M.P., PB 871Alwis I., OC 42.3Amadio P., OC 02.2Ambaglio C., PB 398, PB 1828Ames P., PB 1463Ames P.R.J., PB 1448Amin E., OC 60.3

Amirkhosravi A., PB 1276Anand M., PB 607Andersen E., OC 07.4Anderson D., OC 52.2Andersson N.G., OC 24.3Andresen M.S., PB 874Andrews A., PB 1122Ang A.L., PB 309Ann F., NUR 05.5Annichino-Bizzacchi J.M., PB 1015Antal J., PB 303Antic D., PB 2297Antmen B., PB 847Antoniak S., OC 05.2, OC 05.3Antonijevic N., PB 049Antovic J., PB 2278Antovic J.P., PB 1206Antropova I.P., PB 184Anun S., PB 2134Anyanwu R.A., PB 1955, PO 40Anzej Doma S., PB 2023Apostolovska R., PO 43Apta B., PB 1635Apte S., PB 982, PB 1802Aranda F., PB 1899Arce M., PB 928Arias M.D.V., PB 1178Arias T., PB 504Arias Fernández T., PB 2172, PB 2400Arjakse J., PB 800Armstrong E., PB 1950Armstrong P.C., PB 1562Arocas V., PB 2418Arroyo Rodríguez A.B., ASY 25.4, OC 41.5, PB 2258Arshad N., PB 034Artemenko E., PB 1287Artoni A., OC 63.3, OC 63.5, PB 1523, PB 2233Ascher S., PB 1641Asghari G., PB 2170Ashworth K., PB 1638Asif H., PB 610Aslan J.E., OC 68.4, PB 1306

Asquith N., ASY 28.2Attard C., PB 263, PB 349Attarwala H., PB 1066Atucha N.M., PB 2247Auerswald G., PB 131Aurbach K., PB 2227Auton M., PB 2048Avila M.L., OC 11.4, PB 1010, PB 1011, PB 1013Avila Idrovo L.F., PO 27, PO 35Awodu O., PB 784Ay Y., PB 159Aydogan G., PB 2028Aymé G., OC 38.2Aymonnier K., OC 42.2Ayombil F., ASY 21.3Aytac S., PB 1028Azumaguchi R., PB 308

B

Baaten C.C.F.M.J., PB 566, PB 1588Babkina I., PB 2289Baccouche H., PB 656, PB 1731, PB 2338Bachelot-Loza C., ASY 12.4Bachiri I., PB 1168Back V., OC 45.2Badle S., PB 399Bagoly Z., PB 1160Bagot C., PB 1994Bagot C.N., PB 873Bai C., PB 1139Bai X., PB 717Baile M., PB 2321Bakchoul T., ASY 05.2, PB 2387Baker C., PB 823Baker K., PB 888Baker R.I., PB 1197, PB 2087Bakhtiari K., PB 321Baksaas-Aasen K., OC 49.3Balandina A., PB 605, PB 1170Balestra D., PB 1115Balogh G., PB 1745Bang S.-M., PB 2382, PB 2389

Banzato A., PB 1469, PB 1473Baques A., PB 1812Barber-Singh J., PB 879, PB 880Barbieri S.S., PB 544Barbon E., OC 38.5 Barco S., PB 466, PB 1024, PB 1421Barg A., PB 768Bariana T.K., OC 59.2Bark Jr. D., ASY 11.4Barnes G., PB 289, PB 305, PB 1877Barrachina M.N., PB 559Barreiro K.A., PB 1629Barros V., ASY 37.3, PB 1912, PB 1923, PO 39Barsegov V., ASY 28.1Barthod-Malat A., PB 1224Bartholomew C., PB 1055Baruch D., ASY 33.3Bashari D., NUR 05.10Bastida J.M., PB 750, PB 1314Batorova A., PB 852Batty P., PB 387, PB 1073Bauersachs R., PB 1006Bautista H., PB 2069Baylis J.R., OC 49.4Beaulieu L., OC 04.4Becattini C., PB 463, PB 467Beck S., OC 57.2Becker I., OC 18.3Beckmann L., PB 1727 Begtrup K.M., PB 2327Beke Debreceni I., PB 909Bekendam R.H., PB 1607Bendapudi P., OC 15.3Bendik M., PB 1103Benelhaj N., PB 2291Bennett C., ASY 20.3Bensadok M., PB 1811Berber E., PB 156Bercovitz R., OC 64.3, PB 2408Bereczky Z., PB 117Berens C., PB 1892Bergen K., PB 662, PB 663Berger J., PB 1560

Bermejo E., PB 748Berny-Lang M.A., PB 653Berrueco R., PB 516Bertaggia Calderara D., PB 503, PB 1183Beyer-Westendorf J., PB 480Bhakuni T., PB 1501Bhalla A., PB 1590Bhardwaj P., PB 2154Bhatlekar S., ASY 38.4Bhatt M., PB 517, PB 525, PB 534Bhatt S., PB 1846Bichan V.D., PB 1315Biguzzi E., PB 1998Billett H., PB 2343Biltoft D., PB 1691, PB 1697Binder N., PB 700, PB 2119Birkholz I., OC 17.3Biss T., PB 528Biss T.T., ASY 26.4Bistervels I., ASY 22.4Biswas A., PB 1756, PB 1761Bitsadze V., PB 1893, PO 42, PO 45Bjoernsdottir I., PB 1971Bjøri E., PB 1493, PB 1494Blaauwgeers M., PB 745, PB 751, PB 758Blackshear J., PB 2072Blake L., PB 2335Blanchette V., ASY 27.1Bliden K., PB 483, PB 794, PB 801Blinc A., PB 058Bloem E., OC 16.3Bloemen S., PB 1199Blondon M., OC 12.4, OC 32.3Blouse G.E., PB 1125Blumenstein M., NUR 05.6Bochenek M.L., OC 03.3, OC 32.2, OC 43.3Böckelmann D., PB 2013Bodrozic J., ASY 22.2Boender J., PB 2065Boffa M., PB 170



588 589

Aut

hors

Ind

ex

Bogáti R., PB 005Boisson-Vidal C., PB 2422Boknäs N., OC 76.3Bolshakova O., PB 300Bon C., PB 409Bonaci J., PB 044Bonar R., PB 2064Bonetti N.R., PB 082Bonnard T., OC 19.1Bonstein L., PB 2406Bordbar M., PB 2024Borhany M., PB 1752, PB 1832, PB 2017Bortot M., PB 2058Bosmann M., ASY 32.3Bouck E., OC 67.5Boukerb H., PO 32Boulaftali Y., PB 1623, PB 2273Boulahya R., PB 1566Bouton M.-C., ASY 29.3Bowyer A.E., PB 412, PB 1146, PB 2095Bozic Mijovski M., PB 2149Braekkan S.K., PB 625, PB 775, PB 1487Brambilla M., OC 27.1, OC 27.4, PB 807Brandão L., NUR 05.3Brandt K.J., PB 1445Brandtner A., PB 665Bravo M.C., PB 1083Bravo M.I., PB 1969, PB 1989Breen K., PB 1449Brehm M.A., PB 2056Brekelmans M.P.A., ASY 36.1, PB 277Brennan Y., PB 1234Bridey F., PB 2005Brighton T., PB 400Brinkman H.J.M., PB 356Brisset A.C., PB 128Brisson A., PB 677, PB 1344Brodde M.F., PB 307Brommonschenkel C.C., PB 960Bronic A., PB 1181, PB 1186 Brookman S., PB 1051

Brouns S.L.N., PB 1719Brown A., PB 1845Brown J., OC 46.3, PB 490, PB 2143Bryckaert M., ASY 20.2Bryk A.H., PB 779Bucciarelli P., PB 063, PB 1488Buchholz I., PB 1451Buchmueller A., PB 096Buckner T., PB 201, PB 1771Buczma A., PB 299Budd A., LB 05Budde U., PB 376Buijs J.T., PB 920Buitrago C.L., PB 1300Bulato C., PB 437, PB 2000, PB 2011Bulder I., PB 2253Bury L., PB 730, PB 737Butler L., PB 1625Butta N., PB 2377Butta N.V., PB 226Byrnes J., PB 519Byrnes J.R., ASY 07.2Byskov K., PB 1617, PB 2285

CCalhoon W., PB 1411Calvert L., PB 833Campbell R., OC 58.2, OC 70.2, PB 546Campello E., PB 051, PB 667, PB 672, PB 684, PB 1455, PB 1540, PB 2168, PB 2345Camporese G., PB 1192Canaro M., PB 1826Canault M., PB 1995Cannavò A., PB 955, PB 1799Canobbio I., OC 02.4Cao Z., PB 1770Caranfa J., PB 1674Cardinal M., PB 890Carmona R., PB 1781Carneiro J.D.A., PB 2191Carrasco Exposito M., PB 136,

PB 1546Carson C., PB 659, PB 2315Carvalho M.G., PB 026, PB 1207, PB 1424, PB 1425, PB 1439, PB 1839Casali A., PB 1241Casan J.M.L., PB 577Casari C., OC 22.4Casas C., PB 354Casini A., PB 1749Castaman G., PB 1772, PB 2062, PB 2066Castellone D., OC 65.4Castellucci L.A., PB 932Castoldi E., PB 1716Cavanaugh L., PB 1410Cawthern K., PB 416Ceglarek B., PB 229, PB 248, PB 380, PB 769, PB 1486, PB 1551, PB 1556, PB 2081Celińska-Lowenhoff M., PB 1482Cepo K., PB 2006Ceresetto J.M., PB 1676Cerletti C., OC 27.2Cervio C., OC 64.1Çetin M., PB 1030Cha S.-I., PB 2329Chabert A., PB 1348Chahal J.K., PB 1872Chai-Adisaksopha C., PB 2307Chaireti R., PB 1898, PB 1909Chalmers E., PB 1778Chan A., PB 512, PB 1247Chan J., PB 536Chan M.V., PB 2098Chan V., PB 336Chang C.-Y., OC 50.4, PB 215Chang S., PB 780Chapin J., OC 13.3Chatterjee M., PB 788Chausheva S., PB 1744Chaves D.G., PB 1798Chen D., PB 2074Chen D.-P., PB 1039Chen J., PB 1050Chen V., PB 839, PB 1278

Chen X., PB 1316Chen Y.-C., PB 216Chen Z., PB 236Cherpokova D., PB 539Chhabra A., PB 208Chiasakul T., OC 74.4Chintala M., OC 76.2Chinthammitr Y., PB 704, PB 1948Choi E.J., PB 1803Choi W.-I., PB 1512Chollet Dugarte M.E., PB 2010Chong K.-Y., PB 914Christersson C., PB 562, PB 2238Christophe O.D., OC 26.2Christopherson P., PB 368Chuansumrit A., PB 974Chudzinski-Tavassi A.M., PB 929Chuliber F., PB 1964Chunilal S., PB 1223Claesson K., ASY 33.4Clark C.L., PB 1416Claushuis T.A.M., OC 56.1, PB 2279, PB 1364Cleary S.J., OC 70.4Cloutier N., PB 1382Cnossen M.H., PB 379, PB 947, PB 949Cocca A., PB 998Coen Herak D., PB 417, PB 1646Coffin D., PB 222Coghill P.A., OC 36.3, PB 1729Cohen A., PB 1193Cohen A.T., OC 12.1, OC 52.3Coleman C.I., PB 1007Coll E., PB 1458Collins P., PB 948Comer S., PB 1307Comuth W.J., PB 1190Connolly-Andersen A.-M., PB 061Connor D., PB 473Constantinescu-Bercu A., OC 29.4Contant G., PB 1385Cooke E.J., PB 1065Cooper D., PB 217, PB 988Cortina V., PB 1182

Cosmi B., PB 279Costa L., PB 1475, PB 1928Costa Pinto Prego de Faria J., PB 1947Couturaud F., ASY 14.1Cox T., ASY 14.3Crea R., PB 977Creagh M., PO 37Crescente M., ASY 19.1Criel M., PB 2423Croles F.N., PB 792Cronjé H.T., PB 1714Croteau S.E., PB 1795Crowley M.P., PB 651, PB 941Crowther M., PB 1191, PB 2245Cruz M., PB 377Cruz Gomes H., PB 506Csanyi M.C., PB 362Cui X., PB 840Cullen S., PB 1284Cullmann K., ASY 24.2Czogalla K.J., PB 258

DDager W., PB 1216, PB 1220Dahal K., PO 02Dahlbäck B., ASY 21.4Dahm A.E.A., PB 1887Dai J., ASY 39.3Dai L., ASY 19.3, PB 744Daidone V., PB 2031Dally N., PB 1927D'Amore A.L., PB 312Danielsbacka J.S., NUR 05.7Dannenberg L., PB 2092Darbousset R., OC 53.3Dardik R., PB 2091Dashkevich N., PB 102Dasí Carpio M.Á., PB 531D'Atri L.P., PB 549Däullary T., PB 2300Dave M., PB 1226David-Dufilho M., PB 1195Davies J., PB 1361Davila M., ASY 05.4

Davizon-Castillo P., OC 18.5De Ceunynck K., ASY 30.1De Cristofaro R., OC 76.5, PB 1077De Filippis V., OC 42.5, PB 1454De Jong A., OC 08.2, PB 2060De la Fuente M., OC 66.5De la Morena-Barrio B., ASY 26.2De la Morena-Barrio M.E., OC 55.3, PB 1997De la Peña Díaz A., PB 689De la Rosa M., OC 62.3, PB 1096, PB 1098De Lange Z., OC 19.4De Larrañaga G., PB 1897De Maat M., PB 1654De Maat S., PB 1684De Maistre E., PB 1162De Sloovere M.M.W., PB 447De Souza J.G., PB 2302DeAndrade M., ASY 37.2Debattista J., PB 043Debono J., PB 830Deconinck S., PB 384Decouture B., PB 2210, PB 2219Dekkers I., ASY 16.2Delavenne X., PB 987Delignat S., OC 23.4Delluc A., PB 616Demaistre E., PB 1135Deng X., PB 179, PB 2445Denorme F., PB 1662, PB 1664Dentali F., OC 48.4, PB 052, PB 1648, PB 1655, PB 1871, PB 2316Deo P., PB 647Deppermann C., OC 18.2Der Sheng S., PB 1409Deshpande V., PB 028Devalet B., PB 676Devreese K., PB 415, PB 448, PB 1164, PB 2112Dewarrat N.C., PB 081Di Gennaro A., OC 15.4Di Micco P., PB 457Diaconu N., PO 51



590 591

Aut

hors

Ind

ex

Diallo Y.L., PB 351Diamond S., OC 20.5, PB 1933 Diaz J.A., PB 167 Dicke C., PB 1480 Dickhout A., PB 2437 Didelot M., PB 008 Dineva D., PB 1573 Ding J., PB 2178 Dinsdale R., PB 2249 Disharoon D., OC 01.5 Djaafri M., PO 19 Djambas Khayat C., PB 1999 Djordjevic V., PB 843Djunic I., PB 1819 Dobesh P., PB 294, PB 488 Dobrovolsky A., PB 1532, PB 1571 Doerr A., PB 359 Dolan G., PB 1086 Dolleman S., PB 1268 Domingues A., PB 2415 Donadini M., PB 1222, PB 1229 Donadon I., OC 50.2 Donkor D., PB 819 Donner L., PB 1611 Dos Santos C., PB 722 Doshi B., PB 223 Doubleday M., PB 477 Douketis J., PB 1225 Douxfils J., PB 434, PB 446, PB 2152 Downes K., OC 07.1 Doyle A., PB 2322 Draxler D.F., PB 2283 Dronkers C.E.A., ASY 35.3, OC 73.2, PB 468, PB 1001 Dsouza A., NUR 05.12 Du Y., PB 498 Duarte B.K.L., ASY 17.4 Dubé E., PB 224 Duboscq C., PB 129, PB 440, PB 2107 Dufrost V., PB 1481 Dupuis A., PB 734, PB 2282 Durrant T., OC 06.3 Dusart P., PB 2420

Dusse L., PB 1432, PB 2188 Duval C., ASY 28.4, PB 1743 Dwivedi D.J., PB 2267

EE. Ward S., OC 31.4 Easaw J., PB 649 Echternacht S., PB 2121, PB 2127 Eckart F., PB 1592 Eckly A., OC 04.1 Edem M.S., PB 817 Efthymiou M., PB 584, PB 1452, PB 1467 Egan K., PB 1895 Eggebrecht L., PB 256, PB 464 Eichler H., LB 01.2Eichler S., PB 1360 Eischer L., OC 48.2 Eissa D., PB 1476 Eissa D.S., PB 809 El Habhab A., PB 671 El Mdawar M.-B., PB 1609 Elalamy I., PB 2320 Eligini S., PB 003 Ellingsen T.S., PB 1392 Elm T., PB 1116 El-Maarri O., PB 1981 Emelianov A., PB 905, PB 2240 Emerson M., PB 083 Emmerechts J., PB 1133 Emsley J., PB 1685 Ende-Verhaar Y.M., OC 25.3, OC 60.1, PB 1005 Engelen E.T., PB 338 Engeseth M., PB 1017 Erdem O., PB 1252 Erdem Ö., OC 64.2 Ermoshina S., PB 1954 Erpenbeck L., PB 1277 Escobar M., PB 952, PB 1937 Escuriola-Ettingshausen C., PB 994 Espitia C., OC 35.2 Ethaeb A., PB 896

Etscheid M., ASY 28.3 Ettelaie C., OC 14.3 Etulain J., PB 1355 Eunhye L., PB 2351 Evensen L.H., PB 772, PB 773, PB 2301

FFaes C., PB 077 Faille D., PB 2310, PB 2360 Falet H., OC 17.4 Falter T., PB 701 Fan M.-N., ASY 18.2 Fan X., PB 570 Farah R., PB 2175 Fareed J., PB 810, PB 868, PB 875, PB 884, PB 1347, PB 1440, PB 1736, PB 2148, PB 2264, PB 2353 Farge D., OC 46.2 Farkas Á.Z., PB 1644 Farkas V.J., PB 1265 Farkash I., PB 1593 Farndale R.W., ASY 33.1 Farweez B., PB 910 Favaloro E.J., PB 2083 Featherby S., PB 673 Federici A.B., PB 2077 Federizo A., PB 835 Fedorova D., PB 2165 Feistritzer C., PO 18 Fejes A.V., PB 1351 Feller T., PB 611 Fenclova T., PB 1508 Ferdous F., PB 2257 Fernandes A.R., PB 845 Fernandez-Bello I., PB 154 Fernández-Pardo A., PB 1390 Figueroa R., PB 636 Filippi L., PB 2346 Finsterbusch M., ASY 32.4 Fiore M., PB 1320 Fischer R., PB 1943 Fischer S., ASY 25.2 Fisher M., PB 1658

Fiusa M.M.L., PB 2263, PB 2441 Flick M., OC 28.3 Flommersfeld S., PB 2055 Flood V., PB 2046 Flora G.D., PB 1267 Flores-Garcia M., PB 2158 Fogarty P., PB 1992 Follenzi A., OC 75.5 Fonseca R.J., PB 086 Fontana P., PB 557, PB 1782 Fosbury E., PB 1071, PB 2131 Fox K., PB 2122 Francischetti I., PB 162, PB 604 Franco L., ASY 10.1, OC 25.5 Freato N., PB 140 Freire I., PB 505 Freixo A., PB 857 Frelinger III A.L., PB 1350 Frere C., PB 012, PB 645 Fromell K., PB 1690 Frønes S., PB 461 Frontroth J.P., PB 2082 Fu R.Y., ASY 23.3, PB 1091 Fu W.-M., PB 1652 Fuchigami H., PB 915 Fuentes E., PB 1322 Fuentes H., PB 641, PB 644, PB 815 Fujii S., PB 808 Fujii T., PB 1820 Fujimori Y., PB 157, PB 476 Furukoji E., PB 1622

GGabbeta J., PB 1868 Gabler J., PB 1412 Gaddh M., PB 1554 Gade I.L., PB 615, PB 618 Gage B., OC 12.5 Gagliano F., PB 202, PB 1821 Galanakis D.K., PB 851 Galanaud J.-P., PB 268, PB 630 Gall L.S., OC 49.2 Galletta E., PB 382 Gamba S., PB 1578

Gangadharan B., OC 61.3 Ganta N., PB 1529 Garabet L., PB 2443 Garagiola I., PB 1081 García-Candel F., PB 713, PB 1574 Garciarena C., PB 2252 Gardiner C., PB 436 Garlapati V.S., PB 035, PB 057 Gasecka A., PB 668 Gatt A., PB 1436, PB 2347 Gauberti M., PB 1608, PB 1645, PB 2341 Gawlikowski M., PB 1153 Gebhart J., ASY 37.1, PB 1464 Gee E., NUR 05.15 Geersing G.-J., PB 271 Geisen C., PB 1500 Gendron N., PB 1200, PB 2419 George L., OC 13.1 Georgescu M.T., PB 821 Gerdes C., PB 2198 Gerhardt A., PB 1884 Gerotziafas G., PB 1239, PB 1874, PB 2160, PB 2306 Geue S., PB 1309 Ghalloussi D., OC 44.2, PB 1301 Ghanima W., ASY 35.2 Ghatge M., OC 27.5, PB 001 Ghosh S., OC 07.5, PB 861 Giaccherini C., OC 21.5Ģībietis V., PB 1228 Gidley G., PB 2015 Giesen P., PB 1420 Gillespie S., PB 346 Gillet B., OC 37.1 Gindele R., PB 2085 Girard P., OC 46.5 Giustozzi M., ASY 14.4, PB 1840 Gkotsi S., PB 1602 Glauser I., PB 1112 Glosli H., PB 1109 Goldfinger L., OC 03.2 Goldsmith R., PB 1056 Goliako I., PB 2292 Gollomp K., ASY 39.4, OC 56.4

Golubeva M., PO 09 Gomez-Arteaga A., PB 1929 Goncalves I., PB 191 Gonçalves L., PB 508, PB 1236, PB 1949, PO 65 Gonçalves Chaves D., PB 125, PB 1174 González-López T.J., LB 07Goodeve A., OC 07.3 Gorbacheva L., PB 886 Gottlob L., PB 1616 Goudemand J., PB 2070 Gouider A., PB 848, PB 997, PB 1835 Govers-Riemslag J.W., PB 1696 Govindasamy N., PB 2424 Graf C., OC 05.5 Gran O.V., PB 627, PB 635 Grand B., PB 1545, PO 62 Grandone E., PB 1507, PB 1514, PB 1888, PB 1889, PB 1906, PB 1908, PB 1915, PB 2008, PB 2036 Grasso S., PB 2280 Grech M., PB 2311 Green L., OC 73.5 Greenall R., PB 1057 Gresikova M., PB 2202 Grigorjeva M., PB 1575 Grilz E., OC 46.4 Grimnes G., PB 2251, PB 2254, PB 2255 Gringeri A., PB 209, PB 958, PB 1779 Grippi C., PB 1325 Gris J.-C., PB 597, PB 1882, PB 1896, PB 1914, PB 1921 Groarke E., PB 2379 Groeneveld D., PB 1280 Groß J.C., PO 38 Gross P.L., PB 2208 Grottke O., ASY 10.3 Grover S., OC 72.4, PB 2068 Gubbiotti G., ASY 13.2 Guerra J., PB 2155 Guerrero F., PB 1155, PB 1852



592 593

Aut

hors

Ind

ex

Guerrero J., OC 53.5 Guglielmini G., PB 369, PB 1565 Guglielmone H.A., PB 094, PB 2030, PB 2038 Guillermo C., PB 1544 Gulpen A.J.W., PB 1219 Gümrük F., PB 1768 Gupta N., PB 087 Gupta S., OC 66.2, PB 1305 Guria K.G., PB 2114 Gurney M., OC 48.3 Guthold M., PB 175 Guy A., ASY 18.3, OC 67.1 Gwozdowska A., PB 1521

HHaas S., PB 1188 Hackeng T., PB 838 Hagan K., OC 12.2 Hagen M., PB 1632 Hald E.M., PB 1651, PB 1670 Hall A., PB 1140 Hamaia S., PB 575 Hamid C., PB 353 Hamilton J., OC 45.3 Hammelburger J., PB 132 Hammerschick T., PB 2444 Hampshire D.J., OC 22.5 Han Y., OC 74.1 Handtke S., PB 563 Hansen A.T., ASY 36.3 Hansen J.-B., PB 1414 Hao Y., PB 2363, PB 2366 Hardy L., PB 820 Harenberg J., PB 454 Harper A., PB 2205 Harrison P., PB 1568 Harsfalvi J., PB 1444 Hart G., PB 112, PB 824, PB 832, PB 856 Hartmann R., OC 47.2, PB 1079 Hashimoto E., PB 755 Hassan A., PO 66 Hastings S.M., PB 930 Hasumi K., PB 2350

Haugaard S., PB 586 Hauschner H., PB 1594 Hawkins K., PB 1405 Hay C.R., ASY 01.4 Hayashi H., PB 1379 Hayashi T., PB 883 Hayman M.A., PB 2218 Haynes L.M., OC 72.3 Hayward C.P.M., PB 756 He J., PB 2430 He Y., PB 1591 Hebsgaard J.B., PB 1069 Heestermans M., PB 878, PB 1683 Heijdra J.M., PB 2053 Heitmeier S., PB 2138, PB 2140 Hell L., ASY 06.2 Heller C., OC 24.2 Hellfritzsch M., PB 493 Helten C., PB 426 Hemker H.C., PB 1235 Hendelmeier M., PB 2073 Henriksson C.E., PB 679 Henskens Y., ASY 04.2, PB 2113 Heptinstall S., PB 1423, PB 1673 Heremans J., ASY 20.4 Hermit M.B., OC 10.2 Herrera L., PB 1172 Herrera M.D.L., PB 1218 Hers I., OC 06.5 Hertfelder H.-J., PB 1527 Herzog E., PB 340 Herzog R.W., OC 75.3 Hews-Girard J., PB 1913, NUR 07.2 Higuera D., PB 1643 Hirmerova J., PB 1000 Hisada Y., ASY 29.2, PB 682 Hoellriegl W., PB 1094, PB 1099, PB 1101, PB 1118 Hoesel B., PB 907 Hofer S., PB 371 Hoffman M., PB 1630, PB 2059 Hoffmann M., PB 812 Hoffmann T., PB 1032 Hofman Z.L.M., OC 40.1

Hofmann M., PB 1121 Hogg P., OC 08.5 Hohensinner P., PB 2275 Hohmann J.D., ASY 31.4 Høiland I., PB 582 Høiland I.I., PB 1707 Højen A.A., NUR 05.8 Holbrook L.-M., PB 1261, PB 1319, PB 2196 Holinstat M., PB 1313 Hollerbach A., ASY 06.3 Holme P.A., PB 1780 Holz M.-K., PB 1104 Holzhauer S., PB 529 Honickel M., PB 469, PB 1212 Hop H., PB 199 Hoppensteadt D., OC 36.5, PB 330, PB 797, PB 804, PB 1876, PB 2144 Horie S., PB 1661 Horling F., OC 62.2 Horvei L.D., PB 1394, PB 1496 Ho-Tin-Noé B., PB 1656 Hou Y., PB 2372 Hounkpe B.W., PB 1723 Howard T., OC 61.2 Howhan S., PB 047 Hrdinová J., OC 09.5 Hu L., PB 2215 Hu Y., PB 1330 Hua B., PB 973 Huffman J.E., OC 68.2 Hughes A., PB 413, PB 1145 Hugon-Rodin J., ASY 37.4 Hui S.-K., PB 396 Huisman M., PB 465 Hunter R., NUR 05.11 Huntington J., OC 10.1 Hur W., OC 19.2 Hussain S., PB 2042 Husseinzadeh H., PB 957 Huynh K., PB 2228 Hwang B.-F., PB 065

IIastrebova E., PO 16 Icheva V., PB 2163 Iftikhar T., PB 1354 Iglesias M.J., PB 1649 Iglesias Varela M.L., PB 450 Ignatova A., PB 1585 Ignjatovic V., PB 1255, PB 2169 Ikesaka R., PB 2303 Ikezoe T., PB 2436 Ilich A., PB 171, PB 1167 Imhof D., PB 1725 Induruwa I., OC 66.1 Iqbal A., OC 14.1 Isaksen T., PB 776 Israels S.J., PB 1150 Ito T., PB 1237 Ivanciu L., PB 148 Ivanov I., OC 15.1 Ivaskevicius V., PB 2020 Iversen N., PB 2026 Izzi B., PB 554

JJaffer I., PB 497 Jalal M.M., PB 1264 Jamil M.A., OC 16.1, PB 1757 Jämsä A., OC 72.5 Janaki Krishnamoorthi A., PB 1419 Janbain M., OC 37.5 Janke U., PB 578 Janse van Rensburg W., PB 1087 Jansen A.J.G., ASY 19.2, PB 1340 Jansen M., PB 238 Jansen S.B.G., OC 66.3 Janukonyte J., PB 509 Jaramillo Yepez A., PB 535 Jara-Palomares L., OC 21.4, PB 626 Jasuja R., PB 1080 Jawhara S., ASY 03.3 Jaya-Bodestyne S.L., PB 1885 Jayakody Arachchillage D., PB

1848, PB 1931 Jeanpierre E., PB 188, PB 189 Jen W.Y., PB 1858 Jennings I., OC 65.1, PB 295, PB 405, PB 425, PB 1136, PB 2086 Jensen S.B., OC 51.4 Jeppesen A., PB 134, PB 2236 Jeske W., PB 080, PB 445, PB 1427, PB 2156, PB 2159, PB 2161 Ji S., PB 071 Jiang M., PB 735 Jimenez D., PB 2157 Jin D.-Y., PB 1717 Jingyao M., PB 1383, PB 2398 Jirungda S., PB 1576 Jochmans K., PB 1533 Johnsen H.S., OC 32.5, OC 51.5 Johnsen J., OC 35.3 Johnson A., PB 2220 Johnston I., OC 04.5, OC 34.1 Jokerst J., OC 35.5 Joly B., OC 63.1 Jongen M.S.A., PB 2225 Joseph J., PB 1033 Joubert J., PB 429, PB 442, PB 695 Jouppila A., PB 2204 Jourdi G., PB 287 Jousselme E., PB 1148 Ju L., ASY 08.4, OC 57.4 Juif V., PB 424 Jung S.M., PB 567, PB 1279 Jurk K., PB 361, PB 740 Jurney P., PB 1637 Just S., PB 2132

KKızılocak H., PB 869 Kaatz S., ASY 14.2, ASY 36.2, PB 486 Kabrhel C., PB 613, PB 935, PB 1397, LB 02 Kahn S.R., OC 52.1, PB 1003 Kahr W., PB 1078

Kalabushev S., OC 26.5 Kalaska B., PB 2153 Kalish Y., PB 1862, PB 1870, PB 1907 Kamal F., PB 1698 Kampouraki E., PB 260 Kanematsu T., PB 976 Kaneva V.N., PB 2231 Kang K.-Y., PB 1128 Kanse S., PB 118, PB 1400 Kappelmayer J., PB 1589 Kapteijn M.Y., PB 922 Kar R., PO 14 Karampini E., ASY 12.3 Karbach S.H., PB 2277 Karimi M., PB 685, PB 2037 Karpha I., PB 691 Kartsios C., PB 485 Karumori T., PB 979 Kask L., PB 1386 Kaspřák D., PB 718 Kassim N., PO 49 Katayama H., PB 1822 Kato H., PB 574, PB 733 Katona É., PB 178 Katrii T., PB 1441 Kattula S., ASY 07.3, PB 1497 Kauf T., PB 1084 Kaur D., PB 1253 Kaur H., PB 502 Kautbally S., PB 014 Kavakli K., PB 829 Kawecki C., OC 38.4 Kaya Z., PB 725, PB 2034 Kazanecka B., PB 2333 Kearney K., PB 161 Keenan C., PB 1972 Kehrel B.E., PB 1363 Keipert C., PB 1976 Kelchtermans H., PB 1434 Kelkar A., PB 438 Kempton C., PB 206 Kenet G., PB 1982 Kenny D., PB 1558 Keren Politansky A., PB 2384 Kerényi A., PB 2084



594 595

Aut

hors

Ind

ex

Kessler C., PB 1794 Kessler P., PB 291 Khair K., NUR 05.16 Khaliq S., PB 2166 Khan A., PB 435 Khan F., PB 276 Khan M.T.M., PB 1800 Khan S., NUR 04.5 Khan T., PB 2029, PB 2035 Khatri V., PB 537 Khizroeva D., PB 1911, PB 1916, PB 1917, PO 41 Khokhar S., PB 075 Kim B., PB 1215, PB 1221 Kim D.-E., PB 1647 Kim H.C., PB 996 Kim H.W., PB 1509, PB 1657 Kim J.Y., PB 1474 Kim M.J., PO 21 Kim S.K., PB 245 Kini M., PB 1639 Kiouptsi K., PB 1072 Kirgner I., PB 350 Kishor K., PB 904 Kis-Toth K., PB 2281 Kitchen S., OC 65.2, PB 2089 Kittoe K., PB 1230 Kjelgaard-Hansen M., PB 085 Klamroth R., PB 1791 Klemm U., PB 375 Klier M., OC 70.5 Kline J., OC 74.3, PB 1597, PB 2189 Klok F.A., OC 39.5, PB 290 Kluft C., PB 1699, PB 1704 Klukowska A., PB 1787 Knoch E., PB 2111 Knoop B., PB 1332 Knowles L.M., PB 1275 Ko R., PB 2192 Kobayashi S., PB 2212 Koc B., PO 29 Koenen R.R., PB 1324 Kohli R., PB 2063 Kohli S., PB 1373 Kohn C., PB 2293

Kojok K., OC 06.4 Koltan A., PB 991 Koltsova E., PB 2115 Komanasin N., PB 021 Komvilaisak P., PB 1026, PB 1679, PB 2334 König G., PB 2061 Königsbrügge O., OC 33.3, PB 410 Koornneef J.M., PB 547 Kopec A., OC 54.3 Kornienko E.I., PB 937 Korzh O., PB 011 Kossmann S., PB 1615 Kostal M., PB 2394 Kostelidou T., PB 1580 Kouyama S., PB 2139 Kovac M., PB 124 Kovalenko T., PB 900 Kraaijpoel N., PB 406 Krag A.E., PB 921 Kragh T., PB 391 Kraisin S., PB 1610 Kravchenko O., PB 1678 Kremer Hovinga J., OC 63.2 Kristina B., PB 2195 Kristoffersen A.H., PB 836 Kroone C., PB 2416 Krott K.J., OC 17.5 Krüger I., PB 1334 Krüger S., PB 962 Kruger P., PB 301 Ku D.N., PB 1570 Kulkarni R., PB 844, PB 961 Kumano O., PB 2096 Kumar R., PB 1245 Kun M., PB 1938 Kunapuli S., ASY 08.3, OC 30.2, PB 1299 Kuo Y.-J., PB 1323 Kuperman A.A., PB 1173 Kurbanov B., PB 590 Kurdi M., PB 754, PB 1951 Kurien A., PB 1431 Kurniawan A., PB 654, PB 2337 Kuroiwa Y., PB 1016

Kurtov I., PB 1553

LLacroix R., PB 666, PB 670, PB 683 Ladeira Cruz A.C., PB 1459 Lagrange J., PB 1371, PB 1613, PB 1634 Laguna P., PB 1090, PB 2246 Lai B., PB 1227 Lai J.D., ASY 23.4, OC 23.2 Lambert M., PB 548 Lancellotti S., PB 2344 Langenkamp R., PB 348 Langer F., PB 889 Lanza F., PB 538 Lappegård J., PB 1418, PB 1498 Laridan E., OC 01.3 Larsen J.B., LB 12Larsen L.F., PB 411 Larsen M.L., PB 1557 Larsen O.H., PB 1290, PB 1504 Lasom S., PB 017 Latorre A., PB 1528 Lau C., PB 746, PB 747 Lauridsen S.V., PB 1734 Lauritzen B., PB 1123 Lauw M.N., PB 327 Laux V., PB 877 Lavin M., PB 233 Lazic N., PO 15 Lazo-Langner A., PB 2150 Le Moigne E., ASY 13.4 Lebreton A., PB 841, PB 1147 Lee C., ASY 39.1 Lee H.-Y., PB 1131, PB 2305 Lee J., PB 433 Lee K., PB 984 Lee L.H., PB 2141 Lee R.H., OC 18.4, OC 74.5 Lee S., PB 1740 Leebeek F., PB 2071 Leeds J.M., OC 76.4 Leenaerts D., ASY 15.4 Lefkou E., PB 1465

Lehmann M., OC 17.2 Leksa N., OC 47.5 Lemarie C., OC 20.3, PB 614 Lemos Jardim L., PB 1085 Lentz S., PB 963, PB 964 Lepropre S., PB 1258, PB 1312 Lertthammakiat S., PB 113 Lesyk G., OC 30.3 Levy H., OC 10.3, PB 1119 Levy J., PB 343 Lewis C.S., PB 893 Li C., ASY 02.4 Li H., PB 1595, PB 2371 Li N., ASY 09.1, OC 03.5 Li R., ASY 08.2, OC 08.1, PB 1304 Li Y., PB 2369, PB 2370, PB 2380 Li Z., PB 1308 Liang R.A., PB 587 Liao H.R., PB 2266 Liaw P., OC 56.5 Lickert S., PB 1283 Liesenborghs L., ASY 03.2 Liesner R., PB 207, PB 211, PB 818, PB 1132 Li-Gao R., PB 793, PB 1503 Lijfering W., OC 33.2. LB 03 Lijfering W.M., PB 1203 Lim B., ASY 04.3 Lin B.H., PB 887 Lin L., OC 57.1 Lip G.Y., PB 1187 Liphardt K., PB 293 Litvinenko A., PB 422 Litvinov R., PB 1375, PB 1722 Litvinov R.I., ASY 29.1, PB 1266 Liu J., ASY 10.4 Liu T., OC 75.2 Liu W., PB 2364 Llobet D., PB 1531, PB 1537 Locke M., PB 164, PB 177 Lodigiani C., PB 352, PB 1633 Löf A., PB 367 Loguinova M., PB 045 Lollar P., PB 1968, PB 1973, PB

2078 Lopez M., PB 1604, PB 2276 Lopez S., PB 1524 Lopez-Espina C., PB 347 Lopez-Vilchez I., PB 1141, PB 1271 Louw S., PB 326 Lowe A., PB 428, PB 1157 Loyau S., PB 931, PB 1263 Lozier J., PB 938, PB 2102 Lu X., PB 002, PB 015 Lu Y., PB 1805 Lubetsky A., PB 501 Lubich C., OC 61.5 Luken B.M., PB 581 Lund J., PB 828 Luo B., PB 246 Luo M., PB 2447 Luo Q., PO 55 Lupu C., OC 67.3 Lupu F., OC 56.2 Luyendyk J., PB 2044 Lyapina L., PB 197 Lyapina M., PB 1879 Lyu M., PB 2358

MMa P., PB 1302 Ma S., ASY 05.1 Ma Z., PB 709 Maag A., PB 100 Maas C., PB 692, PB 2221 Maas H., PB 518 Machlus K., OC 04.3 Mackie I., PB 1142 Maclachlan A., ASY 12.1 Maclean J., OC 26.1 Macrae F., PB 588 Macwan A., PB 568 Madan B., PB 985 Madoiwa S., PB 328 Maeda T., PB 2367 Maekawa K., PB 891 Magari Y., PB 1767 Maggiolo S., PB 114, PB 185

Mahajan A., OC 48.5 Mahan C., PB 2361 Mahé I., PB 1384 Mahlangu J., PB 1117, PB 1784 Maier C., PB 1342 Maino A., PB 2295 Maiorov A.S., PB 1353 Maitz M.F., PB 589, PB 1710 Majeed A., PB 339 Majowicz A., PB 1102 Majumder R., PB 109, PB 865, PB 1711 Makatsariya A., PB 1901, PB 1918, PB 1926, PB 1930 Makhaldiani L., PO 46 Malanghu J., PB 1773 Male C., PB 521 Malhotra P., PB 1796 Malisauskas M., OC 16.2, PB 107, PB 144 Mallick R.L., PB 1369 Malvestiti M., ASY 24.3 Mancuso M.E., ASY 23.2, PB 842, PB 989 Manoharan J., OC 43.4 Manresa Manresa P., PB 715, PB 716 Mantovani L.G., PB 1194, PB 1201 Manukjan G., PB 743 Manzoor B.S., PB 462 Marchi R., PB 1758 Marchione V.D., PB 1986 Marco A., PB 1398, PB 1407, PB 1462 Margetić S., PB 2133 Margetic S., PB 1177, PB 1477, PB 1542 Marhoume F., PB 322 Marijnen M.C., ASY 22.3 Maritnez-Marin A., PO 54 Markway B., ASY 15.1 Maroua M., PB 2270 Marquardt T., PB 892 Marshall A., PB 390 Marsman G., PB 2256



596 597

Aut

hors

Ind

ex

Marten S., ASY 10.2 Martin A.-C., PB 1338 Martinelli N., ASY 16.1 Martinez P., PB 2125 Martinez de Lizarrondo S., OC 19.5, OC 43.5 Martínez Martínez I., OC 14.2 Martínez Órdenes J.G., PB 2174 Martinho P., PB 1549 Martins M.A.P., PB 284, PB 285 Martins S.R., PB 674, PB 686, PB 1422 Martinuzzo M., PB 482, PB 1447 Martinuzzo M.E., PB 2124 Martorell M., PB 243 Martos L., PB 041 Martos Thomazini C., PB 1935 Martyanov A., PB 576 Massicotte M.P., OC 64.4 Mastenbroek T., PB 1626 Mastroiacovo D., PB 053 Mateo Arranz J., PB 274 Mathew S., PB 218 Matino D., PB 1068 Matos M., PB 2120 Matsumoto T., PB 2135 Matsumoto Y., PB 1653 Mattila N., PB 925 Matzko C., PB 1272 Mauge L., PB 1939 Mauler M., PB 042 Mauracher L.-M., ASY 18.1 Maurer E., PB 1204 Maurer M., PB 1748 Maurus N., PB 1605 Mavri A., PB 1456 Mayne E., PB 329, PB 331 Mazetto B., PB 1472 Mazurov A., PB 1728 McCaughan G., PB 1232 McCormick A.N., PB 414 McHale T., PB 2440 McKinnon T., OC 22.2, PB 372, PB 1406, PB 2050, PB 2067 McLoughlin E., PB 918 McNeill S., PB 1242

McPherson H., OC 54.2, OC 54.4 McRae S., PB 967 McSorley A., PB 1208, PB 1859 Medina A., PB 453 Medina S.S., OC 69.3 Medina Badenes P., PB 1396 Medved L., OC 54.5 Meeks E., PB 1869 Megalinskiy A., PB 2235 Megías Vericat J.E., PB 237, PB 1088 Meijer K., PB 632, PB 1836 Meireles M., PB 1067 Meiring M., PB 1628 Meldau J., OC 12.3 Melekhov A., PB 805, PB 1847 Mena H.A., PB 2421 Mendonca K.B., PB 1814 Menegatti M., OC 07.2 Meral Güneş A., PB 1257 Merker M., PB 864 Merlen C., PB 959 Merlin S., OC 23.1 Mertens J.C., PB 163 Messaoudi R., PB 760, PB 767 Meyer I., PB 092 Mezei Z.A., PB 1766 Mian O., PB 2348 Miao C.H., PB 1092 Michels A., ASY 29.4 Miesbach W., OC 13.2 Miklosz J., PB 1285 Mikyung K., PB 1834 Miles L., OC 01.2 Milic M., PB 355 Miljic P., PB 950 Miller C.H., PB 225 Miller J., PB 1138, PB 1154 Milos M., PB 190, PB 1159 Min Y., PB 2378 Minami H., PB 146 Mingot-Castellano M.E., PB 661 Mingozzi F., OC 62.4Mirbehbahani N., PB 2404 Mirshahi M., PB 1739 Miszta A., PB 1738

Mitchell J.L., PB 1326 Mitchell L., OC 11.1 Mitchell L.G., ASY 26.3 Mitrovic M., PB 2368 Mitrugno A., OC 03.4, PB 580, PB 2197, PB 2318 Miyajima C., PB 029 Miyata S., PB 2359 Miyazaki K., PB 655 Mkhitaryan S., PB 2413 Moenen F., PB 752 Mohamadi A., OC 31.2 Mohammed B.M., OC 43.1 Mohring A., PB 1563 Mol G.C., PB 1002 Molitor M., PB 039 Momi S., OC 02.3 Monagle P., PB 511 Monreal M., PB 1198 Monroe D., OC 49.5 Montague S.J., PB 1260 Montalvao S., PB 187 Montalvao S.A.L., PB 432, PB 2099, PB 2101 Montano Mejia C.A., PB 992, PO 20 Montaruli B., PB 392 Monteiro R.Q., PB 2287 Moore G.W., PB 2105 Moorlag M., PB 1720 Morales J., PB 1339 Mor-Cohen R., PB 569, PB 1331 Morel-Kopp M.-C., OC 59.3, PB 757 Morelli V.M., PB 827, PB 2342 Morfini M., PB 986 Morishima Y., PB 1211, PB 1233 Moritz E., PB 1636 Moroi A., PB 1298 Morrow G.B., ASY 15.2 Moscardó A., PB 1249, PB 1321, PB 1650, PB 2187 Mosconi M.G., PB 423 Mosnier L.O., OC 71.4 Mousinho F., PB 726 Moustafa F., PB 1189

Moyer G., PB 642 Mrouki M., PB 160, PB 598, PB 2271 Muczynski V., OC 43.2, OC 55.4 Muddana P.S., PB 2110 Mueller J., PB 419 Mukhametova L., PB 1737 Müller J., PB 2261 Müller-Calleja N., ASY 06.4 Mulligan D., PB 1535 Muñoz A., OC 32.4 Munzer P., PB 1296 Münzer P., OC 44.5 Musgrave K., PB 1864 Mussbacher M., OC 41.1 Musuka C.T., PB 1137 Muszbek L., PB 1763 Mya H.T., PB 1541

NNaderi M., PB 2009 Nadir Y., OC 14.5, PB 1712, PB 1726 Nag U., PB 2185 Nagao A., PB 1804 Nagao T., PB 1671 Nagler M., PB 264, PB 270 Nagy M., OC 29.1, PB 2407 Nagy Z., ASY 33.2 Nagy Jr. B., ASY 09.4, ASY 38.3 Naik M., PB 2194 Nair J., PB 006, PB 030 Nair P.M., ASY 07.4 Najjar F., PB 688 Nakao A., PB 975 Nakar C., PB 168, PB 247 Nakase T., PO 07 Nandurkar H., PB 1640 Napolitano M., PB 639, PB 1878 Natesirinilkul R., PB 719, PB 2167 Naudin C., OC 15.2 Navarro-Almenzar B., PB 1214 Navarro-Oviedo M., ASY 31.2, ASY 31.3

Nayak L., PB 1525 Nayak S., PB 898 Naz A., PB 592, PB 855, PB 1963, PB 2021 Nazir S., OC 71.3 Neal M., PB 334 Neceva V., PO 12 Nechipurenko D., PB 360 Needham J., PB 452, PB 1041, PB 2129 Negrotto S., PB 2431 Nemeth B., PB 1851 Nepal B., PB 314, PB 316, PB 1036, PB 1037, PB 1044, PB 1047, PB 1049 Neves J., PB 770 Neves M.A.D., ASY 04.4 Newall F., OC 11.5, PB 523, PB 524, PB 1244 Ng C., PB 365 Nguyen G.N., OC 16.4 Nguyen T., PB 078 Nguyen T.-H., OC 34.2 Nguyen T.M., PB 1801, PB 1952 Ni H., OC 18.1, OC 58.4, PB 105 Ni Ainle F., PB 1721 Nielsen N.V., PB 103 Nikolaev K., PB 1555 Nikolaeva I., PB 2209 Nikolakopoulos K., PB 1855 Nikoloska I., PB 1484 Nikolskaya K., PB 091 Nishihama K., PB 802 Nishioka K., PB 1399 Noble S., PB 621, NUR 05.1 Nolan B., PB 1774, PB 1797 Noll H.F., PB 2272 Nolte M.W., PB 1114 Noris P., PB 729, PB 736 Notley C., PB 370 Noubouossie D., PB 1692 Nougier C., PB 123 Nourse J., PB 1718 Novakowski S., PB 317 Novelli C., PB 441 Novembrino C., PB 2109

Nwagha T., PB 1483, PB 1827 Nwogoh B., PO 58 Nytofte N., PB 1426

OO Halloran T., PB 275, PB 1202 Obergan T., PB 1735 Obermayer G., OC 20.4 Obradovic S., PB 881, PB 936 Obstfeld A., PB 444 Obydennyi S., PB 731, PB 1333 Ogiwara K., PB 1063 Oh D., PB 707 O'Hara J., PB 1789 Ohlenforst S., PO 36 Ohlmann P., ASY 11.1 Ohmori T., OC 62.5 Ohnishi N., PB 1561 Okoye H.C., PB 1978 Okpokam D.C., PB 1054 Oku K., PB 1457 Oladapo A., PB 378, PB 766 Oladapo A.O., PB 126 Olayemi E., PB 1516 Oldenburg J., ASY 01.1, PB 200, PB 946, PB 981, PB 1818 Olgasi C., OC 38.1 Olie R., PB 056 Olson N.C., PB 2274 Olsson M., OC 55.2, PB 1715 Ono T., PB 2145 Oo T.H., PB 2395 Orosz Z.Z., PB 1754 O'Shaughnessy F., OC 73.1 Osman N., PB 798 Osmolovskiy A.A., PB 1165 Osooli M., PB 1785 Østerud B., PB 1378 Otake S., PB 571 Othman M., PB 084, PB 1894, PB 1910 Oto J., ASY 38.2, PB 2319 Ouarhlent Y., PB 397, PB 1089, PO 63 Ouweneel A.B., PB 543



598 599

Aut

hors

Ind

ex

Ow K.W., PB 1569 Owaidah T., PB 2075 Owens P., ASY 16.4, PB 1606 Owens W.E., PB 221, PB 232 Oymak Y., PB 313 Özdemir N., PB 2039, PO 11

PPaauwe M., PB 923 Pabinger I., OC 21.1, PB 213, PB 1903 Padro T., PB 010 Pagel O., OC 68.3 Pailleret Ringuier C., PB 1231 Paiva J., PB 696, PB 710, PB 2079 Pakdeeto S., OC 24.4 Palankar R., OC 58.1 Palla R., ASY 12.2 Palma-Barqueros V., OC 59.1, OC 69.4, PB 572 Palmer O.R., PB 089 Palomo M., PB 585 Panchenko E., PB 262, PB 796 Pandey D., OC 42.1 Panes O., PB 816 Panova-Noeva M., OC 28.5, PB 637, PB 1389 Paoletti O., PB 1965, PB 2414 Pap Á.F., PB 1217 Papadakis E., PB 507, PB 1437 Papageorgiou L., PB 2326 Papayan L., PB 1534, PB 1993, PB 2190 Paredes A.C., PB 220 Paris C., PB 388 Park Y.S., PB 240 Parry B.A., PB 2093 Pasalic L., PB 1374, PB 1559, PB 2383 Pasca S., PB 2180 Pasi K.J., ASY 01.2, PB 212, LB 01.1 Paskaleva I., PB 2147 Pasquier E., PB 2349

Passam F., OC 57.3 Patel V., OC 72.2 Patel-Hett S., PB 1124 Pathare A., PO 06 Patiroglu T., PB 1031, PO 52 Paul D.S., PB 1303 Paulsen B., PB 634, PB 643 Pavlova A., PB 2003 Pavlova I., PB 942 Pawlinski R., PB 2286 Payne A.B., LB 08Paz L., PB 806 Pechlivani N., PB 108 Pedersen O.H., PB 2234 Pelland-Marcotte M.-C., ASY 26.1 Pelzing M., PB 121 Penaloza A., PB 1134 Pequeriaux N., PB 1466 Peraramelli S., OC 28.2 Pereira J., PB 024 Pereira M., PB 1243 Pereira M.S., PB 1856 Pereira Gonçalves M.L., PB 1175 Perés S., PB 595 Pérez L., PB 1433 Persson E., PB 1120 Perveen K., PB 2402 Pesavento R., OC 25.1, OC 25.2 Pestel S., PB 1126 Petermann V., OC 30.4 Petersen M., PB 1082 Petito E., PB 1372 Petkovikj E., PB 1547 Petri A., OC 09.3 Petrillo T., PB 099 Petzold T., PB 133 Peyron I., OC 61.4 Peyvandi F., OC 61.1, PB 363, PB 389, PB 1776 Pezeshkpoor B., PB 151, PB 152, PB 2090 Phatale R., PB 430 Phusanti S., PB 628 Pierce G.F., PB 1808 Pignani S., OC 38.3 Pilch J., OC 50.5, PB 911

Pino M., PB 1270 Pipe S., LB 04Piran S., PB 489 Pitkänen H., PB 2002 Pizzini A.M., PB 532, PB 1681, PB 1829 Planquette B., PB 1393 Plantier J.-L., PB 130, PB 1111, PB 2265 Plantureux L., PB 2308 Platton S., PB 403 Pleines I., ASY 20.1, OC 44.3 Plug T., PB 1755 Podda G.M., PB 771, PB 1596, PB 1601, PB 2232 Podoplelova N., PB 1281 Podorolskaya L., PO 17 Pohlreichova V., PB 706 Poletaev A., PB 2126 Poli D., PB 257, PB 281, PB 1842Pollack C., LB 01.4 Pollard D., PB 1961 Pongtanakul B., PB 2162 Ponnusamy T., PB 022, PB 025 Pons Vila Z., ASY 25.3 Pontarollo G., PB 1706 Poon M.-C., PB 204 Portier I., PB 357 Posch F., ASY 06.1, PB 648, PB 1443, PB 1446 Posma J.J.N., PB 1642 Posthuma J.J., PB 004, PB 867, PB 1713, PB 1730 Potylitsina V., PB 138 Pourtau L., PB 1587 Powell Gray B., OC 35.4 Prabhudesai A., PB 180 Pradella P., PB 1960 Praefcke G.J.K., PB 2108 Prandoni P., OC 25.4, PB 777 Preijers T., PB 158 Preisler B., PB 408 Prévost N., OC 70.1 Prezoto B., PB 090, PB 876 Prezotti A.N., PB 969

Prince R., OC 76.1, PB 1526 Prins M.H., OC 39.1 Prior S., PB 345, PB 831, PB 1701 Privitera V., PB 1850 Prochaska J., OC 20.2, PB 1402 Prochazkova J., PO 28 Protopopova A.D., OC 72.1 Proulle V., PB 364 Provaznikova D., PB 1511 Prüller F., PB 837 Przeradzka M., OC 08.4 Pshenichnikova T., PB 1905 Puetz J., PB 2179, PB 2181, PB 2183 Pugh N., PB 1327, PB 1336 Puy C., OC 40.3, PB 1686

QQaddoori Y., PB 583 Qiao J., PB 2237 Qu C., PB 1582 Quach M., ASY 05.3 Qvigstad C., PB 1792

RRabinovich A., OC 60.4 Rabizadeh E., PB 2216 Rabouel Y., PB 2248 Radic C.P., PB 1975 Radu C., PB 550, PB 1747 Raka F., PO 50 Rakhimov R., PB 660 Rakic L., PB 1061 Raksha N., PB 1577 Rand M., PB 966, PB 1269 Rao A.K., LB 06Raquet E., PB 1129, PB 1130 Rashid A., PB 1880, PB 2032, PO 44 Rastogi P., PB 1518 Rattanawan C., PB 192 Rauch A., PB 373, PB 1940 Rauova L., ASY 39.2

Ravanat C., PB 1048 Rawley O., OC 22.3 Rayes J., ASY 32.1, OC 29.2 Reddel C.J., PB 681 Reed G., ASY 31.1 Rees S., PB 1209 Reinhardt C., PB 009 Reipert B.M., PB 110 Reitsma S.E., PB 1695 Rejtö J., PB 1809 Remijn J.A., PB 1357 Remiker A.S., OC 28.4 Remotti L., PB 2106 Ren L., PB 019 Reny J.-L., PB 556 Reshetnyak T., PB 1471 Restrepo-Avenia J., PO 31 Reusswig F., PB 074 Reverter J.C., PB 1470 Reyes M., PB 1038 Reyes Gil M., ASY 17.2 Rezende D.C., PB 1152 Rezende S.M., PB 2076 Rhodes S., PB 629, PB 1059 Ribeiro D.D., PB 394 Riedl J., PB 2304, PB 2317 Riera-Mestre A., PB 1022 Rigg R., PB 1687 Rigg R.A., PB 2290 Rijken D.C., PB 1760 Rijkers M., PB 1262 Riley P., PB 1171 Rimsans J., PB 2396 Rinde L.B., PB 1490, PB 1491 Riva S., PB 251 Rivera J., OC 69.2 Rivera S., PB 1052 Rivera Rivas J.J., PB 599 Rivera-Caravaca J.M., OC 33.1, PB 787, PB 1660 Rość D., PB 027, PB 814, PB 899 Robert-Ebadi H., PB 407 Robinson M., PB 111 Rocheleau A., PB 2411 Rockwood K., PB 203

Rode F., PB 1974 Rodriguez Moreno S.J., PB 764 Rohmann J.L., PB 1694 Rojas-Hernandez C.M., PB 2298 Roka-Moiia Y., PB 2223 Romano A.V.C., PB 1506 Roncal C., PB 046 Rondina M., PB 541, PB 2434 Roose E., ASY 19.4, OC 09.1, PB 690 Rosas M., PB 902 Rosenberg N., PB 739, PB 2390 Rosendaal F.R., PB 943 Rosovsky R., PB 934 Rossetti L., PB 2214 Rossi E., ASY 17.3, OC 29.3 Rottensteiner H., OC 13.6, PB 1097 Roweth H.G., OC 45.5, PB 2200 Rowswell H., PB 1435, NUR 05.2 Ruchutrakool T., PB 1600, PB 1669 Rühl H., PB 386, PB 1404 Rühle F., PB 1659 Rupa-Matysek J., PB 631 Rupon J., PB 231 Russick J., PB 1113 Ruszkowska-Ciastek B., PB 2433 Rutgers J., OC 11.3, PB 1251, LB 11 Ryu C.S., PB 1667, PB 2442

SSaad A., PB 1515 Sabater-Lleal M., OC 55.1 Sabban A., PB 1759 Sabio F., PB 2330 Sabor L., PB 2151 Sacco M., PB 500, PB 1074 Saes J.L., PB 2025 Saez R.C., PB 2226 Safiullina S., PO 33, PO 47 Saharov G., NUR 05.9 Sahli K.A., PB 1274 Saïd F., PB 066, PB 067, PB



600 601

Aut

hors

Ind

ex

068, PO 03, PO 04, PO 05 Saini S., OC 24.5 Sakane H., PB 1988 Sakata T., PB 427, PB 1176 Sakr M., PB 2375 Salas E., PB 1890 Salas J., PB 147 Salaun P.-Y., PB 617, PB 652 Salazar A.M., PB 115 Salazar-Sanchez L., PB 1991 Salcioglu Z., PB 858 Saleh M., PB 749, PB 765 Salge-Bartels U., PB 1289 Salles-Crawley I.I., PB 1614 Salloum-Asfar S., PB 1688, PB 2097 Salzmann M., OC 57.5 Samelson-Jones B.J., OC 13.4, OC 40.5 Sanchez-Rivera L., PB 1387 Sano H., ASY 17.1 Santagostino E., PB 970, PB 1816 Santamaria A., PB 267, PB 1919, PB 1920, PB 2332 Santoro C., PB 2004, PB 2027 Santoro M.L., PB 901 Santoro R., PB 1107, PO 34 Sarafanov A., PB 141, PB 150 Saraiva S., PB 1453 Saralidze T., PB 2381 Sardo L., NUR 05.4, NUR 05.13, NUR 05.14 Sarig G., PB 699 Sarolo L., PB 475, PB 1020 Sartim M.A., PB 325 Sartori M., PB 059, PB 1391 Sartori M.T., PB 182, PB 2328, PB 2376 Sasmaz I., PB 2016 Saultier P., OC 69.1, PB 759 Savion N., PB 1337 Saxena R., PB 903 Sayar Z., PB 650 Sayinalp N., PB 859 Scalise V., PB 895

Schaffner M., PB 2386 Schaller M., PB 698 Schattner M., OC 58.5, PB 1352, PB 1380 Schelpe A.-S., PB 694 Scheres L.J.J., ASY 22.1, OC 51.2 Schillemans M., OC 22.1, PB 2047 Schlagenhauf A., PB 2186 Schlegel N., PB 560 Schmidgen M.I., ASY 34.1 Schmidt D.E., PB 2405 Schmidt M.V., OC 71.2 Schneppenheim S., PB 366 Schoeman R.M., ASY 04.1 Schoergenhofer C., PB 169 Schönichen C., OC 27.3 Schopohl D., PB 990 Schreiner R., PB 491 Schreuder M., ASY 02.2 Schrottmaier W.C., ASY 32.2 Schubert S., OC 68.1 Schulman S., PB 341, PB 342 Schulze H., OC 59.5 Schüngel L., PB 1370, PB 1377 Schurr Y., PB 565 Schütte L.M., OC 37.2, PB 210, PB 1775 Schved J.-F., PB 1958 Schwartz B.A., PB 1751, PB 1753 Schwarz Y., OC 33.4 Scott M., PB 1793 Seeger S., PB 383 Séguin A., PB 1861 Seidel H., PB 395, PB 1166 Seki Y., PB 1959 Selvam S., PB 2428 Semeraro F., PB 165, PB 1450, PB 1970, PB 2229 Semple J.W., OC 58.3 Sengupta T., PB 116 Senis Y.A., OC 06.2 Sennesael A.-L., PB 1240 Serban M., PB 1110 Serbic O., PB 724

Seregina E., PB 1428 Sermsathanasawadi N., PB 449 Serra J., PB 703 Servais L., PB 1366 Seth Chhabra E., PB 149 Sezgin Evim M., PB 2184 Shabbir S., PB 2137 Shahani T., PB 1732 Shahidi Hamedani N., ASY 21.1, PB 885 Shahneh F., ASY 34.3 Shahni A., PB 609 Shahzad K., PB 018 Shakerian B., PB 939, PB 1962 Shamoun F., PB 781 Shamshirsaz A.A., PB 1169 Shapiro A., PB 1996 Sharathkumar A., PB 2182 Sharif S., PB 2100 Sharkova T., PB 095, PB 940 Sharma A., PB 600, PB 601, PB 606, PB 1510, PB 2049 Sharma S., PB 079 Shatzel J., PB 064, PB 250 Shaw J., PB 282, PB 472 Shaya S.A., PB 1742 Sheffield W., PB 106 Shemenkova V., PB 1517 Shen M.C., PO 57 Shen W., PB 1663 Shepelyuk T., PB 2217 Shi P., PB 040 Shi Q., OC 62.1, PB 098 Shim Y.J., PB 2177 Shimomura T., PB 711 Shin H.-J., PB 255 Shirai T., PB 579, PB 1618 Shoeib S., PO 13 Siddiqui S., PB 272 Sidharthan N., PB 1786 Sidorova Z., PB 1505 Siegemund T., PB 1946 Siguret V., PB 278, PB 479 Sikorska A., PB 2080, PB 2356, PO 59, PO 60, PO 61 Sikorska A.J., PB 763

Silina N., PB 2130 Silva R., PB 241, PB 1833, PO 24, PO 25 Silvey M., PB 1248 Silvis S.M., ASY 36.4 Simpson M., PB 953 Singer H., OC 50.1, PB 1966 Singh M., PB 2269 Singh S., ASY 07.1, ASY 13.3, OC 19.3, PB 527, PB 533, PB 1750, PB 1765, PB 2173 Sinha S., PB 320 Sinkov S., PB 1741 Sirachainan N., PB 1672 Sirotkina O., PB 2241 Siudut J., PB 181, PB 471 Skelly P., PB 593 Skibowska-Bielińska A., PB 1184 Skille H., OC 46.1, PB 623 Skinner M., PB 1985 Slavík L., PB 1513 Småbrekke B., ASY 13.1, PB 1489 Smiers F., PB 520 Smith C.W., PB 564 Smith E.N., OC 51.1 Smith N.L., OC 32.1 Smith S., PB 120, PB 1693 Soares S.M.S., PB 1012 Sobas F., OC 65.5, PB 603 Södergren A., PB 1273 Söker M., PO 22 Sokol J., PB 1210 Solh Z., PB 1144, PB 2164 Soliman A.R., PB 2388 Solms A., PB 971 Solomon L., PB 1053 Solomons H.D., PO 10 Solpova O., PB 1294 Son J., PB 1762 Sood R., OC 02.1 Sorvillo N., OC 09.2 Sosothikul D., PB 2412 Soto I., PB 252 South K., PB 1705 Sovershaev T., PB 2259

Spectre G., PB 459 Speed V., PB 495 Speer O., PB 1376 Speker M., PB 1538 Spengler K., PB 2435 Spiegel P.C., ASY 02.3 Spindler M., OC 04.2 Spirkoska A., PB 825, PB 853 Spourquet C., PB 926 Spyropoulos A.C., OC 33.5 Spyropoulos J., PB 499, PB 1844 Srivastava A., PB 1143 Stafford D., PB 142 Stagaard R., PB 1064 Stainer A., OC 45.4 Stalc M., PB 622 Stalker T.J., PB 1318 Stambolieva D., PO 08 Stanley J., PB 999 Stark K., OC 26.4 Stavik B., ASY 16.3 Stefanini L., OC 06.1 Stefanoni F., PB 789, PB 894 Stefanska-Windyga E., PB 1158 Stegner D., ASY 08.1, OC 44.1 Stehouwer A., OC 49.1, LB 14 Steiner M., PB 242 Stemberger M., PB 1944 Stepanian A., PB 478, PB 1581 Stephens L., PB 2117 Sternebring O., PB 1983 Stivala S., PB 1621 Storage M., OC 02.5 Strijbis V.J.F., PB 1980 Stroo I., PB 1682 Stroobants A.K., PB 2118 Stufano F., PB 381 Su J., PB 968, PB 1783 Subramaniam S., OC 20.1, PB 591 Suchon P., OC 48.1, PB 1495 Sueldo R.E., PB 1180, PB 1810 Suganuma Y., PB 1293 Sugidachi A., PB 2206 Sugimoto M.A., OC 42.4 Sugita N., PB 1415

Sugiura K., PB 799 Sukhanov V., PB 1179 Sumi H., PB 193 Sun B., PB 1953 Sundd P., OC 70.3 Surov S.S., PB 1987 Susen S., ASY 11.2 Suwanawiboon B., PB 288, PB 385, PB 2392 Suzuki A., PB 1151 Suzuki E., ASY 30.4 Suzuki N., PB 234 Suzuki T., PB 494, PB 980 Suzuki-Inoue K., OC 45.1 Sveshnikova A., PB 1310 Swallow G., PB 1904 Swieringa F., PB 738 Swystun L.L., OC 31.1, OC 31.3, OC 31.5 Szanto T., PB 1764 Szklanna P.B., OC 68.5

TTafesh L., PB 304 Tafur A., PB 2294 Tagalakis V., PB 2325 Tagliaferri A., PB 2012 Takagi Y., PB 2123 Takeshita A., PB 872 Taki M., PB 978 Talati R., OC 11.2 Tamura S., PB 1076 Tan C.W., OC 34.4, PB 280, PB 1438 Tan S., PB 1362 Tan S.Y.M., PB 1957Tang N., PB 1408 Tang V.K., PB 2312 Tangada S., LB 09Tanka-Salamon A., PB 933 Tanratana P., PB 1539 Taouli Allal K., PB 2041 Tardy B., OC 34.5 Tardy-Poncet B., OC 34.3, PB 153, PB 1075, PB 1977



602 603

Aut

hors

Ind

ex

Tariket S., ASY 11.3 Tarrant J.L., OC 23.5 Tàssies D., PO 56 Tatsumi E., PB 720 Tatsumi K., PB 596 Tatyana S., PB 135 Tavoly M., PB 1009 Taylor J.A., OC 23.3 Tazi Mezalek Z., PB 306, PB 1550, PB 1853 Tchaikovski S., PB 1891 Teixeira S., PB 333 Teliga-Czajkowska J.M., PB 1924, PB 2401, PO 30 Ten Cate-Hoek A.J., OC 60.5, PB 1395, LB 01.3 Teruel-Montoya R., ASY 38.1 Teryua J., PB 402 Testa S., OC 52.5, PB 292, PB 420, PB 474 Thaler B., PB 2288 Thaler H.W., PB 337 Thaler J., PB 678 Thati M., PB 863 Thelwell C., PB 594 Thomas D., PB 834 Thomas W., PB 332, PB 1530 Thon J., PB 542 Thota L.N.R., OC 41.3, PB 016 Tian J., ASY 09.3, PB 1709 Tiao J.Y., PB 723 Tie J.-K., OC 71.5 Tiede A., ASY 27.2 Tiefenbacher S., PB 1990 Tilburg J., ASY 18.4 Timp J., OC 51.3 Tinholt M., PB 908 Tirado Garcia I., PB 2128 Tittl L., OC 73.4 Toderici M., OC 14.4 Toenges R., PB 228 Tomaiuolo M., OC 17.1, PB 2211 Torramade-Moix S., PB 870 Torres T., ASY 25.1, PB 1417 Tosetto A., OC 39.2, PB 374 Totoki T., PB 862, PB 906

Toulon P., PB 119, PB 1238 Tozawa K., PB 318 Traby L., PB 675, PB 1572 Tran H., PB 219 Trevarrow B., PB 297 Truong T., PB 101 Tsai H.-J., PB 1311 Tselepis A., PB 2203 Tseng E., PB 487 Tseng Y.-L., PB 2199 Tsuda H., PB 882 Tsujii N., PB 705 Tsukiji N., OC 03.1 Tullemans B.M.E., PB 1349 Tuneew I., PB 849 Turkkan E., PB 854 Turpie A.G.G., PB 456, PB 1196 Tyravska Y., PO 01 Tzoran I., PB 122

UUil M., PB 669 Uitte de Willige S., PB 166, PB 174 Ujjan I., PB 137 Ulehlova J., PB 1479 Ulrich B., PB 393 Unal S., PB 1256, PO 68 Underwood M.I., OC 09.4 Ünlü B., OC 28.1 Unuvar A., PO 53 Urano T., PB 1627 Urasinski T., PB 1807 Urbanus R.T., PB 1442 Utne K.K., OC 60.2, PB 496, PB 1004

Vv. Auer-Wegener C., LB 10Vajda Z., PB 451 Vajen T., PB 1612 Vakalopoulou S., PB 2018 Van Asten I., PB 404, PB 1149 Van Balen E., PB 983

Van den Eshof B.L., PB 2438 Van der Flier A., OC 40.2, PB 143 Van der Pol L.M., ASY 35.1, PB 481, PB 1205, PB 1213 Van der Vorm L.N., PB 1863 Van der Wal D.E., PB 1286 Van der Wall S., PB 1881 Van Dijk W.E.M., PB 104 Van Doorn S., PB 813, PB 1837, PB 1843 Van Dreden P., PB 633, PB 640, PB 1873, PB 1902 Van Es N., OC 21.2, OC 21.3, PB 2296, PB 2299 Van Galen J., OC 16.5 Van Geffen J.P., PB 2213 Van Gorp R., PB 007 Van Heerde W., OC 35.1, PB 944, PB 2014, PB 2045 Van Hylckama Vlieg A., PB 1388 Van Mens T.E., PB 1023, PB 1520 Van Miert J.H.A., PB 261 Van Moort I., ASY 27.3, OC 65.3 Van Rein N., PB 259 Van Tonder J.J., PB 1865 Van Velzen A., ASY 23.1 Van Vulpen L., PB 205 Vanassche T., OC 67.4, PB 458 Vangala R.K., PB 2323 Vanoverschelde L., PB 2104 Varela-Magallon A., PB 1838 Varma M., PB 1035 Varma N., PB 1599 Varma S., PB 2426 Vasilenko I., PB 2242 Vasse M., PB 2352 Vavilova T., PB 443, PB 510, PB 1603 Vayne C., PB 2393 Vaynyunskaya N., PB 530 Vázquez-Santiago M., PB 1413 Veen C.S.B., PB 418, PB 266 Veiga A., ASY 24.1 Vene N., PB 344 Verhagen A., OC 10.4

Verhamme I.M., PB 822 Verhamme P., ASY 03.4, OC 56.3 Verhezen P.W.M., PB 1579 Verhoef D., ASY 02.1 Vermeersch E., PB 573 Verzeroli C., PB 646 Vilar R., PB 786 Vilaseca A.B., PB 298, PB 1769 Vilela Oliva M.L., PB 072 Villagra Iturre M.J., PB 1849 Vincenot A., PB 732 Vinicius De Paula E., PB 2260 Vinogradova M., PB 1886, PB 1900 Viola F., PB 1042, PB 1043 Vion A.-C., ASY 30.3, OC 41.2 Visser M., PB 826 Vitola B., PB 2340 Vögtle T., OC 66.4 Vollack N., PB 145 Volland L., OC 37.4 Volz J., OC 53.1 Von Drygalski A., ASY 01.3, OC 37.3, PB 1777 Von Mackensen S., PB 993, PB 1100, PB 1105 Vorobev A., PB 924, PB 2339 Vorobyeva N., PB 1857 Vries M.J.A., ASY 27.4, PB 176 Vučković B., PB 155 Vukelic-Damijani N., PB 311 Vulliamy P., PB 335, PB 1368

WWada H., PB 1161 Wadowski P.P., PB 2244 Wagner L., PB 712, PB 714 Walborn A., OC 36.4, PB 323, PB 324, PB 778 Walenga J., PB 2284 Walker-Allgaier B., PB 540 Wallisch M., PB 088 Walsh T., OC 29.5 Walter E., PB 1317 Wang C., PB 1046

Wang J.-D., PB 2391 Wang Q.J., PB 612 Wang X., OC 75.1, PB 054 Wang Y., PB 846 Warad D., PB 1250 Ward M.P., PB 913 Washington A.V., PB 1343 Watkin R.L., ASY 09.2 Watson S., PB 1329 Webster A., OC 52.4 Wei Y., PB 1027 Weimer T., OC 10.5 Weitz J.I., OC 39.3, PB 460 Wells P., OC 39.4, PB 795 Wendelboe A., PB 1492, PB 1841 Wéra O., PB 1367 Wheeler R., PB 553 Whiteheart S., PB 1359 Whyte C.S., OC 01.1 Widjaja S.S., PB 2355 Wiegand G., PB 1941 Wieland I., PB 2171 Wieland Greguare-Sander A., PB 401 Wilasrusmee C., PB 069 Williams C., OC 53.2, PB 2193 Williams C.M., PB 608 Williams M., PB 1967 Williams S., PB 522, PB 1246 Willis Fox O., ASY 21.2 Wilson S., PB 2142 Wilts I.T., PB 624 Winding B., PB 249 Windyga J., PB 708, PB 1984 Wissel T., PB 421 Witschel V., ASY 15.3 Witte A., PB 1341 Witten A., PB 2365 Wolberg A., PB 1062 Wolf S., PB 951 Woller S., PB 602 Wong P., OC 40.4 Woodruff S., PB 1854 Wool G., PB 431 Woolley A., PB 1163 Worou M.E., PB 1620

Wu H.-L., PB 1619 Wu J., PB 782, PB 2417, PB 2432 Wu R., PB 244, PB 254, PB 956, PB 1825 Wujak L., PB 2250 Wypasek E., PB 1502, PB 1666 Wyseure T.L., OC 50.3, OC 67.2

XXafaki P., PB 945 Xi X., PB 013 Xu N., PB 032, PB 783 Xue C., OC 44.4

YYada K., OC 47.4 Yada N., PB 1401 Yadegari H., PB 358, PB 2054 Yakovleva E., PB 2043 Yakusheva A., PB 076 Yamaguti-Hayakawa G.G., PB 269 Yamakuchi M., PB 2429 Yamanouchi J., PB 727 Yamashita A., PB 897 Yan S., PB 239, PB 253 Yan Y., PB 1365 Yanagisawa Y., PB 198 Yang A., OC 15.5 Yang C.-M., PB 791 Yang R., PB 230 Yao J., PB 036 Yaoi H., PB 2052 Yap Y.Y., PB 702 Yasuda C., PB 1029 Yasuma T., PB 860 Yasumoto A., PB 2374 Yatagai C., PB 195 Yen C.T., PB 1095 Yeung J., OC 63.4 Yip C., PB 785 Yoon H.-J., PB 1813 Young G., OC 24.1, PB 214, PB 1790 Yu Y., PB 1724


605

AUTHORS INDEX


604

FUTURE ISTH MEETINGS AND CONGRESSES

Yuan Y., ASY 03.1 Yunliang C., PB 916, PB 917, PB 927 Yushi C., PB 1823

ZZabczyk M., PB 912 Zadro R., PB 1665 Zaid Y., PB 1700 Zaldivia M.T.K., PB 1345 Zamalek N., PB 1185 Zanon E., OC 36.1, OC 36.2, PB 1788, PB 1936 Zapponi K.C.S., PB 1624 Zara C., PB 555 Zawilska K., PB 1815Żekanowska E., PB 1430 Zelaya M., ASY 34.2 Zelinskiy V., PB 062 Zhang D., PB 741, PB 1979 Zhang L., PB 273, PB 439, PB 1156 Zhang X., PB 2362 Zhao X., OC 05.1, PB 1358 Zhao Y., PB 037 Zharkov P., PB 526, PB 1254, PB 2409 Zheng G., PB 2088 Zheng Z., OC 01.4 Zhmurov A., OC 54.1 Zhou H., PB 2399 Zhou Z., PB 2357 Zhu M., PB 2007 Zibrova D., ASY 30.2 Zieger B., OC 64.5 Ziegler M., ASY 24.4 Zilberman-Rudenko J., PB 310, PB 1631, PB 1689 Zintner S.M., OC 26.3 Zipperle J., PB 1932 Zivelin A., PB 2116 Zotz R.B., PB 1499, PB 1883 Zozulya N., PB 227 Zuñiga P., PB 1106 Zuo Y., PB 1460 Zupančić-Šalek S., PB 235

64TH ANNUAL SSC MEETING

President: Dermot Cox

Date: July 17–21, 2018

Location: Dublin, Ireland

www.ssc2018.org

XXVII ISTH CONGRESSAND 65TH ANNUAL SSC MEETING

President: Robert Medcalf

Date: July 6–10, 2019

Location: Melbourne, Australia

www.isth2019.org



606 607

NOTES

LCM-67828_M3-ISTH_1Pg_BckCvr_JA.indd5-19-2017 2:03 PM Suke Yawata / Paul LaRocca

Client CodeClient

LiveOverall TrimBleed

# of Colors

G.MKT.SM.HEM.05.2017.1337 Bayer Kogenate

136 mm x 198 mm148 mm x 210 mm154 mm x 216 mm

4/4 Process

Colors Cyan, Magenta, Yellow, Black

FontsITC Zapf Dingbats Std (Medium), DINOT (Cond-Regular, CondBold, Regular, Bold)

Job info Fonts & ColorsImages

Saved at

None

from hssyawata7724 by

Printed At

67828_Background_Camping.psd (CMYK; 909 ppi; 33%), Sub1_KOV_Prism_4C_HR_Flattened.eps (16.02%), Bayer_Icon_KO.ai (45.36%), Kovaltry_US_R_Logo_NoGeneric_4C.ai (38.01%)

Notes 2017 ISTH 1 PAge Back Cover Journal Ad

▼ This medicinal product is subject to additional monitoring. Adverse events should be reported. Please report any suspected adverse reaction to your national authority. Please use the following website to find contact details of your respective local health authority: http://www.hma.eu/nationalcontacts_hum.html. Name of the medicinal product: Kovaltry 250 / 500 / 1000 / 2000 / 3000 IU powder and solvent for solution for injection (Refer to full SmPC before prescription.) Composition: Each vial contains nominally 250/500/1000/2000/3000 IU human coagulation factor VIII. Excipients: Powder: Sucrose, histidine, glycine, sodium chloride, calcium chloride and polysorbate 80. Solvent: Water for injections. Indication: Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Known allergic reactions to mouse or hamster proteins. Warnings and Precautions: Allergic type hypersensitivity reactions are possible. The formation of neutralising antibodies (inhibitors) to FVIII is a known complication in the management of individuals with haemophilia A. Haemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-haemophilic patients when clotting has been normalised by treatment with FVIII. If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bactaeremia and catheter site thrombosis should be considered. Undesirable effects: common: lymphadenopathy, palpitation, sinus tachycardia, abdominal pain, abdominal discomfort, dyspepsia, pyrexia, chest discomfort, injection site reactions (incl. injection site extravasation, hematoma, infusion site pain, pruritus, swelling), headache, dizziness, insomnia, pruritus, rash (rash, rash erythematous, rash pruritic), dermatitis allergic; uncommon: hypersensitivity, dysgeusia, urticaria, flushing. On prescription only. Marketing Authorisation Holder: Bayer, 51368 Leverkusen, Germany. Date of revision of the underlying Prescribing Information: 04/2017.

References: 1. KOVALTRY® [Summary of Product Characteristics]. Berlin, Germany: Bayer AG; 2017. 2. Ljung R, Kenet G, Mancuso ME, et al; on behalf of the investigators of the LEOPOLD Kids Trial. Haemophilia. 2016;22(3):354-360. 3. Saxena K, Lalezari S, Oldenburg J, et al. Haemophilia. 2016;22(5):706-712. 4. Enriquez MM, Thrift J, Garger S, Katterle Y. Protein Expr Purif. 2016;127:111-115. 5. Garger S, Severs J, Regan L, et al. Haemophilia. 2017;23(2):e67-e78.

© 2017 Bayer AG. All rights reserved.Bayer, the Bayer Cross, and KOVALTRY are registered trademarks of Bayer.G.MKT.SM.HEM.05.2017.1337

The evolution of an unmodified, full-length recombinant FVIII molecule, developed through innovative manufacturing1-5

Demonstrated efficacy and safety in prophylaxis across all age groups with as few as 2 infusions per week2,3

KOVALTRY®

EXPLORE THE POSSIBILITIES WITH CONFIDENCE

S:136 mmS:198 m

m

T:148 mmT:210 m

m

B:154 mmB:216 m

m



608

Breaking scientific walls in the treatment of haemophilia and rare bleeding disorders: from laboratory assays to patient outcomes

9th July 201716:15 - 17:45, Room A6 novonordiskisth2017.com

Welcome and introductionChairman Robert Klamroth, Germany

Bridging the gap between the laboratory and the patient David Lillicrap, Canada

Prolonging coagulation factor IX activity: a win-win situation Guy Young, USA

Congenital haemophilia with inhibitors and acquired haemophilia: how to treat and how to evaluate Andreas Tiede, Germany

Treating haemophilia A for life Elena Santagostino, Italy

Panel discussion Faculty

Final remarksChairman Robert Klamroth, Germany

Refreshments available

Novo Nordisk is a registered trademark of Novo Nordisk A/S.© 2017 Novo Nordisk HQMMA/NNG/0317/0091 July 2017

limited increasedmobility

changing haemophilia™

CHRIS BOMBARDIERChris has haemophilia BUS

Come and visit us at booth 222 to find out more about our commitment to science

16:15 – 16:20

16:20 – 16:35

16:35 – 16:50

16:50 – 17:05

17:05 – 17:25

17:25 – 17:40

17:40 – 17:45

FINAL PROGRAM

Documents

Transcript of FINAL PROGRAM